All DT CAPITAL All O
All JJ live O
live NNS births O
births JJR > O
> CC or O
or JJ = O
= CD 23 O
23 NNS weeks O
weeks IN at O
at DT the O
the NNP CAPITAL University O
University IN of O
of NNP CAPITAL Vermont O
Vermont IN in O
in CD 1995 O
1995 NN ( O
( NN n O
n JJ = O
= CD 2395 O
2395 NN ) O
) VBD were O
were RB retrospectively O
retrospectively VBN analyzed O
analyzed IN for O
for NN delivery O
delivery NN route O
route , , O
, NN indication O
indication IN for O
for NN cesarean O
cesarean , , O
, JJ gestational O
gestational NN age O
age , , O
, NN parity O
parity , , O
, CC and O
and NN practice O
practice NN group O
group NN ( O
( TO to O
to VB reflect O
reflect NN risk O
risk NN status O
status NN ) O

The DT CAPITAL The O
The JJ total O
total NN cesarean O
cesarean NN rate O
rate VBD was O
was CD 14.4 O
14.4 NN % O
% NN ( O
( CD 344 O
344 IN of O
of CD 2395 O
2395 NN ) O
) , , O
, CC and O
and DT the O
the JJ primary O
primary NN rate O
rate VBD was O
was CD 11.4 O
11.4 NN % O
% NN ( O
( CD 244 O
244 IN of O
of CD 2144 O
2144 NN ) O

Abnormal JJ CAPITAL Abnormal O
Abnormal NN presentation O
presentation VBD was O
was DT the O
the JJS most O
most JJ common O
common NN indication O
indication NN ( O
( CD 25.6 O
25.6 NN % O
% , , O
, CD 88 O
88 IN of O
of CD 344 O
344 NN ) O

The DT CAPITAL The O
The `` `` O
`` VBN corrected O
corrected '' '' O
'' NN cesarean O
cesarean NN rate O
rate NN ( O
( JJ maternal-fetal O
maternal-fetal NN medicine O
medicine CC and O
and VBN transported O
transported NNS patients O
patients VBN excluded O
excluded NN ) O
) VBD was O
was CD 12.4 O
12.4 NN % O
% NN ( O
( CD 273 O
273 IN of O
of CD 2194 O
2194 NN ) O
) , , O
, CC and O
and DT the O
the `` `` O
`` VBN corrected O
corrected '' '' O
'' JJ primary O
primary NN rate O
rate VBD was O
was CD 9.6 O
9.6 NN % O
% NN ( O
( CD 190 O
190 IN of O
of CD 1975 O
1975 NN ) O

Furthermore RB CAPITAL Furthermore O
Furthermore , , O
, WRB when O
when DT all O
all NNS deliveries O
deliveries VBD were O
were VBN analyzed O
analyzed , , O
, RB regardless O
regardless IN of O
of NN risk O
risk NN status O
status CC but O
but JJ limited O
limited TO to O
to JJ gestational O
gestational NN age O
age JJR > O
> CC or O
or JJ = O
= CD 36 O
36 NNS weeks O
weeks , , O
, DT the O
the NNS rates O
rates VBD did O
did RB not O
not NN change O
change NN ( O
( CD 12.6 O
12.6 NN % O
% , , O
, CD 280 O
280 IN of O
of CD 2214 O
2214 : ; O
; JJ primary O
primary CD 9.2 O
9.2 NN % O
% , , O
, CD 183 O
183 IN of O
of CD 1994 O
1994 NN ) O

Arrest NN CAPITAL Arrest O
Arrest IN of O
of NN dilation O
dilation VBD was O
was DT the O
the JJS most O
most JJ common O
common NN indication O
indication IN in O
in DT both O
both `` `` O
`` VBN corrected O
corrected '' '' O
'' NNS subgroups O
subgroups NN ( O
( CD 23.4 O
23.4 CC and O
and CD 24.6 O
24.6 NN % O
% , , O
, RB respectively O
respectively NN ) O

Cesarean JJ CAPITAL Cesarean O
Cesarean NNS rates O
rates IN at O
at JJ tertiary O
tertiary NN care O
care NNS hospitals O
hospitals MD should O
should VB be O
be VBN compared O
compared IN with O
with NNS rates O
rates IN at O
at NN community O
community NNS hospitals O
hospitals RB only O
only IN after O
after VBG correcting O
correcting IN for O
for JJ dissimilar O
dissimilar NN patient O
patient NNS groups O
groups CC or O
or JJ gestational O
gestational NN age O

In IN CAPITAL In O
In DT the O
the JJ third O
third NN trimester O
trimester , , O
, DT the O
the JJ amniotic O
amniotic NN fluid O
fluid NN index O
index NN ( O
( NN CAPITAL AFI O
AFI NN ) O
) MD may O
may VB be O
be VBN affected O
affected IN by O
by JJ maternal O
maternal NN fluid O
fluid NN status O

As IN CAPITAL As O
As DT the O
the JJ ambient O
ambient NN temperature O
temperature NNS increases O
increases , , O
, RB there O
there VBZ is O
is DT an O
an NN increase O
increase IN in O
in JJ insensible O
insensible NN fluid O
fluid NN loss O
loss CC and O
and DT the O
the JJ potential O
potential IN for O
for NN dehydration O

We PRP CAPITAL We O
We VB hypothesize O
hypothesize IN that O
that IN as O
as NN temperature O
temperature NNS increases O
increases RB there O
there MD would O
would VB be O
be DT a O
a JJ concomitant O
concomitant NN decrease O
decrease IN in O
in NN CAPITAL AFI O

From IN CAPITAL From O
From NNP CAPITAL June O
June CD 11 O
11 TO to O
to NNP CAPITAL August O
August CD 16 O
16 , , O
, CD 1993 O
1993 , , O
, IN during O
during DT a O
a NN period O
period IN of O
of JJ unusual O
unusual JJ high O
high NN heat O
heat , , O
, CD 42 O
42 NNS women O
women IN with O
with NN singleton O
singleton NNS pregnancies O
pregnancies IN between O
between CD 27 O
27 CC and O
and CD 40 O
40 NNS weeks O
weeks POS ' O
' JJ gestation O
gestation VBG undergoing O
undergoing JJ serial O
serial JJ antenatal O
antenatal NN testing O
testing VBD had O
had NN CAPITAL AFI O
AFI NNS determinations O
determinations VBN recorded O
recorded IN at O
at JJS least O
least JJ weekly O

The DT CAPITAL The O
The RB daily O
daily JJ high O
high JJ ambient O
ambient NN temperature O
temperature IN in O
in PRP$ our O
our JJ urban O
urban NN area O
area VBD was O
was RB subsequently O
subsequently VBN obtained O

A DT CAPITAL A O
A CD 2- O
2- , , O
, CD 3- O
3- , , O
, CC and O
and JJ 4-day O
4-day VB mean O
mean NN temperature O
temperature RB prior O
prior TO to O
to DT the O
the NN test O
test NN date O
date VBD was O
was VBN compared O
compared TO to O
to NN CAPITAL AFI O
AFI VBG using O
using DT a O
a JJ CAPITAL Spearman-rank O
Spearman-rank NN CAPITAL Correlation O

The DT CAPITAL The O
The RB daily O
daily JJ high O
high NN temperature O
temperature VBD ranged O
ranged IN from O
from CD 71 O
71 TO to O
to CD 104 O
104 NNS degrees O
degrees NN CAPITAL F O
F CC and O
and NN CAPITAL AFI O
AFI NNS values O
values VBD ranged O
ranged IN from O
from CD 1.7 O
1.7 TO to O
to CD 24.7 O
24.7 NN cm O
cm IN during O
during DT the O
the NN study O
study NN period O

There EX CAPITAL There O
There VBD was O
was DT a O
a JJ significant O
significant NN correlation O
correlation IN between O
between DT the O
the CD 2- O
2- , , O
, CD 3- O
3- , , O
, CC and O
and JJ 4-day O
4-day VB mean O
mean NN temperature O
temperature CC and O
and NN CAPITAL AFI O
AFI , , O
, IN with O
with DT the O
the JJ 4-day O
4-day VB mean O
mean VBG being O
being DT the O
the JJS most O
most JJ significant O
significant NN ( O
( NN r O
r JJ = O
= CD 0.31 O
0.31 , , O
, NN p O
p CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0.001 O
0.001 NN ) O

Fluctuations NNS CAPITAL Fluctuations O
Fluctuations IN in O
in JJ ambient O
ambient NN temperature O
temperature VBP are O
are RB inversely O
inversely VBD correlated O
correlated TO to O
to NNS changes O
changes IN in O
in NN CAPITAL AFI O

This DT CAPITAL This O
This NN relationship O
relationship MD should O
should VB be O
be VBN taken O
taken IN into O
into NN account O
account WRB when O
when VBG interpreting O
interpreting DT the O
the NN CAPITAL AFI O
AFI IN as O
as DT a O
a NN measure O
measure IN of O
of JJ fetal O
fetal NN well-being O

This DT CAPITAL This O
This NN study O
study VBN tested O
tested DT the O
the NN hypothesis O
hypothesis IN that O
that TO to O
to VB reduce O
reduce DT the O
the NN rate O
rate IN of O
of JJ macrosomic O
macrosomic NNS infants O
infants IN in O
in JJ gestational O
gestational NN diabetes O
diabetes NNS cases O
cases , , O
, JJ good O
good JJ glycemic O
glycemic NN control O
control MD should O
should VB be O
be VBN initiated O
initiated IN before O
before CD 34 O
34 VBN completed O
completed JJ gestational O
gestational NNS weeks O

The DT CAPITAL The O
The NN study O
study NN population O
population VBN included O
included CD 84 O
84 NNS women O
women IN with O
with JJ gestational D
gestational NN diabetes D
diabetes , , O
, VBN ascertained O
ascertained IN by O
by JJ universal O
universal VBG screening O
screening IN of O
of DT all O
all NNS women O
women VBG attending O
attending DT the O
the JJ antenatal O
antenatal NN clinic O
clinic IN of O
of DT the O
the NNP CAPITAL Hadassah O
Hadassah JJ CAPITAL Medical O
Medical NNP CAPITAL Center O
Center , , O
, IN over O
over DT a O
a JJ 2-year O
2-year NN period O

The DT CAPITAL The O
The CD 60 O
60 NNS women O
women NN ( O
( CD 71 O
71 NN % O
% NN ) O
) , , O
, WP who O
who VBN initiated O
initiated NN treatment O
treatment IN before O
before CD 34 O
34 VBN completed O
completed NNS weeks O
weeks , , O
, VBN composed O
composed DT the O
the `` `` O
`` RB early O
early '' '' O
'' NN group O

The DT CAPITAL The O
The CD 24 O
24 NNS women O
women NN ( O
( CD 29 O
29 NN % O
% NN ) O
) , , O
, WP who O
who VBN initiated O
initiated NN treatment O
treatment IN after O
after DT the O
the JJ 34th O
34th NN week O
week , , O
, VBN composed O
composed DT the O
the `` `` O
`` RB late O
late '' '' O
'' NN group O

All DT CAPITAL All O
All NNS patients O
patients VBD were O
were VBN managed O
managed IN by O
by DT an O
an VBN intensified O
intensified NN protocol O
protocol , , O
, VBG including O
including JJ stringent O
stringent JJ glycemic T
glycemic JJ control T

In IN CAPITAL In O
In DT the O
the `` `` O
`` RB early O
early '' '' O
'' CC and O
and `` `` O
`` RB late O
late '' '' O
'' NNS groups O
groups , , O
, VB mean O
mean JJ gestational O
gestational NN age O
age IN at O
at DT the O
the VBG beginning O
beginning IN of O
of NN treatment O
treatment VBD was O
was CD 30.0 O
30.0 CC +/- O
+/- CD 3.8 O
3.8 CC and O
and CD 36.2 O
36.2 CC +/- O
+/- CD 1.2 O
1.2 NNS weeks O
weeks , , O
, CC and O
and NN duration O
duration IN of O
of NN treatment O
treatment VBD was O
was CD 9.6 O
9.6 CC +/- O
+/- CD 4.1 O
4.1 CC and O
and CD 3.7 O
3.7 CC +/- O
+/- CD 1.8 O
1.8 NNS weeks O
weeks , , O
, RB respectively O

Maternal JJ CAPITAL Maternal O
Maternal NNS characteristics O
characteristics VBD were O
were JJ similar O
similar IN in O
in DT the O
the CD two O
two NNS groups O

The DT CAPITAL The O
The NN rate O
rate IN of O
of JJ macrosomic O
macrosomic CC and O
and JJ large-for-gestational-age O
large-for-gestational-age NNS infants O
infants VBD were O
were CD 5 O
5 CC and O
and CD 11 O
11 NN % O
% , , O
, RB respectively O
respectively , , O
, IN in O
in DT the O
the RB early O
early NN group O
group IN as O
as VBN compared O
compared TO to O
to CD 25 O
25 CC and O
and CD 29 O
29 NN % O
% IN in O
in DT the O
the `` `` O
`` RB late O
late '' '' O
'' NN group O
group NN ( O
( NN p O
p CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0.05 O
0.05 NN ) O

No DT CAPITAL No O
No JJ significant O
significant NNS differences O
differences VBD were O
were VBN found O
found IN between O
between DT the O
the CD two O
two NNS groups O
groups IN in O
in DT the O
the NN mode O
mode IN of O
of NN delivery O
delivery CC or O
or NNP CAPITAL Apgar O
Apgar NNS scores O

We PRP CAPITAL We O
We VBP conclude O
conclude IN that O
that TO to O
to VB reduce O
reduce DT the O
the NN rate O
rate IN of O
of JJ macrosomic D
macrosomic NNS infants D
infants IN in D
in JJ gestational D
gestational NN diabetes D
diabetes NNS cases D
cases , , O
, JJ good T
good JJ glycemic T
glycemic JJ control T
control MD should O
should VB be O
be VBN initiated O
initiated IN before O
before CD 34 O
34 VBN completed O
completed JJ gestational O
gestational NNS weeks O

Our PRP$ CAPITAL Our O
Our NN aim O
aim VBD was O
was TO to O
to VB investigate O
investigate DT the O
the NN contribution O
contribution IN of O
of JJ certain O
certain RB antenatally O
antenatally JJ detectable O
detectable NNS markers O
markers VBG leading O
leading TO to O
to DT the O
the NN diagnosis O
diagnosis IN of O
of JJ trisomic O
trisomic NNS fetuses O
fetuses PRP we O
we VBN observed O
observed IN over O
over DT a O
a NN period O
period IN of O
of CD 6 O
6 NNS years O

In IN CAPITAL In O
In PRP$ our O
our NN study O
study , , O
, PRP we O
we RB specifically O
specifically VBN analyzed O
analyzed DT the O
the NN role O
role VBN played O
played IN by O
by JJ advanced O
advanced JJ maternal O
maternal NN age O
age CC and O
and RB sonographically O
sonographically VBN discovered O
discovered NNS abnormalities O
abnormalities IN in O
in DT the O
the NN detection O
detection IN of O
of JJ autosomal D
autosomal NNS trisomies D

All DT CAPITAL All O
All RB together O
together , , O
, CD 27 O
27 NNS fetuses O
fetuses VBD had O
had DT this O
this NN disorder O
disorder , , O
, VBG representing O
representing CD 28.7 O
28.7 NN % O
% NN ( O
( CD 27 O
27 IN of O
of CD 94 O
94 NN ) O
) IN of O
of DT all O
all JJ cytogenetic D
cytogenetic NNS aberrations D
aberrations VBN detected O
detected IN at O
at PRP$ our O
our NN center O
center IN over O
over DT the O
the JJ same O
same NN period O

Down NN CAPITAL Down D
Down NN syndrome D
syndrome NN ( O
( CD 12 O
12 NNS cases O
cases NN ) O
) CC and O
and NNP CAPITAL Edward D
Edward NN syndrome D
syndrome NN ( O
( CD 11 O
11 NNS cases O
cases NN ) O
) VBD were O
were DT the O
the JJS most O
most JJ common O
common NNS trisomies D
trisomies , , O
, IN while O
while CD 4 O
4 NNS cases O
cases IN of O
of NN CAPITAL Patau D
Patau NN syndrome D
syndrome VBD were O
were RB also O
also VBN diagnosed O

The DT CAPITAL The O
The JJS most O
most JJ common O
common NN indication O
indication VBG leading O
leading TO to O
to NN diagnosis O
diagnosis VBD was O
was JJ abnormal O
abnormal NN ultrasound O
ultrasound VBG finding O
finding NN ( O
( CD 48.2 O
48.2 NN % O
% NN ) O
) , , O
, VBN followed O
followed IN by O
by JJ advanced O
advanced JJ maternal O
maternal NN age O
age NN ( O
( CD 44.4 O
44.4 NN % O
% NN ) O

However RB CAPITAL However O
However , , O
, CD 63 O
63 NN % O
% IN of O
of DT the O
the JJ trisomic O
trisomic NNS fetuses O
fetuses VBD belonged O
belonged TO to O
to NNS mothers O
mothers JJ aged O
aged CD 35 O
35 NNS years O
years CC and O
and IN above O

Down NN CAPITAL Down D
Down NN syndrome D
syndrome NNS fetuses O
fetuses NN ( O
( CD 41.7 O
41.7 NN % O
% NN ) O
) VBD had O
had RB prenatally O
prenatally VBN detected O
detected JJ sonographic O
sonographic NNS anomalies O
anomalies , , O
, CD 63.6 O
63.6 NN % O
% IN for O
for NNP CAPITAL Edward D
Edward NN syndrome D
syndrome , , O
, CC and O
and DT all O
all NNS fetuses O
fetuses IN with O
with NN CAPITAL Patau D
Patau NN syndrome D
syndrome NN ( O
( CD 4 O
4 IN of O
of CD 4 O
4 NN ) O
) VBD showed O
showed JJ abnormal O
abnormal JJ sonographic O
sonographic NNS signs O

Trisomy NN CAPITAL Trisomy D
Trisomy CD 21 D
21 VBN presented O
presented IN with O
with DT the O
the VBG following O
following NNS features O
features : : O
: NNS hydramnios O
hydramnios , , O
, JJ complex O
complex NNS malformations O
malformations , , O
, NN pyelectasis D
pyelectasis , , O
, CC and O
and JJ duodenal D
duodenal NN atresia D

Trisomy NN CAPITAL Trisomy D
Trisomy CD 18 D
18 NNS fetuses O
fetuses VBD showed O
showed NNS hydramnios O
hydramnios , , O
, JJ intrauterine O
intrauterine NN growth O
growth NN retardation O
retardation , , O
, NN microcephaly D
microcephaly , , O
, NN spina D
spina NN bifida D
bifida , , O
, CC and O
and JJ nonimmune D
nonimmune NN hydrops D
hydrops NN fetalis D

Signs NNS CAPITAL Signs O
Signs VBN observed O
observed IN in O
in NNS fetuses O
fetuses IN with O
with NN trisomy D
trisomy CD 13 D
13 VBD were O
were : : O
: NN hydrocephalus O
hydrocephalus , , O
, JJ intrauterine O
intrauterine NN growth O
growth NN retardation O
retardation , , O
, NNS oligoanhydramnios O
oligoanhydramnios , , O
, JJ complex O
complex NNS malformations O
malformations , , O
, JJ severe O
severe JJ fetal O
fetal NN bradycardia D
bradycardia CC and O
and NN hydronephrosis D

The DT CAPITAL The O
The JJ objective O
objective IN of O
of DT this O
this NN study O
study VBD was O
was TO to O
to VB determine O
determine IN if O
if DT the O
the NN rate O
rate IN of O
of NN preeclampsia D
preeclampsia VBZ is O
is VBN increased O
increased IN in O
in NN triplet O
triplet IN as O
as VBN compared O
compared TO to O
to JJ twin O
twin NNS gestations O

Fifty-three CD CAPITAL Fifty-three O
Fifty-three NN triplet O
triplet NNS pregnancies O
pregnancies IN between O
between CD 1986 O
1986 CC and O
and CD 1993 O
1993 IN at O
at DT CAPITAL The O
The NNP CAPITAL New O
New NNP CAPITAL York O
York NNP CAPITAL Hospital-Cornell O
Hospital-Cornell JJ CAPITAL Medical O
Medical NNP CAPITAL Center O
Center VBD were O
were VBN reviewed O

These DT CAPITAL These O
These VBD were O
were VBN matched O
matched IN for O
for JJ maternal O
maternal NN age O
age , , O
, NN parity O
parity , , O
, CC and O
and NN race O
race TO to O
to JJ twin O
twin NNS gestations O
gestations NN ( O
( NN CAPITAL N O
N JJ = O
= CD 53 O
53 NN ) O
) IN from O
from DT the O
the JJ same O
same NN population O

Severe JJ CAPITAL Severe O
Severe NN preeclampsia D
preeclampsia VBD was O
was VBN defined O
defined IN by O
by JJ standard O
standard NNS criteria O

Student NN CAPITAL Student O
Student POS 's O
's NN t-test O
t-test , , O
, NNP CAPITAL Fisher O
Fisher JJ exact O
exact NN test O
test , , O
, CC and O
and JJ CAPITAL Chi-square O
Chi-square VBD were O
were VBN used O
used IN for O
for JJ statistical O
statistical NN analysis O

The DT CAPITAL The O
The NN rate O
rate IN of O
of JJ severe O
severe NN preeclampsia D
preeclampsia VBD was O
was VBN increased O
increased RB significantly O
significantly IN in O
in DT the O
the NN triplet O
triplet NN group O
group CD 12 O
12 IN of O
of CD 53 O
53 NN ( O
( CD 22.6 O
22.6 NN % O
% NN ) O
) IN as O
as VBN compared O
compared IN with O
with DT the O
the JJ twin O
twin NN group O
group CD 3 O
3 IN of O
of CD 53 O
53 NN ( O
( CD 5.7 O
5.7 NN % O
% NN ) O
) NN ( O
( NN CAPITAL OR O
OR JJ = O
= CD 4.9 O
4.9 , , O
, CD 95 O
95 NN % O
% NN CAPITAL CI O
CI CD 1.2-23.5 O
1.2-23.5 , , O
, NN p O
p JJ = O
= CD 0.02 O
0.02 NN ) O

The DT CAPITAL The O
The NN rate O
rate IN of O
of JJ overall O
overall NN preeclampsia D
preeclampsia VBD was O
was RB not O
not RB significantly O
significantly JJ different O
different IN in O
in DT the O
the NN triplet O
triplet CD 18 O
18 IN of O
of CD 53 O
53 NN ( O
( CD 33.96 O
33.96 NN % O
% NN ) O
) CC or O
or JJ twin O
twin CD 12 O
12 IN of O
of CD 53 O
53 NN ( O
( CD 22.6 O
22.6 NN % O
% NN ) O
) NNS groups O

In IN CAPITAL In O
In DT this O
this JJ retrospective O
retrospective , , O
, JJ case-controlled O
case-controlled NN study O
study , , O
, DT the O
the NN rate O
rate IN of O
of JJ severe O
severe NN pre-eclampsia D
pre-eclampsia VBD was O
was RB significantly O
significantly VBN increased O
increased IN in O
in NN triplet O
triplet NNS gestations O
gestations IN as O
as VBN compared O
compared TO to O
to NNS twins O
twins IN although O
although DT the O
the JJ overall O
overall NN rate O
rate IN of O
of NN preeclampsia D
preeclampsia VBD was O
was RB not O

This DT CAPITAL This O
This NN information O
information MD may O
may VB be O
be JJ useful O
useful IN in O
in VBG counseling O
counseling NNS patients O
patients IN with O
with JJ high O
high NN order O
order JJ multifetal O
multifetal NNS gestations O

We PRP CAPITAL We O
We VBN conducted O
conducted DT a O
a NN survey O
survey CC and O
and NN audit O
audit IN of O
of JJ thermal O
thermal NN equipment O
equipment NN use O
use IN in O
in RB very O
very JJ low-birth-weight O
low-birth-weight NNS infants O
infants IN in O
in CD five O
five NNP CAPITAL Ohio O
Ohio JJ neonatal O
neonatal JJ intensive O
intensive NN care O
care NNS units O
units NN ( O
( NNS CAPITAL NICUs O
NICUs NN ) O
) TO to O
to NN document O
document JJ regional O
regional NN practice O

The DT CAPITAL The O
The NN survey O
survey VBD indicated O
indicated DT a O
a NN variety O
variety IN of O
of JJ thermal O
thermal NN care O
care NNS styles O

Two CD CAPITAL Two O
Two NNS CAPITAL NICUs O
NICUs VBN preferred O
preferred TO to O
to VB admit O
admit NNS infants O
infants TO to O
to NNS incubators O
incubators , , O
, DT the O
the JJ other O
other CD three O
three VBG favoring O
favoring JJ radiant O
radiant NNS warmers O

These DT CAPITAL These O
These CD three O
three NNS CAPITAL NICUs O
NICUs VBN moved O
moved NNS infants O
infants IN from O
from JJ radiant O
radiant NNS warmers O
warmers IN into O
into NNS incubators O
incubators IN at O
at RB significantly O
significantly JJ different O
different VB mean O
mean NNS ages O

The DT CAPITAL The O
The NN audit O
audit VBD demonstrated O
demonstrated JJ inconsistent O
inconsistent NN use O
use IN of O
of JJ plastic O
plastic NNS covers O
covers , , O
, VBG warming O
warming NNS mattresses O
mattresses , , O
, CC and O
and VBN added O
added NN humidity O
humidity IN under O
under JJ radiant O
radiant NNS warmers O
warmers , , O
, CC and O
and NNS discrepancies O
discrepancies IN between O
between NN survey O
survey NNS responses O
responses CC and O
and JJ actual O
actual NN use O
use IN within O
within NNS CAPITAL NICUs O

Inter-NICU JJ CAPITAL Inter-NICU O
Inter-NICU NN variability O
variability IN of O
of JJ thermal O
thermal NN equipment O
equipment NN use O
use MD may O
may VB complicate O
complicate NN fluid O
fluid NN management O

This DT CAPITAL This O
This NN report O
report VBZ describes O
describes DT a O
a JJ full-term O
full-term JJ newborn O
newborn IN with O
with JJ massive D
massive JJ fetomaternal D
fetomaternal NN hemorrhage D

Fetal JJ CAPITAL Fetal O
Fetal NNS movements O
movements VBD were O
were VBN decreased O
decreased CD 48 O
48 NN hr O
hr RB prior O
prior TO to O
to NN delivery O

On IN CAPITAL On O
On DT the O
the NN day O
day IN of O
of NN delivery O
delivery , , O
, PRP they O
they VBD were O
were JJ absent O

The DT CAPITAL The O
The JJ nonstress O
nonstress NN test O
test VBD was O
was JJ abnormal O
abnormal IN with O
with JJ low O
low JJ biophysical O
biophysical NN profile O
profile CC and O
and VBN decreased O
decreased NN beat-to-beat O
beat-to-beat NN variability O

The DT CAPITAL The O
The NN infant O
infant VBN presented O
presented IN with O
with JJ extreme O
extreme NN pallor O
pallor , , O
, NN hypotonia D
hypotonia , , O
, RB hepatosplenomegaly D
hepatosplenomegaly , , O
, CC and O
and NNS ascites D

The DT CAPITAL The O
The JJ initial O
initial NN hemoglobin O
hemoglobin VBD was O
was CD 2.2 O
2.2 NN g/dL O
g/dL , , O
, DT the O
the JJ CAPITAL Kleihauer-Betke O
Kleihauer-Betke VB stain O
stain VBD was O
was CD 27.6 O
27.6 NN % O
% NN ( O
( JJS highest O
highest NN level O
level RB ever O
ever VBN reported O
reported NN ) O

Right RB CAPITAL Right O
Right JJ temporal O
temporal CC and O
and NN cerebellar O
cerebellar NNS hemorrhages O
hemorrhages VBD were O
were JJ present O

Sequelae FW CAPITAL Sequelae O
Sequelae VBP include O
include JJ severe O
severe JJ developmental O
developmental NN delay O
delay CC and O
and JJ asymmetric O
asymmetric JJ double O
double NN hemiplegia D

Omphalocele-Exstrophy-Imperforate JJ CAPITAL Omphalocele-Exstrophy-Imperforate D
Omphalocele-Exstrophy-Imperforate JJ anus-Spinal D
anus-Spinal NNS defects D
defects NN ( D
( NN CAPITAL OEIS D
OEIS NN complex D
complex NN ) D
) , , O
, DT a O
a NN combination O
combination IN of O
of NN omphalocele D
omphalocele , , O
, NN exstrophy D
exstrophy IN of D
of DT the D
the NN bladder D
bladder , , O
, DT an O
an JJ imperforate O
imperforate NN anus O
anus CC and O
and JJ spinal D
spinal NNS defects D
defects , , O
, VBZ arises O
arises IN from O
from DT a O
a JJ single O
single JJ localized O
localized NN defect O
defect IN in O
in DT the O
the RB early O
early NN development O
development IN of O
of DT the O
the NN mesoderm O
mesoderm IN that O
that MD will O
will RB later O
later VB contribute O
contribute TO to O
to JJ infraumbilical O
infraumbilical NN mesenchyme O
mesenchyme , , O
, JJ cloacal O
cloacal NN septum O
septum , , O
, CC and O
and JJ caudal O
caudal NNS vertebrae O

In IN CAPITAL In O
In DT this O
this NN report O
report , , O
, PRP we O
we NN document O
document DT the O
the JJ perinatal O
perinatal NNS features O
features IN of O
of CD two O
two NNS cases O
cases IN of O
of NN CAPITAL OEIS D
OEIS NN complex D
complex VBN associated O
associated IN with O
with NNS meningomyeloceles D
meningomyeloceles CC and O
and JJ severe O
severe JJR lower O
lower NN limb O
limb NNS defects O
defects , , O
, CC and O
and VB discuss O
discuss DT the O
the JJ prenatal O
prenatal NN diagnosis O
diagnosis , , O
, NN inheritance O
inheritance , , O
, CC and O
and JJ differential O
differential NN diagnosis O
diagnosis IN of O
of DT this O
this NN association O
association IN of O
of NNS malformations O

Although IN CAPITAL Although O
Although JJ long-term O
long-term NN survival O
survival MD can O
can VB be O
be VBN achieved O
achieved IN by O
by JJ successful O
successful JJ corrective T
corrective NN surgery T
surgery , , O
, DT the O
the VBN associated O
associated JJ structural O
structural NNS defects O
defects JJ such O
such IN as O
as JJ large D
large NN meningomyelocele D
meningomyelocele CC and O
and JJ severe O
severe NN limb D
limb NN aplasia D
aplasia CC or O
or NN hypoplasia D
hypoplasia , , O
, IN as O
as VBN seen O
seen IN in O
in PRP$ our O
our NN patient O
patient , , O
, MD can O
can NN influence O
influence DT the O
the NN patient O
patient POS 's O
's NN quality O
quality IN of O
of NN life O
life . . O

We PRP CAPITAL We O
We MD would O
would IN like O
like TO to O
to VB emphasize O
emphasize IN that O
that DT an O
an JJ accurate O
accurate JJ prenatal O
prenatal NN diagnosis O
diagnosis IN of O
of NN CAPITAL OEIS D
OEIS NN complex D
complex CC and O
and VBN associated O
associated NNS malformations O
malformations VBZ is O
is JJ important O
important IN for O
for DT the O
the JJ detailed O
detailed VBG counseling O
counseling IN of O
of DT the O
the NN family O
family IN as O
as RB well O
well IN as O
as JJ appropriate O
appropriate JJ perinatal O
perinatal NN management O
management IN by O
by DT the O
the NNS obstetricians O
obstetricians , , O
, JJ pediatric O
pediatric NNS surgeons O
surgeons , , O
, NNS urologists O
urologists , , O
, NNS neurosurgeons O
neurosurgeons , , O
, CC and O
and NNS neonatologists O

Nonimmune JJ CAPITAL Nonimmune D
Nonimmune NN hydrops D
hydrops NNS fetails D
fetails VBN diagnosed O
diagnosed IN at O
at CD 21 O
21 NNS weeks O
weeks POS ' O
' JJ gestation O
gestation IN with O
with JJ profound O
profound NNS ascites D
ascites , , O
, NN hydrothorax D
hydrothorax , , O
, CC and O
and JJ pericardial D
pericardial NN effusion D
effusion VBD receded O
receded RB gradually O
gradually IN with O
with NN regression O
regression IN of O
of DT a O
a JJ subchorial O
subchorial JJ placental O
placental NNS lucencies O
lucencies RB immediately O
immediately IN below O
below DT the O
the JJ umbilical O
umbilical NN cord O
cord NN insertion O

Careful JJ CAPITAL Careful O
Careful NN inspection O
inspection IN of O
of DT the O
the VBN delivered O
delivered NN placenta O
placenta VBD revealed O
revealed IN that O
that RB there O
there VBD was O
was DT a O
a JJ yellowish O
yellowish NN lesion O
lesion IN of O
of JJ fibrin O
fibrin NNS deposits O
deposits IN below O
below DT the O
the NN cord O
cord NN insertion O
insertion NN site O
site , , O
, WDT which O
which VBD resulted O
resulted IN from O
from DT the O
the NN absorption O
absorption IN of O
of NN hematoma O

A DT CAPITAL A O
A JJ subchorial O
subchorial JJ placental O
placental NN hematoma D
hematoma , , O
, WDT which O
which VBN detected O
detected IN as O
as DT a O
a JJ subchorial O
subchorial JJ placental O
placental NNS lucencies D
lucencies IN by O
by NN ultrasonography O
ultrasonography , , O
, MD can O
can VB be O
be DT a O
a NN cause O
cause IN of O
of JJ reversible O
reversible JJ nonimmune D
nonimmune NN hydrops D
hydrops NN fetalis D

The DT CAPITAL The O
The JJ mitochondrial D
mitochondrial NNS diseases D
diseases VBP are O
are JJ uncommon O
uncommon NN multisystem O
multisystem NNS disorders O
disorders VBN characterized O
characterized IN by O
by DT the O
the NN presence O
presence IN of O
of RB functionally O
functionally CC and/or O
and/or RB structurally O
structurally JJ abnormal O
abnormal NN mitochondria O

As IN CAPITAL As O
As RB there O
there VB have O
have VBN been O
been JJ few O
few NNS reports O
reports IN of O
of DT the O
the JJ obstetrical O
obstetrical NN care O
care IN of O
of VBN affected O
affected NNS patients O
patients , , O
, PRP we O
we NN wish O
wish TO to O
to NN document O
document CD two O
two NNS pregnancies O
pregnancies IN in O
in DT a O
a NN woman O
woman IN with O
with DT a O
a JJ CAPITAL Chronic D
Chronic JJ CAPITAL Progressive D
Progressive JJ CAPITAL External D
External NN CAPITAL Ophthalmoplegia D
Ophthalmoplegia NN ( D
( JJ CAPITAL Kearns-Sayre-like D
Kearns-Sayre-like NN syndrome D
syndrome NN ) D

Both DT CAPITAL Both O
Both NNS pregnancies O
pregnancies VBD were O
were JJ complicated O
complicated IN by O
by NN preterm O
preterm NN labor O
labor CC and O
and NN hypertension D

CONTEXT NN CAPITAL CONTEXT O
CONTEXT : : O
: CD CAPITAL Four O
Four JJ genetic O
genetic NNS loci O
loci VB have O
have VBN been O
been VBN identified O
identified IN as O
as VBG contributing O
contributing TO to O
to NN CAPITAL Alzheimer D
Alzheimer NN disease D
disease NN ( D
( NN CAPITAL AD D
AD NN ) D
) , , O
, VBG including O
including DT the O
the NN amyloid O
amyloid NN precursor O
precursor NN protein O
protein NN gene O
gene , , O
, DT the O
the NN presenilin O
presenilin CD 1 O
1 NN gene O
gene , , O
, DT the O
the NN presenilin O
presenilin CD 2 O
2 NN gene O
gene , , O
, CC and O
and DT the O
the NN apolipoprotein O
apolipoprotein NN CAPITAL E O
E NN gene O
gene , , O
, CC but O
but VB do O
do RB not O
not NN account O
account IN for O
for DT all O
all DT the O
the JJ genetic O
genetic NN risk O
risk IN for O
for NN CAPITAL AD O

OBJECTIVE NN CAPITAL OBJECTIVE O
OBJECTIVE : : O
: TO CAPITAL To O
To VB identify O
identify JJ additional O
additional JJ genetic O
genetic NN risk O
risk NNS factors O
factors IN for O
for JJ late-onset O
late-onset NN CAPITAL AD O

DESIGN NN CAPITAL DESIGN O
DESIGN : : O
: DT CAPITAL A O
A JJ complete O
complete JJ genomic O
genomic NN screen O
screen VBD was O
was VBN performed O
performed NN ( O
( NN CAPITAL N=280 O
N=280 NNS markers O
markers NN ) O

Critical JJ CAPITAL Critical O
Critical NNS values O
values IN for O
for JJ chromosomal O
chromosomal JJ regional O
regional JJ follow-up O
follow-up VBD were O
were DT a O
a NN CAPITAL P O
P NN value O
value IN of O
of CD .05 O
.05 CC or O
or JJR less O
less IN for O
for VBN affected O
affected JJ relative O
relative NN pair O
pair NN analysis O
analysis CC or O
or NN sibpair O
sibpair NN analysis O
analysis , , O
, DT a O
a JJ parametric O
parametric NN lod O
lod NN score O
score IN of O
of CD 1.0 O
1.0 CC or O
or JJR greater O
greater , , O
, CC or O
or DT both O

Regional NNP CAPITAL Regional O
Regional JJ follow-up O
follow-up VBN included O
included NN analysis O
analysis IN of O
of JJ additional O
additional NNS markers O
markers CC and O
and DT a O
a JJ second O
second NNS data O
data VBN set O

SETTING VBG CAPITAL SETTING O
SETTING : : O
: NNP CAPITAL Clinic O
Clinic NNS populations O
populations IN in O
in DT the O
the JJ continental O
continental NNP CAPITAL United O
United NNPS CAPITAL States O

PATIENTS NNS CAPITAL PATIENTS O
PATIENTS : : O
: JJR > O
> IN CAPITAL From O
From DT a O
a NN series O
series IN of O
of JJ multiplex O
multiplex NNS families O
families VBN affected O
affected IN with O
with JJ late-onset O
late-onset NN ( O
( JJR > O
> CC or O
or CD =60 O
=60 NNS years O
years NN ) O
) NN CAPITAL AD O
AD VBN ascertained O
ascertained IN during O
during DT the O
the JJ last O
last CD 14 O
14 NNS years O
years NN ( O
( NNP CAPITAL National O
National JJ CAPITAL Insititute O
Insititute IN of O
of JJ CAPITAL Neurological O
Neurological NNS CAPITAL Disorders O
Disorders CC and O
and NNP CAPITAL Stroke-Alzheimer O
Stroke-Alzheimer POS 's O
's NN CAPITAL Disease O
Disease CC and O
and JJ CAPITAL Related O
Related NNS CAPITAL Disorders O
Disorders NNP CAPITAL Association O
Association JJ diagnostic O
diagnostic NNS criteria O
criteria NN ) O
) CC and O
and IN for O
for WDT which O
which NN CAPITAL DNA O
DNA VBZ has O
has VBN been O
been VBN obtained O
obtained , , O
, DT a O
a NN subset O
subset IN of O
of CD 16 O
16 NNS families O
families NN ( O
( CD 135 O
135 JJ total O
total NN family O
family NNS members O
members , , O
, CD 52 O
52 IN of O
of WP whom O
whom VBD were O
were NNS patients O
patients IN with O
with NN CAPITAL AD O
AD NN ) O
) VBD was O
was VBN used O
used IN for O
for DT the O
the JJ genomic O
genomic NN screen O

A DT CAPITAL A O
A JJ second O
second NN subset O
subset IN of O
of CD 38 O
38 NNS families O
families NN ( O
( CD 216 O
216 JJ total O
total NN family O
family NNS members O
members , , O
, CD 89 O
89 IN of O
of WP whom O
whom VBD were O
were NNS patients O
patients IN with O
with NN CAPITAL AD O
AD NN ) O
) VBD was O
was VBN used O
used IN for O
for DT the O
the JJ follow-up O
follow-up NN analysis O

MAIN JJS CAPITAL MAIN O
MAIN NN CAPITAL OUTCOME O
OUTCOME NNS CAPITAL MEASURES O
MEASURES : : O
: NN CAPITAL Linkage O
Linkage NN analysis O
analysis NNS results O
results VBN generated O
generated VBG using O
using DT both O
both JJ genetic O
genetic JJ model-dependent O
model-dependent NN ( O
( NN lod O
lod NN score O
score NN ) O
) CC and O
and JJ model-independent O
model-independent NNS methods O

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: CD CAPITAL Fifteen O
Fifteen JJ chromosomal O
chromosomal NNS regions O
regions VBN warranted O
warranted JJ initial O
initial JJ follow-up O

Follow-up JJ CAPITAL Follow-up O
Follow-up NNS analyses O
analyses VBD revealed O
revealed CD 4 O
4 NNS regions O
regions IN of O
of VBN continued O
continued NN interest O
interest IN on O
on NNS chromosomes O
chromosomes CD 4 O
4 , , O
, CD 6 O
6 , , O
, CD 12 O
12 , , O
, CC and O
and CD 20 O
20 , , O
, IN with O
with DT the O
the JJS strongest O
strongest NNS results O
results VBN observed O
observed NN forchromosome O
forchromosome CD 12 O

Peak JJ CAPITAL Peak O
Peak JJ 2-point O
2-point RB affecteds-only O
affecteds-only NN lod O
lod NNS scores O
scores NN ( O
( NN n=54 O
n=54 NN ) O
) VBD were O
were CD 1.3 O
1.3 , , O
, CD 1.6 O
1.6 , , O
, CD 2.7 O
2.7 , , O
, CC and O
and CD 2.2 O
2.2 CC and O
and VBN affected O
affected JJ relative O
relative NNS pairs O
pairs NN CAPITAL P O
P NNS values O
values NN ( O
( NN n=54 O
n=54 NN ) O
) VBD were O
were CD .04 O
.04 , , O
, CD .03 O
.03 , , O
, CD .14 O
.14 , , O
, CC and O
and CD .04 O
.04 IN for O
for NN CAPITAL D12S373 O
D12S373 , , O
, NN CAPITAL D12S1057 O
D12S1057 , , O
, NN CAPITAL D12S1042 O
D12S1042 , , O
, CC and O
and NN CAPITAL D12S390 O
D12S390 , , O
, RB respectively O

Sibpair NNP CAPITAL Sibpair O
Sibpair NN analysis O
analysis NN ( O
( NN n=54 O
n=54 NN ) O
) VBD resulted O
resulted IN in O
in NN maximum O
maximum NN lod O
lod NNS scores O
scores NN ( O
( NNS CAPITAL MLSs O
MLSs NN ) O
) IN of O
of CD 1.5 O
1.5 , , O
, CD 2.6 O
2.6 , , O
, CD 3.2 O
3.2 , , O
, CC and O
and CD 2.3 O
2.3 IN for O
for DT these O
these NNS markers O
markers , , O
, IN with O
with DT a O
a JJ peak O
peak JJ multipoint O
multipoint NN CAPITAL MLS O
MLS IN of O
of CD 3.5 O

A DT CAPITAL A O
A FW priori O
priori NN stratification O
stratification IN by O
by NN CAPITAL APOE O
APOE NN genotype O
genotype VBN identified O
identified CD 27 O
27 NNS families O
families IN that O
that VBD had O
had IN at O
at JJS least O
least CD 1 O
1 NN member O
member IN with O
with NN CAPITAL AD O
AD WP$ whose O
whose NN genotype O
genotype VBD did O
did RB not O
not VB contain O
contain DT an O
an NN CAPITAL APOE*4 O
APOE*4 NN allele O

Analysis NN CAPITAL Analysis O
Analysis IN of O
of DT these O
these CD 27 O
27 NNS families O
families VBD resulted O
resulted IN in O
in NNS CAPITAL MLSs O
MLSs IN of O
of CD 1.0 O
1.0 , , O
, CD 2.4 O
2.4 , , O
, CD 3.7 O
3.7 , , O
, CC and O
and CD 3.3 O
3.3 CC and O
and DT a O
a JJ peak O
peak JJ multipoint O
multipoint NN CAPITAL MLS O
MLS IN of O
of CD 3.9 O

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: DT CAPITAL A O
A JJ complete O
complete JJ genomic O
genomic NN screen O
screen IN in O
in NNS families O
families VBN affected O
affected IN with O
with JJ late-onset O
late-onset NN CAPITAL AD O
AD VBN identified O
identified CD 4 O
4 NNS regions O
regions IN of O
of NN interest O
interest IN after O
after JJ follow-up O

Chromosome NN CAPITAL Chromosome O
Chromosome CD 12 O
12 VBD gave O
gave DT the O
the JJS strongest O
strongest CC and O
and JJS most O
most JJ consistent O
consistent NNS results O
results IN with O
with DT a O
a JJ peak O
peak JJ multipoint O
multipoint NN CAPITAL MLS O
MLS IN of O
of CD 3.5 O
3.5 , , O
, VBG suggesting O
suggesting IN that O
that DT this O
this NN region O
region VBZ contains O
contains DT a O
a JJ new O
new NN susceptibility O
susceptibility NN gene O
gene IN for O
for NN CAPITAL AD O

Additional JJ CAPITAL Additional O
Additional NNS analyses O
analyses VBP are O
are JJ necessary O
necessary TO to O
to VB identify O
identify DT the O
the NN chromosome O
chromosome CD 12 O
12 NN susceptibility O
susceptibility NN gene O
gene IN for O
for NN CAPITAL AD O
AD CC and O
and TO to O
to VB follow O
follow RB up O
up DT the O
the NNS regions O
regions IN of O
of NN interest O
interest IN on O
on NNS chromosomes O
chromosomes CD 4 O
4 , , O
, CD 6 O
6 , , O
, CC and O
and CD 20 O

CONTEXT NN CAPITAL CONTEXT O
CONTEXT : : O
: DT CAPITAL A O
A NN mutation O
mutation IN in O
in DT the O
the NN CAPITAL BRCA1 O
BRCA1 NN gene O
gene MD may O
may VB confer O
confer JJ substantial O
substantial NN risk O
risk IN for O
for NN breast O
breast CC and/or O
and/or JJ ovarian O
ovarian NN cancer D

However RB CAPITAL However O
However , , O
, NN knowledge O
knowledge VBG regarding O
regarding DT all O
all JJ possible O
possible NNS mutations O
mutations CC and O
and DT the O
the NN relationship O
relationship IN between O
between NN risk O
risk NNS factors O
factors CC and O
and NNS mutations O
mutations VBZ is O
is JJ incomplete O

OBJECTIVES NNS CAPITAL OBJECTIVES O
OBJECTIVES : : O
: TO CAPITAL To O
To VB identify O
identify NN CAPITAL BRCA1 O
BRCA1 NNS mutations O
mutations CC and O
and TO to O
to VB determine O
determine NNS factors O
factors IN that O
that RB best O
best VB predict O
predict NN presence O
presence IN of O
of DT a O
a JJ deleterious O
deleterious NN CAPITAL BRCA1 O
BRCA1 NN mutation O
mutation IN in O
in NNS patients O
patients IN with O
with NN breast O
breast CC and/or O
and/or JJ ovarian O
ovarian NN cancer D

DESIGN NN CAPITAL DESIGN O
DESIGN : : O
: DT CAPITAL A O
A JJ complete O
complete NN sequence O
sequence NN analysis O
analysis IN of O
of DT the O
the NN CAPITAL BRCA1 O
BRCA1 VBG coding O
coding NN sequence O
sequence CC and O
and JJ flanking O
flanking JJ intronic O
intronic NNS regions O
regions VBD was O
was VBN performed O
performed IN in O
in CD 798 O
798 NNS women O
women IN in O
in DT a O
a JJ collaborative O
collaborative NN effort O
effort VBG involving O
involving NNS institutions O
institutions IN from O
from DT the O
the NNP CAPITAL United O
United NNPS CAPITAL States O
States , , O
, NNP CAPITAL Italy O
Italy , , O
, NNP CAPITAL Germany O
Germany , , O
, NNP CAPITAL Finland O
Finland , , O
, CC and O
and NNP CAPITAL Switzerland O

PARTICIPANTS NNS CAPITAL PARTICIPANTS O
PARTICIPANTS : : O
: NNS CAPITAL Institutions O
Institutions VBN selected O
selected CD 798 O
798 NNS persons O
persons VBG representing O
representing NNS families O
families NN ( O
( CD 1 O
1 NN person O
person IN for O
for DT each O
each NN family O
family NN ) O
) VBN thought O
thought TO to O
to VB be O
be IN at O
at JJ elevated O
elevated DT a O
a FW priori O
priori NN risk O
risk IN of O
of NN CAPITAL BRCA1 O
BRCA1 NN mutation O
mutation JJ due O
due TO to O
to JJ potential O
potential NN risk O
risk NNS factors O
factors , , O
, JJ such O
such IN as O
as JJ multiple O
multiple NNS cases O
cases IN of O
of NN breast D
breast NN cancer D
cancer , , O
, RB early O
early NN age O
age IN of O
of NN breast D
breast NN cancer D
cancer NN diagnosis O
diagnosis , , O
, CC and O
and NNS cases O
cases IN of O
of JJ ovarian D
ovarian NN cancer D

No DT CAPITAL No O
No NN participant O
participant VBD was O
was IN from O
from DT a O
a NN family O
family IN in O
in WDT which O
which JJ genetic O
genetic NNS markers O
markers VBD showed O
showed NN linkage O
linkage TO to O
to DT the O
the NN CAPITAL BRCA1 O
BRCA1 NN locus O

MAJOR JJ CAPITAL MAJOR O
MAJOR NN CAPITAL OUTCOME O
OUTCOME NNS CAPITAL MEASURES O
MEASURES : : O
: NN CAPITAL Sequence O
Sequence NNS variants O
variants VBN detected O
detected IN in O
in DT this O
this NN sample O
sample VBP are O
are VBN presented O
presented IN along O
along IN with O
with NNS analyses O
analyses VBN designed O
designed TO to O
to VB determine O
determine JJ predictive O
predictive NNS characteristics O
characteristics IN of O
of DT those O
those NN testing O
testing JJ positive O
positive IN for O
for NN CAPITAL BRCA1 O
BRCA1 NNS mutations O

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: IN CAPITAL In O
In CD 102 O
102 NNS women O
women NN ( O
( CD 12.8 O
12.8 NN % O
% NN ) O
) , , O
, RB clearly O
clearly JJ deleterious O
deleterious NNS mutations O
mutations VBD were O
were VBN detected O

Fifty CD CAPITAL Fifty O
Fifty JJ new O
new JJ genetic O
genetic NNS alterations O
alterations VBD were O
were VBN found O
found VBG including O
including CD 24 O
24 JJ deleterious O
deleterious NNS mutations O
mutations , , O
, CD 24 O
24 NNS variants O
variants IN of O
of JJ unknown O
unknown NN significance O
significance , , O
, CC and O
and CD 2 O
2 JJ rare O
rare NNS polymorphisms O

In IN CAPITAL In O
In DT a O
a NN subset O
subset IN of O
of CD 71 O
71 JJ CAPITAL Ashkenazi O
Ashkenazi JJ CAPITAL Jewish O
Jewish NNS women O
women , , O
, RB only O
only CD 2 O
2 JJ distinct O
distinct JJ deleterious O
deleterious NNS mutations O
mutations VBD were O
were VBN found O
found : : O
: NN 185delAG O
185delAG IN in O
in CD 17 O
17 NNS cases O
cases CC and O
and NN 5382insC O
5382insC IN in O
in CD 7 O
7 NNS cases O

A DT CAPITAL A O
A NN bias O
bias IN in O
in RB prior O
prior NNS reports O
reports IN for O
for NNS mutations O
mutations IN in O
in NN exon O
exon CD 11 O
11 VBD was O
was VBD revealed O

Characteristics NNS CAPITAL Characteristics O
Characteristics IN of O
of DT a O
a NN patient O
patient POS 's O
's JJ specific O
specific NN diagnosis O
diagnosis NN ( O
( JJ unilateral O
unilateral CC or O
or JJ bilateral O
bilateral NN breast D
breast NN cancer D
cancer , , O
, IN with O
with CC or O
or IN without O
without JJ ovarian D
ovarian NN cancer D
cancer NN ) O
) , , O
, RB early O
early NN age O
age IN at O
at NN diagnosis O
diagnosis , , O
, JJ CAPITAL Ashkenazi O
Ashkenazi JJ CAPITAL Jewish O
Jewish NN ethnicity O
ethnicity , , O
, CC and O
and NN family O
family NN history O
history IN of O
of NN cancer O
cancer VBD were O
were RB positively O
positively VBN associated O
associated IN with O
with DT the O
the NN probability O
probability IN of O
of PRP$ her O
her VBG carrying O
carrying DT a O
a JJ deleterious O
deleterious NN CAPITAL BRCA1 O
BRCA1 NN mutation O

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: VBG CAPITAL Using O
Using JJ logistic O
logistic NN regression O
regression NN analysis O
analysis , , O
, PRP we O
we VB provide O
provide DT a O
a NN method O
method IN for O
for VBG evaluating O
evaluating DT the O
the NN probability O
probability IN of O
of DT a O
a NN woman O
woman POS 's O
's VBG carrying O
carrying DT a O
a JJ deleterious O
deleterious NN CAPITAL BRCA1 O
BRCA1 NN mutation O
mutation IN for O
for DT a O
a JJ wide O
wide NN range O
range IN of O
of NNS cases O
cases , , O
, WDT which O
which MD can O
can VB be O
be DT an O
an JJ important O
important NN tool O
tool IN for O
for NNS clinicians O
clinicians IN as O
as PRP they O
they VB incorporate O
incorporate JJ genetic O
genetic NN susceptibility O
susceptibility NN testing O
testing IN into O
into PRP$ their O
their JJ medical O
medical NN practice O

CONTEXT NN CAPITAL CONTEXT O
CONTEXT : : O
: RB CAPITAL Approximately O
Approximately CD 9 O
9 NN % O
% IN of O
of NN prostate D
prostate NN cancer D
cancer NNS cases O
cases VB have O
have VBN been O
been VBN estimated O
estimated TO to O
to NN result O
result IN from O
from NN inheritance O
inheritance IN of O
of VBN mutated O
mutated NN prostate O
prostate NN cancer O
cancer NN susceptibility O
susceptibility NNS genes O

Few JJ CAPITAL Few O
Few NNS data O
data VB exist O
exist IN as O
as TO to O
to IN whether O
whether RB there O
there VBP are O
are JJ clinical O
clinical NNS differences O
differences IN between O
between NN prostate D
prostate NNS cancers D
cancers IN that O
that VBP are O
are VBN inherited O
inherited CC and O
and DT those O
those IN that O
that VB occur O
occur IN in O
in DT the O
the JJ general O
general NN population O

OBJECTIVE NN CAPITAL OBJECTIVE O
OBJECTIVE : : O
: TO CAPITAL To O
To VB investigate O
investigate JJ phenotypic O
phenotypic NNS characteristics O
characteristics IN of O
of NNS families O
families RB potentially O
potentially VBN linked O
linked TO to O
to DT the O
the JJ hereditary O
hereditary NN prostate O
prostate NN cancer O
cancer CD 1 O
1 NN ( O
( NN CAPITAL HPC1 O
HPC1 NN ) O
) NN locus O
locus IN on O
on NN chromosome O
chromosome CD 1q24-25 O

DESIGN NN CAPITAL DESIGN O
DESIGN : : O
: JJ CAPITAL Retrospective O
Retrospective NN case O
case NN study O
study IN in O
in WDT which O
which JJ clinical O
clinical NNS data O
data VBD were O
were VBN extracted O
extracted IN from O
from JJ medical O
medical CC and O
and JJ pathological O
pathological NNS records O

FAMILIES NNS CAPITAL FAMILIES O
FAMILIES : : O
: DT CAPITAL A O
A JJ total O
total IN of O
of CD 74 O
74 NNP CAPITAL North O
North JJ CAPITAL American O
American NNS families O
families IN with O
with JJ hereditary O
hereditary NN prostate D
prostate NN cancer D

Prostate NN CAPITAL Prostate O
Prostate NN cancer O
cancer NNS cases O
cases IN from O
from DT the O
the NNP CAPITAL National O
National NN CAPITAL Cancer O
Cancer NNS CAPITAL Data O
Data NNP CAPITAL Base O
Base VBD were O
were VBN used O
used IN as O
as DT a O
a NN reference O
reference NN population O
population IN for O
for NN comparison O

MAIN JJS CAPITAL MAIN O
MAIN NN CAPITAL OUTCOME O
OUTCOME NNS CAPITAL MEASURES O
MEASURES : : O
: DT CAPITAL The O
The NNS families O
families VBD were O
were VBN divided O
divided IN into O
into CD 2 O
2 NNS groups O
groups : : O
: DT either O
either RB potentially O
potentially VBN linked O
linked NN ( O
( CD 33 O
33 NNS families O
families IN with O
with CD 133 O
133 NNS men O
men IN with O
with NN prostate D
prostate NN cancer D
cancer NN ) O
) , , O
, CC and O
and RB thus O
thus JJ likely O
likely TO to O
to VB be O
be VBG carrying O
carrying DT an O
an JJ altered O
altered NN CAPITAL HPC1 O
HPC1 NN gene O
gene , , O
, CC or O
or RB potentially O
potentially JJ unlinked O
unlinked NN ( O
( CD 41 O
41 NNS families O
families IN with O
with CD 172 O
172 NNS men O
men IN with O
with NN prostate D
prostate NN cancer D
cancer NN ) O
) , , O
, IN on O
on DT the O
the NN basis O
basis IN of O
of NN haplotype O
haplotype NN analysis O
analysis IN in O
in DT the O
the NN region O
region IN of O
of NN CAPITAL HPC1 O

The DT CAPITAL The O
The NN age O
age IN at O
at NN diagnosis O
diagnosis IN of O
of NN prostate D
prostate NN cancer D
cancer , , O
, NN serum O
serum JJ prostate-specific O
prostate-specific NN antigen O
antigen NNS levels O
levels , , O
, JJ digital O
digital JJ rectal O
rectal NN examination O
examination NN status O
status , , O
, NN stage O
stage , , O
, NN grade O
grade , , O
, JJ primary O
primary NN treatment O
treatment IN of O
of NN prostate D
prostate NNS cancers D
cancers , , O
, CC and O
and NN occurrence O
occurrence IN of O
of JJ other O
other NNS cancers D
cancers VBD were O
were VBN compared O
compared IN between O
between DT the O
the NNS groups O

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: DT CAPITAL The O
The VB mean O
mean NN age O
age IN at O
at NN diagnosis O
diagnosis IN of O
of NN prostate D
prostate NN cancer D
cancer IN for O
for NNS men O
men IN in O
in RB potentially O
potentially VBN linked O
linked NNS families O
families VBD was O
was RB significantly O
significantly JJR lower O
lower IN than O
than IN for O
for NNS men O
men IN in O
in RB potentially O
potentially JJ unlinked O
unlinked NNS families O
families NN ( O
( CD 63.7 O
63.7 CC vs O
vs CD 65.9 O
65.9 NNS years O
years , , O
, RB respectively O
respectively , , O
, NN CAPITAL P=.01 O
P=.01 : ; O
; VB mean O
mean NN age O
age IN at O
at NN diagnosis O
diagnosis IN in O
in DT the O
the NN reference O
reference NN population O
population VBD was O
was CD 71.6 O
71.6 NNS years O
years NN ) O

Higher-grade JJ CAPITAL Higher-grade O
Higher-grade NNS cancers D
cancers NN ( O
( NN grade O
grade CD 3 O
3 NN ) O
) VBD were O
were RBR more O
more JJ common O
common IN in O
in RB potentially O
potentially VBN linked O
linked NNS families O
families , , O
, CC and O
and JJ advanced-stage O
advanced-stage NN disease O
disease VBD was O
was VBN found O
found IN in O
in CD 41 O
41 NN % O
% IN of O
of DT the O
the NN case O
case NNS patients O
patients IN in O
in RB potentially O
potentially VBN linked O
linked NNS families O
families VBN compared O
compared IN with O
with CD 31 O
31 NN % O
% IN in O
in DT both O
both DT the O
the RB potentially O
potentially JJ unlinked O
unlinked NNS families O
families CC and O
and DT the O
the NN reference O
reference NNS groups O
groups NN ( O
( NN CAPITAL P=.03 O
P=.03 IN for O
for DT the O
the JJ latter O
latter NN comparison O
comparison NN ) O

In IN CAPITAL In O
In DT the O
the JJ other O
other JJ clinical O
clinical NNS parameters O
parameters , , O
, PRP we O
we VBN found O
found DT no O
no JJ significant O
significant NNS differences O
differences IN between O
between DT the O
the NNS groups O

A DT CAPITAL A O
A JJ modest O
modest JJ excess O
excess IN of O
of NN breast D
breast NN cancer D
cancer CC and O
and NN colon D
colon NN cancer D
cancer VBD was O
was VBN found O
found IN in O
in RB potentially O
potentially VBN linked O
linked NNS families O
families IN in O
in NN comparison O
comparison IN with O
with RB potentially O
potentially JJ unlinked O
unlinked NNS families O
families , , O
, CC but O
but DT this O
this NN difference O
difference VBD was O
was RB not O
not RB statistically O
statistically JJ significant O

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: NNS CAPITAL Families O
Families IN that O
that VB provide O
provide NN evidence O
evidence IN for O
for NN segregation O
segregation IN of O
of DT an O
an JJ altered O
altered NN CAPITAL HPC1 O
HPC1 NN gene O
gene VBP are O
are VBN characterized O
characterized IN by O
by JJ multiple O
multiple NNS cases O
cases IN of O
of NN prostate D
prostate NN cancer D
cancer IN that O
that , , O
, IN in O
in JJS most O
most NNS respects O
respects , , O
, VBP are O
are JJ indistinguishable O
indistinguishable IN from O
from JJ nonhereditary O
nonhereditary NNS cases O

However RB CAPITAL However O
However , , O
, CD 3 O
3 NNS characteristics O
characteristics VBD were O
were VBN observed O
observed : : O
: JJR younger O
younger NN age O
age IN at O
at NN diagnosis O
diagnosis , , O
, JJ higher-grade O
higher-grade NNS tumors D
tumors , , O
, CC and O
and RBR more O
more JJ advanced-stage O
advanced-stage NN disease O

Our PRP$ CAPITAL Our O
Our NN study O
study NNS shows O
shows IN that O
that DT a O
a JJ significant O
significant NN fraction O
fraction IN of O
of JJ hereditary O
hereditary NN prostate D
prostate NNS cancers D
cancers VBP are O
are VBN diagnosed O
diagnosed IN in O
in JJ advanced O
advanced NNS stages O
stages , , O
, VBG emphasizing O
emphasizing DT the O
the JJ clinical O
clinical NN importance O
importance IN of O
of RB early O
early NN detection O
detection IN in O
in NNS men O
men RB potentially O
potentially VBG carrying O
carrying NN prostate O
prostate NN cancer O
cancer NN susceptibility O
susceptibility NNS genes O

These DT CAPITAL These O
These NNS findings O
findings NN support O
support DT the O
the JJ current O
current NNS recommendations O
recommendations TO to O
to NN screen O
screen NNS men O
men IN with O
with DT a O
a JJ positive O
positive NN family O
family NN history O
history IN of O
of NN prostate D
prostate NN cancer D
cancer VBG beginning O
beginning IN at O
at NN age O
age CD 40 O
40 NNS years O

CONTEXT NN CAPITAL CONTEXT O
CONTEXT : : O
: NN CAPITAL Susceptibility O
Susceptibility TO to O
to JJ multiple D
multiple NN sclerosis D
sclerosis NN ( D
( NN CAPITAL MS D
MS NN ) D
) VBZ involves O
involves DT a O
a RB genetically O
genetically JJ complex O
complex JJ autoimmune O
autoimmune NN component O

However RB CAPITAL However O
However , , O
, IN except O
except IN for O
for NNS genes O
genes IN in O
in DT the O
the NN CAPITAL HLA O
HLA NN system O
system , , O
, JJ specific O
specific NN susceptibility O
susceptibility NNS loci O
loci VBP are O
are JJ unknown O
unknown CC or O
or JJ unconfirmed O

OBJECTIVE NN CAPITAL OBJECTIVE O
OBJECTIVE : : O
: TO CAPITAL To O
To VB investigate O
investigate JJ several O
several NNS loci O
loci VBG spanning O
spanning CD 3 O
3 NN candidate O
candidate NNS regions O
regions IN for O
for DT a O
a NN role O
role IN in O
in JJ multiple D
multiple NN sclerosis D
sclerosis NN ( D
( NN CAPITAL MS D
MS NN ) D
) NN susceptibility O
susceptibility IN in O
in CD 2 O
2 JJ ethnic O
ethnic NNS groups O
groups VBG using O
using DT both O
both NN single-locus O
single-locus CC and O
and NN haplotype O
haplotype NNS analyses O

The DT CAPITAL The O
The CD 3 O
3 NNS regions O
regions VBP include O
include NN CAPITAL HLA O
HLA IN on O
on NN chromosome O
chromosome JJ 6p21.3 O
6p21.3 , , O
, NN CAPITAL APOE O
APOE IN on O
on NN chromosome O
chromosome JJ 19ql O
19ql CD 3.2 O
3.2 , , O
, CC and O
and NN CAPITAL MBP O
MBP NN ( O
( JJ myelin O
myelin JJ basic O
basic NN protein O
protein NN ) O
) IN on O
on NN chromosome O
chromosome NN 18q23 O

DESIGN NN CAPITAL DESIGN O
DESIGN : : O
: JJ CAPITAL Case-control O
Case-control NN association O
association NN testing O

SUBJECTS NNS CAPITAL SUBJECTS O
SUBJECTS : : O
: DT CAPITAL A O
A JJ total O
total IN of O
of CD 120 O
120 JJ CAPITAL Caucasian O
Caucasian NNS patients O
patients IN with O
with NN CAPITAL MS O
MS CC and O
and CD 107 O
107 JJ unrelated O
unrelated NN control O
control NNS individuals O
individuals IN from O
from NNP CAPITAL California O
California , , O
, CC and O
and CD 32 O
32 NNS patients O
patients CC and O
and CD 32 O
32 JJ unrelated O
unrelated NN control O
control NNS individuals O
individuals IN from O
from NNP CAPITAL Beijing O
Beijing , , O
, NNP CAPITAL China O

All DT CAPITAL All O
All NNS patients O
patients IN with O
with NN CAPITAL MS O
MS VBD were O
were VBN diagnosed O
diagnosed IN as O
as VBG having O
having RB clinically O
clinically JJ definite O
definite NN disease O
disease VBG according O
according TO to O
to VBN published O
published NNS criteria O

MAIN JJS CAPITAL MAIN O
MAIN NN CAPITAL OUTCOME O
OUTCOME NNS CAPITAL MEASURES O
MEASURES : : O
: NN CAPITAL Chi2 O
Chi2 VBG CAPITAL Testing O
Testing IN of O
of NNS loci O
loci CC and O
and JJ individual O
individual NNS alleles O
alleles CC and O
and NNS haplotypes O

Haplotype NN CAPITAL Haplotype O
Haplotype NNS frequencies O
frequencies VBD were O
were VBN estimated O
estimated IN with O
with JJ standard O
standard NN maximum O
maximum NN likelihood O
likelihood NNS methods O

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: DT CAPITAL The O
The NN CAPITAL HLA O
HLA NN effect O
effect VBZ is O
is JJ due O
due TO to O
to DT the O
the NN class O
class NNP CAPITAL II O
II NN CAPITAL DR2 O
DR2 NN haplotype O
haplotype , , O
, NN CAPITAL DRB1*1501-DQA1*0102-DRB1*0602 O
DRB1*1501-DQA1*0102-DRB1*0602 : ; O
; NNS contributions O
contributions TO to O
to NN CAPITAL MS O
MS NN susceptibility O
susceptibility IN from O
from JJ additional O
additional NN CAPITAL DRB1-DQB1 O
DRB1-DQB1 NNS alleles O
alleles CC or O
or JJ other O
other NN CAPITAL HLA O
HLA NN region O
region NNS loci O
loci VBD were O
were RB not O
not VBN observed O

Variation NN CAPITAL Variation O
Variation IN within O
within DT the O
the NN CAPITAL MBP O
MBP NN locus O
locus IN on O
on NN chromosome O
chromosome NN 18q23 O
18q23 VBD showed O
showed DT no O
no NN effect O
effect IN in O
in NN CAPITAL MS O

The DT CAPITAL The O
The NN distribution O
distribution IN of O
of NNS haplotypes O
haplotypes IN from O
from CD 5 O
5 NNS loci O
loci IN within O
within DT the O
the NN chromosome O
chromosome NN 19q13.2 O
19q13.2 NN region O
region , , O
, VBG including O
including NN CAPITAL D19S178 O
D19S178 , , O
, NN CAPITAL D19S574 O
D19S574 , , O
, NN CAPITAL APOE O
APOE , , O
, NN CAPITAL APOC2 O
APOC2 , , O
, CC and O
and NN CAPITAL D19S219 O
D19S219 , , O
, VBN differed O
differed IN between O
between NN patient O
patient CC and O
and NN control O
control NNS samples O

D19S574 NN CAPITAL D19S574 O
D19S574 VBD showed O
showed DT a O
a JJ significant O
significant NN effect O
effect NN ( O
( NN CAPITAL P=.015 O
P=.015 NN ) O
) IN in O
in JJ CAPITAL Caucasian O
Caucasian NNS patients O
patients IN with O
with NN CAPITAL MS O
MS JJ due O
due TO to O
to DT the O
the VBN increased O
increased NN frequency O
frequency IN of O
of DT a O
a JJ single O
single NN allele O
allele NN ( O
( NN CAPITAL P=.002 O
P=.002 NN ) O

The DT CAPITAL The O
The NN CAPITAL APOE O
APOE NN variation O
variation , , O
, JJ prominent O
prominent IN in O
in JJ other O
other JJ neurological O
neurological NNS diseases O
diseases , , O
, VBD showed O
showed DT no O
no NN influence O
influence IN on O
on NN CAPITAL MS O
MS NN susceptibility O
susceptibility , , O
, IN despite O
despite PRP$ its O
its NN location O
location IN within O
within DT the O
the NN chromosome O
chromosome NN 19q13.2 O
19q13.2 NN region O

Interaction NN CAPITAL Interaction O
Interaction NNS effects O
effects IN between O
between NN CAPITAL DR2 O
DR2 CC and O
and NN chromosome O
chromosome NN 19q13.2 O
19q13.2 CC or O
or NN CAPITAL MBP O
MBP IN in O
in NN CAPITAL MS O
MS NN susceptibility O
susceptibility VBD were O
were RB not O
not JJ apparent O

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: DT CAPITAL The O
The JJ significant O
significant NN chromosome O
chromosome NN 19q13.2 O
19q13.2 NN single-locus O
single-locus CC and O
and NN multilocus O
multilocus NN haplotype O
haplotype NNS associations O
associations IN with O
with NN CAPITAL MS O
MS IN in O
in JJ CAPITAL Caucasian O
Caucasian CC and O
and JJ CAPITAL Chinese O
Chinese NN patient O
patient NNS samples O
samples VBP indicate O
indicate DT an O
an NN effect O
effect IN from O
from DT a O
a RB nearby O
nearby NN disease O
disease NN susceptibility O
susceptibility NN locus O

These DT CAPITAL These O
These JJ initial O
initial NNS observations O
observations VBP are O
are DT an O
an JJ encouraging O
encouraging NN step O
step IN toward O
toward DT the O
the NN description O
description IN of O
of JJ non-HLA O
non-HLA JJ genetic O
genetic NN susceptibility O
susceptibility TO to O
to NN CAPITAL MS O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NN CAPITAL CONTEXT O
CONTEXT : : O
: EX CAPITAL There O
There VBZ is O
is DT a O
a JJ substantial O
substantial NN risk O
risk IN of O
of DT a O
a JJ second O
second NN cancer O
cancer IN for O
for NNS persons O
persons IN with O
with JJ hereditary O
hereditary NN retinoblastoma O
retinoblastoma , , O
, WDT which O
which VBZ is O
is VBN enhanced O
enhanced IN by O
by NN radiotherapy O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NN CAPITAL OBJECTIVE O
OBJECTIVE : : O
: TO CAPITAL To O
To VB examine O
examine JJ long-term O
long-term NN risk O
risk IN of O
of JJ new O
new JJ primary O
primary NNS cancers O
cancers IN in O
in NNS survivors O
survivors IN of O
of NN childhood O
childhood NN retinoblastoma O
retinoblastoma CC and O
and VB quantify O
quantify DT the O
the NN role O
role IN of O
of NN radiotherapy O
radiotherapy IN in O
in NN sarcoma O
sarcoma NN development O

DESIGN NN CAPITAL DESIGN O
DESIGN : : O
: NN CAPITAL Cohort O
Cohort NN incidence O
incidence NN study O
study IN of O
of NNS patients O
patients IN with O
with NN retinoblastoma O
retinoblastoma VBN followed O
followed IN for O
for DT a O
a JJ median O
median IN of O
of CD 20 O
20 NNS years O
years , , O
, CC and O
and JJ nested O
nested JJ case-control O
case-control NN study O
study IN of O
of DT a O
a NN radiation O
radiation JJ dose-response O
dose-response NN relationship O
relationship IN for O
for NN bone O
bone CC and O
and JJ soft O
soft NN tissue O
tissue NNS sarcomas O

SETTING/PARTICIPANTS NN CAPITAL SETTING/PARTICIPANTS O
SETTING/PARTICIPANTS : : O
: DT CAPITAL A O
A JJ total O
total IN of O
of CD 1604 O
1604 NNS patients O
patients IN with O
with NN retinoblastoma D
retinoblastoma WP who O
who VBD survived O
survived IN at O
at JJS least O
least CD 1 O
1 NN year O
year IN after O
after NN diagnosis O
diagnosis , , O
, VBN identified O
identified IN from O
from NN hospital O
hospital NNS records O
records IN in O
in NNP CAPITAL Massachusetts O
Massachusetts CC and O
and NNP CAPITAL New O
New NNP CAPITAL York O
York IN during O
during CD 1914 O
1914 TO to O
to CD 1984 O

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: NN CAPITAL Incidence O
Incidence IN of O
of JJ subsequent O
subsequent NNS cancers D
cancers VBD was O
was RB statistically O
statistically RB significantly O
significantly JJ elevated O
elevated RB only O
only IN in O
in DT the O
the CD 961 O
961 NNS patients O
patients IN with O
with JJ hereditary O
hereditary NN retinoblastoma D
retinoblastoma , , O
, IN in O
in WP whom O
whom CD 190 O
190 NNS cancers D
cancers VBD were O
were VBN diagnosed O
diagnosed , , O
, CC vs O
vs CD 6.3 O
6.3 VBN expected O
expected IN in O
in DT the O
the JJ general O
general NN population O
population NN ( O
( JJ relative O
relative NN risk O
risk NN ( O
( NN CAPITAL RR O
RR NN ) O
) , , O
, CD 30 O
30 NN ( O
( CD 95 O
95 NN % O
% NN confidence O
confidence NN interval O
interval , , O
, CD 26-47 O
26-47 NN ) O
) NN ) O

Cumulative JJ CAPITAL Cumulative O
Cumulative NN incidence O
incidence NN ( O
( NN +/-SE O
+/-SE NN ) O
) IN of O
of DT a O
a JJ second O
second NN cancer D
cancer IN at O
at CD 50 O
50 NNS years O
years IN after O
after NN diagnosis O
diagnosis VBD was O
was CD 51.0 O
51.0 NN % O
% NN ( O
( CD +/-6.2 O
+/-6.2 NN % O
% NN ) O
) IN for O
for JJ hereditary O
hereditary NN retinoblastoma D
retinoblastoma , , O
, CC and O
and CD 5.0 O
5.0 NN % O
% NN ( O
( CD +/-3.0 O
+/-3.0 NN % O
% NN ) O
) IN for O
for JJ nonhereditary O
nonhereditary NN retinoblastoma D

All DT CAPITAL All O
All CD 114 O
114 NNS sarcomas D
sarcomas IN of O
of JJ diverse O
diverse JJ histologic O
histologic NNS types O
types VBD occurred O
occurred IN in O
in NNS patients O
patients IN with O
with JJ hereditary O
hereditary NN retinoblastoma D

For IN CAPITAL For O
For JJ soft O
soft NN tissue O
tissue NNS sarcomas D
sarcomas , , O
, DT the O
the NNS CAPITAL RRs O
RRs VBD showed O
showed DT a O
a JJ stepwise O
stepwise NN increase O
increase IN at O
at DT all O
all NN dose O
dose NNS categories O
categories , , O
, CC and O
and VBD were O
were RB statistically O
statistically JJ significant O
significant IN at O
at CD 10 O
10 TO to O
to CD 29.9 O
29.9 NN CAPITAL Gy O
Gy CC and O
and CD 30 O
30 TO to O
to CD 59.9 O
59.9 NN CAPITAL Gy O

A DT CAPITAL A O
A NN radiation O
radiation NN risk O
risk IN for O
for DT all O
all NNS sarcomas O
sarcomas JJ combined O
combined VBD was O
was JJ evident O
evident IN at O
at NNS doses O
doses IN above O
above CD 5 O
5 NN CAPITAL Gy O
Gy , , O
, VBG rising O
rising TO to O
to JJ 10.7-fold O
10.7-fold IN at O
at NNS doses O
doses IN of O
of CD 60 O
60 NN CAPITAL Gy O
Gy CC or O
or JJR greater O
greater NN ( O
( NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD .05 O
.05 NN ) O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: JJ CAPITAL Genetic O
Genetic NN predisposition O
predisposition VBZ has O
has DT a O
a JJ substantial O
substantial NN impact O
impact IN on O
on NN risk O
risk IN of O
of JJ subsequent D
subsequent NNS cancers D
cancers IN in O
in NN retinoblastoma D
retinoblastoma NNS patients O
patients , , O
, WDT which O
which VBZ is O
is RB further O
further VBN increased O
increased IN by O
by NN radiation T
radiation NN treatment T

A DT CAPITAL A O
A NN radiation O
radiation JJ dose-response O
dose-response NN relationship O
relationship VBZ is O
is VBD demonstrated O
demonstrated IN for O
for DT all O
all NNS sarcomas O
sarcomas CC and O
and , , O
, IN for O
for DT the O
the RB first O
first NN time O
time IN in O
in NNS humans O
humans , , O
, IN for O
for JJ soft O
soft NN tissue O
tissue NNS sarcomas O

Retinoblastoma NN CAPITAL Retinoblastoma D
Retinoblastoma NNS patients O
patients MD should O
should VB be O
be VBN examined O
examined IN for O
for JJ new O
new NNS cancers D
cancers CC and O
and VBN followed O
followed IN into O
into RB later O
later NN life O
life TO to O
to VB determine O
determine IN whether O
whether PRP$ their O
their JJ extraordinary O
extraordinary NN cancer O
cancer NN risk O
risk VBZ extends O
extends TO to O
to JJ common O
common NNS cancers D
cancers IN of O
of NN adulthood O

The DT CAPITAL The O
The JJ objective O
objective IN of O
of DT this O
this NN study O
study VBD was O
was TO to O
to VB determine O
determine DT the O
the NN rate O
rate IN of O
of JJ recent O
recent NN cocaine O
cocaine NN use O
use IN among O
among DT a O
a JJ metropolitan O
metropolitan NN population O
population IN of O
of RB predominantly O
predominantly JJ CAPITAL Hispanic O
Hispanic CC and O
and JJ CAPITAL African-American O
African-American NNS women O
women IN with O
with NN preterm O
preterm JJ premature D
premature NN rupture D
rupture IN of D
of DT the D
the NNS membranes D
membranes NN ( D
( NN CAPITAL PROM D
PROM NN ) D
) CC and O
and TO to O
to VB ascertain O
ascertain DT the O
the NN impact O
impact IN of O
of NN cocaine O
cocaine IN on O
on DT the O
the NN latency O
latency NN period O
period IN between O
between NN rupture O
rupture IN of O
of NNS membranes O
membranes CC and O
and NN delivery O

Urine NN CAPITAL Urine O
Urine NN toxicology O
toxicology NNS screens O
screens VBD were O
were RB prospectively O
prospectively VBN obtained O
obtained IN on O
on CD 147 O
147 NNS women O
women IN with O
with NN preterm D
preterm NN CAPITAL PROM D

The DT CAPITAL The O
The NN urine O
urine NN screen O
screen VBD did O
did RB not O
not NN influence O
influence NN management O
management NNS decisions O

All DT CAPITAL All O
All NNS women O
women VBD were O
were RB expectantly O
expectantly VBN managed O
managed IN without O
without NNS tocolytics O
tocolytics IN until O
until CD 37 O
37 NNS weeks O
weeks POS ' O
' JJ gestation O
gestation IN unless O
unless PRP they O
they VBN developed O
developed JJ clinical O
clinical NN chorioamnionitis O
chorioamnionitis , , O
, CC or O
or JJ nonreassuring O
nonreassuring JJ fetal O
fetal NN heart O
heart NN rate O
rate VBG tracing O
tracing CC or O
or JJ biophysical O
biophysical NN profile O

Demographic JJ CAPITAL Demographic O
Demographic NN information O
information , , O
, NNS hours O
hours IN from O
from NN rupture O
rupture IN of O
of NNS membranes O
membranes TO to O
to NN delivery O
delivery , , O
, JJ gestational O
gestational NN age O
age , , O
, CC and O
and NN birth O
birth NN weight O
weight IN at O
at NN delivery O
delivery VBD were O
were VBN compared O
compared VBG using O
using NNP CAPITAL Fisher O
Fisher POS 's O
's JJ exact O
exact , , O
, JJ CAPITAL Mann-Whitney O
Mann-Whitney NNP CAPITAL U O
U , , O
, CC and O
and NN randomization O
randomization NNS tests O
tests WRB where O
where JJ appropriate O

The DT CAPITAL The O
The NN rate O
rate IN of O
of JJ positive O
positive NN urine O
urine NN drug O
drug NNS screens O
screens IN for O
for NN cocaine O
cocaine VBD was O
was CD 8.2 O
8.2 NN % O

Women NNS CAPITAL Women O
Women IN in O
in DT the O
the NN cocaine O
cocaine JJ positive O
positive NN group O
group VBD were O
were IN of O
of JJR higher O
higher NN parity O
parity NN ( O
( CD 3 O
3 , , O
, NN ( O
( CD 0-7 O
0-7 NN ) O
) CC vs. O
vs. CD 1 O
1 , , O
, NN ( O
( CD 0-6 O
0-6 NN ) O
) , , O
, NN p O
p JJ = O
= CD 0.001 O
0.001 NN ) O
) CC and O
and VBD tended O
tended TO to O
to VB be O
be JJR older O
older NN ( O
( CD 27 O
27 , , O
, NN ( O
( CD 23-42 O
23-42 NN ) O
) CC vs. O
vs. CD 25 O
25 , , O
, NN ( O
( CD 14-40 O
14-40 NN ) O
) NN ) O

There EX CAPITAL There O
There VBD was O
was DT a O
a JJR higher O
higher NN rate O
rate IN of O
of JJ recent O
recent NN cocaine O
cocaine NN use O
use IN among O
among JJ CAPITAL African-American O
African-American NNS women O
women NN ( O
( CD 20.4 O
20.4 NN % O
% NN ) O
) IN as O
as VBN compared O
compared TO to O
to NNS non-African-Americans O
non-African-Americans NN ( O
( CD 1.2 O
1.2 NN % O
% , , O
, NN p O
p JJ = O
= CD 0.0001 O
0.0001 NN ) O

Cocaine-positive JJ CAPITAL Cocaine-positive O
Cocaine-positive NNS women O
women VBN presented O
presented IN at O
at DT an O
an JJR earlier O
earlier JJ gestational O
gestational NN age O
age NN ( O
( CD 32 O
32 NNS weeks O
weeks POS ' O
' , , O
, NN ( O
( CD 24-34 O
24-34 NN ) O
) CC vs. O
vs. CD 33 O
33 NNS weeks O
weeks POS ' O
' , , O
, NN ( O
( CD 23-36 O
23-36 NN ) O
) , , O
, NN p O
p JJ = O
= CD 0.02 O
0.02 NN ) O
) CC and O
and VBD had O
had DT a O
a RB significantly O
significantly RB longer O
longer NN membrane O
membrane NN rupture O
rupture TO to O
to NN delivery O
delivery NN interval O
interval IN than O
than NNS women O
women IN with O
with DT a O
a JJ negative O
negative NN urine O
urine NN drug O
drug NN screen O
screen NN ( O
( CD 174 O
174 NN hr O
hr , , O
, NN ( O
( CD 6-475 O
6-475 NN ) O
) CC vs. O
vs. CD 33 O
33 NNS hours O
hours NN ( O
( CD 1-833 O
1-833 NN ) O
) , , O
, NN p O
p JJ = O
= CD 0.01 O
0.01 NN ) O

There EX CAPITAL There O
There VBD was O
was DT no O
no JJ significant O
significant NN difference O
difference IN in O
in DT the O
the NN reason O
reason IN for O
for NN delivery O
delivery IN between O
between DT the O
the CD two O
two NNS groups O
groups IN of O
of NNS patients O

Recent JJ CAPITAL Recent O
Recent NN cocaine O
cocaine NN use O
use IN among O
among NNS women O
women IN with O
with NN preterm D
preterm NN CAPITAL PROM D
PROM VBZ is O
is JJ common O
common IN in O
in RB only O
only DT some O
some NNS segments O
segments IN of O
of DT an O
an JJ urban O
urban NN population O

Women NNS CAPITAL Women O
Women IN with O
with JJ recent O
recent NN cocaine O
cocaine NN use O
use JJ present O
present IN with O
with VBN ruptured O
ruptured NNS membranes O
membranes IN at O
at DT an O
an JJR earlier O
earlier JJ gestational O
gestational NN age O
age CC and O
and MD may O
may RB actually O
actually VB have O
have DT a O
a RB longer O
longer NN latency O
latency NN period O
period IN than O
than NNS women O
women WP who O
who VB do O
do RB not O
not NN use O
use NN cocaine O

The DT CAPITAL The O
The JJ objective O
objective IN of O
of DT this O
this NN article O
article VBZ is O
is TO to O
to VB explore O
explore NNS attitudes O
attitudes IN of O
of DT an O
an JJ inner-city O
inner-city , , O
, JJ pregnant O
pregnant NN cohort O
cohort IN about O
about JJ general O
general CC and O
and JJ CAPITAL HIV-related O
HIV-related JJ prenatal O
prenatal NN care O

Responses NNS CAPITAL Responses O
Responses TO to O
to DT an O
an NN interview O
interview IN at O
at JJ initial O
initial JJ prenatal O
prenatal NN care O
care NN enrollment O
enrollment VBD were O
were VBN compared O
compared VBG using O
using JJ CAPITAL Chi-square O
Chi-square CC and O
and NNP CAPITAL Fisher O
Fisher POS 's O
's JJ exact O
exact NNS tests O

Of IN CAPITAL Of O
Of CD 75 O
75 NNS women O
women , , O
, NN drug O
drug NNS users O
users NN ( O
( CD 51 O
51 NN % O
% NN ) O
) VBD were O
were RBR more O
more JJ likely O
likely TO to O
to VB say O
say IN that O
that PRP they O
they MD would O
would VB defer O
defer VBG initiating O
initiating JJ prenatal O
prenatal NN care O
care NN ( O
( NN CAPITAL P O
P JJ = O
= CD 0.03 O
0.03 NN ) O
) CC and O
and TO to O
to VB minimize O
minimize DT the O
the NN risk O
risk IN of O
of NN drug O
drug CC or O
or NN alcohol O
alcohol NN use O
use TO to O
to DT the O
the NN fetus O
fetus NN ( O
( NN CAPITAL P O
P JJ = O
= CD 0.04 O
0.04 NN ) O

Most JJS CAPITAL Most O
Most NN ( O
( CD 85 O
85 NN % O
% NN ) O
) VBN viewed O
viewed NN pregnancy O
pregnancy IN as O
as JJ inappropriate O
inappropriate IN for O
for NN CAPITAL HIV D
HIV JJ infected O
infected NNS women O
women CC and O
and RB primarily O
primarily NN drug O
drug NNS users O
users NN ( O
( NN CAPITAL P O
P JJ = O
= CD 0.06 O
0.06 NN ) O
) MD would O
would VB abort O
abort IN if O
if NN CAPITAL HIV D
HIV JJ infected O

Over IN CAPITAL Over O
Over DT half O
half VBN thought O
thought NN CAPITAL HIV D
HIV NN transmission O
transmission VBD occurred O
occurred JJS most O
most NNS times O
times CC or O
or RB always O

Only RB CAPITAL Only O
Only CD 20 O
20 NN % O
% VBD had O
had VBN heard O
heard IN of O
of DT a O
a NN drug O
drug TO to O
to VB reduce O
reduce DT this O
this NN risk O
risk , , O
, CC but O
but CD 95 O
95 NN % O
% MD would O
would VB take O
take JJ such O
such DT a O
a NN therapy O

These DT CAPITAL These O
These JJ inner-city O
inner-city , , O
, JJ pregnant O
pregnant NNS women O
women VBN disapproved O
disapproved IN of O
of NN pregnancy O
pregnancy IN if O
if NN CAPITAL HIV D
HIV JJ infected O
infected CC and O
and VBN thought O
thought DT the O
the NN risk O
risk IN of O
of NN transmission O
transmission VBD was O
was JJ high O

They PRP CAPITAL They O
They VBD knew O
knew JJ little O
little IN of O
of WRB how O
how TO to O
to VB reduce O
reduce DT this O
this NN risk O
risk CC but O
but RB nearly O
nearly DT all O
all MD would O
would VB accept O
accept DT a O
a NN drug O
drug TO to O
to VB prevent O
prevent NN transmission O

The DT CAPITAL The O
The NN association O
association IN of O
of NN parvovirus D
parvovirus NN CAPITAL B19 D
B19 NN infection D
infection CC and O
and NN hydrops D
hydrops NN fetalis D
fetalis VBZ is O
is RB well O
well JJ known O

However RB CAPITAL However O
However , , O
, DT the O
the NN association O
association IN of O
of NN parvovirus D
parvovirus CC and O
and JJ fetal O
fetal JJ pleural O
pleural CC or O
or JJ pericardial D
pericardial NNS effusions D
effusions VBZ has O
has RB not O
not VBN been O
been VBN reported O

We PRP CAPITAL We O
We JJ present O
present CD five O
five NNS cases O
cases IN of O
of VBN isolated O
isolated JJ pleural O
pleural CC or O
or JJ pericardial D
pericardial NN effusion D
effusion IN with O
with VBN documented O
documented JJ maternal O
maternal NN parvovirus D
parvovirus NN infection D
infection IN in O
in CD four O
four IN of O
of DT these O
these NNS pregnancies O

In IN CAPITAL In O
In DT the O
the NN absence O
absence IN of O
of JJ structural O
structural CC or O
or JJ karyotypic O
karyotypic NNS abnormalities O
abnormalities , , O
, JJ spontaneous O
spontaneous NN resolution O
resolution IN of O
of DT the O
the NN effusion O
effusion VBZ portends O
portends IN for O
for DT a O
a JJ successful O
successful NN pregnancy O
pregnancy NN outcome O

BACKGROUND NN CAPITAL BACKGROUND O
BACKGROUND : : O
: JJ CAPITAL Cochlear T
Cochlear NN implantation T
implantation VBZ is O
is RB nowadays O
nowadays DT a O
a JJ reliable O
reliable CC and O
and JJ well-accepted O
well-accepted NN method O
method IN of O
of JJ auditory O
auditory NN rehabilitation O
rehabilitation IN in O
in VBN selected O
selected NNS adults O
adults CC and O
and NNS children O

METHODS NNS CAPITAL METHODS O
METHODS : : O
: PRP CAPITAL We O
We JJ present O
present NN rehabilitation O
rehabilitation NNS data O
data IN on O
on CD 21 O
21 JJ adult O
adult NNS patients O
patients VBN provided O
provided IN with O
with DT the O
the NN CAPITAL Nucleus O
Nucleus NN CAPITAL CI22 O
CI22 NN CAPITAL M O
M JJ cochlear O
cochlear VB implant O
implant VBG using O
using DT the O
the VB CAPITAL SPEAK O
SPEAK NN strategy O

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: NNS CAPITAL Results O
Results IN of O
of RB first O
first NN tune-up O
tune-up NN show O
show DT an O
an JJ open O
open VBN set O
set NN speech O
speech VBG understanding O
understanding IN in O
in RB approximately O
approximately CD 50 O
50 NN % O
% IN of O
of NNS patients O

Long-term JJ CAPITAL Long-term O
Long-term NNS results O
results RB also O
also VB reveal O
reveal RB further O
further NN improvement O
improvement IN in O
in NNS patients O
patients WP who O
who VBD had O
had DT no O
no JJ open O
open VBN set O
set NN speech O
speech VBG understanding O

Our PRP$ CAPITAL Our O
Our NNS data O
data VB seem O
seem TO to O
to VBP indicate O
indicate JJ similar O
similar NNS results O
results IN in O
in NN comparison O
comparison TO to O
to JJ other O
other NNS groups O
groups VBG using O
using DT the O
the NN CAPITAL CIS O
CIS NN strategy O

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: IN CAPITAL In O
In NNS adults O
adults , , O
, JJ open O
open VBN set O
set NN speech O
speech VBG understanding O
understanding MD can O
can VB be O
be VBN achieved O
achieved RB even O
even IN at O
at DT the O
the RB first O
first NN tune-up O

Results NNS CAPITAL Results O
Results IN of O
of RB early O
early NN rehabilitation O
rehabilitation VB seem O
seem TO to O
to VB be O
be VBN influenced O
influenced IN by O
by NN duration O
duration CC and O
and NN etiology O
etiology IN of O
of NN deafness D
deafness , , O
, NN experience O
experience IN with O
with VBG hearing O
hearing NNS aids O
aids , , O
, CC and O
and JJ other O
other NNS factors O

Adverse JJ CAPITAL Adverse O
Adverse NN drug O
drug NNS effects O
effects VBP are O
are NN manifold O
manifold CC and O
and JJ heterogenous O

Many JJ CAPITAL Many O
Many NNS situations O
situations MD may O
may VB hamper O
hamper DT the O
the NN signalling O
signalling NN ( O
( NN i.e O
i.e . . O
. DT the O
the NN detection O
detection IN of O
of RB early O
early VBG warning O
warning NNS signs O
signs NN ) O
) IN of O
of JJ adverse O
adverse NNS effects O
effects CC and O
and JJ new O
new NNS signals O
signals RB often O
often VBP differ O
differ IN from O
from JJ previous O
previous NNS experiences O

Signals NNS CAPITAL Signals O
Signals VB have O
have JJ qualitative O
qualitative CC and O
and JJ quantitative O
quantitative NNS aspects O

Different JJ CAPITAL Different O
Different NNS categories O
categories IN of O
of JJ adverse O
adverse NNS effects O
effects NN need O
need JJ different O
different NNS methods O
methods IN for O
for NN detection O

Current JJ CAPITAL Current O
Current NN pharmacovigilance O
pharmacovigilance VBZ is O
is RB predominantly O
predominantly VBN based O
based IN on O
on JJ spontaneous O
spontaneous VBG reporting O
reporting CC and O
and VBZ is O
is RB mainly O
mainly JJ helpful O
helpful IN in O
in VBG detecting O
detecting NN type O
type NN CAPITAL B O
B NNS effects O
effects NN ( O
( DT those O
those NNS effects O
effects IN that O
that VBP are O
are RB often O
often JJ allergic O
allergic CC or O
or JJ idiosyncratic O
idiosyncratic NNS reactions O
reactions , , O
, RB characteristically O
characteristically VBG occurring O
occurring IN in O
in RB only O
only DT a O
a NN minority O
minority IN of O
of NNS patients O
patients CC and O
and RB usually O
usually JJ unrelated O
unrelated TO to O
to NN dosage O
dosage CC and O
and IN that O
that VBP are O
are JJ serious O
serious , , O
, JJ unexpected O
unexpected CC and O
and JJ unpredictable O
unpredictable NN ) O
) CC and O
and JJ unusual O
unusual NN type O
type DT CAPITAL A O
A NNS effects O
effects NN ( O
( DT those O
those NNS effects O
effects IN that O
that VBP are O
are JJ related O
related TO to O
to DT the O
the JJ pharmacological O
pharmacological NNS effects O
effects IN of O
of DT the O
the NN drug O
drug CC and O
and VBP are O
are JJ dosage-related O
dosage-related NN ) O

Examples NNS CAPITAL Examples O
Examples IN of O
of JJ other O
other NNS sources O
sources IN of O
of NNS signals O
signals VBP are O
are NN prescription O
prescription NN event O
event VBG monitoring O
monitoring , , O
, JJ large O
large VBN automated O
automated NNS data O
data NNS resources O
resources IN on O
on NN morbidity O
morbidity CC and O
and NN drug O
drug NN use O
use NN ( O
( VBG including O
including NN record O
record NN linkage O
linkage NN ) O
) , , O
, JJ case-control O
case-control NN surveillance O
surveillance CC and O
and JJ follow-up O
follow-up NNS studies O

Type NN CAPITAL Type O
Type NN CAPITAL C O
C NNS effects O
effects NN ( O
( DT those O
those NNS effects O
effects JJ related O
related TO to O
to DT an O
an VBN increased O
increased NN frequency O
frequency IN of O
of JJ 'spontaneous O
'spontaneous POS ' O
' NN disease O
disease NN ) O
) VBP are O
are JJ difficult O
difficult TO to O
to NN study O
study , , O
, RB however O
however , , O
, CC and O
and VB continue O
continue TO to O
to VB pose O
pose DT a O
a JJ pharmacoepidemiological O
pharmacoepidemiological NN challenge O

Seven CD CAPITAL Seven O
Seven JJ basic O
basic NNS considerations O
considerations MD can O
can VB be O
be VBN identified O
identified IN that O
that VB determine O
determine DT the O
the NN evidence O
evidence VBN contained O
contained IN in O
in DT a O
a NN signal O
signal : : O
: JJ quantitative O
quantitative NN strength O
strength IN of O
of DT the O
the NN association O
association , , O
, NN consistency O
consistency IN of O
of DT the O
the NNS data O
data , , O
, NN exposure O
exposure NN response O
response NN relationship O
relationship , , O
, JJ biological O
biological NN plausibility O
plausibility , , O
, JJ experimental O
experimental NNS findings O
findings , , O
, JJ possible O
possible NNS analogies O
analogies CC and O
and DT the O
the NN nature O
nature CC and O
and NN quality O
quality IN of O
of DT the O
the NNS data O

A DT CAPITAL A O
A NN proposal O
proposal VBZ is O
is VBN made O
made IN for O
for DT a O
a JJ standard O
standard NN signal O
signal NN management O
management NN procedure O
procedure IN at O
at NN pharmacovigilance O
pharmacovigilance NNS centres O
centres , , O
, VBG including O
including DT the O
the VBG following O
following NNS steps O
steps : : O
: NN signal O
signal NN delineation O
delineation , , O
, NN literature O
literature NN search O
search , , O
, JJ preliminary O
preliminary NN inventory O
inventory IN of O
of NNS data O
data , , O
, NN collection O
collection IN of O
of JJ additional O
additional NN information O
information , , O
, NN consultation O
consultation IN with O
with DT the O
the NNP CAPITAL World O
World NNP CAPITAL Health O
Health NNP CAPITAL Organization O
Organization NNP CAPITAL Centre O
Centre IN for O
for NNP CAPITAL International O
International NN CAPITAL Drug O
Drug VBG CAPITAL Monitoring O
Monitoring CC and O
and DT the O
the JJ relevant O
relevant NN drug O
drug NNS companies O
companies , , O
, JJ aggregated O
aggregated NNS data O
data NN assessment O
assessment CC and O
and DT a O
a NN report O
report IN in O
in VBG writing O

A DT CAPITAL A O
A JJR better O
better VBG understanding O
understanding IN of O
of DT the O
the NNS conditions O
conditions CC and O
and NNS mechanisms O
mechanisms VBN involved O
involved IN in O
in DT the O
the NN detection O
detection IN of O
of JJ adverse O
adverse NN drug O
drug NNS effects O
effects MD may O
may RB further O
further VB improve O
improve NNS strategies O
strategies IN for O
for NN pharmacovigilance O

OBJECTIVE NN CAPITAL OBJECTIVE O
OBJECTIVE : : O
: TO CAPITAL To O
To NN study O
study DT the O
the NN safety O
safety CC and O
and NN efficacy O
efficacy IN of O
of NN methylphenidate T
methylphenidate IN in O
in NNS children O
children IN with O
with DT the O
the JJ dual O
dual NN diagnosis O
diagnosis IN of O
of NN epilepsy D
epilepsy CC and O
and NN attention D
attention NN deficit D
deficit NN hyperactivity D
hyperactivity NN disorder D
disorder NN ( D
( NN CAPITAL ADHD D
ADHD NN ) D

STUDY NN CAPITAL STUDY O
STUDY NN CAPITAL DESIGN O
DESIGN : : O
: CD CAPITAL Thirty O
Thirty NNS children O
children , , O
, JJ aged O
aged CD 6.4 O
6.4 TO to O
to CD 16.4 O
16.4 NNS years O
years , , O
, IN with O
with NN epilepsy D
epilepsy CC and O
and NN CAPITAL ADHD D
ADHD VBD were O
were VBN studied O
studied IN during O
during DT a O
a JJ 4-month O
4-month NN period O

During IN CAPITAL During O
During DT the O
the JJ initial O
initial CD 2 O
2 NNS months O
months IN of O
of DT the O
the NN study O
study , , O
, DT the O
the NNS children O
children VBD were O
were VBN treated O
treated IN with O
with JJ antiepileptic T
antiepileptic NNS drugs T
drugs NN ( T
( NNS CAPITAL AEDs T
AEDs NN ) T
) RB only O
only , , O
, CC and O
and IN for O
for DT the O
the VBG remaining O
remaining CD 2 O
2 NNS months O
months , , O
, NN methylphenidate T
methylphenidate VBD was O
was VBN added O
added IN at O
at DT a O
a NN morning O
morning NN dose O
dose IN of O
of CD 0.3 O
0.3 NN mg/kg O

They PRP CAPITAL They O
They VBD underwent O
underwent JJ neurologic O
neurologic NN assessment O
assessment , , O
, NN brain O
brain VBN computed O
computed NN tomography O
tomography , , O
, NNP CAPITAL IQ O
IQ NN testing O
testing , , O
, CC and O
and NN assessment O
assessment IN with O
with DT the O
the NN CAPITAL Childhood O
Childhood NN CAPITAL Behavior O
Behavior NNP CAPITAL Checklist O
Checklist IN at O
at NN baseline O
baseline IN before O
before NN methylphenidate T
methylphenidate NN therapy T

Electroencephalography NN CAPITAL Electroencephalography O
Electroencephalography , , O
, NN CAPITAL AED O
AED NNS determinations O
determinations , , O
, CC and O
and DT the O
the NN continuous-performance O
continuous-performance NN task O
task NN ( O
( NNP CAPITAL CPT O
CPT NN ) O
) NN test O
test VBD were O
were VBN done O
done IN at O
at NN baseline O
baseline CC and O
and IN after O
after CD 2 O
2 NNS months O
months IN of O
of NN methylphenidate O
methylphenidate NN therapy O

A DT CAPITAL A O
A JJ double-blind O
double-blind , , O
, NN crossover O
crossover NN design O
design VBD was O
was VBN used O
used TO to O
to VB compare O
compare DT the O
the NNS effects O
effects IN of O
of NN methylphenidate T
methylphenidate CC versus O
versus NN placebo O
placebo IN on O
on DT an O
an NN electroencephalogram O
electroencephalogram , , O
, NN CAPITAL AED O
AED NNS levels O
levels , , O
, CC and O
and DT the O
the NNP CAPITAL CPT O

On IN CAPITAL On O
On DT the O
the CD 2 O
2 NNS days O
days IN of O
of NN testing O
testing , , O
, DT the O
the NN child O
child VBN received O
received NNS CAPITAL AEDs T
AEDs CC and O
and DT a O
a NN capsule O
capsule VBG containing O
containing DT either O
either NN placebo O
placebo CC or O
or NN methylphenidate T

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: NN CAPITAL None O
None IN of O
of DT the O
the CD 25 O
25 NNS children O
children IN of O
of DT this O
this NN sample O
sample WP who O
who VBD were O
were NN seizure O
seizure JJ free O
free VBD had O
had NNS attacks O
attacks IN while O
while VBG taking O
taking NN methylphenidate O

Of IN CAPITAL Of O
Of DT the O
the CD 5 O
5 NNS children O
children IN with O
with NNS seizures D
seizures , , O
, CD 3 O
3 VBD had O
had DT an O
an NN increase O
increase IN in O
in NNS attacks O
attacks , , O
, IN whereas O
whereas DT the O
the JJ other O
other CD 2 O
2 VBD showed O
showed DT no O
no NN change O
change CC or O
or DT a O
a NN reduction O

There EX CAPITAL There O
There VBD were O
were DT no O
no JJ significant O
significant NNS changes O
changes IN in O
in NN CAPITAL AED O
AED NNS levels O
levels CC or O
or JJ electroencephalographic O
electroencephalographic NNS findings O

Methylphenidate NNP CAPITAL Methylphenidate T
Methylphenidate VBD benefited O
benefited CD 70 O
70 NN % O
% IN of O
of NNS children O
children VBG according O
according TO to O
to JJ parental O
parental NN report O
report : ; O
; NN methylphenidate T
methylphenidate RB also O
also VBN enhanced O
enhanced NN performance O
performance IN on O
on DT the O
the NNP CAPITAL CPT O

Side NN CAPITAL Side O
Side NNS effects O
effects IN of O
of NN methylphenidate T
methylphenidate VBD were O
were JJ mild O
mild CC and O
and JJ transient O

CONCLUSION NN CAPITAL CONCLUSION O
CONCLUSION : : O
: NNP CAPITAL Methylphenidate T
Methylphenidate VBZ is O
is JJ effective O
effective IN in O
in VBG treating O
treating NNS children O
children IN with O
with NN epilepsy D
epilepsy CC and O
and NN CAPITAL ADHD D
ADHD CC and O
and JJ safe O
safe IN in O
in NNS children O
children WP who O
who VBP are O
are NN seizure O
seizure JJ free O

Caution NN CAPITAL Caution O
Caution VBZ is O
is VBN warranted O
warranted IN for O
for DT those O
those RB still O
still VBG having O
having NNS seizures O
seizures IN while O
while VBG receiving O
receiving NN CAPITAL AED O
AED NN therapy O

The DT CAPITAL The O
The JJ temporal O
temporal NNS properties O
properties IN of O
of JJ semantic O
semantic CC and O
and JJ phonological O
phonological NNS processes O
processes IN in O
in NN speech O
speech NN production O
production VBD were O
were VBN investigated O
investigated IN in O
in DT a O
a JJ new O
new JJ experimental O
experimental NN paradigm O
paradigm VBG using O
using JJ movement-related O
movement-related NN brain O
brain NNS potentials O

The DT CAPITAL The O
The JJ main O
main JJ experimental O
experimental NN task O
task VBD was O
was NN picture O
picture VBG naming O

In IN CAPITAL In O
In NN addition O
addition , , O
, DT a O
a JJ 2-choice O
2-choice NN reaction O
reaction NN go/no-go O
go/no-go NN procedure O
procedure VBD was O
was VBN included O
included , , O
, VBG involving O
involving DT a O
a JJ semantic O
semantic CC and O
and DT a O
a JJ phonological O
phonological NN categorization O
categorization IN of O
of DT the O
the NN picture O
picture NN name O

Lateralized VBN CAPITAL Lateralized O
Lateralized NN readiness O
readiness NNS potentials O
potentials NN ( O
( NNS CAPITAL LRPs O
LRPs NN ) O
) VBD were O
were VBN derived O
derived TO to O
to NN test O
test IN whether O
whether JJ semantic O
semantic CC and O
and JJ phonological O
phonological NN information O
information VBN activated O
activated NN motor O
motor NNS processes O
processes IN at O
at JJ separate O
separate NNS moments O
moments IN in O
in NN time O

An DT CAPITAL An O
An NN CAPITAL LRP O
LRP VBD was O
was RB only O
only VBN observed O
observed IN on O
on JJ no-go O
no-go NNS trials O
trials WRB when O
when DT the O
the JJ semantic O
semantic NN ( O
( RB not O
not DT the O
the JJ phonological O
phonological NN ) O
) NN decision O
decision VBN determined O
determined DT the O
the NN response O
response NN hand O

Varying JJ CAPITAL Varying O
Varying DT the O
the NN position O
position IN of O
of DT the O
the JJ critical O
critical NN phoneme O
phoneme IN in O
in DT the O
the NN picture O
picture NN name O
name VBD did O
did RB not O
not VB affect O
affect DT the O
the NN onset O
onset IN of O
of DT the O
the NN CAPITAL LRP O
LRP CC but O
but RB rather O
rather VBN influenced O
influenced WRB when O
when DT the O
the NN CAPITAL LRP O
LRP VBD began O
began TO to O
to VBP differ O
differ IN on O
on VB go O
go CC and O
and JJ no-go O
no-go NNS trials O
trials CC and O
and VBN allowed O
allowed DT the O
the NN duration O
duration IN of O
of JJ phonological O
phonological VBG encoding O
encoding IN of O
of DT a O
a NN word O
word TO to O
to VB be O
be VBN estimated O

These DT CAPITAL These O
These NNS results O
results VB provide O
provide JJ electrophysiological O
electrophysiological NN evidence O
evidence IN for O
for RB early O
early JJ semantic O
semantic NN activation O
activation CC and O
and RB later O
later JJ phonological O
phonological VBG encoding O

The DT CAPITAL The O
The NNS effects O
effects IN of O
of NN alanine O
alanine CC and O
and NN glycine O
glycine NN substitution O
substitution IN for O
for NN tryptophan O
tryptophan IN upon O
upon DT the O
the NNS species O
species NN heterogeneity O
heterogeneity IN of O
of NN gramicidin O
gramicidin DT CAPITAL A O
A NNS analogs O
analogs VBN incorporated O
incorporated IN into O
into NN CAPITAL SDS O
SDS NNS micelles O
micelles VB have O
have VBN been O
been VBN investigated O

The DT CAPITAL The O
The JJ sequential O
sequential NN replacement O
replacement IN of O
of DT the O
the CD four O
four NN tryptophan O
tryptophan NNS residues O
residues IN in O
in NN gramicidin O
gramicidin DT CAPITAL A O
A IN at O
at NNS positions O
positions CD 15 O
15 , , O
, CD 13 O
13 , , O
, CD 11 O
11 , , O
, CC and O
and CD 9 O
9 IN with O
with NN glycine O
glycine VBD showed O
showed IN that O
that RB there O
there VBD was O
was DT no O
no JJ detectable O
detectable NN effect O
effect IN at O
at NN position O
position CD 15 O
15 CC but O
but VBG increasing O
increasing NN heterogeneity O
heterogeneity IN of O
of NNS species O
species IN in O
in DT the O
the NNS micelles O
micelles VBG proceeding O
proceeding IN toward O
toward DT the O
the JJ interior O
interior IN of O
of DT the O
the NN micelle O
micelle IN at O
at NN position O
position CD 9 O

The DT CAPITAL The O
The NN replacement O
replacement IN of O
of NN tryptophan O
tryptophan IN at O
at NNS positions O
positions CD 15 O
15 CC and O
and CD 9 O
9 IN with O
with NN alanine O
alanine VBD was O
was VBN found O
found TO to O
to VB produce O
produce RBR more O
more NNS species O
species NN heterogeneity O
heterogeneity IN than O
than VBN found O
found IN with O
with NN glycine O
glycine NN substitution O
substitution IN at O
at DT the O
the JJ same O
same NNS positions O

An DT CAPITAL An O
An NN increase O
increase IN in O
in DT the O
the NN CAPITAL SDS O
SDS NN concentration O
concentration VBZ reduces O
reduces DT the O
the NN number O
number IN of O
of JJ different O
different NNS species O
species JJ present O
present IN in O
in NNS micelles O

With IN CAPITAL With O
With DT the O
the NN CAPITAL Gly-11 O
Gly-11 , , O
, NN CAPITAL Gly-13 O
Gly-13 , , O
, CC and O
and NN CAPITAL Gly-15 O
Gly-15 NNS analogs O
analogs , , O
, DT the O
the NN increase O
increase IN in O
in NN CAPITAL SDS O
SDS NN concentration O
concentration NNS results O
results IN in O
in DT the O
the NN formation O
formation IN of O
of DT a O
a JJ single O
single NNS species O
species : ; O
; RB however O
however , , O
, IN for O
for DT the O
the NN CAPITAL Gly-9 O
Gly-9 , , O
, NN CAPITAL Ala-9 O
Ala-9 , , O
, CC and O
and NN CAPITAL Ala-15 O
Ala-15 NNS analogs O
analogs , , O
, NN heterogeneity O
heterogeneity VBZ remains O

Molecular JJ CAPITAL Molecular O
Molecular NNS dynamics O
dynamics IN in O
in JJ torsion-angle O
torsion-angle NN space O
space VBD was O
was VBN applied O
applied TO to O
to JJ nuclear O
nuclear JJ magnetic O
magnetic NN resonance O
resonance NN structure O
structure NN calculation O
calculation VBG using O
using JJ nuclear O
nuclear NNP CAPITAL Overhauser O
Overhauser JJ effect-derived O
effect-derived NNS distances O
distances CC and O
and JJ CAPITAL J-coupling-constant-derived O
J-coupling-constant-derived JJ dihedral O
dihedral NN angle O
angle NNS restraints O

Compared VBN CAPITAL Compared O
Compared TO to O
to CD two O
two JJ other O
other RB commonly O
commonly VBN used O
used NNS algorithms O
algorithms , , O
, JJ molecular O
molecular NNS dynamics O
dynamics IN in O
in JJ CAPITAL Cartesian O
Cartesian NN space O
space CC and O
and JJ metric-matrix O
metric-matrix NN geometry O
geometry JJ combined O
combined IN with O
with JJ CAPITAL Cartesian O
Cartesian JJ molecular O
molecular NNS dynamics O
dynamics , , O
, DT the O
the NN method O
method NNS shows O
shows VBN increased O
increased JJ computational O
computational NN efficiency O
efficiency CC and O
and NN success O
success NN rate O
rate IN for O
for JJ large O
large NNS proteins O
proteins , , O
, CC and O
and PRP it O
it NNS shows O
shows DT a O
a RB dramatically O
dramatically VBN increased O
increased NN radius O
radius IN of O
of NN convergence O
convergence IN for O
for NN CAPITAL DNA O

The DT CAPITAL The O
The JJ torsion-angle O
torsion-angle JJ molecular O
molecular NNS dynamics O
dynamics NN algorithm O
algorithm NNS starts O
starts IN from O
from DT an O
an VBN extended O
extended NN strand O
strand NN conformation O
conformation CC and O
and NNS proceeds O
proceeds IN in O
in CD four O
four NNS stages O
stages : : O
: JJ high-temperature O
high-temperature JJ torsion-angle O
torsion-angle JJ molecular O
molecular NNS dynamics O
dynamics , , O
, NN slow-cooling O
slow-cooling JJ torsion-angle O
torsion-angle JJ molecular O
molecular NNS dynamics O
dynamics , , O
, JJ CAPITAL Cartesian O
Cartesian JJ molecular O
molecular NNS dynamics O
dynamics , , O
, CC and O
and NN minimization O

Tests NNS CAPITAL Tests O
Tests VBD were O
were VBD carried O
carried IN out O
out VBG using O
using JJ experimental O
experimental NN CAPITAL NMR O
NMR NNS data O
data IN for O
for NN protein O
protein NN CAPITAL G O
G , , O
, NN interleukin-8 O
interleukin-8 , , O
, NN villin O
villin CD 14T O
14T , , O
, CC and O
and DT a O
a CD 12 O
12 NN base-pair O
base-pair NN duplex O
duplex IN of O
of NN CAPITAL DNA O
DNA , , O
, CC and O
and JJ simulated O
simulated NN CAPITAL NMR O
NMR NNS data O
data IN for O
for JJ bovine O
bovine JJ pancreatic O
pancreatic NN trypsin O
trypsin NN inhibitor O

For IN CAPITAL For O
For NN villin O
villin CD 14T O
14T , , O
, DT a O
a NN monomer O
monomer VBG consisting O
consisting IN of O
of CD 126 O
126 NNS residues O
residues , , O
, NN structure O
structure NN determination O
determination IN by O
by JJ torsion-angle O
torsion-angle JJ molecular O
molecular NNS dynamics O
dynamics VBZ has O
has DT a O
a NN success O
success NN rate O
rate IN of O
of CD 85 O
85 NN % O
% , , O
, DT a O
a RBR more O
more IN than O
than RB twofold O
twofold NN improvement O
improvement IN over O
over JJ other O
other NNS methods O

In IN CAPITAL In O
In DT the O
the NN case O
case IN of O
of DT the O
the CD 12 O
12 NN base-pair O
base-pair NN CAPITAL DNA O
DNA NN duplex O
duplex , , O
, JJ torsion-angle O
torsion-angle JJ molecular O
molecular NNS dynamics O
dynamics VBD had O
had DT a O
a NN success O
success NN rate O
rate IN of O
of CD 52 O
52 NN % O
% IN while O
while JJ CAPITAL Cartesian O
Cartesian JJ molecular O
molecular NNS dynamics O
dynamics CC and O
and JJ metric-matrix O
metric-matrix NN distance O
distance NN geometry O
geometry RB always O
always VBD failed O

The DT CAPITAL The O
The JJ wavelet-transform O
wavelet-transform NN method O
method VBZ is O
is VBN used O
used TO to O
to VB quantify O
quantify DT the O
the JJ magnetic O
magnetic NN resonance O
resonance NN spectroscopy O
spectroscopy NN ( O
( NNP CAPITAL MRS O
MRS NN ) O
) NNS parameters O
parameters : : O
: NN chemical O
chemical NN shift O
shift , , O
, JJ apparent O
apparent NN relaxation O
relaxation NN time O
time NN CAPITAL T2 O
T2 , , O
, NN resonance O
resonance NN amplitude O
amplitude , , O
, CC and O
and NN phase O

Wavelet NNP CAPITAL Wavelet O
Wavelet NN transformation O
transformation VBZ is O
is DT a O
a NN time-frequency O
time-frequency NN representation O
representation WDT which O
which VBZ separates O
separates DT each O
each NN component O
component IN from O
from DT the O
the NN CAPITAL FID O
FID , , O
, RB then O
then RB successively O
successively VBZ quantifies O
quantifies PRP it O
it CC and O
and VBZ subtracts O
subtracts PRP it O
it IN from O
from DT the O
the JJ raw O
raw NN signal O

Two CD CAPITAL Two O
Two JJ iterative O
iterative NNS procedures O
procedures VB have O
have VBN been O
been VBN developed O

They PRP CAPITAL They O
They VB have O
have VBN been O
been JJ combined O
combined IN with O
with DT a O
a JJ nonlinear O
nonlinear NN regression O
regression NN analysis O
analysis NN method O
method CC and O
and VBN tested O
tested IN on O
on DT both O
both JJ simulated O
simulated CC and O
and JJ real O
real NNS sets O
sets IN of O
of JJ biomedical O
biomedical NNP CAPITAL MRS O
MRS NNS data O
data VBN selected O
selected IN with O
with NN respect O
respect TO to O
to DT the O
the JJ main O
main NNS problems O
problems RB usually O
usually VBN encountered O
encountered IN in O
in VBG quantifying O
quantifying JJ biomedical O
biomedical NNP CAPITAL MRS O
MRS , , O
, RB specifically O
specifically `` `` O
`` NN chemical O
chemical NN noise O
noise , , O
, '' '' O
'' VBG resulting O
resulting IN from O
from VBG overlapping O
overlapping NNS resonances O
resonances , , O
, CC and O
and NN baseline O
baseline NN distortion O

The DT CAPITAL The O
The NNS results O
results VBP indicate O
indicate IN that O
that DT the O
the JJ wavelet-transform O
wavelet-transform NN method O
method MD can O
can VB provide O
provide JJ efficient O
efficient CC and O
and JJ accurate O
accurate NN quantification O
quantification IN of O
of NNP CAPITAL MRS O
MRS NNS data O

BACKGROUND NN CAPITAL BACKGROUND O
BACKGROUND : : O
: JJ CAPITAL Antiplatelet T
Antiplatelet NN therapy T
therapy IN with T
with NN aspirin T
aspirin CC and T
and JJ systematic T
systematic NN anticoagulation T
anticoagulation IN with T
with NN warfarin T
warfarin VB reduce O
reduce JJ cardiovascular D
cardiovascular NN morbidity D
morbidity CC and D
and NN mortality D
mortality IN after D
after JJ myocardial D
myocardial NN infarction D
infarction WRB when O
when VBN given O
given RB alone O

In IN CAPITAL In O
In DT the O
the NNP CAPITAL Coumadin O
Coumadin NN CAPITAL Aspirin O
Aspirin NN CAPITAL Reinfarction O
Reinfarction NNP CAPITAL Study O
Study NN ( O
( NNS CAPITAL CARS O
CARS NN ) O
) , , O
, PRP we O
we VBN aimed O
aimed TO to O
to VB find O
find IN out O
out IN whether O
whether DT a O
a NN combination O
combination IN of O
of JJ low-dose O
low-dose NN warfarin T
warfarin CC and O
and JJ low-dose T
low-dose NN aspirin T
aspirin MD would O
would VB give O
give JJ superior O
superior NNS results O
results TO to O
to JJ standard O
standard NN aspirin T
aspirin JJ monotherapy T
monotherapy IN without O
without JJ excessive O
excessive VBG bleeding O
bleeding NN risk O

METHODS NNS CAPITAL METHODS O
METHODS : : O
: PRP CAPITAL We O
We VBN used O
used DT a O
a VBN randomised O
randomised JJ double-blind O
double-blind NN study O
study NN design O

At IN CAPITAL At O
At CD 293 O
293 NNS sites O
sites , , O
, PRP we O
we RB randomly O
randomly VBN assigned O
assigned CD 8803 O
8803 NNS patients O
patients WP who O
who VBD had O
had VBD had O
had JJ myocardial D
myocardial NN infarction D
infarction , , O
, NN treatment O
treatment IN with O
with CD 160 T
160 NN mg T
mg NN aspirin T
aspirin , , O
, CD 3 T
3 NN mg T
mg NN warfarin T
warfarin IN with T
with CD 80 T
80 NN mg T
mg NN aspirin T
aspirin , , O
, CC or O
or CD 1 T
1 NN mg T
mg NN warfarin T
warfarin IN with T
with CD 80 T
80 NN mg T
mg NN aspirin T

Patients NNS CAPITAL Patients O
Patients VBD took O
took DT a O
a JJ single O
single NN tablet O
tablet RB daily O
daily , , O
, CC and O
and VBD attended O
attended IN for O
for NN prothrombin O
prothrombin NN time O
time NN ( O
( NN CAPITAL PT O
PT NN ) O
) NNS measurements O
measurements IN at O
at NNS weeks O
weeks CD 1 O
1 , , O
, CD 2 O
2 , , O
, CD 3 O
3 , , O
, CD 4 O
4 , , O
, CD 6 O
6 , , O
, CC and O
and CD 12 O
12 , , O
, CC and O
and RB then O
then DT every O
every CD 3 O
3 NNS months O

Patients NNS CAPITAL Patients O
Patients VBD were O
were VBN followed O
followed RB up O
up IN for O
for DT a O
a NN maximum O
maximum IN of O
of CD 33 O
33 NNS months O
months NN ( O
( JJ median O
median CD 14 O
14 NNS months O
months NN ) O

FINDINGS NNS CAPITAL FINDINGS O
FINDINGS : : O
: DT CAPITAL The O
The JJ primary O
primary NN event O
event VBD was O
was RB first O
first NN occurrence O
occurrence IN of O
of NN reinfarction O
reinfarction , , O
, JJ non-fatal O
non-fatal JJ ischaemic D
ischaemic NN stroke D
stroke , , O
, CC or O
or JJ cardiovascular O
cardiovascular NN death O

1-year JJ 1-year O
1-year JJ life-table O
life-table NNS estimates O
estimates IN for O
for DT the O
the JJ primary O
primary NN event O
event VBD were O
were CD 8.6 O
8.6 NN % O
% NN ( O
( CD 95 O
95 NN % O
% NN CAPITAL CI O
CI CD 7.6-9.6 O
7.6-9.6 NN ) O
) IN for O
for CD 160 O
160 NN mg O
mg NN aspirin T
aspirin , , O
, CD 8.4 O
8.4 NN % O
% NN ( O
( CD 7.4-9.4 O
7.4-9.4 NN ) O
) IN for O
for CD 3 O
3 NN mg O
mg NN warfarin T
warfarin IN with O
with CD 80 O
80 NN mg O
mg NN aspirin T
aspirin , , O
, CC and O
and CD 8.8 O
8.8 NN % O
% NN ( O
( CD 7.6-10 O
7.6-10 NN ) O
) IN for O
for CD 1 O
1 NN mg O
mg NN warfarin T
warfarin IN with O
with CD 80 O
80 NN mg O
mg NN aspirin T

Primary JJ CAPITAL Primary O
Primary NNS comparisons O
comparisons VBD were O
were VBN done O
done IN with O
with DT all O
all JJ follow-up O
follow-up NNS data O

The DT CAPITAL The O
The JJ relative O
relative NN risk O
risk IN of O
of DT the O
the JJ primary O
primary NN event O
event IN for O
for DT the O
the CD 160 O
160 NN mg O
mg NN aspirin O
aspirin NN group O
group VBN compared O
compared IN with O
with DT the O
the CD 3 O
3 NN mg O
mg NN warfarin O
warfarin IN with O
with CD 80 O
80 NN mg O
mg NN aspirin O
aspirin NN group O
group VBD was O
was CD 0.95 O
0.95 NN ( O
( CD 0.81-1.12 O
0.81-1.12 , , O
, NN p O
p JJ = O
= CD 0.57 O
0.57 NN ) O

For IN CAPITAL For O
For JJ spontaneous O
spontaneous JJ major O
major NN haemorrhage O
haemorrhage NN ( O
( RB not O
not NN procedure O
procedure JJ related O
related NN ) O
) , , O
, JJ 1-year O
1-year JJ life-table O
life-table NNS estimates O
estimates VBD were O
were CD 0.74 O
0.74 NN % O
% NN ( O
( CD 0.43-1.1 O
0.43-1.1 NN ) O
) IN in O
in DT the O
the CD 160 O
160 NN mg O
mg NN aspirin O
aspirin NN group O
group CC and O
and CD 1.4 O
1.4 NN % O
% NN ( O
( CD 0.94-1.8 O
0.94-1.8 NN ) O
) IN in O
in DT the O
the CD 3 O
3 NN mg O
mg NN warfarin O
warfarin IN with O
with CD 80 O
80 NN mg O
mg NN aspirin O
aspirin NN group O
group NN ( O
( NN p O
p JJ = O
= CD 0.014 O
0.014 NN log O
log NN rank O
rank IN on O
on JJ follow-up O
follow-up NN ) O

For IN CAPITAL For O
For DT the O
the CD 3382 O
3382 NNS patients O
patients VBN assigned O
assigned CD 3 O
3 NN mg O
mg NN warfarin T
warfarin IN with O
with CD 80 O
80 NN mg O
mg NN aspirin T
aspirin , , O
, DT the O
the NN CAPITAL INR O
INR NNS results O
results VBD were O
were : : O
: IN at O
at NN week O
week CD 1 O
1 NN ( O
( NN n O
n JJ = O
= CD 2985 O
2985 NN ) O
) JJ median O
median CD 1.51 O
1.51 NN ( O
( NN CAPITAL IQR O
IQR CD 1.23-2.13 O
1.23-2.13 NN ) O
) : ; O
; IN at O
at NN week O
week CD 4 O
4 NN ( O
( NN n O
n JJ = O
= CD 2701 O
2701 NN ) O
) CD 1.27 O
1.27 NN ( O
( CD 1.13-1.64 O
1.13-1.64 NN ) O
) : ; O
; IN at O
at NN month O
month CD 6 O
6 NN ( O
( NN n O
n JJ = O
= CD 2145 O
2145 NN ) O
) CD 1.19 O
1.19 NN ( O
( CD 1.08-1.44 O
1.08-1.44 NN ) O

INTERPRETATION NN CAPITAL INTERPRETATION O
INTERPRETATION : : O
: JJ CAPITAL Low O
Low , , O
, JJ fixed-dose O
fixed-dose NN warfarin T
warfarin NN ( T
( CD 1 T
1 NN mg T
mg CC or T
or CD 3 T
3 NN mg T
mg NN ) T
) VBN combined T
combined IN with T
with JJ low-dose T
low-dose NN aspirin T
aspirin NN ( T
( CD 80 T
80 NN mg T
mg NN ) T
) IN in O
in NNS patients O
patients WP who O
who VB have O
have VBD had O
had JJ myocardial D
myocardial NN infarction D
infarction VBZ does O
does RB not O
not VB provide O
provide JJ clinical O
clinical NN benefit O
benefit IN beyond O
beyond IN that O
that JJ achievable O
achievable IN with O
with CD 160 O
160 NN mg O
mg NN aspirin T
aspirin JJ monotherapy T

BACKGROUND NN CAPITAL BACKGROUND O
BACKGROUND : : O
: EX CAPITAL There O
There VBZ is O
is JJ serological O
serological NN evidence O
evidence IN for O
for DT an O
an NN association O
association IN between O
between NN CAPITAL Chlamydia D
Chlamydia FW pneumoniae D
pneumoniae CC and O
and JJ coronary D
coronary NN heart D
heart NN disease D

We PRP CAPITAL We O
We VBN investigated O
investigated DT the O
the NN hypothesis O
hypothesis IN that O
that DT an T
an JJ antichlamydial T
antichlamydial NN macrolide T
macrolide JJ antibiotic T
antibiotic , , T
, NN roxithromycin T
roxithromycin , , O
, MD can O
can VB prevent O
prevent CC or O
or VB reduce O
reduce JJ recurrent O
recurrent JJ major O
major JJ ischaemic O
ischaemic NNS events O
events IN in O
in NNS patients O
patients IN with O
with JJ unstable D
unstable NN angina D

METHODS NNS CAPITAL METHODS O
METHODS : : O
: DT CAPITAL The O
The NN effect O
effect IN of O
of NN roxithromycin T
roxithromycin VBD was O
was VBN assessed O
assessed IN in O
in DT a O
a JJ double-blind O
double-blind , , O
, VBN randomised O
randomised , , O
, JJ prospective O
prospective , , O
, JJ multicentre O
multicentre , , O
, JJ parallel-group O
parallel-group , , O
, JJ placebo-controlled O
placebo-controlled NN pilot O
pilot NN study O
study IN of O
of CD 202 O
202 NNS patients O
patients IN with O
with JJ unstable D
unstable NN angina D
angina CC or O
or JJ non-Q-wave D
non-Q-wave JJ myocardial D
myocardial NN infarction D

Patients NNS CAPITAL Patients O
Patients VBD were O
were RB randomly O
randomly VBN assigned O
assigned DT either O
either NN roxithromycin T
roxithromycin CD 150 O
150 NN mg O
mg RB orally O
orally RB twice O
twice DT a O
a NN day O
day NN ( O
( NN n O
n JJ = O
= CD 102 O
102 NN ) O
) CC or O
or NN placebo O
placebo RB orally O
orally RB twice O
twice DT a O
a NN day O
day NN ( O
( NN n O
n JJ = O
= CD 100 O
100 NN ) O

The DT CAPITAL The O
The NN treatment O
treatment VBD was O
was IN for O
for CD 30 O
30 NNS days O

Patients NNS CAPITAL Patients O
Patients VBD were O
were VBN followed O
followed RB up O
up IN for O
for CD 6 O
6 NNS months O

We PRP CAPITAL We O
We NN report O
report DT the O
the JJ primary O
primary JJ clinical O
clinical NNS endpoints O
endpoints NN ( O
( JJ cardiac D
cardiac JJ ischaemic D
ischaemic NN death D
death , , O
, JJ myocardial D
myocardial NN infarction D
infarction , , O
, CC and O
and JJ severe O
severe JJ recurrent O
recurrent NN ischaemia D
ischaemia NN ) O
) , , O
, VBN assessed O
assessed IN at O
at NN day O
day CD 31 O
31 , , O
, IN in O
in CD 202 O
202 NNS patients O
patients IN on O
on DT an O
an NN intention-to-treat O
intention-to-treat NN basis O

FINDINGS NNS CAPITAL FINDINGS O
FINDINGS : : O
: DT CAPITAL A O
A RB statistically O
statistically JJ significant O
significant NN reduction O
reduction IN in O
in DT the O
the JJ primary O
primary JJ composite O
composite JJ triple O
triple NN endpoint O
endpoint NNS rates O
rates VBD was O
was VBN observed O
observed IN in O
in DT the O
the NN roxithromycin O
roxithromycin NN group O
group : : O
: NN p O
p JJ = O
= CD 0.032 O

The DT CAPITAL The O
The NN rate O
rate IN of O
of JJ severe O
severe JJ recurrent O
recurrent NN ischaemia O
ischaemia , , O
, JJ myocardial O
myocardial NN infarction O
infarction , , O
, CC and O
and JJ ischaemic O
ischaemic NN death O
death VBD was O
was CD 5.4 O
5.4 NN % O
% , , O
, CD 2.2 O
2.2 NN % O
% , , O
, CC and O
and CD 2.2 O
2.2 NN % O
% IN in O
in DT the O
the NN placebo O
placebo NN group O
group CC and O
and CD 1.1 O
1.1 NN % O
% , , O
, CD 0 O
0 NN % O
% , , O
, CC and O
and CD 0 O
0 NN % O
% , , O
, IN in O
in DT the O
the NN roxithromycin O
roxithromycin NN group O
group , , O
, RB respectively O

No DT CAPITAL No O
No JJ major O
major JJ drug-related O
drug-related JJ adverse O
adverse NNS effects O
effects VBD were O
were VBN observed O

INTERPRETATION NN CAPITAL INTERPRETATION O
INTERPRETATION : : O
: JJ CAPITAL Antichlamydial T
Antichlamydial NNS antibiotics T
antibiotics MD may O
may VB be O
be JJ useful O
useful IN in O
in JJ therapeutic O
therapeutic NN intervention O
intervention IN in O
in NN addition O
addition TO to O
to JJ standard O
standard NN medication O
medication IN in O
in NNS patients O
patients IN with O
with NN coronary-artery D
coronary-artery NN disease D

Large-scale JJ CAPITAL Large-scale O
Large-scale NNS trials O
trials VBP are O
are VBN needed O
needed TO to O
to VBP confirm O
confirm DT these O
these JJ preliminary O
preliminary NNS observations O

BACKGROUND NN CAPITAL BACKGROUND O
BACKGROUND : : O
: NN CAPITAL Stage D
Stage NN CAPITAL Ib D
Ib CC and D
and NN CAPITAL IIa D
IIa JJ cervical D
cervical NN carcinoma D
carcinoma MD can O
can VB be O
be VBN cured O
cured IN by O
by JJ radical T
radical NN surgery T
surgery CC or O
or NN radiotherapy T

These DT CAPITAL These O
These CD two O
two NNS procedures O
procedures VBP are O
are RB equally O
equally JJ effective O
effective , , O
, CC but O
but VBP differ O
differ IN in O
in VBN associated O
associated NN morbidity O
morbidity CC and O
and NN type O
type IN of O
of NNS complications O

In IN CAPITAL In O
In DT this O
this JJ prospective O
prospective VBN randomised O
randomised NN trial O
trial IN of O
of NN radiotherapy T
radiotherapy CC versus O
versus NN surgery T
surgery , , O
, PRP$ our O
our NN aim O
aim VBD was O
was TO to O
to VB assess O
assess DT the O
the JJ 5-year O
5-year NN survival O
survival CC and O
and DT the O
the NN rate O
rate CC and O
and NN pattern O
pattern IN of O
of NNS complications O
complications CC and O
and NNS recurrences O
recurrences VBN associated O
associated IN with O
with DT each O
each NN treatment O

METHODS NNS CAPITAL METHODS O
METHODS : : O
: IN CAPITAL Between O
Between NNP CAPITAL September O
September , , O
, CD 1986 O
1986 , , O
, CC and O
and NNP CAPITAL December O
December , , O
, CD 1991 O
1991 , , O
, CD 469 O
469 NNS women O
women IN with O
with RB newly O
newly VBN diagnosed O
diagnosed NN stage O
stage NN CAPITAL Ib O
Ib CC and O
and NN CAPITAL IIa O
IIa JJ cervical T
cervical NN carcinoma T
carcinoma VBD were O
were VBN referred O
referred TO to O
to PRP$ our O
our NN institute O

343 CD 343 O
343 JJ eligible O
eligible NNS patients O
patients VBD were O
were VBN randomised O
randomised : : O
: CD 172 O
172 TO to O
to NN surgery T
surgery CC and O
and CD 171 O
171 TO to O
to JJ radical O
radical NN radiotherapy T

Adjuvant JJ CAPITAL Adjuvant O
Adjuvant NN radiotherapy O
radiotherapy VBD was O
was VBN delivered O
delivered IN after O
after NN surgery O
surgery IN for O
for NNS women O
women IN with O
with JJ surgical O
surgical NN stage O
stage NN pT2b O
pT2b CC or O
or JJR greater O
greater , , O
, JJR less O
less IN than O
than CD 3 O
3 NN mm O
mm IN of O
of JJ safe O
safe JJ cervical O
cervical NN stroma O
stroma , , O
, JJ cut-through O
cut-through , , O
, CC or O
or JJ positive O
positive NNS nodes O

The DT CAPITAL The O
The JJ primary O
primary NN outcome O
outcome NNS measures O
measures VBD were O
were JJ 5-year O
5-year NN survival O
survival CC and O
and DT the O
the NN rate O
rate IN of O
of NNS complications O

The DT CAPITAL The O
The NN analysis O
analysis IN of O
of NN survival O
survival CC and O
and NN recurrence O
recurrence VBD was O
was IN by O
by NN intention O
intention TO to O
to VB treat O
treat CC and O
and NN analysis O
analysis IN of O
of NNS complications O
complications VBD was O
was IN by O
by NN treatment O
treatment VBN delivered O

FINDINGS NNS CAPITAL FINDINGS O
FINDINGS : : O
: CD 170 O
170 NNS patients O
patients IN in O
in DT the O
the NN surgery O
surgery NN group O
group CC and O
and CD 167 O
167 IN in O
in DT the O
the NN radiotherapy O
radiotherapy NN group O
group VBD were O
were VBN included O
included IN in O
in DT the O
the NN intention-to-treat O
intention-to-treat NN analysis O
analysis : ; O
; VBN scheduled O
scheduled NN treatment O
treatment VBD was O
was VBN delivered O
delivered TO to O
to CD 169 O
169 CC and O
and CD 158 O
158 NNS women O
women , , O
, RB respectively O
respectively , , O
, CD 62 O
62 IN of O
of CD 114 O
114 NNS women O
women IN with O
with JJ cervical O
cervical NNS diameters O
diameters IN of O
of CD 4 O
4 NN cm O
cm CC or O
or JJR smaller O
smaller CC and O
and CD 46 O
46 IN of O
of CD 55 O
55 IN with O
with NNS diameters O
diameters JJR larger O
larger IN than O
than CD 4 O
4 NN cm O
cm VBN received O
received JJ adjuvant O
adjuvant NN therapy O

After IN CAPITAL After O
After DT a O
a JJ median O
median JJ follow-up O
follow-up IN of O
of CD 87 O
87 NN ( O
( NN range O
range JJ 57-120 O
57-120 NN ) O
) NNS months O
months , , O
, JJ 5-year O
5-year JJ overall O
overall CC and O
and JJ disease-free O
disease-free NN survival O
survival VBD were O
were JJ identical O
identical IN in O
in DT the O
the NN surgery O
surgery CC and O
and NN radiotherapy O
radiotherapy NNS groups O
groups NN ( O
( CD 83 O
83 NN % O
% CC and O
and CD 74 O
74 NN % O
% , , O
, RB respectively O
respectively , , O
, IN for O
for DT both O
both NNS groups O
groups NN ) O
) , , O
, CD 86 O
86 NNS women O
women VBN developed O
developed JJ recurrent O
recurrent NN disease O
disease : : O
: CD 42 O
42 NN ( O
( CD 25 O
25 NN % O
% NN ) O
) IN in O
in DT the O
the NN surgery O
surgery NN group O
group CC and O
and CD 44 O
44 NN ( O
( CD 26 O
26 NN % O
% NN ) O
) IN in O
in DT the O
the NN radiotherapy O
radiotherapy NN group O

Significant JJ CAPITAL Significant O
Significant NNS factors O
factors IN for O
for NN survival O
survival IN in O
in JJ univariate O
univariate CC and O
and JJ multivariate O
multivariate NNS analyses O
analyses VBD were O
were : : O
: JJ cervical O
cervical NN diameter O
diameter , , O
, JJ positive O
positive NN lymphangiography O
lymphangiography , , O
, CC and O
and JJ adeno-carcinomatous O
adeno-carcinomatous NN histotype O

48 CD 48 O
48 NN ( O
( CD 28 O
28 NN % O
% NN ) O
) JJ surgery-group O
surgery-group NNS patients O
patients VBD had O
had JJ severe O
severe NN morbidity O
morbidity VBN compared O
compared IN with O
with CD 19 O
19 NN ( O
( CD 12 O
12 NN % O
% NN ) O
) JJ radiotherapy-group O
radiotherapy-group NNS patients O
patients NN ( O
( NN p O
p JJ = O
= CD 0.0004 O
0.0004 NN ) O

INTERPRETATION NN CAPITAL INTERPRETATION O
INTERPRETATION : : O
: EX CAPITAL There O
There VBZ is O
is DT no O
no NN treatment O
treatment IN of O
of NN choice O
choice IN for O
for JJ early-stage O
early-stage JJ cervical D
cervical NN carcinoma D
carcinoma IN in O
in NNS terms O
terms IN of O
of JJ overall O
overall CC or O
or JJ disease-free O
disease-free NN survival O

The DT CAPITAL The O
The NN combination O
combination IN of O
of NN surgery D
surgery CC and O
and NN radiotherapy D
radiotherapy VBZ has O
has DT the O
the JJS worst O
worst NN morbidity O
morbidity , , O
, RB especially O
especially JJ urological O
urological NNS complications O

The DT CAPITAL The O
The JJ optimum O
optimum NN therapy O
therapy IN for O
for DT each O
each NN patient O
patient MD should O
should VB take O
take NN account O
account IN of O
of JJ clinical O
clinical NNS factors O
factors JJ such O
such IN as O
as JJ menopausal O
menopausal NN status O
status , , O
, NN age O
age , , O
, JJ medical O
medical NN illness O
illness , , O
, JJ histological O
histological NN type O
type , , O
, CC and O
and JJ cervical O
cervical NN diameter O
diameter TO to O
to NN yield O
yield DT the O
the RB best O
best NN cure O
cure IN with O
with JJ minimum O
minimum NNS complications O

Today NN CAPITAL Today O
Today POS 's O
's NN technology O
technology NNS links O
links NN health O
health NN care O
care NNS providers O
providers CC and O
and NNS patients O
patients IN across O
across NN town O
town , , O
, IN in O
in DT the O
the JJ next O
next NN state O
state CC or O
or RB even O
even DT another O
another NN country O

Nursing NNP CAPITAL Nursing O
Nursing IN across O
across NN state O
state NNS lines O
lines VBZ poses O
poses NNS complications O
complications : : O
: JJ state-bound O
state-bound JJ regulatory O
regulatory CC and O
and NN licensure O
licensure NNS issues O

This DT CAPITAL This O
This NN article O
article VBZ discusses O
discusses JJ many O
many IN of O
of DT the O
the JJ nutritional O
nutritional NNS topics O
topics JJ important O
important TO to O
to DT the O
the NN intensivist O

Nutritional NNP CAPITAL Nutritional O
Nutritional NN assessment O
assessment , , O
, JJ substrate O
substrate NN immunonutrition O
immunonutrition , , O
, CC and O
and NN disease O
disease JJ specific O
specific NNS issues O
issues VBP are O
are VBN presented O

Early RB CAPITAL Early O
Early NN introduction O
introduction IN of O
of JJ enteral O
enteral VBZ feeds O
feeds CC and O
and DT the O
the NN use O
use IN of O
of JJ nutritional O
nutritional NN modulation O
modulation VBP are O
are VBN emphasized O

PROBLEM NN CAPITAL PROBLEM O
PROBLEM : : O
: TO CAPITAL To O
To VB compare O
compare DT the O
the NN expression O
expression IN by O
by NNS CAPITAL T-lymphocytes O
T-lymphocytes IN of O
of DT an O
an JJ immunomodulatory O
immunomodulatory NN protein O
protein JJ known O
known IN as O
as JJ progesterone-induced O
progesterone-induced VBG blocking O
blocking NN factor O
factor NN ( O
( NN CAPITAL PIBF O
PIBF NN ) O
) IN in O
in NN conception O
conception CC versus O
versus JJ non-conception O
non-conception NNS cycles O
cycles RB even O
even WRB when O
when RB there O
there VBZ has O
has VBN been O
been JJ definite O
definite NN fertilization O
fertilization CC and O
and NN embryo O
embryo NN formation O

METHOD NN CAPITAL METHOD O
METHOD : : O
: NN CAPITAL PIBF O
PIBF NN expression O
expression IN on O
on NN CAPITAL T O
T NNS lymphocytes O
lymphocytes VBD was O
was VBN measured O
measured VBG using O
using DT an O
an JJ immunohistochemical O
immunohistochemical NN method O
method IN with O
with DT a O
a JJ CAPITAL PIBF-specific O
PIBF-specific JJ polyclonal O
polyclonal NN antibody O

These DT CAPITAL These O
These NNS levels O
levels VBD were O
were VBN determined O
determined IN in O
in NNS patients O
patients VBG undergoing O
undergoing CD three O
three NNS types O
types IN of O
of NN therapy O
therapy : : O
: JJ non-in O
non-in FW vitro O
vitro NN fertilization O
fertilization NN ( O
( NN CAPITAL IVF O
IVF NN ) O
) , , O
, JJ CAPITAL IVF-embryo O
IVF-embryo NN transfer O
transfer NN ( O
( NNP CAPITAL ET O
ET NN ) O
) , , O
, CC and O
and JJ frozen O
frozen NNP CAPITAL ET O

Sera NNP CAPITAL Sera O
Sera VBD were O
were VBN drawn O
drawn CD 12 O
12 NNS days O
days IN from O
from NN ovulation O
ovulation IN in O
in JJ non-IVF O
non-IVF NNS cycles O
cycles CC or O
or CD 9 O
9 NNS days O
days IN after O
after NNP CAPITAL ET O
ET CC and O
and VBD were O
were VBN assayed O
assayed IN for O
for NN CAPITAL PIBF O
PIBF CC and O
and NN beta O
beta JJ human O
human JJ chorionic O
chorionic NN gondotropin O

Comparison NN CAPITAL Comparison O
Comparison IN of O
of DT the O
the NN frequency O
frequency IN of O
of NN lymphocyte O
lymphocyte NN expression O
expression IN of O
of NN CAPITAL PIBF O
PIBF IN in O
in JJ pregnant O
pregnant CC versus O
versus JJ non-pregnant O
non-pregnant NNS women O
women VBD were O
were VBN made O

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: NN CAPITAL PIBF O
PIBF VBD was O
was VBN detected O
detected IN in O
in CD 29.5 O
29.5 NN % O
% IN of O
of JJ non-pregnant O
non-pregnant NNS women O
women CC and O
and CD 52.5 O
52.5 NN % O
% IN of O
of JJ pregnant O
pregnant NNS women O

There EX CAPITAL There O
There VBD were O
were DT no O
no NNS differences O
differences IN in O
in NN CAPITAL PIBF O
PIBF NNS levels O
levels IN by O
by NN therapy O
therapy VBN used O
used IN in O
in JJ non-pregnant O
non-pregnant NNS cases O
cases CC or O
or IN in O
in DT the O
the JJ pregnant O
pregnant NN group O

CONCLUSION NN CAPITAL CONCLUSION O
CONCLUSION : : O
: DT CAPITAL These O
These NNS data O
data VBP are O
are JJ consistent O
consistent IN with O
with DT the O
the NN hypothesis O
hypothesis IN that O
that JJ maternal O
maternal NN expression O
expression IN of O
of NN CAPITAL PIBF O
PIBF IN in O
in NNS CAPITAL T-lymphocytes O
T-lymphocytes RB soon O
soon IN after O
after NN trophoblast O
trophoblast NN invasion O
invasion MD may O
may VB depend O
depend IN on O
on JJ successful O
successful NN implantation O

Many JJ CAPITAL Many O
Many NN amino O
amino NNS acids O
acids VB contain O
contain DT an O
an JJ asymmetric O
asymmetric NN centre O
centre , , O
, VBG occurring O
occurring IN as O
as JJ laevorotatory O
laevorotatory , , O
, NN CAPITAL L O
L , , O
, CC or O
or JJ dextrorotatory O
dextrorotatory , , O
, NN CAPITAL D O
D , , O
, NNS compounds O

It PRP CAPITAL It O
It VBZ is O
is RB generally O
generally VBN assumed O
assumed IN that O
that JJ abiotic O
abiotic NN synthesis O
synthesis IN of O
of NN amino O
amino NNS acids O
acids IN on O
on DT the O
the RB early O
early NNP CAPITAL Earth O
Earth VBD resulted O
resulted IN in O
in JJ racemic O
racemic NNS mixtures O
mixtures NN ( O
( JJ CAPITAL L- O
L- CC and O
and NNS CAPITAL D-enantiomers O
D-enantiomers IN in O
in JJ equal O
equal NN abundance O
abundance NN ) O

But CC CAPITAL But O
But DT the O
the NN origin O
origin IN of O
of NN life O
life VBN required O
required , , O
, VBG owing O
owing TO to O
to JJ conformational O
conformational NNS constraints O
constraints , , O
, DT the O
the RB almost O
almost JJ exclusive O
exclusive NN selection O
selection IN of O
of DT either O
either JJ CAPITAL L- O
L- CC or O
or NNS CAPITAL D-enantiomers O
D-enantiomers , , O
, CC and O
and DT the O
the NN question O
question IN of O
of WRB why O
why VBG living O
living NNS systems O
systems IN on O
on DT the O
the NNP CAPITAL Earth O
Earth VBP consist O
consist IN of O
of NNS CAPITAL L-enantiomers O
L-enantiomers RB rather O
rather IN than O
than NNS CAPITAL D-enantiomers O
D-enantiomers VBZ is O
is JJ unresolved O

A DT CAPITAL A O
A JJ substantial O
substantial NN fraction O
fraction IN of O
of DT the O
the JJ organic O
organic NNS compounds O
compounds IN on O
on DT the O
the RB early O
early NNP CAPITAL Earth O
Earth MD may O
may VB have O
have VBN been O
been VBN derived O
derived IN from O
from NN comet O
comet CC and O
and NN meteorite O
meteorite NNS impacts O

It PRP CAPITAL It O
It VBZ has O
has VBN been O
been VBN reported O
reported RB previously O
previously IN that O
that NN amino O
amino NNS acids O
acids IN in O
in DT the O
the NNP CAPITAL Murchison O
Murchison NN meteorite O
meteorite NN exhibit O
exhibit DT an O
an JJ excess O
excess IN of O
of NNS CAPITAL L-enantiomers O
L-enantiomers , , O
, VBG raising O
raising DT the O
the NN possibility O
possibility IN that O
that DT a O
a JJ similar O
similar JJ excess O
excess VBD was O
was JJ present O
present IN in O
in DT the O
the JJ initial O
initial NN inventory O
inventory IN of O
of JJ organic O
organic NNS compounds O
compounds IN on O
on DT the O
the NNP CAPITAL Earth O

The DT CAPITAL The O
The JJ stable O
stable NN carbon O
carbon NN isotope O
isotope NNS compositions O
compositions IN of O
of JJ individual O
individual NN amino O
amino NNS acids O
acids IN in O
in NNP CAPITAL Murchison O
Murchison NN support O
support DT an O
an JJ extraterrestrial O
extraterrestrial NN origin O
origin : -- O
-- RB rather O
rather IN than O
than DT a O
a JJ terrestrial O
terrestrial NN overprint O
overprint IN of O
of JJ biological O
biological NN amino O
amino JJ acids-although O
acids-although NNS reservations O
reservations VB have O
have VBD persisted O

Here RB CAPITAL Here O
Here PRP we O
we NN show O
show IN that O
that JJ individual O
individual JJ amino-acid O
amino-acid NNS enantiomers O
enantiomers IN from O
from NNP CAPITAL Murchison O
Murchison VBP are O
are JJ enriched O
enriched IN in O
in NN 15N O
15N JJ relative O
relative TO to O
to PRP$ their O
their JJ terrestrial O
terrestrial NNS counterparts O
counterparts , , O
, RB so O
so VBG confirming O
confirming DT an O
an JJ extraterrestrial O
extraterrestrial NN source O
source IN for O
for DT an O
an NN CAPITAL L-enantiomer O
L-enantiomer JJ excess O
excess IN in O
in DT the O
the NNP CAPITAL Solar O
Solar NNP CAPITAL System O
System IN that O
that MD may O
may VB predate O
predate DT the O
the NN origin O
origin IN of O
of NN life O
life IN on O
on DT the O
the NNP CAPITAL Earth O

Home NNP CAPITAL Home O
Home NN care O
care NNS workers O
workers NN face O
face DT an O
an VBG increasing O
increasing NN risk O
risk IN for O
for NN workplace O
workplace NN violence O

A DT CAPITAL A O
A JJ proactive O
proactive JJ preventive O
preventive NN approach O
approach VBZ is O
is VBN presented O
presented IN that O
that VBZ suggests O
suggests NNS strategies O
strategies TO to O
to NN use O
use IN during O
during DT the O
the NN previsit O
previsit NN phase O
phase , , O
, DT the O
the NN visit O
visit NN experience O
experience , , O
, CC and O
and IN on O
on DT an O
an JJ ongoing O
ongoing NN basis O

The DT CAPITAL The O
The NN miracidia O
miracidia IN of O
of JJ CAPITAL Fasciola O
Fasciola NN hepatica O
hepatica CC and O
and FW CAPITAL Trichobilharzia O
Trichobilharzia NN ocellata O
ocellata NN approach O
approach PRP$ their O
their NN host O
host NNS snails O
snails NN CAPITAL Lymnaea O
Lymnaea NN truncatula O
truncatula CC and O
and NNP CAPITAL L. O
L. NN stagnalis O
stagnalis IN by O
by VBG increasing O
increasing PRP$ their O
their NN rate O
rate IN of O
of NN change O
change IN of O
of NN direction O
direction NN ( O
( NN CAPITAL RCD O
RCD NN ) O
) IN in O
in VBG increasing O
increasing NNS gradients O
gradients IN of O
of JJ snail-conditioned O
snail-conditioned NN water O
water NN ( O
( NN CAPITAL SCW O
SCW NN ) O
) , , O
, CC and O
and PRP they O
they VB perform O
perform DT a O
a NN turnback O
turnback VBG swimming O
swimming IN in O
in VBG decreasing O
decreasing NNS gradients O

Both DT CAPITAL Both O
Both VBG hostfinding O
hostfinding NNS responses O
responses IN in O
in DT both O
both NNS species O
species VBD were O
were VBN induced O
induced IN by O
by NNS glycoconjugates O
glycoconjugates IN with O
with DT a O
a JJ molecular O
molecular NN weight O
weight IN of O
of JJR > O
> CD 30 O
30 NN kDa O
kDa IN that O
that VBD were O
were JJ sensitive O
sensitive TO to O
to NN hydrolysis O
hydrolysis IN with O
with NN pronase O
pronase NN CAPITAL E O
E CC and O
and NN oxidation O
oxidation IN with O
with NN CAPITAL NaIO4 O

Alkaline NN CAPITAL Alkaline O
Alkaline NN cleavage O
cleavage VBD revealed O
revealed IN that O
that PRP they O
they VBN contained O
contained NNS carbohydrates O
carbohydrates VBN linked O
linked RB CAPITAL O-glycosidically O
O-glycosidically IN via O
via NN serine O
serine CC and O
and NN CAPITAL N-acetylgalactosamine O

Miracidia NNP CAPITAL Miracidia O
Miracidia RB clearly O
clearly VBN preferred O
preferred NN CAPITAL SCW O
SCW IN from O
from PRP$ their O
their JJ specific O
specific NN host O
host NN snail O
snail CC versus O
versus JJ other O
other JJ sympatric O
sympatric NN snail O
snail NNS species O
species CC and O
and VBD did O
did RB not O
not NN respond O
respond TO to O
to NN water O
water VBN conditioned O
conditioned IN with O
with NN fish O
fish , , O
, NNS tadpoles O
tadpoles , , O
, CC or O
or NNS leeches O

Differences NNS CAPITAL Differences O
Differences IN in O
in DT the O
the NN chemical O
chemical NNS characteristics O
characteristics IN of O
of NN CAPITAL SCW O
SCW IN from O
from DT the O
the JJ intermediate O
intermediate NNS hosts O
hosts NNP CAPITAL L. O
L. NN truncatula O
truncatula CC and O
and NNP CAPITAL L. O
L. NN stagnalis O
stagnalis MD could O
could VB be O
be VBN shown O
shown IN by O
by NN sodium O
sodium NN dodecyl O
dodecyl JJ sulfate-polyacrylamide O
sulfate-polyacrylamide NN gel O
gel NN electrophoresis O
electrophoresis , , O
, VBG blotting O
blotting , , O
, CC and O
and JJ subsequent O
subsequent NN carbohydrate O
carbohydrate NN detection O

The DT CAPITAL The O
The RB first O
first NN step O
step IN of O
of NN purification O
purification IN of O
of DT the O
the JJ effective O
effective VBG signaling O
signaling NN CAPITAL SCW O
SCW NNS components O
components IN from O
from DT both O
both NN snail O
snail NNS species O
species VBD was O
was VBN achieved O
achieved IN by O
by JJ ion-exchange O
ion-exchange NN chromatography O

Black JJ CAPITAL Black O
Black NNS patients O
patients IN with O
with NN colon D
colon NN cancer D
cancer IN in O
in DT the O
the NN CAPITAL Black/White O
Black/White NN CAPITAL Cancer O
Cancer NN CAPITAL Survival O
Survival NNP CAPITAL Study O
Study VBD were O
were VBN found O
found TO to O
to VB have O
have DT a O
a JJR poorer O
poorer NN survival O
survival IN than O
than JJ white O
white NNS patients O

More RBR CAPITAL More O
More JJ advanced-stage O
advanced-stage NN disease O
disease IN at O
at NN diagnosis O
diagnosis VBD was O
was DT the O
the JJ primary O
primary NN determinant O
determinant , , O
, VBG accounting O
accounting IN for O
for CD 60 O
60 NN % O
% IN of O
of DT the O
the JJ excess O
excess NN mortality O

After IN CAPITAL After O
After VBG adjusting O
adjusting IN for O
for NN stage O
stage , , O
, NNS factors O
factors JJ such O
such IN as O
as NN poverty O
poverty , , O
, JJ other O
other JJ socioeconomic O
socioeconomic NNS conditions O
conditions , , O
, CC and O
and NN treatment O
treatment VBD did O
did RB not O
not RB further O
further VB explain O
explain DT the O
the VBG remaining O
remaining NN survival O
survival NN deficit O

This DT CAPITAL This O
This NN study O
study VBN examined O
examined DT the O
the NN aggressiveness O
aggressiveness IN of O
of NN colon D
colon NNS tumors D
tumors IN in O
in NNS blacks O
blacks CC and O
and NNS whites O
whites TO to O
to VB explore O
explore PRP$ its O
its NN role O
role IN in O
in DT the O
the JJ racial O
racial NN survival O
survival NNS differences O

Tumor NN CAPITAL Tumor O
Tumor NNS characteristics O
characteristics IN of O
of CD 703 O
703 NNS cases O
cases IN of O
of RB newly O
newly VBN diagnosed O
diagnosed JJ invasive O
invasive NN colon O
colon NN adenocarcinoma D
adenocarcinoma VBD were O
were RB centrally O
centrally VBN evaluated O
evaluated IN by O
by DT a O
a JJ gastrointestinal O
gastrointestinal NN pathologist O
pathologist , , O
, VBN blinded O
blinded IN in O
in NN regard O
regard TO to O
to DT the O
the NN age O
age , , O
, NN race O
race , , O
, CC and O
and NN sex O
sex IN of O
of DT the O
the NNS patients O

Blacks NNPS CAPITAL Blacks O
Blacks VBD were O
were JJR less O
less JJ likely O
likely TO to O
to VB have O
have RB poorly O
poorly VBN differentiated O
differentiated NN ( O
( NN grade O
grade CD 3 O
3 NN ) O
) NNS tumors D
tumors NN ( O
( NNS odds O
odds NN ratio O
ratio NN ( O
( NN CAPITAL OR O
OR NN ) O
) , , O
, CD 0.44 O
0.44 : ; O
; CD 95 O
95 NN % O
% NN confidence O
confidence NN interval O
interval , , O
, CD 0.22-0.88 O
0.22-0.88 NN ) O
) CC and O
and JJ lymphoid O
lymphoid NN reaction O
reaction NN ( O
( NN CAPITAL OR O
OR , , O
, CD 0.49 O
0.49 : ; O
; CD 95 O
95 NN % O
% NN confidence O
confidence NN interval O
interval , , O
, CD 0.26-0.90 O
0.26-0.90 NN ) O
) WRB when O
when VBN compared O
compared IN with O
with NNS whites O

These DT CAPITAL These O
These JJ black/white O
black/white NN ( O
( NN CAPITAL B/W O
B/W NN ) O
) NNS differences O
differences VBD remained O
remained RB statistically O
statistically JJ significant O
significant IN after O
after VBG adjusting O
adjusting IN for O
for NN age O
age , , O
, NN sex O
sex , , O
, JJ metropolitan O
metropolitan NN area O
area , , O
, NN summary O
summary NN stage O
stage , , O
, JJ socioeconomic O
socioeconomic NN status O
status , , O
, NN body O
body NN mass O
mass NN index O
index , , O
, CC and O
and NN health O
health NN care O
care NN access O
access CC and O
and NN utilization O

In IN CAPITAL In O
In NN addition O
addition , , O
, NNS blacks O
blacks VBD were O
were JJR less O
less JJ likely O
likely TO to O
to VB have O
have JJ high-grade O
high-grade NN ( O
( NN grade O
grade CD 3 O
3 NN ) O
) JJ nuclear D
nuclear NN atypia D
atypia , , O
, JJ mitotic O
mitotic NN activity O
activity , , O
, CC and O
and NN tubule O
tubule NN formation O
formation , , O
, IN although O
although DT these O
these NNS CAPITAL ORs O
ORs VBD did O
did RB not O
not VB reach O
reach DT a O
a JJ statistical O
statistical NN significance O
significance NN level O
level IN of O
of CD 0.05 O

Similar JJ CAPITAL Similar O
Similar NN CAPITAL B/W O
B/W NNS differences O
differences VBD were O
were VBN observed O
observed IN for O
for NNS patients O
patients IN with O
with JJ advanced O
advanced NN disease O
disease CC but O
but RB not O
not IN with O
with RB early O
early NN stage O

Comparison NN CAPITAL Comparison O
Comparison IN by O
by JJ anatomical O
anatomical JJ subsite O
subsite VBD showed O
showed IN that O
that NNS blacks O
blacks VBD had O
had RB statistically O
statistically RB significantly O
significantly JJR better O
better VBN differentiated O
differentiated NNS tumors D
tumors IN for O
for NNS cancers D
cancers IN of O
of DT the O
the JJ proximal O
proximal CC and O
and JJ transverse O
transverse NN colon O
colon CC but O
but RB not O
not IN for O
for DT the O
the JJ distal O

No DT CAPITAL No O
No JJ racial O
racial NNS differences O
differences VBD were O
were VBN found O
found IN for O
for NN blood O
blood NN vessel O
vessel CC and O
and JJ lymphatic D
lymphatic NN invasion D
invasion , , O
, NN necrosis D
necrosis , , O
, NN fibrosis D
fibrosis , , O
, CC and O
and JJ mucinous O
mucinous NN type O
type IN of O
of NN histology O

The DT CAPITAL The O
The NNS findings O
findings , , O
, RB therefore O
therefore , , O
, VBP are O
are DT the O
the JJ opposite O
opposite IN of O
of DT those O
those VBN hypothesized O

After IN CAPITAL After O
After VBG adjusting O
adjusting IN for O
for NN stage O
stage , , O
, RBR more O
more JJ aggressive O
aggressive NN tumor O
tumor NNS characteristics O
characteristics VB do O
do RB not O
not VB explain O
explain DT the O
the JJ adverse O
adverse NN survival O
survival JJ differential O
differential IN in O
in NNS blacks O

This DT CAPITAL This O
This VBZ suggests O
suggests IN that O
that RB there O
there MD may O
may VB be O
be JJ racial O
racial NNS differences O
differences IN in O
in JJ environmental O
environmental NN exposure O
exposure , , O
, CC and O
and IN that O
that DT the O
the NN intensity O
intensity CC and O
and NN mode O
mode IN of O
of NN delivery O
delivery IN of O
of NN carcinogen O
carcinogen NN insult O
insult IN as O
as RB well O
well IN as O
as NN host O
host NN susceptibility O
susceptibility MD may O
may VBP differ O
differ IN by O
by NN race O
race CC and O
and JJ anatomical O
anatomical JJ subsite O

Future JJ CAPITAL Future O
Future NNS studies O
studies MD should O
should VB explore O
explore DT the O
the NN CAPITAL B/W O
B/W NNS differences O
differences IN in O
in NN tumor O
tumor NN biology O
biology VBG using O
using JJ molecular O
molecular NNS markers O
markers IN that O
that VB precede O
precede DT the O
the JJ conventional O
conventional JJ histological O
histological NNS parameters O
parameters VBN evaluated O
evaluated RB here O

A DT CAPITAL A O
A JJ new O
new NN method O
method VBZ is O
is VBN described O
described IN for O
for NN detection O
detection IN of O
of NNS mutations O
mutations IN in O
in DT the O
the JJ lysosomal O
lysosomal NN alpha-glucosidase O
alpha-glucosidase NN gene O
gene NN ( O
( NN CAPITAL GAA O
GAA NN ) O
) VBG leading O
leading TO to O
to NN CAPITAL Glycogen D
Glycogen NN CAPITAL Storage D
Storage NN CAPITAL Disease D
Disease NN type D
type NNP CAPITAL II D
II NN ( D
( NN CAPITAL GSDII D
GSDII NN ) D

A DT CAPITAL A O
A JJ key O
key NN feature O
feature IN of O
of DT the O
the NN method O
method VBZ is O
is NN isolation O
isolation CC and O
and JJ reverse O
reverse NN transcription O
transcription IN of O
of NN mRNA O
mRNA VBN followed O
followed IN by O
by NN CAPITAL PCR O
PCR NN amplification O
amplification IN of O
of JJ lysosomal O
lysosomal NN alpha-glucosidase O
alpha-glucosidase NN cDNA O
cDNA IN with O
with JJ CAPITAL M13-extended O
M13-extended NNS primers O

Dye VB CAPITAL Dye O
Dye VBN labeled O
labeled NNS primers O
primers VBP are O
are VBN used O
used IN for O
for NN cycle O
cycle NN sequencing O
sequencing CC and O
and DT an O
an NN CAPITAL ABI O
ABI NN CAPITAL PRISM O
PRISM CD 377 O
377 NN CAPITAL DNA O
DNA NN sequencing O
sequencing NN system O
system IN for O
for NN analysis O

The DT CAPITAL The O
The NN method O
method VBZ is O
is JJ rapid O
rapid CC and O
and JJ complementary O
complementary TO to O
to DT the O
the VBN automated O
automated NN sequencing O
sequencing IN of O
of DT all O
all DT the O
the CD 19 O
19 , , O
, NN CAPITAL PCR O
PCR VBN amplified O
amplified , , O
, VBG coding O
coding NNS exons O
exons IN of O
of DT the O
the NN CAPITAL GAA O
GAA NN gene O

The DT CAPITAL The O
The NNS advantages O
advantages CC and O
and NNS pitfalls O
pitfalls IN of O
of DT this O
this JJ new O
new NN method O
method VBP are O
are VBN discussed O
discussed IN in O
in DT the O
the JJ light O
light IN of O
of DT the O
the NNS results O
results VBN obtained O
obtained IN with O
with DT an O
an JJ infantile O
infantile CD CAPITAL GSDII O
GSDII NN patient O

A DT CAPITAL A O
A JJ new O
new NN splice O
splice NN site O
site NN mutation O
mutation IN in O
in DT the O
the NN CAPITAL GAA O
GAA NN gene O
gene IN of O
of DT this O
this NN patient O
patient VBD was O
was VBN identified O
identified , , O
, NN CAPITAL IVS16 O
IVS16 NN ( O
( NN +2T O
+2T : -- O
-- JJR > O
> NN CAPITAL C O
C NN ) O
) , , O
, VBG resulting O
resulting IN in O
in DT the O
the NN deletion O
deletion IN of O
of CD 16 O
16 NN base O
base NNS pairs O
pairs IN of O
of NN exon O
exon CD 16 O

The DT CAPITAL The O
The NN presence O
presence IN of O
of JJ clinical O
clinical JJ autonomic D
autonomic NN dysfunction D
dysfunction IN in O
in NNS patients O
patients IN with O
with JJ neurologic D
neurologic NNS diseases D
diseases , , O
, JJ such O
such IN as O
as JJ multiple D
multiple NN sclerosis D
sclerosis , , O
, NNP CAPITAL Parkinson D
Parkinson POS 's D
's NN disease D
disease , , O
, CC and O
and JJ cerebrovascular O
cerebrovascular NN accident O
accident , , O
, VBZ has O
has VBN become O
become RB increasingly O
increasingly VBN recognized O
recognized IN in O
in DT the O
the JJ past O
past NN decade O

Very RB CAPITAL Very O
Very JJ few O
few JJ autonomic O
autonomic NNS tests O
tests VB have O
have VBN been O
been VBN done O
done IN on O
on JJ pediatric O
pediatric NNS patients O
patients RB thus O
thus RB far O

The DT CAPITAL The O
The NN purpose O
purpose IN of O
of DT this O
this NN study O
study VBD was O
was TO to O
to VB investigate O
investigate DT the O
the JJ autonomic O
autonomic NN function O
function IN in O
in NNS patients O
patients IN with O
with JJ cerebral D
cerebral NN palsy D
palsy VBG using O
using CD two O
two JJ noninvasive O
noninvasive NNS tests O
tests : : O
: JJ sympathetic O
sympathetic NN skin O
skin NN response O
response NN ( O
( NN CAPITAL SSR O
SSR NN ) O
) CC and O
and NN CAPITAL R-R O
R-R NN interval O
interval NN variation O
variation NN ( O
( NN CAPITAL RRIV O
RRIV NN ) O

Twenty-four CD CAPITAL Twenty-four O
Twenty-four NNS patients O
patients IN with O
with JJ cerebral D
cerebral NN palsy D
palsy CC and O
and CD 24 O
24 NN control O
control NNS subjects O
subjects IN between O
between DT the O
the NNS ages O
ages IN of O
of CD 4 O
4 CC and O
and CD 12 O
12 NN yr O
yr VBD were O
were VBN enrolled O
enrolled IN in O
in DT this O
this NN study O

There EX CAPITAL There O
There VBD was O
was DT no O
no JJ significant O
significant NN difference O
difference IN of O
of VB mean O
mean NN latency O
latency , , O
, NN amplitude O
amplitude , , O
, CC or O
or NN amplitude O
amplitude NN ratio O
ratio IN of O
of NN CAPITAL SSR O
SSR IN between O
between DT the O
the CD two O
two NNS groups O
groups IN under O
under JJ electric O
electric NN stimulus O
stimulus , , O
, JJ startling O
startling NN stimulus O
stimulus , , O
, CC and O
and JJ deep O
deep VBG breathing O
breathing NNS conditions O

No DT CAPITAL No O
No JJ significant O
significant NN difference O
difference IN in O
in NN frequency O
frequency IN of O
of JJ absent O
absent NN response O
response CC and O
and JJ asymmetric O
asymmetric NN response O
response VBD was O
was RB also O
also VBN noted O

Mean NN CAPITAL Mean O
Mean NN heart O
heart NN rate O
rate IN under O
under VBN relaxed O
relaxed VBG sitting O
sitting NN condition O
condition VBD was O
was RB significantly O
significantly JJR higher O
higher IN in O
in DT the O
the NN study O
study NN group O

Significant JJ CAPITAL Significant O
Significant JJ negative O
negative NN correlation O
correlation IN between O
between NN heart O
heart NN rate O
rate CC and O
and NN age O
age VBD was O
was VBN noted O
noted IN in O
in DT the O
the NN control O
control NN group O
group CC but O
but VBD was O
was RB not O
not JJ present O
present IN in O
in DT the O
the NN study O
study NN group O

Also RB CAPITAL Also O
Also , , O
, RB there O
there VBD was O
was DT no O
no JJ statistical O
statistical NN difference O
difference IN of O
of VB mean O
mean NN CAPITAL RRIV O
RRIV IN between O
between DT the O
the CD two O
two NNS groups O

No DT CAPITAL No O
No JJ objective O
objective NN evidence O
evidence IN of O
of JJ autonomic O
autonomic NN disturbance O
disturbance IN in O
in NNS patients O
patients IN with O
with JJ cerebral D
cerebral NN palsy D
palsy VBD was O
was VBN found O
found IN in O
in DT this O
this NN study O

A DT CAPITAL A O
A JJ two-credits O
two-credits IN per O
per NN semester O
semester JJ clinical O
clinical NN medicine O
medicine NN course O
course VBD was O
was VBN established O
established IN in O
in DT the O
the NNP CAPITAL Department O
Department IN of O
of JJ CAPITAL Physical O
Physical NNP CAPITAL Medicine O
Medicine CC and O
and NNP CAPITAL Rehabilitation O
Rehabilitation NN ( O
( NN CAPITAL PM O
PM CC & O
& # # O
# CD 38 O
38 : ; O
; NN CAPITAL R O
R NN ) O
) IN in O
in NN cooperation O
cooperation IN with O
with DT the O
the NNP CAPITAL Johns O
Johns NNP CAPITAL Hopkins O
Hopkins NNP CAPITAL University O
University JJ undergraduate O
undergraduate JJ CAPITAL Human O
Human NN CAPITAL Biology O
Biology NN faculty O
faculty TO to O
to JJ present O
present DT the O
the NN variety O
variety IN of O
of JJ inpatient O
inpatient NN consultation O
consultation NNS personnel O
personnel , , O
, NNS units O
units , , O
, NN patient O
patient JJ diagnostic O
diagnostic NNS groups O
groups , , O
, CC and O
and JJ functional O
functional NNS problems O

College NNP CAPITAL College O
College NNS students O
students VB spend O
spend CD 4 O
4 NN hr O
hr JJ weekly O
weekly IN on O
on DT the O
the NN CAPITAL PM O
PM CC & O
& # # O
# CD 38 O
38 : ; O
; NN CAPITAL R O
R NN consultation O
consultation NN service O
service IN as O
as NN team O
team NNS members O
members IN under O
under JJ resident O
resident NN supervision O

The DT CAPITAL The O
The NN curriculum O
curriculum VBZ emphasizes O
emphasizes NN student O
student VBG understanding O
understanding IN of O
of DT the O
the NNS roles O
roles IN of O
of NN rehabilitation O
rehabilitation NN team O
team NNS members O

Objectives NNS CAPITAL Objectives O
Objectives VBP include O
include NN demonstration O
demonstration IN of O
of VBG working O
working NN knowledge O
knowledge IN of O
of DT the O
the JJ CAPITAL Biopsychosocial O
Biopsychosocial NNP CAPITAL Model O
Model , , O
, DT the O
the NNP CAPITAL World O
World NNP CAPITAL Health O
Health NNP CAPITAL Organization O
Organization NNP CAPITAL Model O
Model IN of O
of NN disablement O
disablement CC and O
and JJ interdisciplinary O
interdisciplinary NN rehabilitation O
rehabilitation NN intervention O

The DT CAPITAL The O
The NN course O
course VBZ includes O
includes NNS simulations O
simulations IN of O
of JJ physical O
physical NNS impairments O
impairments , , O
, NNS demonstrations O
demonstrations IN of O
of JJ adaptive O
adaptive NN equipment O
equipment , , O
, JJ interactive O
interactive NN chart O
chart NNS reviews O
reviews , , O
, NNS readings O
readings , , O
, CC and O
and JJ audio O
audio VBZ lectures O

A DT CAPITAL A O
A JJ retrospective O
retrospective JJ sequential O
sequential NN review O
review VBD was O
was VBN made O
made IN of O
of DT the O
the JJ last O
last CD 100 O
100 JJ physical O
physical NN medicine O
medicine CC and O
and NN rehabilitation O
rehabilitation NNS consultations O
consultations IN with O
with NN student O
student NN attendance O

The DT CAPITAL The O
The NNS results O
results VBP confirm O
confirm NN student O
student NN exposure O
exposure TO to O
to JJ many O
many NN ward O
ward NNS settings O
settings NN ( O
( NN surgery O
surgery , , O
, CD 30 O
30 NN % O
% : ; O
; NN neurology/neurosurgery O
neurology/neurosurgery , , O
, CD 28 O
28 NN % O
% : ; O
; NN medicine O
medicine , , O
, CD 24 O
24 NN % O
% : ; O
; JJ intensive O
intensive NN care O
care , , O
, CD 15 O
15 NN % O
% : ; O
; NN oncology O
oncology , , O
, CD 2 O
2 NN % O
% : ; O
; CC and O
and NN psychiatry O
psychiatry , , O
, CD 1 O
1 NN % O
% NN ) O
) , , O
, NN patient O
patient NN complexity O
complexity NN ( O
( VBG averaging O
averaging CD 10 O
10 NNS problems O
problems NN ) O
) , , O
, CC and O
and JJ multiple O
multiple NN CAPITAL ICD-9 O
ICD-9 NN diagnosis O
diagnosis NNS categories O
categories NN ( O
( JJ circulatory O
circulatory , , O
, CD 36 O
36 NN % O
% : ; O
; JJ neurologic O
neurologic , , O
, CD 22 O
22 NN % O
% : ; O
; JJ musculoskeletal O
musculoskeletal , , O
, CD 17 O
17 NN % O
% : ; O
; NNS neoplasms O
neoplasms , , O
, CD 10 O
10 NN % O
% : ; O
; NN injury O
injury , , O
, CD 5 O
5 NN % O
% : ; O
; JJ endocrine O
endocrine , , O
, CD 4 O
4 NN % O
% : ; O
; NNS infections O
infections , , O
, CD 3 O
3 NN % O
% : ; O
; CC and O
and NNS others O
others , , O
, CD 3 O
3 NN % O
% NN ) O

The DT CAPITAL The O
The NN rehabilitation O
rehabilitation NN consultation O
consultation NN service O
service VBZ is O
is RB particularly O
particularly JJ effective O
effective IN as O
as DT an O
an NN introduction O
introduction TO to O
to JJ hospital-based O
hospital-based JJ medical O
medical NN practice O
practice JJ due O
due TO to O
to DT the O
the JJ diagnostic O
diagnostic NN variety O
variety IN of O
of DT the O
the NNS patients O
patients , , O
, DT the O
the JJ functional O
functional NN approach O
approach IN of O
of NN rehabilitation O
rehabilitation , , O
, CC and O
and NN student O
student NN exposure O
exposure TO to O
to JJ multiple O
multiple NN hospital O
hospital NNS settings O

The DT CAPITAL The O
The JJ CAPITAL Biopsychosocial O
Biopsychosocial NNP CAPITAL Model O
Model IN of O
of JJ medical O
medical NN practice O
practice VBZ is O
is VBD demonstrated O
demonstrated IN through O
through JJ multiple O
multiple JJ interdisciplinary O
interdisciplinary NNS perspectives O
perspectives IN of O
of NNS needs O
needs CC and O
and NNS interventions O
interventions IN for O
for NNS patients O
patients IN with O
with JJ obvious O
obvious JJ functional O
functional NNS deficits O

This DT CAPITAL This O
This NN process O
process VBZ develops O
develops DT a O
a JJ rudimentary O
rudimentary VBG understanding O
understanding IN of O
of DT the O
the NN effect O
effect IN of O
of NN illness O
illness IN on O
on DT the O
the NN person O
person CC and O
and DT the O
the NN variety O
variety IN of O
of RB medically O
medically JJ effective O
effective JJ therapeutic O
therapeutic NNS modalities O

This DT CAPITAL This O
This NN study O
study VBZ is O
is VBN designed O
designed TO to O
to VB investigate O
investigate DT the O
the JJ immediate O
immediate NN effectiveness O
effectiveness IN of O
of JJ electrotherapy T
electrotherapy IN on O
on JJ myofascial D
myofascial NN trigger D
trigger NNS points D
points IN of D
of JJ upper D
upper NN trapezius D
trapezius NN muscle D

Sixty CD CAPITAL Sixty O
Sixty NNS patients O
patients NN ( O
( CD 25 O
25 NNS males O
males CC and O
and CD 35 O
35 NNS females O
females NN ) O
) WP who O
who VBD had O
had JJ myofascial D
myofascial NN trigger D
trigger NNS points D
points IN in O
in CD one O
one NN side O
side IN of O
of DT the O
the JJ upper O
upper NN trapezius O
trapezius NNS muscles O
muscles VBD were O
were VBN studied O

The DT CAPITAL The O
The VBN involved O
involved JJ upper O
upper NN trapezius O
trapezius NNS muscles O
muscles VBD were O
were VBN treated O
treated IN with O
with CD three O
three JJ different O
different NNS methods O
methods VBG according O
according TO to O
to DT a O
a JJ random O
random NN assignment O
assignment : : O
: NN group O
group DT CAPITAL A O
A NNS muscles O
muscles NN ( O
( NN n O
n JJ = O
= CD 18 O
18 NN ) O
) VBD were O
were VBN given O
given NN placebo O
placebo NN treatment O
treatment NN ( O
( NN control O
control NN group O
group NN ) O
) : ; O
; NN group O
group NN CAPITAL B O
B NNS muscles O
muscles NN ( O
( NN n O
n JJ = O
= CD 20 O
20 NN ) O
) VBD were O
were VBN treated O
treated IN with O
with JJ electrical T
electrical NN nerve T
nerve NN stimulation T
stimulation NN ( T
( NN CAPITAL ENS T
ENS NN ) T
) NN therapy T
therapy : ; O
; CC and O
and NN group O
group NN CAPITAL C O
C NNS muscles O
muscles NN ( O
( NN n O
n JJ = O
= CD 22 O
22 NN ) O
) VBD were O
were VBN given O
given JJ electrical T
electrical NN muscle T
muscle NN stimulation T
stimulation NN ( T
( NNP CAPITAL EMS T
EMS NN ) T
) NN therapy T

The DT CAPITAL The O
The NN effectiveness O
effectiveness IN of O
of NN treatment O
treatment VBD was O
was VBN assessed O
assessed IN by O
by VBG conducting O
conducting CD three O
three NNS measurements O
measurements IN on O
on DT each O
each NN muscle O
muscle IN before O
before CC and O
and RB immediately O
immediately IN after O
after NN treatment O
treatment : : O
: JJ subjective O
subjective NN pain O
pain NN intensity O
intensity NN ( O
( NN ( O
( NN CAPITAL PI O
PI NN ) O
) IN with O
with DT a O
a JJ visual O
visual NN analog O
analog NN scale O
scale NN ) O
) , , O
, NN pressure O
pressure NN pain O
pain NN threshold O
threshold NN ( O
( NN ( O
( NN CAPITAL PT O
PT NN ) O
) IN with O
with NN algometry O
algometry NN ) O
) , , O
, CC and O
and NN range O
range IN of O
of NN motion O
motion NN ( O
( NN ( O
( NN CAPITAL ROM O
ROM NN ) O
) IN with O
with DT a O
a NN goniometer O
goniometer NN ) O
) IN of O
of JJ upper O
upper NN trapezius O
trapezius NN muscle O
muscle NN ( O
( JJ lateral O
lateral VBG bending O
bending IN of O
of JJ cervical O
cervical NN spine O
spine TO to O
to DT the O
the JJ opposite O
opposite NN side O
side NN ) O

When WRB CAPITAL When O
When DT the O
the NN effectiveness O
effectiveness IN of O
of NN treatment O
treatment VBD was O
was VBN compared O
compared IN with O
with IN that O
that IN of O
of DT the O
the NN placebo O
placebo NN group O
group NN ( O
( NN group O
group DT CAPITAL A O
A NN ) O
) , , O
, RB there O
there VBD was O
was JJ significant O
significant NN improvement O
improvement IN in O
in NN CAPITAL PI O
PI CC and O
and NN CAPITAL PT O
PT IN in O
in NN group O
group NN CAPITAL B O
B NN ( O
( NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0.01 O
0.01 NN ) O
) CC but O
but RB not O
not IN in O
in NN group O
group NN CAPITAL C O
C NN ( O
( NN CAPITAL P O
P JJR > O
> CD 0.05 O
0.05 NN ) O

The DT CAPITAL The O
The NN improvement O
improvement IN of O
of NN CAPITAL ROM O
ROM VBD was O
was RB significantly O
significantly RBR more O
more IN in O
in NN group O
group NN CAPITAL C O
C NN ( O
( NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0.01 O
0.01 NN ) O
) IN as O
as VBN compared O
compared IN with O
with IN that O
that IN in O
in NN group O
group DT CAPITAL A O
A CC or O
or NN group O
group NN CAPITAL B O

When WRB CAPITAL When O
When DT each O
each NN group O
group VBD was O
was VBN divided O
divided IN into O
into CD two O
two JJ additional O
additional NNS subgroups O
subgroups VBN based O
based IN on O
on DT the O
the JJ initial O
initial NN CAPITAL PI O
PI , , O
, PRP it O
it VBD was O
was VBN found O
found IN that O
that NN CAPITAL ENS O
ENS MD could O
could VB reduce O
reduce NN CAPITAL PI O
PI CC and O
and NN increase O
increase NN CAPITAL PT O
PT RB significantly O
significantly NN ( O
( NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0.05 O
0.05 NN ) O
) , , O
, CC but O
but VBD did O
did RB not O
not RB significantly O
significantly NN ( O
( NN CAPITAL P O
P JJR > O
> CD 0.05 O
0.05 NN ) O
) VB improve O
improve NN CAPITAL ROM O
ROM , , O
, IN as O
as VBN compared O
compared IN with O
with DT the O
the NN placebo O
placebo NN group O
group IN for O
for DT both O
both NNS subgroups O

EMS NNP CAPITAL EMS O
EMS MD could O
could RB significantly O
significantly NN ( O
( NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0.05 O
0.05 NN ) O
) VB improve O
improve NN CAPITAL ROM O
ROM , , O
, CC but O
but RB not O
not NN CAPITAL PT O
PT , , O
, JJR better O
better IN than O
than DT the O
the NN placebo O
placebo NNS groups O
groups , , O
, IN for O
for DT either O
either NN subgroup O

It PRP CAPITAL It O
It MD could O
could VB reduce O
reduce NN CAPITAL PI O
PI RB significantly O
significantly RBR more O
more NN ( O
( NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0.05 O
0.05 NN ) O
) IN than O
than NN placebo O
placebo NNS controls O
controls RB only O
only IN for O
for DT the O
the NN subgroup O
subgroup IN with O
with JJ mild O
mild TO to O
to JJ moderate O
moderate NN pain O
pain , , O
, CC but O
but RB not O
not IN with O
with JJ severe O
severe NN pain O

For IN CAPITAL For O
For NN pain O
pain NN relief O
relief , , O
, NN CAPITAL ENS O
ENS VBD was O
was RB significantly O
significantly JJR better O
better NN ( O
( NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0.05 O
0.05 NN ) O
) IN than O
than NNP CAPITAL EMS O
EMS : ; O
; CC but O
but IN for O
for DT the O
the NN improvement O
improvement IN of O
of NN CAPITAL ROM O
ROM , , O
, NNP CAPITAL EMS O
EMS VBD was O
was RB significantly O
significantly JJR better O
better NN ( O
( NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0.05 O
0.05 NN ) O
) IN than O
than NN CAPITAL ENS O

It PRP CAPITAL It O
It VBZ is O
is VBD concluded O
concluded IN that O
that NN CAPITAL ENS T
ENS VBZ is O
is RBR more O
more JJ effective O
effective IN for O
for JJ immediate O
immediate NN relief O
relief IN of O
of JJ myofascial D
myofascial NN trigger D
trigger NN point D
point NN pain D
pain IN than O
than NNP CAPITAL EMS T
EMS , , O
, CC and O
and NNP CAPITAL EMS T
EMS VBZ has O
has DT a O
a JJR better O
better NN effect O
effect IN on O
on JJ immediate O
immediate NN release O
release IN of O
of NN muscle D
muscle NN tightness D
tightness IN than O
than NN CAPITAL ENS T

Because IN CAPITAL Because O
Because NN activity O
activity CC and O
and JJ regular O
regular NN exercise O
exercise VBP are O
are JJ important O
important NNS factors O
factors TO to O
to VB maintain O
maintain JJ general O
general JJ good O
good NN health O
health IN in O
in JJ senior O
senior NNS citizens O
citizens , , O
, PRP we O
we VBN investigated O
investigated IN whether O
whether JJ senior O
senior VBG dancing O
dancing VBZ has O
has DT any O
any NN effect O
effect IN on O
on JJ peripheral O
peripheral CC or O
or JJ lumbar O
lumbar NN bone O
bone NN density O

We PRP CAPITAL We O
We VBN performed O
performed DT a O
a JJ prospective O
prospective NN study O
study IN over O
over JJ a12-mo O
a12-mo NN period O
period IN on O
on NN bone O
bone NN density O
density IN at O
at DT a O
a JJ spinal O
spinal CC and O
and JJ peripheral O
peripheral VBG measuring O
measuring NN site O
site IN in O
in CD 28 O
28 JJ female O
female JJ senior O
senior NNS members O
members NN ( O
( VB mean O
mean NN age O
age : : O
: CD 67 O
67 CC +/- O
+/- CD 2 O
2 NN yr O
yr NN ) O
) IN of O
of DT a O
a VBG dancing O
dancing NN group O
group IN in O
in NNP CAPITAL Vienna O

Lumbar JJ CAPITAL Lumbar O
Lumbar NN bone O
bone NN mineral O
mineral NN density O
density VBD was O
was VBN assessed O
assessed IN by O
by JJ quantitative O
quantitative VBN computed O
computed NN tomography O
tomography NN ( O
( NN qCT O
qCT NN ) O
) CC and O
and JJ radial O
radial NN bone O
bone NN density O
density IN by O
by JJ single O
single NN photon O
photon NN absorptiometry O
absorptiometry IN of O
of DT the O
the JJ distal O
distal NN forearm O

The DT CAPITAL The O
The VB mean O
mean NN training O
training NN time O
time IN per O
per NN week O
week VBD was O
was CD 3.2 O
3.2 CC +/- O
+/- CD 0.8 O
0.8 NN h. O
h. IN CAPITAL In O
In DT the O
the JJ entire O
entire NN group O
group IN of O
of JJ female O
female NNS dancers O
dancers , , O
, DT no O
no JJ significant O
significant NNS effects O
effects IN of O
of VBG dancing O
dancing IN on O
on JJ radial O
radial CC or O
or JJ lumbar O
lumbar NN bone O
bone NN density O
density MD could O
could VB be O
be VBN observed O

Linear JJ CAPITAL Linear O
Linear NN regression O
regression NN analysis O
analysis VBD showed O
showed IN that O
that DT the O
the JJR lower O
lower DT the O
the NN qCT O
qCT IN at O
at DT the O
the VBG beginning O
beginning IN of O
of DT the O
the NN observation O
observation NN period O
period , , O
, DT the O
the JJR higher O
higher VBD was O
was DT the O
the NN percentage O
percentage NN increase O
increase IN of O
of JJ spinal O
spinal NN qCT O
qCT IN in O
in DT the O
the JJ entire O
entire NN group O
group IN during O
during CD 12 O
12 NN mo O
mo IN of O
of VBG dancing O
dancing NN ( O
( NN r O
r JJ = O
= CD 0.52 O
0.52 , , O
, NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0.0001 O
0.0001 NN ) O

For IN CAPITAL For O
For JJ additional O
additional NN evaluation O
evaluation , , O
, NNS females O
females VBD were O
were VBN divided O
divided IN into O
into CD two O
two NNS subgroups O
subgroups , , O
, JJ osteoporotic O
osteoporotic CC or O
or JJ nonosteoporotic O
nonosteoporotic , , O
, VBN based O
based IN on O
on NNPS x-rays O
x-rays CC and O
and JJ lumbar O
lumbar NN bone O
bone NN mineral O
mineral NN density O
density NN ( O
( NN CAPITAL BMD O
BMD NN ) O
) IN as O
as VBN measured O
measured IN by O
by NN qCT O

The DT CAPITAL The O
The NN group O
group VBN classified O
classified IN as O
as NNS dancers O
dancers IN with O
with NN osteoporosis O
osteoporosis NN ( O
( NN group O
group PRP CAPITAL I O
I NN ) O
) VBD showed O
showed DT a O
a JJ significant O
significant NN increase O
increase IN in O
in JJ lumbar O
lumbar NN bone O
bone NN density O
density , , O
, IN whereas O
whereas IN in O
in DT the O
the NN group O
group IN of O
of NNS dancers O
dancers IN without O
without NNS signs O
signs IN of O
of NN osteoporosis D
osteoporosis NN ( O
( NN group O
group NNP CAPITAL II O
II NN ) O
) , , O
, NN CAPITAL BMD O
BMD VBD remained O
remained JJ unchanged O

Additionally RB CAPITAL Additionally O
Additionally , , O
, JJ radial O
radial NN bone O
bone NN density O
density VBD did O
did RB not O
not NN show O
show DT any O
any NNS changes O
changes IN in O
in DT either O
either NN group O

Group NNP CAPITAL Group O
Group PRP CAPITAL I O
I VBD showed O
showed DT a O
a JJ significant O
significant NN correlation O
correlation IN between O
between JJ basal O
basal JJ spinal O
spinal NN CAPITAL BMD O
BMD CC and O
and DT the O
the NN percentage O
percentage NN change O
change IN of O
of NN CAPITAL BMD O
BMD IN during O
during DT the O
the NN observation O
observation NN period O
period NN ( O
( NN r O
r JJ = O
= CD 0.7 O
0.7 , , O
, NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0.001 O
0.001 NN ) O

Changes NNS CAPITAL Changes O
Changes IN of O
of DT the O
the JJ biochemical O
biochemical NNS parameters O
parameters VBD were O
were VBN observed O
observed IN in O
in DT the O
the JJ bone-specific O
bone-specific NN isoenzyme O
isoenzyme IN of O
of NN alkaline O
alkaline NN phosphatase O
phosphatase , , O
, DT a O
a NN marker O
marker IN of O
of JJ osteoblastic O
osteoblastic NN activity O
activity , , O
, IN in O
in NN group O
group PRP CAPITAL I O
I VBG giving O
giving JJ additional O
additional NN evidence O
evidence IN of O
of VBN increased O
increased NN bone O
bone NN formation O

OBJECTIVES NNS CAPITAL OBJECTIVES O
OBJECTIVES : : O
: TO CAPITAL To O
To NN estimate O
estimate DT the O
the NN prevalence O
prevalence IN of O
of NN CAPITAL Chlamydia D
Chlamydia NN trachomatis D
trachomatis IN in O
in JJ asymptomatic O
asymptomatic NNS women O
women VBG attending O
attending JJ general O
general NN practice O
practice : : O
: TO to O
to VB assess O
assess DT the O
the JJ potential O
potential IN of O
of DT the O
the NN ligase O
ligase NN chain O
chain NN reaction O
reaction IN as O
as DT a O
a VBG screening O
screening NN tool O
tool : ; O
; CC and O
and TO to O
to VB evaluate O
evaluate JJ selective O
selective VBG screening O
screening NNS criteria O

DESIGN NN CAPITAL DESIGN O
DESIGN : : O
: NNP CAPITAL Cross O
Cross JJ sectional O
sectional NN survey O

SETTING VBG CAPITAL SETTING O
SETTING : : O
: CD CAPITAL Four O
Four JJ general O
general NNS practices O
practices IN in O
in RB northeast O
northeast NNP CAPITAL London O

SUBJECTS NNS CAPITAL SUBJECTS O
SUBJECTS : : O
: CD 890 O
890 NNS women O
women JJ aged O
aged CD 18-35 O
18-35 NNS years O
years VBG attending O
attending JJ general O
general NN practice O
practice IN for O
for DT a O
a JJ cervical O
cervical JJ smear O
smear CC or O
or DT a O
a `` `` O
`` JJ young O
young RB well O
well NN woman O
woman '' '' O
'' NN check O
check IN between O
between NNP CAPITAL October O
October CD 1994 O
1994 CC and O
and NNP CAPITAL January O
January CD 1996 O

The DT CAPITAL The O
The NNS women O
women VBD were O
were VBN tested O
tested IN for O
for NN CAPITAL C D
C NN trachomatis D
trachomatis IN with O
with VBN confirmed O
confirmed NN enzyme O
enzyme NN immunoassay O
immunoassay NN ( O
( JJ endocervical O
endocervical NNS specimens O
specimens NN ) O
) CC and O
and NN ligase O
ligase NN chain O
chain NN reaction O
reaction NN assay O
assay IN on O
on NN urine O
urine NNS specimens O

MAIN JJS CAPITAL MAIN O
MAIN NN CAPITAL OUTCOME O
OUTCOME NNS CAPITAL MEASURES O
MEASURES : : O
: NN CAPITAL Prevalence O
Prevalence IN of O
of NN CAPITAL C D
C NN trachomatis D
trachomatis NN infection D
infection IN in O
in NNS women O
women JJ aged O
aged CD 18-35 O
18-35 IN on O
on DT the O
the NN basis O
basis IN of O
of DT each O
each NN test O
test : ; O
; NN sensitivity O
sensitivity CC and O
and NN specificity O
specificity IN of O
of DT both O
both NNS tests O
tests IN in O
in DT this O
this NN population O

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: NN CAPITAL Prevalence O
Prevalence IN of O
of VBN confirmed O
confirmed NN infection O
infection VBD was O
was CD 2.6 O
2.6 NN % O
% NN ( O
( CD 95 O
95 NN % O
% NN confidence O
confidence NN interval O
interval CD 1.6 O
1.6 NN % O
% TO to O
to CD 3.6 O
3.6 NN % O
% NN ) O
) IN in O
in DT all O
all NNS women O

Prevalence NN CAPITAL Prevalence O
Prevalence IN on O
on DT the O
the NN basis O
basis IN of O
of NN enzyme O
enzyme NN immunoassay O
immunoassay VBD was O
was CD 1.6 O
1.6 NN % O
% NN ( O
( CD 0.8 O
0.8 NN % O
% TO to O
to CD 2.7 O
2.7 NN % O
% NN ) O
) , , O
, IN with O
with DT a O
a NN sensitivity O
sensitivity IN of O
of CD 60 O
60 NN % O
% CC and O
and DT a O
a NN specificity O
specificity IN of O
of CD 100 O
100 NN % O

Prevalence NN CAPITAL Prevalence O
Prevalence IN on O
on DT the O
the NN basis O
basis IN of O
of NN ligase O
ligase NN chain O
chain NN reaction O
reaction VBD was O
was CD 2.5 O
2.5 NN % O
% NN ( O
( CD 1.5 O
1.5 NN % O
% TO to O
to CD 3.9 O
3.9 NN % O
% NN ) O
) , , O
, IN with O
with CD 90 O
90 NN % O
% NN sensitivity O
sensitivity CC and O
and CD 99.8 O
99.8 NN % O
% NN specificity O

Screening VBG CAPITAL Screening O
Screening DT all O
all NNS women O
women JJ aged O
aged CC & O
& # # O
# CD 60 O
60 : ; O
; CC or O
or JJ = O
= CD 25 O
25 CC and O
and DT all O
all NNS women O
women WP who O
who VBD had O
had VBD had O
had CD two O
two CC or O
or RBR more O
more NNS partners O
partners IN in O
in DT the O
the JJ past O
past NN year O
year MD would O
would VB have O
have VBN detected O
detected CD 87 O
87 NN % O
% NN ( O
( CD 20/23 O
20/23 NN ) O
) IN of O
of NNS infections O

CONCLUSION NN CAPITAL CONCLUSION O
CONCLUSION : : O
: NN CAPITAL Ligase O
Ligase NN chain O
chain NN reaction O
reaction IN on O
on NN urine O
urine NNS samples O
samples VBZ performs O
performs IN at O
at JJS least O
least IN as O
as RB well O
well IN as O
as NN enzyme O
enzyme NN immunoassay O
immunoassay IN on O
on JJ cervical O
cervical NNS specimens O
specimens IN in O
in DT this O
this JJ low O
low NN prevalence O
prevalence NN population O

It PRP CAPITAL It O
It NNS offers O
offers JJ potential O
potential IN as O
as DT a O
a JJ non-invasive O
non-invasive VBG screening O
screening NN tool O

A DT CAPITAL A O
A JJ simple O
simple JJ selective O
selective VBG screening O
screening NN strategy O
strategy MD might O
might VB be O
be JJ appropriate O
appropriate CC and O
and MD would O
would VB be O
be JJ able O
able TO to O
to VB detect O
detect JJS most O
most NNS cases O
cases IN of O
of NN infection D

However RB CAPITAL However O
However , , O
, DT a O
a JJ rigorous O
rigorous JJ economic O
economic NN evaluation O
evaluation IN of O
of JJ possible O
possible VBG screening O
screening NNS strategies O
strategies VBZ is O
is VBN needed O
needed RB first O

Recently RB CAPITAL Recently O
Recently , , O
, JJ many O
many NNS advances O
advances VB have O
have VBN been O
been VBN made O
made IN in O
in DT the O
the NN study O
study IN of O
of JJ sexual O
sexual NN differentiation O
differentiation , , O
, VBG including O
including DT the O
the NNS discoveries O
discoveries IN of O
of DT the O
the NN gene O
gene IN for O
for antim1/4llerian O
antim1/4llerian NN hormone O
hormone IN as O
as RB well O
well IN as O
as DT the O
the NN gene O
gene IN for O
for PRP$ its O
its NN receptor O

However RB CAPITAL However O
However , , O
, DT the O
the NN etiology O
etiology IN of O
of DT the O
the JJ clinical O
clinical NN syndrome O
syndrome IN of O
of m1/4llerian O
m1/4llerian NN agenesis O
agenesis VBZ remains O
remains JJ elusive O

We PRP CAPITAL We O
We VB hypothesize O
hypothesize IN that O
that VBG activating O
activating NNS mutations O
mutations IN of O
of DT either O
either DT the O
the antim1/4llerian O
antim1/4llerian NN hormone O
hormone NN gene O
gene CC or O
or PRP$ its O
its NN receptor O
receptor NN gene O
gene MD may O
may NN cause O
cause m1/4llerian O
m1/4llerian NN duct O
duct NN regression O
regression IN in O
in DT a O
a JJ genetic O
genetic JJ female O
female IN during O
during NN embryogenesis O

This DT CAPITAL This O
This JJ clinical O
clinical NN commentary O
commentary VBZ discusses O
discusses DT the O
the JJ current O
current NN management O
management IN of O
of DT the O
the NN syndrome O
syndrome VBG including O
including DT the O
the JJ CAPITAL Abbe-McIndoe T
Abbe-McIndoe NN procedure T
procedure , , O
, DT the O
the JJS most O
most RB commonly O
commonly VBN used O
used NN method O
method IN of O
of JJ surgical T
surgical NN correction T
correction , , O
, CC and O
and DT the O
the NNP CAPITAL Frank T
Frank JJ vaginal T
vaginal NN dilation T
dilation NN method T
method , , O
, DT the O
the JJS most O
most JJ common O
common JJ nonsurgical O
nonsurgical NN method O
method IN of O
of NN correction O

OBJECTIVES NNS CAPITAL OBJECTIVES O
OBJECTIVES : : O
: NN CAPITAL Obesity D
Obesity VBZ is O
is DT an O
an JJ important O
important JJ clinical O
clinical NN problem O
problem , , O
, CC and O
and DT the O
the NN use O
use IN of O
of NN dexfenfluramine T
dexfenfluramine NN hydrochloride T
hydrochloride IN for O
for NN weight O
weight NN reduction O
reduction VBZ has O
has VBN been O
been RB widely O
widely VBN publicized O
publicized IN since O
since PRP$ its O
its NN approval O
approval IN by O
by DT the O
the NNP CAPITAL Food O
Food CC and O
and NN CAPITAL Drug O
Drug NNP CAPITAL Administration O

However RB CAPITAL However O
However , , O
, NN animal O
animal CC and O
and JJ human O
human NNS studies O
studies VB have O
have VBD demonstrated O
demonstrated JJ toxic O
toxic NNS effects O
effects IN of O
of NNS fenfluramines T
fenfluramines IN that O
that NNS clinicians O
clinicians MD should O
should VB be O
be JJ aware O
aware IN of O
of WRB when O
when VBG considering O
considering VBG prescribing O
prescribing DT the O
the NNS drugs O

Our PRP$ CAPITAL Our O
Our NN purpose O
purpose VBD was O
was TO to O
to RB systematically O
systematically NN review O
review NNS data O
data IN on O
on NN brain O
brain NN serotonin O
serotonin NN neurotoxicity O
neurotoxicity IN in O
in NNS animals O
animals VBN treated O
treated IN with O
with NNS fenfluramines T
fenfluramines CC and O
and DT the O
the NN evidence O
evidence VBG linking O
linking NNS fenfluramines T
fenfluramines TO to O
to JJ primary D
primary JJ pulmonary D
pulmonary NN hypertension D
hypertension NN ( D
( NN CAPITAL PPH D
PPH NN ) D

DATA NNP CAPITAL DATA O
DATA NNS CAPITAL SOURCES O
SOURCES : : O
: JJ CAPITAL Archival O
Archival NNS articles O
articles CC and O
and NNS reviews O
reviews VBN identified O
identified IN through O
through DT a O
a JJ computerized O
computerized NN search O
search IN of O
of NN CAPITAL MEDLINE O
MEDLINE IN from O
from CD 1966 O
1966 TO to O
to NNP CAPITAL April O
April CD 1997 O
1997 VBG using O
using `` `` O
`` NN fenfluramine O
fenfluramine NN ( O
( NNS s O
s NN ) O
) , , O
, '' '' O
'' `` `` O
`` NN serotonin O
serotonin , , O
, '' '' O
'' `` `` O
`` NN neurotoxicity O
neurotoxicity , , O
, '' '' O
'' `` `` O
`` NN behavior O
behavior , , O
, '' '' O
'' `` `` O
`` NNS anorexigens O
anorexigens , , O
, '' '' O
'' `` `` O
`` NN weight O
weight NN loss O
loss , , O
, '' '' O
'' CC and O
and `` `` O
`` JJ primary O
primary JJ pulmonary O
pulmonary NN hypertension O
hypertension '' '' O
'' IN as O
as NN index O
index NNS terms O

STUDY NN CAPITAL STUDY O
STUDY NN CAPITAL SELECTION O
SELECTION : : O
: NNS CAPITAL Reports O
Reports VBG dealing O
dealing IN with O
with JJ long-term O
long-term NNS effects O
effects IN of O
of NNS fenfluramines T
fenfluramines IN on O
on NN brain O
brain NN serotonin O
serotonin NNS neurons O
neurons , , O
, NN body O
body NN weight O
weight , , O
, CC and O
and JJ pulmonary O
pulmonary NN function O
function IN in O
in NNS animals O
animals CC and O
and NNS humans O

DATA NNP CAPITAL DATA O
DATA NN CAPITAL EXTRACTION O
EXTRACTION : : O
: NNS CAPITAL Reports O
Reports VBD were O
were VBN reviewed O
reviewed IN by O
by NNS individuals O
individuals IN with O
with NN expertise O
expertise IN in O
in NN serotonin O
serotonin NN neurobiology O
neurobiology , , O
, NN neurotoxicity O
neurotoxicity , , O
, NN neuropsychiatry O
neuropsychiatry , , O
, CC and O
and JJ pulmonary O
pulmonary NN medicine O
medicine CC and O
and VBN evaluated O
evaluated IN for O
for NN appropriateness O
appropriateness IN for O
for NN inclusion O
inclusion IN in O
in DT this O
this NN review O

DATA NNP CAPITAL DATA O
DATA NN CAPITAL SYNTHESIS O
SYNTHESIS : : O
: NNS CAPITAL Fenfluramines T
Fenfluramines NN cause O
cause JJ dose-related O
dose-related , , O
, JJ long-lasting O
long-lasting NNS reductions O
reductions IN in O
in NN serotonin O
serotonin JJ axonal O
axonal NNS markers O
markers IN in O
in DT all O
all DT the O
the NN animal O
animal NNS species O
species VBN tested O
tested CC and O
and IN with O
with DT all O
all DT the O
the NNS routes O
routes IN of O
of NN drug O
drug NN administration O
administration VBN used O

Doses NNS CAPITAL Doses O
Doses IN of O
of NNS fenfluramines O
fenfluramines IN that O
that VB produce O
produce NNS signs O
signs IN of O
of NN brain O
brain NN serotonin O
serotonin NN neurotoxicity O
neurotoxicity IN in O
in NNS animals O
animals VBP are O
are IN on O
on DT the O
the JJ same O
same NN order O
order IN as O
as DT those O
those VBN used O
used TO to O
to VB treat O
treat NNS humans O
humans IN for O
for NN weight O
weight NN loss O
loss WRB when O
when CD one O
one VBZ takes O
takes IN into O
into NN account O
account JJ known O
known NNS relations O
relations IN between O
between NN body O
body NN mass O
mass CC and O
and NN drug O
drug NN clearance O

However RB CAPITAL However O
However , , O
, DT no O
no JJ human O
human NNS studies O
studies VB have O
have VBN been O
been VBN conducted O
conducted , , O
, CC and O
and DT the O
the JJ pathological O
pathological CC and O
and JJ clinical O
clinical JJ potential O
potential IN for O
for NN neurotoxicity O
neurotoxicity IN in O
in NNS humans O
humans VBZ is O
is JJ unknown O

Appetite NN CAPITAL Appetite O
Appetite JJ suppressants-most O
suppressants-most RB commonly O
commonly NNS fenfluramines T
fenfluramines NN -increase O
-increase DT the O
the NN risk O
risk IN of O
of VBG developing O
developing NN CAPITAL PPH D
PPH NN ( O
( NNS odds O
odds NN ratio O
ratio , , O
, CD 6.3 O
6.3 NN ) O
) , , O
, RB particularly O
particularly WRB when O
when VBN used O
used IN for O
for RBR more O
more IN than O
than CD 3 O
3 NNS months O
months NN ( O
( NNS odds O
odds NN ratio O
ratio , , O
, JJR > O
> CD 20 O
20 NN ) O

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: NN CAPITAL Fenfluramine T
Fenfluramine CC and O
and NN dexfenfluramine T
dexfenfluramine VB have O
have VBN been O
been VBD demonstrated O
demonstrated TO to O
to NN damage O
damage NN brain O
brain NN serotonin O
serotonin NNS neurons O
neurons IN in O
in NN animal O
animal NNS studies O

It PRP CAPITAL It O
It VBZ is O
is RB not O
not JJ known O
known IN if O
if JJ such O
such NN damage O
damage VBZ occurs O
occurs IN in O
in NNS humans O
humans CC or O
or IN if O
if RB there O
there VBP are O
are JJ clinical O
clinical NNS consequences O

Use NNP CAPITAL Use O
Use IN of O
of NNS fenfluramines T
fenfluramines VBZ is O
is VBN associated O
associated IN with O
with DT an O
an VBN increased O
increased NN risk O
risk IN of O
of NN CAPITAL PPH D

Future JJ CAPITAL Future O
Future NNS studies O
studies MD should O
should NN address O
address DT the O
the JJ long-term O
long-term NNS consequences O
consequences IN of O
of JJ prolonged O
prolonged NN use O
use IN of O
of NNS fenfluramines T

Moxonidine NN CAPITAL Moxonidine T
Moxonidine NN ( T
( JJ CAPITAL Physiotens-Solvay T
Physiotens-Solvay NN ) T
) VBD was O
was VBN introduced O
introduced JJ last O
last NN year O
year IN as O
as DT the O
the RB first O
first IN of O
of DT a O
a JJ new O
new NN class O
class IN of O
of JJ centrally-acting O
centrally-acting JJ antihypertensive T
antihypertensive NNS agents T
agents , , O
, DT the O
the JJ selective O
selective NN imidazoline O
imidazoline NN receptor O
receptor NNS agonists O

The DT CAPITAL The O
The NN manufacturer O
manufacturer NNS claims O
claims IN that O
that NN moxonidine T
moxonidine `` `` O
`` RB accurately O
accurately NNS targets O
targets NN imidazoline O
imidazoline NNS receptors O
receptors IN at O
at DT the O
the JJ cardiovascular O
cardiovascular NN control O
control NN centre O
centre IN in O
in DT the O
the NN brainstem O
brainstem '' '' O
'' CC and O
and VBZ is O
is `` `` O
`` IN as O
as JJ effective O
effective IN as O
as JJ current O
current JJ first-line O
first-line NNS therapies O
therapies IN for O
for JJ essential D
essential NN hypertension D
hypertension `` `` O

Other JJ CAPITAL Other O
Other NNS claims O
claims VBP suggest O
suggest IN that O
that PRP it O
it NNS causes O
causes JJR fewer O
fewer JJ unwanted O
unwanted NNS effects O
effects IN than O
than JJR older O
older JJ centrally-acting O
centrally-acting JJ antihypertensive T
antihypertensive NNS drugs T
drugs JJ such O
such IN as O
as NN clonidine T
clonidine CC and O
and NN methyldopa T

Is VBZ CAPITAL Is O
Is NN moxonidine T
moxonidine DT a O
a JJ useful O
useful NN addition O
addition TO to O
to DT the O
the VBG growing O
growing NN number O
number IN of O
of NNS antihypertensives O
antihypertensives IN on O
on DT the O
the NN market O
market . ? O

This DT CAPITAL This O
This NN article O
article VBZ discusses O
discusses JJ dental O
dental NN anxiety O
anxiety CC and O
and NN phobia O

The DT CAPITAL The O
The NN author O
author NNS presents O
presents NN background O
background NN information O
information , , O
, VBG including O
including NN incidence O
incidence CC and O
and NN etiology O

A DT CAPITAL A O
A NN discussion O
discussion IN of O
of JJ evaluative O
evaluative NNS techniques O
techniques IN for O
for VBG assessing O
assessing NN anxiety O
anxiety NNS levels O
levels VBZ follows O

Examination NN CAPITAL Examination O
Examination CC and O
and NN treatment O
treatment VBG planning O
planning VBP are O
are VBN considered O
considered IN in O
in NN relation O
relation TO to O
to DT this O
this NN patient O
patient POS 's O
's JJ special O
special NNS needs O

The DT CAPITAL The O
The NN article O
article NNS stresses O
stresses JJ behavioral O
behavioral NN treatment O
treatment NNS modalities O
modalities IN that O
that VB eliminate O
eliminate DT the O
the VBG debilitating O
debilitating NN phobia O

In IN CAPITAL In O
In VBG closing O
closing , , O
, DT the O
the NN author O
author NNS presents O
presents JJ practical O
practical NN information O
information VBG regarding O
regarding NN prevention O
prevention IN of O
of JJ dental O
dental NN phobia O
phobia CC and O
and DT the O
the NNS merits O
merits IN of O
of VBG incorporating O
incorporating DT this O
this NN type O
type IN of O
of NN patient O
patient IN into O
into DT a O
a JJ dental O
dental NN practice O

In IN CAPITAL In O
In NN order O
order TO to O
to VB evaluate O
evaluate DT the O
the NN applicability O
applicability IN of O
of JJ anthelminthic T
anthelminthic NN treatment T
treatment IN of O
of JJ wild O
wild NNS foxes O
foxes NN ( O
( NNP CAPITAL Vulpes O
Vulpes NNS vulpes O
vulpes NN ) O
) TO to O
to NN limit O
limit PRP$ their O
their NN infection D
infection IN with D
with NN CAPITAL Echinococcus D
Echinococcus NN multilocularis D
multilocularis , , O
, NN bait O
bait NNS pellets O
pellets , , O
, DT each O
each VBG containing O
containing CD 50 O
50 NN mg O
mg NN praziquantel T
praziquantel , , O
, VBD were O
were RB repeatedly O
repeatedly VBN distributed O
distributed IN in O
in DT an O
an NN area O
area IN of O
of CD 566 O
566 NN km2 O
km2 WRB where O
where JJ many O
many NNS foxes O
foxes VBP are O
are JJ infected O
infected , , O
, IN in O
in JJ southern O
southern NNP CAPITAL Germany O

After IN CAPITAL After O
After CD six O
six VBG baiting O
baiting NNS campaigns O
campaigns NN ( O
( CD 15-20 O
15-20 NN baits/km2 O
baits/km2 NN ) O
) IN over O
over DT a O
a NN period O
period IN of O
of CD 14 O
14 NNS months O
months , , O
, DT the O
the NN prevalence O
prevalence IN of O
of DT the O
the NN cestode O
cestode IN in O
in NNS foxes O
foxes , , O
, RB initially O
initially CD 32 O
32 NN % O
% , , O
, VBD had O
had VBN fallen O
fallen TO to O
to CD 4 O
4 NN % O

The DT CAPITAL The O
The NN effect O
effect VBD was O
was JJS most O
most JJ pronounced O
pronounced IN in O
in DT the O
the JJ central O
central NN part O
part IN of O
of DT the O
the VBN treated O
treated NN area O
area , , O
, WRB where O
where DT no O
no JJ positive O
positive NN fox O
fox VBD was O
was VBN found O
found IN in O
in DT the O
the CD 2 O
2 NNS months O
months IN before O
before DT the O
the NN end O
end IN of O
of DT the O
the NN trial O

The DT CAPITAL The O
The NN study O
study VBD was O
was JJ controlled O
controlled IN for O
for JJ other O
other NNS factors O
factors IN that O
that MD could O
could NN influence O
influence DT the O
the NN parasite O
parasite POS 's O
's NN prevalence O
prevalence , , O
, JJ such O
such IN as O
as DT the O
the NN availability O
availability IN of O
of JJ intermediate O
intermediate NNS hosts O

While IN CAPITAL While O
While DT the O
the JJ potential O
potential IN of O
of DT this O
this VBG baiting O
baiting NN method O
method TO to O
to VB remove O
remove NN CAPITAL E O

multilocularis JJ multilocularis O
multilocularis IN from O
from JJ wild O
wild NNS hosts O
hosts VBZ has O
has VBN been O
been VBD demonstrated O
demonstrated , , O
, DT the O
the NN question O
question IN of O
of PRP$ its O
its JJ long-term O
long-term NN efficacy O
efficacy CC and O
and JJ other O
other JJ unresolved O
unresolved NNS problems O
problems VB have O
have TO to O
to VB be O
be VBD addressed O
addressed IN by O
by JJ consecutive O
consecutive NNS studies O
studies IN before O
before JJ routine O
routine NN application O
application MD can O
can VB be O
be VBN recommended O

In IN CAPITAL In O
In NNS patients O
patients IN with O
with JJ chronic D
chronic JJ myeloid D
myeloid NN leukemia D
leukemia NN ( D
( NN CAPITAL CML D
CML NN ) D
) , , O
, DT the O
the JJ neoplastic O
neoplastic NN ( O
( JJ CAPITAL BCR-ABL+ O
BCR-ABL+ NN ) O
) NN progenitor O
progenitor NNS cells O
cells VBP are O
are VBN characterized O
characterized IN by O
by DT an O
an VBN increased O
increased JJ proliferative O
proliferative NN activity O

Whether IN CAPITAL Whether O
Whether DT these O
these NNS cells O
cells VBP are O
are RB also O
also JJ resistant O
resistant TO to O
to NN apoptosis O
apoptosis CC and O
and IN if O
if RB so O
so , , O
, IN under O
under WDT what O
what NNS conditions O
conditions VBZ remains O
remains JJ controversial O

We PRP CAPITAL We O
We RB now O
now NN show O
show IN that O
that RB highly O
highly VBN purified O
purified NNS populations O
populations IN of O
of RB very O
very JJ primitive O
primitive JJ neoplastic O
neoplastic NN progenitor O
progenitor NNS cells O
cells VBN obtained O
obtained RB directly O
directly IN from O
from NN CAPITAL CML O
CML NNS patients O
patients VB survive O
survive CC and O
and VB proliferate O
proliferate IN in O
in FW vitro O
vitro IN for O
for JJ several O
several NNS weeks O
weeks IN in O
in DT the O
the NN absence O
absence IN of O
of DT any O
any VBN added O
added NN growth O
growth NNS factors O
factors NN ( O
( IN except O
except NN insulin O
insulin NN ) O

In IN CAPITAL In O
In NN contrast O
contrast , , O
, VBN purified O
purified JJ primary O
primary JJ normal O
normal NNS progenitors O
progenitors JJ maintained O
maintained IN under O
under DT the O
the JJ same O
same NNS conditions O
conditions VB die O
die RB rapidly O

Nevertheless RB CAPITAL Nevertheless O
Nevertheless , , O
, DT both O
both JJ primary O
primary NN CAPITAL CML O
CML NNS cells O
cells CC and O
and JJ CAPITAL BCR-ABL+ O
BCR-ABL+ NN CAPITAL BAF3 O
BAF3 NNS cells O
cells NN show O
show DT the O
the JJ same O
same JJ dose-dependent O
dose-dependent NN sensitivity O
sensitivity TO to O
to NN CAPITAL TNF-alpha O
TNF-alpha CC or O
or JJ ceramide-induced O
ceramide-induced NN apoptosis O
apoptosis IN as O
as PRP$ their O
their JJ respective O
respective JJ normal O
normal NNS counterparts O

In IN CAPITAL In O
In NN fact O
fact , , O
, NN time O
time NN course O
course NNS studies O
studies VBD demonstrated O
demonstrated DT an O
an RB even O
even RBR faster O
faster NN onset O
onset IN of O
of NN apoptosis O
apoptosis IN in O
in JJ ceramide-treated O
ceramide-treated JJ CAPITAL BCR-ABL+ O
BCR-ABL+ NN CAPITAL BAF3 O
BAF3 NNS cells O
cells IN as O
as VBN compared O
compared TO to O
to JJ normal O
normal NNS controls O

BCR-ABL+ JJ CAPITAL BCR-ABL+ O
BCR-ABL+ NNS cells O
cells VBN treated O
treated IN with O
with NN ceramide O
ceramide RB also O
also VBD showed O
showed DT a O
a JJ rapid O
rapid CC and O
and JJ sequential O
sequential NN increase O
increase IN in O
in DT the O
the NN tyrosine O
tyrosine NN phosphorylation O
phosphorylation IN of O
of NN p210 O
p210 NN ( O
( NN CAPITAL BCR-ABL O
BCR-ABL NN ) O
) , , O
, NN p46-56SHC O
p46-56SHC CC and O
and NN p120Cbl O

These DT CAPITAL These O
These NNS findings O
findings VBP suggest O
suggest NN growth O
growth NN factor O
factor NN deprivation O
deprivation CC and O
and NN treatment O
treatment IN with O
with NN CAPITAL TNF-alpha O
TNF-alpha CC or O
or NN ceramide O
ceramide NN trigger O
trigger JJ different O
different JJ initial O
initial NNS events O
events DT both O
both IN of O
of WDT which O
which MD can O
can JJ lead O
lead TO to O
to NN apoptosis O
apoptosis IN in O
in JJ factor-dependent O
factor-dependent JJ hematopoietic O
hematopoietic NNS cells O

However RB CAPITAL However O
However , , O
, IN in O
in DT the O
the RB first O
first NN case O
case , , O
, NN activation O
activation IN of O
of NN apoptosis O
apoptosis VBZ is O
is VBN blocked O
blocked IN by O
by DT the O
the JJ basal O
basal NN activity O
activity IN of O
of NN p210 O
p210 NN ( O
( NN CAPITAL BCR-ABL O
BCR-ABL NN ) O
) , , O
, IN whereas O
whereas IN in O
in DT the O
the JJ second O
second , , O
, DT the O
the NN presence O
presence IN of O
of NN p210 O
p210 NN ( O
( NN CAPITAL BCR-ABL O
BCR-ABL NN ) O
) VBZ appears O
appears TO to O
to VB accelerate O
accelerate DT the O
the NN onset O
onset IN of O
of NN apoptosis O
apoptosis IN by O
by DT a O
a NN mechanism O
mechanism IN that O
that MD may O
may VB involve O
involve DT an O
an NN activation O
activation IN of O
of PRP$ its O
its NN kinase O
kinase NN function O

Clinically RB CAPITAL Clinically O
Clinically , , O
, DT the O
the NN hallmark O
hallmark IN of O
of DT the O
the JJ human D
human JJ amnesic D
amnesic NN syndrome D
syndrome VBZ is O
is DT an O
an JJ impaired O
impaired NN ability O
ability TO to O
to RB consciously O
consciously NN recollect O
recollect CC or O
or VB remember O
remember RB daily O
daily NNS events O

If IN CAPITAL If O
If DT the O
the JJ medial O
medial NN region O
region IN of O
of DT the O
the JJ temporal O
temporal NNS lobes O
lobes , , O
, VBG including O
including DT the O
the NN hippocampus O
hippocampus CC and O
and JJ related O
related NNS structures O
structures , , O
, VBZ is O
is JJ critical O
critical IN for O
for VBG establishing O
establishing DT these O
these JJ new O
new NNS memories O
memories , , O
, RB then O
then DT this O
this NN brain O
brain NN region O
region MD should O
should VB be O
be JJ active O
active WRB whenever O
whenever NNS events O
events VBP are O
are JJ experienced O
experienced , , O
, RB regardless O
regardless IN of O
of IN whether O
whether NNS subjects O
subjects VBP are O
are VBD asked O
asked RB explicitly O
explicitly TO to O
to VB learn O
learn CC and O
and VB remember O

Here RB CAPITAL Here O
Here PRP we O
we NN show O
show IN that O
that DT the O
the JJ medial O
medial JJ temporal O
temporal NN region O
region VBZ is O
is JJ active O
active IN during O
during VBG encoding O
encoding CC and O
and IN that O
that DT the O
the NN hemisphere O
hemisphere VBN activated O
activated CC and O
and DT the O
the NN amount O
amount IN of O
of NN activation O
activation VB depend O
depend IN on O
on DT the O
the NN type O
type IN of O
of NN stimulus O
stimulus VBN presented O
presented NN ( O
( NNS objects O
objects CC or O
or NNS words O
words NN ) O
) , , O
, IN whether O
whether DT the O
the NN stimulus O
stimulus MD can O
can VB be O
be VBN encoded O
encoded IN for O
for VBG meaning O
meaning NN ( O
( JJ real O
real NNS objects O
objects CC and O
and NNS words O
words CC versus O
versus NN nonsense O
nonsense NNS objects O
objects CC and O
and NNS words O
words NN ) O
) , , O
, CC and O
and NN task O
task NN experience O
experience NN ( O
( RB first O
first CC versus O
versus DT the O
the JJ second O
second NN time O
time DT a O
a NN task O
task VBZ is O
is VBN performed O
performed NN ) O

These DT CAPITAL These O
These NNS findings O
findings VB demonstrate O
demonstrate IN that O
that DT the O
the JJ medial O
medial JJ temporal O
temporal NN lobe O
lobe NN memory O
memory NN system O
system VBZ is O
is VBN engaged O
engaged RB automatically O
automatically WRB when O
when PRP we O
we VB attend O
attend TO to O
to DT a O
a JJ perceptual O
perceptual NN event O
event CC and O
and IN that O
that DT the O
the NN location O
location CC and O
and NN amount O
amount IN of O
of NN activation O
activation VB depend O
depend IN on O
on NN stimulus O
stimulus NNS characteristics O
characteristics NN ( O
( JJ physical O
physical NN form O
form , , O
, VBG meaning O
meaning NN ) O
) CC and O
and NN experience O

The DT CAPITAL The O
The NN involvement O
involvement IN of O
of NNS structures O
structures IN in O
in DT the O
the JJ medial O
medial JJ temporal O
temporal NN lobe O
lobe IN during O
during DT the O
the VBG encoding O
encoding IN of O
of JJ visual O
visual NNS associations O
associations VBD was O
was VBN studied O
studied IN with O
with JJ functional O
functional JJ magnetic O
magnetic NN resonance O
resonance NN imaging O

In IN CAPITAL In O
In CD 11 O
11 IN out O
out IN of O
of CD 12 O
12 JJ normal O
normal JJ healthy O
healthy NNS volunteers O
volunteers DT this O
this NN task O
task VBD resulted O
resulted IN in O
in NN activation O
activation IN in O
in JJ posterior O
posterior NNS portions O
portions IN of O
of DT the O
the JJ parahippocampal O
parahippocampal NN region O
region , , O
, RB close O
close TO to O
to DT the O
the NN collateral O
collateral NN sulcus O

In IN CAPITAL In O
In CD seven O
seven NNS subjects O
subjects NN activation O
activation VBD was O
was VBN encountered O
encountered IN in O
in DT the O
the JJ hippocampal O
hippocampal NN formation O

The DT CAPITAL The O
The JJ visual O
visual NN association O
association NN task O
task IN as O
as VBN adapted O
adapted IN for O
for DT this O
this NN study O
study MD may O
may VB provide O
provide DT a O
a JJ sensitive O
sensitive NN measure O
measure TO to O
to NN study O
study NN anterograde O
anterograde NN amnesia O
amnesia JJ prevalent O
prevalent IN in O
in NN CAPITAL Alzheimer O
Alzheimer POS 's O
's NN disease O

Therefore RB CAPITAL Therefore O
Therefore , , O
, DT the O
the JJ present O
present NN paradigm O
paradigm VBZ enables O
enables DT the O
the NN study O
study IN of O
of JJ individual O
individual NNS changes O
changes IN in O
in VBG learning O
learning CC and O
and NN memory O
memory NNS capacities O
capacities IN over O
over NN time O

Altered JJ CAPITAL Altered O
Altered NN calcium O
calcium NN ( O
( NN CAPITAL Ca2+ O
Ca2+ NN ) O
) NN homeostasis O
homeostasis VBZ is O
is VBN thought O
thought TO to O
to VB play O
play DT a O
a JJ key O
key NN role O
role IN in O
in VBG aging O
aging CC and O
and NN neuropathology O
neuropathology VBG resulting O
resulting IN in O
in NN memory O
memory NNS deficits O

Several JJ CAPITAL Several O
Several NNS forms O
forms IN of O
of JJ hippocampal O
hippocampal JJ synaptic O
synaptic NN plasticity O
plasticity VBP are O
are JJ dependent O
dependent IN on O
on NN CAPITAL Ca2+ O
Ca2+ , , O
, VBG providing O
providing DT a O
a JJ potential O
potential NN link O
link IN between O
between JJ altered O
altered NN CAPITAL Ca2+ O
Ca2+ NN homeostasis O
homeostasis CC and O
and NN memory O
memory NNS deficits O
deficits VBN associated O
associated IN with O
with VBG aging O

The DT CAPITAL The O
The JJ current O
current NN study O
study NNS reviews O
reviews NN evidence O
evidence IN for O
for NN CAPITAL Ca2+ O
Ca2+ NN dysregulation O
dysregulation IN during O
during VBG aging O
aging WDT which O
which MD could O
could VBP interact O
interact IN with O
with NN CAPITAL Ca O
Ca NN ( O
( JJ 2+ O
2+ NN ) O
) JJ -dependent O
-dependent JJ synaptic O
synaptic NN plasticity O

The DT CAPITAL The O
The NNS authors O
authors VBP suggest O
suggest IN that O
that NNS changes O
changes IN in O
in NN CAPITAL Ca2+ O
Ca2+ NN regulation O
regulation MD could O
could VBP adjust O
adjust DT the O
the NNS thresholds O
thresholds IN for O
for JJ synaptic O
synaptic NN modification O
modification , , O
, VBG favoring O
favoring NNS processes O
processes IN for O
for NN depression O
depression IN of O
of JJ synaptic O
synaptic NN strength O
strength IN during O
during VBG aging O

Transiently RB CAPITAL Transiently O
Transiently VBN evolked O
evolked JJ otoacoustic O
otoacoustic NNS emissions O
emissions NN ( O
( NN CAPITAL TEOAE O
TEOAE NN ) O
) VB have O
have VBN been O
been VBN reported O
reported IN in O
in JJ several O
several NNS studies O
studies IN as O
as JJ absent O
absent IN in O
in DT a O
a JJ small O
small NN minority O
minority IN of O
of JJ normal O
normal NNS ears O

Other JJ CAPITAL Other O
Other NNS studies O
studies VB have O
have VBN reported O
reported NNS CAPITAL TEOAEs O
TEOAEs IN in O
in DT all O
all JJ normal O
normal NNS ears O

Differences NNS CAPITAL Differences O
Differences IN between O
between NNS studies O
studies MD may O
may VB arise O
arise RB directly O
directly IN from O
from NNS criteria O
criteria IN for O
for NN CAPITAL TEOAE O
TEOAE NN identification O
identification , , O
, NNS criteria O
criteria IN for O
for NN selection O
selection IN of O
of NNS normals O
normals , , O
, CC or O
or RB statistically O
statistically JJ due O
due TO to O
to JJ limited O
limited NN sample O
sample NNS sizes O

In IN CAPITAL In O
In NN order O
order TO to O
to VB understand O
understand CC and O
and NN model O
model JJ cochlear O
cochlear NNS processes O
processes VBN involved O
involved IN in O
in NN CAPITAL TEOAE O
TEOAE NN generation O
generation , , O
, PRP it O
it NNS needs O
needs TO to O
to VB be O
be JJ known O
known IN whether O
whether DT the O
the NN presence O
presence IN of O
of JJ normal O
normal VBG hearing O
hearing VBZ leads O
leads RB automatically O
automatically TO to O
to NN generation O
generation IN of O
of NNS CAPITAL TEOAEs O

The DT CAPITAL The O
The JJ present O
present NN study O
study VBN set O
set IN out O
out TO to O
to VB establish O
establish IN in O
in DT a O
a JJ large O
large NN sample O
sample IN if O
if DT any O
any NNS ears O
ears MD could O
could VB be O
be VBN found O
found IN that O
that VBD lacked O
lacked NNS CAPITAL TEOAEs O
TEOAEs IN despite O
despite JJ normal O
normal VBG hearing O
hearing NN threshold O
threshold NNS levels O
levels NN ( O
( NN CAPITAL HTL O
HTL NN ) O

A DT CAPITAL A O
A JJ total O
total IN of O
of CD 397 O
397 NNS ears O
ears IN from O
from RB highly O
highly JJ cooperative O
cooperative JJ adult O
adult NNS subjects O
subjects VBD were O
were VBN examined O
examined IN under O
under NN laboratory O
laboratory NNS conditions O

Using VBG CAPITAL Using O
Using JJ cross O
cross NN correlation O
correlation IN between O
between VB replicate O
replicate JJ nonlinear O
nonlinear NNS waveforms O
waveforms IN as O
as DT the O
the NN criterion O
criterion , , O
, NNS CAPITAL TEOAEs O
TEOAEs VBD were O
were JJ present O
present IN in O
in CD 99.2 O
99.2 NN % O
% IN of O
of DT the O
the NN sample O
sample NN ( O
( JJR lower O
lower NN CAPITAL CI O
CI CD 98.1 O
98.1 NN % O
% NN ) O

However RB CAPITAL However O
However , , O
, JJ careful O
careful JJ visual O
visual NN assessment O
assessment IN of O
of DT the O
the VBN recorded O
recorded NNS waveforms O
waveforms IN for O
for DT the O
the VBG remaining O
remaining NNS ears O
ears VBD did O
did RB not O
not RB unequivocally O
unequivocally NN show O
show NN absence O
absence IN of O
of NN CAPITAL TEOAE O
TEOAE NNS characteristics O
characteristics IN in O
in DT any O
any NN ear O
ear IN with O
with JJ normal O
normal NNS CAPITAL HTLs O

While IN CAPITAL While O
While NN CAPITAL TEOAE O
TEOAE NN strength O
strength VBZ varies O
varies RB widely O
widely IN among O
among NNS ears O
ears , , O
, DT no O
no JJ clear O
clear NN evidence O
evidence VBD was O
was VBN found O
found TO to O
to NN show O
show IN that O
that NNS CAPITAL TEOAEs O
TEOAEs MD can O
can VB be O
be JJ absent O
absent WRB when O
when NNS CAPITAL HTLs O
HTLs VBP are O
are JJ normal O

In IN CAPITAL In O
In NN addition O
addition TO to O
to DT a O
a RB long O
long NN form O
form IN of O
of CD 591 O
591 NN amino O
amino NNS acids O
acids NN ( O
( NN aa O
aa NN ) O
) , , O
, CD two O
two JJ other O
other NNS forms O
forms IN of O
of NN CAPITAL PRL O
PRL NN receptor O
receptor NN ( O
( NN CAPITAL PRLR O
PRLR NN ) O
) , , O
, VBG differing O
differing IN in O
in DT the O
the NN length O
length IN of O
of PRP$ their O
their JJ cytoplasmic O
cytoplasmic NNS domains O
domains , , O
, VB have O
have VBN been O
been VBN identified O
identified IN in O
in DT the O
the NN rat O

The DT CAPITAL The O
The NN CAPITAL Nb2 O
Nb2 NN form O
form , , O
, VBG lacking O
lacking CD 198 O
198 NN aa O
aa IN in O
in DT the O
the JJ cytoplasmic O
cytoplasmic NN domain O
domain , , O
, VBZ is O
is JJ able O
able TO to O
to VB transmit O
transmit DT a O
a JJ lactogenic O
lactogenic NN signal O
signal JJ similar O
similar TO to O
to DT the O
the RB long O
long NN form O
form , , O
, IN whereas O
whereas DT the O
the JJ short O
short NN form O
form IN of O
of CD 291 O
291 NN aa O
aa VBZ is O
is JJ inactive O

The DT CAPITAL The O
The NN ability O
ability IN of O
of NN CAPITAL PRL O
PRL TO to O
to VB activate O
activate DT the O
the NN promoter O
promoter IN of O
of DT the O
the NN beta-casein O
beta-casein NN gene O
gene CC or O
or DT the O
the JJ lactogenic O
lactogenic NN hormone O
hormone JJ responsive O
responsive NN element O
element VBN fused O
fused TO to O
to DT the O
the NN luciferase O
luciferase NN reporter O
reporter VBD was O
was VBN assessed O
assessed IN in O
in JJ CAPITAL Chinese O
Chinese NN hamster O
hamster JJ ovary O
ovary NNS cells O
cells CC or O
or CD 293 O
293 NNS fibroblasts O
fibroblasts RB transiently O
transiently VBN transfected O
transfected IN with O
with NN CAPITAL PRLR O
PRLR NNS cDNAs O

The DT CAPITAL The O
The NN function O
function IN of O
of DT the O
the JJ short O
short NN form O
form VBD was O
was VBN examined O
examined IN after O
after NN cotransfection O
cotransfection IN of O
of DT both O
both DT the O
the RB long O
long CC and O
and JJ short O
short NNS forms O

These DT CAPITAL These O
These NNS results O
results RB clearly O
clearly NN show O
show IN that O
that DT the O
the JJ short O
short NN form O
form NNS acts O
acts IN as O
as DT a O
a JJ dominant O
dominant JJ negative O
negative NN inhibitor O
inhibitor IN through O
through DT the O
the NN formation O
formation IN of O
of JJ inactive O
inactive NNS heterodimers O
heterodimers , , O
, VBG resulting O
resulting IN in O
in DT an O
an NN inhibition O
inhibition IN of O
of NN CAPITAL Janus O
Janus NN kinase O
kinase CD 2 O
2 NN ( O
( NN CAPITAL JAK2 O
JAK2 NN ) O
) NN activation O

The DT CAPITAL The O
The JJ present O
present NN study O
study RB also O
also VBZ investigates O
investigates DT the O
the JJ possible O
possible NN participation O
participation IN of O
of JJ cytoplasmic O
cytoplasmic NNS receptors O
receptors IN in O
in DT the O
the NN signal O
signal NN transduction O
transduction NN pathway O
pathway , , O
, VBG using O
using NN cotransfection O
cotransfection NNS experiments O
experiments CC and O
and DT a O
a JJ new O
new NN approach O
approach IN that O
that RB selectively O
selectively VBZ determines O
determines DT the O
the NN contribution O
contribution IN of O
of JJ cytoplasmic O
cytoplasmic NNS receptors O
receptors IN in O
in DT the O
the NN process O
process IN of O
of NN signal O
signal NN transduction O

We PRP CAPITAL We O
We VBN cotransfected O
cotransfected JJ CAPITAL Chinese O
Chinese NN hamster O
hamster JJ ovary O
ovary NNS cells O
cells IN with O
with CD two O
two NN cDNA O
cDNA NNS constructs O
constructs : : O
: DT a O
a JJ cytoplasmic O
cytoplasmic NN ( O
( JJ soluble O
soluble NN ) O
) NN form O
form IN of O
of DT the O
the NN receptor O
receptor IN with O
with DT a O
a VBN deleted O
deleted NN signal O
signal NN peptide O
peptide NN ( O
( NN delta-19 O
delta-19 NN ) O
) , , O
, WDT which O
which VBZ is O
is JJ unable O
unable TO to O
to VB bind O
bind NN CAPITAL PRL O
PRL , , O
, CC and O
and DT a O
a RB functionally O
functionally JJ inactive O
inactive NN receptor O
receptor JJ mutant O
mutant NN ( O
( VBG lacking O
lacking NN box O
box CD 1 O
1 NN ) O
) , , O
, WDT which O
which VBZ is O
is VBN anchored O
anchored IN in O
in DT the O
the NN plasma O
plasma NN membrane O
membrane CC and O
and JJ able O
able TO to O
to VB bind O
bind NN CAPITAL PRL O

This DT CAPITAL This O
This NN approach O
approach VBZ has O
has VBN allowed O
allowed PRP us O
us TO to O
to NN show O
show IN that O
that NN delta-19 O
delta-19 , , O
, VBG lacking O
lacking NN expression O
expression IN at O
at DT the O
the NN plasma O
plasma NN membrane O
membrane , , O
, MD can O
can VB transduce O
transduce DT the O
the JJ hormonal O
hormonal NN message O
message , , O
, IN at O
at JJS least O
least TO to O
to DT a O
a JJ limited O
limited NN extent O
extent NN ( O
( RB up O
up TO to O
to CD 30 O
30 NN % O
% IN of O
of JJ wild O
wild NN type O
type NN efficiency O
efficiency NN ) O
) , , O
, VBG providing O
providing IN that O
that NN association/activation O
association/activation VBZ occurs O
occurs IN with O
with DT a O
a NN CAPITAL PRL-PRLR O
PRL-PRLR JJ complex O
complex VBN initiated O
initiated IN at O
at DT the O
the NN cell O
cell NN surface O
surface NN level O
level : ; O
; NN box O
box CD 1 O
1 IN of O
of DT the O
the JJ cytoplasmic O
cytoplasmic NN form O
form VBZ is O
is JJ necessary O
necessary TO to O
to NN rescue O
rescue DT this O
this JJ partial O
partial JJ transcriptional O
transcriptional NN activity O
activity IN of O
of DT the O
the JJ inactive O
inactive JJ mutant O

This DT CAPITAL This O
This JJ partial O
partial NN recovery O
recovery VBZ is O
is RB also O
also JJ parallel O
parallel TO to O
to DT the O
the JJ partial O
partial NN activation O
activation IN of O
of NN CAPITAL JAK2 O
JAK2 , , O
, VBG indicating O
indicating IN that O
that DT the O
the NN signal O
signal NN transduction O
transduction NN pathway O
pathway VBN implicated O
implicated NN CAPITAL JAK2 O

Our PRP$ CAPITAL Our O
Our NNS results O
results VB provide O
provide NN evidence O
evidence IN that O
that NN heterodimerization O
heterodimerization IN of O
of NNS receptors O
receptors MD can O
can VB be O
be VBN implicated O
implicated DT either O
either IN in O
in DT the O
the JJ positive O
positive CC or O
or IN in O
in JJ negative O
negative NN activation O
activation IN of O
of NN gene O
gene NN transcription O

BACKGROUND NN CAPITAL BACKGROUND O
BACKGROUND : : O
: JJ CAPITAL Inadequate O
Inadequate JJ dietary O
dietary NN intake O
intake IN of O
of NN calcium O
calcium CC and O
and NN vitamin O
vitamin NN CAPITAL D O
D MD may O
may VB contribute O
contribute TO to O
to DT the O
the JJ high O
high NN prevalence O
prevalence IN of O
of NN osteoporosis D
osteoporosis IN among O
among JJR older O
older NNS persons O

METHODS NNS CAPITAL METHODS O
METHODS : : O
: PRP CAPITAL We O
We VBN studied O
studied DT the O
the NNS effects O
effects IN of O
of CD three O
three NNS years O
years IN of O
of JJ dietary O
dietary NN supplementation O
supplementation IN with O
with NN calcium O
calcium CC and O
and NN vitamin O
vitamin NN CAPITAL D O
D IN on O
on NN bone O
bone NN mineral O
mineral NN density O
density , , O
, JJ biochemical O
biochemical NNS measures O
measures IN of O
of NN bone O
bone NN metabolism O
metabolism , , O
, CC and O
and DT the O
the NN incidence O
incidence IN of O
of JJ nonvertebral O
nonvertebral NNS fractures O
fractures IN in O
in CD 176 O
176 NNS men O
men CC and O
and CD 213 O
213 NNS women O
women CD 65 O
65 NNS years O
years IN of O
of NN age O
age CC or O
or JJR older O
older WP who O
who VBD were O
were VBG living O
living IN at O
at NN home O

They PRP CAPITAL They O
They VBN received O
received DT either O
either CD 500 O
500 NN mg O
mg IN of O
of NN calcium O
calcium CC plus O
plus CD 700 O
700 NN CAPITAL IU O
IU IN of O
of NN vitamin O
vitamin NN CAPITAL D3 O
D3 NN ( O
( NN cholecalciferol O
cholecalciferol NN ) O
) IN per O
per NN day O
day CC or O
or NN placebo O

Bone NN CAPITAL Bone O
Bone NN mineral O
mineral NN density O
density VBD was O
was VBN measured O
measured IN by O
by JJ dual-energy O
dual-energy NN x-ray O
x-ray NN absorptiometry O
absorptiometry , , O
, NN blood O
blood CC and O
and NN urine O
urine VBD were O
were VBN analyzed O
analyzed DT every O
every CD six O
six NNS months O
months , , O
, CC and O
and NNS cases O
cases IN of O
of JJ nonvertebral O
nonvertebral NN fracture O
fracture VBD were O
were VBN ascertained O
ascertained IN by O
by NNS means O
means IN of O
of NNS interviews O
interviews CC and O
and VBN verified O
verified IN with O
with NN use O
use IN of O
of NN hospital O
hospital NNS records O

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: DT CAPITAL The O
The VB mean O
mean NN ( O
( NN +/-SD O
+/-SD NN ) O
) NNS changes O
changes IN in O
in NN bone O
bone NN mineral O
mineral NN density O
density IN in O
in DT the O
the JJ calcium-vitamin O
calcium-vitamin NN CAPITAL D O
D CC and O
and NN placebo O
placebo NNS groups O
groups VBD were O
were IN as O
as VBZ follows O
follows : : O
: JJ femoral O
femoral NN neck O
neck , , O
, CD +0.50+/-4.80 O
+0.50+/-4.80 CC and O
and CD -0.70+/-5.03 O
-0.70+/-5.03 NN percent O
percent , , O
, RB respectively O
respectively NN ( O
( NN CAPITAL P=0.02 O
P=0.02 NN ) O
) : ; O
; NN spine O
spine , , O
, CD +2.12+/-4.06 O
+2.12+/-4.06 CC and O
and CD +1.22+/-4.25 O
+1.22+/-4.25 NN percent O
percent NN ( O
( NN CAPITAL P=0.04 O
P=0.04 NN ) O
) : ; O
; CC and O
and JJ total O
total NN body O
body , , O
, CD +0.06+/-1.83 O
+0.06+/-1.83 CC and O
and CD -1.09+/-1.71 O
-1.09+/-1.71 NN percent O
percent NN ( O
( NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0.001 O
0.001 NN ) O

The DT CAPITAL The O
The NN difference O
difference IN between O
between DT the O
the JJ calcium-vitamin O
calcium-vitamin NN CAPITAL D O
D CC and O
and NN placebo O
placebo NNS groups O
groups VBD was O
was JJ significant O
significant IN at O
at DT all O
all JJ skeletal O
skeletal NNS sites O
sites IN after O
after CD one O
one NN year O
year , , O
, CC but O
but PRP it O
it VBD was O
was JJ significant O
significant RB only O
only IN for O
for JJ total-body O
total-body NN bone O
bone NN mineral O
mineral NN density O
density IN in O
in DT the O
the JJ second O
second CC and O
and JJ third O
third NNS years O

Of IN CAPITAL Of O
Of CD 37 O
37 NNS subjects O
subjects WP who O
who VBD had O
had JJ nonvertebral O
nonvertebral NNS fractures O
fractures , , O
, CD 26 O
26 VBD were O
were IN in O
in DT the O
the NN placebo O
placebo NN group O
group CC and O
and CD 11 O
11 VBD were O
were IN in O
in DT the O
the JJ calcium-vitamin O
calcium-vitamin NN CAPITAL D O
D NN group O
group NN ( O
( NN CAPITAL P=0.02 O
P=0.02 NN ) O

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: IN CAPITAL In O
In NNS men O
men CC and O
and NNS women O
women CD 65 O
65 NNS years O
years IN of O
of NN age O
age CC or O
or JJR older O
older WP who O
who VBP are O
are VBG living O
living IN in O
in DT the O
the NN community O
community , , O
, JJ dietary T
dietary NN supplementation T
supplementation IN with T
with NN calcium T
calcium CC and T
and NN vitamin T
vitamin NN CAPITAL D T
D RB moderately O
moderately VBN reduced O
reduced NN bone D
bone NN loss D
loss VBN measured O
measured IN in O
in DT the O
the JJ femoral O
femoral NN neck O
neck , , O
, NN spine O
spine , , O
, CC and O
and JJ total O
total NN body O
body IN over O
over DT the O
the JJ three-year O
three-year NN study O
study NN period O
period CC and O
and VBN reduced O
reduced DT the O
the NN incidence O
incidence IN of O
of JJ nonvertebral D
nonvertebral NNS fractures D

The DT CAPITAL The O
The NN sterilization O
sterilization CC and O
and VBN contaminated O
contaminated NN waste O
waste NN disposal O
disposal NNS practices O
practices IN in O
in DT all O
all CD 14 O
14 JJ dental O
dental NNS clinics O
clinics VBN operated O
operated IN by O
by DT the O
the NNP CAPITAL Southern O
Southern NNP CAPITAL Sydney O
Sydney NNP CAPITAL Area O
Area NNP CAPITAL Health O
Health NNP CAPITAL Service O
Service VBD were O
were VBN surveyed O

All DT CAPITAL All O
All IN of O
of DT the O
the NNS clinics O
clinics VBN used O
used NNS autoclaves O
autoclaves IN for O
for NN sterilization O

All DT CAPITAL All O
All NN hand O
hand NNS instruments O
instruments , , O
, NNS handpieces O
handpieces CC and O
and JJ triplex O
triplex NNS syringes O
syringes VBD were O
were JJ autoclaved O
autoclaved IN between O
between NNS patients O

Chemical NNP CAPITAL Chemical O
Chemical NN disinfection O
disinfection NNS solutions O
solutions VBD were O
were VBN used O
used IN in O
in CD 12 O
12 IN of O
of DT the O
the CD 14 O
14 JJ dental O
dental NNS clinics O
clinics , , O
, RB mainly O
mainly IN for O
for NN surface O
surface NN decontamination O

Five CD CAPITAL Five O
Five JJ dental O
dental NNS clinics O
clinics VBD had O
had JJ separate O
separate NN storage O
storage NNS areas O
areas IN for O
for VBN contaminated O
contaminated NN waste O
waste WDT which O
which VBN compiled O
compiled IN with O
with VBN contaminated O
contaminated NN waste O
waste NN separation O
separation CC and O
and NN disposal O
disposal NNS guidelines O

The DT CAPITAL The O
The NN practice O
practice IN of O
of VBG recapping O
recapping NNS needles O
needles IN with O
with NNS fingers O
fingers CC and O
and DT some O
some JJ inadequate O
inadequate VBG washing O
washing NNS facilities O
facilities VBP are O
are NNS areas O
areas IN that O
that VB require O
require JJ particular O
particular NN attention O

Safety NN CAPITAL Safety O
Safety CC and O
and NN efficacy O
efficacy VBP are O
are JJ crucial O
crucial CC but O
but JJ separate O
separate NNS issues O
issues IN for O
for NN vitamin O
vitamin CC and O
and NN mineral O
mineral NNS supplements O

Misinterpretation NN CAPITAL Misinterpretation O
Misinterpretation IN of O
of `` `` O
`` JJ safe O
safe CC and O
and JJ adequate O
adequate '' '' O
'' TO to O
to VB mean O
mean `` `` O
`` NN safety O
safety NN limit O
limit '' '' O
'' MD would O
would VB impose O
impose NNS restrictions O
restrictions IN on O
on NN vitamin O
vitamin CC and O
and NN mineral O
mineral NN intakes O
intakes IN that O
that VBP are O
are RB not O
not VBN needed O
needed TO to O
to VB ensure O
ensure NN safety O

Substantial JJ CAPITAL Substantial O
Substantial NN evidence O
evidence VBZ indicates O
indicates IN that O
that NN intakes O
intakes JJR greater O
greater IN than O
than DT the O
the VBN recommended O
recommended JJ dietary O
dietary NNS allowances O
allowances NN ( O
( NNS CAPITAL RDAs O
RDAs NN ) O
) IN of O
of JJ certain O
certain NNS vitamins O
vitamins CC and O
and NNS minerals O
minerals JJ such O
such IN as O
as NN calcium O
calcium , , O
, JJ folic O
folic NN acid O
acid , , O
, NN vitamin O
vitamin NN CAPITAL E O
E , , O
, NN selenium O
selenium , , O
, CC and O
and NN chromium O
chromium VB reduce O
reduce DT the O
the NN risk O
risk IN of O
of JJ certain O
certain NNS diseases O
diseases IN for O
for DT some O
some NNS people O

Limitation NN CAPITAL Limitation O
Limitation IN of O
of NN intakes O
intakes TO to O
to DT the O
the NNS CAPITAL RDAs O
RDAs MD would O
would VB preclude O
preclude NNS reductions O
reductions IN in O
in NN disease O
disease NN risk O
risk IN from O
from DT these O
these NNS nutrients O

The DT CAPITAL The O
The NN margin O
margin IN of O
of NN safety O
safety IN between O
between DT the O
the JJ usual O
usual JJ dietary O
dietary NN intake O
intake CC and O
and DT the O
the NN intake O
intake IN that O
that MD would O
would VB produce O
produce JJ adverse O
adverse NNS effects O
effects VBZ varies O
varies RB greatly O
greatly IN among O
among DT the O
the JJ different O
different NNS nutrients O

Very RB CAPITAL Very O
Very JJ high O
high NN intakes O
intakes IN of O
of NNS vitamins O
vitamins DT CAPITAL A O
A CC and O
and NN CAPITAL D O
D , , O
, NN niacin O
niacin , , O
, NN pyridoxine O
pyridoxine , , O
, CC and O
and NN selenium O
selenium VB have O
have VBN produced O
produced JJ adverse O
adverse NNS effects O

Many JJ CAPITAL Many O
Many RB widely O
widely VBN discussed O
discussed JJ putative O
putative JJ adverse O
adverse NNS effects O
effects IN of O
of NN vitamin O
vitamin NN CAPITAL C O
C , , O
, NN vitamin O
vitamin NN CAPITAL E O
E , , O
, CC and O
and JJ trivalent O
trivalent NN chromium O
chromium VB have O
have JJ little O
little JJ factual O
factual NN basis O

There EX CAPITAL There O
There VBZ is O
is DT no O
no NN evidence O
evidence IN of O
of JJ adverse O
adverse NNS effects O
effects IN from O
from NN beta-carotene O
beta-carotene NNS supplements O
supplements IN except O
except IN in O
in JJ current O
current JJ heavy O
heavy NNS smokers O

The DT CAPITAL The O
The NN mutator O
mutator NN hypothesis O
hypothesis IN of O
of NN tumorigenesis O
tumorigenesis VBZ suggests O
suggests IN that O
that NN loss O
loss IN of O
of JJ chromosomal O
chromosomal NN stability O
stability CC or O
or NN maintenance O
maintenance NNS functions O
functions NNS results O
results IN in O
in JJ elevated O
elevated NN mutation O
mutation NNS rates O
rates , , O
, VBG leading O
leading TO to O
to DT the O
the NN accumulation O
accumulation IN of O
of DT the O
the JJ numerous O
numerous NNS mutations O
mutations VBN required O
required IN for O
for JJ multistep O
multistep NN carcinogenesis O

The DT CAPITAL The O
The JJ human O
human NN CAPITAL DNA O
DNA NN mismatch O
mismatch NN repair O
repair NN ( O
( NN CAPITAL MMR O
MMR NN ) O
) NNS genes O
genes VBP are O
are RB highly O
highly VBN conserved O
conserved NNS homologues O
homologues IN of O
of DT the O
the FW CAPITAL Escherichia O
Escherichia NN coli O
coli NN CAPITAL MutHLS O
MutHLS NN system O
system , , O
, WDT which O
which VB contribute O
contribute TO to O
to JJ genomic O
genomic NN stability O
stability IN by O
by NN surveillance O
surveillance CC and O
and NN repair O
repair IN of O
of NN replication O
replication NN misincorporation O
misincorporation NNS errors O
errors CC and O
and JJ exogenous O
exogenous NN CAPITAL DNA O
DNA NN damage O

Mutations NNS CAPITAL Mutations O
Mutations IN in O
in CD one O
one IN of O
of DT these O
these NN CAPITAL MMR O
MMR NNS genes O
genes , , O
, NN hMSH2 O
hMSH2 , , O
, NN account O
account IN for O
for IN about O
about DT half O
half IN of O
of DT all O
all NNS cases O
cases IN of O
of RB genetically O
genetically VBN linked O
linked JJ hereditary O
hereditary JJ non-polyposis O
non-polyposis JJ colorectal O
colorectal NN cancer O

Loss NN CAPITAL Loss O
Loss IN of O
of NN function O
function IN of O
of NN p53 O
p53 VBZ has O
has RB also O
also VBN been O
been VBN proposed O
proposed TO to O
to NN increase O
increase JJ cellular O
cellular NN hypermutability O
hypermutability , , O
, RB thereby O
thereby VBG accelerating O
accelerating NN carcinogenesis O
carcinogenesis , , O
, IN although O
although DT a O
a JJ clear O
clear NN role O
role IN for O
for NN p53 O
p53 IN in O
in JJ genomic O
genomic NN instability O
instability VBZ remains O
remains JJ controversial O

p53 NN p53 O
p53 VBZ is O
is VBN mutated O
mutated RB frequently O
frequently IN in O
in DT a O
a JJ wide O
wide NN range O
range IN of O
of JJ human O
human NNS cancers D
cancers , , O
, VBG including O
including JJ colonic D
colonic NNS tumours D

Both DT CAPITAL Both O
Both NN CAPITAL Msh2- O
Msh2- CC and O
and JJ p53-targeted O
p53-targeted NN knockout O
knockout NNS mice O
mice VBP are O
are JJ viable O
viable CC and O
and JJ susceptible O
susceptible TO to O
to NN cancer D

Here RB CAPITAL Here O
Here PRP we O
we VB demonstrate O
demonstrate IN that O
that JJ combined O
combined NN CAPITAL Msh2 O
Msh2 CC and O
and NN p53 O
p53 NN ablation O
ablation NN ( O
( JJ CAPITAL Msh2-/-p53-/- O
Msh2-/-p53-/- NN ) O
) NNS results O
results IN in O
in JJ developmental O
developmental NN arrest O
arrest IN of O
of DT all O
all JJ female O
female NNS embryos O
embryos IN at O
at CD 9.5 O
9.5 NNS days O

In IN CAPITAL In O
In NN contrast O
contrast , , O
, JJ male O
male JJ CAPITAL Msh2-/-p53-/- O
Msh2-/-p53-/- NNS mice O
mice VBP are O
are JJ viable O
viable , , O
, CC but O
but VB succumb O
succumb TO to O
to NNS tumours D
tumours RB significantly O
significantly JJR earlier O
earlier NN ( O
( NN t1-2 O
t1-2 VBZ is O
is CD 73 O
73 NNS days O
days NN ) O
) IN than O
than DT either O
either JJ CAPITAL Msh2-/- O
Msh2-/- CC or O
or JJ p53-/- O
p53-/- NNS littermates O

Furthermore RB CAPITAL Furthermore O
Furthermore , , O
, DT the O
the NN frequency O
frequency IN of O
of NN microsatellite O
microsatellite NN instability O
instability NN ( O
( NN CAPITAL MSI O
MSI NN ) O
) IN in O
in NNS tumours O
tumours IN from O
from JJ CAPITAL Msh2-/-p53-/- O
Msh2-/-p53-/- NNS mice O
mice VBZ is O
is RB not O
not RB significantly O
significantly JJ different O
different IN than O
than IN in O
in JJ CAPITAL Msh2-/- O
Msh2-/- NNS mice O

Synergism NN CAPITAL Synergism O
Synergism IN in O
in NN tumorigenesis O
tumorigenesis CC and O
and JJ independent O
independent NN segregation O
segregation IN of O
of DT the O
the NN CAPITAL MSI O
MSI NN phenotype O
phenotype VBP suggest O
suggest IN that O
that NN CAPITAL Msh2 O
Msh2 CC and O
and NN p53 O
p53 VBP are O
are RB not O
not RB genetically O
genetically JJ epistatic O

Our PRP$ CAPITAL Our O
Our NNS data O
data NN ( O
( NNP CAPITAL Reddy O
Reddy FW et O
et NNP al O
al . . O
. , , O
, NN CAPITAL Radiat O

Res NNP CAPITAL Res O

141 CD 141 O
141 , , O
, CD 252-258 O
252-258 , , O
, CD 1995 O
1995 NN ) O
) IN on O
on DT the O
the NNS kinetics O
kinetics IN of O
of DT the O
the NN repair O
repair IN of O
of RB potentially O
potentially JJ lethal O
lethal NN damage O
damage IN in O
in JJ log-phase O
log-phase JJ CAPITAL Chinese O
Chinese NN hamster O
hamster NN CAPITAL V79 O
V79 NNS cells O
cells VBP are O
are VBN used O
used TO to O
to NN test O
test DT some O
some NNS predictions O
predictions WDT which O
which VB arise O
arise IN from O
from DT the O
the JJ different O
different NNS assumptions O
assumptions IN of O
of DT the O
the JJ repair-misrepair O
repair-misrepair NN ( O
( NN CAPITAL RMR O
RMR NN ) O
) NN ( O
( NN CAPITAL C O

A DT CAPITAL A O

Tobias NNP CAPITAL Tobias O
Tobias , , O
, NN CAPITAL Radiat O

Res NNP CAPITAL Res O

104 CD 104 O
104 , , O
, NN CAPITAL S77-S95 O
S77-S95 , , O
, CD 1985 O
1985 NN ) O
) , , O
, RB lethal-potentially O
lethal-potentially JJ lethal O
lethal NN ( O
( NN CAPITAL LPL O
LPL NN ) O
) NN ( O
( NNP CAPITAL S. O
S. NN CAPITAL B O

Curtis NNP CAPITAL Curtis O
Curtis , , O
, NN CAPITAL Radiat O

Res NNP CAPITAL Res O

106 CD 106 O
106 , , O
, CD 252-270 O
252-270 , , O
, CD 1986 O
1986 NN ) O
) CC and O
and JJ double-strand O
double-strand NN break O
break NN ( O
( NN CAPITAL DSB O
DSB NN ) O
) NN ( O
( NN CAPITAL J O

Y NN CAPITAL Y O

Ostashevsky NNP CAPITAL Ostashevsky O
Ostashevsky , , O
, NN CAPITAL Radiat O

Res NNP CAPITAL Res O

118 CD 118 O
118 , , O
, CD 437-466 O
437-466 , , O
, CD 1989 O
1989 NN ) O
) NNS models O

The DT CAPITAL The O
The NN CAPITAL LPL O
LPL NN model O
model VBZ defines O
defines DT the O
the NN time O
time JJ available O
available IN for O
for NN repair O
repair IN of O
of NN CAPITAL PLD O
PLD NN ( O
( NN t O
t NN ( O
( NN rep O
rep NN ) O
) NN ) O
) IN as O
as DT the O
the NN time O
time VBN taken O
taken TO to O
to VB reach O
reach JJ maximal O
maximal NN survival O
survival IN in O
in DT a O
a JJ delayed-plating O
delayed-plating NN recovery O
recovery NN experiment O

Those DT CAPITAL Those O
Those NNS data O
data NN show O
show IN that O
that IN after O
after DT this O
this NN time O
time VBZ has O
has VBN elapsed O
elapsed , , O
, JJ contrary O
contrary TO to O
to DT the O
the NN expectation O
expectation IN of O
of DT the O
the NN CAPITAL LPL O
LPL NN model O
model , , O
, NN survival O
survival MD can O
can VB be O
be VBN increased O
increased IN by O
by VBG changing O
changing DT the O
the NN medium O
medium VBN used O
used IN for O
for VBN delayed O
delayed VBG plating O
plating IN from O
from JJ fresh O
fresh NN growth O
growth NN medium O
medium TO to O
to VBN conditioned O
conditioned NN medium O

According VBG CAPITAL According O
According TO to O
to DT the O
the NN CAPITAL RMR O
RMR NN model O
model , , O
, DT all O
all RB potentially O
potentially JJ lethal O
lethal NNS lesions O
lesions MD should O
should RB also O
also VB be O
be JJ committed O
committed IN by O
by IN that O
that NN time O
time CC and O
and VB be O
be JJ unavailable O
unavailable IN for O
for NN repair O
repair IN in O
in DT the O
the JJ new O
new NN medium O

Only RB CAPITAL Only O
Only DT the O
the NN CAPITAL DSB O
DSB NN model O
model RB correctly O
correctly VBN predicted O
predicted IN that O
that NN CAPITAL PLD O
PLD NN ( O
( JJ = O
= NNS CAPITAL DSBs O
DSBs NN ) O
) MD would O
would RB still O
still VB be O
be JJ available O
available IN for O
for NN repair O
repair IN after O
after IN that O
that NN time O

Second JJ CAPITAL Second O
Second , , O
, NNS data O
data IN for O
for NN split-dose O
split-dose NN recovery O
recovery VBP are O
are VBN used O
used TO to O
to VB predict O
predict DT the O
the JJ first-order O
first-order NNS kinetics O
kinetics NN time O
time JJ constant O
constant IN for O
for NN CAPITAL DSB O
DSB NN repair O
repair NN ( O
( NN tau O
tau NN ( O
( NN CAPITAL DSBR O
DSBR NN ) O
) NN ) O
) VBG using O
using DT the O
the NN CAPITAL DSB O
DSB NN model O
model NN ( O
( CD 24 O
24 CC +/- O
+/- CD 1.5 O
1.5 NN min O
min NN ) O

This DT CAPITAL This O
This NN value O
value VBZ is O
is RB nearly O
nearly JJ identical O
identical TO to O
to DT the O
the NN value O
value IN of O
of CD 27 O
27 CC +/- O
+/- CD 1 O
1 NN min O
min VBN determined O
determined IN from O
from DT the O
the NNS data O
data VBN obtained O
obtained IN by O
by NNP CAPITAL Cheong O
Cheong FW et O
et NNP al O
al . . O
. VBG using O
using JJ pulsed-field O
pulsed-field NN gel O
gel NN electrophoresis O
electrophoresis NN ( O
( NN CAPITAL PFGE O
PFGE NN ) O
) NN ( O
( NN CAPITAL Mutat O

Res NNP CAPITAL Res O

274 CD 274 O
274 , , O
, CD 111-122 O
111-122 , , O
, CD 1992 O
1992 NN ) O

The DT CAPITAL The O
The NN value O
value VBN based O
based IN on O
on NN CAPITAL PFGE O
PFGE VBZ is O
is VBN used O
used TO to O
to VB calculate O
calculate DT the O
the NN value O
value IN of O
of NN t O
t NN ( O
( NN rep O
rep NN ) O
) VBN predicted O
predicted IN by O
by DT the O
the NN CAPITAL DSB O
DSB NN model O
model NN ( O
( CD 2.6 O
2.6 CC +/- O
+/- CD 0.1 O
0.1 NN h O
h NN ) O
) , , O
, WDT which O
which VBZ agrees O
agrees IN with O
with DT the O
the NN value O
value VBN determined O
determined RB experimentally O
experimentally IN as O
as DT the O
the NN time O
time WRB when O
when VBG changing O
changing DT the O
the JJ delayed-plating O
delayed-plating NN medium O
medium IN from O
from NN growth O
growth NN medium O
medium TO to O
to VBN conditioned O
conditioned NN medium O
medium DT no O
no RB longer O
longer VBZ gives O
gives DT the O
the JJ full O
full NN recovery O
recovery VBN seen O
seen IN with O
with VBN delayed O
delayed VBG plating O
plating IN in O
in VBN conditioned O
conditioned NN medium O
medium NN ( O
( CD 2.5 O
2.5 NN h O
h NN ) O

However RB CAPITAL However O
However , , O
, DT some O
some NN recovery O
recovery VBD was O
was VBN seen O
seen IN for O
for DT a O
a NN change O
change IN in O
in DT the O
the NN medium O
medium NN ( O
( NN growth O
growth NN medium O
medium TO to O
to VBN conditioned O
conditioned NN medium O
medium NN ) O
) RB up O
up TO to O
to CD 5-6 O
5-6 NN h O
h NN postirradiation O

Reanalysis NNP CAPITAL Reanalysis O
Reanalysis IN of O
of DT the O
the JJ original O
original NNS data O
data IN on O
on NN CAPITAL DSB O
DSB NN repair O
repair NNS shows O
shows IN that O
that PRP they O
they VBP are O
are JJ consistent O
consistent IN with O
with CD two O
two JJ first-order O
first-order NN repair O
repair NNS rates O
rates NN ( O
( CD 18 O
18 CC +/- O
+/- CD 7 O
7 NN min O
min CC and O
and IN about O
about CD 52 O
52 NN min O
min NN ) O

These DT CAPITAL These O
These NNS results O
results VBP are O
are JJ consistent O
consistent IN with O
with CD two O
two NNS pools O
pools IN of O
of NNS CAPITAL DSBs O
DSBs NN ( O
( CC or O
or NNS cells O
cells NN ) O
) , , O
, DT each O
each IN with O
with PRP$ their O
their JJ own O
own NN t O
t NN ( O
( NN rep O
rep NN ) O

The DT CAPITAL The O
The RB early O
early NN t O
t NN ( O
( NN rep O
rep NN ) O
) , , O
, VBN associated O
associated IN with O
with NN tau O
tau NN ( O
( RB fast O
fast NN ) O
) , , O
, VBZ is O
is VBN predicted O
predicted TO to O
to VB be O
be CD 1.7 O
1.7 CC +/- O
+/- CD 0.7 O
0.7 NN h O
h , , O
, CC and O
and DT the O
the RB late O
late NN t O
t NN ( O
( NN rep O
rep NN ) O
) , , O
, VBN associated O
associated IN with O
with NN tau O
tau NN ( O
( JJ slow O
slow NN ) O
) , , O
, VBZ is O
is VBN predicted O
predicted TO to O
to VB be O
be IN about O
about CD 5 O
5 NN h. O
h. DT CAPITAL Both O
Both NNS values O
values VBP are O
are IN in O
in JJ excellent O
excellent NN agreement O
agreement IN with O
with DT the O
the NNS times O
times IN at O
at WDT which O
which VBG changing O
changing IN from O
from NN growth O
growth NN medium O
medium TO to O
to VBN conditioned O
conditioned NN medium O
medium DT no O
no RB longer O
longer VBZ gives O
gives DT the O
the JJ full O
full NN recovery O
recovery VBN seen O
seen IN in O
in VBN conditioned O
conditioned NN medium O
medium RB only O
only NN ( O
( DT the O
the RB early O
early NN t O
t NN ( O
( NN rep O
rep NN ) O
) NN ) O
) , , O
, CC and O
and DT the O
the NN time O
time WRB when O
when VBG changing O
changing IN from O
from NN growth O
growth NN medium O
medium TO to O
to VBN conditioned O
conditioned NN medium O
medium VBZ produces O
produces DT no O
no RB further O
further NN increase O
increase IN in O
in NN survival O
survival NN ( O
( DT the O
the RB late O
late NN t O
t NN ( O
( NN rep O
rep NN ) O
) NN ) O
) , , O
, RB respectively O

It PRP CAPITAL It O
It VBZ is O
is VBN noted O
noted IN that O
that NNS attempts O
attempts TO to O
to VB correlate O
correlate NN radiosensitivity O
radiosensitivity IN with O
with DT the O
the NNS rates O
rates IN of O
of NN CAPITAL DSB O
DSB NN repair O
repair , , O
, RB rather O
rather IN than O
than VBG using O
using DT an O
an JJ explicit O
explicit NN model O
model JJ such O
such IN as O
as DT the O
the NN CAPITAL DSB O
DSB NN model O
model , , O
, VBP are O
are JJ unlikely O
unlikely TO to O
to VB be O
be JJ productive O
productive IN since O
since NN survival O
survival VBZ depends O
depends IN on O
on DT both O
both NN tau O
tau NN ( O
( NN CAPITAL DSBR O
DSBR NN ) O
) CC and O
and NN t O
t NN ( O
( NN rep O
rep NN ) O
) NN ( O
( IN as O
as VBN defined O
defined IN in O
in DT the O
the NN CAPITAL DSB O
DSB NN model O
model NN ) O
) CC and O
and DT the O
the JJ latter O
latter MD may O
may VB be O
be DT the O
the RBR more O
more JJ important O
important NN determinant O
determinant IN of O
of NN radiosensitivity O
radiosensitivity NN ( O
( IN as O
as PRP it O
it VBZ appears O
appears TO to O
to VB be O
be IN for O
for NN ataxia O
ataxia NN telangiectasia O
telangiectasia NNS cells O
cells VBN compared O
compared TO to O
to JJ normal O
normal NNS fibroblasts O
fibroblasts CC and O
and IN for O
for NNS irs O
irs VBN compared O
compared TO to O
to NN CAPITAL V79 O
V79 NNS cells O
cells NN ) O

CONTEXT NN CAPITAL CONTEXT O
CONTEXT : : O
: NNS CAPITAL Adolescents O
Adolescents POS ' O
' NNS concerns O
concerns IN about O
about NN privacy O
privacy IN in O
in JJ clinical O
clinical NNS settings O
settings NN decrease O
decrease PRP$ their O
their NN willingness O
willingness TO to O
to VB seek O
seek NN health O
health NN care O
care IN for O
for JJ sensitive O
sensitive NNS problems O
problems CC and O
and MD may O
may VB inhibit O
inhibit PRP$ their O
their NN communication O
communication IN with O
with NNS physicians O

OBJECTIVE NN CAPITAL OBJECTIVE O
OBJECTIVE : : O
: TO CAPITAL To O
To VB investigate O
investigate DT the O
the NN influence O
influence IN of O
of NNS physicians O
physicians POS ' O
' NNS assurances O
assurances IN of O
of NN confidentiality O
confidentiality IN on O
on NNS adolescents O
adolescents POS ' O
' NN willingness O
willingness TO to O
to VB disclose O
disclose NN information O
information CC and O
and VB seek O
seek JJ future O
future NN health O
health NN care O

DESIGN NN CAPITAL DESIGN O
DESIGN : : O
: VBN CAPITAL Randomized O
Randomized JJ controlled O
controlled NN trial O

SETTING VBG CAPITAL SETTING O
SETTING : : O
: CD CAPITAL Three O
Three JJ suburban O
suburban JJ public O
public JJ high O
high NNS schools O
schools IN in O
in NNP CAPITAL California O

PARTICIPANTS NNS CAPITAL PARTICIPANTS O
PARTICIPANTS : : O
: DT CAPITAL The O
The CD 562 O
562 VBG participating O
participating NNS adolescents O
adolescents VBN represented O
represented CD 92 O
92 NN % O
% IN of O
of NNS students O
students IN in O
in JJ mandatory O
mandatory NNS classes O

INTERVENTION NN CAPITAL INTERVENTION O
INTERVENTION : : O
: IN CAPITAL After O
After JJ random O
random NN assignment O
assignment TO to O
to CD 1 O
1 IN of O
of CD 3 O
3 NNS groups O
groups , , O
, DT the O
the NNS adolescents O
adolescents VBD listened O
listened TO to O
to DT a O
a JJ standardized O
standardized NN audiotape O
audiotape NN depiction O
depiction IN of O
of DT an O
an NN office O
office NN visit O
visit IN during O
during WDT which O
which PRP they O
they VBN heard O
heard DT a O
a NN physician O
physician WP who O
who VBN assured O
assured JJ unconditional O
unconditional NN confidentiality O
confidentiality , , O
, DT a O
a NN physician O
physician WP who O
who VBN assured O
assured JJ conditional O
conditional NN confidentiality O
confidentiality , , O
, CC or O
or DT a O
a NN physician O
physician WP who O
who VBD did O
did RB not O
not NN mention O
mention NN confidentiality O

MAIN JJS CAPITAL MAIN O
MAIN NN CAPITAL OUTCOME O
OUTCOME NNS CAPITAL MEASURES O
MEASURES : : O
: NNS CAPITAL Adolescents O
Adolescents POS ' O
' NN willingness O
willingness TO to O
to VB disclose O
disclose JJ general O
general NN information O
information , , O
, NN willingness O
willingness TO to O
to VB disclose O
disclose NN information O
information IN about O
about JJ sensitive O
sensitive NNS topics O
topics , , O
, JJ intended O
intended NN honesty O
honesty , , O
, CC and O
and NN likelihood O
likelihood IN of O
of NN return O
return NNS visits O
visits TO to O
to DT the O
the NN physician O
physician VBN depicted O
depicted IN in O
in DT the O
the NN scenario O
scenario VBD were O
were VBN assessed O
assessed IN by O
by JJ anonymous O
anonymous VBN written O
written NN questionnaire O

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: NNP CAPITAL Assurances O
Assurances IN of O
of NN confidentiality O
confidentiality VBN increased O
increased DT the O
the NN number O
number IN of O
of NNS adolescents O
adolescents JJ willing O
willing TO to O
to VB disclose O
disclose JJ sensitive O
sensitive NN information O
information IN about O
about NN sexuality O
sexuality , , O
, NN substance O
substance NN use O
use , , O
, CC and O
and JJ mental O
mental NN health O
health IN from O
from CD 39 O
39 NN % O
% NN ( O
( CD 68/175 O
68/175 NN ) O
) TO to O
to CD 46.5 O
46.5 NN % O
% NN ( O
( CD 178/383 O
178/383 NN ) O
) NN ( O
( NN beta=.10 O
beta=.10 , , O
, NN CAPITAL P=.02 O
P=.02 NN ) O
) CC and O
and VBN increased O
increased DT the O
the NN number O
number JJ willing O
willing TO to O
to VB seek O
seek JJ future O
future NN health O
health NN care O
care IN from O
from CD 53 O
53 NN % O
% NN ( O
( CD 93/175 O
93/175 NN ) O
) TO to O
to CD 67 O
67 NN % O
% NN ( O
( CD 259/386 O
259/386 NN ) O
) NN ( O
( NN beta=.17 O
beta=.17 , , O
, NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD .001 O
.001 NN ) O

When WRB CAPITAL When O
When VBG comparing O
comparing DT the O
the JJ unconditional O
unconditional IN with O
with DT the O
the JJ conditional O
conditional NNS groups O
groups , , O
, NNS assurances O
assurances IN of O
of JJ unconditional O
unconditional NN confidentiality O
confidentiality VBN increased O
increased DT the O
the NN number O
number IN of O
of NNS adolescents O
adolescents JJ willing O
willing TO to O
to NN return O
return IN for O
for DT a O
a JJ future O
future NN visit O
visit IN by O
by CD 10 O
10 NN percentage O
percentage NNS points O
points , , O
, IN from O
from CD 62 O
62 NN % O
% NN ( O
( CD 122/196 O
122/196 NN ) O
) TO to O
to CD 72 O
72 NN % O
% NN ( O
( CD 137/190 O
137/190 NN ) O
) NN ( O
( NN beta=.14 O
beta=.14 , , O
, NN CAPITAL P=.001 O
P=.001 NN ) O

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: NNS CAPITAL Adolescents O
Adolescents VBP are O
are RBR more O
more JJ willing O
willing TO to O
to VBP communicate O
communicate IN with O
with CC and O
and VB seek O
seek NN health O
health NN care O
care IN from O
from NNS physicians O
physicians WP who O
who VB assure O
assure NN confidentiality O

Further JJ CAPITAL Further O
Further NN investigation O
investigation VBZ is O
is VBN needed O
needed TO to O
to VB identify O
identify DT a O
a NN confidentiality O
confidentiality NN assurance O
assurance NN statement O
statement IN that O
that VBZ explains O
explains DT the O
the JJ legal O
legal CC and O
and JJ ethical O
ethical NNS limitations O
limitations IN of O
of NN confidentiality O
confidentiality IN without O
without VBG decreasing O
decreasing NNS adolescents O
adolescents POS ' O
' NN likelihood O
likelihood IN of O
of VBG seeking O
seeking JJ future O
future NN health O
health NN care O
care IN for O
for JJ routine O
routine CC and O
and JJ nonreportable O
nonreportable JJ sensitive O
sensitive NN health O
health NNS concerns O

BACKGROUND NN CAPITAL BACKGROUND O
BACKGROUND : : O
: NNP CAPITAL Diabetic O
Diabetic NN foot D
foot NNS infections D
infections NN cause O
cause JJ substantial O
substantial NN morbidity O
morbidity CC and O
and NN mortality O

Neutrophil NN CAPITAL Neutrophil O
Neutrophil NN superoxide O
superoxide NN generation O
generation , , O
, DT a O
a JJ crucial O
crucial NN part O
part IN of O
of NN neutrophil O
neutrophil JJ bactericidal O
bactericidal NN activity O
activity , , O
, VBZ is O
is JJ impaired O
impaired IN in O
in NN diabetes D

Granulocyte-colony JJ CAPITAL Granulocyte-colony O
Granulocyte-colony VBG stimulating O
stimulating NN factor O
factor NN ( O
( NN CAPITAL G-CSF O
G-CSF NN ) O
) NNS increases O
increases DT the O
the NN release O
release IN of O
of NNS neutrophils O
neutrophils IN from O
from DT the O
the NN bone O
bone NN marrow O
marrow CC and O
and VBZ improves O
improves NN neutrophil O
neutrophil NN function O

We PRP CAPITAL We O
We VBN assessed O
assessed NN CAPITAL G-CSF T
G-CSF IN as O
as JJ adjuvant O
adjuvant NN therapy O
therapy IN for O
for DT the O
the NN treatment O
treatment IN of O
of JJ severe D
severe NN foot D
foot NNS infections D
infections IN in D
in JJ diabetic D
diabetic NNS patients D

METHODS NNS CAPITAL METHODS O
METHODS : : O
: CD 40 O
40 JJ diabetic O
diabetic NNS patients O
patients IN with O
with NN foot D
foot NNS infections D
infections VBD were O
were VBN enrolled O
enrolled IN in O
in DT a O
a JJ double-blind O
double-blind JJ placebo-controlled O
placebo-controlled NN study O

On IN CAPITAL On O
On NN admission O
admission , , O
, NNS patients O
patients VBD were O
were RB randomly O
randomly VBN assigned O
assigned NN CAPITAL G-CSF T
G-CSF NN ( T
( NN filgrastim T
filgrastim NN ) T
) NN therapy T
therapy NN ( O
( NN n O
n JJ = O
= CD 20 O
20 NN ) O
) CC or O
or NN placebo O
placebo NN ( O
( NN n O
n JJ = O
= CD 20 O
20 NN ) O
) IN for O
for CD 7 O
7 NNS days O

Both DT CAPITAL Both O
Both NNS groups O
groups VBN received O
received JJ similar O
similar JJ antibiotic T
antibiotic CC and T
and NN insulin T
insulin NN treatment T

Neutrophils NNS CAPITAL Neutrophils O
Neutrophils IN from O
from DT the O
the JJ peripheral O
peripheral NN blood O
blood IN of O
of DT these O
these NNS participants O
participants CC and O
and IN from O
from JJ healthy O
healthy NNS controls O
controls VBD were O
were VBN stimulated O
stimulated IN with O
with VBN opsonised O
opsonised NN zymosan O
zymosan , , O
, CC and O
and NN superoxide O
superoxide NN production O
production VBD was O
was VBN measured O
measured IN by O
by DT a O
a JJ spectrophotometric O
spectrophotometric NN assay O
assay NN ( O
( NN reduction O
reduction IN of O
of JJ ferricytochrome O
ferricytochrome NN CAPITAL C O
C NN ) O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NNS CAPITAL FINDINGS O
FINDINGS : : O
: NN CAPITAL G-CSF O
G-CSF NN therapy O
therapy VBD was O
was VBN associated O
associated IN with O
with JJR earlier O
earlier NN eradication O
eradication IN of O
of NNS pathogens O
pathogens IN from O
from DT the O
the JJ infected O
infected NN ulcer O
ulcer NN ( O
( JJ median O
median CD 4 O
4 NN ( O
( NN range O
range CD 2-10 O
2-10 NN ) O
) CC vs O
vs CD 8 O
8 NN ( O
( CD 2-79 O
2-79 NN ) O
) NNS days O
days IN in O
in DT the O
the NN placebo O
placebo NN group O
group : ; O
; NN p O
p JJ = O
= CD 0.02 O
0.02 NN ) O
) , , O
, JJR quicker O
quicker NN resolution O
resolution IN of O
of NN cellulitis O
cellulitis JJR < O
< NN ( O
( CD 7 O
7 NN ( O
( CD 5-20 O
5-20 NN ) O
) CC vs O
vs CD 12 O
12 NN ( O
( CD 5-93 O
5-93 NN ) O
) NNS days O
days : ; O
; NN p O
p JJ = O
= CD 0.03 O
0.03 NN ) O
) , , O
, JJR shorter O
shorter NN hospital O
hospital VB stay O
stay NN ( O
( CD 10 O
10 NN ( O
( CD 7-31 O
7-31 NN ) O
) CC vs O
vs CD 17.5 O
17.5 NN ( O
( CD 9-100 O
9-100 NN ) O
) NNS days O
days : ; O
; NN p O
p JJ = O
= CD 0.02 O
0.02 NN ) O
) , , O
, CC and O
and DT a O
a JJR shorter O
shorter NN duration O
duration IN of O
of JJ intravenous O
intravenous JJ antibiotic O
antibiotic NN treatment O
treatment NN ( O
( CD 8.5 O
8.5 NN ( O
( CD 5-30 O
5-30 NN ) O
) CC vs O
vs CD 14.5 O
14.5 NN ( O
( CD 8-63 O
8-63 NN ) O
) NNS days O
days : ; O
; NN p O
p JJ = O
= CD 0.02 O
0.02 NN ) O

No DT CAPITAL No O
No JJ CAPITAL G-CSF-treated O
G-CSF-treated NN patient O
patient VBN needed O
needed NN surgery T
surgery , , O
, IN whereas O
whereas CD two O
two NN placebo O
placebo NNS recipients O
recipients VBD underwent O
underwent TO to O
to NN amputation T
amputation CC and O
and CD two O
two VBD had O
had JJ extensive O
extensive NN debridement T
debridement IN under O
under NN anaesthesia O

After IN CAPITAL After O
After CD 7 O
7 NNS days O
days POS ' O
' NN treatment O
treatment , , O
, NN neutrophil O
neutrophil NN superoxide O
superoxide NN production O
production VBD was O
was RB significantly O
significantly JJR higher O
higher IN in O
in DT the O
the NN CAPITAL G-CSF O
G-CSF NN group O
group IN than O
than IN in O
in DT the O
the NN placebo O
placebo NN group O
group NN ( O
( CD 16.1 O
16.1 NN ( O
( CD 4.2-24.2 O
4.2-24.2 NN ) O
) CC vs O
vs CD 7.3 O
7.3 NN ( O
( CD 2.1-11.5 O
2.1-11.5 NN ) O
) NN nmol O
nmol IN per O
per CD 10 O
10 NN ( O
( CD 6 O
6 NN ) O
) NNS neutrophils O
neutrophils IN in O
in CD 30 O
30 NN min O
min : ; O
; NN p O
p CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0.0001 O
0.0001 NN ) O

G-CSF NN CAPITAL G-CSF T
G-CSF NN therapy T
therapy VBD was O
was RB generally O
generally RB well O
well VBN tolerated O

INTERPRETATION NN CAPITAL INTERPRETATION O
INTERPRETATION : : O
: NN CAPITAL G-CSF T
G-CSF NN treatment T
treatment VBD was O
was VBN associated O
associated IN with O
with VBN improved O
improved JJ clinical O
clinical NN outcome O
outcome IN of O
of NN foot D
foot NN infection D
infection IN in D
in JJ diabetic D
diabetic NNS patients D

This DT CAPITAL This O
This NN improvement O
improvement MD may O
may VB be O
be JJ related O
related TO to O
to DT an O
an NN increase O
increase IN in O
in NN neutrophil O
neutrophil NN superoxide O
superoxide NN production O

BACKGROUND NN CAPITAL BACKGROUND O
BACKGROUND : : O
: VBN CAPITAL Accelerated T
Accelerated NN infusion T
infusion IN of T
of RB alteplase T
alteplase NN ( T
( NN tissue T
tissue NN plasminogen T
plasminogen NN activator T
activator NN ) T
) IN over O
over DT a O
a NN period O
period IN of O
of CD 90 O
90 NNS minutes O
minutes VBZ induces O
induces RBR more O
more JJ rapid O
rapid NN lysis O
lysis IN of O
of NN coronary-artery D
coronary-artery NN thrombi D
thrombi IN than O
than DT a O
a JJ 3-hour O
3-hour NN infusion O

With IN CAPITAL With O
With CD two O
two NN bolus O
bolus NNS doses O
doses IN of O
of RB alteplase T
alteplase , , O
, RB further O
further VBG shortening O
shortening DT the O
the NN duration O
duration IN of O
of NN administration O
administration , , O
, JJ complete O
complete NN reperfusion O
reperfusion VBD was O
was VBN achieved O
achieved IN in O
in RBR more O
more IN than O
than CD 85 O
85 NN percent O
percent IN of O
of DT the O
the NNS patients O
patients IN in O
in JJ initial O
initial JJ angiographic O
angiographic NNS studies O

We PRP CAPITAL We O
We VBN tested O
tested DT the O
the NN hypothesis O
hypothesis IN that O
that JJ double-bolus T
double-bolus RB alteplase T
alteplase VBZ is O
is IN at O
at JJS least O
least IN as O
as JJ effective O
effective IN as O
as VBN accelerated O
accelerated NN infusion O

METHODS NNS CAPITAL METHODS O
METHODS : : O
: IN CAPITAL In O
In CD 398 O
398 NNS hospitals O
hospitals , , O
, CD 7169 O
7169 NNS patients O
patients IN with O
with JJ acute D
acute JJ myocardial D
myocardial NN infarction D
infarction VBD were O
were RB randomly O
randomly VBN assigned O
assigned TO to O
to JJ weight-adjusted O
weight-adjusted , , O
, VBN accelerated O
accelerated NN infusion O
infusion IN of O
of CD 100 O
100 NN mg O
mg IN of O
of RB alteplase T
alteplase CC or O
or TO to O
to DT a O
a NN bolus O
bolus IN of O
of CD 50 O
50 NN mg O
mg IN of O
of RB alteplase T
alteplase IN over O
over DT a O
a NN period O
period IN of O
of CD 1 O
1 TO to O
to CD 3 O
3 NNS minutes O
minutes VBN followed O
followed CD 30 O
30 NNS minutes O
minutes RB later O
later IN by O
by DT a O
a JJ second O
second NN bolus O
bolus IN of O
of CD 50 O
50 NN mg O
mg NN ( O
( CC or O
or CD 40 O
40 NN mg O
mg IN for O
for NNS patients O
patients WP who O
who VBD weighed O
weighed JJR less O
less IN than O
than CD 60 O
60 NN kg O
kg NN ) O

The DT CAPITAL The O
The JJ primary O
primary NN end O
end NN point O
point VBD was O
was NN death O
death IN from O
from DT any O
any NN cause O
cause IN at O
at CD 30 O
30 NNS days O

The DT CAPITAL The O
The NN trial O
trial VBD was O
was VBD stopped O
stopped RB prematurely O
prematurely IN because O
because IN of O
of NN concern O
concern IN about O
about DT the O
the NN safety O
safety IN of O
of DT the O
the JJ double-bolus T
double-bolus NN injection T

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: JJ CAPITAL Thirty-day O
Thirty-day NN mortality O
mortality VBD was O
was JJR higher O
higher IN in O
in DT the O
the JJ double-bolus O
double-bolus NN group O
group IN than O
than IN in O
in DT the O
the NN accelerated-infusion O
accelerated-infusion NN group O
group : : O
: CD 7.98 O
7.98 NN percent O
percent IN as O
as VBN compared O
compared IN with O
with CD 7.53 O
7.53 NN percent O

The DT CAPITAL The O
The JJ absolute O
absolute NN difference O
difference VBD was O
was CD 0.44 O
0.44 NN percent O
percent , , O
, IN with O
with DT a O
a JJ one-sided O
one-sided CD 95 O
95 NN percent O
percent JJ upper O
upper NN boundary O
boundary IN of O
of CD 1.49 O
1.49 NN percent O
percent , , O
, WDT which O
which VBD exceeded O
exceeded DT the O
the VBD prespecified O
prespecified JJ upper O
upper NN limit O
limit IN of O
of CD 0.40 O
0.40 NN percent O
percent TO to O
to VBP indicate O
indicate JJ equivalence O
equivalence IN in O
in JJ 30-day O
30-day NN mortality O
mortality IN between O
between DT the O
the CD two O
two NNS regimens O

The DT CAPITAL The O
The JJ respective O
respective NNS rates O
rates IN of O
of DT any O
any NN stroke D
stroke CC and O
and IN of O
of JJ hemorrhagic D
hemorrhagic NN stroke D
stroke VBD were O
were CD 1.92 O
1.92 CC and O
and CD 1.12 O
1.12 NN percent O
percent IN after O
after JJ double-bolus O
double-bolus RB alteplase T
alteplase , , O
, IN as O
as VBN compared O
compared IN with O
with CD 1.53 O
1.53 CC and O
and CD 0.81 O
0.81 NN percent O
percent IN after O
after DT an O
an VBN accelerated O
accelerated NN infusion O
infusion IN of O
of RB alteplase T
alteplase NN ( O
( NN CAPITAL P=0.24 O
P=0.24 CC and O
and NN CAPITAL P=0.23 O
P=0.23 , , O
, RB respectively O
respectively NN ) O

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: JJ CAPITAL Double-bolus O
Double-bolus RB alteplase T
alteplase VBD was O
was RB not O
not VBN shown O
shown TO to O
to VB be O
be JJ equivalent O
equivalent , , O
, VBG according O
according TO to O
to DT the O
the VBD prespecified O
prespecified NNS criteria O
criteria , , O
, TO to O
to VBN accelerated O
accelerated NN infusion O
infusion IN with O
with NN regard O
regard TO to O
to JJ 30-day O
30-day NN mortality O

There EX CAPITAL There O
There VBD was O
was RB also O
also DT a O
a RB slightly O
slightly JJR higher O
higher NN rate O
rate IN of O
of JJ intracranial D
intracranial NN hemorrhage D
hemorrhage IN with O
with DT the O
the JJ double-bolus T
double-bolus NN method T

Therefore RB CAPITAL Therefore O
Therefore , , O
, VBN accelerated T
accelerated NN infusion T
infusion IN of T
of RB alteplase T
alteplase IN over O
over DT a O
a NN period O
period IN of O
of CD 90 O
90 NNS minutes O
minutes VBZ remains O
remains DT the O
the VBN preferred O
preferred NN regimen O

BACKGROUND NN CAPITAL BACKGROUND O
BACKGROUND : : O
: NN CAPITAL Fenfluramine T
Fenfluramine CC and O
and NN phentermine T
phentermine VB have O
have VBN been O
been RB individually O
individually VBN approved O
approved IN as O
as JJ anorectic T
anorectic NNS agents T
agents IN by O
by DT the O
the NNP CAPITAL Food O
Food CC and O
and NN CAPITAL Drug O
Drug NNP CAPITAL Administration O
Administration NN ( O
( NNP CAPITAL FDA O
FDA NN ) O

When WRB CAPITAL When O
When VBN used O
used IN in O
in NN combination O
combination DT the O
the NNS drugs O
drugs MD may O
may VB be O
be RB just O
just IN as O
as JJ effective O
effective IN as O
as DT either O
either NN drug O
drug RB alone O
alone , , O
, IN with O
with DT the O
the VBN added O
added NNS advantages O
advantages IN of O
of DT the O
the NN need O
need IN for O
for JJR lower O
lower NNS doses O
doses IN of O
of DT each O
each NN agent O
agent CC and O
and RB perhaps O
perhaps JJR fewer O
fewer NN side O
side NNS effects O

Although IN CAPITAL Although O
Although DT the O
the NN combination O
combination VBZ has O
has RB not O
not VBN been O
been VBN approved O
approved IN by O
by DT the O
the NNP CAPITAL FDA O
FDA , , O
, IN in O
in CD 1996 O
1996 DT the O
the JJ total O
total NN number O
number IN of O
of NNS prescriptions O
prescriptions IN in O
in DT the O
the NNP CAPITAL United O
United NNPS CAPITAL States O
States IN for O
for NN fenfluramine T
fenfluramine CC and O
and NN phentermine T
phentermine VBD exceeded O
exceeded CD 18 O
18 CD million O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NNS CAPITAL METHODS O
METHODS : : O
: PRP CAPITAL We O
We VBN identified O
identified JJ valvular O
valvular NN heart O
heart NN diseasein O
diseasein CD 24 O
24 NNS women O
women VBN treated O
treated IN with O
with JJ fenfluramine-phentermine O
fenfluramine-phentermine WP who O
who VBD had O
had DT no O
no NN history O
history IN of O
of JJ cardiac O
cardiac NN disease O

The DT CAPITAL The O
The NNS women O
women VBN presented O
presented IN with O
with JJ cardiovascular D
cardiovascular NNS symptoms D
symptoms CC or O
or DT a O
a NN heart D
heart NN murmur D

As IN CAPITAL As O
As VBG increasing O
increasing NNS numbers O
numbers IN of O
of DT these O
these NNS patients O
patients IN with O
with JJ similar O
similar JJ clinical O
clinical NNS features O
features VBD were O
were VBN identified O
identified , , O
, RB there O
there VBD appeared O
appeared TO to O
to VB be O
be DT an O
an NN association O
association IN between O
between DT these O
these NNS features O
features CC and O
and JJ fenfluramine-phentermine T
fenfluramine-phentermine NN therapy T

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: CD CAPITAL Twenty-four O
Twenty-four NNS women O
women NN ( O
( VB mean O
mean NN ( O
( NN +/-SD O
+/-SD NN ) O
) NN age O
age , , O
, CD 44+/-8 O
44+/-8 NNS years O
years NN ) O
) VBD were O
were VBN evaluated O
evaluated CD 12.3+/-7.1 O
12.3+/-7.1 NNS months O
months IN after O
after DT the O
the NN initiation O
initiation IN of O
of JJ fenfluramine-phentermine T
fenfluramine-phentermine NN therapy T

Echocardiography NN CAPITAL Echocardiography O
Echocardiography VBD demonstrated O
demonstrated JJ unusual O
unusual JJ valvular O
valvular NN morphology O
morphology CC and O
and NN regurgitation O
regurgitation IN in O
in DT all O
all NNS patients O

Both DT CAPITAL Both O
Both JJ right-sided O
right-sided CC and O
and JJ left-sided O
left-sided NN heart O
heart NNS valves O
valves VBD were O
were VBN involved O

Eight CD CAPITAL Eight O
Eight NNS women O
women RB also O
also VBD had O
had RB newly O
newly VBN documented O
documented JJ pulmonary D
pulmonary NN hypertension D

To TO CAPITAL To O
To NN date O
date , , O
, JJ cardiac T
cardiac JJ surgical T
surgical NN intervention T
intervention VBZ has O
has VBN been O
been VBN required O
required IN in O
in CD five O
five NNS patients O

The DT CAPITAL The O
The NN heart O
heart NNS valves O
valves VBD had O
had DT a O
a VBG glistening O
glistening JJ white O
white NN appearance O

Histopathological JJ CAPITAL Histopathological O
Histopathological NNS findings O
findings VBN included O
included JJ plaque-like O
plaque-like NN encasement O
encasement IN of O
of DT the O
the NNS leaflets O
leaflets CC and O
and JJ chordal O
chordal NNS structures O
structures IN with O
with JJ intact O
intact NN valve O
valve NN architecture O

The DT CAPITAL The O
The JJ histopathological O
histopathological NNS features O
features VBD were O
were JJ identical O
identical TO to O
to DT those O
those VBN seen O
seen IN in O
in NN carcinoid O
carcinoid CC or O
or JJ ergotamine-induced O
ergotamine-induced NN valve D
valve NN disease D

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: DT CAPITAL These O
These NNS cases O
cases VB arouse O
arouse NN concern O
concern IN that O
that JJ fenfluramine-phentermine T
fenfluramine-phentermine NN therapy T
therapy MD may O
may VB be O
be VBN associated O
associated IN with O
with JJ valvular D
valvular NN heart D
heart NN disease D

Candidates NNS CAPITAL Candidates O
Candidates IN for O
for JJ fenfluramine-phentermine T
fenfluramine-phentermine NN therapy T
therapy MD should O
should VB be O
be VBN informed O
informed IN about O
about JJ serious O
serious JJ potential O
potential JJ adverse O
adverse NNS effects O
effects , , O
, VBG including O
including JJ pulmonary D
pulmonary NN hypertension D
hypertension CC and O
and JJ valvular D
valvular NN heart D
heart NN disease D

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> IN CAPITAL Between O
Between CD 1987 O
1987 CC and O
and CD 1992 O
1992 , , O
, DT all O
all NNS patients O
patients VBG presenting O
presenting TO to O
to DT the O
the JJ senior O
senior NN author O
author IN with O
with DT a O
a JJ symptomatic O
symptomatic VBD failed O
failed NN silicone O
silicone VB implant O
implant NN arthroplasty O
arthroplasty JJ refractory O
refractory TO to O
to JJ conservative O
conservative NN treatment O
treatment VBD were O
were VBN converted O
converted TO to O
to DT a O
a NN metatarsophalangeal O
metatarsophalangeal JJ joint O
joint NN arthrodesis O

Internal JJ CAPITAL Internal O
Internal NN fixation O
fixation VBD was O
was VBN achieved O
achieved IN with O
with DT either O
either JJ dual O
dual JJ intrameduilary O
intrameduilary VBN threaded O
threaded NNP CAPITAL Steinmann O
Steinmann NNS pins O
pins CC or O
or DT an O
an RB obliquely O
obliquely VBN placed O
placed JJ CAPITAL AO O
AO NN compression O
compression VB screw O
screw CC and O
and DT a O
a CD three- O
three- CC or O
or JJ four-hole O
four-hole JJ one-third O
one-third JJ tubular O
tubular NN dorsal O
dorsal NN neutralization O
neutralization NN plate O

Bone NN CAPITAL Bone T
Bone VBG grafting T
grafting VBD was O
was VBN used O
used TO to O
to VB maintain O
maintain NN hallux O
hallux NN length O

Successful JJ CAPITAL Successful O
Successful NN arthrodesis T
arthrodesis VBD was O
was VBN achieved O
achieved IN in O
in DT all O
all CD five O
five NNS feet O
feet IN in O
in NNS patients O
patients IN with O
with JJ rheumatoid D
rheumatoid NN arthritis D

Subjectively RB CAPITAL Subjectively O
Subjectively , , O
, NNS patients O
patients VBN improved O
improved IN from O
from DT an O
an JJ average O
average IN of O
of CD 0.69 O
0.69 IN before O
before NN arthrodesis T
arthrodesis TO to O
to CD 4.89 O
4.89 IN after O
after NN arthrodesis T

The DT CAPITAL The O
The JJ average O
average VBG walking O
walking NN tolerance O
tolerance VBN improved O
improved IN from O
from CD 1.11 O
1.11 TO to O
to CD 4.80 O
4.80 , , O
, CC and O
and DT the O
the JJ overall O
overall NN level O
level IN of O
of NN satisfaction O
satisfaction VBN improved O
improved IN from O
from CD 0.0 O
0.0 TO to O
to CD 4.79 O

The DT CAPITAL The O
The NN patient O
patient POS 's O
's NN ability O
ability TO to O
to VB wear O
wear NNS shoes O
shoes VBN improved O
improved IN from O
from CD 0.87 O
0.87 TO to O
to CD 3.1 O

Successful JJ CAPITAL Successful O
Successful NN arthrodesis T
arthrodesis VBZ produces O
produces DT a O
a NN foot O
foot IN that O
that VBZ is O
is RBR more O
more JJ functional O
functional CC and O
and JJ durable O
durable IN than O
than JJ excisional T
excisional NN arthroplasty T

Subjectively RB CAPITAL Subjectively O
Subjectively , , O
, DT these O
these NNS patients O
patients VBN stated O
stated IN that O
that PRP$ their O
their NN level O
level IN of O
of NN pain O
pain , , O
, VBG walking O
walking NN tolerance O
tolerance , , O
, CC and O
and JJ overall O
overall NN satisfaction O
satisfaction VBN improved O
improved RB significantly O
significantly IN after O
after DT the O
the NN arthrodesis T

Clinically RB CAPITAL Clinically O
Clinically , , O
, RB there O
there VBD was O
was DT no O
no NN evidence O
evidence IN of O
of NN transfer D
transfer NNS lesions D
lesions , , O
, NN tenderness O
tenderness , , O
, CC or O
or NN hallux D
hallux NN subluxation D

Hallux NNP CAPITAL Hallux O
Hallux NN length O
length VBD was O
was RB well O
well JJ maintained O
maintained IN after O
after NN surgery T
surgery IN with O
with NN bone T
bone VBG grafting T
grafting , , O
, CC but O
but PRP it O
it VBD was O
was RBR more O
more JJ difficult O
difficult TO to O
to VB obtain O
obtain DT the O
the NN alignment O
alignment NNS goals O

The DT CAPITAL The O
The JJ average O
average JJ postoperative O
postoperative NN metatarsophalangeal O
metatarsophalangeal NN dorsiflexion O
dorsiflexion NN angle O
angle VBD was O
was CD 15.6 O
15.6 NNS degrees O
degrees CC and O
and DT the O
the RB first O
first NN metatarsophalangeal O
metatarsophalangeal NN angle O
angle VBD was O
was CD 3.1 O
3.1 NNS degrees O

Despite IN CAPITAL Despite O
Despite DT this O
this , , O
, NN patient O
patient NN satisfaction O
satisfaction VBD was O
was JJ high O

Arthrodesis FW CAPITAL Arthrodesis T
Arthrodesis IN of O
of DT the O
the RB first O
first NN metatarsophalangeal O
metatarsophalangeal JJ joint O
joint VBG using O
using DT a O
a NN bone T
bone NN graft T
graft TO to O
to NN salvage O
salvage VBD failed O
failed NN silicone T
silicone VB implant T
implant NN arthroplasty T
arthroplasty VBZ produces O
produces JJ acceptable O
acceptable JJ subjective O
subjective CC and O
and JJ radiographic O
radiographic NNS results O

Although IN CAPITAL Although O
Although RB technically O
technically VBG demanding O
demanding , , O
, PRP it O
it VBZ provides O
provides JJ long-term O
long-term NN stability O
stability TO to O
to DT the O
the NN hallux O
hallux , , O
, VBZ restores O
restores VBG weightbearing O
weightbearing , , O
, CC and O
and VBZ allows O
allows IN for O
for NN maintenance O
maintenance IN of O
of DT a O
a JJ propulsive O
propulsive NN gait O

We PRP CAPITAL We O
We VB recommend O
recommend DT this O
this NN procedure O
procedure RB instead O
instead IN of O
of DT an O
an JJ excisional T
excisional NN arthroplasty T
arthroplasty TO to O
to VB maintain O
maintain JJ high O
high NN level O
level IN of O
of NN function O
function CC and O
and JJ overall O
overall NN patient O
patient NN satisfaction O

OBJECTIVE NN CAPITAL OBJECTIVE O
OBJECTIVE : : O
: TO CAPITAL To O
To NN estimate O
estimate DT the O
the JJ crude O
crude NN incidence O
incidence NNS rates O
rates IN of O
of JJ cerebrovascular D
cerebrovascular NNS accidents D
accidents IN among O
among DT the O
the JJ black O
black NNS residents O
residents IN of O
of NNP CAPITAL Harare O

DESIGN NN CAPITAL DESIGN O
DESIGN : : O
: JJ CAPITAL Prospective O
Prospective JJ community-based O
community-based NN study O

SETTING VBG CAPITAL SETTING O
SETTING : : O
: JJ CAPITAL Black O
Black NNS residents O
residents IN of O
of NNP CAPITAL Harare O
Harare , , O
, NNP CAPITAL Zimbabwe O

PARTICIPANTS NNS CAPITAL PARTICIPANTS O
PARTICIPANTS : : O
: CD CAPITAL Two O
Two CD hundred O
hundred CC and O
and CD seventy-three O
seventy-three JJ 'first-ever O
'first-ever POS ' O
' NNS strokes D
strokes RB prospectively O
prospectively VBN identified O
identified IN over O
over DT a O
a JJ 12-month O
12-month NN period O

MAIN JJS CAPITAL MAIN O
MAIN NN CAPITAL OUTCOME O
OUTCOME NN CAPITAL STUDY O
STUDY NNS CAPITAL FACTORS O
FACTORS : : O
: JJ CAPITAL Cerebrovascular D
Cerebrovascular NN accident D
accident JJ first-week O
first-week NN fatality O
fatality NN rate O
rate : ; O
; NN age- O
age- CC and O
and JJ sex-related O
sex-related NN incidence O

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: DT CAPITAL The O
The JJ crude O
crude NN incidence O
incidence NN rate O
rate VBD was O
was VBN estimated O
estimated TO to O
to VB be O
be CD 30.7 O
30.7 IN per O
per CD 100000 O
100000 NN ( O
( CD 95 O
95 NN % O
% NN confidence O
confidence NN interval O
interval CD 27.1-34.4 O
27.1-34.4 NN ) O
) CC and O
and DT the O
the JJ standardised O
standardised NN rate O
rate VBD was O
was CD 68 O
68 IN per O
per CD 100000 O

Fifty-one CD CAPITAL Fifty-one O
Fifty-one IN per O
per NN cent O
cent IN of O
of NN stroke D
stroke NNS victims O
victims VBD were O
were IN below O
below DT the O
the NN age O
age IN of O
of CD 54 O
54 NNS years O

Thirty-five CD CAPITAL Thirty-five O
Thirty-five IN per O
per NN cent O
cent IN of O
of NNS patients O
patients VBD died O
died IN within O
within CD 1 O
1 NN week O
week IN of O
of DT the O
the NN stroke O

Overall JJ CAPITAL Overall O
Overall , , O
, DT the O
the JJ age-specific O
age-specific NNS rates O
rates IN for O
for DT both O
both NNS sexes O
sexes VBD rose O
rose IN with O
with NN age O
age , , O
, IN with O
with DT the O
the NNS rates O
rates IN for O
for NNS women O
women VBG being O
being JJR higher O
higher IN at O
at DT all O
all NN age O
age NN strata O
strata IN except O
except IN for O
for DT the O
the NN group O
group CD 45-54 O
45-54 NNS years O

CONCLUSION NN CAPITAL CONCLUSION O
CONCLUSION : : O
: IN CAPITAL With O
With DT a O
a JJ standardised O
standardised NN rate O
rate IN of O
of CD 68 O
68 IN per O
per CD 100000 O
100000 CC and O
and DT a O
a JJ first-week O
first-week NN mortality O
mortality NN rate O
rate IN of O
of CD 35 O
35 NN % O
% , , O
, NN stroke D
stroke MD must O
must RB now O
now VB be O
be VBN considered O
considered DT an O
an JJ important O
important NN cause O
cause IN of O
of NN morbidity O
morbidity CC and O
and NN mortality O
mortality IN in O
in DT the O
the NN population O

OBJECTIVE NN CAPITAL OBJECTIVE O
OBJECTIVE : : O
: TO CAPITAL To O
To VB explore O
explore DT the O
the JJ long-term O
long-term NN effect O
effect IN of O
of NN calcium T
calcium NN supplementation T
supplementation IN during O
during NN pregnancy O
pregnancy IN on O
on DT the O
the NN offspring O
offspring POS 's O
's NN blood O
blood NN pressure O
pressure IN during O
during NN childhood O

DESIGN NN CAPITAL DESIGN O
DESIGN : : O
: VB CAPITAL Follow O
Follow RB up O
up IN of O
of DT a O
a NN population O
population VBN enrolled O
enrolled IN in O
in DT a O
a JJ double O
double JJ blind O
blind , , O
, VBN randomised O
randomised , , O
, NN placebo O
placebo JJ controlled O
controlled NN trial O

SETTING VBG CAPITAL SETTING O
SETTING : : O
: JJ CAPITAL Perinatal O
Perinatal NN research O
research NN unit O
unit , , O
, NNP CAPITAL World O
World NNP CAPITAL Health O
Health NNP CAPITAL Organisation O
Organisation POS 's O
's JJ collaborative O
collaborative NN research O
research NN centre O

SUBJECTS NNS CAPITAL SUBJECTS O
SUBJECTS : : O
: CD 591 O
591 NNS children O
children IN at O
at DT a O
a VB mean O
mean NN age O
age IN of O
of CD 7 O
7 NNS years O
years WP$ whose O
whose NNS mothers O
mothers VBD were O
were RB randomly O
randomly VBN assigned O
assigned IN during O
during NN pregnancy O
pregnancy TO to O
to VB receive O
receive CD 2 O
2 NN g/day O
g/day IN of O
of JJ elemental O
elemental NN calcium O
calcium NN ( O
( NN n O
n JJ = O
= CD 298 O
298 NN ) O
) CC or O
or NN placebo O
placebo NN ( O
( NN n O
n JJ = O
= CD 293 O
293 NN ) O

MAIN JJS CAPITAL MAIN O
MAIN NN CAPITAL OUTCOME O
OUTCOME NNS CAPITAL MEASURES O
MEASURES : : O
: NN CAPITAL Mean O
Mean NN blood O
blood NN pressure O
pressure CC and O
and NN rate O
rate IN of O
of JJ high D
high NN blood D
blood NN pressure D
pressure IN of O
of NNS children O

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: JJ CAPITAL Overall O
Overall , , O
, JJ systolic O
systolic NN blood O
blood NN pressure O
pressure VBD was O
was JJR lower O
lower IN in O
in DT the O
the NN calcium O
calcium NN group O
group NN ( O
( VB mean O
mean NN difference O
difference CD -1.4 O
-1.4 NN mm O
mm NN CAPITAL Hg O
Hg : ; O
; CD 95 O
95 NN % O
% NN confidence O
confidence NN interval O
interval CD -3.2 O
-3.2 TO to O
to CD 0.5 O
0.5 NN ) O
) IN than O
than IN in O
in DT the O
the NN placebo O
placebo NN group O

The DT CAPITAL The O
The NN effect O
effect VBD was O
was VBN found O
found RB predominantly O
predominantly IN among O
among NNS children O
children WP$ whose O
whose NN body O
body NN mass O
mass NN index O
index IN at O
at NN assessment O
assessment VBD was O
was IN above O
above DT the O
the JJ median O
median IN for O
for DT this O
this NN population O
population NN ( O
( VB mean O
mean NN difference O
difference IN in O
in JJ systolic O
systolic NN blood O
blood NN pressure O
pressure CD -5.8 O
-5.8 NN mm O
mm NN CAPITAL Hg O
Hg NN ( O
( CD -9.8 O
-9.8 NN mm O
mm NN CAPITAL Hg O
Hg TO to O
to CD -1.7 O
-1.7 NN mm O
mm NN CAPITAL Hg O
Hg NN ) O
) IN for O
for NNS children O
children IN with O
with DT an O
an NN index O
index JJR > O
> CD 17.5 O
17.5 CC and O
and CD -3.2 O
-3.2 NN mm O
mm NN CAPITAL Hg O
Hg NN ( O
( CD -6.3 O
-6.3 NN mm O
mm NN CAPITAL Hg O
Hg TO to O
to CD -0.1 O
-0.1 NN mm O
mm NN CAPITAL Hg O
Hg NN ) O
) IN for O
for DT those O
those IN with O
with DT an O
an NN index O
index IN of O
of JJR > O
> CD 15.7 O
15.7 TO to O
to CD 17.5 O
17.5 NN ) O

The DT CAPITAL The O
The NN risk O
risk IN of O
of JJ high O
high JJ systolic O
systolic NN blood O
blood NN pressure O
pressure VBD was O
was RB also O
also JJR lower O
lower IN in O
in DT the O
the NN calcium O
calcium NN group O
group IN than O
than IN in O
in DT the O
the NN placebo O
placebo NN group O
group NN ( O
( JJ relative O
relative NN risk O
risk CD 0.59 O
0.59 : ; O
; CD 0.39 O
0.39 TO to O
to CD 0.90 O
0.90 NN ) O
) CC and O
and RB particularly O
particularly IN among O
among NNS children O
children IN in O
in DT the O
the JJS highest O
highest JJ fourth O
fourth IN of O
of NN body O
body NN mass O
mass NN index O
index NN ( O
( CD 0.43 O
0.43 : ; O
; CD 0.26 O
0.26 TO to O
to CD 0.71 O
0.71 NN ) O

CONCLUSION NN CAPITAL CONCLUSION O
CONCLUSION : : O
: NN CAPITAL Calcium T
Calcium NN supplementation T
supplementation IN during O
during NN pregnancy O
pregnancy VBZ is O
is VBN associated O
associated IN with O
with JJR lower O
lower JJ systolic O
systolic NN blood O
blood NN pressure O
pressure IN in O
in DT the O
the NN offspring O
offspring , , O
, RB particularly O
particularly IN among O
among JJ overweight O
overweight NNS children O

The DT CAPITAL The O
The RB fast O
fast NN reaction O
reaction IN of O
of NN peroxynitrite O
peroxynitrite IN with O
with NN CAPITAL CO2 O
CO2 CC and O
and DT the O
the JJ high O
high NN concentration O
concentration IN of O
of VBN dissolved O
dissolved NN CAPITAL CO2 O
CO2 IN in O
in FW vivo O
vivo NN ( O
( MD ca O

1 CD 1 O
1 NN mM O
mM NN ) O
) VBP suggest O
suggest IN that O
that NN CAPITAL CO2 O
CO2 VBZ modulates O
modulates JJS most O
most IN of O
of DT the O
the NNS reactions O
reactions IN of O
of NN peroxynitrite O
peroxynitrite IN in O
in JJ biological O
biological NNS systems O

The DT CAPITAL The O
The NN addition O
addition IN of O
of NN peroxynitrite O
peroxynitrite TO to O
to NN CAPITAL CO2 O
CO2 VBZ produces O
produces IN of O
of DT the O
the NN adduct O
adduct CD CAPITAL ONOO-CO2- O
ONOO-CO2- NN ( O
( CD 1 O
1 NN ) O

The DT CAPITAL The O
The NN production O
production IN of O
of CD 1 O
1 RB greatly O
greatly VBZ accelerates O
accelerates DT the O
the NN decomposition O
decomposition IN of O
of NN peroxynitrite O
peroxynitrite TO to O
to VB give O
give JJ nitrate O

We PRP CAPITAL We O
We RB now O
now NN show O
show IN that O
that DT the O
the NN formation O
formation IN of O
of CD 1 O
1 VBZ is O
is VBN followed O
followed IN by O
by NN reformation O
reformation IN of O
of NN CAPITAL CO2 O
CO2 NN ( O
( RB rather O
rather IN than O
than DT another O
another NN carbonate O
carbonate NNS species O
species JJ such O
such IN as O
as NN CAPITAL CO3 O
CO3 JJ = O
= CC or O
or JJ CAPITAL HCO3- O
HCO3- NN ) O

To TO CAPITAL To O
To NN show O
show DT this O
this , , O
, PRP it O
it VBZ is O
is JJ necessary O
necessary TO to O
to NN study O
study NNS systems O
systems IN with O
with VBG limiting O
limiting NNS concentrations O
concentrations IN of O
of NN CAPITAL CO2 O

( NN ( O
( WRB CAPITAL When O
When NN CAPITAL CO2 O
CO2 VBZ is O
is JJ present O
present IN in O
in JJ excess O
excess , , O
, PRP$ its O
its NN concentration O
concentration VBZ remains O
remains RB nearly O
nearly JJ constant O
constant IN during O
during DT the O
the NN decomposition O
decomposition IN of O
of NN peroxynitrite O
peroxynitrite , , O
, CC and O
and DT the O
the VBG recycling O
recycling IN of O
of NN CAPITAL CO2 O
CO2 , , O
, IN although O
although PRP it O
it VBZ occurs O
occurs , , O
, MD can O
can RB not O
not VB be O
be VBN detected O
detected RB kinetically O
kinetically NN ) O

We PRP CAPITAL We O
We VB find O
find IN that O
that NN CAPITAL CO2 O
CO2 VBZ is O
is DT a O
a JJ true O
true NN catalyst O
catalyst IN of O
of DT the O
the NN decomposition O
decomposition IN of O
of NN peroxynitrite O
peroxynitrite , , O
, CC and O
and DT this O
this JJ fundamental O
fundamental NN insight O
insight IN into O
into PRP$ its O
its NN action O
action MD must O
must VB be O
be VBN rationalized O
rationalized IN by O
by DT any O
any IN in O
in FW vivo O
vivo CC or O
or IN in O
in FW vitro O
vitro NN reaction O
reaction NN mechanism O
mechanism IN that O
that VBZ is O
is VBN proposed O

When WRB CAPITAL When O
When DT the O
the NN concentration O
concentration IN of O
of NN CAPITAL CO2 O
CO2 VBZ is O
is JJR lower O
lower IN than O
than IN that O
that IN of O
of NN peroxynitrite O
peroxynitrite , , O
, DT the O
the NN reformation O
reformation IN of O
of NN CAPITAL CO2 O
CO2 VBZ amplifies O
amplifies DT the O
the NN fraction O
fraction IN of O
of NN peroxynitrite O
peroxynitrite IN that O
that VBZ reacts O
reacts IN with O
with NN CAPITAL CO2 O

Even RB CAPITAL Even O
Even JJ low O
low NNS concentrations O
concentrations IN of O
of NN CAPITAL CO2 O
CO2 IN that O
that NN result O
result IN from O
from DT the O
the NN dissolution O
dissolution IN of O
of JJ ambient O
ambient NN CAPITAL CO2 O
CO2 MD can O
can VB have O
have JJ pronounced O
pronounced JJ catalytic O
catalytic NNS effects O

These DT CAPITAL These O
These NNS effects O
effects MD can O
can NN cause O
cause NNS deviations O
deviations IN from O
from VBN predicted O
predicted JJ kinetic O
kinetic NN behavior O
behavior IN in O
in NNS studies O
studies IN of O
of NN peroxynitrite O
peroxynitrite IN in O
in JJ noncarbonate O
noncarbonate NNS buffers O
buffers IN in O
in FW vitro O
vitro , , O
, CC and O
and IN since O
since CD 1 O
1 CC and O
and JJ other O
other NNS intermediates O
intermediates VBN derived O
derived IN from O
from PRP it O
it VBP are O
are NNS oxidants O
oxidants CC and/or O
and/or VBG nitrating O
nitrating NNS agents O
agents , , O
, DT some O
some IN of O
of DT the O
the NNS reactions O
reactions VBN attributed O
attributed TO to O
to NN peroxynitrite O
peroxynitrite MD may O
may VB depend O
depend IN on O
on DT the O
the NN availability O
availability IN of O
of NN CAPITAL CO2 O

A DT CAPITAL A O
A JJ prospective O
prospective , , O
, VBN randomized O
randomized , , O
, JJ placebo-controlled O
placebo-controlled , , O
, JJ double-blind O
double-blind , , O
, JJ parallel-group O
parallel-group , , O
, JJ 6-month O
6-month NN study O
study VBN assessed O
assessed DT the O
the NN efficacy O
efficacy CC and O
and NN safety O
safety IN of O
of NN ropinirole T
ropinirole , , T
, DT a T
a JJ nonergoline T
nonergoline NN CAPITAL D2-dopamine T
D2-dopamine NN agonist T
agonist , , O
, IN in O
in NNS patients O
patients IN with O
with RB early D
early NNP CAPITAL Parkinson D
Parkinson POS 's D
's NN disease D
disease NN ( O
( NN n O
n JJ = O
= CD 241 O
241 : ; O
; NNP CAPITAL Hoehn O
Hoehn CC & O
& # # O
# CD 38 O
38 : ; O
; NN CAPITAL Yahr O
Yahr NNS stages O
stages PRP CAPITAL I O
I TO to O
to NNP CAPITAL III O
III NN ) O
) IN with O
with JJ limited O
limited CC or O
or DT no O
no RB prior O
prior JJ dopaminergic T
dopaminergic NN therapy T

Patients NNS CAPITAL Patients O
Patients NN ( O
( VB mean O
mean NN age O
age , , O
, CD 62.8 O
62.8 NNS years O
years NN ) O
) , , O
, VBN stratified O
stratified IN by O
by JJ concomitant O
concomitant NN use O
use IN of O
of NN selegiline T
selegiline , , O
, VBD were O
were VBN randomized O
randomized TO to O
to NN ropinirole T
ropinirole NN ( O
( NN n O
n JJ = O
= CD 116 O
116 NN ) O
) CC or O
or NN placebo O
placebo NN ( O
( NN n O
n JJ = O
= CD 125 O
125 NN ) O

The DT CAPITAL The O
The VBG starting O
starting NN dose O
dose IN of O
of NN ropinirole T
ropinirole VBD was O
was CD 0.25 O
0.25 NN mg O
mg NN tid O
tid IN with O
with NN titration O
titration TO to O
to IN at O
at JJS least O
least CD 1.5 O
1.5 NN mg O
mg NN tid O
tid NN ( O
( NN maximum O
maximum NN dose O
dose , , O
, CD 8 O
8 NN mg O
mg NN tid O
tid NN ) O

Primary JJ CAPITAL Primary O
Primary NN efficacy O
efficacy NN endpoint O
endpoint VBD was O
was DT the O
the NN percentage O
percentage NN improvement O
improvement IN in O
in JJ CAPITAL Unified O
Unified NNP CAPITAL Parkinson D
Parkinson POS 's D
's NN CAPITAL Disease D
Disease NNP CAPITAL Rating O
Rating NNP CAPITAL Scale O
Scale NN ( O
( NN CAPITAL UPDRS O
UPDRS NN ) O
) NN motor O
motor NN score O

Ropinirole-treated JJ CAPITAL Ropinirole-treated O
Ropinirole-treated NNS patients O
patients VBD had O
had DT a O
a RB significantly O
significantly JJR greater O
greater NN percentage O
percentage NN improvement O
improvement IN in O
in NN CAPITAL UPDRS O
UPDRS NN motor O
motor NN score O
score IN than O
than NNS patients O
patients WP who O
who VBN received O
received NN placebo O
placebo NN ( O
( CD +24 O
+24 NN % O
% CC vs O
vs CD -3 O
-3 NN % O
% : ; O
; NN p O
p CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0.001 O
0.001 NN ) O

Ropinirole NNP CAPITAL Ropinirole T
Ropinirole VBD was O
was RB well O
well VBN tolerated O
tolerated CC and O
and NN patient O
patient NNS withdrawals O
withdrawals VBD were O
were JJ infrequent O

Most JJS CAPITAL Most O
Most JJ adverse O
adverse NNS experiences O
experiences VBD were O
were JJ related O
related TO to O
to JJ peripheral O
peripheral JJ dopaminergic O
dopaminergic NN activity O

Ropinirole NNP CAPITAL Ropinirole T
Ropinirole JJ monotherapy T
monotherapy VBZ is O
is DT an O
an JJ effective O
effective CC and O
and JJ well-tolerated O
well-tolerated JJ therapeutic O
therapeutic NN option O
option IN for O
for NN treatment O
treatment IN of O
of RB early D
early NNP CAPITAL Parkinson D
Parkinson POS 's D
's NN disease D

Starfish JJ CAPITAL Starfish O
Starfish NNS oocytes O
oocytes MD can O
can VB be O
be VBN fertilized O
fertilized IN after O
after JJ germinal O
germinal NN vesicle O
vesicle NN breakdown O
breakdown NN ( O
( NN CAPITAL GVBD O
GVBD NN ) O
) CC and O
and JJ artificial O
artificial NN parthenogenesis O
parthenogenesis MD can O
can VB be O
be VBN induced O
induced IN by O
by VBG activating O
activating DT the O
the NNS oocytes O
oocytes IN after O
after NN CAPITAL GVBD O
GVBD NN ( O
( JJ post-GVBD O
post-GVBD NN activation O
activation NN ) O

In IN CAPITAL In O
In DT the O
the JJ present O
present NN study O
study , , O
, NNS parthenogenotes O
parthenogenotes VBD were O
were VBN obtained O
obtained IN by O
by DT the O
the NN activation O
activation IN of O
of JJ immature O
immature NNS oocytes O
oocytes IN with O
with NN caffeine O
caffeine IN before O
before NN treatment O
treatment IN with O
with JJ 1-methyladenine T
1-methyladenine NN ( T
( JJ 1-MeAde T
1-MeAde NN ) T
) TO to O
to VB induce O
induce NN oocyte O
oocyte NN maturation O

Most JJS CAPITAL Most O
Most IN of O
of DT the O
the JJ caffeine-treated O
caffeine-treated NNS eggs O
eggs VBN developed O
developed IN as O
as NNS tetraploids O
tetraploids , , O
, IN as O
as NNS parthenogenotes O
parthenogenotes VBN produced O
produced IN by O
by DT the O
the JJ post-GVBD O
post-GVBD NN activation O

The DT CAPITAL The O
The NNS parthengenotes O
parthengenotes VBD were O
were VBN derived O
derived RB only O
only IN from O
from NNS eggs O
eggs IN that O
that VBD failed O
failed TO to O
to VB extrude O
extrude JJ polar O
polar NNS bodies O
bodies , , O
, RB mostly O
mostly IN from O
from NNS eggs O
eggs VBG failing O
failing TO to O
to VB extrude O
extrude DT a O
a JJ second O
second JJ polar O
polar NN body O

Eggs NNP CAPITAL Eggs O
Eggs VBN derived O
derived IN from O
from JJ immature O
immature NNS oocytes O
oocytes VBN activated O
activated IN by O
by NN CAPITAL A23187 O
A23187 , , O
, VBN treated O
treated IN with O
with JJ 1-MeAde T
1-MeAde CC and O
and JJ post-treated O
post-treated IN with O
with NN cytochalasin T
cytochalasin NN CAPITAL B T
B VBD failed O
failed TO to O
to VB extrude O
extrude JJ polar O
polar NNS bodies O
bodies , , O
, CC and O
and RB eventually O
eventually VBN developed O
developed IN into O
into JJ parthenogenetic O
parthenogenetic NNS embryos O

These DT CAPITAL These O
These NNS results O
results VBP indicate O
indicate IN that O
that DT the O
the JJ present O
present NN parthenogenesis O
parthenogenesis NN mechanism O
mechanism NNS shares O
shares DT the O
the JJ same O
same NNS characteristics O
characteristics IN as O
as IN that O
that VBN achieved O
achieved IN by O
by JJ post-GVBD O
post-GVBD NN activation O
activation IN in O
in DT the O
the NN suppression O
suppression IN of O
of JJ polar O
polar NN body O
body NN formation O
formation IN as O
as DT a O
a JJ key O
key NNS means O
means IN for O
for JJ successful O
successful NN starfish O
starfish NN parthenogenesis O

We PRP CAPITAL We O
We VBN hypothesized O
hypothesized IN that O
that NN fluoride T
fluoride RB partly O
partly NNS acts O
acts IN by O
by VBG changing O
changing DT the O
the NNS levels O
levels IN of O
of VBG circulating O
circulating JJ calcium-regulating O
calcium-regulating NNS hormones O
hormones CC and O
and JJ skeletal O
skeletal NN growth O
growth NNS factors O

The DT CAPITAL The O
The NNS effects O
effects IN of O
of JJ oral T
oral NN fluoride T
fluoride IN on O
on CD 24 O
24 JJ female O
female , , O
, JJ CAPITAL Dutch-Belted O
Dutch-Belted , , O
, JJ young O
young JJ adult O
adult NNS rabbits O
rabbits VBD were O
were VBN studied O

The DT CAPITAL The O
The NNS rabbits O
rabbits VBD were O
were VBN divided O
divided IN into O
into CD two O
two NN study O
study NNS groups O
groups , , O
, CD one O
one NN control O
control CC and O
and DT the O
the JJ other O
other VBG receiving O
receiving IN about O
about CD 16 O
16 NN mg O
mg NN fluoride/rabbit/day O
fluoride/rabbit/day IN in O
in PRP$ their O
their NN drinking O
drinking NN water O

After IN CAPITAL After O
After CD 6 O
6 NNS months O
months IN of O
of NN fluoride T
fluoride NN dosing T
dosing , , O
, DT all O
all NNS rabbits O
rabbits VBD were O
were VBN euthanized O
euthanized CC and O
and NN bone O
bone CC and O
and NN blood O
blood NNS samples O
samples VBD were O
were VBN taken O
taken IN for O
for NNS analyses O

Fluoride NN CAPITAL Fluoride T
Fluoride NN treatment T
treatment VBN increased O
increased NN serum O
serum CC and O
and NN bone O
bone NN fluoride O
fluoride NNS levels O
levels IN by O
by IN over O
over DT an O
an NN order O
order IN of O
of NN magnitude O
magnitude NN ( O
( NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0.001 O
0.001 NN ) O
) , , O
, CC but O
but VBD did O
did RB not O
not VB affect O
affect NN body O
body NN weight O
weight CC or O
or DT the O
the VBG following O
following NN serum O
serum JJ biochemical O
biochemical NNS variables O
variables : : O
: NN urea O
urea , , O
, NN creatinine O
creatinine , , O
, NN phosphorus O
phosphorus , , O
, JJ total O
total NN protein O
protein , , O
, NN albumin O
albumin , , O
, NN bilirubin O
bilirubin , , O
, NN CAPITAL SGOT O
SGOT , , O
, CC or O
or JJ total O
total NN alkaline O
alkaline NN phosphatase O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> DT CAPITAL No O
No JJ skeletal D
skeletal NN fluorosis D
fluorosis CC or O
or NN osteomalacia D
osteomalacia VBD was O
was VBN observed O
observed RB histologically O
histologically , , O
, CC nor O
nor VBD did O
did NN fluoride T
fluoride VB affect O
affect NN serum O
serum NN CAPITAL PTH O
PTH CC or O
or NN CAPITAL Vitamin O
Vitamin NN CAPITAL D O
D NNS metabolites O
metabolites NN ( O
( NN CAPITAL P O
P JJR > O
> CD 0.4 O
0.4 NN ) O

BAP NN CAPITAL BAP O
BAP VBD was O
was VBN increased O
increased CD 37 O
37 NN % O
% NN ( O
( NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0.05 O
0.05 NN ) O
) IN by O
by NN fluoride O
fluoride : ; O
; NN serum O
serum NN CAPITAL TRAP O
TRAP VBD was O
was VBN increased O
increased CD 42 O
42 NN % O
% NN ( O
( NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0.05 O
0.05 NN ) O
) : ; O
; NN serum O
serum NN CAPITAL IGF-1 O
IGF-1 VBD was O
was VBN increased O
increased CD 40 O
40 NN % O
% NN ( O
( NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0.05 O
0.05 NN ) O

Fluoride NN CAPITAL Fluoride T
Fluoride VBN increased O
increased DT the O
the JJ vertebral O
vertebral NN CAPITAL BV/TV O
BV/TV IN by O
by CD 35 O
35 NN % O
% NN ( O
( NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0.05 O
0.05 NN ) O
) CC and O
and JJ tibial O
tibial JJ ash O
ash NN weight O
weight IN by O
by CD 10 O
10 NN % O
% NN ( O
( NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0.05 O
0.05 NN ) O

However RB CAPITAL However O
However , , O
, DT the O
the NNS increases O
increases IN in O
in NN bone O
bone NN mass O
mass CC and O
and NN bone O
bone NN formation O
formation VBD were O
were RB not O
not VBN reflected O
reflected IN in O
in VBN improved O
improved NN bone O
bone NN strength O

Fluoride NN CAPITAL Fluoride O
Fluoride VBN decreased O
decreased NN bone O
bone NN strength O
strength IN by O
by IN about O
about CD 19 O
19 NN % O
% IN in O
in DT the O
the NN CAPITAL L5 O
L5 NN vertebra O
vertebra NN ( O
( NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0.01 O
0.01 NN ) O
) CC and O
and CD 25 O
25 NN % O
% IN in O
in DT the O
the JJ femoral O
femoral NN neck O
neck NN ( O
( NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0 O

05 CD 05 O
05 NN ) O

X-ray NN CAPITAL X-ray O
X-ray NN diffraction O
diffraction VBD showed O
showed JJ altered O
altered NN mineral O
mineral NN crystal O
crystal NN thickness O
thickness IN in O
in JJ fluoride-treated O
fluoride-treated NNS bones O
bones NN ( O
( NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0.001 O
0.001 NN ) O
) , , O
, CC and O
and RB there O
there VBD was O
was DT a O
a JJ negative O
negative NN association O
association IN between O
between NN crystal O
crystal NN width O
width CC and O
and NN fracture O
fracture NN stress O
stress IN of O
of DT the O
the NN femur O
femur NN ( O
( NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0.02 O
0.02 NN ) O

In IN CAPITAL In O
In NN conclusion O
conclusion , , O
, NN fluoride O
fluoride POS 's O
's NNS effects O
effects IN on O
on NN bone O
bone NN mass O
mass CC and O
and NN bone O
bone NN turnover O
turnover VBD were O
were RB not O
not VBN mediated O
mediated IN by O
by NN CAPITAL PTH O

IGF-1 NN CAPITAL IGF-1 O
IGF-1 VBD was O
was VBN increased O
increased IN by O
by NN fluoride O
fluoride CC and O
and VBD was O
was VBN associated O
associated IN with O
with VBN increased O
increased NN bone O
bone NN turnover O
turnover , , O
, CC but O
but VBD was O
was RB not O
not VBD correlated O
correlated IN with O
with NN bone O
bone NN formation O
formation NNS markers O

High-dose JJ CAPITAL High-dose O
High-dose NN fluoride T
fluoride NN treatment T
treatment VBD did O
did RB not O
not VB improve O
improve , , O
, CC but O
but VBN decreased O
decreased , , O
, NN bone O
bone NN strength O
strength IN in O
in NNS rabbits O
rabbits , , O
, RB even O
even IN in O
in DT the O
the NN absence O
absence IN of O
of JJ impaired O
impaired NN mineralization O

PURPOSE NN CAPITAL PURPOSE O
PURPOSE : : O
: TO CAPITAL To O
To VB determine O
determine DT the O
the NN effect O
effect IN of O
of JJ various O
various NNS methods O
methods IN of O
of VBG managing O
managing DT the O
the JJ posterior O
posterior NN capsule O
capsule CC and O
and JJ anterior O
anterior JJ vitreous O
vitreous IN on O
on DT the O
the NN rate O
rate IN of O
of NN posterior D
posterior NN capsule D
capsule NN opacification D
opacification IN in O
in JJ pediatric O
pediatric NNS eyes O
eyes VBN implanted O
implanted IN with O
with JJ posterior T
posterior NN chamber T
chamber JJ intraocular T
intraocular NNS lenses T
lenses NN ( T
( NN CAPITAL PC T
PC NNS CAPITAL IOLs T
IOLs NN ) T

SETTING VBG CAPITAL SETTING O
SETTING : : O
: NNP CAPITAL Cullen O
Cullen NNP CAPITAL Eye O
Eye NNP CAPITAL Institute O
Institute , , O
, NNP CAPITAL Baylor O
Baylor NNP CAPITAL College O
College IN of O
of NNP CAPITAL Medicine O
Medicine , , O
, NNP CAPITAL Houston O
Houston , , O
, NNP CAPITAL Texas O
Texas , , O
, NNP CAPITAL USA O

METHODS NNS CAPITAL METHODS O
METHODS : : O
: PRP CAPITAL We O
We VBN reviewed O
reviewed DT the O
the NNS charts O
charts IN of O
of CD 20 O
20 NNS eyes O
eyes IN of O
of CD 15 O
15 NNS children O
children NN ( O
( JJ aged O
aged CD 1.5 O
1.5 TO to O
to CD 2 O
2 NNS years O
years NN ) O
) WP who O
who VBD had O
had JJ primary O
primary NN cataract D
cataract NN surgery T
surgery IN with T
with NN CAPITAL PC T
PC NNP CAPITAL IOL T
IOL NN implantation T
implantation IN during O
during DT the O
the JJ past O
past CD 5 O
5 NNS years O

The DT CAPITAL The O
The JJ posterior O
posterior NN capsule O
capsule CC and O
and JJ anterior O
anterior JJ vitreous O
vitreous VBD were O
were VBN managed O
managed IN in O
in DT a O
a NN variety O
variety IN of O
of NNS ways O
ways : : O
: IN CAPITAL In O
In CD 5 O
5 NNS eyes O
eyes , , O
, DT the O
the JJ posterior O
posterior NN capsule O
capsule VBD was O
was RB left O
left JJ intact O
intact : ; O
; IN in O
in CD 15 O
15 NNS eyes O
eyes , , O
, DT a O
a JJ posterior T
posterior JJ continuous T
continuous JJ curvilinear T
curvilinear NN capsulorhexis T
capsulorhexis NN ( T
( NN CAPITAL PCCC T
PCCC NN ) T
) VBD was O
was VBN performed O
performed : - O
- CD 6 O
6 IN with O
with CC and O
and CD 9 O
9 IN without O
without JJ anterior T
anterior NN vitrectomy T
vitrectomy : ; O
; IN in O
in CD 8 O
8 NNS eyes O
eyes , , O
, JJ posterior T
posterior JJ optic T
optic NN capture T
capture VBD was O
was VBN performed O
performed : - O
- CD 3 O
3 IN with O
with CC and O
and CD 5 O
5 IN without O
without NN vitrectomy T

The DT CAPITAL The O
The JJ follow-up O
follow-up VBD ranged O
ranged IN from O
from CD 1 O
1 TO to O
to CD 4.5 O
4.5 NNS years O
years NN ( O
( VB mean O
mean CD 2 O
2 NNS years O
years NN ) O

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: RB CAPITAL Visually O
Visually JJ significant O
significant JJ secondary O
secondary NN cataract D
cataract VBN developed O
developed IN in O
in DT the O
the CD five O
five NNS eyes O
eyes IN with O
with JJ intact O
intact JJ posterior O
posterior NNS capsules O
capsules CC and O
and IN in O
in DT the O
the CD four O
four NNS eyes O
eyes IN that O
that VBD had O
had NN CAPITAL PCCC T
PCCC IN without O
without NN vitrectomy T
vitrectomy CC and O
and IN without O
without JJ posterior T
posterior JJ optic T
optic NN capture T
capture NN ( O
( NN i.e O
i.e . . O
. , , O
, DT the O
the JJ optic O
optic VBD was O
was RB left O
left IN in O
in DT the O
the JJ capsular O
capsular NN bag O
bag NN ) O

The DT CAPITAL The O
The JJ optical O
optical NN axis O
axis VBD remained O
remained JJ clear O
clear IN in O
in DT the O
the CD six O
six NNS eyes O
eyes IN that O
that VBD had O
had NN CAPITAL PC T
PC NNP CAPITAL IOL T
IOL NN implantation T
implantation IN with O
with NN vitrectomy T
vitrectomy NN ( O
( IN with O
with CC or O
or IN without O
without JJ posterior T
posterior JJ optic T
optic NN capture T
capture NN ) O

Initially RB CAPITAL Initially O
Initially , , O
, DT all O
all NNS eyes O
eyes IN that O
that VBD had O
had JJ optic T
optic NN capture T
capture IN without O
without NN vitrectomy T
vitrectomy RB also O
also VBD remained O
remained JJ clear O
clear , , O
, CC but O
but IN after O
after CD 6 O
6 NNS months O
months , , O
, CD four O
four IN of O
of CD five O
five VBN developed O
developed NN opacification D

CONCLUSION NN CAPITAL CONCLUSION O
CONCLUSION : : O
: IN CAPITAL In O
In DT this O
this NN series O
series , , O
, NN CAPITAL PCCC T
PCCC IN with T
with JJ anterior T
anterior NN vitrectomy T
vitrectomy VBD was O
was DT the O
the RB only O
only JJ effective O
effective NN method O
method IN of O
of VBG preventing O
preventing CC or O
or VBG delaying O
delaying JJ secondary D
secondary NN cataract D
cataract NN formation D
formation IN in O
in NNS infants O
infants CC and O
and NNS children O

Evidence NN CAPITAL Evidence O
Evidence IN for O
for DT the O
the NN presence O
presence IN of O
of DT a O
a NN serotonin1A O
serotonin1A NN ( O
( NN 5-HT1A O
5-HT1A NN ) O
) NN receptor O
receptor NN subtype O
subtype IN in O
in DT the O
the NN salmonid O
salmonid NN fish O
fish NN brain O
brain VBZ has O
has RB recently O
recently VBN been O
been VBN presented O

In IN CAPITAL In O
In DT the O
the JJ present O
present NN study O
study DT the O
the JJ potent O
potent NN 5-HT1A O
5-HT1A NN receptor O
receptor NN agonist O
agonist , , O
, JJ 8-hydroxy-2- O
8-hydroxy-2- NN ( O
( NN di-n-propylamino O
di-n-propylamino NN ) O
) NN -tetralin O
-tetralin NN ( O
( NN 8-OH-DPAT O
8-OH-DPAT NN ) O
) VBD was O
was VBN tested O
tested IN for O
for PRP$ its O
its NN effect O
effect IN on O
on NN plasma O
plasma NN cortisol O
cortisol NNS concentrations O
concentrations IN in O
in NN rainbow O
rainbow NNS trout O
trout NN ( O
( NNP CAPITAL Oncorhynchus O
Oncorhynchus JJ mykiss O
mykiss NN ) O

Blood NN CAPITAL Blood O
Blood VBD was O
was VBN sampled O
sampled CC and O
and NN 8-OH-DPAT O
8-OH-DPAT VBN administered O
administered IN through O
through DT a O
a NN catheter O
catheter IN in O
in DT the O
the NN dorsal O
dorsal NN aorta O

Thirty CD CAPITAL Thirty O
Thirty NNS minutes O
minutes IN after O
after DT the O
the NN injection O
injection IN of O
of CD 40 O
40 NN microg O
microg IN of O
of NN 8-OH-DPAT/kg O
8-OH-DPAT/kg , , O
, NN plasma O
plasma NN cortisol O
cortisol NNS levels O
levels VBD had O
had VBN increased O
increased IN from O
from CD 12 O
12 TO to O
to CD 149 O
149 NN ng/ml O
ng/ml , , O
, NN whereupon O
whereupon PRP they O
they VBD fell O
fell , , O
, VBG reaching O
reaching NN baseline O
baseline NNS levels O
levels IN after O
after CD 4 O
4 NN h. O
h. DT CAPITAL The O
The NN effect O
effect IN of O
of CD 1-40 O
1-40 NN microg O
microg NN 8-OH-DPAT/kg O
8-OH-DPAT/kg IN on O
on NN plasma O
plasma NN cortisol O
cortisol NNS concentrations O
concentrations VBD was O
was JJ dose-dependent O

The DT CAPITAL The O
The NNS results O
results VBZ lends O
lends RB further O
further NN support O
support TO to O
to DT the O
the NN hypothesis O
hypothesis IN that O
that DT the O
the NN brain O
brain JJ serotonergic O
serotonergic NN system O
system NNS plays O
plays DT a O
a JJ key O
key NN role O
role IN in O
in VBG integrating O
integrating JJ autonomic O
autonomic , , O
, JJ behavioral O
behavioral CC and O
and NN neuroendocrine O
neuroendocrine NNS stress-responses O
stress-responses IN in O
in NN fish O
fish IN as O
as RB well O
well IN as O
as NNS mammals O
mammals , , O
, VBG suggesting O
suggesting IN that O
that RB not O
not RB only O
only DT the O
the JJ structural O
structural CC and O
and JJ biochemical O
biochemical NN organization O
organization , , O
, CC but O
but RB also O
also DT the O
the NN function O
function IN of O
of DT the O
the JJ serotonergic O
serotonergic NN system O
system VBZ has O
has VBN been O
been VBN conserved O
conserved IN during O
during JJ vertebrate O
vertebrate NN evolution O

OBJECTIVE NN CAPITAL OBJECTIVE O
OBJECTIVE : : O
: TO CAPITAL To O
To VB assess O
assess DT the O
the VBG medicalising O
medicalising NN effect O
effect IN of O
of VBG prescribing O
prescribing NNS antibiotics T
antibiotics IN for O
for JJ sore D
sore NN throat D

SETTING VBG CAPITAL SETTING O
SETTING : : O
: CD 11 O
11 JJ general O
general NNS practices O
practices IN in O
in NNP CAPITAL England O

DESIGN NN CAPITAL DESIGN O
DESIGN : : O
: VBN CAPITAL Randomised O
Randomised NN trial O
trial IN of O
of CD three O
three NNS approaches O
approaches TO to O
to JJ sore D
sore NN throat D
throat : : O
: DT a O
a CD 10 O
10 NN day O
day NN prescription O
prescription IN of O
of NNS antibiotics T
antibiotics , , O
, DT no O
no NNS antibiotics O
antibiotics , , O
, CC or O
or DT a O
a VBN delayed O
delayed NN prescription O
prescription IN if O
if DT the O
the JJ sore D
sore NN throat D
throat VBD had O
had RB not O
not VBD started O
started TO to O
to VB settle O
settle IN after O
after CD three O
three NNS days O

PATIENTS NNS CAPITAL PATIENTS O
PATIENTS : : O
: CD 716 O
716 NNS patients O
patients JJ aged O
aged CD 4 O
4 CC and O
and IN over O
over IN with O
with JJ sore D
sore NN throat D
throat CC and O
and DT an O
an JJ abnormal O
abnormal JJ physical O
physical NN sign O
sign : : O
: CD 84 O
84 NN % O
% VBD had O
had NN tonsillitis D
tonsillitis CC or O
or NN pharyngitis D

OUTCOME NN CAPITAL OUTCOME O
OUTCOME NNS CAPITAL MEASURES O
MEASURES : : O
: NN CAPITAL Number O
Number CC and O
and NN rate O
rate IN of O
of NNS patients O
patients VBG making O
making DT a O
a RB first O
first NN return O
return IN with O
with JJ sore D
sore NN throat D
throat , , O
, NN pharyngitis D
pharyngitis , , O
, CC or O
or NN tonsillitis D

Early RB CAPITAL Early O
Early NNS returns O
returns NN ( O
( IN within O
within CD two O
two NNS weeks O
weeks NN ) O
) CC and O
and NNS complications O
complications NN ( O
( NN otitis D
otitis NNS media D
media , , O
, NN sinusitis D
sinusitis , , O
, NN quinsy D
quinsy NN ) O

Outcomes NNS CAPITAL Outcomes O
Outcomes VBD were O
were VBN documented O
documented IN in O
in CD 675 O
675 NNS subjects O
subjects NN ( O
( CD 94 O
94 NN % O
% NN ) O

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: NN CAPITAL Mean O
Mean VB follow O
follow RB up O
up NN time O
time VBD was O
was JJ similar O
similar NN ( O
( JJ antibiotic O
antibiotic NN group O
group CD 1.07 O
1.07 NNS years O
years , , O
, JJ other O
other CD two O
two NNS groups O
groups CD 1.03 O
1.03 NNS years O
years NN ) O

More RBR CAPITAL More O
More IN of O
of DT those O
those RB initially O
initially VBN prescribed O
prescribed NNS antibiotics T
antibiotics RB initially O
initially VBD returned O
returned TO to O
to DT the O
the NN surgery O
surgery IN with O
with JJ sore D
sore NN throat D
throat NN ( O
( CD 38 O
38 NN % O
% LS v O
v CD 27 O
27 NN % O
% , , O
, VBN adjusted O
adjusted NN hazard O
hazard NN ratio O
ratio IN for O
for NN return O
return CD 1.39 O
1.39 NN % O
% , , O
, CD 95 O
95 NN % O
% NN confidence O
confidence NN interval O
interval CD 1.03 O
1.03 TO to O
to CD 1.89 O
1.89 NN ) O

Antibiotics NNS CAPITAL Antibiotics T
Antibiotics VBN prescribed O
prescribed IN for O
for JJ sore D
sore NN throat D
throat IN during O
during DT the O
the JJ previous O
previous NN year O
year VBD had O
had DT an O
an JJ additional O
additional NN effect O
effect NN ( O
( NN hazard O
hazard NN ratio O
ratio CD 1.69 O
1.69 , , O
, CD 1.20 O
1.20 TO to O
to CD 2.37 O
2.37 NN ) O

Longer JJR CAPITAL Longer O
Longer NN duration O
duration IN of O
of NN illness O
illness NN ( O
( JJR > O
> CD 5 O
5 NNS days O
days NN ) O
) VBD was O
was VBN associated O
associated IN with O
with VBN increased O
increased NN return O
return IN within O
within CD six O
six NNS weeks O
weeks NN ( O
( NN hazard O
hazard NN ratio O
ratio CD 2.90 O
2.90 , , O
, CD 1.70 O
1.70 TO to O
to CD 4.92 O
4.92 NN ) O

Prior RB CAPITAL Prior O
Prior NN attendance O
attendance IN with O
with JJ upper D
upper JJ respiratory D
respiratory NNS conditions D
conditions VBD was O
was RB also O
also VBN associated O
associated IN with O
with VBN increased O
increased NN reattendance O

There EX CAPITAL There O
There VBD was O
was DT no O
no NN difference O
difference IN between O
between NNS groups O
groups IN in O
in RB early O
early NN return O
return NN ( O
( CD 13/238 O
13/238 NN ( O
( CD 5.5 O
5.5 NN % O
% NN ) O
) LS v O
v CD 27/437 O
27/437 NN ( O
( CD 6 O
6 NN % O
% NN ) O
) NN ) O
) , , O
, CC or O
or NNS complications O
complications NN ( O
( CD 2/236 O
2/236 NN ( O
( CD 0.8 O
0.8 NN % O
% NN ) O
) LS v O
v CD 3/434 O
3/434 NN ( O
( CD 0.7 O
0.7 NN % O
% NN ) O
) NN ) O

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: NNS CAPITAL Complications O
Complications CC and O
and RB early O
early NN return O
return VBG resulting O
resulting IN from O
from DT no O
no CC or O
or VBN delayed O
delayed VBG prescribing O
prescribing IN of O
of NNS antibiotics T
antibiotics IN for O
for JJ sore D
sore NN throat D
throat VBP are O
are JJ rare O

Both DT CAPITAL Both O
Both JJ current O
current CC and O
and JJ previous O
previous VBG prescribing O
prescribing IN for O
for JJ sore D
sore NN throat D
throat NN increase O
increase NN reattendance O

To TO CAPITAL To O
To VB avoid O
avoid VBG medicalising O
medicalising DT a O
a NN self O
self VBG limiting O
limiting NN illness O
illness NNS doctors O
doctors MD should O
should VB avoid O
avoid NNS antibiotics T
antibiotics CC or O
or NN offer O
offer DT a O
a VBN delayed O
delayed NN prescription O
prescription IN for O
for JJS most O
most NNS patients O
patients IN with O
with JJ sore D
sore NN throat D

This DT CAPITAL This O
This NN study O
study VBD was O
was VBN designed O
designed TO to O
to VB determine O
determine CC and O
and VB compare O
compare DT the O
the JJ dose-response O
dose-response NNS characteristics O
characteristics , , O
, NN speed O
speed IN of O
of NN onset O
onset , , O
, CC and O
and JJ relative O
relative NN potency O
potency IN of O
of JJ single-dose O
single-dose JJ epidural T
epidural NN fentanyl T
fentanyl NN ( T
( NN CAPITAL F T
F NN ) T
) CC and O
and NN sufentanil T
sufentanil NN ( T
( NN CAPITAL S T
S NN ) T
) IN for O
for JJ postoperative D
postoperative NN pain D
pain NN relief D

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> CD CAPITAL Eighty O
Eighty NNS women O
women VBG undergoing O
undergoing NN cesarean O
cesarean NN section O
section NN ( O
( NN CAPITAL C/S O
C/S NN ) O
) IN with O
with JJ epidural O
epidural CD 2 O
2 NN % O
% NN lidocaine O
lidocaine IN with O
with NN epinephrine O
epinephrine NN ( O
( CD 1 O
1 : : O
: CD 200 O
200 , , O
, CD 000 O
000 NN ) O
) VBD were O
were RB randomly O
randomly VBN assigned O
assigned TO to O
to VB receive O
receive JJ double-blind O
double-blind JJ epidural O
epidural NN administration O
administration IN of O
of NN CAPITAL F O
F NN ( O
( CD 25 O
25 , , O
, CD 50 O
50 , , O
, CD 100 O
100 , , O
, CC or O
or CD 200 O
200 NN microg O
microg NN ) O
) CC or O
or NN CAPITAL S O
S NN ( O
( CD 5 O
5 , , O
, CD 10 O
10 , , O
, CD 20 O
20 , , O
, CC or O
or CD 30 O
30 NN microg O
microg NN ) O
) NN ( O
( NN n O
n JJ = O
= CD 10 O
10 IN per O
per NN group O
group NN ) O
) IN upon O
upon NN complaint O
complaint IN of O
of NN pain O
pain RB postoperatively O

Visual JJ CAPITAL Visual O
Visual NN analog O
analog NNS scales O
scales NN ( O
( NNP CAPITAL VAS O
VAS , , O
, CD 0-100 O
0-100 NN mm O
mm NN ) O
) VBD were O
were VBN used O
used TO to O
to VB assess O
assess NN pain O
pain CC and O
and NN sedation O
sedation IN at O
at NN baseline O
baseline : ; O
; IN at O
at CD 3 O
3 , , O
, CD 6 O
6 , , O
, CD 9 O
9 , , O
, CD 12 O
12 , , O
, CD 15 O
15 , , O
, CD 20 O
20 , , O
, CD 25 O
25 , , O
, CD 30 O
30 , , O
, CD 45 O
45 , , O
, CC and O
and CD 60 O
60 NN min O
min : ; O
; CC and O
and DT every O
every CD 30 O
30 NN min O
min IN until O
until RB further O
further NN analgesia O
analgesia VBD was O
was VBN requested O

The DT CAPITAL The O
The NN study O
study VBD was O
was VBN terminated O
terminated IN at O
at CD 30 O
30 NN min O
min IN if O
if JJ satisfactory O
satisfactory NN analgesia O
analgesia VBD was O
was RB not O
not VBN achieved O

Side NN CAPITAL Side O
Side NNS effects O
effects VBD were O
were VBN recorded O

A DT CAPITAL A O
A JJ dose-response O
dose-response VBD was O
was VBD demonstrated O
demonstrated IN for O
for DT both O
both NNS opioids O

F NN CAPITAL F O
F CD 25 O
25 NN microg O
microg CC and O
and NN CAPITAL S O
S CD 5 O
5 NN microg O
microg VBD were O
were JJ ineffective O
ineffective , , O
, IN with O
with RB significantly O
significantly JJR fewer O
fewer NNS women O
women VBG achieving O
achieving NNP CAPITAL VAS O
VAS NNS scores O
scores CC & O
& # # O
# CD 60 O
60 : ; O
; CD 10 O
10 NN mm O
mm NN ( O
( NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0.05 O
0.05 VBN compared O
compared IN with O
with NN CAPITAL F O
F CD 100 O
100 CC or O
or CD 200 O
200 NN microg O
microg CC and O
and NN CAPITAL S O
S CD 20 O
20 CC or O
or CD 30 O
30 NN microg O
microg NN ) O

F NN CAPITAL F O
F CD 100 O
100 CC and O
and CD 200 O
200 NN microg O
microg CC and O
and NN CAPITAL S O
S CD 20 O
20 CC and O
and CD 30 O
30 NN microg O
microg DT all O
all VBN achieved O
achieved NNP CAPITAL VAS O
VAS NNS scores O
scores CC & O
& # # O
# CD 60 O
60 : ; O
; CD 10 O
10 NN mm O
mm IN in O
in DT all O
all NNS women O
women IN with O
with DT no O
no NNS differences O
differences IN in O
in NN time O
time TO to O
to CD 50 O
50 NN % O
% NN reduction O
reduction IN in O
in NNP CAPITAL VAS O
VAS NN ( O
( VB mean O
mean CD 11-16 O
11-16 NN min O
min NN ) O
) CC and O
and DT no O
no NNS differences O
differences IN in O
in NN duration O
duration IN of O
of NN analgesia O
analgesia NN ( O
( VB mean O
mean CD 117-138 O
117-138 NN min O
min NN ) O

The DT CAPITAL The O
The CD 50 O
50 NN % O
% CC and O
and CD 95 O
95 NN % O
% JJ effective O
effective NN dose O
dose NNS values O
values IN for O
for DT each O
each JJ opioid O
opioid TO to O
to VB achieve O
achieve DT a O
a NNP CAPITAL VAS O
VAS NN score O
score CC & O
& # # O
# CD 60 O
60 : ; O
; CD 10 O
10 NN mm O
mm VBD were O
were NN CAPITAL F O
F CD 33 O
33 NN microg O
microg CC and O
and CD 92 O
92 NN microg O
microg CC and O
and NN CAPITAL S O
S CD 6.7 O
6.7 NN microg O
microg CC and O
and CD 17.5 O
17.5 NN microg O

There EX CAPITAL There O
There VBD were O
were DT no O
no NNS differences O
differences IN among O
among NNS groups O
groups IN in O
in NN sedation O
sedation NNS scores O
scores CC or O
or NN side O
side NNS effects O

Our PRP$ CAPITAL Our O
Our NNS data O
data VBP suggest O
suggest IN that O
that DT the O
the JJ relative O
relative JJ analgesic O
analgesic NN potency O
potency IN of O
of JJ epidural O
epidural NN CAPITAL S O
S : : O
: NN CAPITAL F O
F VBZ is O
is RB approximately O
approximately CD 5 O
5 CC and O
and IN that O
that RB there O
there VBP are O
are DT no O
no NNS differences O
differences IN between O
between DT the O
the NNS opioids O
opioids IN in O
in DT the O
the NN onset O
onset , , O
, NN duration O
duration , , O
, CC and O
and NN effectiveness O
effectiveness IN of O
of NN analgesia O
analgesia WRB when O
when JJ equianalgesic O
equianalgesic NNS doses O
doses VBP are O
are VBN administered O
administered RB postoperatively O
postoperatively IN after O
after NN lidocaine O
lidocaine NN anesthesia O
anesthesia IN for O
for NN CAPITAL C/S O

We PRP CAPITAL We O
We VBP describe O
describe CD 2 O
2 NNS cases O
cases IN in O
in WDT which O
which JJ intraoperative O
intraoperative NN transesophageal O
transesophageal NN echocardiography O
echocardiography VBN detected O
detected NNS complications O
complications JJ related O
related TO to O
to DT the O
the JJ proximal O
proximal JJ coronary O
coronary NNS arteries O
arteries IN during O
during NN homograft T
homograft JJ aortic T
aortic NN valve T
valve CC and T
and NN root T
root NN replacement T

In IN CAPITAL In O
In DT both O
both NNS cases O
cases , , O
, JJ cardiopulmonary T
cardiopulmonary NN bypass T
bypass MD could O
could RB not O
not VB be O
be VBN discontinued O
discontinued IN despite O
despite DT the O
the NN use O
use IN of O
of JJ large O
large NNS doses O
doses IN of O
of JJ inotropic T
inotropic NNS drugs T

Transesophageal JJ CAPITAL Transesophageal O
Transesophageal NN echocardiography O
echocardiography VBD demonstrated O
demonstrated VBG aliasing O
aliasing IN on O
on NN color O
color NN flow O
flow VBG mapping O
mapping IN in O
in DT the O
the RB left O
left JJ main O
main JJ coronary O
coronary NN artery O
artery IN in O
in CD 1 O
1 NN case O
case CC and O
and JJ proximal O
proximal RB right O
right JJ coronary O
coronary NN artery O
artery IN in O
in DT the O
the JJ other O
other , , O
, IN along O
along IN with O
with RB severely O
severely JJ depressed O
depressed RB left O
left JJ ventricular O
ventricular JJ anterior O
anterior NN wall O
wall CC and O
and RB right O
right JJ ventricular O
ventricular NN function O
function , , O
, RB respectively O

Coronary JJ CAPITAL Coronary T
Coronary NN artery T
artery NN bypass T
bypass VBG grafting T
grafting VBD was O
was VBN performed O
performed IN in O
in DT both O
both NNS cases O
cases , , O
, CC and O
and DT the O
the NN outcome O
outcome VBD was O
was JJ successful O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NN CAPITAL Granulocyte O
Granulocyte JJ colony-stimulating O
colony-stimulating NN factor O
factor NN ( O
( NN CAPITAL G-CSF O
G-CSF NN ) O
) VBZ has O
has VBN been O
been VBN used O
used TO to O
to VB improve O
improve NN granulocyte O
granulocyte NN count O
count IN in O
in JJ chronic O
chronic NN neutropenia O
neutropenia CC and O
and NN myelodysplasia O
myelodysplasia , , O
, TO to O
to VB minimize O
minimize DT the O
the NN incidence O
incidence CC and O
and NN duration O
duration IN of O
of NN neutropenia O
neutropenia IN during O
during JJ conventional O
conventional NN chemotherapy O
chemotherapy , , O
, CC and O
and TO to O
to VB mobilize O
mobilize JJ peripheral O
peripheral NN blood O
blood NN stem O
stem NNS cells O
cells RB prior O
prior TO to O
to NN leukapheresis O
leukapheresis IN for O
for NN use O
use IN in O
in JJ autologous O
autologous CC and O
and JJ allogeneic O
allogeneic NN marrow O
marrow NN transplantation O

The DT CAPITAL The O
The JJS most O
most JJ common O
common NN toxicity O
toxicity VBZ is O
is NN bone D
bone NN pain D
pain , , O
, CC and O
and JJ other O
other NNS reactions O
reactions JJ such O
such IN as O
as NN inflammation D
inflammation IN at O
at DT the O
the NN site O
site IN of O
of NN injection T
injection VB have O
have RB also O
also VBD occurred O

In IN CAPITAL In O
In NNS patients O
patients IN with O
with JJ chronic D
chronic NN neutropenia D
neutropenia , , O
, NN splenomegaly D
splenomegaly VBZ has O
has VBN been O
been VBN described O
described IN with O
with JJ long-term O
long-term NN use O
use , , O
, CC and O
and JJ extramedullary D
extramedullary NN hematopoiesis D
hematopoiesis VBZ has O
has RB also O
also VBN been O
been VBN reported O

However RB CAPITAL However O
However , , O
, RB thus O
thus RB far O
far , , O
, DT no O
no JJ life-threatening O
life-threatening NN sequelae O
sequelae IN of O
of DT these O
these NNS effects O
effects VBP are O
are VBN found O
found IN in O
in DT the O
the NN literature O

We PRP CAPITAL We O
We RB now O
now VBP describe O
describe DT a O
a NN case O
case IN of O
of JJ spontaneous O
spontaneous JJ splenic D
splenic NN rupture D
rupture CD four O
four NNS days O
days VBG following O
following DT a O
a JJ six-day O
six-day NN course O
course IN of O
of NN CAPITAL G-CSF T
G-CSF NN therapy T
therapy IN in O
in DT an O
an JJ allogeneic O
allogeneic NN donor O
donor IN of O
of JJ peripheral O
peripheral NN blood O
blood NN stem O
stem NNS cells O

Evidence-based JJ CAPITAL Evidence-based O
Evidence-based NN medicine O
medicine NN ( O
( NN CAPITAL EBM O
EBM NN ) O
) NNS aids O
aids JJ clinical O
clinical NN decision O
decision VBG making O
making IN in O
in DT all O
all NNS fields O
fields IN of O
of NN medicine O
medicine , , O
, VBG including O
including JJ primary O
primary NN care O

General NNP CAPITAL General O
General NN practice O
practice VBZ is O
is VBN characterized O
characterized IN by O
by JJ particular O
particular NN emphasis O
emphasis IN on O
on DT the O
the JJ doctor-patient O
doctor-patient NN relationship O
relationship CC and O
and IN on O
on JJ biomedical O
biomedical , , O
, JJ personal O
personal CC and O
and JJ contextual O
contextual NNS perspectives O
perspectives IN in O
in NN diagnosis O

Most JJS CAPITAL Most O
Most NN evidence O
evidence JJ available O
available TO to O
to JJ general O
general NNS practitioners O
practitioners NN ( O
( NNS CAPITAL GPs O
GPs NN ) O
) NNS addresses O
addresses RB only O
only DT the O
the JJ bio-medical O
bio-medical NN perspective O
perspective CC and O
and VBZ is O
is RB often O
often RB not O
not RB directly O
directly JJ applicable O
applicable TO to O
to JJ primary O
primary NN care O
care , , O
, IN as O
as PRP it O
it VBZ derives O
derives IN from O
from JJ secondary O
secondary CC or O
or JJ tertiary O
tertiary NN care O

Emphasis NN CAPITAL Emphasis O
Emphasis IN on O
on DT the O
the JJ biomedical O
biomedical NN domain O
domain CC and O
and DT the O
the VBN randomized O
randomized JJ controlled O
controlled NN trial O
trial NN ( O
( NN CAPITAL RCT O
RCT NN ) O
) RB alone O
alone VBZ reflects O
reflects DT a O
a JJ reductionist O
reductionist NN approach O
approach IN that O
that VBZ fails O
fails TO to O
to VB do O
do NN justice O
justice TO to O
to DT the O
the NN philosophy O
philosophy IN of O
of JJ general O
general NN practice O

The DT CAPITAL The O
The NN art O
art IN of O
of NN medicine O
medicine VBZ is O
is VBN founded O
founded IN on O
on NN context O
context , , O
, NN anecdote O
anecdote , , O
, NN patient O
patient NNS stories O
stories IN of O
of NN illness O
illness CC and O
and JJ personal O
personal NN experience O
experience , , O
, CC and O
and PRP we O
we MD should O
should VB continue O
continue TO to O
to VB blend O
blend DT this O
this IN with O
with JJ good O
good NN quality O
quality CC and O
and JJ appropriate O
appropriate NN research O
research NNS findings O
findings IN in O
in NN patient O
patient NN care O

Abdominal JJ CAPITAL Abdominal D
Abdominal NN tuberculosis D
tuberculosis VBZ is O
is RB not O
not JJ uncommon O
uncommon IN in O
in DT the O
the NNP CAPITAL UK O
UK , , O
, RB especially O
especially IN in O
in JJ CAPITAL Asian O
Asian NNS immigrants O

It PRP CAPITAL It O
It VBZ resembles O
resembles NN CAPITAL Crohn D
Crohn POS 's D
's NN disease D
disease RB clinically O
clinically CC and O
and RB radiologically O
radiologically , , O
, CC and O
and PRP it O
it MD may O
may VB be O
be JJ difficult O
difficult TO to O
to VB differentiate O
differentiate IN between O
between PRP them O
them , , O
, RB even O
even IN at O
at NN laparotomy O
laparotomy CC or O
or NN histology O

The DT CAPITAL The O
The NN distinction O
distinction VBZ is O
is JJ important O
important , , O
, RB however O
however , , O
, IN for O
for JJ proper O
proper NN management O
management IN of O
of DT the O
the CD two O
two NNS conditions O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> DT CAPITAL Every O
Every NN effort O
effort MD must O
must VB be O
be VBN made O
made TO to O
to VB exclude O
exclude JJ abdominal D
abdominal NN tuberculosis D
tuberculosis IN before O
before DT the O
the NN patient O
patient VBZ is O
is VBN diagnosed O
diagnosed IN as O
as VBG having O
having NN CAPITAL Crohn D
Crohn POS 's D
's NN disease D
disease CC and O
and VBZ is O
is VBN treated O
treated IN with O
with NNS steroids T

PURPOSE NN CAPITAL PURPOSE O
PURPOSE : : O
: DT CAPITAL The O
The JJ CAPITAL American O
American JJ CAPITAL Urological O
Urological NNP CAPITAL Association O
Association VBN convened O
convened DT the O
the JJ CAPITAL Female D
Female NN CAPITAL Stress D
Stress JJ CAPITAL Urinary D
Urinary NN CAPITAL Incontinence D
Incontinence JJ CAPITAL Clinical O
Clinical NNS CAPITAL Guidelines O
Guidelines NN CAPITAL Panel O
Panel TO to O
to VB analyze O
analyze DT the O
the NN literature O
literature VBG regarding O
regarding JJ surgical T
surgical NNS procedures T
procedures IN for O
for VBG treating O
treating NN stress D
stress JJ urinary D
urinary NN incontinence D
incontinence IN in O
in DT the O
the RB otherwise O
otherwise JJ healthy O
healthy JJ female O
female JJ subject O
subject CC and O
and TO to O
to VB make O
make NN practice O
practice NNS recommendations O
recommendations VBN based O
based IN on O
on DT the O
the NN treatment O
treatment NNS outcomes O
outcomes NNS data O

MATERIALS NNS CAPITAL MATERIALS O
MATERIALS CC CAPITAL AND O
AND NNS CAPITAL METHODS O
METHODS : : O
: DT CAPITAL The O
The NN panel O
panel VBD searched O
searched DT the O
the NN CAPITAL MEDLINE O
MEDLINE NNS data O
data NN base O
base IN for O
for DT all O
all NNS articles O
articles IN through O
through CD 1993 O
1993 IN on O
on JJ surgical T
surgical NN treatment T
treatment IN of O
of JJ female D
female NN stress D
stress JJ urinary D
urinary NN incontinence D

Outcomes NNS CAPITAL Outcomes O
Outcomes NNS data O
data VBD were O
were VBN extracted O
extracted IN from O
from NNS articles O
articles VBN accepted O
accepted IN after O
after NN panel O
panel NN review O

The DT CAPITAL The O
The NNS data O
data VBD were O
were RB then O
then JJ meta-analyzed O
meta-analyzed TO to O
to VB produce O
produce NN outcome O
outcome NNS estimates O
estimates IN for O
for JJ alternative O
alternative JJ surgical T
surgical NNS procedures T

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: DT CAPITAL The O
The NNS data O
data VBP indicate O
indicate IN that O
that IN after O
after CD 48 O
48 NNS months O
months JJ retropubic T
retropubic NNS suspensions T
suspensions CC and O
and NNS slings T
slings VB appear O
appear TO to O
to VB be O
be RBR more O
more JJ efficacious O
efficacious IN than O
than JJ transvaginal T
transvaginal NNS suspensions T
suspensions , , O
, CC and O
and RB also O
also RBR more O
more JJ efficacious O
efficacious IN than O
than JJ anterior T
anterior NNS repairs T

The DT CAPITAL The O
The NN literature O
literature VBZ suggests O
suggests JJR higher O
higher NN complication O
complication NNS rates O
rates WRB when O
when JJ synthetic O
synthetic NNS materials O
materials VBP are O
are VBN used O
used IN for O
for NNS slings T

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: DT CAPITAL The O
The NN panel O
panel VBN found O
found JJ sufficient O
sufficient JJ acceptable O
acceptable JJ long-term O
long-term NNS outcomes O
outcomes NNS data O
data NN ( O
( RB longer O
longer IN than O
than CD 48 O
48 NNS months O
months NN ) O
) TO to O
to VBP conclude O
conclude IN that O
that JJ surgical T
surgical NN treatment T
treatment IN of O
of JJ female D
female NN stress D
stress JJ urinary D
urinary NN incontinence D
incontinence VBZ is O
is JJ effective O
effective , , O
, VBG offering O
offering DT a O
a JJ long-term O
long-term NN cure O
cure IN in O
in DT a O
a JJ significant O
significant NN percentage O
percentage IN of O
of NNS women O

The DT CAPITAL The O
The NN evidence O
evidence VBZ supports O
supports NN surgery T
surgery IN as O
as JJ initial O
initial NN therapy O
therapy CC and O
and IN as O
as DT a O
a JJ secondary O
secondary NN form O
form IN of O
of NN therapy O
therapy IN after O
after NN failure O
failure IN of O
of JJ other O
other NNS treatments O
treatments IN for O
for NN stress D
stress JJ urinary D
urinary NN incontinence D

Retropubic JJ CAPITAL Retropubic T
Retropubic NNS suspensions T
suspensions CC and O
and NNS slings T
slings VBP are O
are DT the O
the JJS most O
most JJ efficacious O
efficacious NNS procedures O
procedures IN for O
for JJ long-term O
long-term NN success O
success NN ( O
( VBN based O
based IN on O
on NN cure/dry O
cure/dry NNS rates O
rates NN ) O

However RB CAPITAL However O
However , , O
, IN in O
in DT the O
the NN panel O
panel POS 's O
's NN opinion O
opinion JJ retropubic T
retropubic NNS suspensions T
suspensions CC and O
and NN sling T
sling NNS procedures T
procedures VBP are O
are VBN associated O
associated IN with O
with RB slightly O
slightly JJR higher O
higher NN complication O
complication NNS rates O
rates , , O
, VBG including O
including RB longer O
longer NN convalescence O
convalescence CC and O
and JJ postoperative D
postoperative VBG voiding D
voiding NN dysfunction D

A DT CAPITAL A O
A JJ 55-year-old O
55-year-old NN lady O
lady VBD underwent O
underwent NN repeat O
repeat JJ aortic T
aortic NN valve T
valve NN replacement T
replacement VBG using O
using DT a O
a JJ 16-mm O
16-mm NNS CAPITAL Carbomedics O
Carbomedics NN prosthesis O

She PRP CAPITAL She O
She VBN made O
made DT an O
an JJ uneventful O
uneventful JJ postoperative O
postoperative NN recovery O
recovery CC and O
and RB now O
now VBZ leads O
leads DT an O
an JJ unrestricted O
unrestricted NN life O

Doppler NNP CAPITAL Doppler O
Doppler NN echocardiography O
echocardiography VBZ reveals O
reveals DT a O
a JJ 21-mm O
21-mm NN CAPITAL Hg O
Hg NN gradient O
gradient IN across O
across DT the O
the NN valve O
valve IN at O
at NN rest O

This DT CAPITAL This O
This VBD did O
did RB not O
not NN increase O
increase IN with O
with DT an O
an NN infusion O
infusion IN of O
of CD 30 O
30 NN mcg/kg O
mcg/kg IN per O
per NN min O
min IN of O
of NN dobutamine O
dobutamine , , O
, WDT which O
which VBD resulted O
resulted IN in O
in DT an O
an NN increase O
increase IN in O
in DT the O
the JJ cardiac O
cardiac NN output O
output IN from O
from CD 1.96 O
1.96 TO to O
to CD 5.46 O
5.46 JJ l/min O

BACKGROUND NN CAPITAL BACKGROUND O
BACKGROUND : : O
: IN CAPITAL For O
For RBR more O
more IN than O
than CD 30 O
30 NNS years O
years PRP it O
it VBZ has O
has VBN been O
been JJ known O
known IN that O
that JJ gastric O
gastric NN acid O
acid NN secretion O
secretion VBZ is O
is RB inversely O
inversely JJ related O
related TO to O
to DT the O
the NN extent O
extent CC and O
and NN severity O
severity IN of O
of NN corpal D
corpal NN gastritis D

We PRP CAPITAL We O
We RB therefore O
therefore VBN evaluated O
evaluated DT the O
the NN effect O
effect IN of O
of NN cure O
cure IN of O
of NN CAPITAL Helicobacter D
Helicobacter NN pylori D
pylori NN infection D
infection IN on O
on JJ basal O
basal CC and O
and JJ pentagastrin-stimulated O
pentagastrin-stimulated NN acid O
acid NN secretion O

METHODS NNS CAPITAL METHODS O
METHODS : : O
: JJ CAPITAL Basal O
Basal NN acid O
acid NN output O
output NN ( O
( NNP CAPITAL BAO O
BAO NN ) O
) CC and O
and JJ maximal O
maximal NN acid O
acid NN output O
output NN ( O
( NNP CAPITAL MAO O
MAO NN ) O
) VBD were O
were VBN assessed O
assessed IN in O
in CD 11 O
11 NNP CAPITAL H. O
H. JJ pylori-infected O
pylori-infected JJ dyspeptic O
dyspeptic NNS patients O
patients NN ( O
( CD 8 O
8 NNS women O
women CC and O
and CD 3 O
3 NNS men O
men : ; O
; VB mean O
mean NN age O
age , , O
, CD 28 O
28 NNS years O
years NN ) O
) IN before O
before CC and O
and IN after O
after JJ successful O
successful JJ anti-H O

pylori NN pylori O
pylori NN therapy O

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: DT CAPITAL The O
The NN gastritis O
gastritis NN index O
index VBD was O
was RB significantly O
significantly JJR lower O
lower IN after O
after NN therapy O
therapy CC and O
and VBD was O
was VBN associated O
associated IN with O
with DT an O
an NN increase O
increase IN in O
in DT both O
both NNP CAPITAL BAO O
BAO CC and O
and NNP CAPITAL MAO O
MAO IN after O
after NN cure O
cure IN of O
of DT the O
the NN CAPITAL H. D
H. NN pylori D
pylori NN infection D
infection NN ( O
( NNP CAPITAL BAO O
BAO IN from O
from CD 0.3 O
0.3 JJ mmol/h O
mmol/h CC and O
and NNP CAPITAL MAO O
MAO IN from O
from CD 4.8 O
4.8 JJ mmol/h O
mmol/h TO to O
to CD 19 O
19 NN mmol/ O
mmol/ NN h O
h NN ) O

Basal JJ CAPITAL Basal O
Basal CC and O
and VBN stimulated O
stimulated NN acid O
acid NNS concentrations O
concentrations RB also O
also VBN increased O
increased NN ( O
( CD 29.1 O
29.1 CC +/- O
+/- CD 36.6 O
36.6 TO to O
to CD 54 O
54 CC +/- O
+/- CD 31 O
31 NN mmol/l O
mmol/l CC and O
and CD 72.5 O
72.5 CC +/- O
+/- CD 46 O
46 TO to O
to CD 120.1 O
120.1 CC +/- O
+/- CD 30 O
30 NN mmol/l O
mmol/l , , O
, RB respectively O
respectively , , O
, IN for O
for JJ basal O
basal CC and O
and VBN stimulated O
stimulated NN acid O
acid NNS concentrations O
concentrations : ; O
; NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0.05 O
0.05 IN for O
for JJ peak O
peak CC and O
and NNP CAPITAL MAO O
MAO , , O
, NN CAPITAL P O
P JJ = O
= CD 0.07 O
0.07 IN for O
for NNP CAPITAL BAO O
BAO NN ) O

CONCLUSION NN CAPITAL CONCLUSION O
CONCLUSION : : O
: JJ CAPITAL Gastric O
Gastric NN acid O
acid NN secretion O
secretion VBN increased O
increased IN into O
into DT the O
the JJ normal O
normal NN range O
range IN after O
after JJ successful O
successful NN treatment O
treatment IN of O
of NN CAPITAL H. D
H. NN pylori D
pylori NN infection D
infection , , O
, VBG suggesting O
suggesting IN that O
that JJ gastric O
gastric NN function O
function MD can O
can VB recover O
recover TO to O
to JJ normal O
normal CC or O
or RB almost O
almost JJ normal O
normal IN after O
after NN cure O
cure IN of O
of NN CAPITAL H. D
H. NN pylori D
pylori NN infection D

OBJECTIVE NN CAPITAL OBJECTIVE O
OBJECTIVE : : O
: NNS CAPITAL Reports O
Reports VBP suggest O
suggest IN that O
that RB there O
there VBZ is O
is DT an O
an VBN increased O
increased NN incidence O
incidence IN of O
of NN preeclampsia D
preeclampsia IN after O
after DT a O
a RB previously O
previously JJ normal O
normal NN pregnancy O
pregnancy IN if O
if RB there O
there VBZ is O
is DT a O
a NN change O
change IN in O
in NN paternity O

We PRP CAPITAL We O
We VB hypothesize O
hypothesize IN that O
that RB there O
there VBZ is O
is DT a O
a JJR higher O
higher NN incidence O
incidence IN of O
of NN preeclampsia D
preeclampsia NN ( D
( JJ proteinuric D
proteinuric NN hypertension D
hypertension NN ) D
) IN in O
in NNS women O
women VBG conceiving O
conceiving IN by O
by JJ intrauterine O
intrauterine NN insemination O
insemination IN with O
with NN donor O
donor NN sperm O
sperm CC versus O
versus JJ intrauterine O
intrauterine NN insemination O
insemination IN with O
with NN partner O
partner NN sperm O

STUDY NN CAPITAL STUDY O
STUDY NN CAPITAL DESIGN O
DESIGN : : O
: DT CAPITAL This O
This VBD was O
was DT a O
a JJ retrospective O
retrospective NN cohort O
cohort NN study O

In IN CAPITAL In O
In NNS women O
women IN with O
with JJ primary O
primary NN infertility D
infertility DT all O
all NNS pregnancies O
pregnancies VBN achieved O
achieved IN by O
by DT either O
either NN partner O
partner CC or O
or NN donor O
donor JJ intrauterine T
intrauterine NN insemination T
insemination VBD carried O
carried TO to O
to NN birth O
birth IN of O
of DT a O
a NN fetus O
fetus NN ( O
( JJR > O
> CD 20 O
20 NNS weeks O
weeks NN ) O
) VBD were O
were VBN identified O

The DT CAPITAL The O
The JJ medical O
medical NNS records O
records VBD were O
were VBN examined O
examined IN for O
for DT the O
the JJ maternal O
maternal CC and O
and NN pregnancy O
pregnancy NN outcome O
outcome NNS data O

The DT CAPITAL The O
The JJ relative O
relative NN risk O
risk CC and O
and CD 95 O
95 NN % O
% NN confidence O
confidence NN interval O
interval VBD were O
were VBN calculated O
calculated IN for O
for DT the O
the NN risk O
risk IN of O
of NN preeclampsia D

The DT CAPITAL The O
The NN baseline O
baseline NNS data O
data VBD were O
were VBN compared O
compared IN with O
with NN t O
t NNS tests O
tests , , O
, NN chi O
chi CD 2 O
2 NN analysis O
analysis CC and O
and NNP CAPITAL Fisher O
Fisher POS 's O
's JJ exact O
exact NN test O
test WRB where O
where JJ appropriate O

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: CD CAPITAL Forty-four O
Forty-four NNS patients O
patients IN in O
in DT the O
the NN partner O
partner JJ intrauterine T
intrauterine NN insemination T
insemination NN group O
group CC and O
and CD 37 O
37 IN in O
in DT the O
the NN donor T
donor NN insemination T
insemination NN group O
group VBD were O
were VBN identified O
identified IN as O
as VBG having O
having JJ primary O
primary NN infertility D

Three CD CAPITAL Three O
Three NNS cases O
cases IN of O
of JJ mild O
mild NN preeclampsia D
preeclampsia VBD were O
were VBN found O
found IN in O
in DT the O
the NN partner T
partner NN insemination T
insemination NN program O
program CC and O
and CD nine O
nine NNS cases O
cases IN of O
of NN preeclampsia D
preeclampsia NN ( O
( CD five O
five JJ severe O
severe , , O
, CD four O
four JJ mild O
mild NN ) O
) IN in O
in DT the O
the NN donor T
donor NN insemination T
insemination NN program O
program NN ( O
( JJ relative O
relative NN risk O
risk CD 1.85 O
1.85 , , O
, CD 95 O
95 NN % O
% NN confidence O
confidence NN interval O
interval CD 1.20 O
1.20 TO to O
to CD 2.85 O
2.85 NN ) O
) . . O

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: EX CAPITAL There O
There VBZ is O
is DT a O
a JJR higher O
higher NN incidence O
incidence IN of O
of NN preeclampsia D
preeclampsia IN in O
in NNS women O
women VBG conceiving O
conceiving IN by O
by JJ intrauterine T
intrauterine NN insemination T
insemination IN with O
with VBN washed O
washed NN donor O
donor NN sperm O
sperm VBN compared O
compared IN with O
with JJ intrauterine T
intrauterine NN insemination T
insemination IN with O
with VBN washed O
washed NN partner O
partner NN sperm O
sperm . . O

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: EX CAPITAL There O
There VBZ is O
is DT a O
a JJR higher O
higher NN incidence O
incidence IN of O
of NN preeclampsia D
preeclampsia IN in O
in NNS women O
women VBG conceiving O
conceiving IN by O
by JJ intrauterine T
intrauterine NN insemination T
insemination IN with O
with VBN washed O
washed NN donor O
donor NN sperm O
sperm VBN compared O
compared IN with O
with JJ intrauterine T
intrauterine NN insemination T
insemination IN with O
with VBN washed O
washed NN partner O
partner NN sperm O
sperm . . O

This DT CAPITAL This O
This VBZ supports O
supports , , O
, RB indirectly O
indirectly , , O
, DT an O
an JJ immunologic O
immunologic NN basis O
basis IN for O
for NN preeclampsia D

The DT CAPITAL The O
The JJ antigenic O
antigenic NN factor O
factor MD would O
would VB appear O
appear TO to O
to VB be O
be JJ located O
located IN on O
on DT the O
the NN sperm O
sperm IN as O
as VBN opposed O
opposed TO to O
to DT the O
the JJ seminal O
seminal NN fluid O
fluid PRP itself O

After IN CAPITAL After O
After DT a O
a JJ rapid O
rapid NN examination O
examination IN of O
of DT a O
a JJ few O
few JJ basic O
basic NNS concepts O
concepts VBG concerning O
concerning JJ cellular O
cellular VBG aging O
aging CC and O
and VBN programmed O
programmed NN cell O
cell NN death O
death , , O
, DT the O
the VBG aging O
aging IN of O
of DT the O
the NNS tissues O
tissues CC and O
and NNS organs O
organs , , O
, DT the O
the NNS authors O
authors VB discuss O
discuss DT the O
the JJ principal O
principal NNS theories O
theories IN on O
on NN senescence O

They PRP CAPITAL They O
They VB underline O
underline IN that O
that PRP it O
it VBZ is O
is JJ necessary O
necessary TO to O
to VB agree O
agree IN in O
in VBG considering O
considering DT the O
the JJ various O
various JJ genetic O
genetic CC and O
and JJ epigenetic O
epigenetic , , O
, JJ endogenous O
endogenous CC and O
and JJ exogenous O
exogenous NNS mechanisms O
mechanisms IN that O
that JJ lead O
lead TO to O
to DT the O
the JJ complex O
complex VBG aging O
aging NN phenomenon O
phenomenon JJ multiple O
multiple CC and O
and JJ interrelated O

In IN CAPITAL In O
In JJ particular O
particular PRP they O
they NN stress O
stress DT the O
the NN hypothesis O
hypothesis IN that O
that NN senescence O
senescence MD can O
can VB be O
be JJ due O
due TO to O
to DT a O
a NN sum O
sum IN of O
of JJ molecular O
molecular NNS damages O
damages VBN caused O
caused IN by O
by JJ free O
free NNS radicals O
radicals , , O
, CC and O
and TO to O
to DT the O
the NN loss O
loss IN of O
of JJ telomeric O
telomeric NN CAPITAL DNA O

Radical NNP CAPITAL Radical O
Radical NNS reactions O
reactions MD can O
can NN cause O
cause NNS mutations O
mutations , , O
, NN inactivation O
inactivation CC or O
or DT a O
a NN decrease O
decrease IN in O
in DT the O
the NN turnover O
turnover IN of O
of JJ mitochondrial O
mitochondrial NN CAPITAL DNA O
DNA WDT which O
which VBZ is O
is RBR more O
more JJ vulnerable O
vulnerable IN than O
than DT the O
the JJ nuclear O
nuclear NN genoma O
genoma TO to O
to DT the O
the NN attack O
attack IN of O
of JJ mutagenic O
mutagenic NNS agents O
agents , , O
, VBG acting O
acting RB also O
also IN as O
as DT a O
a JJ continuous O
continuous NN source O
source IN of O
of JJ initial O
initial CC and/or O
and/or VBG promoting O
promoting NNS factors O
factors IN of O
of DT the O
the JJ carcinogenetic O
carcinogenetic NN process O

The DT CAPITAL The O
The JJ somatic O
somatic NNS cells O
cells VBN become O
become JJ senescent O
senescent IN because O
because IN during O
during NN cell O
cell NN division O
division , , O
, PRP they O
they VB lose O
lose DT the O
the NNS mechanisms O
mechanisms IN for O
for DT the O
the VBG lengthening O
lengthening IN of O
of DT the O
the NN telomere O

The DT CAPITAL The O
The NN telomerase O
telomerase VBZ prevents O
prevents DT the O
the VBG shortening O
shortening IN of O
of NNS telomeres O
telomeres IN in O
in JJ neoplastic O
neoplastic NNS cells O
cells CC and O
and RB therefore O
therefore VBZ renders O
renders PRP them O
them JJ immortal O

Paradoxically RB CAPITAL Paradoxically O
Paradoxically DT the O
the NN protection O
protection IN of O
of DT the O
the NN telomere O
telomere VBZ is O
is RB exactly O
exactly WDT what O
what MD must O
must VB be O
be VBN avoided O
avoided IN in O
in DT the O
the NN case O
case IN of O
of NN tumor O
tumor NNS cells O

Recently RB CAPITAL Recently O
Recently DT the O
the NN demonstration O
demonstration IN that O
that NN telomerase O
telomerase VBZ is O
is RB not O
not RB always O
always VBN involved O
involved IN in O
in DT the O
the NN restoration O
restoration IN of O
of NN telomere O
telomere NN length O
length NNS shows O
shows DT the O
the NN complexity O
complexity IN of O
of DT the O
the NNS problems O
problems JJ connected O
connected TO to O
to DT the O
the NN cause O
cause IN of O
of NN senescence O

Chromosomally RB CAPITAL Chromosomally O
Chromosomally VBN integrated O
integrated JJ retroviral O
retroviral NN switch O
switch NN ( O
( NN CAPITAL S O
S NN ) O
) NNS substrates O
substrates VB have O
have VBN been O
been VBN developed O
developed TO to O
to VB reveal O
reveal NN switch O
switch JJ recombinase-like O
recombinase-like NNS activities O
activities NN ( O
( NN CAPITAL SRLA O
SRLA NN ) O
) IN in O
in JJ pre-B O
pre-B CC and O
and JJ mature O
mature NN CAPITAL B O
B NN cell O
cell NNS lines O

Switch VB CAPITAL Switch O
Switch JJ substrate O
substrate NNS retrovectors O
retrovectors NN ( O
( NN CAPITAL SSR O
SSR NN ) O
) VB contain O
contain DT a O
a JJ long-terminal O
long-terminal JJ repeat-driven O
repeat-driven NN neomycin O
neomycin NN ( O
( NN CAPITAL Neo O
Neo NN ) O
) NN gene O
gene IN for O
for JJ proviral O
proviral JJ chromosomal O
chromosomal NN maintenance O
maintenance NN ( O
( JJ pre- O
pre- CC and O
and JJ post-S O
post-S NN recombination O
recombination NN ) O
) CC and O
and DT a O
a NN CAPITAL CMV O
CMV JJ promoter-driven O
promoter-driven , , O
, JJ chimeric O
chimeric NN hygromycin-thymidine O
hygromycin-thymidine NN kinase O
kinase NN ( O
( NN CAPITAL Hytk O
Hytk NN ) O
) NN gene O
gene NN ( O
( VBN flanked O
flanked IN by O
by NN CAPITAL S O
S NN mu O
mu CC and O
and NN CAPITAL S O
S NN gamma O
gamma JJ 2b O
2b NN recombination O
recombination NNS targets O
targets NN ) O
) TO to O
to JJ select O
select IN for O
for NN ( O
( NN ganciclovir O
ganciclovir NN ) O
) CC and O
and IN against O
against NN ( O
( NN hygromycin O
hygromycin NN CAPITAL B O
B NN ) O
) NN CAPITAL S O
S NN region O
region NN recombination O

The DT CAPITAL The O
The JJ retro-substrates O
retro-substrates POS ' O
' JJ strong O
strong , , O
, JJ constitutive O
constitutive NNS promoters O
promoters VB ensure O
ensure IN that O
that NNS variations O
variations IN in O
in JJ cellular O
cellular NN switch O
switch NN recombinase O
recombinase NNS activities O
activities VBP are O
are JJ independent O
independent IN of O
of NN CAPITAL S O
S NN region O
region NN accessibility O
accessibility NN control O

By IN CAPITAL By O
By RB initially O
initially VBG selecting O
selecting IN for O
for JJ proviral O
proviral NNS integrants O
integrants IN in O
in NN hygromycin O
hygromycin VBN followed O
followed IN by O
by VBG shifting O
shifting IN into O
into NN neomycin O
neomycin CC + O
+ NN ganciclovir O
ganciclovir TO to O
to JJ select O
select IN for O
for NN CAPITAL S O
S JJ sequence-mediated O
sequence-mediated NNS deletions O
deletions , , O
, NN switch O
switch NNS recombinations O
recombinations MD can O
can VB be O
be RB specifically O
specifically VBN forestalled O
forestalled IN in O
in NN CAPITAL B O
B NN cell O
cell NNS lines O
lines IN whilst O
whilst JJS most O
most JJ switch-incompetent O
switch-incompetent NNS cells O
cells VB do O
do RB not O
not VB survive O
survive JJ secondary O
secondary NN selection O

A DT CAPITAL A O
A JJ qualitative O
qualitative , , O
, JJ direct O
direct NN CAPITAL PCR O
PCR NN assay O
assay VBZ reveals O
reveals IN that O
that NN CAPITAL SSR O
SSR NNS recombinations O
recombinations VBP are O
are JJ stochastic O
stochastic IN in O
in NN CAPITAL B O
B NN cell O
cell NNS lines O
lines VBG generating O
generating DT a O
a NN product O
product NN array O
array JJ akin O
akin TO to O
to JJ natural O
natural NN CAPITAL GH O
GH NN class O
class VBG switching O

A DT CAPITAL A O
A JJ semi-quantitative O
semi-quantitative NN CAPITAL DC-PCR O
DC-PCR NN assay O
assay VBZ detects O
detects DT a O
a JJ significant O
significant NN recombinase O
recombinase NN activity O
activity RB only O
only IN in O
in DT a O
a JJ restricted O
restricted VBN set O
set IN of O
of RB late O
late NN stage O
stage JJ pre-B O
pre-B CC and O
and JJ mature O
mature NN CAPITAL B O
B NN cell O
cell NNS lines O

BCL1B1 NN CAPITAL BCL1B1 O
BCL1B1 JJ mature O
mature NN CAPITAL B O
B NNS cells O
cells VB have O
have DT the O
the JJS highest O
highest NN level O
level IN of O
of NN recombinase O
recombinase NN activity O
activity IN with O
with CD 25 O
25 NN % O
% CC or O
or RBR more O
more IN of O
of JJ proviral O
proviral NNS integrants O
integrants VBG accumulating O
accumulating NN CAPITAL S O
S NN mu/S O
mu/S NN gamma O
gamma JJ 2b O
2b JJ substrate O
substrate NNS recombinations O
recombinations IN within O
within CD 10-14 O
10-14 NN cell O
cell NNS generations O

The DT CAPITAL The O
The NN CAPITAL SSR O
SSR NN recombinase O
recombinase NN assay O
assay MD can O
can VB be O
be VBN performed O
performed IN in O
in DT a O
a JJ transient O
transient NN fashion O
fashion WRB wherein O
wherein JJ extensive O
extensive , , O
, NN CAPITAL B O
B JJ cell-specific O
cell-specific NN recombination O
recombination MD can O
can VB be O
be VBN visualized O
visualized IN within O
within RB only O
only DT a O
a JJ few O
few NN cell O
cell NNS divisions O
divisions NN post O
post JJ proviral O
proviral NN integration O

We PRP CAPITAL We O
We VBP propose O
propose IN that O
that NN switch O
switch NN recombinase O
recombinase NN activity O
activity VBZ becomes O
becomes VBN activated O
activated IN during O
during NN CAPITAL B O
B NN cell O
cell NN ontogeny O
ontogeny JJ independent O
independent IN of O
of CC or O
or RB prior O
prior TO to O
to DT the O
the NN acquisition O
acquisition IN of O
of NN CAPITAL CH O
CH NN locus O
locus NN accessibility O
accessibility CC and O
and IN that O
that JJ endogenous O
endogenous NN CAPITAL S O
S NN segment O
segment VBG targeting O
targeting TO to O
to JJ pre-existing O
pre-existing NN recombinase O
recombinase VBZ requires O
requires DT a O
a NN level O
level IN of O
of NN accessibility O
accessibility IN beyond O
beyond JJ transcriptional O
transcriptional NN activation O

OBJECTIVE NN CAPITAL OBJECTIVE O
OBJECTIVE : : O
: TO CAPITAL To O
To VB determine O
determine DT the O
the NN prevalence O
prevalence IN of O
of JJ illicit O
illicit NN drug O
drug NN abuse O
abuse CC and O
and NN alcohol O
alcohol NN use O
use IN in O
in DT an O
an JJ obstetric O
obstetric NN population O
population VBN based O
based IN in O
in DT an O
an JJ urban O
urban NN maternity O
maternity NN hospital O

SETTING VBG CAPITAL SETTING O
SETTING : : O
: DT CAPITAL A O
A JJ collaborative O
collaborative NN study O
study IN between O
between DT the O
the NN CAPITAL Rotunda O
Rotunda NNP CAPITAL Hospital O
Hospital , , O
, NNP CAPITAL Dublin O
Dublin CC and O
and DT the O
the JJ CAPITAL Irish O
Irish NNP CAPITAL National O
National NN CAPITAL Drug O
Drug NNP CAPITAL Advisory O
Advisory CC & O
& # # O
# CD 38 O
38 : ; O
; NN CAPITAL Treatment O
Treatment NNP CAPITAL Centre O

DESIGN NN CAPITAL DESIGN O
DESIGN : : O
: DT CAPITAL A O
A JJ prospective O
prospective NN study O
study VBG consisting O
consisting IN of O
of JJ anonymous O
anonymous , , O
, JJ unlinked O
unlinked NN urine O
urine NN testing O
testing IN of O
of CD 504 O
504 JJ 'first O
'first NN visit O
visit POS ' O
' JJ antenatal O
antenatal NNS patients O
patients CC and O
and DT a O
a JJ separate O
separate NN group O
group IN of O
of CD 515 O
515 NNS patients O
patients CD six O
six NNS weeks O
weeks IN after O
after NN delivery O

METHODS NNS CAPITAL METHODS O
METHODS CC & O
& # # O
# CD 38 O
38 : ; O
; NN CAPITAL OUTCOME O
OUTCOME NNS CAPITAL MEASURES O
MEASURES : : O
: JJ CAPITAL Toxicological O
Toxicological VBG screening O
screening VBG using O
using JJ enzyme-linked O
enzyme-linked NN immunoassay O
immunoassay NNS techniques O
techniques , , O
, IN with O
with DT all O
all JJ positive O
positive NNS samples O
samples VBG being O
being VBN reanalysed O

Drug NN CAPITAL Drug O
Drug NNS histories O
histories VBD were O
were VBN taken O
taken CC and O
and NNS samples O
samples VBD were O
were VBN tested O
tested IN for O
for NN alcohol O
alcohol CC and O
and CD six O
six IN of O
of DT the O
the JJS most O
most RB commonly O
commonly JJ abused O
abused NNS drugs O

The DT CAPITAL The O
The JJ pre- O
pre- CC and O
and JJ postnatal O
postnatal NN prevalence O
prevalence IN of O
of NN abuse O
abuse VBD was O
was VBN matched O
matched IN with O
with JJ demographic O
demographic NNS data O

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: DT CAPITAL The O
The NN prevalence O
prevalence IN of O
of NN chemical O
chemical NN substance O
substance NN misuse O
misuse IN in O
in DT the O
the JJ antenatal O
antenatal NN population O
population VBD was O
was CD 2.8 O
2.8 NN % O
% CC and O
and CD 5.6 O
5.6 NN % O
% IN in O
in DT the O
the JJ postnatal O
postnatal NN population O

Substances NNS CAPITAL Substances O
Substances VBN identified O
identified VBN included O
included NNS benzodiazepines O
benzodiazepines , , O
, NN cannabis O
cannabis , , O
, NNS amphetamines O
amphetamines , , O
, NNS opiates O
opiates CC and O
and NN cocaine O

Less RBR CAPITAL Less O
Less IN than O
than CD 2 O
2 NN % O
% IN of O
of NNS samples O
samples VBN tested O
tested JJ positive O
positive IN for O
for NN alcohol O

None NN CAPITAL None O
None IN of O
of DT the O
the NNS women O
women VBG yielding O
yielding JJ positive O
positive NNS samples O
samples VBD had O
had VBN been O
been JJ pre-identified O
pre-identified IN on O
on DT the O
the NN basis O
basis IN of O
of NN history O

A DT CAPITAL A O
A JJ significant O
significant NN proportion O
proportion IN of O
of DT the O
the NNS women O
women VBD were O
were IN in O
in DT the O
the JJ high O
high NN risk O
risk NNS categories O
categories IN with O
with NN regard O
regard TO to O
to NN age O
age CC and O
and JJ socio-economic O
socio-economic NN status O

CONCLUSION NN CAPITAL CONCLUSION O
CONCLUSION : : O
: DT CAPITAL The O
The NN prevalence O
prevalence IN of O
of NN drug O
drug NN misuse O
misuse RB antenatally O
antenatally VBD was O
was RB nearly O
nearly CD 3 O
3 NN % O
% CC and O
and RB postnatally O
postnatally RB almost O
almost CD 6 O
6 NN % O

Substance NN CAPITAL Substance O
Substance NNS abusers O
abusers IN in O
in NN pregnancy O
pregnancy VBP are O
are RBR more O
more JJ likely O
likely TO to O
to VB be O
be JJ single O
single , , O
, JJ unemployed O
unemployed , , O
, CC and O
and TO to O
to VB have O
have VBD had O
had DT a O
a JJ previous O
previous NN pregnancy O

Schizophrenic JJ CAPITAL Schizophrenic D
Schizophrenic NNS illnesses D
illnesses VB occur O
occur IN with O
with RB approximately O
approximately DT the O
the JJ same O
same NN incidence O
incidence IN in O
in DT all O
all JJ human O
human NNS populations O
populations IN with O
with DT a O
a JJ characteristic O
characteristic NN distribution O
distribution NN ( O
( RB slightly O
slightly JJR earlier O
earlier IN in O
in NNS males O
males NN ) O
) IN of O
of NNS ages O
ages IN of O
of NN onset O

Given VBN CAPITAL Given O
Given IN that O
that DT the O
the NN predisposition O
predisposition NN ( O
( WDT which O
which RB presumably O
presumably VBZ is O
is JJ genetic O
genetic NN ) O
) VBZ is O
is VBN associated O
associated IN with O
with DT a O
a JJ procreative O
procreative NN disadvantage O
disadvantage WRB why O
why VB do O
do JJ such O
such NNS illnesses O
illnesses VB persist O
persist . ? O
? RB CAPITAL Here O
Here PRP it O
it VBZ is O
is VBN suggested O
suggested IN that O
that DT these O
these NNS conditions O
conditions VBP are O
are DT a O
a NN manifestation O
manifestation IN of O
of JJ genetic O
genetic NN diversity O
diversity IN in O
in DT the O
the NN evolution O
evolution IN of O
of DT the O
the RB specifically O
specifically JJ human O
human JJ characteristic O
characteristic IN of O
of NN language O
language , , O
, DT an O
an NN innovation O
innovation IN that O
that VBZ has O
has VBD occurred O
occurred IN by O
by DT a O
a NN process O
process IN of O
of JJ progressive O
progressive JJ hemispheric O
hemispheric JJ specialization-the O
specialization-the NN establishment O
establishment IN of O
of NN dominance O
dominance IN for O
for DT some O
some JJ critical O
critical NN component O
component IN of O
of NN language O
language IN in O
in CD one O
one CC or O
or DT the O
the JJ other O
other NN hemisphere O

Individuals NNS CAPITAL Individuals O
Individuals WP who O
who VB develop O
develop JJ schizophrenic D
schizophrenic NNS symptoms D
symptoms NN show O
show JJR lesser O
lesser JJ anatomical O
anatomical CC and O
and JJ functional O
functional NNS asymmetries O
asymmetries IN than O
than DT the O
the NN population O
population IN as O
as DT a O
a JJ whole O
whole : ; O
; JJ such O
such NNS symptoms O
symptoms MD may O
may VB reflect O
reflect NN 'dominance O
'dominance NN failure O
failure POS ' O
' IN for O
for NN language O

Cloacal JJ CAPITAL Cloacal D
Cloacal NNS anomalies D
anomalies VBP are O
are RB extremely O
extremely JJ rare O
rare CC and O
and VB have O
have JJ variable O
variable NNS presentations O

Prenatal JJ CAPITAL Prenatal O
Prenatal NN diagnosis O
diagnosis MD can O
can VB be O
be JJ difficult O
difficult RB especially O
especially IN if O
if PRP they O
they JJ present O
present IN in O
in RB late O
late JJ gestation O

Here RB CAPITAL Here O
Here PRP we O
we JJ present O
present CD two O
two NNS cases O
cases VBN diagnosed O
diagnosed IN in O
in DT the O
the RB late O
late JJ third O
third NN trimester O
trimester CC and O
and NN review O
review DT the O
the NN literature O
literature VBG regarding O
regarding JJ prenatal O
prenatal NN diagnosis O
diagnosis IN of O
of JJ cloacal D
cloacal NNS anomalies D

OBJECTIVE NN CAPITAL OBJECTIVE O
OBJECTIVE : : O
: TO CAPITAL To O
To VB determine O
determine IN whether O
whether NNS patients O
patients IN with O
with JJ myocardial D
myocardial NN amyloidosis D
amyloidosis JJ due O
due DT either O
either TO to O
to NNP CAPITAL AL O
AL NN ( O
( JJ primary O
primary NN ) O
) NN amyloid O
amyloid CC or O
or JJ familial O
familial NN amyloid O
amyloid VB have O
have VBG distinguishing O
distinguishing JJ echocardiographic O
echocardiographic CC or O
or JJ electrocardiographic O
electrocardiographic NNS features O
features : ; O
; CC and O
and TO to O
to VB compare O
compare DT the O
the NN prevalence O
prevalence IN of O
of NN heart D
heart NN failure D
failure CC and O
and NN survival O
survival IN in O
in DT the O
the CD two O
two NNS types O
types IN of O
of NN amyloidosis D
amyloidosis IN in O
in NN relation O
relation TO to O
to JJ echocardiographic O
echocardiographic NNS findings O

DESIGN NN CAPITAL DESIGN O
DESIGN : : O
: VBN CAPITAL Blinded O
Blinded NN group O
group NN comparison O
comparison IN of O
of RB randomly O
randomly VBN selected O
selected NNS cases O
cases IN of O
of JJ cardiac D
cardiac NN amyloidosis D

SETTING VBG CAPITAL SETTING O
SETTING : : O
: NNP CAPITAL International O
International NN referral O
referral NN centre O
centre IN for O
for NN amyloid O
amyloid NN research O
research CC and O
and NN treatment O

PATIENTS NNS CAPITAL PATIENTS O
PATIENTS : : O
: CD 36 O
36 NNS patients O
patients IN with O
with JJ cardiac D
cardiac NN amyloid D
amyloid NN heart D
heart NN disease D
disease , , O
, IN of O
of WP whom O
whom CD 12 O
12 VBD had O
had JJ familial O
familial CC and O
and CD 24 O
24 VBD had O
had JJ primary O
primary NNP CAPITAL AL O
AL NN amyloidosis D

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: JJ CAPITAL Familial O
Familial CC and O
and NNP CAPITAL AL O
AL NNS echocardiograms O
echocardiograms VBD were O
were RB morphologically O
morphologically JJ indistinguishable O
indistinguishable , , O
, IN with O
with JJ similar O
similar RB left O
left JJ ventricular O
ventricular NN wall O
wall NN thickness O
thickness , , O
, VB mean O
mean NN ( O
( NN CAPITAL SD O
SD NN ) O
) CD 15.4 O
15.4 NN ( O
( CD 2.3 O
2.3 NN ) O
) NN nu O
nu CD 15.8 O
15.8 NN ( O
( CD 2.5 O
2.5 NN ) O
) NN mm O
mm , , O
, RB respectively O
respectively : ; O
; RB right O
right JJ ventricular O
ventricular NN wall O
wall NN thickness O
thickness VBD was O
was RB also O
also JJ similar O
similar IN between O
between NN amyloid O
amyloid NNS types O
types : : O
: CD 9.6 O
9.6 NN ( O
( CD 2.8 O
2.8 NN ) O
) NN nu O
nu CD 9.7 O
9.7 NN ( O
( CD 6.5 O
6.5 NN ) O
) NN mm O
mm , , O
, RB respectively O

Doppler NNP CAPITAL Doppler O
Doppler NNS indices O
indices IN of O
of RB left O
left CC and O
and RB right O
right JJ ventricular O
ventricular NN function O
function , , O
, RB left O
left JJ ventricular O
ventricular NN volume O
volume , , O
, CC and O
and NN ejection O
ejection NN fraction O
fraction VBD were O
were RB also O
also JJ similar O

Low JJ CAPITAL Low O
Low NN voltage O
voltage NN electrocardiograms O
electrocardiograms NN ( O
( CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0.5 O
0.5 NN mV O
mV NN ) O
) VBD were O
were RBR more O
more JJ common O
common IN in O
in DT the O
the NNP CAPITAL AL O
AL NN ( O
( CD 16/24 O
16/24 , , O
, CD 67 O
67 NN % O
% NN ) O
) IN than O
than IN in O
in DT the O
the JJ familial O
familial NN group O
group NN ( O
( CD 4/12 O
4/12 , , O
, CD 25 O
25 NN % O
% NN ) O
) , , O
, NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0.05 O

The DT CAPITAL The O
The CD one O
one NN year O
year NN survival O
survival IN for O
for JJ familial O
familial CC and O
and NNP CAPITAL AL O
AL NNS forms O
forms VBD was O
was CD 92 O
92 NN % O
% NN ( O
( CD 11/12 O
11/12 NN ) O
) NN nu O
nu CD 38 O
38 NN % O
% NN ( O
( CD 6/24 O
6/24 NN ) O
) , , O
, RB respectively O
respectively , , O
, IN with O
with RB virtually O
virtually DT all O
all NNS deaths O
deaths JJ due O
due TO to O
to JJ cardiac O
cardiac NNS causes O

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: IN CAPITAL Although O
Although JJ cardiac O
cardiac NN involvement O
involvement VBZ is O
is RB echocardiographically O
echocardiographically JJ indistinguishable O
indistinguishable , , O
, JJ cardiac O
cardiac NN mortality O
mortality VBZ is O
is RB very O
very JJ different O
different IN between O
between DT the O
the CD two O
two NNS forms O
forms IN of O
of NN amyloidosis D

Preservation NN CAPITAL Preservation O
Preservation IN of O
of JJ electrocardiographic O
electrocardiographic NN voltage O
voltage IN in O
in JJ familial O
familial NN amyloidosis D
amyloidosis VBZ suggests O
suggests IN that O
that DT the O
the JJ particular O
particular JJ biochemical O
biochemical NNS characteristics O
characteristics IN of O
of JJ distinct O
distinct NNS types O
types IN of O
of NN amyloid O
amyloid NN fibril O
fibril VB have O
have JJ different O
different JJ pathological O
pathological NNS effects O
effects IN on O
on DT the O
the NN myocardium O

This DT CAPITAL This O
This NN distinction O
distinction VBZ becomes O
becomes JJ critical O
critical IN in O
in DT the O
the NN evaluation O
evaluation , , O
, NN treatment O
treatment , , O
, CC and O
and NN management O
management IN of O
of NNS patients O
patients WP who O
who VB have O
have DT a O
a NN diagnosis O
diagnosis IN within O
within DT the O
the NN spectrum O
spectrum IN of O
of DT the O
the NN protein D
protein NN deposition D
deposition NNS diseases D

OBJECTIVE NN CAPITAL OBJECTIVE O
OBJECTIVE : : O
: TO CAPITAL To O
To VB examine O
examine DT the O
the NN relationship O
relationship IN between O
between NN plasma O
plasma NN plasminogen O
plasminogen NN activator O
activator NN inhibitor O
inhibitor CD 1 O
1 NN ( O
( NN CAPITAL PAI-1 O
PAI-1 NN ) O
) NN activity O
activity CC and O
and NN CAPITAL PAI-1 O
PAI-1 NN gene O
gene NN ( O
( NN 4G/5G O
4G/5G NN ) O
) NN polymorphism O
polymorphism CC and O
and JJ diabetic D
diabetic NN retinopathy D
retinopathy IN in O
in NNP CAPITAL Pima O
Pima NNPS CAPITAL Indians O
Indians IN with O
with NN type O
type CD 2 O
2 NN diabetes D

RESEARCH NN CAPITAL RESEARCH O
RESEARCH NN CAPITAL DESIGN O
DESIGN CC CAPITAL AND O
AND NNS CAPITAL METHODS O
METHODS : : O
: PRP CAPITAL We O
We VBN studied O
studied CD 171 O
171 NNP CAPITAL Pima O
Pima NNPS CAPITAL Indians O
Indians IN with O
with NN type O
type CD 2 O
2 NN diabetes D
diabetes IN between O
between DT the O
the NNS ages O
ages IN of O
of CD 30-70 O
30-70 NNS years O
years IN in O
in DT a O
a JJ population-based O
population-based JJ epidemiological O
epidemiological NN survey O

Plasma NN CAPITAL Plasma O
Plasma NN CAPITAL PAI-1 O
PAI-1 NN activity O
activity VBD was O
was VBN measured O
measured IN by O
by DT a O
a JJ spectrophotometric O
spectrophotometric NN assay O
assay CC and O
and NN CAPITAL PAI-1 O
PAI-1 NN 4G/5G O
4G/5G NN promoter O
promoter NN genotype O
genotype IN by O
by DT the O
the NN polymerase O
polymerase NN chain O
chain NN reaction O
reaction NN ( O
( NN CAPITAL PCR O
PCR NN ) O
) VBG using O
using JJ allele-specific O
allele-specific NNS primers O

Retinopathy NN CAPITAL Retinopathy D
Retinopathy VBD was O
was VBN assessed O
assessed IN by O
by JJ ophthalmoscopy O
ophthalmoscopy IN after O
after JJ pupillary O
pupillary NN dilation O
dilation CC and O
and VBN classified O
classified IN as O
as DT any O
any NN retinopathy D
retinopathy CC or O
or IN as O
as JJ nonproliferative O
nonproliferative CC and O
and JJ proliferative O

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: NN CAPITAL Retinopathy D
Retinopathy VBD was O
was JJ present O
present IN in O
in CD 70 O
70 NN ( O
( CD 41 O
41 NN % O
% NN ) O
) NNS subjects O
subjects , , O
, CC and O
and CD 4 O
4 NN ( O
( CD 2.3 O
2.3 NN % O
% NN ) O
) NNS subjects O
subjects VBD had O
had JJ proliferative O
proliferative NN retinopathy D

Plasma NN CAPITAL Plasma O
Plasma NN CAPITAL PAI-1 O
PAI-1 NN activity O
activity VBD was O
was RB not O
not RB significantly O
significantly JJ different O
different IN among O
among NNS subjects O
subjects IN with O
with CC and O
and IN without O
without NN retinopathy D
retinopathy NN ( O
( CD 17.1 O
17.1 CC +/- O
+/- CC vs. O
vs. CD 19.7 O
19.7 CC +/- O
+/- CD 9.1 O
9.1 JJ arbitrary O
arbitrary NNS units O
units NN ( O
( NN CAPITAL AU O
AU NN ) O
) NN /ml O
/ml , , O
, NN CAPITAL P O
P JJ = O
= CD 0.09 O
0.09 NN ) O

PAI-1 NN CAPITAL PAI-1 O
PAI-1 NN activity O
activity VBD was O
was RB negatively O
negatively VBD correlated O
correlated IN with O
with NN duration O
duration IN of O
of NN diabetes D
diabetes NN ( O
( NNS rs O
rs JJ = O
= CD -0.18 O
-0.18 , , O
, NN CAPITAL P O
P JJ = O
= CD 0.02 O
0.02 NN ) O

In IN CAPITAL In O
In DT a O
a JJ logistic O
logistic NN regression O
regression NN analysis O
analysis JJ controlled O
controlled IN for O
for NN age O
age , , O
, NN sex O
sex , , O
, NN CAPITAL BMI O
BMI , , O
, CC and O
and NN duration O
duration IN of O
of NN diabetes D
diabetes , , O
, DT any O
any NN retinopathy D
retinopathy VBD was O
was RB significantly O
significantly VBN associated O
associated IN with O
with VBG fasting O
fasting NN plasma O
plasma NN glucose O
glucose NNS concentrations O
concentrations NN ( O
( NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0.05 O
0.05 NN ) O
) , , O
, JJ 2-h O
2-h NN postload O
postload NN glucose O
glucose NN ( O
( NN CAPITAL P O
P JJ = O
= CD 0.02 O
0.02 NN ) O
) , , O
, CC and O
and NN CAPITAL HbA1c O
HbA1c NN ( O
( NN CAPITAL P O
P JJ = O
= CD 0.008 O
0.008 NN ) O
) , , O
, CC but O
but RB not O
not IN with O
with NN CAPITAL PAI-1 O
PAI-1 NN activity O
activity NN ( O
( NN CAPITAL P O
P JJ = O
= CD 0.48 O
0.48 NN ) O

The DT CAPITAL The O
The NN prevalence O
prevalence IN of O
of NN retinopathy D
retinopathy IN in O
in DT the O
the CD three O
three NN genotype O
genotype NNS groups O
groups VBN differed O
differed RB significantly O
significantly NN ( O
( NN 4G/4G O
4G/4G , , O
, NN 4G/5G O
4G/5G , , O
, CC and O
and NN 5G/5G O
5G/5G VBD were O
were CD 44 O
44 , , O
, CD 49 O
49 , , O
, CC and O
and CD 24 O
24 NN % O
% , , O
, RB respectively O
respectively : ; O
; NN chi O
chi CD 2 O
2 JJ = O
= CD 8.22 O
8.22 , , O
, NN df O
df JJ = O
= CD 2 O
2 , , O
, NN CAPITAL P O
P JJ = O
= CD 0.016 O
0.016 NN ) O
) CC and O
and VBD remained O
remained JJ significant O
significant IN after O
after VBG controlling O
controlling IN for O
for NN age O
age , , O
, NN sex O
sex , , O
, NN CAPITAL BMI O
BMI , , O
, NN duration O
duration IN of O
of NN diabetes D
diabetes , , O
, VBN glycated O
glycated NN hemoglobin O
hemoglobin , , O
, CC and O
and NN urine O
urine JJ albumin-to-creatine O
albumin-to-creatine NN ratio O
ratio IN in O
in DT a O
a JJ logistic O
logistic NN regression O
regression NN analysis O

The DT CAPITAL The O
The NNS odds O
odds NNS ratios O
ratios IN for O
for NN retinopathy D
retinopathy IN in O
in NNS subjects O
subjects IN with O
with NN 4G/4G O
4G/4G CC and O
and NN 4G/5G O
4G/5G , , O
, VBN compared O
compared IN with O
with DT the O
the NN 5G/5G O
5G/5G NN genotype O
genotype , , O
, VBD were O
were CD 2.0 O
2.0 CC and O
and CD 3.1 O
3.1 , , O
, RB respectively O

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: IN CAPITAL Although O
Although JJ diabetic D
diabetic NN retinopathy D
retinopathy IN in O
in NNP CAPITAL Pima O
Pima NNPS CAPITAL Indians O
Indians IN with O
with NN type O
type CD 2 O
2 NN diabetes D
diabetes VBZ is O
is RB not O
not VBN associated O
associated IN with O
with NN CAPITAL PAI-1 O
PAI-1 NN activity O
activity , , O
, NNS subjects O
subjects IN with O
with DT the O
the NN 4G/4G O
4G/4G CC and O
and NN 4G/5G O
4G/5G NN genotype O
genotype VBD had O
had DT a O
a JJR higher O
higher NN prevalence O
prevalence IN of O
of NN retinopathy D
retinopathy VBN compared O
compared IN with O
with NN 5G/5G O
5G/5G JJ CAPITAL PAI-1genotype O

These DT CAPITAL These O
These JJ preliminary O
preliminary NNS findings O
findings VBP indicate O
indicate IN that O
that IN in O
in NNP CAPITAL Pima O
Pima NNPS CAPITAL Indians O
Indians IN with O
with NN type O
type CD 2 O
2 NN diabetes D
diabetes , , O
, NN presence O
presence IN of O
of DT the O
the NN 4G O
4G NN allele O
allele IN of O
of DT the O
the NN CAPITAL PAI-1 O
PAI-1 NN gene O
gene VBD was O
was VBN associated O
associated IN with O
with DT a O
a JJR higher O
higher NN risk O
risk IN of O
of JJ diabetic D
diabetic NN retinopathy D

BACKGROUND NN CAPITAL BACKGROUND O
BACKGROUND : : O
: JJ CAPITAL Diagnostic O
Diagnostic JJ peritoneal O
peritoneal NN lavage O
lavage NN ( O
( NNP CAPITAL DPL O
DPL NN ) O
) VBZ is O
is VBN used O
used TO to O
to VB diagnose O
diagnose JJ intra-abdominal D
intra-abdominal NN injury D
injury IN in O
in NNS patients O
patients IN with O
with NN stab D
stab NNS wounds D
wounds CC and O
and JJ blunt D
blunt NN trauma D

Because IN CAPITAL Because O
Because JJ exploratory T
exploratory JJ celiotomy T
celiotomy VBZ is O
is RB routinely O
routinely VBN performed O
performed IN on O
on NNS patients O
patients IN with O
with NN gunshot D
gunshot NNS wounds D
wounds TO to D
to DT the D
the NN abdomen D
abdomen , , O
, NNP CAPITAL DPL O
DPL VBZ is O
is RB rarely O
rarely VBN employed O

However RB CAPITAL However O
However , , O
, JJ several O
several NNS studies O
studies VB have O
have VBD questioned O
questioned JJ routine O
routine NN exploration O
exploration CC and O
and VB have O
have VBN drawn O
drawn NN attention O
attention TO to O
to DT the O
the VBN associated O
associated NN morbidity O
morbidity IN of O
of JJ negative O
negative NN celiotomy O

Diagnostic JJ CAPITAL Diagnostic O
Diagnostic JJ peritoneal O
peritoneal NN lavage O
lavage VBZ is O
is DT an O
an RB easily O
easily VBN performed O
performed CC and O
and JJ inexpensive O
inexpensive NN test O
test IN that O
that MD may O
may VB be O
be JJ useful O
useful IN in O
in DT this O
this NN situation O

OBJECTIVE NN CAPITAL OBJECTIVE O
OBJECTIVE : : O
: TO CAPITAL To O
To VB evaluate O
evaluate DT the O
the NN performance O
performance IN of O
of NNP CAPITAL DPL O
DPL IN in O
in DT the O
the NN diagnosis O
diagnosis IN of O
of JJ intra-abdominal D
intra-abdominal NN injury D
injury IN in O
in RB hemodynamically O
hemodynamically JJ stable O
stable NNS patients O
patients IN with O
with NN gunshot D
gunshot NNS wounds D
wounds TO to O
to DT the O
the NN abdomen O

DESIGN NN CAPITAL DESIGN O
DESIGN : : O
: DT CAPITAL A O
A JJ prospective O
prospective JJ clinical O
clinical NN trial O

SETTING VBG CAPITAL SETTING O
SETTING : : O
: CD CAPITAL Two O
Two JJ urban O
urban NN trauma O
trauma NNS centers O

PATIENTS NNS CAPITAL PATIENTS O
PATIENTS : : O
: NNS CAPITAL Patients O
Patients IN with O
with NN gunshot D
gunshot NNS wounds D
wounds TO to O
to DT the O
the NN abdomen O
abdomen CC and O
and DT a O
a JJ systolic O
systolic NN blood O
blood NN pressure O
pressure IN of O
of IN at O
at JJS least O
least CD 90 O
90 NN mm O
mm NN CAPITAL Hg O

INTERVENTIONS NNS CAPITAL INTERVENTIONS O
INTERVENTIONS : : O
: JJ CAPITAL Clinical O
Clinical NN predication O
predication IN of O
of JJ intra-abdominal D
intra-abdominal NN injury D
injury IN in O
in DT the O
the NN emergency O
emergency NN department O
department CC and O
and NNP CAPITAL DPL O
DPL VBN performed O
performed IN in O
in DT the O
the VBG operating O
operating NN room O
room IN before O
before DT the O
the NN initiation O
initiation IN of O
of NN celiotomy O

Injuries NNS CAPITAL Injuries O
Injuries VBN found O
found IN during O
during DT the O
the NN celiotomy O
celiotomy VBD were O
were VBN recorded O

MAIN JJS CAPITAL MAIN O
MAIN NN CAPITAL OUTCOME O
OUTCOME NNS CAPITAL MEASURES O
MEASURES : : O
: DT CAPITAL The O
The NNS results O
results IN of O
of DT the O
the JJ clinical O
clinical NN evaluation O
evaluation CC and O
and NNP CAPITAL DPL O
DPL VBD were O
were VBN compared O
compared IN with O
with DT the O
the NNS findings O
findings IN of O
of DT the O
the NN celiotomy O

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: CD CAPITAL Forty-four O
Forty-four NNS patients O
patients VBD were O
were VBN enrolled O
enrolled IN into O
into DT the O
the NN study O

Intra-abdominal JJ CAPITAL Intra-abdominal D
Intra-abdominal NN injury D
injury VBD was O
was JJ present O
present IN in O
in CD 32 O
32 NN ( O
( CD 73 O
73 NN % O
% NN ) O
) IN of O
of DT these O
these NNS patients O

The DT CAPITAL The O
The JJ senior O
senior NN surgery O
surgery JJ resident O
resident RB correctly O
correctly VBN predicted O
predicted DT the O
the NN presence O
presence IN of O
of JJ intra-abdominal D
intra-abdominal NN injury D
injury IN in O
in CD 36 O
36 NN ( O
( CD 82 O
82 NN % O
% NN ) O
) IN of O
of DT the O
the NNS patients O
patients NN ( O
( NN sensitivity O
sensitivity JJ = O
= CD 90.0 O
90.0 NN % O
% , , O
, NN specificity O
specificity JJ = O
= CD 58.3 O
58.3 NN % O
% , , O
, JJ positive O
positive JJ predictive O
predictive NN value O
value JJ = O
= CD 85.3 O
85.3 NN % O
% , , O
, JJ negative O
negative JJ predictive O
predictive NN value O
value JJ = O
= CD 63.6 O
63.6 NN % O
% , , O
, NN phi O
phi JJ = O
= CD 0.52 O
0.52 , , O
, NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD .01 O
.01 NN ) O
) IN in O
in DT the O
the NN emergency O
emergency NN department O
department IN before O
before NNP CAPITAL DPL O
DPL CC and O
and NN celiotomy O
celiotomy VBD were O
were VBN performed O

Diagnostic JJ CAPITAL Diagnostic O
Diagnostic JJ peritoneal O
peritoneal NN lavage O
lavage RB correctly O
correctly VBN identified O
identified DT the O
the NN presence O
presence CC or O
or NN absence O
absence IN of O
of JJ intra-abdominal D
intra-abdominal NN injury D
injury IN in O
in CD 40 O
40 NN ( O
( CD 91 O
91 NN % O
% NN ) O
) IN of O
of DT the O
the NNS patients O
patients NN ( O
( JJ positive O
positive JJ predictive O
predictive NN value O
value JJ = O
= CD 96.7 O
96.7 NN % O
% , , O
, JJ negative O
negative JJ predictive O
predictive NN value O
value JJ = O
= CD 78.6 O
78.6 NN % O
% , , O
, NN phi O
phi JJ = O
= CD 0.79 O
0.79 , , O
, NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD .01 O
.01 NN ) O

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: JJ CAPITAL Clinical O
Clinical NN judgment O
judgment VBZ is O
is RB highly O
highly JJ accurate O
accurate IN in O
in VBG separating O
separating NNS patients O
patients IN with O
with JJ tangential O
tangential NN gunshot D
gunshot NNS wounds D
wounds TO to O
to DT the O
the NN abdomen O
abdomen IN from O
from DT those O
those IN with O
with JJ intra-abdominal D
intra-abdominal NN injury D
injury CC but O
but MD may O
may VB miss O
miss NNS patients O
patients IN with O
with JJ intra-abdominal D
intra-abdominal NN hemorrhage D

Diagnostic JJ CAPITAL Diagnostic O
Diagnostic JJ peritoneal O
peritoneal NN lavage O
lavage VBZ is O
is RB highly O
highly JJ predictive O
predictive IN of O
of DT the O
the NN presence O
presence IN of O
of JJ intra-abdominal D
intra-abdominal NN injury D

The DT CAPITAL The O
The NN return O
return IN of O
of JJ gross O
gross NN blood O
blood IN on O
on NN aspiration O
aspiration CC or O
or DT a O
a NN lavage O
lavage JJ red O
red NN blood O
blood NN cell O
cell NN count O
count JJR greater O
greater IN than O
than CD 10 O
10 CC x O
x CD 10 O
10 NN ( O
( CD 9 O
9 NN ) O
) NN /L O
/L MD should O
should JJ prompt O
prompt DT an O
an JJ urgent O
urgent NN celiotomy O

Missed VBN CAPITAL Missed O
Missed NNS injuries O
injuries VBP are O
are JJ rare O
rare CC and O
and JJS most O
most JJ likely O
likely TO to O
to VB be O
be NN bowel D
bowel NNS perforations D

Diagnostic JJ CAPITAL Diagnostic O
Diagnostic JJ peritoneal O
peritoneal NN lavage O
lavage VBZ is O
is DT an O
an JJ objective O
objective NN test O
test IN that O
that MD may O
may VBP augment O
augment JJ clinical O
clinical NN judgment O
judgment IN in O
in VBG selecting O
selecting RB hemodynamically O
hemodynamically JJ stable O
stable NNS patients O
patients IN with O
with JJ potential O
potential JJ tangential O
tangential NN gunshot D
gunshot NNS wounds D
wounds IN for O
for NN observation O
observation CC and O
and VBZ is O
is RB especially O
especially JJ useful O
useful IN in O
in VBG identifying O
identifying JJ intra-abdominal D
intra-abdominal NN hemorrhage D

BACKGROUND NN CAPITAL BACKGROUND O
BACKGROUND : : O
: TO CAPITAL To O
To VB evaluate O
evaluate DT the O
the NN frequency O
frequency IN of O
of NN CAPITAL Blastocystis D
Blastocystis NN hominis D
hominis NN parasitation D
parasitation CC and O
and TO to O
to VB ascertain O
ascertain PRP$ its O
its NN role O
role IN as O
as DT an O
an JJ intestinal O
intestinal DT a O
a JJ prospective O
prospective NN study O
study IN during O
during CD 18 O
18 NNS months O
months NN pathogen O
pathogen VBZ has O
has VBN been O
been VBD carried O
carried IN out O

SUBJECTS NNS CAPITAL SUBJECTS O
SUBJECTS CC CAPITAL AND O
AND NNS CAPITAL METHODS O
METHODS : : O
: DT CAPITAL The O
The NN study O
study VBN included O
included CD 2 O
2 , , O
, CD 039 O
039 NNS patients O
patients , , O
, WDT which O
which VBD were O
were VBN classified O
classified IN in O
in CD three O
three NNS groups O
groups NN ( O
( JJ asymptomatic O
asymptomatic NN ( O
( NN group O
group DT CAPITAL A O
A NN ) O
) , , O
, IN with O
with NN suspicion O
suspicion IN of O
of NN parasitosis D
parasitosis NN ( O
( NN group O
group NN CAPITAL B O
B NN ) O
) , , O
, IN with O
with NN diarrhoea D
diarrhoea NN ( O
( NN group O
group NN CAPITAL C O
C NN ) O
) NN ) O

In IN CAPITAL In O
In DT all O
all NNS cases O
cases DT a O
a JJ coproparasitological O
coproparasitological NN study O
study VBD was O
was VBN performed O

In IN CAPITAL In O
In DT the O
the NN group O
group NN CAPITAL C O
C DT the O
the NN presence O
presence IN of O
of JJ non-parasitic O
non-parasitic NNS enteropathogens O
enteropathogens VBD was O
was RB also O
also VBN investigated O

In IN CAPITAL In O
In NNS patients O
patients IN with O
with NN CAPITAL B O

hominis NN hominis O
hominis IN in O
in DT the O
the NN absence O
absence IN of O
of JJ other O
other NNS pathogens O
pathogens JJ clinical O
clinical CC and O
and JJ epidemiological O
epidemiological NNS characteristics O
characteristics VBD were O
were VBN evaluated O

Also RB CAPITAL Also O
Also , , O
, PRP$ its O
its VBD was O
was VBN determined O
determined DT the O
the NN morphology O
morphology CC and O
and NN quantification O
quantification IN of O
of NNS parasites O

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: NNS CAPITAL Parasites O
Parasites VBD were O
were VBN identified O
identified IN in O
in CD 26.2 O
26.2 NN % O
% IN of O
of NN population O

B NN CAPITAL B O

hominis NN hominis O
hominis VBD was O
was VBN identified O
identified IN in O
in CD 336 O
336 NNS patients O
patients NN ( O
( CD 16.5 O
16.5 NN % O
% NN ) O

The DT CAPITAL The O
The NN frequency O
frequency IN of O
of NN parasitation D
parasitation VBD was O
was JJ superior O
superior IN in O
in NNS adults O
adults NN ( O
( NN p O
p CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0.0001 O
0.0001 NN ) O
) , , O
, IN with O
with DT a O
a JJ slight O
slight NN predominance O
predominance IN in O
in DT the O
the JJ female O
female NN sex O

The DT CAPITAL The O
The NN rate O
rate IN of O
of JJ asymptomatic O
asymptomatic NNS carriers O
carriers VBD was O
was CD 3.3 O
3.3 NN % O

In IN CAPITAL In O
In CD 21 O
21 NNS patients O
patients NN CAPITAL B O

hominis NN hominis O
hominis NN ( O
( NN group O
group NN CAPITAL C O
C NN ) O
) VBD was O
was VBN observed O
observed IN in O
in NN absence O
absence IN of O
of JJ other O
other NNS enteropathogens O

Statistical JJ CAPITAL Statistical O
Statistical JJ significant O
significant NN association O
association VBD was O
was VBN found O
found IN between O
between NN CAPITAL B O

hominis NN hominis O
hominis , , O
, IN in O
in NN absence O
absence IN of O
of JJ other O
other NNS pathogens O
pathogens CC and O
and DT the O
the NN presence O
presence IN of O
of JJ clinical O
clinical NNS manifestations O
manifestations NN ( O
( NN p O
p CC & O
& # # O
# CD 60 O
60 : ; O
; CD 0.0001 O
0.0001 NN ) O
) , , O
, DT the O
the JJS most O
most JJ common O
common IN of O
of WDT which O
which VBD were O
were NN diarrhoea D
diarrhoea CC and O
and JJ abdominal D
abdominal NN pain D

We PRP CAPITAL We O
We VBD did O
did RB not O
not VB find O
find DT a O
a RB statistically O
statistically JJ significant O
significant NN association O
association IN between O
between DT the O
the NN number O
number IN of O
of NN CAPITAL B O

hominis NN hominis O
hominis JJ present O
present CC and O
and NN stool O
stool NNS characteristics O

The DT CAPITAL The O
The JJ vacuolar O
vacuolar NN form O
form VBD was O
was DT the O
the JJ predominant O
predominant JJ morphological O
morphological NN type O

The DT CAPITAL The O
The JJ ameboid O
ameboid NN form O
form VBD was O
was VBN observed O
observed RB only O
only IN in O
in NN diarrhoeal O
diarrhoeal NNS stools O

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: NN CAPITAL B O

hominis NN hominis O
hominis VBZ is O
is DT the O
the JJS most O
most JJ frequent O
frequent NN parasite O
parasite VBN found O
found IN in O
in JJ faecal O
faecal JJ parasitological O
parasitological NN investigation O

In IN CAPITAL In O
In NN absence O
absence IN of O
of JJ other O
other NNS causes O
causes , , O
, NN CAPITAL B O

hominis NN hominis O
hominis MD must O
must VB be O
be VBN considered O
considered IN as O
as DT a O
a NN pathogen O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NN CAPITAL BACKGROUND O
BACKGROUND : : O
: DT CAPITAL The O
The NN cause O
cause IN of O
of JJ severe O
severe VBN acquired O
acquired NN hyperammonemia O
hyperammonemia , , O
, DT an O
an JJ uncommon O
uncommon CC but O
but RB often O
often JJ fatal O
fatal NN complication O
complication IN of O
of NN organ O
organ NN transplantation O
transplantation CC and O
and NN chemotherapy O
chemotherapy IN for O
for NN cancer O
cancer , , O
, VBZ is O
is JJ obscure O

< JJR < O
< NN /TO_SEES O
/TO_SEES JJR > O
> NN CAPITAL OBJECTIVE O
OBJECTIVE : : O
: TO CAPITAL To O
To NN test O
test DT the O
the NN hypothesis O
hypothesis IN that O
that NN liver O
liver NN glutamine O
glutamine NN synthetase O
synthetase NN deficiency O
deficiency MD may O
may VB explain O
explain NN hyperammonemia D
hyperammonemia IN in O
in NNS patients O
patients WP who O
who VB have O
have VBD had O
had NN organ T
organ NN transplantation T
transplantation CC or O
or VBP are O
are VBG receiving O
receiving NN chemotherapy T

DESIGN NN CAPITAL DESIGN O
DESIGN : : O
: NNP CAPITAL Case O
Case NN report O

PATIENTS NNS CAPITAL PATIENTS O
PATIENTS : : O
: CD CAPITAL Two O
Two NNS patients O
patients WP who O
who VBD had O
had JJ fatal O
fatal NN hyperammonemia D
hyperammonemia IN after O
after JJ orthotopic O
orthotopic NN lung T
lung NN transplantation T
transplantation . . O

MEASUREMENTS NNS CAPITAL MEASUREMENTS O
MEASUREMENTS : : O
: NN CAPITAL Liver O
Liver NN tissue O
tissue VBD was O
was VBN analyzed O
analyzed TO to O
to VB determine O
determine DT the O
the NNS activities O
activities IN of O
of CD two O
two NN urea O
urea NN cycle O
cycle NNS enzymes O
enzymes CC and O
and NN glutamine O
glutamine NN synthetase O

Western JJ CAPITAL Western O
Western NN blot O
blot NNS assays O
assays IN for O
for JJ hepatic O
hepatic NN glutamine O
glutamine NN synthetase O
synthetase VBD were O
were VBN performed O
performed TO to O
to VB determine O
determine IN whether O
whether NN glutamine O
glutamine NN synthetase O
synthetase NN deficiency O
deficiency VBD resulted O
resulted IN from O
from VBN reduced O
reduced NN enzyme O
enzyme NNS levels O

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: NNS CAPITAL Activities O
Activities IN of O
of NN carbamoyl O
carbamoyl NN phosphate O
phosphate NN synthetase O
synthetase PRP CAPITAL I O
I CC and O
and NN ornithine O
ornithine NN carbamoyltransferase O
carbamoyltransferase IN in O
in DT the O
the NN liver O
liver VBD were O
were JJ normal O

The DT CAPITAL The O
The NN activity O
activity IN of O
of JJ hepatic O
hepatic NN glutamine O
glutamine NN synthetase O
synthetase VBD was O
was RB markedly O
markedly VBN reduced O
reduced NN ( O
( IN in O
in NN patient O
patient CD 1 O
1 , , O
, CD 12 O
12 NN % O
% IN of O
of DT the O
the VB mean O
mean NN value O
value IN in O
in NNS controls O
controls : ; O
; IN in O
in NN patient O
patient CD 2 O
2 , , O
, CD 28 O
28 NN % O
% IN of O
of DT the O
the VB mean O
mean NN value O
value IN in O
in NNS controls O
controls NN ) O
) , , O
, CC and O
and DT a O
a JJ concomitant O
concomitant NN reduction O
reduction IN in O
in DT the O
the NN amount O
amount IN of O
of NN glutamine O
glutamine NN synthetase O
synthetase NN protein O
protein VBD was O
was VBN observed O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NN CAPITAL CONCLUSION O
CONCLUSION : : O
: NN CAPITAL Hyperammonemia O
Hyperammonemia IN after O
after NN transplantation O
transplantation VBD was O
was VBN associated O
associated IN with O
with JJ hepatic O
hepatic NN glutamine O
glutamine NN synthetase O
synthetase NN deficiency O
deficiency IN in O
in CD two O
two NNS patients O
patients , , O
, CC but O
but DT the O
the JJ causal O
causal NN relation O
relation IN between O
between DT these O
these CD two O
two NNS conditions O
conditions MD must O
must VB be O
be RB further O
further VBN studied O

Postnatal JJ CAPITAL Postnatal O
Postnatal NN growth O
growth VBD was O
was RB prospectively O
prospectively VBN measured O
measured IN from O
from NN birth O
birth TO to O
to CD 1 O
1 NN y O
y IN in O
in CD 54 O
54 NN term O
term NNS infants O
infants VBN born O
born JJ small O
small IN for O
for JJ gestational O
gestational NN age O
age NN ( O
( NNP CAPITAL SGA O
SGA NN ) O
) , , O
, VBN fed O
fed DT either O
either NN breast O
breast NN milk O
milk CC or O
or DT a O
a JJ standard O
standard NN term O
term NN infant O
infant NN formula O

Breastfeeding VBG CAPITAL Breastfeeding O
Breastfeeding VBD was O
was VBN associated O
associated IN with O
with DT a O
a CD 0.36 O
0.36 CC and O
and CD 0.64 O
0.64 JJ standard O
standard NN deviation O
deviation NN ( O
( NN CAPITAL SD O
SD NN ) O
) NN increase O
increase IN in O
in NN weight O
weight IN at O
at CD 2 O
2 NNS weeks O
weeks CC and O
and CD 3 O
3 NNS months O
months IN of O
of NN age O
age , , O
, RB respectively O
respectively , , O
, WDT which O
which VBD persisted O
persisted IN beyond O
beyond DT the O
the VBG breastfeeding O
breastfeeding NN period O
period NN ( O
( CD 0.64 O
0.64 NN CAPITAL SD O
SD IN at O
at CD 1 O
1 NN y O
y NN ) O

Breastfed VBN CAPITAL Breastfed O
Breastfed NNS infants O
infants RB also O
also VBD showed O
showed JJR greater O
greater NN catch-up O
catch-up NN growth O
growth IN in O
in NN head O
head NN circumference O
circumference NN ( O
( NN CAPITAL SD O
SD NN score O
score NN ( O
( NN CAPITAL SDS O
SDS NN ) O
) CD 0.53 O
0.53 JJR higher O
higher IN at O
at CD 3 O
3 NNS months O
months NN ) O
) , , O
, CC and O
and JJR greater O
greater NN body O
body NN length O
length NN gain O
gain NN ( O
( NN CAPITAL SDS O
SDS CD 0.68 O
0.68 JJR higher O
higher IN at O
at CD 6 O
6 NNS months O
months NN ) O

This DT CAPITAL This O
This VBN increased O
increased NN growth O
growth VBD was O
was JJ independent O
independent IN of O
of RB potentially O
potentially VBG confounding O
confounding JJ obstetric O
obstetric , , O
, JJ social O
social CC and O
and JJ demographic O
demographic NNS factors O

Our PRP$ CAPITAL Our O
Our NNS findings O
findings VBP suggest O
suggest IN that O
that VBG breastfeeding O
breastfeeding MD may O
may VB promote O
promote RBR faster O
faster NN growth O
growth IN in O
in NNS infants O
infants VBN compromised O
compromised IN by O
by JJ poor O
poor NN growth O
growth IN in O
in NN utero O

SGA NNP CAPITAL SGA O
SGA NNS infants O
infants MD may O
may VB be O
be VBN programmed O
programmed IN for O
for DT a O
a NN number O
number IN of O
of JJ adverse O
adverse NNS outcomes O
outcomes : ; O
; DT the O
the NN possibility O
possibility IN that O
that JJ such O
such NNS events O
events VBP are O
are JJ altered O
altered IN by O
by NN choice O
choice IN of O
of JJ postnatal O
postnatal NN diet O
diet VBZ is O
is DT a O
a JJ key O
key NN issue O
issue IN for O
for JJ future O
future NN research O

BACKGROUND NN CAPITAL BACKGROUND O
BACKGROUND : : O
: JJ CAPITAL Few O
Few NNS studies O
studies VB have O
have VBN explored O
explored DT the O
the NN health O
health NNS practices O
practices IN of O
of JJ critical O
critical NN care O
care NNS nurses O

Critical JJ CAPITAL Critical O
Critical NN care O
care NNS nurses O
nurses RB routinely O
routinely VB teach O
teach NNS patients O
patients IN about O
about VBG using O
using JJ healthy O
healthy NNS practices O
practices JJ such O
such IN as O
as JJ low-fat O
low-fat NNS diets O
diets , , O
, NN exercise O
exercise , , O
, CC and O
and JJ routine O
routine VBG screening O
screening NNS examinations O

However RB CAPITAL However O
However , , O
, PRP it O
it MD may O
may VB be O
be RB even O
even RBR more O
more JJ important O
important IN that O
that DT the O
the NNS nurses O
nurses PRP themselves O
themselves VB have O
have DT a O
a JJ healthy O
healthy NN lifestyle O
lifestyle , , O
, RB thus O
thus VBG serving O
serving IN as O
as NN role O
role NNS models O
models IN for O
for NNS patients O

Nurses NNS CAPITAL Nurses O
Nurses VBP are O
are VBG selling O
selling DT a O
a NN product O
product , , O
, CC and O
and IN that O
that NN product O
product VBZ is O
is NN health O

The DT CAPITAL The O
The RB best O
best NNS salespersons O
salespersons VBP are O
are DT those O
those WP who O
who VBP are O
are RB genuinely O
genuinely JJ committed O
committed TO to O
to PRP$ their O
their NN product O
product CC and O
and NN model O
model PRP$ its O
its NNS benefits O

Therefore RB CAPITAL Therefore O
Therefore , , O
, JJ critical O
critical NN care O
care NNS nurses O
nurses POS ' O
' JJ healthful O
healthful NNS practices O
practices MD can O
can VB have O
have DT a O
a JJ profound O
profound NN effect O
effect IN on O
on PRP$ their O
their NNS patients O

OBJECTIVES NNS CAPITAL OBJECTIVES O
OBJECTIVES : : O
: DT CAPITAL The O
The NN purpose O
purpose IN of O
of DT this O
this JJ descriptive O
descriptive JJ exploratory O
exploratory NN study O
study VBD was O
was TO to O
to VB examine O
examine JJ critical O
critical NN care O
care NNS nurses O
nurses POS ' O
' NNS responses O
responses TO to O
to CD three O
three NNS questions O
questions IN about O
about NN health O
health NNS practices O
practices IN in O
in PRP$ their O
their RB daily O
daily NNS lives O
lives : : O
: NN ( O
( CD 1 O
1 NN ) O
) WDT CAPITAL What O
What VBP are O
are JJ critical O
critical NN care O
care NNS nurses O
nurses VBG doing O
doing RB currently O
currently TO to O
to VB stay O
stay JJ healthy O
healthy . ? O
? NN ( O
( CD 2 O
2 NN ) O
) VB CAPITAL Do O
Do PRP they O
they VB anticipate O
anticipate VBG making O
making DT any O
any NNS changes O
changes IN in O
in PRP$ their O
their NN lifestyle O
lifestyle IN in O
in DT the O
the JJ future O
future . ? O
? NN ( O
( CD 3 O
3 NN ) O
) MD CAPITAL Would O
Would PRP they O
they VB recommend O
recommend PRP$ their O
their NN lifestyle O
lifestyle TO to O
to PRP$ their O
their NNS patients O
patients . ? O
? NNS CAPITAL METHODS O
METHODS : : O
: CD CAPITAL One O
One CD hundred O
hundred CD twenty-seven O
twenty-seven JJ critical O
critical NN care O
care NNS nurses O
nurses VBG attending O
attending DT a O
a JJ midwestern O
midwestern JJ critical O
critical NN care O
care NN conference O
conference VBN completed O
completed DT a O
a JJ two-part O
two-part NN questionnaire O
questionnaire VBN designed O
designed TO to O
to VB produce O
produce DT a O
a NN health O
health NN profile O

In IN CAPITAL In O
In DT a O
a JJ man-on-the-street O
man-on-the-street NN approach O
approach , , O
, CD 23 O
23 NNS nurses O
nurses VBD participated O
participated IN in O
in DT an O
an NN interview O
interview IN via O
via NN video O
video NN camera O

Descriptive JJ CAPITAL Descriptive O
Descriptive NNS statistics O
statistics VBD were O
were VBN used O
used TO to O
to VB analyze O
analyze DT the O
the NNS data O
data VBN retrieved O
retrieved IN from O
from DT the O
the NNS questionnaires O

Interviews NNS CAPITAL Interviews O
Interviews VBD were O
were VBN transcribed O
transcribed JJ verbatim O
verbatim CC and O
and VBN analyzed O
analyzed IN for O
for NNS themes O
themes IN with O
with DT a O
a JJ constant O
constant JJ comparative O
comparative NN method O

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: RBR CAPITAL More O
More IN than O
than CD 70 O
70 NN % O
% IN of O
of DT the O
the JJ critical O
critical NN care O
care NNS nurses O
nurses WP who O
who VBD responded O
responded VB engage O
engage IN in O
in NN exercise O
exercise CC and O
and VB follow O
follow DT a O
a JJ healthy O
healthy , , O
, JJ low-fat O
low-fat NN diet O

Seventy-one CD CAPITAL Seventy-one O
Seventy-one NN percent O
percent VBD said O
said IN that O
that PRP they O
they VB anticipate O
anticipate VBG making O
making DT a O
a NN change O
change IN in O
in PRP$ their O
their NN lifestyle O
lifestyle IN in O
in DT the O
the JJ future O
future , , O
, CC and O
and CD 70 O
70 NN % O
% VBD said O
said IN that O
that PRP they O
they MD would O
would VB recommend O
recommend PRP$ their O
their NN lifestyle O
lifestyle TO to O
to PRP$ their O
their NNS patients O

Five CD CAPITAL Five O
Five NNS themes O
themes VBD emerged O
emerged IN from O
from DT the O
the JJ videotaped O
videotaped NNS interviews O
interviews : : O
: NN ( O
( CD 1 O
1 NN ) O
) JJ CAPITAL Heart-healthy O
Heart-healthy NNS practices O
practices VBD predominated O
predominated DT the O
the NNS responses O

( NN ( O
( CD 2 O
2 NN ) O
) VBG CAPITAL Incorporating O
Incorporating DT a O
a JJ healthy O
healthy NN lifestyle O
lifestyle VBD was O
was JJ easy O
easy IN for O
for DT some O
some CC and O
and DT a O
a NN struggle O
struggle IN for O
for NNS others O

( NN ( O
( CD 3 O
3 NN ) O
) JJ CAPITAL Critical O
Critical NN care O
care NNS nurses O
nurses RB readily O
readily VBN listed O
listed NNS barriers O
barriers TO to O
to JJ healthy O
healthy VBG living O

( NN ( O
( CD 4 O
4 NN ) O
) DT CAPITAL The O
The NNS nurses O
nurses VBD had O
had DT a O
a JJ positive O
positive NN attitude O
attitude IN about O
about PRP$ their O
their JJ healthy O
healthy NNS lifestyles O
lifestyles CC and O
and VBD felt O
felt JJ optimistic O
optimistic IN about O
about VBG being O
being NN role O
role NNS models O
models IN for O
for PRP$ their O
their NNS patients O

( NN ( O
( CD 5 O
5 NN ) O
) JJ CAPITAL Future O
Future NNS plans O
plans VBD were O
were DT either O
either JJ singular O
singular IN in O
in NN focus O
focus CC or O
or JJ limited O
limited TO to O
to NN maintenance O
maintenance IN of O
of JJ current O
current NN health O
health NNS habits O

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: DT CAPITAL The O
The NN majority O
majority IN of O
of DT the O
the NNS nurses O
nurses VBN reported O
reported VBG practicing O
practicing DT a O
a JJ healthy O
healthy NN lifestyle O
lifestyle CC and O
and VBN thought O
thought IN that O
that PRP they O
they VBD were O
were JJ good O
good NN role O
role NNS models O
models IN for O
for NNS patients O

Cytochrome NN CAPITAL Cytochrome O
Cytochrome NN CAPITAL P450 O
P450 NN 1A1 O
1A1 NN ( O
( NN CAPITAL CYP1A1 O
CYP1A1 NN ) O
) CC and O
and NN glutathione O
glutathione NN CAPITAL S-transferase O
S-transferase NN CAPITAL M1 O
M1 NN ( O
( NN CAPITAL GSTM1 O
GSTM1 NN ) O
) JJ genetic O
genetic NNS polymorphisms O
polymorphisms VBP are O
are VBN involved O
involved IN in O
in DT the O
the NN activation O
activation CC and O
and NN detoxification O
detoxification IN of O
of NN chemical O
chemical NNS carcinogens O
carcinogens VBN found O
found IN in O
in NN tobacco O
tobacco NN smoke O
smoke : ; O
; RB thus O
thus PRP they O
they MD may O
may NN influence O
influence NN host O
host NN susceptibility O
susceptibility TO to O
to NN lung D
lung NN cancer D

In IN CAPITAL In O
In DT this O
this NN study O
study IN at O
at NNP CAPITAL Massachusetts O
Massachusetts NNP CAPITAL General O
General NNP CAPITAL Hospital O
Hospital NN ( O
( NNP CAPITAL Boston O
Boston , , O
, NNP CAPITAL MA O
MA , , O
, NNP CAPITAL USA O
USA NN ) O
) IN of O
of CD 416 O
416 NNS cases O
cases CC and O
and CD 446 O
446 NNS controls O
controls NN ( O
( RB mostly O
mostly NNP CAPITAL White O
White NN ) O
) PRP we O
we VBN evaluated O
evaluated DT the O
the NN association O
association IN between O
between DT the O
the NN CAPITAL CYP1A1 O
CYP1A1 NN CAPITAL MspI O
MspI CC and O
and NN CAPITAL GSTM1 O
GSTM1 NNS polymorphisms O
polymorphisms CC and O
and NN lung D
lung NN cancer D
cancer NN risk O
risk , , O
, CC and O
and PRP$ their O
their NN interaction O
interaction IN with O
with NN cigarette O
cigarette NN smoke O

The DT CAPITAL The O
The NN CAPITAL CYP1A1 O
CYP1A1 NN CAPITAL MspI O
MspI JJ heterozygous O
heterozygous NN genotype O
genotype VBD was O
was JJ present O
present IN in O
in CD 18 O
18 NN percent O
percent IN of O
of NNS cases O
cases CC and O
and CD 16 O
16 NN percent O
percent IN of O
of NNS controls O
controls , , O
, CC and O
and CD one O
one NN percent O
percent IN of O
of NNS cases O
cases CC and O
and NNS controls O
controls VBD were O
were NN CAPITAL CYP1A1 O
CYP1A1 NN CAPITAL MspI O
MspI JJ homozygous O
homozygous JJ variant O

The DT CAPITAL The O
The NN CAPITAL GSTM1 O
GSTM1 JJ null O
null NN genotype O
genotype VBD was O
was VBN detected O
detected IN in O
in CD 54 O
54 NN percent O
percent IN of O
of NNS cases O
cases CC and O
and CD 52 O
52 NN percent O
percent IN of O
of NNS controls O

After IN CAPITAL After O
After VBG adjusting O
adjusting IN for O
for NN age O
age , , O
, NN gender O
gender , , O
, NNS pack-years O
pack-years IN of O
of NN smoking O
smoking , , O
, CC and O
and NNS years O
years IN since O
since VBG quitting O
quitting NN smoking O
smoking , , O
, IN while O
while DT neither O
neither DT the O
the NN CAPITAL CYP1A1 O
CYP1A1 NN CAPITAL MspI O
MspI JJ heterozygous O
heterozygous NN genotype O
genotype RB alone O
alone CC nor O
nor DT the O
the NN CAPITAL GSTM1 O
GSTM1 JJ null O
null NN genotype O
genotype RB alone O
alone VBD were O
were VBN associated O
associated IN with O
with DT a O
a JJ significant O
significant NN increase O
increase IN in O
in NN lung D
lung NN cancer D
cancer NN risk O
risk , , O
, VBG having O
having DT both O
both JJ genetic O
genetic NNS traits O
traits VBD was O
was VBN associated O
associated IN with O
with DT a O
a RB twofold O
twofold NN increase O
increase IN in O
in NN risk O
risk NN ( O
( CD 95 O
95 NN percent O
percent NN confidence O
confidence NN interval O
interval NN ( O
( NN CAPITAL CI O
CI NN ) O
) JJ = O
= CD 1.0-3.4 O
1.0-3.4 NN ) O

Our PRP$ CAPITAL Our O
Our NNS data O
data VBD did O
did RB not O
not VB provide O
provide RB enough O
enough NN evidence O
evidence IN for O
for DT a O
a JJ substantial O
substantial NN modification O
modification IN of O
of DT the O
the NN effect O
effect IN of O
of NNS pack-years O
pack-years IN on O
on NN lung D
lung NN cancer D
cancer NN risk O
risk IN by O
by DT the O
the NN CAPITAL CYP1A1 O
CYP1A1 NN CAPITAL MspI O
MspI CC and O
and NN CAPITAL GSTM1 O
GSTM1 NNS genotypes O

However RB CAPITAL However O
However , , O
, NNS limitations O
limitations IN of O
of PRP$ our O
our NN study O
study VB preclude O
preclude DT a O
a NN conclusion O
conclusion IN about O
about DT this O
this JJ potential O
potential NN interaction O

BACKGROUND NN CAPITAL BACKGROUND O
BACKGROUND : : O
: JJ CAPITAL Thrombolytic T
Thrombolytic NN treatment T
treatment VBZ has O
has VBN been O
been VBN shown O
shown TO to O
to VB accelerate O
accelerate NN resolution O
resolution IN of O
of JJ major D
major JJ pulmonary D
pulmonary NN embolism D
embolism CC and O
and JJ lead O
lead TO to O
to DT a O
a JJ rapid O
rapid NN improvement O
improvement IN of O
of JJ right-side O
right-side NNS hemodynamics O

However RB CAPITAL However O
However , , O
, DT the O
the NN association O
association IN between O
between DT these O
these JJ favorable O
favorable NNS effects O
effects CC and O
and DT the O
the JJ clinical O
clinical NN outcome O
outcome IN of O
of NNS patients O
patients WP who O
who VB have O
have DT no O
no JJ severe O
severe JJ hemodynamic D
hemodynamic NN compromise D
compromise IN at O
at NN presentation O
presentation VBZ remains O
remains JJ unknown O

METHODS NNS CAPITAL METHODS O
METHODS CC CAPITAL AND O
AND NNS CAPITAL RESULTS O
RESULTS : : O
: DT CAPITAL The O
The JJ present O
present JJ multicenter O
multicenter NN registry O
registry VBN included O
included CD 719 O
719 JJ consecutive O
consecutive NNS patients O
patients IN with O
with JJ major D
major JJ pulmonary D
pulmonary NN embolism D
embolism VBG according O
according TO to O
to JJ clinical O
clinical , , O
, JJ echocardiographic O
echocardiographic , , O
, JJ scintigraphic O
scintigraphic , , O
, CC and O
and JJ cardiac O
cardiac NN catheterization O
catheterization NNS criteria O

Symptom NN CAPITAL Symptom O
Symptom NN onset O
onset VBD was O
was JJ acute O
acute NN ( O
( CC & O
& # # O
# CD 60 O
60 : ; O
; CD 48 O
48 NNS hours O
hours NN ) O
) IN in O
in CD 63 O
63 NN % O
% IN of O
of NNS patients O

All DT CAPITAL All O
All NNS patients O
patients VBD were O
were RB hemodynamically O
hemodynamically JJ stable O
stable NN ( O
( FW ie O
ie , , O
, IN without O
without NN evidence O
evidence IN of O
of JJ cardiogenic D
cardiogenic NN shock D
shock NN ) O
) IN at O
at NN presentation O

treatment NN treatment T
treatment NN ( O
( IN within O
within CD 24 O
24 NNS hours O
hours IN of O
of NN diagnosis O
diagnosis NN ) O
) VBD was O
was VBN given O
given TO to O
to CD 169 O
169 NNS patients O
patients NN ( O
( CD 23.5 O
23.5 NN % O
% NN ) O
) , , O
, IN whereas O
whereas DT the O
the VBG remaining O
remaining CD 550 O
550 NNS patients O
patients VBD were O
were RB initially O
initially VBN treated O
treated IN with O
with NN heparin T
heparin RB alone O

Overall JJ CAPITAL Overall O
Overall JJ 30-day O
30-day NN mortality O
mortality VBD was O
was RB significantly O
significantly JJR lower O
lower IN in O
in DT the O
the NNS patients O
patients WP who O
who VBN received O
received JJ thrombolytic T
thrombolytic NNS agents T
agents NN ( O
( CD 4.7 O
4.7 CC versus O
versus CD 11.1 O
11.1 NN % O
% , , O
, NN CAPITAL P=.016 O
P=.016 NN ) O

Clinical JJ CAPITAL Clinical O
Clinical NNS factors O
factors VBN associated O
associated IN with O
with DT a O
a JJR higher O
higher NN death O
death NN rate O
rate VBD were O
were NN syncope D
syncope NN ( O
( NN CAPITAL P=.012 O
P=.012 NN ) O
) , , O
, JJ arterial D
arterial NN hypotension D
hypotension NN ( O
( NN CAPITAL P=.021 O
P=.021 NN ) O
) , , O
, NN history O
history IN of O
of JJ congestive D
congestive NN heart D
heart NN failure D
failure NN ( O
( NN CAPITAL P=.013 O
P=.013 NN ) O
) , , O
, CC and O
and JJ chronic D
chronic JJ pulmonary D
pulmonary NN disease D
disease NN ( O
( NN CAPITAL P=.032 O
P=.032 NN ) O

However RB CAPITAL However O
However , , O
, RB only O
only JJ primary D
primary NN thrombolysis D
thrombolysis VBD was O
was VBN found O
found IN by O
by JJ multivariate O
multivariate NN analysis O
analysis TO to O
to VB be O
be DT an O
an JJ independent O
independent NN predictor O
predictor IN of O
of NN survival O
survival NN ( O
( NNS odds O
odds NN ratio O
ratio IN for O
for JJ in-hospital O
in-hospital NN death O
death , , O
, CD 0.46 O
0.46 : ; O
; CD 95 O
95 NN % O
% NN confidence O
confidence NN interval O
interval , , O
, CD 0.21 O
0.21 TO to O
to CD 1.00 O
1.00 NN ) O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NNS CAPITAL Patients O
Patients WP who O
who VBD underwent O
underwent RB early O
early JJ thrombolytic O
thrombolytic NN treatment O
treatment VBD had O
had DT a O
a VBN reduced O
reduced NN rate O
rate IN of O
of JJ recurrent O
recurrent JJ pulmonary O
pulmonary NN embolism O
embolism NN ( O
( CD 7.7 O
7.7 CC versus O
versus CD 18.7 O
18.7 NN % O
% , , O
, NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD .001 O
.001 NN ) O
) CC but O
but RB also O
also DT a O
a JJR higher O
higher NN frequency O
frequency IN of O
of JJ major O
major VBG bleeding O
bleeding NNS episodes O
episodes NN ( O
( CD 21.9 O
21.9 NN % O
% CC versus O
versus CD 7.8 O
7.8 NN % O
% , , O
, NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD .001 O
.001 NN ) O

Cerebral JJ CAPITAL Cerebral D
Cerebral NN bleeding D
bleeding VBD occurred O
occurred IN in O
in CD 2 O
2 NNS patients O
patients IN in O
in DT each O
each NN treatment O
treatment NN group O
group , , O
, CC and O
and CD 1 O
1 NN patient O
patient IN in O
in DT each O
each NN group O
group VBD died O
died IN of O
of DT a O
a NN bleeding D
bleeding NN complication O

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: DT CAPITAL The O
The NNS results O
results IN of O
of PRP$ our O
our NN study O
study VBP suggest O
suggest IN that O
that NN thrombolysis T
thrombolysis MD may O
may RB favorably O
favorably VB affect O
affect DT the O
the JJ clinical O
clinical NN outcome O
outcome IN of O
of RB hemodynamically O
hemodynamically JJ stable O
stable NNS patients O
patients IN with O
with JJ major D
major JJ pulmonary D
pulmonary NN embolism D

A DT CAPITAL A O
A JJ 66-year-old O
66-year-old JJ male O
male NN engineer O
engineer VBN diagnosed O
diagnosed IN with O
with JJ malignant D
malignant JJ pleural D
pleural NN mesothelioma D
mesothelioma CD 4 O
4 NNS years O
years RB previously O
previously VBD had O
had NN thoracotomy T
thoracotomy , , T
, NN radiotherapy T
radiotherapy , , T
, CC and T
and NN chemotherapy T

He PRP CAPITAL He O
He VBD was O
was VBN followed O
followed RB regularly O
regularly IN with O
with NN chest O
chest VBN computed O
computed NN tomography O
tomography NN ( O
( NN CAPITAL CT O
CT NN ) O
) VB scan O
scan CC and O
and VBD had O
had VBN been O
been JJ asymptomatic O

During IN CAPITAL During O
During CD one O
one IN of O
of PRP$ his O
his JJ physical O
physical NNS examinations O
examinations , , O
, JJ routine O
routine NN sigmoidoscopy O
sigmoidoscopy VBD showed O
showed JJ incidental O
incidental JJ colonic D
colonic NNS polyps D
polyps WDT which O
which VBD were O
were VBN biopsied O

Subsequently RB CAPITAL Subsequently O
Subsequently , , O
, NN recurrence O
recurrence IN of O
of JJ pleural D
pleural NN mesothelioma D
mesothelioma CC and O
and JJ peritoneal O
peritoneal NN involvement O
involvement IN by O
by NN mesothelioma D
mesothelioma VBD was O
was VBN documented O

Two CD CAPITAL Two O
Two IN of O
of DT the O
the NNS polyps O
polyps VBD showed O
showed JJ metastatic D
metastatic JJ malignant D
malignant NN mesothelioma D
mesothelioma IN in O
in DT the O
the NN lamina O
lamina NN propia O
propia WDT which O
which RB strongly O
strongly VBD resembled O
resembled NN adenocarcinoma D
adenocarcinoma RB histologically O
histologically VBG causing O
causing NN difficulty O
difficulty IN in O
in VBG making O
making JJ definitive O
definitive NN diagnosis O

Review NN CAPITAL Review O
Review IN of O
of DT the O
the NN literature O
literature VBN disclosed O
disclosed DT no O
no RB previously O
previously VBN documented O
documented JJ similar O
similar NN occurrence O

This DT CAPITAL This O
This NN case O
case NNS shows O
shows DT the O
the NN importance O
importance IN of O
of JJ clinical O
clinical NN history O
history CC and O
and JJ ancillary O
ancillary NN laboratory O
laboratory NNS procedures O
procedures JJ such O
such IN as O
as NN immunohistochemistry O
immunohistochemistry CC and O
and NN electron O
electron NN microscopy O
microscopy TO to O
to VB avoid O
avoid JJ diagnostic O
diagnostic NNS pitfalls O

The DT CAPITAL The O
The NNS authors O
authors NN report O
report DT the O
the JJ postoperative O
postoperative JJ magnetic O
magnetic NN resonance O
resonance NN ( O
( NN CAPITAL MR O
MR NN ) O
) NN imaging O
imaging NNS findings O
findings IN in O
in CD 36 O
36 NNS patients O
patients IN with O
with JJ advanced D
advanced NNP CAPITAL Parkinson D
Parkinson POS 's D
's NN disease D
disease WP who O
who VBD underwent O
underwent JJ unilateral T
unilateral JJ microelectrode-guided T
microelectrode-guided JJ posteroventral T
posteroventral NN pallidotomy T

The DT CAPITAL The O
The NNS lesions O
lesions VBD were O
were VBN placed O
placed IN within O
within CD 1 O
1 NN mm O
mm IN of O
of DT the O
the JJ ventral O
ventral NN border O
border IN of O
of DT the O
the NN globus O
globus NN pallidus O
pallidus NN internus O
internus NN ( O
( NN CAPITAL GPi O
GPi NN ) O
) TO to O
to VBP include O
include JJ pallidothalamic O
pallidothalamic NN outflow O
outflow NNS pathways O

Sequential JJ CAPITAL Sequential O
Sequential NN CAPITAL MR O
MR NNS studies O
studies VBD were O
were VBN obtained O
obtained IN within O
within CD 1 O
1 TO to O
to CD 3 O
3 NNS days O
days RB postoperatively O
postoperatively CC and O
and IN at O
at JJ 6-month O
6-month JJ follow-up O
follow-up NN examination O

Thirty-four CD CAPITAL Thirty-four O
Thirty-four NN ( O
( CD 94 O
94 NN % O
% NN ) O
) IN of O
of DT the O
the CD 36 O
36 NNS patients O
patients VBN enjoyed O
enjoyed JJ sustained O
sustained JJ moderate O
moderate CC or O
or JJ marked O
marked NN improvement O
improvement IN of O
of PRP$ their O
their NN parkinsonian D
parkinsonian NNS symptoms D
symptoms CD 6 O
6 NNS months O
months RB postoperatively O

Transient JJ CAPITAL Transient O
Transient NN side O
side NNS effects O
effects VBD occurred O
occurred IN in O
in CD five O
five NNS patients O
patients NN ( O
( CD 14 O
14 NN % O
% NN ) O
) , , O
, CC but O
but RB there O
there VBD were O
were DT no O
no JJ persistent O
persistent NNS complications O

The DT CAPITAL The O
The JJ pallidal O
pallidal NN radiofrequency O
radiofrequency NNS lesions O
lesions VBD were O
were JJ prolate O
prolate NN spheroid O
spheroid JJ shaped O
shaped CC and O
and VBD were O
were VBN composed O
composed IN of O
of CD three O
three JJ concentric O
concentric NNS zones O
zones IN in O
in DT the O
the RB early O
early JJ postoperative O
postoperative NNS studies O

The DT CAPITAL The O
The VB mean O
mean NN volume O
volume IN of O
of DT the O
the JJ middle O
middle NN zone O
zone , , O
, JJ corresponding O
corresponding TO to O
to DT the O
the NN area O
area IN of O
of JJ hemorrhagic D
hemorrhagic NN coagulation D
coagulation NN necrosis D
necrosis , , O
, VBD was O
was CD 44.4 O
44.4 CC +/- O
+/- CD 17.6 O
17.6 NN mm3 O
mm3 : ; O
; DT the O
the VB mean O
mean NN lesion O
lesion NN volume O
volume IN as O
as VBN defined O
defined IN by O
by DT the O
the JJ outer O
outer NN zone O
zone , , O
, JJ corresponding O
corresponding TO to O
to JJ perilesional D
perilesional NN edema D
edema , , O
, VBD was O
was CD 262.2 O
262.2 CC +/- O
+/- CD 111.6 O
111.6 NN mm3 O

Additional JJ CAPITAL Additional O
Additional NN edema D
edema VBG spreading O
spreading TO to O
to DT the O
the JJ internal O
internal NN capsule O
capsule VBD was O
was VBN noted O
noted IN in O
in CD 32 O
32 IN of O
of CD 34 O
34 NNS cases O
cases CC and O
and TO to O
to DT the O
the JJ optic O
optic NN tract O
tract IN in O
in CD 11 O
11 IN of O
of CD 34 O
34 NNS cases O

In IN CAPITAL In O
In CD two O
two NNS patients O
patients JJ small O
small JJ ischemic D
ischemic NNS infarctions D
infarctions VBG involving O
involving DT the O
the NN corona O
corona NN radiata O
radiata VBD were O
were VBN found O
found , , O
, CC and O
and IN in O
in CD one O
one DT a O
a JJ venous D
venous NN infarction D
infarction VBD was O
was VBN detected O

Ischemic JJ CAPITAL Ischemic D
Ischemic NN infarction D
infarction VBD resulted O
resulted IN in O
in JJ mild O
mild JJ transient O
transient NN CAPITAL Broca D
Broca POS 's D
's NN aphasia D
aphasia IN in O
in CD one O
one NN patient O
patient , , O
, CC but O
but RB there O
there VBD was O
was DT no O
no JJ detectable O
detectable JJ neurological O
neurological NN deficit O
deficit IN in O
in DT the O
the JJ other O
other CD two O

The DT CAPITAL The O
The VB mean O
mean NN volume O
volume IN of O
of JJ late-phase O
late-phase NN ( O
( CD 6 O
6 NNS months O
months NN ) O
) NNS lesions O
lesions VBD was O
was CD 22 O
22 CC +/- O
+/- CD 28.8 O
28.8 NN mm3 O

In IN CAPITAL In O
In CD three O
three NNS patients O
patients DT no O
no NN lesion O
lesion VBD was O
was VBN identified O
identified IN despite O
despite JJ sustained O
sustained JJ clinical O
clinical NN improvement O

The DT CAPITAL The O
The NN lesion O
lesion VBD was O
was JJ located O
located IN in O
in DT the O
the JJ posteroventral O
posteroventral NN CAPITAL GPi O
GPi IN in O
in DT all O
all NNS cases O
cases IN except O
except IN in O
in CD one O
one NN patient O
patient IN in O
in WP whom O
whom PRP it O
it VBD was O
was VBN confined O
confined TO to O
to DT the O
the NN CAPITAL GP O
GP NN externus O
externus NN ( O
( NNP CAPITAL GPe O
GPe NN ) O

This DT CAPITAL This O
This JJ 49-year-old O
49-year-old NN woman O
woman VBD did O
did RB not O
not NN experience O
experience JJ sustained O
sustained NN benefit O

The DT CAPITAL The O
The NNS authors O
authors VBN found O
found DT no O
no JJ consistent O
consistent NNS correlations O
correlations IN between O
between NN lesion O
lesion NN size O
size CC and O
and NN location O
location CC and O
and JJ clinical O
clinical NN outcome O
outcome IN as O
as VBN measured O
measured IN by O
by DT a O
a JJ global O
global NN outcome O
outcome NN score O
score , , O
, DT the O
the JJ CAPITAL Unified O
Unified NNP CAPITAL Parkinson O
Parkinson POS 's O
's NN CAPITAL Disease O
Disease NNP CAPITAL Rating O
Rating NNP CAPITAL Scale O
Scale NN motor O
motor , , O
, NNS activities O
activities IN of O
of RB daily O
daily VBG living O
living , , O
, CC and O
and NN bradykinesia O
bradykinesia `` `` O
`` IN off O
off '' '' O
'' NNS scores O
scores CC or O
or NN rating O
rating IN of O
of NN dyskinesias O

Lesioning VBG CAPITAL Lesioning O
Lesioning IN of O
of JJ pallidal O
pallidal CC and O
and JJ subpallidal O
subpallidal NNS pathways O
pathways MD may O
may VB contribute O
contribute TO to O
to DT the O
the JJ sustained O
sustained JJ clinical O
clinical NN benefit O
benefit IN in O
in DT this O
this NN series O

Magnetic JJ CAPITAL Magnetic O
Magnetic NN resonance O
resonance NN imaging O
imaging NN analysis O
analysis VBD showed O
showed IN that O
that JJ intraoperative O
intraoperative NN microelectrode O
microelectrode VBG recording O
recording VBN facilitated O
facilitated JJ accurate O
accurate NN placement O
placement IN of O
of DT the O
the NN lesion O
lesion IN in O
in DT this O
this JJ critical O
critical NN area O

A DT CAPITAL A O
A RB commercially O
commercially JJ available O
available NN health O
health NN food O
food NN product O
product IN of O
of JJ cold-pressed O
cold-pressed NN hemp O
hemp NN seed O
seed NN oil O
oil VBN ingested O
ingested IN by O
by CD one O
one NN volunteer O
volunteer RB twice O
twice DT a O
a NN day O
day IN for O
for CD 4 O
4 CD 1/2 O
1/2 NNS days O
days NN ( O
( CD 135 O
135 NN mL O
mL JJ total O
total NN ) O

Urine NN CAPITAL Urine O
Urine NNS specimens O
specimens VBN collected O
collected IN from O
from DT the O
the NN volunteer O
volunteer VBD were O
were VBN subjected O
subjected TO to O
to JJ standard O
standard NN workplace O
workplace NN urine O
urine NN drug O
drug NN testing O
testing NNS procedures O
procedures , , O
, CC and O
and DT the O
the VBG following O
following NNS concentrations O
concentrations IN of O
of JJ 11-nor-delta9- O
11-nor-delta9- NN tetrahydrocannabinol O
tetrahydrocannabinol JJ carboxylic O
carboxylic NN acid O
acid NN ( O
( NN 9-THCA O
9-THCA NN ) O
) VBD were O
were VBN detected O
detected : : O
: CD 41 O
41 NN ng/mL O
ng/mL NN 9-THCA O
9-THCA IN at O
at CD 45 O
45 NN h O
h , , O
, CD 49 O
49 NN ng/mL O
ng/mL IN at O
at CD 69 O
69 NN h O
h , , O
, CC and O
and CD 55 O
55 NN ng/mL O
ng/mL IN at O
at CD 93 O
93 NN h. O
h. NN CAPITAL Ingestion O
Ingestion VBD was O
was VBN discontinued O
discontinued IN after O
after CD 93 O
93 NN h O
h , , O
, CC and O
and DT the O
the VBG following O
following NNS concentrations O
concentrations VBD were O
were VBN detected O
detected : : O
: CD 68 O
68 NN ng/mL O
ng/mL IN at O
at CD 108 O
108 NN h O
h , , O
, CD 57 O
57 NN ng/mL O
ng/mL IN at O
at CD 117 O
117 NN h O
h , , O
, CD 31 O
31 NN ng/mL O
ng/mL IN at O
at CD 126 O
126 NN h O
h , , O
, CC and O
and CD 20 O
20 NN ng/mL O
ng/mL IN at O
at CD 142 O
142 NN h. O
h. DT CAPITAL The O
The RB first O
first NN specimen O
specimen IN that O
that VBN tested O
tested JJ negative O
negative NN ( O
( CD 50 O
50 NN ng/mL O
ng/mL JJ initial O
initial NN immunoassay O
immunoassay NN test O
test , , O
, CD 15 O
15 NN ng/mL O
ng/mL JJ confirmatory O
confirmatory NN gas O
gas JJ chromatographic-mass O
chromatographic-mass JJ spectrometric O
spectrometric NN test O
test NN ) O
) VBD was O
was IN at O
at CD 146 O
146 NN h O
h , , O
, WDT which O
which VBD was O
was CD 53 O
53 NN h O
h IN after O
after DT the O
the JJ last O
last NN hemp O
hemp NN seed O
seed NN oil O
oil NN ingestion O

Four CD CAPITAL Four O
Four JJ subsequent O
subsequent NNS specimens O
specimens VBN taken O
taken TO to O
to CD 177 O
177 NN h O
h VBD were O
were RB also O
also JJ negative O

This DT CAPITAL This O
This NN study O
study VBZ indicates O
indicates IN that O
that DT a O
a NN workplace O
workplace NN urine O
urine NN drug O
drug NN test O
test JJ positive O
positive IN for O
for NNS cannabinoids O
cannabinoids MD may O
may VB arise O
arise IN from O
from DT the O
the NN consumption O
consumption IN of O
of RB commercially O
commercially JJ available O
available JJ cold-pressed O
cold-pressed NN hemp O
hemp NN seed O
seed NN oil O

OBJECTIVE NN CAPITAL OBJECTIVE O
OBJECTIVE : : O
: PRP CAPITAL We O
We VBN determined O
determined DT the O
the NN sensitivity O
sensitivity CC and O
and NN specificity O
specificity IN of O
of JJ neonatal O
neonatal NN brain-stem O
brain-stem JJ auditory O
auditory VBN evoked O
evoked NNS potentials O
potentials NN ( O
( NN CAPITAL BAEP O
BAEP NN ) O
) IN as O
as NNS markers O
markers IN for O
for JJ subsequent O
subsequent NN hearing D
hearing NN impairment D
impairment CC and O
and IN for O
for JJ developmental D
developmental NNS problems D
problems VBN found O
found RB later O
later IN in O
in NN infancy O
infancy CC and O
and NN childhood O

METHODS NNS CAPITAL METHODS O
METHODS : : O
: NN CAPITAL BAEP O
BAEP NNS studies O
studies VBD were O
were VBN performed O
performed IN before O
before NN discharge O
discharge IN in O
in NNS infants O
infants VBN treated O
treated IN with O
with JJ extracorporeal T
extracorporeal NN membrane T
membrane NN oxygenation T
oxygenation NN ( T
( NN CAPITAL ECMO T
ECMO NN ) T
) , , O
, CC and O
and CD two O
two JJ specific O
specific NNS abnormalities O
abnormalities VBD were O
were VBN analyzed O
analyzed : : O
: JJ elevated O
elevated NN threshold O
threshold CC and O
and VBN delayed O
delayed JJ central O
central JJ auditory O
auditory NN conduction O

Behavioral JJ CAPITAL Behavioral O
Behavioral NN audiometry O
audiometry VBD was O
was VBN repeated O
repeated IN during O
during JJ periodic O
periodic JJ follow-up O
follow-up IN until O
until JJ reliable O
reliable NNS responses O
responses VBD were O
were VBN obtained O
obtained IN for O
for DT all O
all NNS frequencies O
frequencies , , O
, CC and O
and JJ standardized O
standardized JJ developmental O
developmental NN testing O
testing VBD was O
was RB also O
also VBN conducted O

The DT CAPITAL The O
The NN sensitivity O
sensitivity CC and O
and NN specificity O
specificity IN of O
of DT an O
an JJ elevated O
elevated NN threshold O
threshold IN on O
on DT the O
the JJ neonatal O
neonatal NN CAPITAL BAEP O
BAEP IN for O
for VBG detecting O
detecting JJ subsequent O
subsequent VBG hearing O
hearing NN loss O
loss , , O
, CC and O
and DT the O
the NN relationship O
relationship IN of O
of DT any O
any JJ neonatal O
neonatal NN CAPITAL BAEP O
BAEP NN abnormality O
abnormality TO to O
to NN language O
language CC or O
or JJ developmental O
developmental NNS disorders O
disorders IN in O
in NN infancy O
infancy , , O
, VBD were O
were VBN calculated O

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: NN CAPITAL Test O
Test NNS results O
results IN for O
for CD 46 O
46 JJ CAPITAL ECMO-treated O
ECMO-treated NNS infants O
infants NN ( O
( CD 57.5 O
57.5 NN % O
% NN ) O
) VBD were O
were JJ normal O
normal , , O
, CC and O
and DT those O
those IN for O
for CD 34 O
34 NNS infants O
infants NN ( O
( CD 42.5 O
42.5 NN % O
% NN ) O
) VBD were O
were JJ abnormal O
abnormal , , O
, IN with O
with DT either O
either JJ elevated O
elevated NN wave O
wave NN CAPITAL V O
V NN threshold O
threshold , , O
, JJ prolonged O
prolonged NN wave O
wave NN CAPITAL I-V O
I-V NN interval O
interval , , O
, CC or O
or DT both O
both IN on O
on JJ neonatal O
neonatal NN CAPITAL BAEP O
BAEP NNS recordings O

Most JJS CAPITAL Most O
Most RB significantly O
significantly , , O
, CD 7 O
7 NN ( O
( CD 58 O
58 NN % O
% NN ) O
) IN of O
of DT the O
the CD 12 O
12 NNS children O
children IN with O
with JJ subsequent O
subsequent NN sensorineural D
sensorineural NN hearing D
hearing NN loss D
loss VBD had O
had RB left O
left DT the O
the NN hospital O
hospital IN after O
after VBG showing O
showing JJ normal O
normal NNS results O
results IN on O
on NN threshold O
threshold NNS tests O

There EX CAPITAL There O
There VBD was O
was DT no O
no JJ significant O
significant NN difference O
difference IN in O
in DT the O
the NN frequency O
frequency IN of O
of NN hearing D
hearing NN loss D
loss IN between O
between NNS subjects O
subjects IN with O
with JJ abnormal O
abnormal NN ( O
( CD 5/21 O
5/21 , , O
, CC or O
or CD 24 O
24 NN % O
% NN ) O
) CC and O
and DT those O
those IN with O
with JJ normal O
normal NN CAPITAL BAEP O
BAEP NNS thresholds O
thresholds NN ( O
( CD 7/59 O
7/59 , , O
, CC or O
or CD 12 O
12 NN % O
% : ; O
; NNP CAPITAL Fisher O
Fisher JJ CAPITAL Exact O
Exact NN CAPITAL Test O
Test , , O
, NN p O
p JJ = O
= CD 0.28 O
0.28 NN ) O

Therefore RB CAPITAL Therefore O
Therefore DT the O
the NN sensitivity O
sensitivity IN of O
of JJ neonatal O
neonatal NN CAPITAL BAEP O
BAEP NN testing O
testing IN for O
for VBG predicting O
predicting JJ subsequent O
subsequent NN hearing D
hearing NN loss D
loss VBD was O
was RB only O
only CD 42 O
42 NN % O

Neonatal JJ CAPITAL Neonatal O
Neonatal NN CAPITAL BAEP O
BAEP NN specificity O
specificity IN for O
for VBG excluding O
excluding JJ subsequent O
subsequent NN hearing D
hearing NN loss D
loss VBD was O
was CD 76 O
76 NN % O

In IN CAPITAL In O
In NN contrast O
contrast , , O
, IN on O
on NN language O
language NN development O
development NN testing O
testing , , O
, CD 19 O
19 NNS children O
children VBD demonstrated O
demonstrated JJ receptive O
receptive NN language O
language NN delay O

Of IN CAPITAL Of O
Of DT these O
these NNS children O
children , , O
, CD 12 O
12 NN ( O
( CD 63 O
63 NN % O
% NN ) O
) VBD had O
had JJ abnormal O
abnormal JJ neonatal O
neonatal NN CAPITAL BAEP O
BAEP NNS recordings O
recordings CC and O
and CD 7 O
7 NN ( O
( CD 37 O
37 NN % O
% NN ) O
) VBD had O
had DT a O
a JJ normal O
normal NN CAPITAL BAEP O
BAEP NN threshold O
threshold , , O
, JJ normal O
normal JJ central O
central JJ auditory O
auditory NN conduction O
conduction NN test O
test NNS results O
results , , O
, CC or O
or DT both O
both NN ( O
( NN p O
p JJ = O
= CD 0.04 O
0.04 NN ) O

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: JJ CAPITAL Neonatal O
Neonatal NN CAPITAL BAEP O
BAEP NN threshold O
threshold NNS recordings O
recordings VBD were O
were IN of O
of JJ limited O
limited NN value O
value IN for O
for VBG predicting O
predicting JJ subsequent O
subsequent NN hearing D
hearing NN loss D
loss JJ common O
common IN in O
in NN CAPITAL ECMO T
ECMO JJ -treated O
-treated NNS survivors O

However RB CAPITAL However O
However , , O
, DT an O
an JJ abnormal O
abnormal JJ neonatal O
neonatal NN CAPITAL BAEP O
BAEP RB significantly O
significantly VBN increased O
increased DT the O
the NN probability O
probability IN of O
of VBG finding O
finding DT a O
a JJ receptive O
receptive NN language O
language NN delay O
delay IN during O
during RB early O
early NN childhood O
childhood , , O
, RB even O
even IN in O
in DT those O
those IN with O
with RB subsequently O
subsequently JJ normal O
normal NN audiometry O
audiometry NNS findings O

Because IN CAPITAL Because O
Because JJ neonatal O
neonatal NN CAPITAL ECMO T
ECMO VBZ is O
is VBN associated O
associated IN with O
with DT a O
a JJ high O
high NN risk O
risk IN of O
of NN hearing D
hearing CC and D
and JJ receptive D
receptive NN language D
language NNS disorders D
disorders , , O
, NNS parents O
parents MD should O
should VB be O
be VBN counseled O
counseled IN that O
that JJ audiologic O
audiologic CC and O
and JJ developmental O
developmental JJ follow-up O
follow-up NNS evaluations O
evaluations IN in O
in VBG surviving O
surviving NNS children O
children VBP are O
are JJ essential O
essential RB regardless O
regardless IN of O
of DT the O
the NNS results O
results IN of O
of JJ neonatal O
neonatal NN CAPITAL BAEP O
BAEP NN testing O

The DT CAPITAL The O
The NNP CAPITAL Federated O
Federated NNP CAPITAL Council O
Council IN of O
of JJ CAPITAL Internal O
Internal NNP CAPITAL Medicine O
Medicine VBZ has O
has VBN developed O
developed DT a O
a NN resource O
resource NN guide O
guide TO to O
to NN help O
help JJ internal O
internal NN medicine O
medicine NN residency O
residency NNS programs O
programs VB produce O
produce NNS internists O
internists WP who O
who VBP are O
are JJ prepared O
prepared IN for O
for NN today O
today POS 's O
's NN practice O
practice IN of O
of JJ internal O
internal NN medicine O
medicine CC and O
and DT the O
the NNS challenges O
challenges IN of O
of NN practice O
practice IN in O
in DT the O
the JJ future O

The DT CAPITAL The O
The NN guide O
guide VBZ situates O
situates JJ general O
general JJ internal O
internal NN medicine O
medicine IN as O
as DT the O
the JJ primary O
primary NN care O
care NN profession O
profession IN that O
that VBZ focuses O
focuses IN on O
on JJ preventive O
preventive , , O
, JJ short-term O
short-term , , O
, CC and O
and JJ long-term O
long-term NN care O
care IN of O
of JJ adult O
adult NNS patients O

It PRP CAPITAL It O
It VBZ assumes O
assumes IN that O
that DT a O
a JJ single O
single NN pathway O
pathway VBZ is O
is JJ sufficient O
sufficient IN for O
for VBG educating O
educating JJ general O
general NNS internists O
internists CC and O
and JJ subspecialty-bound O
subspecialty-bound NNS trainees O

It PRP CAPITAL It O
It VBZ identifies O
identifies DT the O
the VBG learning O
learning NNS experiences O
experiences IN that O
that MD should O
should VB be O
be NN part O
part IN of O
of JJ general O
general JJ internal O
internal NN medicine O
medicine NN residency O
residency NN training O
training , , O
, NNS lists O
lists DT the O
the JJ clinical O
clinical NNS competencies O
competencies IN that O
that VBP are O
are JJ important O
important IN for O
for JJ primary O
primary NN care O
care NN practice O
practice , , O
, CC and O
and VBZ describes O
describes DT the O
the NN role O
role IN of O
of DT the O
the JJ integrative O
integrative NNS disciplines O
disciplines IN that O
that MD should O
should VB inform O
inform DT the O
the NN care O
care IN of O
of DT every O
every NN patient O

It PRP CAPITAL It O
It RB also O
also VBZ describes O
describes DT a O
a NN process O
process IN that O
that NN program O
program NNS directors O
directors CC and O
and JJ local O
local NN program O
program NNS committees O
committees MD can O
can NN use O
use TO to O
to VB develop O
develop JJ competency-based O
competency-based NN curricula O

BACKGROUND NN CAPITAL BACKGROUND O
BACKGROUND : : O
: NN CAPITAL Darier D
Darier NN disease D
disease VBZ is O
is DT an O
an JJ uncommon O
uncommon NN genodermatosis D
genodermatosis VBN characterized O
characterized IN by O
by DT the O
the JJ symmetrical O
symmetrical NN eruption O
eruption IN of O
of JJ keratotic O
keratotic JJ reddish-brown O
reddish-brown NNS papules O
papules VBG occurring O
occurring IN in O
in DT the O
the JJ seborrheic O
seborrheic NNS areas O
areas IN of O
of DT the O
the NN body O

A DT CAPITAL A O
A JJ unilateral O
unilateral , , O
, CC or O
or JJ localized O
localized , , O
, JJ variant O
variant VBZ has O
has VBN been O
been VBN identified O

We PRP CAPITAL We O
We NN report O
report CD 4 O
4 JJ new O
new NNS cases O
cases IN of O
of JJ localized O
localized NN CAPITAL Darier D
Darier NN disease D
disease CC and O
and NN review O
review DT the O
the JJ CAPITAL English-language O
English-language NN literature O

The DT CAPITAL The O
The NNS implications O
implications IN of O
of DT these O
these NNS cases O
cases IN on O
on JJ future O
future JJ genetic O
genetic NNS studies O
studies VBP are O
are RB also O
also VBN discussed O

OBSERVATIONS NNS CAPITAL OBSERVATIONS O
OBSERVATIONS : : O
: JJ CAPITAL Localized O
Localized NN CAPITAL Darier D
Darier NN disease D
disease VBD occurred O
occurred IN with O
with JJ equal O
equal NN frequency O
frequency IN in O
in NNS males O
males CC and O
and NNS females O

The DT CAPITAL The O
The JJ average O
average NN age O
age IN at O
at NN onset O
onset VBD was O
was CD 27 O
27 NNS years O

The DT CAPITAL The O
The JJS most O
most JJ frequent O
frequent NN site O
site IN of O
of NN involvement O
involvement VBD was O
was DT the O
the NN trunk O
trunk NN ( O
( CD 40 O
40 NN % O
% NN ( O
( CD 16/40 O
16/40 NN ) O
) NN ) O

This DT CAPITAL This O
This NN condition O
condition VBD was O
was VBN aggravated O
aggravated IN by O
by NN sunlight O
sunlight , , O
, NN heat O
heat , , O
, CC or O
or NN sweating O
sweating IN in O
in CD 42 O
42 NN % O
% NN ( O
( CD 19/40 O
19/40 NN ) O
) IN of O
of VBN reported O
reported NNS cases O
cases , , O
, CC and O
and CD 38 O
38 NN % O
% NN ( O
( CD 15/40 O
15/40 NN ) O
) IN of O
of DT the O
the NNS patients O
patients VBD responded O
responded TO to O
to NN treatment O
treatment IN with O
with JJ topical O
topical NN tretinoin T

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: JJ CAPITAL Many O
Many IN of O
of DT the O
the JJ clinical O
clinical NNS features O
features IN of O
of JJ localized O
localized NN CAPITAL Darier D
Darier NN disease D
disease VBP suggest O
suggest IN that O
that PRP it O
it VBZ is O
is DT a O
a JJ genetic O
genetic JJ mosaic O
mosaic IN of O
of VBN generalized O
generalized NN CAPITAL Darier D
Darier NN disease D

Further JJ CAPITAL Further O
Further NNS studies O
studies IN of O
of JJ localized O
localized NN CAPITAL Darier D
Darier NN disease D
disease MD may O
may RB therefore O
therefore VB prove O
prove TO to O
to VB be O
be JJ instrumental O
instrumental IN in O
in DT the O
the NN search O
search IN for O
for DT the O
the NN CAPITAL Darier D
Darier NN disease D
disease NN gene O

UV NN CAPITAL UV O
UV NN radiation O
radiation VBZ induces O
induces CD two O
two JJ major O
major NN CAPITAL DNA O
DNA NN damage O
damage NNS products O
products , , O
, DT the O
the NN cyclobutane O
cyclobutane NN pyrimidine O
pyrimidine NN dimer O
dimer NN ( O
( NN CAPITAL CPD O
CPD NN ) O
) CC and O
and , , O
, IN at O
at DT a O
a JJR lower O
lower NN frequency O
frequency , , O
, DT the O
the NN pyrimidine O
pyrimidine NN ( O
( CD 6-4 O
6-4 NN ) O
) NN pyrimidinone O
pyrimidinone NN dimer O
dimer NN ( O
( CD 6-4 O
6-4 NN product O
product NN ) O

Although IN CAPITAL Although O
Although FW CAPITAL Escherichia O
Escherichia NN coli O
coli CC and O
and NNS CAPITAL Saccharomyes O
Saccharomyes FW cerevisiae O
cerevisiae VB produce O
produce DT a O
a JJ CAPITAL CPD-specific O
CPD-specific NN photolyase O
photolyase IN that O
that VBZ eliminates O
eliminates RB only O
only DT this O
this NN class O
class IN of O
of NN dimer O
dimer , , O
, NNP CAPITAL Arabidopsis O
Arabidopsis NN thaliana O
thaliana , , O
, NN CAPITAL Drosphila O
Drosphila FW melanogaster O
melanogaster , , O
, NNP CAPITAL Crotalus O
Crotalus NN atrox O
atrox , , O
, CC and O
and NN CAPITAL Xenopus O
Xenopus NN laevis O
laevis VB have O
have RB recently O
recently VBN been O
been VBN shown O
shown TO to O
to NN photoreactivate O
photoreactivate DT both O
both NNS CAPITAL CPDs O
CPDs CC and O
and CD 6-4 O
6-4 NNS products O

We PRP CAPITAL We O
We VBP describe O
describe DT the O
the NN isolation O
isolation CC and O
and NN characterization O
characterization IN of O
of CD two O
two JJ new O
new NNS classes O
classes IN of O
of NNS mutants O
mutants IN of O
of NNP CAPITAL Arabidopsis O
Arabidopsis , , O
, VBN termed O
termed NN uvr2 O
uvr2 CC and O
and NN uvr3 O
uvr3 , , O
, IN that O
that VBP are O
are JJ defective O
defective IN in O
in DT the O
the NN photoreactivation O
photoreactivation IN of O
of NNS CAPITAL CPDs O
CPDs CC and O
and CD 6-4 O
6-4 NNS products O
products , , O
, RB respectively O

We PRP CAPITAL We O
We VB demonstrate O
demonstrate IN that O
that DT the O
the NN CAPITAL CPD O
CPD NN photolyase O
photolyase NN mutation O
mutation VBZ is O
is RB genetically O
genetically VBN linked O
linked TO to O
to DT a O
a NN CAPITAL DNA O
DNA NN sequence O
sequence VBG encoding O
encoding DT a O
a NN type O
type NNP CAPITAL II O
II NN ( O
( NN metazoan O
metazoan NN ) O
) NN CAPITAL CPD O
CPD NN photolyase O

In IN CAPITAL In O
In NN addition O
addition , , O
, PRP we O
we VBP are O
are JJ able O
able TO to O
to VB generate O
generate NNS plants O
plants IN in O
in WDT which O
which RB only O
only NNS CAPITAL CPDs O
CPDs CC or O
or CD 6-4 O
6-4 NNS products O
products VBP are O
are VBN photoreactivated O
photoreactivated IN in O
in DT the O
the JJ nuclear O
nuclear NN genome O
genome IN by O
by VBG exposing O
exposing DT these O
these NNS mutants O
mutants TO to O
to NN CAPITAL UV O
UV JJ light O
light CC and O
and RB then O
then VBG allowing O
allowing PRP them O
them TO to O
to NN repair O
repair CD one O
one CC or O
or DT the O
the JJ other O
other NN class O
class IN of O
of NNS dimers O

This DT CAPITAL This O
This VBZ provides O
provides PRP us O
us IN with O
with DT a O
a JJ unique O
unique NN opportunity O
opportunity TO to O
to NN study O
study DT the O
the JJ biological O
biological NNS consequences O
consequences IN of O
of DT each O
each IN of O
of DT these O
these CD two O
two JJ major O
major JJ CAPITAL UV-induced O
UV-induced NNS photoproducts O
photoproducts IN in O
in DT an O
an JJ intact O
intact VBG living O
living NN system O

A DT CAPITAL A O
A JJ diffuse O
diffuse JJ macular D
macular NN erythroderma D
erythroderma CC and O
and JJ subsequent O
subsequent NN desquamation D
desquamation IN after O
after CD 1 O
1 TO to O
to CD 2 O
2 NNS weeks O
weeks VBP are O
are CD two O
two IN of O
of DT the O
the CD five O
five JJ major O
major JJ diagnostic O
diagnostic NNS criteria O
criteria IN of O
of JJ toxic D
toxic NN shock D
shock NN syndrome D
syndrome NN ( D
( NN CAPITAL TSS D
TSS NN ) D

We PRP CAPITAL We O
We JJ present O
present DT the O
the NN case O
case IN of O
of DT a O
a JJ 15-month-old O
15-month-old NN girl O
girl IN with O
with NN CAPITAL TSS D
TSS , , O
, CC but O
but IN without O
without NN erythroderma D
erythroderma CC or O
or NN desquamation D

She PRP CAPITAL She O
She VBD was O
was VBN admitted O
admitted IN with O
with JJ high D
high NN fever D
fever , , O
, NN shock D
shock , , O
, CC and O
and JJ multiorgan O
multiorgan NN involvement O

Minimal JJ CAPITAL Minimal O
Minimal CC or O
or DT no O
no JJ cutaneous O
cutaneous NNS signs O
signs VBD were O
were JJ present O

Initially RB CAPITAL Initially O
Initially DT the O
the NN diagnosis O
diagnosis IN of O
of DT the O
the NN syndrome O
syndrome IN of O
of JJ hemorrhagic D
hemorrhagic NN shock D
shock CC and O
and NN encephalopathy D
encephalopathy VBD was O
was VBN made O

After IN CAPITAL After O
After CD 7 O
7 NNS days O
days , , O
, DT a O
a NN CAPITAL TSS D
TSS NN toxin O
toxin JJ 1-producing O
1-producing NN strain O
strain IN of O
of FW CAPITAL Staphylococcus O
Staphylococcus NN aureus O
aureus VBD was O
was VBN cultured O
cultured IN from O
from DT an O
an JJ inguinal O
inguinal NN lymph O
lymph NN node O
node , , O
, WRB where O
where NN inflammation D
inflammation VBD had O
had RB already O
already VBN been O
been VBN noticed O
noticed IN on O
on NN admission O

Moreover RB CAPITAL Moreover O
Moreover , , O
, DT the O
the NN girl O
girl VBD had O
had DT no O
no NNS antibodies O
antibodies IN against O
against DT this O
this NN toxin O

The DT CAPITAL The O
The NN serum O
serum NN cytokine O
cytokine NN profile O
profile IN during O
during DT the O
the JJ acute O
acute NN phase O
phase IN of O
of PRP$ her O
her NN illness O
illness VBD showed O
showed JJ high O
high NNS levels O
levels IN of O
of NN tumor O
tumor NN necrosis O
necrosis NN factor-alpha O
factor-alpha , , O
, NN interleukin-6 O
interleukin-6 CC and O
and NN interferon-gamma O
interferon-gamma , , O
, IN as O
as VBZ is O
is VBN seen O
seen IN during O
during NN activation O
activation IN of O
of DT the O
the JJ immune O
immune NN system O
system IN by O
by NN CAPITAL TSS D
TSS NN toxin O
toxin CD 1 O

Other JJ CAPITAL Other O
Other JJ possible O
possible NNS causes O
causes IN for O
for DT the O
the NN patient O
patient POS 's O
's NN illness O
illness VBD were O
were VBN excluded O

We PRP CAPITAL We O
We VBP conclude O
conclude IN that O
that DT the O
the NN patient O
patient VBD had O
had NN CAPITAL TSS D
TSS IN without O
without NN rash D

Without IN CAPITAL Without O
Without DT the O
the NN evidence O
evidence VBG implicating O
implicating DT a O
a NN CAPITAL TSS D
TSS NN toxin O
toxin JJ 1-producing O
1-producing NN strain O
strain IN of O
of NNP CAPITAL S. O
S. NN aureus O
aureus IN as O
as DT the O
the NN cause O
cause IN of O
of PRP$ her O
her NN disease O
disease , , O
, DT a O
a NN diagnosis O
diagnosis IN of O
of NN syndrome O
syndrome IN of O
of JJ hemorrhagic D
hemorrhagic NN shock D
shock CC and O
and NN encephalopathy D
encephalopathy MD would O
would VB have O
have VBN been O
been VBN made O

It PRP CAPITAL It O
It VBZ is O
is JJ possible O
possible IN that O
that DT some O
some NNS cases O
cases IN of O
of NN syndrome O
syndrome IN of O
of JJ hemorrhagic D
hemorrhagic NN shock D
shock CC and O
and NN encephalopathy D
encephalopathy VB represent O
represent DT a O
a JJ variant O
variant IN of O
of NN CAPITAL TSS D
TSS IN in O
in JJ small O
small NNS children O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NN CAPITAL BACKGROUND O
BACKGROUND : : O
: DT CAPITAL The O
The VBG growing O
growing NN teratoma O
teratoma NN syndrome O
syndrome VBZ refers O
refers TO to O
to DT the O
the NN phenomenon O
phenomenon WRB whereby O
whereby NN germ O
germ NN cell O
cell NNS tumors O
tumors VB enlarge O
enlarge IN after O
after NN chemotherapy O
chemotherapy IN despite O
despite JJ complete O
complete NN eradication O
eradication IN of O
of JJ malignant O
malignant NNS cells O
cells CC and O
and NN normalization O
normalization IN of O
of NN serum O
serum NN tumor O
tumor NNS markers O

This DT CAPITAL This O
This JJ clinical O
clinical NN scenario O
scenario MD must O
must VB be O
be VBN differentiated O
differentiated IN from O
from IN that O
that IN in O
in WDT which O
which NN germ D
germ NN cell D
cell NNS tumors D
tumors VB maintain O
maintain PRP$ their O
their JJ malignant O
malignant NNS characteristics O
characteristics IN with O
with JJ elevated O
elevated NNS levels O
levels IN of O
of NN serum O
serum NN tumor O
tumor NNS markers O

METHODS NNS CAPITAL METHODS O
METHODS : : O
: NNP CAPITAL Hospital O
Hospital NN record O
record NN review O
review VBD was O
was VBN conducted O
conducted IN of O
of CD 2 O
2 NNS cases O

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: CD CAPITAL Two O
Two JJ male O
male NNS patients O
patients VBP are O
are VBN presented O
presented , , O
, CD 1 O
1 IN with O
with DT a O
a JJ metastatic D
metastatic NN germ D
germ NN cell D
cell NN tumor D
tumor IN of O
of DT both O
both DT the O
the NN retroperitoneum O
retroperitoneum CC and O
and NN mediastinum O
mediastinum NN ( O
( IN with O
with JJ elevated O
elevated NN alpha-fetoprotein O
alpha-fetoprotein NN level O
level NN ) O
) CC and O
and CD 1 O
1 IN with O
with DT a O
a JJ primary D
primary NN germ D
germ NN cell D
cell NN tumor D
tumor IN of O
of DT the O
the NN mediastinum O
mediastinum NN ( O
( IN with O
with JJ elevated O
elevated NN alpha-fetoprotein O
alpha-fetoprotein CC and O
and NN beta-human O
beta-human JJ chorionic O
chorionic NN gonadotropin O
gonadotropin NNS levels O
levels NN ) O

After IN CAPITAL After O
After NN completion O
completion IN of O
of NN chemotherapy T
chemotherapy CC and O
and NN normalization O
normalization IN of O
of NN tumor O
tumor NNS markers O
markers , , O
, DT both O
both NNS patients O
patients VBN presented O
presented IN with O
with JJ pulmonary D
pulmonary NNS symptoms D
symptoms JJ attributable O
attributable TO to O
to PRP$ their O
their RB massively O
massively VBG enlarging O
enlarging JJ mediastinal D
mediastinal NNS teratomas D
teratomas . . O

The DT CAPITAL The O
The JJ clinical O
clinical CC and O
and JJ roentgenographic O
roentgenographic NNS features O
features IN of O
of NNS patients O
patients IN with O
with JJ thoracic O
thoracic NNS manifestations O
manifestations IN of O
of DT the O
the VBG growing O
growing NN teratoma D
teratoma NN syndrome D
syndrome , , O
, IN as O
as RB well O
well IN as O
as PRP$ its O
its NN management O
management , , O
, VBP are O
are VBN reviewed O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: IN CAPITAL After O
After NN chemotherapy T
chemotherapy IN in O
in NNS patients O
patients IN with O
with JJ primary D
primary CC or D
or JJ metastatic D
metastatic JJ mediastinal D
mediastinal NN germ D
germ NN cell D
cell NNS tumors D
tumors WP$ whose O
whose NN tumor O
tumor NNS markers O
markers VB normalize O
normalize , , O
, DT a O
a VBG growing O
growing NN mass O
mass IN in O
in DT the O
the NN mediastinum O
mediastinum MD may O
may VB represent O
represent DT the O
the VBG growing O
growing NN teratoma D
teratoma NN syndrome D

The DT CAPITAL The O
The NN chicken O
chicken NN calmodulin O
calmodulin PRP CAPITAL I O
I NN ( O
( NN CAPITAL CaMI O
CaMI NN ) O
) NN gene O
gene VBZ has O
has VBN been O
been VBN isolated O
isolated CC and O
and VBN characterized O
characterized IN on O
on DT the O
the NN level O
level IN of O
of NN cDNA O
cDNA CC and O
and JJ genomic O
genomic NN CAPITAL DNA O

The DT CAPITAL The O
The VBN deduced O
deduced NN amino O
amino NN acid O
acid NN ( O
( NN aa O
aa NN ) O
) NN sequence O
sequence VBZ is O
is JJ identical O
identical TO to O
to DT the O
the CD one O
one IN of O
of NN chicken O
chicken NN CAPITAL CaMII O
CaMII WDT which O
which VBZ consists O
consists IN of O
of CD 148 O
148 NN aa O

The DT CAPITAL The O
The NN CAPITAL CaMI O
CaMI NN gene O
gene VBZ contains O
contains CD six O
six NNS exons O

Its PRP$ CAPITAL Its O
Its NN intron/exon O
intron/exon NN organization O
organization VBZ is O
is JJ identical O
identical TO to O
to IN that O
that IN of O
of DT the O
the NN chicken O
chicken NN CAPITAL CaMII O
CaMII CC and O
and DT the O
the NN CAPITAL CaMI O
CaMI CC and O
and NN CAPITAL CaMIII O
CaMIII NNS genes O
genes IN of O
of NN rat O
rat CC and O
and JJ human O

Expression NN CAPITAL Expression O
Expression IN of O
of DT the O
the NN CAPITAL CaMI O
CaMI NN gene O
gene VBD was O
was VBN detected O
detected IN in O
in DT all O
all NN chicken O
chicken NNS tissues O
tissues VBN examined O
examined , , O
, IN although O
although IN at O
at VBG varying O
varying NNS levels O

The DT CAPITAL The O
The NN gene O
gene VBZ is O
is VBN transcribed O
transcribed IN into O
into CD four O
four NNS mRNAs O
mRNAs IN of O
of CD 0.8 O
0.8 , , O
, CD 1.4 O
1.4 , , O
, CD 1.7 O
1.7 CC and O
and CD 4.4 O
4.4 NN kb O
kb IN as O
as VBN determined O
determined IN by O
by JJ CAPITAL Northern O
Northern NN blot O
blot NN analysis O

Our PRP$ CAPITAL Our O
Our NNS results O
results VB demonstrate O
demonstrate IN that O
that DT the O
the `` `` O
`` JJ multigene-one-protein O
multigene-one-protein '' '' O
'' NN principle O
principle IN of O
of NN CAPITAL CaM O
CaM NN synthesis O
synthesis VBZ is O
is RB not O
not RB only O
only JJ applicable O
applicable TO to O
to NNS mammals O
mammals WP$ whose O
whose NN CAPITAL CaM O
CaM VBZ is O
is VBN encoded O
encoded IN by O
by CD three O
three JJ different O
different NNS genes O
genes , , O
, CC but O
but RB also O
also TO to O
to NNS chickens O

BACKGROUND NN CAPITAL BACKGROUND O
BACKGROUND : : O
: PRP CAPITAL We O
We VBN assessed O
assessed DT the O
the NN accuracy O
accuracy IN of O
of CD two O
two NN electron O
electron NN beam O
beam VBN computed O
computed NN tomography O
tomography NN ( O
( NN CAPITAL EBCT O
EBCT NN ) O
) NNS protocols O
protocols IN for O
for VBG predicting O
predicting JJ coronary D
coronary NNS events D

METHODS NNS CAPITAL METHODS O
METHODS CC CAPITAL AND O
AND NNS CAPITAL RESULTS O
RESULTS : : O
: IN CAPITAL In O
In CD 1994 O
1994 , , O
, CD 24 O
24 NNS months O
months IN after O
after NN enrollment O
enrollment IN in O
in DT a O
a JJ longitudinal O
longitudinal NN study O
study , , O
, CD 326 O
326 JJ high-risk O
high-risk NNS adults O
adults VBD underwent O
underwent DT both O
both CD 3- O
3- CC and O
and JJ 6-mm O
6-mm JJ image-slice O
image-slice NN thickness O
thickness NN CAPITAL EBCT O
EBCT NN scanning O
scanning CC and O
and VBD were O
were VBN followed O
followed RB up O
up IN for O
for CD 32.0+/-4.0 O
32.0+/-4.0 JJ additional O
additional NNS months O

Events NNS CAPITAL Events O
Events VBD were O
were VBN defined O
defined IN as O
as DT either O
either JJ coronary O
coronary NN death O
death , , O
, JJ myocardial D
myocardial NN infarction D
infarction , , O
, CC or O
or NN revascularization D

We PRP CAPITAL We O
We VBN monitored O
monitored DT these O
these NNS subjects O
subjects IN for O
for DT the O
the JJ 32-month O
32-month VBG postscanning O
postscanning NN period O
period IN with O
with JJ yearly O
yearly NN phone O
phone NNS calls O
calls CC and O
and NN acquisition O
acquisition IN of O
of NNS records O
records IN for O
for DT all O
all NN hospital O
hospital NNS admissions O

At IN CAPITAL At O
At DT the O
the NN time O
time IN of O
of NN scanning O
scanning , , O
, CD 11 O
11 NNS subjects O
subjects NN ( O
( CD 3 O
3 NN % O
% NN ) O
) VBD had O
had RB already O
already VBN suffered O
suffered CD 12 O
12 NNS events O
events NN ( O
( CD 5 O
5 NNS infarctions D
infarctions CC and O
and CD 7 O
7 NNS revascularizations D
revascularizations NN ) O
) IN during O
during DT the O
the JJ 24-month O
24-month VBG prescanning O
prescanning NN period O

During IN CAPITAL During O
During DT the O
the VBG postscanning O
postscanning NN period O
period , , O
, CD 18 O
18 NNS subjects O
subjects NN ( O
( CD 6 O
6 NN % O
% NN ) O
) VBN suffered O
suffered CD 23 O
23 NNS events O
events NN ( O
( CD 5 O
5 JJ coronary O
coronary NNS deaths O
deaths , , O
, CD 6 O
6 NNS infarctions D
infarctions , , O
, CC and O
and CD 12 O
12 NNS revascularizations D
revascularizations NN ) O

Thus RB CAPITAL Thus O
Thus , , O
, CD 28 O
28 NNS subjects O
subjects NN ( O
( CD 9 O
9 NN % O
% NN ) O
) VBN suffered O
suffered CD 35 O
35 NNS events O

Calcium NN CAPITAL Calcium O
Calcium NNS quantities O
quantities VBN calculated O
calculated IN for O
for DT both O
both NNS protocols O
protocols , , O
, VBN performed O
performed IN on O
on DT the O
the JJ same O
same NNS subjects O
subjects , , O
, VBD were O
were VBN sorted O
sorted IN in O
in VBG ascending O
ascending NN order O
order CC and O
and VBN divided O
divided IN into O
into JJ equal O
equal NNS quartiles O

When WRB CAPITAL When O
When NNS revascularizations D
revascularizations VBD were O
were VBN included O
included , , O
, RB there O
there VBD was O
was DT a O
a JJ significant O
significant NN trend O
trend IN toward O
toward JJR higher O
higher NNS frequencies O
frequencies IN of O
of NNS events O
events IN with O
with VBG increasing O
increasing NN calcium O
calcium NN quantity O
quantity NN ( O
( NN CAPITAL P O
P CC & O
& # # O
# CD 60 O
60 : ; O
; CD .01 O
.01 NN ) O

However RB CAPITAL However O
However , , O
, JJ coronary O
coronary NN death O
death CC and O
and NN infarction D
infarction VBD were O
were RB not O
not RB significantly O
significantly RBR more O
more JJ frequent O
frequent IN in O
in JJR higher O
higher NNS quartiles O

These DT CAPITAL These O
These NNS relationships O
relationships VBD were O
were JJ preserved O
preserved IN in O
in DT the O
the NNS subjects O
subjects IN without O
without RB prior O
prior NNS events O
events IN at O
at DT the O
the NN time O
time IN of O
of NN scanning O

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: NN CAPITAL Calcium O
Calcium NNS quantities O
quantities IN from O
from DT the O
the JJ 3-mm O
3-mm CC and O
and DT the O
the RBR more O
more JJ reproducible O
reproducible JJ 6-mm O
6-mm NN scanning O
scanning VBP are O
are RB equally O
equally JJ accurate O
accurate IN for O
for VBG predicting O
predicting NNS events O

Coronary JJ CAPITAL Coronary O
Coronary NN calcium O
calcium NN amount O
amount VBZ appears O
appears TO to O
to VB be O
be DT a O
a JJ weak O
weak NN predictor O
predictor IN of O
of JJ coronary O
coronary NN death O
death CC and O
and NN infarction D

Its PRP$ CAPITAL Its O
Its JJ predictive O
predictive NN accuracy O
accuracy VBZ is O
is JJ superior O
superior IN for O
for VBG predicting O
predicting NN revascularization D

Research NNP CAPITAL Research O
Research IN into O
into DT the O
the JJ genetic O
genetic NN component O
component IN of O
of DT some O
some JJ complex O
complex NNS behaviors O
behaviors RB often O
often NNS causes O
causes NN controversy O
controversy , , O
, VBG depending O
depending IN on O
on DT the O
the JJ social O
social VBG meaning O
meaning CC and O
and NN significance O
significance IN of O
of DT the O
the NN behavior O
behavior IN under O
under NN study O

Research NNP CAPITAL Research O
Research IN into O
into JJ sexual O
sexual RB orientation-simplistically O
orientation-simplistically VBN referred O
referred TO to O
to IN as O
as `` `` O
`` JJ gay O
gay NN gene O
gene '' '' O
'' JJ research-is O
research-is DT an O
an NN example O
example IN of O
of NN research O
research IN that O
that VBZ provokes O
provokes JJ intense O
intense NN controversy O

This DT CAPITAL This O
This NN research O
research VBZ is O
is JJ worrisome O
worrisome IN for O
for JJ many O
many NNS reasons O
reasons , , O
, VBG including O
including DT the O
the NN fact O
fact IN that O
that PRP it O
it VBZ has O
has VBN been O
been VBN used O
used TO to O
to NN harm O
harm NNS lesbians O
lesbians CC and O
and JJ gay O
gay NNS men O

Many JJ CAPITAL Many O
Many JJ homosexual O
homosexual NNS people O
people VB have O
have VBN been O
been VBN forced O
forced TO to O
to VB undergo O
undergo `` `` O
`` NNS treatments O
treatments '' '' O
'' TO to O
to NN change O
change PRP$ their O
their JJ sexual O
sexual NN orientation O

Other JJ CAPITAL Other O
Other VBD chose O
chose TO to O
to VB undergo O
undergo PRP them O
them TO to O
to NN escape O
escape NN discrimination O
discrimination CC and O
and JJ social O
social NN disapprobation O

But CC CAPITAL But O
But RB there O
there VBP are O
are JJ other O
other NNS reasons O
reasons TO to O
to NN worry O
worry IN about O
about JJ such O
such NN research O

The DT CAPITAL The O
The RB very O
very NN motivation O
motivation IN for O
for VBG seeking O
seeking DT an O
an `` `` O
`` NN origin O
origin '' '' O
'' IN of O
of NN homosexuality O
homosexuality VBZ reveals O
reveals NN homophobia O

Moreover RB CAPITAL Moreover O
Moreover , , O
, JJ such O
such NN research O
research MD may O
may JJ lead O
lead TO to O
to JJ prenatal O
prenatal NNS tests O
tests IN that O
that NN claim O
claim TO to O
to VB predict O
predict IN for O
for NN homosexuality O

For IN CAPITAL For O
For JJ homosexual O
homosexual NNS people O
people WP who O
who JJ live O
live IN in O
in NNS countries O
countries IN with O
with DT no O
no JJ legal O
legal NNS protections O
protections DT these O
these NNS dangers O
dangers VBP are O
are RB particularly O
particularly JJ serious O

The DT CAPITAL The O
The NN efficiency O
efficiency IN of O
of JJ testicular T
testicular NN sperm T
sperm NN retrieval T
retrieval IN by T
by JJ testicular T
testicular JJ fine T
fine NN needle T
needle NN aspiration T
aspiration NN ( T
( NN CAPITAL TEFNA T
TEFNA NN ) T
) VBD was O
was VBN compared O
compared IN with O
with JJ open T
open NN biopsy T
biopsy CC and T
and JJ testicular T
testicular NN sperm T
sperm NN extraction T
extraction NN ( T
( NN CAPITAL TESE T
TESE NN ) T
) , , O
, IN in O
in CD 37 O
37 RB rigorously O
rigorously VBN selected O
selected NNS patients O
patients IN with O
with JJ non-obstructive D
non-obstructive NN azoospermia D

All DT CAPITAL All O
All NNS patients O
patients VBD underwent O
underwent NN CAPITAL TEFNA T
TEFNA CC and O
and NN CAPITAL TESE T
TESE RB consecutively O

Thus RB CAPITAL Thus O
Thus , , O
, DT each O
each NN patient O
patient VBD served O
served IN as O
as PRP$ his O
his JJ own O
own NN control O

The DT CAPITAL The O
The NN case O
case VBD was O
was VBN regarded O
regarded IN as O
as JJ successful O
successful IN if O
if IN at O
at JJS least O
least CD one O
one JJ testicular O
testicular NN spermatozoon O
spermatozoon VBD was O
was VBN found O
found VBG allowing O
allowing JJ intracytoplasmic O
intracytoplasmic NN sperm O
sperm NN injection O
injection NN ( O
( NN CAPITAL ICSI O
ICSI NN ) O
) IN of O
of IN at O
at JJS least O
least CD one O
one NN oocyte O

The DT CAPITAL The O
The VB mean O
mean NN age O
age IN of O
of DT the O
the JJ male O
male NNS patients O
patients VBD was O
was CD 32.7 O
32.7 NNS years O
years NN ( O
( NN range O
range CD 24-47 O
24-47 NN ) O

Whereas IN CAPITAL Whereas O
Whereas IN by O
by NN CAPITAL TEFNA T
TEFNA NN spermatozoa O
spermatozoa VBG enabling O
enabling NN performance O
performance IN of O
of NN CAPITAL ICSI O
ICSI VBD were O
were VBN found O
found IN in O
in RB only O
only CD four O
four NNS patients O
patients IN out O
out IN of O
of CD 37 O
37 NN ( O
( CD 11 O
11 NN % O
% NN ) O
) , , O
, JJ open T
open NN biopsy T
biopsy CC and T
and NN CAPITAL TESE T
TESE VBD yielded O
yielded NN spermatozoa O
spermatozoa IN in O
in CD 16 O
16 NNS cases O
cases NN ( O
( CD 43 O
43 NN % O
% NN ) O

The DT CAPITAL The O
The JJ negative O
negative JJ predictive O
predictive NN value O
value IN of O
of JJ high O
high NN serum O
serum NN follicle O
follicle VBG stimulating O
stimulating NN hormone O
hormone NN ( O
( NN CAPITAL FSH O
FSH NN ) O
) NNS concentrations O
concentrations NN ( O
( JJR > O
> CC or O
or CD =10 O
=10 NN CAPITAL IU/l O
IU/l NN ) O
) NN ( O
( VBG predicting O
predicting NN failure O
failure TO to O
to VB find O
find NN spermatozoa O
spermatozoa IN for O
for NN CAPITAL ICSI O
ICSI NN ) O
) VBD was O
was JJ low O
low NN ( O
( CD 38.4 O
38.4 NN % O
% NN ) O

The DT CAPITAL The O
The JJ positive O
positive JJ predictive O
predictive NN value O
value NN ( O
( VBG predicting O
predicting DT the O
the NN chance O
chance TO to O
to VB find O
find NN spermatozoa O
spermatozoa IN for O
for NN CAPITAL ICSI O
ICSI NN ) O
) IN of O
of JJ normal-sized O
normal-sized NN testicle O
testicle VBD was O
was RB not O
not JJ different O
different IN from O
from IN that O
that IN of O
of JJ small-sized O
small-sized NN ( O
( CC & O
& # # O
# CD 60 O
60 : ; O
; CD 15 O
15 NN ml O
ml NN ) O
) NN testicle O
testicle NN ( O
( CD 50 O
50 NN % O
% NN ) O

Complications NNS CAPITAL Complications O
Complications VBN included O
included CD one O
one NN case O
case IN of O
of JJ testicular D
testicular NN bleeding D
bleeding VBG following O
following JJ fine T
fine NN needle T
needle NN aspiration T
aspiration , , O
, VBN treated O
treated RB locally O
locally , , O
, CC and O
and CD two O
two NNS cases O
cases IN of O
of JJ extratunical D
extratunical NN haematomata D
haematomata VBG following O
following NN CAPITAL TESE O
TESE VBG requiring O
requiring DT no O
no NN intervention O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> IN CAPITAL In O
In NNS patients O
patients IN with O
with JJ non-obstructive O
non-obstructive NN azoospermia O
azoospermia , , O
, NN CAPITAL TEFNA O
TEFNA VBZ has O
has DT a O
a RB significantly O
significantly JJR lower O
lower NN yield O
yield VBN compared O
compared TO to O
to NN CAPITAL TESE O

Performance NNP CAPITAL Performance O
Performance IN of O
of NN CAPITAL ICSI O
ICSI IN with O
with JJ testicular O
testicular NN sperm O
sperm IN in O
in DT these O
these NNS cases O
cases VBD resulted O
resulted IN in O
in JJ satisfactory O
satisfactory NN fertilization O
fertilization CC and O
and JJ high O
high NN embryo O
embryo NN transfer O
transfer NNS rates O

The DT CAPITAL The O
The NN implantation O
implantation CC and O
and NN pregnancy O
pregnancy NNS rates O
rates IN per O
per NN embryo O
embryo NN transfer O
transfer VBD were O
were CD 13 O
13 CC and O
and CD 29 O
29 NN % O
% RB respectively O

Neither DT CAPITAL Neither O
Neither NN serum O
serum NN CAPITAL FSH O
FSH NNS values O
values CC nor O
nor JJ testicular O
testicular NN size O
size VBD were O
were JJ predictive O
predictive IN of O
of DT the O
the NNS chances O
chances TO to O
to VB find O
find NN spermatozoa O
spermatozoa IN for O
for NN CAPITAL ICSI O

Some DT CAPITAL Some O
Some NNS complications O
complications MD may O
may VB occur O
occur RB even O
even VBG following O
following NN CAPITAL TEFNA T

Cyclin NN CAPITAL Cyclin O
Cyclin NN CAPITAL D1 O
D1 , , O
, DT the O
the JJ regulatory O
regulatory NN subunit O
subunit IN of O
of JJ certain O
certain NN protein O
protein NNS kinases O
kinases VBN thought O
thought TO to O
to NN advance O
advance DT the O
the NN CAPITAL G1 O
G1 NN phase O
phase IN of O
of DT the O
the NN cell O
cell NN cycle O
cycle , , O
, VBZ is O
is RB now O
now VBN established O
established IN as O
as DT a O
a NN proto-oncogene O
proto-oncogene , , O
, IN with O
with NN evidence O
evidence VBG indicating O
indicating IN that O
that PRP$ its O
its NN derangement O
derangement MD may O
may VB contribute O
contribute TO to O
to DT the O
the JJ uncontrolled O
uncontrolled NN cell O
cell NN growth O
growth JJ characteristic O
characteristic IN of O
of NNS tumors D

The DT CAPITAL The O
The JJ chromosomal O
chromosomal NN translocation O
translocation NN t O
t NN ( O
( CD 11 O
11 : ; O
; CD 14 O
14 NN ) O
) NN ( O
( NN q13 O
q13 : : O
: NN q32 O
q32 NN ) O
) , , O
, VBG involving O
involving NN rearrangement O
rearrangement IN of O
of DT the O
the NN CAPITAL BCL-1 O
BCL-1 NN locus O
locus , , O
, VBZ is O
is RB closely O
closely VBN associated O
associated IN with O
with JJ human D
human JJ lymphoid D
lymphoid NN neoplasia D
neoplasia VBG affecting O
affecting NN mantle D
mantle NN cell D
cell NNS lymphomas D
lymphomas NN ( D
( NN CAPITAL MCL D
MCL NN ) D

Recently RB CAPITAL Recently O
Recently , , O
, DT the O
the JJ putative O
putative NN CAPITAL BCL-1 O
BCL-1 NN proto-oncogene O
proto-oncogene VBD turned O
turned IN out O
out TO to O
to VB be O
be NN none O
none JJ other O
other IN than O
than DT the O
the NN cyclin O
cyclin NN CAPITAL D1 O
D1 NN gene O

Although IN CAPITAL Although O
Although DT the O
the VBN observed O
observed NN break O
break NNS points O
points IN in O
in DT the O
the NN CAPITAL BCL-1 O
BCL-1 NN locus O
locus VBP are O
are RB not O
not RB tightly O
tightly VBN clustered O
clustered , , O
, PRP$ its O
its NN rearrangement O
rearrangement VBZ has O
has VBN been O
been VBN documented O
documented IN in O
in CD 40-70 O
40-70 NN % O
% IN of O
of NNS cases O
cases IN of O
of NN mantle D
mantle NN cell D
cell NN lymphoma D
lymphoma , , O
, IN whereas O
whereas PRP it O
it RB only O
only RB rarely O
rarely VBZ occurs O
occurs IN in O
in JJ other O
other NN CAPITAL B D
B NN cell D
cell NNS lymphomas D

Of IN CAPITAL Of O
Of NN note O
note , , O
, DT all O
all IN of O
of DT the O
the JJ known O
known NN break O
break NNS points O
points VB leave O
leave DT the O
the NN cyclin O
cyclin NN CAPITAL D1 O
D1 VBG coding O
coding NN region O
region RB structurally O
structurally JJ intact O
intact CC and O
and NN result O
result IN in O
in VBN increased O
increased NN protein O
protein NN expression O
expression , , O
, VBG implying O
implying IN that O
that DT this O
this MD may O
may VB provide O
provide DT a O
a RB highly O
highly JJ sensitive O
sensitive CC and O
and JJ specific O
specific NN marker O
marker IN for O
for NN CAPITAL MCL D

Recent JJ CAPITAL Recent O
Recent NNS studies O
studies VBD demonstrated O
demonstrated IN that O
that JJ immunohistochemical O
immunohistochemical NN detection O
detection IN in O
in JJ paraffin-embedded O
paraffin-embedded NN material O
material , , O
, VBG using O
using DT a O
a JJ monoclonal O
monoclonal NN antibody O
antibody , , O
, VBZ is O
is RB very O
very JJ useful O
useful IN for O
for JJ routine O
routine NN diagnosis O

Current JJ CAPITAL Current O
Current NN knowledge O
knowledge IN of O
of NN cyclin O
cyclin NN CAPITAL D1 O
D1 NN overexpression O
overexpression IN in O
in JJ malignant D
malignant NNS lymphomas D
lymphomas , , O
, IN with O
with NN emphasis O
emphasis IN on O
on PRP$ its O
its JJ clinicopathologic O
clinicopathologic NN significance O
significance , , O
, VBZ is O
is VBN reviewed O

In IN CAPITAL In O
In DT the O
the JJ mammalian O
mammalian JJ central O
central JJ nervous O
nervous NN system O
system , , O
, DT a O
a JJ diverse O
diverse NN group O
group IN of O
of JJ basic O
basic JJ helix-loop-helix O
helix-loop-helix NN ( O
( JJ bHLH O
bHLH NN ) O
) NNS proteins O
proteins VBZ is O
is VBN involved O
involved IN in O
in DT the O
the NN determination O
determination IN of O
of NN progenitor O
progenitor NNS cells O
cells CC and O
and , , O
, RB subsequently O
subsequently , , O
, IN in O
in VBG regulating O
regulating JJ neuronal O
neuronal NN differentiation O

Here RB CAPITAL Here O
Here PRP we O
we NN report O
report DT the O
the NN identification O
identification IN of O
of DT a O
a JJ novel O
novel NN subfamily O
subfamily IN of O
of JJ bHLH O
bHLH NNS proteins O
proteins , , O
, VBN defined O
defined IN by O
by CD two O
two JJ mammalian O
mammalian JJ enhancer-of-split- O
enhancer-of-split- CC and O
and JJ hairy-related O
hairy-related NNS proteins O
proteins , , O
, VBN termed O
termed NN CAPITAL SHARP-1 O
SHARP-1 CC and O
and NN CAPITAL SHARP-2 O

In IN CAPITAL In O
In NN contrast O
contrast TO to O
to JJ known O
known JJ bHLH O
bHLH NNS genes O
genes , , O
, JJ detectable O
detectable NN transcription O
transcription IN of O
of JJ CAPITAL SHARP O
SHARP NNS genes O
genes VBZ begins O
begins IN at O
at DT the O
the NN end O
end IN of O
of JJ embryonic O
embryonic NN development O
development VBG marking O
marking VBN differentiated O
differentiated NNS neurons O
neurons IN that O
that VB have O
have VBN reached O
reached DT a O
a JJ final O
final NN position O
position , , O
, CC and O
and NNS increases O
increases IN as O
as JJ postnatal O
postnatal NN development O
development NNS proceeds O

In IN CAPITAL In O
In DT the O
the JJ adult O
adult , , O
, JJ CAPITAL SHARP O
SHARP NNS genes O
genes VBP are O
are VBN expressed O
expressed IN in O
in NNS subregions O
subregions IN of O
of DT the O
the NN CAPITAL CNS O
CNS IN that O
that VB have O
have VBN been O
been VBN associated O
associated IN with O
with JJ adult O
adult NN plasticity O

In IN CAPITAL In O
In NN CAPITAL PC12 O
PC12 NNS cells O
cells , , O
, DT a O
a NN model O
model NN system O
system TO to O
to NN study O
study NN neurite O
neurite NN outgrowth O
outgrowth , , O
, JJ CAPITAL SHARP O
SHARP NNS genes O
genes MD can O
can VB be O
be VBN induced O
induced IN by O
by NN CAPITAL NGF O
NGF IN with O
with DT the O
the NNS kinetics O
kinetics IN of O
of DT an O
an JJ immediate-early O
immediate-early NN gene O

Similarly RB CAPITAL Similarly O
Similarly , , O
, IN within O
within CD 1 O
1 NN h O
h IN after O
after DT the O
the NN administration O
administration IN of O
of JJ kainic O
kainic NN acid O
acid IN in O
in FW vivo O
vivo , , O
, NN CAPITAL SHARP-2 O
SHARP-2 VBZ is O
is VBN induced O
induced IN in O
in NNS neurons O
neurons IN throughout O
throughout DT the O
the NN rat O
rat JJ cerebral O
cerebral NN cortex O

This DT CAPITAL This O
This VBZ suggests O
suggests IN that O
that JJ neuronal O
neuronal JJ bHLH O
bHLH NNS proteins O
proteins VBP are O
are RB also O
also VBN involved O
involved IN in O
in DT the O
the `` `` O
`` JJ adaptive O
adaptive '' '' O
'' NNS changes O
changes IN of O
of JJ mature O
mature NN CAPITAL CNS O
CNS NNS neurons O
neurons WDT which O
which VBP are O
are VBN coupled O
coupled TO to O
to JJ glutamatergic O
glutamatergic NN stimulation O

The DT CAPITAL The O
The JJ embryonic O
embryonic NN development O
development IN of O
of DT the O
the NN face O
face VBZ has O
has VBN been O
been VBN studied O
studied IN in O
in JJ many O
many NNS reviews O
reviews , , O
, DT this O
this NN work O
work NNS purposes O
purposes RB only O
only TO to O
to JJ clear O
clear RB up O
up DT some O
some NNS points O
points WDT which O
which VBP remain O
remain JJ obscure O
obscure VBG concerning O
concerning JJ cervico-facial O
cervico-facial NN morphogenesis O

In IN CAPITAL In O
In DT the O
the RB first O
first NN part O
part IN of O
of DT this O
this NN study O
study RB only O
only DT the O
the JJ facial O
facial NN development O
development , , O
, RB properly O
properly VBG speaking O
speaking , , O
, VBZ is O
is VBN considered O
considered , , O
, IN although O
although PRP it O
it MD can O
can RB not O
not VB be O
be JJ separate O
separate IN of O
of JJ cervical O
cervical NN development O
development TO to O
to WDT which O
which DT a O
a JJ second O
second NN study O
study MD will O
will VB be O
be VBN reserved O

In IN CAPITAL In O
In DT the O
the JJ present O
present NN study O
study PRP we O
we NN recall O
recall DT the O
the JJ particular O
particular NNS aspects O
aspects IN of O
of DT the O
the NN neurulation O
neurulation IN in O
in DT the O
the JJ cephalic O
cephalic NN area O
area , , O
, RB then O
then DT the O
the NN establishment O
establishment IN of O
of DT the O
the JJ facial O
facial NNS processes O

Then RB CAPITAL Then O
Then PRP we O
we NN approach O
approach IN among O
among JJ other O
other NNS things O
things DT the O
the NN way O
way TO to O
to VB consider O
consider DT the O
the JJ maxillary O
maxillary NN process O
process IN with O
with NN regard O
regard TO to O
to DT the O
the JJ other O
other JJ facial O
facial NNS processes O

After IN CAPITAL After O
After VBZ is O
is VBN considered O
considered NN constitution O
constitution CC and O
and JJ natured O
natured IN of O
of DT the O
the JJ prechordal O
prechordal NN plate O
plate WDT which O
which VBZ has O
has VBN been O
been RB diversely O
diversely VBN explained O

Finally RB CAPITAL Finally O
Finally , , O
, DT the O
the VBG modelling O
modelling IN of O
of DT the O
the NN face O
face VBZ is O
is VBN evocated O
evocated , , O
, IN in O
in WDT which O
which DT the O
the NN dissociation O
dissociation IN between O
between DT the O
the JJ olfactive O
olfactive CC and O
and JJ buccal O
buccal NNS spheres O
spheres VBZ is O
is JJ pointed O
pointed IN out O
out , , O
, IN with O
with DT the O
the NN disparition O
disparition IN of O
of DT the O
the NN muzzle O
muzzle , , O
, IN as O
as PRP it O
it VBZ is O
is VBN established O
established IN in O
in DT the O
the NN haplorhinae O
haplorhinae , , O
, DT a O
a NN class O
class IN of O
of NNS primates O
primates IN in O
in WDT which O
which DT the O
the JJ human O
human VBG being O
being VBZ is O
is VBN involved O

This DT CAPITAL This O
This NN phenomenon O
phenomenon VBZ raises O
raises JJ different O
different NNS questions O
questions , , O
, IN in O
in JJ particular O
particular IN about O
about DT the O
the NN relation O
relation IN of O
of DT this O
this NN disposition O
disposition IN with O
with DT the O
the JJ nasoseptal O
nasoseptal NN center O
center , , O
, DT the O
the JJ medial O
medial NN part O
part IN of O
of DT the O
the JJ nasodorsal O
nasodorsal NN center O

A DT CAPITAL A O
A JJ case-control O
case-control NN study O
study VBD was O
was VBN performed O
performed IN in O
in CD eight O
eight NNS pairs O
pairs IN of O
of NNS women O
women TO to O
to VB determine O
determine IN whether O
whether JJ preeclamptic O
preeclamptic NNS women O
women VBN developed O
developed NNS abnormalities O
abnormalities IN in O
in JJ minor O
minor NNS hemoglobins O
hemoglobins , , O
, JJ glycolytic O
glycolytic NNS enzymes O
enzymes , , O
, CC or O
or JJ other O
other NN blood O
blood NNS components O
components IN that O
that MD might O
might VB provide O
provide NN insight O
insight IN into O
into DT the O
the NN pathophysiology O
pathophysiology IN of O
of NN preeclampsia D
preeclampsia , , O
, CC or O
or IN that O
that IN in O
in NN combination O
combination MD might O
might VB be O
be VBN used O
used IN as O
as DT a O
a NN marker O
marker IN for O
for DT the O
the NN condition O

These DT CAPITAL These O
These NNS variables O
variables CC and O
and JJ standard O
standard JJ clinical O
clinical NNS tests O
tests VBD were O
were VBN analyzed O
analyzed IN as O
as NNS discriminators O
discriminators IN between O
between JJ preeclamptic O
preeclamptic CC and O
and NN control O
control NNS women O

The DT CAPITAL The O
The NNS subjects O
subjects VBD were O
were VBN matched O
matched IN for O
for NN age O
age , , O
, NN ethnicity O
ethnicity , , O
, NN parity O
parity , , O
, CC and O
and JJ gestational O
gestational NN age O

Blood NN CAPITAL Blood O
Blood NNS samples O
samples VBD were O
were VBN taken O
taken IN at O
at DT the O
the NN time O
time IN of O
of NN diagnosis O
diagnosis IN of O
of NN preeclampsia D
preeclampsia CC and O
and IN at O
at JJ comparable O
comparable JJ gestational O
gestational NNS ages O
ages IN for O
for VBN matched O
matched JJ normal O
normal NNS controls O

Variables NNS CAPITAL Variables O
Variables VBG differing O
differing RB significantly O
significantly IN between O
between NNS groups O
groups VBN included O
included NNS increases O
increases IN in O
in JJ uric O
uric NN acid O
acid NN ( O
( NNP CAPITAL UA O
UA NN ) O
) , , O
, JJ low-density O
low-density NNS lipoproteins O
lipoproteins NN ( O
( NN CAPITAL LDL O
LDL NN ) O
) , , O
, NN phosphoglycerate O
phosphoglycerate NN kinase O
kinase NN ( O
( NN CAPITAL PGK O
PGK NN ) O
) , , O
, CC and O
and VB mean O
mean NN platelet O
platelet NN volume O
volume NN ( O
( NN CAPITAL MPV O
MPV NN ) O
) , , O
, CC and O
and NNS decreases O
decreases IN in O
in NN glyceraldehyde O
glyceraldehyde NN phosphate O
phosphate NN dehydrogenase O
dehydrogenase NN ( O
( NN CAPITAL G3PD O
G3PD NN ) O
) IN in O
in JJ preeclamptic O
preeclamptic NNS women O
women VBN compared O
compared TO to O
to JJ normal O
normal NNS controls O

Discriminant JJ CAPITAL Discriminant O
Discriminant NN analysis O
analysis VBD revealed O
revealed DT the O
the VBG following O
following NN function O
function TO to O
to JJ separate O
separate DT the O
the NNS groups O
groups : : O
: CD 0.7764 O
0.7764 NN ( O
( NNP CAPITAL UA O
UA NN ) O
) CC + O
+ CD 0.8086 O
0.8086 NN ( O
( NN CAPITAL PGK O
PGK NN ) O
) CD -0.7032 O
-0.7032 NN ( O
( NN CAPITAL G3PD O
G3PD NN ) O
) CC + O
+ CD 0.1399 O
0.1399 NN ( O
( NN CAPITAL LDL O
LDL NN ) O
) CD -0.2386 O
-0.2386 NN ( O
( NN CAPITAL MPV O
MPV NN ) O

A DT CAPITAL A O
A JJ discriminant O
discriminant NN score O
score IN of O
of JJR > O
> CC or O
or JJ = O
= CD 275 O
275 VBD indicated O
indicated DT a O
a JJR > O
> CC or O
or JJ = O
= CD 90 O
90 NN % O
% NN probability O
probability IN of O
of NN preeclampsia D

The DT CAPITAL The O
The NNS results O
results VBP are O
are JJ consistent O
consistent IN with O
with NNS perturbations O
perturbations IN in O
in JJ red O
red NN cell O
cell NN glycolysis O
glycolysis IN in O
in NN preeclampsia D

Further JJ CAPITAL Further O
Further JJ prospective O
prospective NNS studies O
studies VBP are O
are VBN warranted O
warranted TO to O
to NN test O
test DT the O
the NN efficacy O
efficacy IN of O
of DT this O
this JJ discriminant O
discriminant NN function O
function IN in O
in VBG predicting O
predicting NN preeclampsia D

A DT CAPITAL A O
A JJ novel O
novel NN technique O
technique IN for O
for NN patterning O
patterning VBN immobilized O
immobilized NN antibody O
antibody NNS layers O
layers VBN based O
based IN upon O
upon NN photolithography O
photolithography CC and O
and NN oxygen O
oxygen NN plasma O
plasma NN exposure O
exposure VBZ has O
has VBN been O
been VBN developed O

Mouse NN CAPITAL Mouse O
Mouse JJ monoclonal O
monoclonal NNS antibodies O
antibodies JJ specific O
specific IN for O
for JJ thiabendazole T
thiabendazole NN ( O
( DT a O
a JJ post-harvest O
post-harvest NN fungicide O
fungicide CC and O
and JJ veterinary O
veterinary JJ anthelmintic O
anthelmintic NN ) O
) VBD were O
were RB covalently O
covalently VBN linked O
linked IN through O
through JJ free O
free NN amine O
amine NNS groups O
groups TO to O
to VBN aminosilanized O
aminosilanized NN silicon O
silicon NN dioxide O
dioxide NNS films O
films VBG using O
using NN glutaraldehyde O

Immobilized VBN CAPITAL Immobilized O
Immobilized NN antibody O
antibody NNS layers O
layers VBD were O
were VBN stabilized O
stabilized IN with O
with NN sucrose O
sucrose , , O
, JJ dehydrated O
dehydrated , , O
, CC and O
and VBN stored O
stored VBN refrigerated O
refrigerated IN with O
with JJ desiccant O

Photolithographic JJ CAPITAL Photolithographic O
Photolithographic NN patterning O
patterning VBD was O
was VBN performed O
performed IN with O
with DT a O
a JJ positive O
positive NN photoresist O
photoresist IN with O
with VBN modified O
modified VB bake O
bake NNS temperatures O
temperatures CC and O
and NNS times O
times , , O
, JJ selective O
selective NN CAPITAL UV O
UV NN exposure O
exposure IN with O
with DT a O
a NN contact O
contact NN mask O
mask , , O
, CC and O
and JJ aqueous O
aqueous NN alkaline O
alkaline NN solubilization O
solubilization IN of O
of VBN exposed O
exposed VB resist O

Exposed VBN CAPITAL Exposed O
Exposed NNS regions O
regions IN of O
of VBN immobilized O
immobilized NN antibody O
antibody VBD were O
were RB then O
then VBN removed O
removed IN by O
by NN exposure O
exposure TO to O
to DT a O
a JJ low O
low NN power O
power , , O
, NN radio O
radio NN frequency O
frequency NN oxygen O
oxygen NN discharge O

Residual JJ CAPITAL Residual O
Residual VB resist O
resist VBD was O
was VBN stripped O
stripped IN with O
with NN acetone O

Successful JJ CAPITAL Successful O
Successful NN patterning O
patterning VBD was O
was VBD demonstrated O
demonstrated IN by O
by VBG challenging O
challenging NNS surfaces O
surfaces IN with O
with NN goat O
goat JJ anti-mouse O
anti-mouse NN antibody O
antibody VBN conjugated O
conjugated TO to O
to NN tetramethylrhodamine O
tetramethylrhodamine NN isothiocyanate O

Sucrose NN CAPITAL Sucrose O
Sucrose NN stabilization O
stabilization VBD was O
was JJ necessary O
necessary IN for O
for NN antibody O
antibody TO to O
to VB undergo O
undergo NN photoresist O
photoresist VBG processing O
processing IN without O
without NN loss O
loss IN of O
of VBG binding O
binding NN activity O

Challenge NN CAPITAL Challenge O
Challenge IN with O
with NN enzyme O
enzyme VBN linked O
linked NN antigen O
antigen IN of O
of NN oxygen O
oxygen NN plasma O
plasma VBN exposed O
exposed NN antibody O
antibody NNS layers O
layers VBD demonstrated O
demonstrated IN that O
that NN plasma O
plasma NN treatment O
treatment RB completely O
completely VBD neutralized O
neutralized NN antibody O
antibody NN capture O
capture NN ability O

Ellipsometry NN CAPITAL Ellipsometry O
Ellipsometry NNS measurements O
measurements IN of O
of NN oxygen O
oxygen NN plasma O
plasma VBN exposed O
exposed NN antibody O
antibody NNS layers O
layers VBD indicated O
indicated JJ complete O
complete NN removal O
removal IN of O
of VBN immobilized O
immobilized NNS antibodies O

Fluorescent JJ CAPITAL Fluorescent O
Fluorescent NN imaging O
imaging VBD demonstrated O
demonstrated JJS smallest O
smallest NN line O
line NNS widths O
widths IN of O
of CD 2-3 O
2-3 NNS microns O

Immune JJ CAPITAL Immune O
Immune NNS cells O
cells IN in O
in FW vivo O
vivo RB routinely O
routinely VB perform O
perform RB highly O
highly JJ selective O
selective NN immunosensing O
immunosensing IN in O
in NN blood O
blood CC and O
and NNS tissues O
tissues IN as O
as NN part O
part IN of O
of PRP$ their O
their JJ normal O
normal JJ immune O
immune NN surveillance O
surveillance NNS functions O

We PRP CAPITAL We O
We VB have O
have VBN been O
been VBG investigating O
investigating DT the O
the JJ potential O
potential IN of O
of VBG exploiting O
exploiting DT the O
the NN immunosensing O
immunosensing NN detection O
detection NNS abilities O
abilities IN of O
of JJ excitable O
excitable JJ immune O
immune NNS cells O
cells NN ( O
( NN i.e O
i.e . . O
. DT the O
the NN mast O
mast NN cell O
cell NN ) O
) IN for O
for DT the O
the NN development O
development IN of O
of JJ whole O
whole NN cell O
cell NNS immunobiosensors O

A DT CAPITAL A O
A JJ key O
key NN feature O
feature VBZ is O
is IN that O
that DT these O
these JJ immune O
immune NNS cells O
cells MD can O
can VB be O
be RB selectively O
selectively VBN engineered O
engineered TO to O
to VB recognize O
recognize JJ specific O
specific NNS antigens O
antigens IN in O
in FW vitro O

In IN CAPITAL In O
In DT the O
the NN presence O
presence IN of O
of NN antigen O
antigen , , O
, DT these O
these NNS cells O
cells VB undergo O
undergo JJ excitable O
excitable NN activation O
activation NNS responses O
responses WDT which O
which NN result O
result IN in O
in VBN increased O
increased NN metabolism O
metabolism CC and O
and DT the O
the NN exocytosis O
exocytosis IN of O
of VBN stored O
stored JJ intracellular O
intracellular NNS mediators O

We PRP CAPITAL We O
We VB have O
have RB previously O
previously VBN determined O
determined IN that O
that NN mast O
mast NN cell O
cell JJ metabolic O
metabolic NNS responses O
responses MD can O
can VB be O
be RB thermally O
thermally VBN transduced O
transduced IN in O
in JJ real O
real NN time O
time , , O
, RB thus O
thus VBG indicating O
indicating DT the O
the NN possibility O
possibility IN of O
of JJ whole O
whole NN cell O
cell JJ thermoelectric O
thermoelectric NN immunobiosensing O

In IN CAPITAL In O
In DT this O
this NN work O
work PRP we O
we VBN investigated O
investigated DT the O
the NN use O
use IN of O
of NN enzyme O
enzyme NN amplification O
amplification NNS systems O
systems TO to O
to VB enhance O
enhance DT the O
the JJ direct O
direct NN transduction O
transduction IN of O
of JJ immune O
immune NN cell O
cell NNS responses O
responses TO to O
to NN analyte O

It PRP CAPITAL It O
It VBD was O
was VBN found O
found IN that O
that IN with O
with JJ appropriate O
appropriate NNS enzymes O
enzymes , , O
, JJ peak O
peak NNS outputs O
outputs VBD occurred O
occurred IN within O
within RB approximately O
approximately CD 5 O
5 NN min O
min NN ( O
( CD 4-20 O
4-20 NNS times O
times RBR faster O
faster IN than O
than IN without O
without NNS enzymes O
enzymes NN ) O
) CC and O
and JJ peak O
peak NN response O
response NNS magnitudes O
magnitudes VBD were O
were RB up O
up TO to O
to JJ nine-fold O
nine-fold JJR greater O
greater IN than O
than IN without O
without NNS enzymes O

An DT CAPITAL An O
An JJ easy-to-use O
easy-to-use NN technique O
technique IN for O
for NN detection O
detection IN of O
of NNS antibodies O
antibodies JJ specific O
specific IN for O
for DT the O
the NN parasite O
parasite NNP CAPITAL L. O
L. JJ donovani O
donovani IN in O
in JJ human O
human NN serum O
serum NN sample O
sample VBZ has O
has VBN been O
been VBN developed O

The DT CAPITAL The O
The NN method O
method VBZ is O
is VBN based O
based IN on O
on DT an O
an JJ evanescent O
evanescent NN wave O
wave VBN generated O
generated IN from O
from DT a O
a VBN tapered O
tapered NN configuration O
configuration IN of O
of VBN decladded O
decladded JJ optical O
optical NN fibre O
fibre CC and O
and VBZ does O
does RB not O
not VB require O
require DT any O
any JJ volumetric O
volumetric NN measurement O

Tapered VBN CAPITAL Tapered O
Tapered NNS fibres O
fibres VBP are O
are VBN immobilized O
immobilized IN with O
with DT the O
the VBN purified O
purified NN cell O
cell NN surface O
surface NN protein O
protein IN of O
of NNP CAPITAL L. O
L. JJ donovani O
donovani IN by O
by JJ covalent O
covalent NN bonding O

Treated VBN CAPITAL Treated O
Treated NNS fibres O
fibres VBP are O
are VBN incubated O
incubated IN with O
with DT the O
the NN patient O
patient NN serum O
serum IN for O
for CD 10 O
10 NN min O
min VBN followed O
followed IN by O
by NN incubation O
incubation IN with O
with NN goat O
goat JJ anti O
anti JJ human O
human NN CAPITAL IgG O
IgG VBN tagged O
tagged NN CAPITAL FITC O

Fluorescent JJ CAPITAL Fluorescent O
Fluorescent NN intensity O
intensity IN from O
from DT the O
the NN fibre O
fibre VBZ has O
has VBN been O
been VBN shown O
shown TO to O
to VB be O
be JJ proportional O
proportional TO to O
to NNP CAPITAL L. O
L. JJ donovani O
donovani JJ specific O
specific NNS antibodies O
antibodies JJ present O
present IN in O
in DT the O
the NN test O
test NNS sera O

Direct JJ CAPITAL Direct O
Direct NNS readings O
readings MD can O
can VB be O
be VBN obtained O
obtained IN after O
after NN signal O
signal NN enhancement O
enhancement IN through O
through DT a O
a NN photomultiplier O
photomultiplier NN tube O
tube IN within O
within CD 5 O
5 NN min O

The DT CAPITAL The O
The NN system O
system , , O
, WRB when O
when VBN tested O
tested IN on O
on CD 12 O
12 JJ positive O
positive NNS sera O
sera , , O
, VBD did O
did RB not O
not NN show O
show DT any O
any JJ false O
false JJ negative O
negative NN result O

Also RB CAPITAL Also O
Also , , O
, DT no O
no JJ false O
false JJ positive O
positive NN result O
result VBD was O
was VBN obtained O
obtained IN with O
with NN serum O
serum NNS samples O
samples IN of O
of NNS patients O
patients JJ infected O
infected IN with O
with NNP leprosy D
leprosy , , O
, NN tuberculosis D
tuberculosis , , O
, NN typhoid D
typhoid CC and O
and NN malaria D
malaria , , O
, VBG showing O
showing DT the O
the NN specificity O
specificity IN of O
of DT the O
the NN sensor O
sensor CC and O
and NN efficacy O
efficacy IN of O
of DT the O
the NN technique O

We PRP CAPITAL We O
We JJ present O
present DT an O
an JJ optical O
optical NN biosensor O
biosensor NN design O
design IN that O
that NNS expands O
expands DT the O
the NN utility O
utility IN of O
of NN enzyme O
enzyme NNS biosensors O

These DT CAPITAL These O
These NNS biosensors O
biosensors VBP are O
are VBN fabricated O
fabricated IN by O
by JJ site-selective O
site-selective NN photodeposition O
photodeposition IN of O
of JJ analyte-sensitive O
analyte-sensitive NN polymer O
polymer NNS matrices O
matrices IN on O
on JJ optical O
optical NN imaging O
imaging NNS fibres O

These DT CAPITAL These O
These JJ dual-analyte O
dual-analyte NNS arrays O
arrays VB allow O
allow IN for O
for DT the O
the JJ simultaneous O
simultaneous , , O
, JJ independent O
independent NN measurement O
measurement IN of O
of DT the O
the NN analyte O
analyte IN of O
of NN interest O
interest CC and O
and DT the O
the VBG transducing O
transducing NN analyte O

The DT CAPITAL The O
The RB first O
first VBN integrated O
integrated NNS optical-biosensors O
optical-biosensors VBG using O
using DT this O
this NN design O
design VB have O
have VBN been O
been JJ prepared O
prepared IN that O
that VB allow O
allow DT both O
both DT the O
the JJ dependent O
dependent CC and O
and JJ independent O
independent NNS analytes O
analytes TO to O
to VB be O
be VBN measured O
measured RB simultaneously O
simultaneously , , O
, IN for O
for NN example O
example NN penicillin O
penicillin CC and O
and NN pH O
pH NN ( O
( NNP CAPITAL Healey O
Healey CC & O
& # # O
# CD 38 O
38 : ; O
; NNP CAPITAL Walt O
Walt , , O
, CD 1995 O
1995 NN ) O
) CC or O
or NN glucose O
glucose CC and O
and CD CAPITAL O2 O
O2 NN ( O
( NNP CAPITAL Li O
Li CC & O
& # # O
# CD 38 O
38 : ; O
; NNP CAPITAL Walt O
Walt , , O
, CD 1995 O
1995 NN ) O

Independent NNP CAPITAL Independent O
Independent NN measurement O
measurement IN of O
of DT the O
the VBG transducing O
transducing NN analyte O
analyte VBZ allows O
allows NN penicillin T
penicillin CC or O
or NN glucose O
glucose TO to O
to VB be O
be VBN quantitated O
quantitated IN in O
in DT the O
the NN presence O
presence IN of O
of DT a O
a JJ concurrent O
concurrent NN pH O
pH CC or O
or CD CAPITAL O2 O
O2 NN change O
change , , O
, RB respectively O

Penicillin NN CAPITAL Penicillin T
Penicillin MD can O
can VB be O
be VBN measured O
measured IN in O
in DT the O
the NN range O
range CD 0.25-10.0 O
0.25-10.0 NN mM O
mM IN in O
in DT the O
the NN pH O
pH NN range O
range CD 6.2-7.5 O

Glucose NN CAPITAL Glucose O
Glucose MD can O
can VB be O
be VBN measured O
measured IN in O
in DT the O
the NN range O
range CD 0.6-20.0 O
0.6-20.0 NN mM O
mM IN in O
in DT the O
the CD CAPITAL O2 O
O2 NN range O
range CD 20-100 O
20-100 NN % O

The DT CAPITAL The O
The NN utility O
utility IN of O
of DT the O
the NN sensor O
sensor NN design O
design VBD was O
was VBD demonstrated O
demonstrated IN by O
by VBG using O
using DT the O
the JJ penicillin-dual-analyte O
penicillin-dual-analyte NN biosensor O
biosensor TO to O
to VB quantitate O
quantitate NN penicillin T
penicillin VBN produced O
produced IN during O
during DT a O
a NNP CAPITAL Penicillium O
Penicillium NN chrysogenum O
chrysogenum NN fermentation O

The DT CAPITAL The O
The NN characterization O
characterization IN of O
of JJ low O
low JJ molecular O
molecular NN weight O
weight NN ligand O
ligand NN interaction O
interaction IN with O
with NN receptor O
receptor NNS molecules O
molecules VBZ is O
is IN of O
of NN importance O
importance IN for O
for DT the O
the NN investigation O
investigation IN of O
of JJ biological O
biological NNS processes O
processes CC and O
and IN for O
for NN drug O
drug NN research O

We PRP CAPITAL We O
We NN report O
report IN on O
on DT the O
the NN investigation O
investigation IN of O
of DT the O
the VBG binding O
binding IN of O
of JJ low O
low JJ molecular O
molecular NN weight O
weight NNS ligands O
ligands TO to O
to VBN immobilized O
immobilized NNS receptors O
receptors IN by O
by JJ label-free O
label-free NN detection O

Reflectometric JJ CAPITAL Reflectometric O
Reflectometric NN interference O
interference NN spectroscopy O
spectroscopy , , O
, DT an O
an JJ optical O
optical NN transducer O
transducer WDT which O
which VBZ allows O
allows DT the O
the VBG monitoring O
monitoring IN of O
of DT a O
a JJ few O
few NN picograms O
picograms IN per O
per JJ square O
square JJ millimetre O
millimetre NNS changes O
changes IN in O
in NN surface O
surface NN coverage O
coverage , , O
, VBD was O
was VBN used O
used TO to O
to NN study O
study CD two O
two NN model O
model NNS systems O

In IN CAPITAL In O
In DT both O
both NNS cases O
cases NN detection O
detection IN of O
of DT the O
the VBG binding O
binding NN event O
event VBD was O
was JJ successful O

High JJ CAPITAL High O
High NN affinity O
affinity VBG binding O
binding IN of O
of NN biotin O
biotin TO to O
to VBN immobilized O
immobilized NN streptavidin O
streptavidin VBD was O
was RB clearly O
clearly JJ detectable O
detectable IN at O
at NN receptor O
receptor NN surface O
surface NNS concentrations O
concentrations IN as O
as JJ low O
low IN as O
as CD 1-2 O
1-2 CC x O
x CD 10 O
10 NN ( O
( CD 10 O
10 NN ) O
) VBG binding O
binding NN sites/mm2 O

Linear JJ CAPITAL Linear O
Linear NN correlation O
correlation IN between O
between DT the O
the NN receptor O
receptor NN surface O
surface NN concentration O
concentration CC and O
and DT the O
the NN response O
response TO to O
to NN biotin O
biotin VBG binding O
binding VBD was O
was VBN observed O

Using VBG CAPITAL Using O
Using VBN immobilized O
immobilized NN CAPITAL DNA O
DNA , , O
, PRP we O
we VBN investigated O
investigated DT the O
the VBG binding O
binding IN of O
of JJ common O
common NNS intercalators O
intercalators IN with O
with NN respect O
respect TO to O
to NNS kinetics O
kinetics CC and O
and NNS thermodynamics O
thermodynamics IN by O
by NN evaluation O
evaluation IN of O
of DT the O
the NN association O
association CC and O
and DT the O
the NN dissociation O
dissociation NN part O
part IN of O
of DT the O
the VBG binding O
binding NN curve O

Bi-exponential JJ CAPITAL Bi-exponential O
Bi-exponential NN increase O
increase CC and O
and NN decrease O
decrease IN of O
of NN intercalator O
intercalator VBG loading O
loading VBD was O
was VBN observed O
observed , , O
, VBG indicating O
indicating JJ complex O
complex NN interaction O
interaction NNS kinetics O

The DT CAPITAL The O
The CD four O
four RB structurally O
structurally JJ different O
different NNS intercalators O
intercalators VBD showed O
showed JJ significant O
significant NN distinction O
distinction IN in O
in VBG binding O
binding NNS kinetics O
kinetics CC and O
and NN equilibrium O
equilibrium NNS signals O

Improvement NN CAPITAL Improvement O
Improvement IN of O
of JJ experimental O
experimental NNS parameters O
parameters VBZ is O
is VBN required O
required TO to O
to VB obtain O
obtain RBR more O
more JJ reliable O
reliable JJ kinetic O
kinetic NNS data O

An DT CAPITAL An O
An JJ amperometric O
amperometric NN lactate O
lactate NN oxidase O
oxidase NN catheter O
catheter VBZ has O
has VBN been O
been VBN developed O
developed IN for O
for IN in O
in FW vivo O
vivo NN application O
application TO to O
to JJ real-time O
real-time NN lactate O
lactate VBG monitoring O

The DT CAPITAL The O
The JJ electrochemical O
electrochemical NN behaviour O
behaviour IN of O
of DT the O
the CD 1 O
1 CC x O
x CD 3 O
3 NN mm O
mm NN CAPITAL Pt-Ag/AgCl O
Pt-Ag/AgCl JJ thin O
thin NN film O
film NN electrode O
electrode VBZ is O
is RB not O
not RB significantly O
significantly VBN influenced O
influenced IN by O
by NN lactate O
lactate NN oxidase-polyurethane O
oxidase-polyurethane VBG covering O

Gamma-irradiation NN CAPITAL Gamma-irradiation O
Gamma-irradiation NN ( O
( CD 25 O
25 NN kGy O
kGy NN ) O
) VBZ is O
is JJ suitable O
suitable IN for O
for DT the O
the NN sterilization O
sterilization NN procedure O

The DT CAPITAL The O
The JJ final O
final NN lactate O
lactate NN catheter O
catheter VBZ is O
is VBN characterized O
characterized IN by O
by DT a O
a JJ linear O
linear NN concentration O
concentration NN range O
range IN between O
between CD 0.5 O
0.5 CC and O
and CD 20 O
20 NN mmol/l O
mmol/l NN lactate O
lactate IN with O
with DT a O
a NN sensitivity O
sensitivity IN around O
around CD 2 O
2 NN nA O
nA NN mmol-1 O
mmol-1 NN l-1 O
l-1 NN lactate O

The DT CAPITAL The O
The NN accuracy O
accuracy VBZ is O
is VBD demonstrated O
demonstrated IN by O
by DT the O
the NN measurement O
measurement IN of O
of NN control O
control NNS sera O

Both DT CAPITAL Both O
Both JJ physiological O
physiological CC and O
and JJ pathological O
pathological NNS materials O
materials VB correlate O
correlate RB well O
well IN with O
with DT the O
the VBD declared O
declared NNS values O

The DT CAPITAL The O
The JJ dry O
dry VBN stored O
stored NN lactate O
lactate NN catheter O
catheter NNS needs O
needs IN about O
about CD 10 O
10 NN min O
min IN for O
for NN hydration O
hydration CC and O
and VBZ is O
is VBN characterized O
characterized IN by O
by NN response O
response NNS times O
times NN t98 O
t98 NN % O
% IN of O
of JJR less O
less IN than O
than CD 2 O
2 NN min O

Ex FW CAPITAL Ex O
Ex FW vivo O
vivo JJ whole O
whole NN blood O
blood NNS measurements O
measurements VBG using O
using DT the O
the NN lactate O
lactate NN catheter O
catheter NN ( O
( NN y O
y NN ) O
) VB give O
give DT a O
a NN correlation O
correlation IN with O
with DT the O
the NN CAPITAL BIOSEN O
BIOSEN VBN CAPITAL Med O
Med NN CAPITAL L O
L NN ( O
( CC x O
x NN ) O
) IN of O
of NN y O
y JJ = O
= NN ( O
( NN 1.010x O
1.010x CC + O
+ CD 0.513 O
0.513 NN ) O
) NN mmol/l O
mmol/l NN ( O
( NN r O
r JJ = O
= CD 0.9748 O
0.9748 NN ) O

Lactate NN CAPITAL Lactate O
Lactate NNS values O
values VBN obtained O
obtained IN by O
by JJ continuous O
continuous NN catheter O
catheter NN operation O
operation FW ex O
ex FW vivo O
vivo VB correlate O
correlate RB well O
well IN with O
with DT those O
those VBN obtained O
obtained IN by O
by NN CAPITAL BIOSEN O
BIOSEN VBN CAPITAL Med O
Med NNP CAPITAL L. O
L. NNP CAPITAL First O
First JJ subcutaneous O
subcutaneous NN implantation O
implantation NN ( O
( NN dog O
dog NN ) O
) VBZ underlines O
underlines DT the O
the NNS characteristics O
characteristics VBN obtained O
obtained FW ex O
ex FW vivo O
vivo : : O
: IN after O
after CD 30 O
30 NN min O
min NN hydration O
hydration DT the O
the NN lactate O
lactate NN catheter O
catheter VBZ follows O
follows DT the O
the NN lactate O
lactate NN concentration O
concentration VBN measured O
measured FW ex O
ex FW vivo O
vivo IN with O
with NNS samples O
samples IN from O
from DT the O
the NN leg O
leg NN vein O
vein IN by O
by NN CAPITAL BIOSEN O
BIOSEN VBN CAPITAL Med O
Med NNP CAPITAL L. O

The DT CAPITAL The O
The JJ diffusion-limited O
diffusion-limited VBG binding O
binding NNS kinetics O
kinetics IN of O
of NN antigen O
antigen NN ( O
( CC or O
or NN antibody O
antibody NN ) O
) IN in O
in NN solution O
solution TO to O
to NN antibody O
antibody NN ( O
( CC or O
or NN antigen O
antigen NN ) O
) VBN immobilized O
immobilized IN on O
on DT a O
a NN biosensor O
biosensor CC and O
and JJ other O
other NNS surfaces O
surfaces VBZ is O
is VBN analyzed O
analyzed IN within O
within DT a O
a JJ fractal O
fractal NN framework O

Often RB CAPITAL Often O
Often , , O
, DT the O
the VBG binding O
binding NNS kinetics O
kinetics MD may O
may VB be O
be VBN described O
described IN by O
by DT a O
a JJ single-fractal O
single-fractal NN analysis O

In IN CAPITAL In O
In DT some O
some NNS cases O
cases , , O
, DT the O
the VBG binding O
binding NN curve O
curve VBZ exhibits O
exhibits NNS complexities O

Then RB CAPITAL Then O
Then , , O
, IN for O
for DT these O
these NNS cases O
cases , , O
, DT the O
the JJ dual-fractal O
dual-fractal NN analysis O
analysis VBZ provides O
provides DT an O
an VBN improved O
improved JJ fit O
fit WRB when O
when VBN compared O
compared IN with O
with DT a O
a JJ single-fractal O
single-fractal NN analysis O

This DT CAPITAL This O
This VBZ indicates O
indicates DT a O
a NN change O
change IN in O
in DT the O
the NN reaction O
reaction NN mechanism O
mechanism IN on O
on DT the O
the NN surface O

It PRP CAPITAL It O
It VBZ is O
is IN of O
of NN interest O
interest TO to O
to NN note O
note IN that O
that DT the O
the NN state O
state IN of O
of NN disorder O
disorder NN ( O
( CC or O
or DT the O
the JJ fractal O
fractal NN dimension O
dimension NN ) O
) CC and O
and DT the O
the VBG binding O
binding NN rate O
rate NN coefficient O
coefficient DT both O
both NN increase O
increase IN as O
as DT the O
the NN reaction O
reaction VBZ progresses O
progresses IN on O
on DT the O
the NN biosensor O
biosensor NN surface O

For IN CAPITAL For O
For NN example O
example , , O
, IN for O
for DT the O
the VBG binding O
binding IN of O
of CD 10 O
10 NN nM O
nM NN insulin O
insulin NN growth O
growth NN factor-1 O
factor-1 IN in O
in NN solution O
solution TO to O
to NN insulin O
insulin NN growth O
growth NN factor O
factor VBG binding O
binding NN protein-1 O
protein-1 VBN immobilized O
immobilized IN on O
on DT a O
a NN biosensor O
biosensor NN surface O
surface , , O
, DT a O
a CD 64 O
64 NN % O
% NN increase O
increase IN in O
in DT the O
the JJ fractal O
fractal NN dimension O
dimension IN from O
from CD 1.73 O
1.73 NN ( O
( NN CAPITAL Df1 O
Df1 NN ) O
) TO to O
to CD 2.85 O
2.85 NN ( O
( NN CAPITAL Df2 O
Df2 NN ) O
) VBZ leads O
leads TO to O
to DT an O
an NN increase O
increase IN in O
in DT the O
the VBG binding O
binding NN rate O
rate NN coefficient O
coefficient IN by O
by DT a O
a NN factor O
factor IN of O
of CD 31.8 O
31.8 IN from O
from CD 3.92 O
3.92 NN ( O
( NN k1 O
k1 NN ) O
) TO to O
to CD 125 O
125 NN ( O
( NN k2 O
k2 NN ) O

Furthermore RB CAPITAL Furthermore O
Furthermore , , O
, IN as O
as DT the O
the NN CAPITAL IGF-1 O
IGF-1 NN concentration O
concentration IN in O
in NN solution O
solution NNS increases O
increases IN from O
from CD 10 O
10 TO to O
to CD 80 O
80 NN nM O
nM IN in O
in NN solution O
solution , , O
, NN k2 O
k2 CC and O
and NN CAPITAL Df2 O
Df2 NN exhibit O
exhibit DT a O
a JJ linear O
linear NN increase O

k1 NN k1 O
k1 CC and O
and NN CAPITAL Df1 O
Df1 NN exhibit O
exhibit DT a O
a JJ linear O
linear NN increase O
increase IN with O
with DT the O
the JJ reciprocal O
reciprocal IN of O
of DT the O
the NN CAPITAL IGF-1 O
IGF-1 NN concentration O
concentration IN in O
in NN solution O

The DT CAPITAL The O
The JJ different O
different NNS examples O
examples VBN analyzed O
analyzed CC and O
and VBN presented O
presented RB together O
together VB provide O
provide DT a O
a NNS means O
means IN by O
by WDT which O
which DT the O
the JJ antigen-antibody O
antigen-antibody NNS reactions O
reactions MD may O
may VB be O
be JJR better O
better JJ controlled O
controlled IN by O
by VBG noting O
noting DT the O
the NN magnitude O
magnitude IN of O
of DT the O
the NNS changes O
changes IN in O
in DT the O
the JJ fractal O
fractal NN dimension O
dimension CC and O
and IN in O
in DT the O
the VBG binding O
binding NN rate O
rate NN coefficient O
coefficient IN as O
as DT the O
the NN reaction O
reaction VBZ progresses O
progresses IN on O
on DT the O
the NN biosensor O
biosensor NN surface O

Also RB CAPITAL Also O
Also , , O
, DT the O
the NN magnitude O
magnitude IN of O
of DT the O
the NNS changes O
changes IN in O
in DT the O
the VBG binding O
binding NN rate O
rate NNS coefficients O
coefficients NN ( O
( NN k1 O
k1 CC and O
and NN k2 O
k2 NN ) O
) CC and O
and IN in O
in DT the O
the JJ fractal O
fractal NNS dimensions O
dimensions NN ( O
( NN CAPITAL Df1 O
Df1 CC and O
and NN CAPITAL Df2 O
Df2 NN ) O
) IN as O
as JJ different O
different NNS parameters O
parameters VBP are O
are VBN changed O
changed IN for O
for DT the O
the JJ different O
different NN biosensor O
biosensor NNS applications O
applications VBP are O
are IN of O
of JJ particular O
particular NN value O
value , , O
, IN since O
since PRP they O
they VB provide O
provide PRP us O
us IN with O
with DT a O
a NN measure O
measure CC or O
or NN extent O
extent IN of O
of NNS changes O
changes IN in O
in DT the O
the VBG binding O
binding NN rate O
rate NN coefficient O
coefficient IN on O
on VBG changing O
changing JJ different O
different JJ experimental O
experimental NN parameter O
parameter NNS values O

It PRP CAPITAL It O
It VBZ is O
is IN of O
of NN interest O
interest TO to O
to NN note O
note DT the O
the NN effect O
effect IN of O
of JJ different O
different NNS parameters O
parameters IN on O
on DT the O
the NN extent O
extent CC or O
or NN heterogeneity O
heterogeneity IN that O
that VBZ exists O
exists IN on O
on DT the O
the NN surface O
surface CC and O
and WRB how O
how DT this O
this VBZ influences O
influences DT the O
the VBG binding O
binding NN rate O
rate NNS coefficients O

This DT CAPITAL This O
This MD may O
may VB be O
be CD one O
one NN method O
method TO to O
to NN help O
help VB manipulate O
manipulate CC or O
or NN control O
control DT the O
the VBG binding O
binding NN rate O
rate NNS coefficients O
coefficients IN on O
on DT the O
the NN reaction O
reaction NN surface O

To TO CAPITAL To O
To VB determine O
determine IN if O
if JJ microscopic O
microscopic NN urinalysis O
urinalysis VBZ is O
is VBN needed O
needed IN in O
in DT all O
all JJ pediatric O
pediatric NN emergency O
emergency NN room O
room NNS patients O
patients VBN screened O
screened IN for O
for JJ urinary D
urinary NN tract D
tract NNS infections D
infections NN ( D
( NN CAPITAL UTI D
UTI NN ) D
) , , O
, PRP we O
we VBN compared O
compared DT the O
the NN dipstick O
dipstick NN urinalysis O
urinalysis CC and O
and JJ complete O
complete NN urinalysis O
urinalysis NN ( O
( NN dipstick O
dipstick CC and O
and NN microscopy O
microscopy NN ) O
) IN with O
with NN urine O
urine NNS cultures O
cultures IN in O
in CD 236 O
236 NNS children O
children , , O
, JJ aged O
aged CD 3 O
3 NNS weeks O
weeks TO to O
to CD 21 O
21 NNS years O

The DT CAPITAL The O
The NN ability O
ability TO to O
to VB detect O
detect NN CAPITAL UTI D
UTI IN by O
by NN dipstick O
dipstick RB only O
only CC and O
and IN by O
by JJ complete O
complete NN urinalysis O
urinalysis VBD was O
was DT the O
the JJ same O
same , , O
, RB however O
however JJ microscopic O
microscopic NN evaluation O
evaluation VBN added O
added JJ many O
many JJ false-positive O
false-positive NNS results O
results IN without O
without VBG detecting O
detecting JJ additional O
additional NNS CAPITAL UTIs D

Because IN CAPITAL Because O
Because DT the O
the NN ability O
ability TO to O
to VB detect O
detect NN CAPITAL UTI D
UTI NN ( O
( NN sensitivity O
sensitivity NN ) O
) VBZ is O
is JJ maintained O
maintained , , O
, PRP we O
we RB now O
now NN offer O
offer DT a O
a NN dipstick O
dipstick RB only O
only NN urinalysis O
urinalysis TO to O
to PRP$ our O
our NN emergency O
emergency NN room O
room IN for O
for NNS children O
children CD 2 O
2 NNS years O
years IN of O
of NN age O
age CC or O
or JJR older O
older , , O
, IN with O
with DT a O
a JJ microscopic O
microscopic NN analysis O
analysis VBN performed O
performed RB automatically O
automatically IN if O
if NN dipstick O
dipstick NNS results O
results VBP are O
are JJ positive O

If IN CAPITAL If O
If DT no O
no JJ microscopic O
microscopic NN urinalysis O
urinalysis VBZ is O
is VBN required O
required , , O
, NN testing O
testing NN turn-around O
turn-around NN time O
time VBZ is O
is VBN reduced O
reduced IN by O
by CD 12.3 O
12.3 JJS min/test O
min/test CC and O
and DT the O
the NN hospital O
hospital NN charge O
charge VBZ is O
is VBN reduced O
reduced IN from O
from JJ CAPITAL U.S O

$ $ $ O
$ CD 32 O
32 TO to O
to JJ CAPITAL U.S O

$ $ $ O
$ CD 12 O

Using VBG CAPITAL Using O
Using JJ video-intensified O
video-intensified NN fluorescence O
fluorescence NN microscopy O
microscopy CC and O
and DT a O
a NN pseudocolor O
pseudocolor NN display O
display IN of O
of NN fluorescence O
fluorescence NN intensity O
intensity , , O
, PRP we O
we VBN analyzed O
analyzed DT the O
the NN distribution O
distribution IN of O
of VBN microinjected O
microinjected NNS molecules O
molecules IN within O
within DT the O
the JJ nurse-cell/oocyte O
nurse-cell/oocyte NN syncytium O
syncytium IN of O
of FW CAPITAL Drosophila O
Drosophila JJ ovarian O
ovarian NNS follicles O

We PRP CAPITAL We O
We JJ varied O
varied DT the O
the NN composition O
composition CC and O
and DT the O
the NN osmolarity O
osmolarity IN of O
of DT the O
the NN culture O
culture NN solution O
solution IN as O
as RB well O
well IN as O
as DT the O
the JJ electrical O
electrical NN charge O
charge CC and O
and DT the O
the JJ molecular O
molecular NN mass O
mass IN of O
of DT the O
the VBN microinjected O
microinjected JJ fluorescent O
fluorescent NN probe O

As IN CAPITAL As O
As NN culture O
culture NNS solutions O
solutions , , O
, PRP we O
we VBN used O
used CD four O
four JJ simple O
simple NNS salines O
salines NN ( O
( NN CAPITAL IMADS O
IMADS NN ) O
) CC and O
and DT a O
a JJ complex O
complex NN tissue-culture O
tissue-culture NN medium O
medium NN ( O
( NN CAPITAL R-14 O
R-14 NN ) O
) IN that O
that VBN matched O
matched DT the O
the NN osmolarity O
osmolarity IN of O
of JJ adult O
adult NN hemolymph O

Small JJ CAPITAL Small O
Small NNS amounts O
amounts IN of O
of CD two O
two JJ anionic O
anionic NNS dyes O
dyes NN ( O
( NN CAPITAL Lucifer O
Lucifer JJ CAPITAL Yellow O
Yellow NN CAPITAL CH O
CH CC and O
and NN CAPITAL Lucifer O
Lucifer JJ CAPITAL Yellow O
Yellow NN dextran O
dextran NN ) O
) IN as O
as RB well O
well IN as O
as IN of O
of CD two O
two JJ cationic O
cationic NNS dyes O
dyes NN ( O
( NN rhodamine O
rhodamine NN 6G O
6G CC and O
and NN tetramethylrhodamine O
tetramethylrhodamine JJ dextran-lysine O
dextran-lysine NN ) O
) VBD were O
were RB iontophoretically O
iontophoretically VBN microinjected O
microinjected DT either O
either IN into O
into DT a O
a NN nurse O
nurse NN cell O
cell CC or O
or IN into O
into DT the O
the NN oocyte O
oocyte IN of O
of JJ stage-10 O
stage-10 NNS follicles O

In IN CAPITAL In O
In DT the O
the NN tissue-culture O
tissue-culture NN medium O
medium , , O
, IN within O
within DT a O
a JJ few O
few NNS seconds O
seconds VBG following O
following NN microinjection O
microinjection , , O
, DT all O
all VBN tested O
tested NNS dyes O
dyes VBN passed O
passed IN through O
through DT the O
the JJ intercellular O
intercellular NNS bridges O
bridges IN in O
in DT both O
both DT the O
the JJ anterior O
anterior NN direction O
direction NN ( O
( TO to O
to DT the O
the NN nurse O
nurse NNS cells O
cells NN ) O
) CC and O
and DT the O
the JJ posterior O
posterior NN direction O
direction NN ( O
( TO to O
to DT the O
the NN oocyte O
oocyte NN ) O
) , , O
, JJ independent O
independent IN of O
of PRP$ their O
their JJ electrical O
electrical NN charge O
charge CC or O
or JJ molecular O
molecular NN mass O

In IN CAPITAL In O
In DT all O
all JJ simple O
simple NNS salines O
salines , , O
, RB irrespective O
irrespective IN of O
of PRP$ their O
their NN osmolarity O
osmolarity , , O
, NN CAPITAL Lucifer O
Lucifer JJ CAPITAL Yellow O
Yellow NN CAPITAL CH O
CH VBD was O
was VBN found O
found TO to O
to RB preferentially O
preferentially VB migrate O
migrate IN in O
in DT the O
the JJ posterior O
posterior NN direction O
direction CC and O
and TO to O
to VB accumulate O
accumulate IN in O
in DT the O
the NN oocyte O
oocyte JJ due O
due TO to O
to JJ progressive O
progressive VBG binding O
binding TO to O
to NN yolk O
yolk NNS spheres O

Thus RB CAPITAL Thus O
Thus , , O
, IN with O
with DT this O
this JJ sensitive O
sensitive NN method O
method , , O
, DT no O
no NN correlation O
correlation VBD was O
was JJ detectable O
detectable IN between O
between DT the O
the JJ external O
external NN osmolarity O
osmolarity , , O
, DT the O
the JJ electrical O
electrical NN charge O
charge CC and O
and DT the O
the JJ preferential O
preferential NN direction O
direction IN of O
of NN migration O
migration IN of O
of DT a O
a VBN microinjected O
microinjected NN probe O

Our PRP$ CAPITAL Our O
Our NNS results O
results VBP indicate O
indicate IN that O
that DT the O
the JJ electrical O
electrical NN gradient O
gradient VBN described O
described IN by O
by JJ other O
other NNS authors O
authors VBZ does O
does RB not O
not VB exert O
exert JJ significant O
significant NN influence O
influence IN on O
on DT the O
the NN migration O
migration IN of O
of VBN charged O
charged NNS molecules O
molecules IN through O
through JJ intercellular O
intercellular NNS bridges O
bridges IN in O
in FW situ O

The DT CAPITAL The O
The NN CAPITAL AF-4 O
AF-4 NN gene O
gene IN on O
on JJ human O
human NN chromosome O
chromosome NN 4q21 O
4q21 VBZ is O
is VBN involved O
involved IN in O
in JJ reciprocal O
reciprocal NNS translocations O
translocations TO to O
to DT the O
the NN CAPITAL ALL-1 O
ALL-1 NN gene O
gene IN on O
on NN chromosome O
chromosome NN 11q23 O
11q23 , , O
, WDT which O
which VBP are O
are VBN associated O
associated IN with O
with JJ acute D
acute JJ lymphoblastic D
lymphoblastic NNS leukaemias D

A DT CAPITAL A O
A VBN set O
set IN of O
of JJ recombinant O
recombinant NN phage O
phage VBG carrying O
carrying JJ genomic O
genomic NNS fragments O
fragments IN for O
for DT the O
the VBG coding O
coding NN region O
region CC and O
and JJ flanking O
flanking NNS sequences O
sequences IN of O
of DT the O
the NN CAPITAL AF-4 O
AF-4 NN gene O
gene VBD were O
were VBN isolated O

Phage NN CAPITAL Phage O
Phage NNS inserts O
inserts VBD were O
were VBN assembled O
assembled IN into O
into CD four O
four NNS contigs O
contigs IN with O
with CD 21 O
21 NNS exons O
exons , , O
, CC and O
and DT an O
an NN intron O
intron NN phase O
phase NN map O
map VBD was O
was VBN produced O
produced VBG enabling O
enabling DT the O
the NN interpretation O
interpretation IN of O
of JJ translocation-generated O
translocation-generated NN fusion O
fusion NNS proteins O

The DT CAPITAL The O
The NN gene O
gene VBZ contains O
contains CD two O
two JJ alternative O
alternative RB first O
first NNS exons O
exons , , O
, NN 1a O
1a CC and O
and NN 1b O
1b , , O
, DT both O
both VBG including O
including DT a O
a NN translation O
translation NN initiation O
initiation NN codon O

The DT CAPITAL The O
The NN translocation O
translocation NN breakpoint O
breakpoint NN cluster O
cluster NN region O
region VBZ is O
is VBN flanked O
flanked IN by O
by NNS exons O
exons CD 3 O
3 CC and O
and CD 6 O
6 CC and O
and CD two O
two JJ different O
different NN polyadenylation O
polyadenylation NNS signals O
signals VBD were O
were VBN identified O

Polyclonal JJ CAPITAL Polyclonal O
Polyclonal NNS antisera O
antisera VBN directed O
directed IN against O
against CD three O
three JJ different O
different NNS portions O
portions IN of O
of DT the O
the NN CAPITAL AF-4 O
AF-4 NN protein O
protein VBD were O
were VBN produced O
produced CC and O
and VBN used O
used TO to O
to VB detect O
detect DT a O
a CD 116 O
116 NN kD O
kD NN protein O
protein IN in O
in JJ cellular O
cellular NNS extracts O
extracts IN of O
of JJ human O
human JJ CAPITAL B-lymphoblastoid O
B-lymphoblastoid CC and O
and NN proB O
proB NN cell O
cell NNS lines O

In IN CAPITAL In O
In JJ mitogen-stimulated O
mitogen-stimulated JJ human O
human JJ peripheral O
peripheral NN blood O
blood JJ mononuclear O
mononuclear NNS cells O
cells DT the O
the NN CAPITAL AF-4 O
AF-4 NN antigen O
antigen VBD was O
was RB predominantly O
predominantly JJ located O
located IN in O
in DT the O
the NN nucleus O

The DT CAPITAL The O
The NN CAPITAL AF-4 O
AF-4 NN gene O
gene VBZ is O
is DT a O
a NN member O
member IN of O
of DT the O
the NN CAPITAL AF-4 O
AF-4 , , O
, NN CAPITAL LAF-4 O
LAF-4 CC and O
and NN CAPITAL FMR-2 O
FMR-2 NN gene O
gene NN family O

The DT CAPITAL The O
The NNS members O
members IN of O
of DT this O
this NN family O
family VBP encode O
encode JJ serine-proline-rich O
serine-proline-rich NNS proteins O
proteins IN with O
with NNS properties O
properties IN of O
of JJ nuclear O
nuclear NN transcription O
transcription NNS factors O

Comparison NN CAPITAL Comparison O
Comparison IN of O
of NN CAPITAL AF-4 O
AF-4 NN protein O
protein VBG coding O
coding NNS sequences O
sequences IN with O
with DT the O
the NN CAPITAL LAF-4 O
LAF-4 CC and O
and NN CAPITAL FMR-2 O
FMR-2 NNS sequences O
sequences VBD revealed O
revealed CD five O
five RB highly O
highly VBN conserved O
conserved NNS domains O
domains IN of O
of JJ potential O
potential JJ functional O
functional NN relevance O

Immunoglobulin NN CAPITAL Immunoglobulin O
Immunoglobulin NN superfamily O
superfamily NNS molecules O
molecules IN in O
in DT the O
the NN brain O
brain VBP are O
are VBN involved O
involved IN in O
in JJ distinct O
distinct NNS aspects O
aspects IN of O
of JJ nervous O
nervous NN system O
system NN histogenesis O
histogenesis , , O
, IN for O
for NN example O
example JJ neuronal O
neuronal NN migration O
migration CC and O
and JJ axonal O
axonal NN growth O

To TO CAPITAL To O
To VB identify O
identify JJ novel O
novel NNS members O
members IN of O
of DT this O
this NN superfamily O
superfamily IN in O
in DT the O
the NN chick O
chick JJ nervous O
nervous NN system O
system , , O
, PRP we O
we VBN developed O
developed DT a O
a NN polymerase O
polymerase NN chain O
chain JJ reaction-based O
reaction-based NN approach O
approach VBG making O
making NN use O
use IN of O
of NN sequence O
sequence NNS motifs O
motifs IN of O
of JJ immunoglobulin-like O
immunoglobulin-like NNS domains O

In IN CAPITAL In O
In DT the O
the JJ present O
present NN study O
study , , O
, PRP we O
we NN report O
report DT the O
the JJ molecular O
molecular VBG cloning O
cloning IN of O
of CD three O
three NNS isoforms O
isoforms , , O
, DT the O
the JJ biochemical O
biochemical NN analysis O
analysis CC and O
and DT the O
the JJ immunohistochemical O
immunohistochemical NN characterization O
characterization IN of O
of CD one O
one IN of O
of DT the O
the NNS proteins O
proteins VBN identified O
identified IN in O
in DT this O
this NN screen O

This DT CAPITAL This O
This NN molecule O
molecule VBZ has O
has CD 91 O
91 NN % O
% NN sequence O
sequence NN identity O
identity IN with O
with DT the O
the JJ limbic O
limbic JJ system-associated O
system-associated NN membrane O
membrane NN protein O
protein NN ( O
( NN CAPITAL LAMP O
LAMP NN ) O
) VBN characterized O
characterized IN in O
in DT the O
the NN rat O
rat CC and O
and VBZ is O
is RB therefore O
therefore VBN referred O
referred TO to O
to IN as O
as DT the O
the NN chicken O
chicken NN homologue O
homologue IN of O
of DT the O
the JJ latter O
latter NN ( O
( NN chLAMP O
chLAMP NN ) O

The DT CAPITAL The O
The NN molecule O
molecule VBZ is O
is DT a O
a JJ glycosylphosphatidyl-inositol-anchored O
glycosylphosphatidyl-inositol-anchored CD 60 O
60 NN kDa O
kDa NN protein O
protein IN with O
with CD three O
three JJ immunoglobulin-like O
immunoglobulin-like NNS domains O
domains CC and O
and VBZ contains O
contains CD 40 O
40 NN % O
% JJ CAPITAL N-linked O
N-linked NN carbohydrate O

We PRP CAPITAL We O
We VB identify O
identify CD three O
three JJ different O
different NN mRNA O
mRNA NNS forms O
forms IN of O
of NN chLAMP O
chLAMP CC and O
and NN show O
show IN that O
that CD two O
two NNS forms O
forms IN with O
with JJ distinct O
distinct JJ 5'-termini O
5'-termini VBP are O
are RB differentially O
differentially VBN transcribed O
transcribed IN in O
in JJ neural O
neural NN development O

In IN CAPITAL In O
In NN addition O
addition , , O
, PRP we O
we VB demonstrate O
demonstrate VBG using O
using DT a O
a NN fusion O
fusion NN protein O
protein VBN expressed O
expressed IN in O
in JJ eukaryotic O
eukaryotic NNS cells O
cells IN that O
that NN chLAMP O
chLAMP VBZ has O
has JJ homophilic O
homophilic VBG binding O
binding NN activity O

The DT CAPITAL The O
The NN protein O
protein VBD was O
was VBN found O
found IN on O
on DT a O
a NN subset O
subset IN of O
of NNS axons O
axons IN in O
in DT the O
the JJ central O
central CC and O
and JJ peripheral O
peripheral JJ nervous O
nervous NN system O
system CC and O
and VBZ is O
is JJ likely O
likely TO to O
to VB be O
be VBN involved O
involved IN in O
in JJ specific O
specific JJ cell-cell O
cell-cell NNS interactions O
interactions IN in O
in NN neurohistogenesis O

Two CD CAPITAL Two O
Two JJ novel O
novel NNS cDNAs O
cDNAs , , O
, NN CAPITAL DNAS1L2 O
DNAS1L2 CC and O
and NN CAPITAL DNAS1L3 O
DNAS1L3 , , O
, VBP are O
are VBN predicted O
predicted TO to O
to VBP encode O
encode NNS proteins O
proteins IN of O
of CD 299 O
299 CC and O
and CD 305 O
305 NN amino O
amino NNS acids O
acids IN with O
with CD 56 O
56 CC and O
and CD 46 O
46 NN % O
% NN residue O
residue NN identity O
identity NN ( O
( CD 71 O
71 CC and O
and CD 63 O
63 NN % O
% NN similarity O
similarity NN ) O
) , , O
, RB respectively O
respectively , , O
, TO to O
to NN deoxyribonuclease O
deoxyribonuclease PRP CAPITAL I O
I NN ( O
( NN CAPITAL DNase O
DNase PRP CAPITAL I O
I NN ) O

DNAS1L2 NN CAPITAL DNAS1L2 O
DNAS1L2 VBZ is O
is JJ located O
located IN on O
on DT a O
a NN 16p13.3 O
16p13.3 NN cosmid O
cosmid , , O
, IN while O
while NN CAPITAL DNAS1L3 O
DNAS1L3 NNS maps O
maps TO to O
to NN 3p14.3-p21.1 O
3p14.3-p21.1 IN by O
by NN fluorescence O
fluorescence IN in O
in FW situ O
situ NN hybridization O
hybridization CC and O
and IN by O
by NN CAPITAL PCR O
PCR NN analysis O
analysis IN of O
of DT a O
a NN radiation O
radiation NN hybrid O
hybrid NN panel O

Northern JJ CAPITAL Northern O
Northern NN analysis O
analysis VBD revealed O
revealed NN CAPITAL DNAS1L3 O
DNAS1L3 NN expression O
expression RB nearly O
nearly RB exclusively O
exclusively IN in O
in NN liver O
liver , , O
, IN while O
while NN CAPITAL DNAS1L2 O
DNAS1L2 NN expression O
expression VBD was O
was VBN detected O
detected IN in O
in NN brain O
brain IN by O
by NN CAPITAL RT-PCR O

The DT CAPITAL The O
The RB previously O
previously VBN defined O
defined NN CAPITAL DNL1L O
DNL1L CC or O
or NN CAPITAL DNAS1L1 O
DNAS1L1 VBZ is O
is VBN expressed O
expressed JJS highest O
highest IN in O
in NN heart O
heart CC and O
and JJ skeletal O
skeletal NN muscle O
muscle , , O
, IN while O
while NN CAPITAL DNase O
DNase PRP CAPITAL I O
I VBZ is O
is VBN expressed O
expressed IN in O
in DT the O
the NN pancreas O
pancreas , , O
, NN parotid O
parotid NN gland O
gland , , O
, CC and O
and NN kidney O

Thus RB CAPITAL Thus O
Thus , , O
, TO to O
to NN date O
date , , O
, CD four O
four NN CAPITAL DNase O
DNase JJ CAPITAL I-like O
I-like NNS genes O
genes IN that O
that NN show O
show JJ different O
different NN tissue O
tissue NN expression O
expression NNS patterns O
patterns VBP are O
are JJ known O

A DT CAPITAL A O
A NN comparison O
comparison IN of O
of NN CAPITAL DNAS1L1 O
DNAS1L1 , , O
, NN CAPITAL DNAS1L2 O
DNAS1L2 , , O
, CC and O
and NN CAPITAL DNAS1L3 O
DNAS1L3 IN with O
with DT the O
the JJ well-characterized O
well-characterized NN CAPITAL DNase O
DNase PRP CAPITAL I O
I VBZ suggests O
suggests IN that O
that DT the O
the NN CAPITAL DNAS1L O
DNAS1L NNS proteins O
proteins VBP are O
are JJ unlikely O
unlikely TO to O
to VB be O
be VBN glycosylated O
glycosylated CC or O
or VB bind O
bind NN actin O
actin : ; O
; RB however O
however , , O
, JJ catalytic O
catalytic CC and O
and NN calcium- O
calcium- CC and O
and JJ CAPITAL DNA-binding O
DNA-binding NNS residues O
residues VBP are O
are VBN conserved O
conserved , , O
, CC and O
and RB potentially O
potentially JJ cleavable O
cleavable NN signal O
signal NNS peptides O
peptides VBP are O
are JJ present O
present IN among O
among DT all O
all DT these O
these NNS proteins O

This DT CAPITAL This O
This NN analysis O
analysis RB also O
also VBZ identifies O
identifies NNS regions O
regions IN of O
of JJ high O
high NN conservation O
conservation IN among O
among DT these O
these NNS proteins O
proteins IN with O
with DT no O
no RB currently O
currently VBN assigned O
assigned NN function O

Two CD CAPITAL Two O
Two JJ different O
different NNS responses O
responses TO to O
to DT the O
the NN therapy O
therapy VBD were O
were VBN observed O
observed IN in O
in DT a O
a NN group O
group IN of O
of NNS patients O
patients VBG receiving O
receiving DT the O
the NN protease T
protease NN inhibitor T
inhibitor NN indinavir T

In IN CAPITAL In O
In CD one O
one , , O
, NN suppression O
suppression IN of O
of NN virus O
virus NN replication O
replication VBD occurred O
occurred CC and O
and VBZ has O
has VBD persisted O
persisted IN for O
for CD 90 O
90 NNS weeks O
weeks NN ( O
( NN bDNA O
bDNA , , O
, CC & O
& # # O
# CD 60 O
60 : ; O
; CD 500 O
500 JJ human O
human NN immunodeficiency O
immunodeficiency NN virus O
virus NN type O
type CD 1 O
1 NN ( O
( NN CAPITAL HIV-1 O
HIV-1 NN ) O
) NN CAPITAL RNA O
RNA NN copies/ml O
copies/ml NN ) O

In IN CAPITAL In O
In DT the O
the JJ second O
second NN group O
group , , O
, DT a O
a VB rebound O
rebound IN in O
in NN virus O
virus NNS levels O
levels IN in O
in NN plasma O
plasma VBN followed O
followed DT the O
the JJ initial O
initial JJ sharp O
sharp NN decline O
decline VBN observed O
observed IN at O
at DT the O
the VB start O
start IN of O
of NN therapy O

This DT CAPITAL This O
This VBD was O
was VBN associated O
associated IN with O
with DT the O
the NN emergence O
emergence IN of O
of JJ drug-resistant O
drug-resistant NNS variants O

Sequence NN CAPITAL Sequence O
Sequence NN analysis O
analysis IN of O
of DT the O
the NN protease O
protease NN gene O
gene IN during O
during DT the O
the NN course O
course IN of O
of NN therapy O
therapy VBD revealed O
revealed IN that O
that IN in O
in DT this O
this JJ second O
second NN group O
group RB there O
there VBD was O
was DT a O
a JJ sequential O
sequential NN acquisition O
acquisition IN of O
of NN protease O
protease NNS mutations O
mutations IN at O
at NN amino O
amino NNS acids O
acids CD 46 O
46 , , O
, CD 82 O
82 , , O
, CD 54 O
54 , , O
, CD 71 O
71 , , O
, CD 89 O
89 , , O
, CC and O
and CD 90 O

In IN CAPITAL In O
In DT the O
the CD six O
six NNS patients O
patients IN in O
in DT this O
this NN group O
group , , O
, RB there O
there VBD was O
was RB also O
also DT an O
an JJ identical O
identical NN mutation O
mutation IN in O
in DT the O
the NN gag O
gag NN p7/p1 O
p7/p1 NN gag O
gag NN protease O
protease NN cleavage O
cleavage NN site O

In IN CAPITAL In O
In CD three O
three IN of O
of DT the O
the NNS patients O
patients , , O
, DT this O
this NN change O
change VBD was O
was VBN seen O
seen IN as O
as RB early O
early IN as O
as CD 6 O
6 TO to O
to CD 10 O
10 NNS weeks O
weeks IN after O
after DT the O
the VB start O
start IN of O
of NN therapy O

In IN CAPITAL In O
In CD one O
one NN patient O
patient , , O
, DT a O
a JJ second O
second NN mutation O
mutation VBD occurred O
occurred IN at O
at DT the O
the NN gag O
gag NN p1/p6 O
p1/p6 NN cleavage O
cleavage NN site O
site , , O
, CC but O
but PRP it O
it VBD appeared O
appeared CD 18 O
18 NNS weeks O
weeks IN after O
after DT the O
the NN time O
time IN of O
of NN appearance O
appearance IN of O
of DT the O
the NN p7/p1 O
p7/p1 NN mutation O

Recombinant JJ CAPITAL Recombinant O
Recombinant NN CAPITAL HIV-1 O
HIV-1 NNS variants O
variants VBG containing O
containing CD two O
two CC or O
or CD three O
three NNS mutations O
mutations IN in O
in DT the O
the NN protease O
protease NN gene O
gene VBD were O
were VBN constructed O
constructed DT either O
either IN with O
with NNS mutations O
mutations IN at O
at DT the O
the NN p7/p1 O
p7/p1 NN cleavage O
cleavage NN site O
site CC or O
or IN with O
with JJ wild-type O
wild-type NN ( O
( JJ CAPITAL WT O
WT NN ) O
) NN gag O
gag NNS sequences O

When WRB CAPITAL When O
When JJ recombinant O
recombinant JJ CAPITAL HIV-1-containing O
HIV-1-containing NN protease O
protease NNS mutations O
mutations IN at O
at CD 46 O
46 CC and O
and CD 82 O
82 VBD was O
was VBN grown O
grown IN in O
in NN CAPITAL MT2 O
MT2 NNS cells O
cells , , O
, RB there O
there VBD was O
was DT a O
a CD 68 O
68 NN % O
% NN reduction O
reduction IN in O
in PRP$ its O
its NN rate O
rate IN of O
of NN replication O
replication VBN compared O
compared TO to O
to DT the O
the JJ CAPITAL WT O
WT NN virus O

Introduction NN CAPITAL Introduction O
Introduction IN of O
of DT an O
an JJ additional O
additional NN mutation O
mutation IN at O
at DT the O
the NN gag O
gag NN p7/p1 O
p7/p1 NN protease O
protease NN cleavage O
cleavage NN site O
site VBN compensated O
compensated IN for O
for DT the O
the RB partially O
partially JJ defective O
defective NN protease O
protease NN gene O

Similarly RB CAPITAL Similarly O
Similarly , , O
, NNS rates O
rates IN of O
of NN replication O
replication IN of O
of NNS viruses O
viruses IN with O
with NNS mutations O
mutations NN CAPITAL M46L/I O
M46L/I , , O
, NN CAPITAL I54V O
I54V , , O
, CC and O
and NN CAPITAL V82A O
V82A IN in O
in NN protease O
protease VBD were O
were VBN enhanced O
enhanced DT both O
both IN in O
in DT the O
the NN presence O
presence CC and O
and IN in O
in DT the O
the NN absence O
absence IN of O
of NNP CAPITAL Indinavir O
Indinavir WRB when O
when JJ combined O
combined IN with O
with NNS mutations O
mutations IN in O
in DT the O
the NN gag O
gag NN p7/p1 O
p7/p1 CC and O
and DT the O
the NN gag O
gag NN p1/p6 O
p1/p6 NN cleavage O
cleavage NNS sites O

Optimal JJ CAPITAL Optimal O
Optimal NNS rates O
rates IN of O
of NN virus O
virus NN replication O
replication VB require O
require NN protease O
protease NN cleavage O
cleavage IN of O
of NN precursor O
precursor NNS polyproteins O

A DT CAPITAL A O
A NN mutation O
mutation IN in O
in DT the O
the NN cleavage O
cleavage NN site O
site IN that O
that VBN enhanced O
enhanced DT the O
the NN availability O
availability IN of O
of DT a O
a NN protein O
protein IN that O
that VBD was O
was NN rate O
rate VBG limiting O
limiting IN for O
for NN virus O
virus NN maturation O
maturation MD would O
would VB confer O
confer IN on O
on IN that O
that NN virus O
virus DT a O
a JJ significant O
significant NN growth O
growth NN advantage O
advantage CC and O
and MD may O
may VB explain O
explain DT the O
the JJ uniform O
uniform NN emergence O
emergence IN of O
of NNS viruses O
viruses IN with O
with NNS alterations O
alterations IN at O
at DT the O
the NN p7/p1 O
p7/p1 NN cleavage O
cleavage NN site O

This DT CAPITAL This O
This VBZ is O
is DT the O
the RB first O
first NN report O
report IN of O
of DT the O
the NN emergence O
emergence IN of O
of NNS mutations O
mutations IN in O
in DT the O
the NN gag O
gag NN p7/p1 O
p7/p1 NN protease O
protease NN cleavage O
cleavage NNS sites O
sites IN in O
in NNS patients O
patients VBG receiving O
receiving NN protease T
protease NN therapy T
therapy CC and O
and VBZ identifies O
identifies DT this O
this NN change O
change IN as O
as DT an O
an JJ important O
important NN determinant O
determinant IN of O
of NN CAPITAL HIV-1 O
HIV-1 NN resistance O
resistance TO to O
to NN protease O
protease NNS inhibitors O
inhibitors IN in O
in NN patient O
patient NNS populations O

A DT CAPITAL A O
A JJ novel O
novel JJ intracellular O
intracellular JJ calcium-binding O
calcium-binding NN protein O
protein IN from O
from NN CAPITAL Echinococcus O
Echinococcus NN granulosus O
granulosus VBZ is O
is VBN described O
described IN in O
in DT this O
this NN work O

A DT CAPITAL A O
A NN cDNA O
cDNA VBD was O
was VBN isolated O
isolated IN from O
from DT a O
a NN lambdagt11 O
lambdagt11 NN protoscolex O
protoscolex NN expression O
expression NN library O
library CC and O
and DT the O
the VBN deduced O
deduced NN amino O
amino NN acid O
acid NN sequence O
sequence VBZ has O
has IN at O
at JJS least O
least CD fifteen O
fifteen RB sequentially O
sequentially VBN repeated O
repeated JJ twelve-residue O
twelve-residue NNS repeats O
repeats IN that O
that VB resemble O
resemble DT the O
the JJ calcium-binding O
calcium-binding NN loop O
loop IN of O
of NNS CAPITAL EF-hands O
EF-hands : ; O
; RB however O
however , , O
, DT the O
the NN dodecamer O
dodecamer NN motif O
motif VBZ has O
has DT no O
no JJ flanking O
flanking NNS helices O

The DT CAPITAL The O
The NN cDNA O
cDNA VBD was O
was VBN expressed O
expressed IN in O
in FW CAPITAL Escherichia O
Escherichia NN coli O
coli VBG using O
using DT the O
the NN pGEX O
pGEX NN vector O
vector , , O
, CC and O
and DT a O
a JJ recombinant O
recombinant NN fusion O
fusion NN protein O
protein NN ( O
( NN CAPITAL EgCaBP1-GST O
EgCaBP1-GST NN ) O
) VBD was O
was VBN obtained O

The DT CAPITAL The O
The JJ recombinant O
recombinant NN fusion O
fusion NN protein O
protein VBZ binds O
binds NN calcium O
calcium WRB when O
when VBN assayed O
assayed IN with O
with NN 45Ca O

It PRP CAPITAL It O
It VBZ is O
is JJ possible O
possible IN that O
that DT the O
the JJ calcium-binding O
calcium-binding NNS motifs O
motifs JJ present O
present DT a O
a JJ secondary O
secondary NN structure O
structure JJ similar O
similar TO to O
to DT the O
the JJ parallel O
parallel NN beta O
beta NN roll O
roll NN structure O
structure VBN described O
described IN for O
for DT an O
an NN alkaline O
alkaline NN protease O
protease IN from O
from FW CAPITAL Pseudomonas O
Pseudomonas FW aeruginosa O

A DT CAPITAL A O
A JJ native O
native NN protein O
protein IN of O
of RBR more O
more IN than O
than CD 300 O
300 NN kDa O
kDa VBD was O
was VBN recognized O
recognized IN by O
by DT an O
an JJ anti-EgCaBP1 O
anti-EgCaBP1 JJ monoclonal O
monoclonal NN antibody O
antibody IN by O
by JJ CAPITAL Western-blot O
Western-blot NN analysis O

Immunohistochemistry NN CAPITAL Immunohistochemistry O
Immunohistochemistry VBG using O
using DT a O
a NN pool O
pool IN of O
of JJ anti-EgCaBP1-GST O
anti-EgCaBP1-GST NN mouse O
mouse NNS sera O
sera VBD demonstrated O
demonstrated DT a O
a JJ strong O
strong NN association O
association IN of O
of DT the O
the NN protein O
protein IN with O
with JJ calcareous O
calcareous NNS corpuscles O

The DT CAPITAL The O
The JJ possible O
possible NN role O
role IN of O
of DT this O
this NN protein O
protein CC and O
and IN that O
that IN of O
of DT the O
the JJ calcareous O
calcareous NNS corpuscles O
corpuscles IN in O
in DT the O
the NN protoscolex O
protoscolex VBP are O
are VBN discussed O

The DT CAPITAL The O
The NN enzyme O
enzyme NN activity O
activity IN of O
of JJ mitogen-activated O
mitogen-activated NN protein O
protein NN kinase O
kinase NN ( O
( NN CAPITAL MAP O
MAP NN kinase O
kinase NN ) O
) NNS increases O
increases IN in O
in NN response O
response TO to O
to NNS agents O
agents VBG acting O
acting IN on O
on DT a O
a NN variety O
variety IN of O
of NN cell O
cell NN surface O
surface NNS receptors O
receptors , , O
, VBG including O
including NNS receptors O
receptors VBN linked O
linked TO to O
to JJ heterotrimeric O
heterotrimeric NN CAPITAL G O
G NNS proteins O

In IN CAPITAL In O
In DT this O
this NN report O
report , , O
, PRP we O
we VBD demonstrated O
demonstrated IN that O
that NN CAPITAL Raf-1 O
Raf-1 NN protein O
protein NN kinase O
kinase NN activity O
activity IN in O
in DT the O
the NN mouse O
mouse NN parotid O
parotid NNS glands O
glands VBD was O
was VBN induced O
induced IN by O
by JJ chronic O
chronic NN isoproterenol O
isoproterenol NN administration O
administration IN in O
in JJ whole O
whole NNS animals O

To TO CAPITAL To O
To VB investigate O
investigate DT the O
the JJ molecular O
molecular NN nature O
nature VBG underlying O
underlying JJ cellular O
cellular NNS responses O
responses TO to O
to NN CAPITAL Raf-1 O
Raf-1 NN activation O
activation , , O
, PRP we O
we VB have O
have RB stably O
stably VBN transfected O
transfected NN rat O
rat JJ salivary O
salivary JJ epithelial O
epithelial NN CAPITAL Pa-4 O
Pa-4 NNS cells O
cells IN with O
with JJ human O
human JJ CAPITAL Raf-1-estrogen O
Raf-1-estrogen NN receptor O
receptor NN fusion O
fusion NN gene O
gene NN ( O
( NN CAPITAL DeltaRaf-1 O
DeltaRaf-1 : : O
: NN CAPITAL ER O
ER NN ) O
) CC and O
and VBN used O
used NN mRNA O
mRNA JJ differential O
differential NN display O
display IN in O
in NN search O
search IN of O
of NNS messages O
messages VBN induced O
induced IN by O
by NN CAPITAL DeltaRaf-1 O
DeltaRaf-1 : : O
: NN CAPITAL ER O
ER NN activation O

Through IN CAPITAL Through O
Through DT this O
this NN approach O
approach , , O
, DT the O
the NN gene O
gene VBG encoding O
encoding JJ non-histone O
non-histone JJ chromosomal O
chromosomal NN protein O
protein NN CAPITAL HMGI-C O
HMGI-C VBD was O
was VBN identified O
identified IN as O
as CD one O
one IN of O
of DT the O
the NN target O
target NNS genes O
genes VBN activated O
activated IN by O
by JJ oncogenic O
oncogenic NN CAPITAL Raf-1 O
Raf-1 NN kinase O

Activation NN CAPITAL Activation O
Activation IN of O
of NN CAPITAL Raf-1 O
Raf-1 NN kinase O
kinase VBD resulted O
resulted IN in O
in DT a O
a VBN delayed O
delayed CC and O
and JJ sustained O
sustained NN increase O
increase IN of O
of NN CAPITAL HMGI-C O
HMGI-C NN expression O
expression IN in O
in DT the O
the NN CAPITAL Pa-4 O
Pa-4 NNS cells O

The DT CAPITAL The O
The NN induction O
induction IN of O
of NN CAPITAL HMGI-C O
HMGI-C NN mRNA O
mRNA NN level O
level VBZ is O
is JJ sensitive O
sensitive TO to O
to DT both O
both DT the O
the NN protein O
protein NN synthesis O
synthesis NN inhibitor O
inhibitor NN cycloheximide O
cycloheximide CC and O
and NN transcription O
transcription NN inhibitor O
inhibitor JJ actinomycin O
actinomycin NN CAPITAL D O

The DT CAPITAL The O
The NN role O
role IN of O
of DT the O
the JJ extracellular O
extracellular JJ signal-related O
signal-related NN kinase O
kinase NN ( O
( NN CAPITAL ERK O
ERK NN ) O
) VBG signaling O
signaling NN pathway O
pathway IN in O
in DT the O
the NN CAPITAL HMGI-C O
HMGI-C NN induction O
induction VBD was O
was VBN highlighted O
highlighted IN by O
by DT the O
the NN result O
result IN that O
that DT the O
the NN CAPITAL MAP O
MAP NN kinase O
kinase NN kinase O
kinase NN ( O
( NN CAPITAL MEK O
MEK NN ) O
) NN inhibitor O
inhibitor , , O
, NN CAPITAL PD O
PD CD 98059 O
98059 , , O
, VBN blocked O
blocked NN CAPITAL DeltaRaf-1 O
DeltaRaf-1 : : O
: JJ CAPITAL ER- O
ER- CC and O
and JJ 12-O-tetradecanoylphorbol-13-acetate-stimulated O
12-O-tetradecanoylphorbol-13-acetate-stimulated NN CAPITAL HMGI-C O
HMGI-C NN induction O

Altogether RB CAPITAL Altogether O
Altogether , , O
, DT these O
these NNS findings O
findings NN support O
support DT the O
the NN notion O
notion IN that O
that DT the O
the NN CAPITAL Raf/MEK/ERK O
Raf/MEK/ERK VBG signaling O
signaling NN module O
module , , O
, IN at O
at JJS least O
least IN in O
in NN part O
part , , O
, VBZ regulates O
regulates JJ transcriptional O
transcriptional NN activation O
activation IN of O
of DT the O
the JJ chromosomal O
chromosomal JJ architectural O
architectural NN protein O
protein NN CAPITAL HMGI-C O

Pendred VBN CAPITAL Pendred D
Pendred NN syndrome D
syndrome VBZ is O
is DT a O
a RB recessively O
recessively VBN inherited O
inherited NN disorder O
disorder IN with O
with DT the O
the NN hallmark O
hallmark NNS features O
features IN of O
of JJ congenital D
congenital NN deafness D
deafness CC and O
and NN thyroid D
thyroid NN goitre D

By IN CAPITAL By O
By DT some O
some NNS estimates O
estimates , , O
, DT the O
the NN disorder O
disorder MD may O
may NN account O
account IN for O
for NNS upwards O
upwards IN of O
of CD 10 O
10 NN % O
% IN of O
of JJ hereditary D
hereditary NN deafness D

Previous JJ CAPITAL Previous O
Previous JJ genetic O
genetic NN linkage O
linkage NNS studies O
studies JJ localized O
localized DT the O
the NN gene O
gene TO to O
to DT a O
a JJ broad O
broad NN interval O
interval IN on O
on JJ human O
human NN chromosome O
chromosome JJ 7q22-31.1 O

Using VBG CAPITAL Using O
Using DT a O
a JJ positional O
positional VBG cloning O
cloning NN strategy O
strategy , , O
, PRP we O
we VB have O
have VBN identified O
identified DT the O
the NN gene O
gene NN ( O
( NN CAPITAL PDS O
PDS NN ) O
) VBN mutated O
mutated IN in O
in VBN CAPITAL Pendred D
Pendred NN syndrome D
syndrome CC and O
and VBN found O
found CD three O
three RB apparently O
apparently JJ deleterious O
deleterious NNS mutations O
mutations , , O
, DT each O
each VBG segregating O
segregating IN with O
with DT the O
the NN disease O
disease IN in O
in DT the O
the JJ respective O
respective NNS families O
families IN in O
in WDT which O
which PRP they O
they VB occur O

PDS NN CAPITAL PDS O
PDS VBZ produces O
produces DT a O
a NN transcript O
transcript IN of O
of RB approximately O
approximately CD 5 O
5 NN kb O
kb IN that O
that VBD was O
was VBN found O
found TO to O
to VB be O
be VBN expressed O
expressed IN at O
at JJ significant O
significant NNS levels O
levels RB only O
only IN in O
in DT the O
the NN thyroid O

The DT CAPITAL The O
The VBN predicted O
predicted NN protein O
protein , , O
, NN pendrin O
pendrin , , O
, VBZ is O
is RB closely O
closely JJ related O
related TO to O
to DT a O
a NN number O
number IN of O
of JJ known O
known NN sulphate O
sulphate NNS transporters O

These DT CAPITAL These O
These NNS studies O
studies VB provide O
provide JJ compelling O
compelling NN evidence O
evidence IN that O
that NNS defects O
defects IN in O
in NN pendrin O
pendrin NN cause O
cause VBN CAPITAL Pendred D
Pendred NN syndrome D
syndrome RB thereby O
thereby VBG launching O
launching DT a O
a JJ new O
new NN area O
area IN of O
of NN investigation O
investigation IN into O
into NN thyroid O
thyroid NN physiology O
physiology , , O
, DT the O
the NN pathogenesis O
pathogenesis IN of O
of JJ congenital D
congenital NN deafness D
deafness CC and O
and DT the O
the NN role O
role IN of O
of JJ altered O
altered NN sulphate O
sulphate NN transport O
transport IN in O
in JJ human O
human NN disease O

We PRP CAPITAL We O
We NN report O
report DT the O
the NN cDNA O
cDNA VBG cloning O
cloning , , O
, JJ partial O
partial JJ genomic O
genomic NN organization O
organization , , O
, CC and O
and NN expression O
expression NN pattern O
pattern IN of O
of NN CAPITAL Stra10 O
Stra10 , , O
, DT a O
a JJ novel O
novel JJ retinoic O
retinoic JJ acid-inducible O
acid-inducible NN gene O
gene IN in O
in NN CAPITAL P19 O
P19 JJ embryonal D
embryonal NN carcinoma D
carcinoma NNS cells O

Four CD CAPITAL Four O
Four JJ murine O
murine NN cDNA O
cDNA NNS isoforms O
isoforms VB have O
have VBN been O
been VBN isolated O
isolated , , O
, WDT which O
which VBP are O
are JJ likely O
likely TO to O
to NN result O
result IN from O
from JJ alternative O
alternative NN splicing O

The DT CAPITAL The O
The VBN predicted O
predicted NN protein O
protein NNS sequences O
sequences NN exhibit O
exhibit RB approximately O
approximately CD 85 O
85 NN % O
% NN identity O
identity IN with O
with DT the O
the JJ CAPITAL Pbx-related O
Pbx-related NN CAPITAL Meis1 O
Meis1 NN homeobox O
homeobox NN gene O
gene NNS products O
products , , O
, WDT which O
which VBP are O
are VBN involved O
involved IN in O
in JJ myeloid D
myeloid NN leukemia D
leukemia IN in O
in NN CAPITAL BXH-2 O
BXH-2 NNS mice O
mice , , O
, CC and O
and CD one O
one IN of O
of DT the O
the NN CAPITAL Stra10 O
Stra10 NNS isoforms O
isoforms VBZ corresponds O
corresponds TO to O
to DT the O
the RB recently O
recently VBN published O
published NN CAPITAL Meis2 O
Meis2 NN sequence O
sequence NN ( O
( NNP CAPITAL Nakamura O
Nakamura FW et O
et NNP al O
al . . O
. NN ( O
( CD 1996 O
1996 NN ) O
) NN CAPITAL Oncogene O
Oncogene CD 13 O
13 : : O
: CD 2235-2242 O
2235-2242 NN ) O

The DT CAPITAL The O
The NN CAPITAL Meis2 O
Meis2 NN homeodomain O
homeodomain VBZ is O
is JJ identical O
identical TO to O
to IN that O
that IN of O
of NN CAPITAL Meis1 O
Meis1 , , O
, CC and O
and VBZ is O
is JJS most O
most RB closely O
closely JJ related O
related TO to O
to DT those O
those IN of O
of DT the O
the NN CAPITAL Pbx/TGIF O
Pbx/TGIF NN homeobox O
homeobox NN gene O
gene NNS products O

By IN CAPITAL By O
By IN in O
in FW situ O
situ NN hybridization O
hybridization NN analysis O
analysis , , O
, PRP we O
we NN show O
show IN that O
that DT the O
the NN CAPITAL Meis2 O
Meis2 NN gene O
gene NNS displays O
displays RB spatially O
spatially JJ restricted O
restricted NN expression O
expression NNS patterns O
patterns IN in O
in DT the O
the VBG developing O
developing JJ nervous O
nervous NN system O
system , , O
, NNS limbs O
limbs , , O
, NN face O
face , , O
, CC and O
and IN in O
in JJ various O
various NN viscera O

In IN CAPITAL In O
In JJ adult O
adult NNS mice O
mice , , O
, NN CAPITAL Meis2 O
Meis2 VBZ is O
is RB mainly O
mainly VBN expressed O
expressed IN in O
in DT the O
the NN brain O
brain CC and O
and JJ female O
female JJ genital O
genital NN tract O
tract , , O
, IN with O
with DT a O
a JJ different O
different NN distribution O
distribution IN of O
of DT the O
the JJ alternative O
alternative NN splice O
splice NNS forms O
forms IN in O
in DT these O
these NNS organs O

A DT CAPITAL A O
A JJ methodical O
methodical NN strategy O
strategy IN for O
for DT the O
the NN isolation O
isolation IN of O
of NN microsatellite O
microsatellite NNS markers O
markers JJ specific O
specific IN for O
for VBN targeted O
targeted NNS regions O
regions IN of O
of JJ bovine O
bovine NNS chromosomes O
chromosomes VBZ is O
is VBN presented O

The DT CAPITAL The O
The NN procedure O
procedure VBZ involves O
involves VBN directed O
directed NN microdissection O
microdissection IN of O
of CD one O
one VBN defined O
defined JJ subchromosomal O
subchromosomal NN area O
area , , O
, PRP$ its O
its NN CAPITAL DOP-PCR-amplification O
DOP-PCR-amplification CC and O
and VBG cloning O

With IN CAPITAL With O
With DT this O
this NN approach O
approach , , O
, DT a O
a NN library O
library JJ specific O
specific TO to O
to DT the O
the NN CAPITAL BTA O
BTA JJ 6q21-31 O
6q21-31 JJ chromosomal O
chromosomal NN region O
region VBD was O
was VBN constructed O

Eleven CD CAPITAL Eleven O
Eleven JJ unique O
unique JJ microsatellite-containing O
microsatellite-containing NNS sequences O
sequences VBD were O
were VBN isolated O
isolated , , O
, VBN converted O
converted IN into O
into JJ sequence-tagged O
sequence-tagged NN microsatellite O
microsatellite NNS sites O
sites , , O
, CC and O
and VBN characterized O
characterized VBG concerning O
concerning PRP$ their O
their JJ species-specific O
species-specific NN origin O

Seven CD CAPITAL Seven O
Seven NN primer O
primer NNS pairs O
pairs VBN generated O
generated JJ bovine-specific O
bovine-specific NN CAPITAL PCR O
PCR NNS products O
products CC and O
and VBN provided O
provided DT a O
a VBN set O
set IN of O
of NN microsatellite O
microsatellite NNS markers O
markers IN that O
that RB generally O
generally VBD revealed O
revealed JJ high O
high NN informativity O
informativity IN in O
in DT the O
the NN CAPITAL HF O
HF NN breed O

Linkage NN CAPITAL Linkage O
Linkage NN analysis O
analysis VBN assigned O
assigned CD six O
six IN of O
of PRP them O
them TO to O
to PRP$ their O
their VBN predefined O
predefined JJ subchromosomal O
subchromosomal NN origin O
origin IN on O
on NN CAPITAL BTA O
BTA CD 6 O
6 JJ corresponding O
corresponding TO to O
to DT the O
the JJ specific O
specific NN rehybridization O
rehybridization NN signal O
signal IN of O
of DT the O
the NN CAPITAL DOP-PCR O
DOP-PCR NN product O
product VBN generated O
generated IN from O
from DT the O
the VBN microdissected O
microdissected NN chromosome O
chromosome NN area O
area JJ 6q21-31 O

The DT CAPITAL The O
The NNS results O
results VB underline O
underline DT the O
the NN usefulness O
usefulness IN of O
of DT the O
the NN CAPITAL BTA O
BTA JJ 6q21-31 O
6q21-31 NN library O
library IN for O
for VBN targeted O
targeted NN isolation O
isolation IN of O
of JJ unique O
unique NNS sequences O
sequences IN that O
that VBP are O
are JJ specific O
specific IN for O
for DT the O
the VBN dissected O
dissected JJ chromosomal O
chromosomal NN region O
region IN as O
as VBD demonstrated O
demonstrated RB here O
here IN by O
by DT the O
the NN isolation O
isolation IN of O
of NN microsatellite O
microsatellite NNS markers O

Phylogeographic JJ CAPITAL Phylogeographic O
Phylogeographic NN structure O
structure VBD was O
was VBN determined O
determined IN for O
for DT the O
the JJ yellow O
yellow NN mongoose O
mongoose , , O
, NN CAPITAL Cynictis O
Cynictis NN penicillata O
penicillata , , O
, VBG using O
using NN mtDNA O
mtDNA NNS CAPITAL RFLPs O
RFLPs CC and O
and NN control O
control NN region O
region NNS sequences O

The DT CAPITAL The O
The NN CAPITAL RFLP O
RFLP NN analysis O
analysis VBD revealed O
revealed CD 13 O
13 NNS haplotypes O
haplotypes WDT which O
which VBD showed O
showed JJ weak O
weak JJ geographical O
geographical NN patterning O
patterning JJ consistent O
consistent IN with O
with DT a O
a JJ recent O
recent NN range O
range NN expansion O
expansion IN from O
from DT a O
a JJ refugial O
refugial NN population O
population NN ( O
( NNS s O
s NN ) O

An DT CAPITAL An O
An NN analysis O
analysis IN of O
of JJ molecular O
molecular NN variance O
variance NN ( O
( NNP CAPITAL AMOVA O
AMOVA NN ) O
) VBD revealed O
revealed DT no O
no NN correspondence O
correspondence IN between O
between NN mtDNA O
mtDNA NN phylogeography O
phylogeography CC and O
and NNS subspecies O
subspecies NN delimitation O
delimitation , , O
, CC nor O
nor IN between O
between NNS matrilines O
matrilines CC and O
and NNS areas O
areas VBN characterized O
characterized IN by O
by DT a O
a JJ high O
high NN incidence O
incidence IN of O
of DT the O
the JJ viverrid-type D
viverrid-type NNP rabies D
rabies , , O
, IN of O
of WDT which O
which DT the O
the JJ yellow O
yellow NN mongoose O
mongoose VBZ is O
is DT the O
the JJ principal O
principal NN vector O

The DT CAPITAL The O
The NN lack O
lack IN of O
of NN structure O
structure VBD was O
was RB also O
also VBN shown O
shown IN by O
by NN control O
control NN region O
region NNS sequences O
sequences IN although O
although CD four O
four IN of O
of DT the O
the JJ maternal O
maternal NNS lineages O
lineages VBN shared O
shared DT a O
a JJ near-perfect O
near-perfect CD 81 O
81 NN bp O
bp NN repeat O

We PRP CAPITAL We O
We VBP speculate O
speculate IN that O
that JJ regional O
regional JJ hot O
hot NNS spots O
spots IN of O
of DT the O
the NN viverrid D
viverrid NNP rabies D
rabies NN biotype O
biotype VB reflect O
reflect NN population O
population NN density O
density NNS differences O
differences IN in O
in DT the O
the JJ yellow O
yellow NN mongoose O
mongoose IN that O
that VBP are O
are RB not O
not VBN underscored O
underscored IN by O
by JJ genetic O
genetic VBG partitioning O
partitioning , , O
, IN at O
at JJS least O
least IN at O
at DT the O
the NN level O
level IN of O
of NN resolution O
resolution VBN provided O
provided IN by O
by PRP$ our O
our NNS analyses O

The DT CAPITAL The O
The JJ indoor O
indoor NN pollution O
pollution , , O
, WRB where O
where DT the O
the NNS patients O
patients NN pass O
pass IN in O
in JJ general O
general RB close O
close TO to O
to CD 90 O
90 NN % O
% IN of O
of PRP$ their O
their NN time O
time , , O
, VBZ is O
is DT an O
an JJ important O
important NN factor O
factor TO to O
to VB take O
take IN in O
in NN consideration O
consideration IN if O
if CD one O
one VBZ wants O
wants TO to O
to VB evaluate O
evaluate RB suitably O
suitably DT the O
the NNS effects O
effects IN of O
of DT the O
the NN air O
air NN pollution O
pollution IN on O
on DT the O
the NN health O

Causes VBZ CAPITAL Causes O
Causes IN of O
of DT this O
this RB kind O
kind IN of O
of NN pollution O
pollution VBP are O
are RB partially O
partially VBN linked O
linked TO to O
to DT the O
the JJ external O
external NN pollution O
pollution CC and O
and DT the O
the JJ outdoor O
outdoor NN environment O
environment CC and O
and RB also O
also VBP are O
are NN function O
function IN of O
of JJ human O
human NNS activities O
activities CC and O
and VBN introduced O
introduced NNS products O
products IN in O
in DT the O
the NN habitat O
habitat NN ( O
( NN heating O
heating , , O
, NN tabagisme O
tabagisme , , O
, NN handywork O
handywork , , O
, NNS products O
products IN of O
of NN maintenance O
maintenance , , O
, NNS coatings O
coatings , , O
, NNS materials O
materials IN of O
of NN construction O
construction , , O
, FW etc O

) NN ) O

The DT CAPITAL The O
The NNS effects O
effects IN on O
on NN health O
health VBP are O
are IN as O
as JJ various O
various IN as O
as DT the O
the NNS pollutants O
pollutants , , O
, VBG going O
going IN from O
from JJ sharp O
sharp NN intoxication O
intoxication TO to O
to NNS irritations O
irritations CC or O
or RB simply O
simply NNS desagreements O

In IN CAPITAL In O
In DT this O
this NN problem O
problem IN of O
of JJ public O
public NN health O
health PRP we O
we MD may O
may RB not O
not VBD underestimated O
underestimated JJ sensitive O
sensitive NNS persons O
persons CC and O
and JJ risky O
risky NN group O
group IN as O
as RB well O
well IN as O
as RB long O
long NN terme O
terme NNS effects O
effects , , O
, CC and O
and JJ chronic O
chronic NN exposition O
exposition NNS effects O

The DT CAPITAL The O
The NN search O
search IN of O
of NNS solutions O
solutions NNS needs O
needs JJ multiple O
multiple NNS competences O
competences IN from O
from DT the O
the NN physician O
physician , , O
, WP who O
who VBZ has O
has TO to O
to VB play O
play DT an O
an JJ essential O
essential NN role O

Dioxins NNS CAPITAL Dioxins O
Dioxins VBP are O
are DT a O
a NN family O
family IN of O
of VBN chlorinated O
chlorinated JJ aromatic O
aromatic NNS hydrocarbons O
hydrocarbons IN that O
that VBP are O
are VBN produced O
produced IN during O
during NN combustion O
combustion NNS processes O
processes IN in O
in DT the O
the NN presence O
presence IN of O
of DT a O
a NN chlorine O
chlorine NN donor O
donor CC and O
and IN as O
as NNS by-products O
by-products IN of O
of DT the O
the JJ chlorine-processing O
chlorine-processing NN chemical O
chemical NNS industries O

Several JJ CAPITAL Several O
Several NNS dioxins O
dioxins VBP are O
are RB extremely O
extremely JJ stable O
stable NNS compounds O
compounds CC and O
and VB persist O
persist IN for O
for NNS years O
years IN in O
in DT the O
the NN environment O

Exposure NN CAPITAL Exposure O
Exposure TO to O
to NNS dioxins O
dioxins VBZ occurs O
occurs RB mainly O
mainly IN via O
via DT the O
the NN ingestion O
ingestion IN of O
of VBN contaminated O
contaminated NN food O

The DT CAPITAL The O
The JJ lipophilic O
lipophilic NN character O
character IN of O
of NNS dioxins O
dioxins VBZ prevents O
prevents PRP$ their O
their NN excretion O
excretion IN in O
in DT the O
the NN urine O
urine CC and O
and NNS causes O
causes PRP$ their O
their NN accumulation O
accumulation IN in O
in NN body O
body JJ fat O

The DT CAPITAL The O
The NNS mechanisms O
mechanisms IN of O
of NN dioxin O
dioxin NN action O
action VBP are O
are JJ similar O
similar TO to O
to DT those O
those IN of O
of DT a O
a NN hormone O

Dioxins NNS CAPITAL Dioxins O
Dioxins VB bind O
bind TO to O
to DT a O
a JJ specific O
specific JJ intracellular O
intracellular NN receptor O
receptor CC and O
and DT the O
the JJ complex O
complex NNS acts O
acts IN as O
as DT a O
a NN transcription O
transcription NN factor O
factor IN that O
that VBZ induces O
induces DT the O
the NN production O
production IN of O
of DT a O
a JJ great O
great NN number O
number IN of O
of NNS proteins O

Certain JJ CAPITAL Certain O
Certain NNS dioxins O
dioxins , , O
, RB particularly O
particularly CD 2 O
2 , , O
, CD 3 O
3 , , O
, CD 7 O
7 , , O
, NN 8-tetrachlorodibenzo-p-dioxin O
8-tetrachlorodibenzo-p-dioxin , , O
, VBP are O
are RB very O
very JJ toxic O
toxic CC and O
and JJ able O
able TO to O
to VB induce O
induce JJ numerous O
numerous JJ clinical O
clinical NNS conditions O

The DT CAPITAL The O
The NN carcinogenicity O
carcinogenicity IN of O
of NNS dioxins O
dioxins VBZ is O
is RB well O
well VBN documented O
documented IN in O
in NN animal O
animal NNS models O
models CC and O
and VBZ has O
has VBN been O
been VBN described O
described IN in O
in NNS humans O
humans IN after O
after JJ professional O
professional CC and O
and JJ accidental O
accidental NNS exposures O

Recent JJ CAPITAL Recent O
Recent JJ experimental O
experimental NNS data O
data RB also O
also VBP indicate O
indicate IN that O
that NNS dioxins O
dioxins MD can O
can NN cause O
cause NN dysfunction D
dysfunction IN of D
of DT the D
the JJ sexual D
sexual CC and D
and NN thyroid D
thyroid NN hormone D
hormone NNS systems D
systems CC and O
and IN that O
that DT the O
the NN administration O
administration IN of O
of NNS dioxins O
dioxins VBZ induces O
induces JJ several O
several NNS conditions O
conditions JJ related O
related TO to O
to JJ hormonal D
hormonal NN dysfunction D

Chronic JJ CAPITAL Chronic O
Chronic NN exposure O
exposure IN of O
of JJ female O
female NN CAPITAL Rhesus O
Rhesus NNS monkeys O
monkeys NNS increases O
increases DT the O
the NN incidence O
incidence CC and O
and NN severity O
severity IN of O
of NN endometriosis D

The DT CAPITAL The O
The NN administration O
administration IN of O
of NNS dioxins O
dioxins IN during O
during NN pregnancy O
pregnancy CC and O
and NN nursing O
nursing NNS causes O
causes JJ altered O
altered NN development O
development IN of O
of DT the O
the JJ reproductive O
reproductive NN system O
system , , O
, VBN decreased O
decreased NN spermatogenesis O
spermatogenesis , , O
, NN hypothyroidism D
hypothyroidism CC and O
and JJ disturbed O
disturbed NN psychomotor O
psychomotor NN development O
development IN in O
in DT the O
the NN offspring O

The DT CAPITAL The O
The JJ particular O
particular NN sensibility O
sensibility IN of O
of DT the O
the NN fetus O
fetus CC and O
and JJ newborn O
newborn VBZ is O
is IN of O
of NN concern O
concern IN because O
because DT the O
the NN exposition O
exposition TO to O
to NNS dioxins O
dioxins VBZ is O
is RB particularly O
particularly JJ important O
important IN during O
during DT those O
those NNS periods O
periods IN of O
of NN life O

In IN CAPITAL In O
In NNS humans O
humans DT a O
a NN series O
series IN of O
of NNS conditions O
conditions JJ related O
related TO to O
to JJ hormonal D
hormonal NN dysfunction D
dysfunction IN as O
as JJ undescended O
undescended NN testis O
testis , , O
, VBN decreased O
decreased NN spermatogenesis O
spermatogenesis , , O
, JJ testicular D
testicular NN cancer D
cancer CC and O
and NN endometriosis D
endometriosis VB have O
have VBN increased O
increased IN in O
in NN incidence O
incidence IN during O
during DT the O
the JJ last O
last NNS decades O

The DT CAPITAL The O
The JJ chronological O
chronological NN parallelism O
parallelism IN with O
with DT the O
the NN appearance O
appearance IN of O
of NNS dioxins O
dioxins IN in O
in DT the O
the NN environment O
environment VBZ suggests O
suggests IN that O
that DT these O
these MD might O
might VB exert O
exert JJ biological O
biological NNS effects O
effects IN at O
at DT the O
the VBG prevailing O
prevailing NN level O
level IN of O
of NN exposure O

Nevertheless RB CAPITAL Nevertheless O
Nevertheless DT this O
this NN hypothesis O
hypothesis VBZ is O
is RB currently O
currently JJ unconfirmed O
unconfirmed IN by O
by JJ epidemiological O
epidemiological NNS studies O

The DT CAPITAL The O
The NNS implications O
implications IN of O
of DT this O
this JJ scientific O
scientific NN incertitude O
incertitude IN for O
for DT the O
the NN implementation O
implementation IN of O
of JJ preventive O
preventive NNS measures O
measures VBP are O
are RB briefly O
briefly VBN discussed O

This DT CAPITAL This O
This NN presentation O
presentation VBZ summarizes O
summarizes DT the O
the NN debate O
debate IN on O
on DT the O
the VBN suggested O
suggested JJ progressive O
progressive NN impairment O
impairment IN of O
of NN semen O
semen NN quality O
quality NN ( O
( DT the O
the `` `` O
`` NN sperm O
sperm NN fall O
fall '' '' O
'' NN ) O
) IN in O
in DT the O
the JJ last O
last CD forty O
forty NNS years O
years IN in O
in DT the O
the VBN developed O
developed NNS countries O

The DT CAPITAL The O
The JJ various O
various JJ available O
available NNS data O
data RB strongly O
strongly VBG suggesting O
suggesting DT an O
an JJ environmental O
environmental JJ toxic O
toxic NN origin O
origin IN for O
for DT the O
the `` `` O
`` NN sperm O
sperm NN fall O
fall '' '' O
'' MD will O
will VB be O
be VBN presented O
presented IN as O
as RB well O
well IN as O
as DT the O
the JJS most O
most RB frequently O
frequently VBN suspected O
suspected NN class O
class IN of O
of NNS substances O
substances , , O
, DT the O
the NNS xenoestrogens O

Diabetes NNP CAPITAL Diabetes D
Diabetes NN mellitus D
mellitus VBZ is O
is DT a O
a RB still O
still VBG growing O
growing NN disease O

New NNP CAPITAL New O
New JJ diagnostic O
diagnostic NNS criteria O
criteria JJ lowered O
lowered DT the O
the NN cut O
cut IN off O
off NN value O
value TO to O
to CD 126 O
126 NN mg/dl O
mg/dl , , O
, IN in O
in NN order O
order TO to O
to VB detect O
detect RBR more O
more RB rapidly O
rapidly NN diabetes D
diabetes CC and O
and PRP$ its O
its NNS complications O

The DT CAPITAL The O
The NN treatment O
treatment IN of O
of NN diabetes D
diabetes LS 2 D
2 IN by O
by DT the O
the JJ classic T
classic JJ oral T
oral JJ antidiabetic T
antidiabetic NNS drugs T
drugs NN ( T
( NNS sulfamides T
sulfamides CC and T
and NNS biguanides T
biguanides NN ) T
) VBZ is O
is VBN completed O
completed IN by O
by JJ intestinal T
intestinal NNS glycosidases T
glycosidases NNS inhibitors T
inhibitors CC and O
and NNS thiazolidendiones T

These DT CAPITAL These O
These JJ last O
last NNS drugs O
drugs VB seem O
seem RB very O
very JJ attractive O
attractive IN because O
because PRP they O
they NN decrease O
decrease NN insulin O
insulin NN resistance O
resistance IN in O
in JJ obese O
obese , , O
, NNS diabetics O

Their PRP$ CAPITAL Their O
Their JJ hepatic O
hepatic NN side O
side NNS effects O
effects MD must O
must VB be O
be RB however O
however IN under O
under NN control O

Better RBR CAPITAL Better O
Better NN knowledge O
knowledge IN of O
of JJ non O
non JJ lipidic O
lipidic NNS effects O
effects IN of O
of NNS statins O
statins IN on O
on DT the O
the JJ arterial O
arterial NN wall O
wall CC and O
and DT the O
the NN discovery O
discovery IN of O
of DT the O
the NN action O
action IN of O
of NNS fibrates O
fibrates IN on O
on NN CAPITAL PPAR O
PPAR NN ( O
( NN CAPITAL Peroxisome O
Peroxisome NN CAPITAL Proliferator O
Proliferator VBN CAPITAL Activated O
Activated NNS CAPITAL Receptors O
Receptors NN ) O
) VBN improved O
improved RB strongly O
strongly DT the O
the JJ therapeutic O
therapeutic NN management O
management IN of O
of NN hyperlipidemias D

Recent JJ CAPITAL Recent O
Recent NN intervention O
intervention NNS studies O
studies VB have O
have VBD demonstrated O
demonstrated DT the O
the NN necessity O
necessity TO to O
to VB treat O
treat RB vigorously O
vigorously NN dysipidemias D

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> IN CAPITAL Despite O
Despite JJ CAPITAL Beta-blockade T
Beta-blockade NN therapy T
therapy VBZ has O
has VBN been O
been VBN considered O
considered IN as O
as DT an O
an JJ absolute O
absolute NN contraindication O
contraindication IN in O
in DT the O
the NN treatment O
treatment IN of O
of NN heart D
heart NN failure D
failure , , O
, PRP it O
it VBZ has O
has VBN been O
been VBN shown O
shown IN that O
that PRP they O
they MD could O
could VB have O
have DT a O
a JJ beneficial O
beneficial NN effect O
effect , , O
, VBN provided O
provided IN that O
that PRP they O
they VBD were O
were VBN introduced O
introduced IN at O
at RB very O
very JJ low O
low NN dose O
dose , , O
, CC and O
and RB very O
very RB progressively O
progressively IN in O
in NN addition O
addition IN of O
of DT the O
the JJ traditional O
traditional NN treatment O

The DT CAPITAL The O
The NNS advances O
advances IN in O
in DT the O
the VBG understanding O
understanding IN of O
of DT the O
the JJ neuro-hormonal O
neuro-hormonal NNS mechanisms O
mechanisms IN of O
of NN heart O
heart NN failure O
failure VB have O
have VBN modified O
modified DT the O
the JJ therapeutic O
therapeutic NN strategy O
strategy : : O
: DT the O
the JJ deleterious O
deleterious NN effect O
effect IN of O
of DT the O
the NN activation O
activation IN of O
of DT the O
the JJ sympathetic O
sympathetic JJ nervous O
nervous NN system O
system IN on O
on DT the O
the NN myocardium O
myocardium VBZ has O
has VBD served O
served IN as O
as DT the O
the NN rationale O
rationale IN for O
for VBN randomized O
randomized JJ clinical O
clinical NNS trials O
trials VBG comparing O
comparing NN beta-blockade O
beta-blockade TO to O
to NN placebo O
placebo : : O
: DT the O
the JJ current O
current NNS data O
data VBP are O
are JJ promising O
promising , , O
, VBG suggesting O
suggesting DT a O
a JJ beneficial O
beneficial NN effect O
effect IN on O
on NN survival O
survival IN as O
as RB well O
well IN as O
as IN on O
on NN quality O
quality IN of O
of NN life O

However RB CAPITAL However O
However , , O
, DT these O
these NNS results O
results VB have O
have TO to O
to VB be O
be VBN confirmed O
confirmed IN by O
by JJR larger O
larger NNS trials O
trials , , O
, RB currently O
currently NN underway O
underway , , O
, IN before O
before TO to O
to VB consider O
consider IN that O
that NN beta-blockade O
beta-blockade MD should O
should RB definitely O
definitely VB be O
be VBN incorporated O
incorporated IN in O
in DT the O
the NN treatment O
treatment IN of O
of NN heart O
heart NN failure O

Calcium NN CAPITAL Calcium T
Calcium NNS antagonists T
antagonists VB have O
have VBN been O
been VBN used O
used IN for O
for NN treatment O
treatment IN of O
of JJ cardiovascular D
cardiovascular NNS diseases D
diseases IN for O
for RBR more O
more IN than O
than CD 25 O
25 NNS years O

Several JJ CAPITAL Several O
Several JJ recent O
recent JJ retrospective O
retrospective NNS studies O
studies VB have O
have VBN suggested O
suggested IN that O
that JJ chronic O
chronic NN treatment O
treatment IN with O
with JJ short-acting T
short-acting NNS dihydropyridines T
dihydropyridines VBN increased O
increased DT the O
the NN incidence O
incidence IN of O
of JJ cardiac D
cardiac NNS events D
events , , O
, NN cancer D
cancer CC and O
and JJ gastrointestinal D
gastrointestinal NNS bleedings D

Randomized VBN CAPITAL Randomized O
Randomized JJ prospective O
prospective NNS studies O
studies VB have O
have , , O
, RB however O
however , , O
, RB never O
never VBN been O
been JJ able O
able TO to O
to VBP confirm O
confirm DT these O
these NNS observations O

In IN CAPITAL In O
In NN addition O
addition , , O
, JJ well-conducted O
well-conducted NNS studies O
studies VBG using O
using NN verapamil T
verapamil CC and O
and NN diltiazem T
diltiazem VB have O
have VBN suggested O
suggested IN that O
that DT these O
these NN calcium T
calcium NNS antagonists T
antagonists MD may O
may RB even O
even VB improve O
improve JJ cardiovascular D
cardiovascular NN mortality D
mortality CC and D
and NN morbidity D
morbidity IN of O
of DT the O
the JJ hypertensive O
hypertensive NN patient O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> EX CAPITAL There O
There VBZ is O
is RB therefore O
therefore DT no O
no NN reason O
reason TO to O
to VB believe O
believe IN that O
that DT the O
the JJ questionable O
questionable NNS results O
results VBN derived O
derived IN from O
from JJ retrospective O
retrospective NNS studies O
studies IN of O
of DT the O
the NNS effects O
effects IN of O
of JJ short-acting O
short-acting NN calcium O
calcium NNS antagonists O
antagonists IN on O
on JJ cardiac O
cardiac CC and O
and JJ noncardiac O
noncardiac NNS events O
events MD may O
may VB apply O
apply TO to O
to DT the O
the JJR newer O
newer NN generation O
generation IN of O
of JJ long-acting O
long-acting NN calcium O
calcium NNS antagonists O

Sumatriptan NNP CAPITAL Sumatriptan T
Sumatriptan CC and O
and JJ other O
other JJ selective O
selective NN serotonin T
serotonin NNS agonists T
agonists VB represent O
represent DT a O
a JJ major O
major NN breakthrough O
breakthrough IN in O
in JJ acute D
acute NN migraine D
migraine NN treatment O

These DT CAPITAL These O
These NNS drugs O
drugs VBP are O
are RB very O
very JJ efficacious O
efficacious CC and O
and RB generally O
generally VBN devoided O
devoided IN of O
of JJ important O
important NN side O
side NNS effects O
effects , , O
, CC but O
but PRP they O
they VBP are O
are JJ expensive O
expensive CC and O
and RB therefore O
therefore VB have O
have TO to O
to VB be O
be VBN compared O
compared IN with O
with JJ other O
other , , O
, RBR more O
more JJ conventional O
conventional NNS drugs O
drugs IN with O
with VBN established O
established CC or O
or VBN assumed O
assumed NN efficacy O

We PRP CAPITAL We O
We VB summarize O
summarize DT the O
the JJ pharmacologic O
pharmacologic NNS characteristics O
characteristics IN of O
of NNP CAPITAL Sumatriptan T
Sumatriptan CC and O
and VB give O
give NNS recommendations O
recommendations IN about O
about PRP$ its O
its NN use O
use IN in O
in JJ clinical O
clinical NN practice O

Fiercer JJR CAPITAL Fiercer O
Fiercer NN competition O
competition IN between O
between NNS athletes O
athletes CC and O
and DT a O
a JJR wider O
wider NN knowledge O
knowledge IN of O
of JJ optimal O
optimal NN training O
training NNS regimens O
regimens RB dramatically O
dramatically NN influence O
influence JJ current O
current NN training O
training NNS methods O

A DT CAPITAL A O
A JJ single O
single NN training O
training NN bout O
bout IN per O
per NN day O
day VBD was O
was RB previously O
previously VBN considered O
considered JJ sufficient O
sufficient , , O
, IN whereas O
whereas NN today O
today NNS athletes O
athletes RB regularly O
regularly NN train O
train RB twice O
twice DT a O
a NN day O
day CC or O
or RBR more O

Consequently RB CAPITAL Consequently O
Consequently , , O
, DT the O
the NN number O
number IN of O
of NNS athletes O
athletes WP who O
who VBP are O
are VBG overtraining O
overtraining CC and O
and VB have O
have JJ insufficient O
insufficient NN rest O
rest VBZ is O
is VBG increasing O

Positive JJ CAPITAL Positive O
Positive VBG overtraining O
overtraining MD can O
can VB be O
be VBN regarded O
regarded IN as O
as DT a O
a JJ natural O
natural NN process O
process WRB when O
when DT the O
the NN end O
end NN result O
result VBZ is O
is NN adaptation O
adaptation CC and O
and VBN improved O
improved NN performance O
performance : : O
: DT the O
the NN supercompensation O
supercompensation NN principle O
principle : -- O
-- WDT which O
which VBZ includes O
includes DT the O
the NN breakdown O
breakdown NN process O
process NN ( O
( NN training O
training NN ) O
) VBN followed O
followed IN by O
by DT the O
the NN recovery O
recovery NN process O
process NN ( O
( NN rest O
rest NN ) O
) : -- O
-- VBZ is O
is RB well O
well JJ known O
known IN in O
in NNS sports O

However RB CAPITAL However O
However , , O
, JJ negative O
negative VBG overtraining O
overtraining , , O
, VBG causing O
causing NN maladaptation O
maladaptation CC and O
and JJ other O
other JJ negative O
negative NNS consequences O
consequences JJ such O
such IN as O
as NN staleness O
staleness , , O
, MD can O
can VB occur O

Physiological JJ CAPITAL Physiological O
Physiological , , O
, JJ psychological O
psychological , , O
, JJ biochemical O
biochemical CC and O
and JJ immunological O
immunological NNS symptoms O
symptoms MD must O
must VB be O
be VBN considered O
considered , , O
, DT both O
both RB independently O
independently CC and O
and RB together O
together , , O
, TO to O
to RB fully O
fully VB understand O
understand DT the O
the NN 'staleness O
'staleness POS ' O
' NN syndrome O

However RB CAPITAL However O
However , , O
, JJ psychological O
psychological NN testing O
testing MD may O
may VB reveal O
reveal JJ early-warning O
early-warning NNS signs O
signs RBR more O
more RB readily O
readily IN than O
than DT the O
the JJ various O
various JJ physiological O
physiological CC or O
or JJ immunological O
immunological NNS markers O

The DT CAPITAL The O
The NN time O
time NN frame O
frame IN of O
of NN training O
training CC and O
and NN recovery O
recovery VBZ is O
is RB also O
also JJ important O
important IN since O
since DT the O
the NNS consequences O
consequences IN of O
of JJ negative O
negative VBG overtraining O
overtraining VBP comprise O
comprise DT an O
an JJ overtraining-response O
overtraining-response NN continuum O
continuum IN from O
from JJ short O
short TO to O
to RB long O
long NN term O
term NNS effects O

An DT CAPITAL An O
An NN athlete O
athlete VBG failing O
failing TO to O
to VB recover O
recover IN within O
within CD 72 O
72 NNS hours O
hours VBZ has O
has RB presumably O
presumably RB negatively O
negatively VBN overtrained O
overtrained CC and O
and VBZ is O
is IN in O
in DT an O
an VBD overreached O
overreached NN state O

For IN CAPITAL For O
For DT an O
an NN elite O
elite NN athlete O
athlete TO to O
to NN refrain O
refrain IN from O
from NN training O
training IN for O
for JJR > O
> CD 72 O
72 NNS hours O
hours VBZ is O
is RB extremely O
extremely JJ undesirable O
undesirable , , O
, VBG highlighting O
highlighting DT the O
the NN importance O
importance IN of O
of DT a O
a RB carefully O
carefully VBN monitored O
monitored NN recovery O
recovery NN process O

There EX CAPITAL There O
There VBP are O
are JJ many O
many NNS methods O
methods VBN used O
used TO to O
to NN measure O
measure DT the O
the NN training O
training NN process O
process CC but O
but JJ few O
few IN with O
with WDT which O
which TO to O
to NN match O
match DT the O
the NN recovery O
recovery NN process O
process IN against O
against PRP it O

One CD CAPITAL One O
One JJ such O
such NN framework O
framework IN for O
for DT this O
this VBZ is O
is VBN referred O
referred TO to O
to IN as O
as DT the O
the JJ total O
total NN quality O
quality NN recovery O
recovery NN ( O
( NN CAPITAL TQR O
TQR NN ) O
) NN process O

By IN CAPITAL By O
By VBG using O
using DT a O
a NN CAPITAL TQR O
TQR NN scale O
scale , , O
, JJ structured O
structured IN around O
around DT the O
the NN scale O
scale VBN developed O
developed IN for O
for NNS ratings O
ratings IN of O
of VBN perceived O
perceived NN exertion O
exertion NN ( O
( NN CAPITAL RPE O
RPE NN ) O
) , , O
, DT the O
the NN recovery O
recovery NN process O
process MD can O
can VB be O
be VBN monitored O
monitored CC and O
and VBN matched O
matched IN against O
against DT the O
the NN breakdown O
breakdown NN ( O
( NN training O
training NN ) O
) NN process O
process NN ( O
( NN CAPITAL TQR O
TQR CC versus O
versus NN CAPITAL RPE O
RPE NN ) O

The DT CAPITAL The O
The NN CAPITAL TQR O
TQR NN scale O
scale VBZ emphasises O
emphasises DT both O
both DT the O
the NN athlete O
athlete POS 's O
's NN perception O
perception IN of O
of NN recovery O
recovery CC and O
and DT the O
the NN importance O
importance IN of O
of JJ active O
active NNS measures O
measures TO to O
to VB improve O
improve DT the O
the NN recovery O
recovery NN process O

Furthermore RB CAPITAL Furthermore O
Furthermore , , O
, VBG directing O
directing NN attention O
attention TO to O
to JJ psychophysiological O
psychophysiological NNS cues O
cues VBZ serves O
serves DT the O
the JJ same O
same NN purpose O
purpose IN as O
as IN in O
in NN CAPITAL RPE O
RPE , , O
, NN i.e O
i.e . . O
. VBG increasing O
increasing NN self-awareness O

This DT CAPITAL This O
This NN article O
article NNS reviews O
reviews CC and O
and NNS conceptualises O
conceptualises DT the O
the JJ whole O
whole VBG overtraining O
overtraining NN process O

In IN CAPITAL In O
In VBG doing O
doing RB so O
so , , O
, PRP it O
it NN ( O
( LS i O
i NN ) O
) NNS aims O
aims TO to O
to VB differentiate O
differentiate IN between O
between DT the O
the NNS types O
types IN of O
of NN stress O
stress VBG affecting O
affecting DT an O
an NN athlete O
athlete POS 's O
's NN performance O
performance : : O
: NN ( O
( LS ii O
ii NN ) O
) VBZ identifies O
identifies NNS factors O
factors VBG influencing O
influencing DT an O
an NN athlete O
athlete POS 's O
's NN ability O
ability TO to O
to VB adapt O
adapt TO to O
to JJ physical O
physical NN training O
training : : O
: NN ( O
( LS iii O
iii NN ) O
) NNS structures O
structures DT the O
the NN recovery O
recovery NN process O

The DT CAPITAL The O
The NN CAPITAL TQR O
TQR NN method O
method TO to O
to VB facilitate O
facilitate VBG monitoring O
monitoring IN of O
of DT the O
the NN recovery O
recovery NN process O
process VBZ is O
is RB then O
then VBN suggested O
suggested CC and O
and DT a O
a JJ conceptual O
conceptual NN model O
model IN that O
that VBZ incorporates O
incorporates DT all O
all IN of O
of DT the O
the JJ important O
important NNS parameters O
parameters IN for O
for NN performance O
performance NN gain O
gain NN ( O
( NN adaptation O
adaptation NN ) O
) CC and O
and NN loss O
loss NN ( O
( NN maladaptation O
maladaptation NN ) O

Little JJ CAPITAL Little O
Little NN attention O
attention VBZ has O
has VBN been O
been VBN directed O
directed IN toward O
toward VBG identifying O
identifying DT the O
the NNS changes O
changes WDT which O
which VB occur O
occur IN in O
in JJ salivary O
salivary NN composition O
composition IN in O
in NN response O
response TO to O
to NN exercise O

To TO CAPITAL To O
To NN address O
address DT this O
this , , O
, PRP$ our O
our NN article O
article RB first O
first VBZ refers O
refers TO to O
to DT the O
the JJ main O
main NNS aspects O
aspects IN of O
of JJ salivary O
salivary NN gland O
gland NN physiology O

A DT CAPITAL A O
A NN knowledge O
knowledge IN of O
of DT the O
the JJ neural O
neural NN control O
control IN of O
of JJ salivary O
salivary NN secretion O
secretion VBZ is O
is RB especially O
especially JJ important O
important IN for O
for DT the O
the VBG understanding O
understanding IN of O
of DT the O
the NNS effects O
effects IN of O
of NN exertion O
exertion IN on O
on JJ salivary O
salivary NN secretion O

Both DT CAPITAL Both O
Both JJ salivary O
salivary NN output O
output CC and O
and NN composition O
composition VB depend O
depend IN on O
on DT the O
the NN activity O
activity IN of O
of DT the O
the JJ autonomic O
autonomic JJ nervous O
nervous NN system O
system CC and O
and DT any O
any NN modification O
modification IN of O
of DT this O
this NN activity O
activity MD can O
can VB be O
be VBN observed O
observed RB indirectly O
indirectly IN by O
by NNS alternations O
alternations IN in O
in DT the O
the JJ salivary O
salivary NN excretion O

The DT CAPITAL The O
The NNS effects O
effects IN of O
of JJ physical O
physical NN activity O
activity NN ( O
( IN with O
with NN reference O
reference TO to O
to NNS factors O
factors JJ such O
such IN as O
as NN exercise O
exercise NN intensity O
intensity CC and O
and NN duration O
duration , , O
, CC or O
or NN type O
type IN of O
of NN exercise O
exercise NN protocol O
protocol NN ) O
) IN on O
on JJ salivary O
salivary NN composition O
composition VBP are O
are RB then O
then VBN considered O

Exercise NN CAPITAL Exercise O
Exercise MD might O
might RB indeed O
indeed VB induce O
induce NNS changes O
changes IN in O
in JJ several O
several JJ salivary O
salivary NNS components O
components JJ such O
such IN as O
as NNS immunoglobulins O
immunoglobulins , , O
, NNS hormones O
hormones , , O
, NN lactate O
lactate , , O
, NNS proteins O
proteins CC and O
and NNS electrolytes O

Saliva FW CAPITAL Saliva O
Saliva NN composition O
composition MD might O
might RB therefore O
therefore VB be O
be VBN used O
used IN as O
as DT an O
an JJ alternative O
alternative JJ noninvasive O
noninvasive NN indicator O
indicator IN of O
of DT the O
the NN response O
response IN of O
of DT the O
the JJ different O
different NN body O
body NNS tissues O
tissues CC and O
and NNS systems O
systems TO to O
to JJ physical O
physical NN exertion O

In IN CAPITAL In O
In DT this O
this NN respect O
respect , , O
, DT the O
the NN response O
response IN of O
of JJ salivary O
salivary NN amylase O
amylase CC and O
and JJ salivary O
salivary NNS electrolytes O
electrolytes TO to O
to JJ incremental O
incremental NNS levels O
levels IN of O
of NN exercise O
exercise VBZ is O
is IN of O
of JJ particular O
particular NN interest O

Beyond IN CAPITAL Beyond O
Beyond DT a O
a JJ certain O
certain NN intensity O
intensity IN of O
of NN exercise O
exercise , , O
, CC and O
and VBG coinciding O
coinciding IN with O
with DT the O
the NN accumulation O
accumulation IN of O
of NN blood O
blood NN lactate O
lactate NN ( O
( JJ anaerobic O
anaerobic NN threshold O
threshold CC or O
or IN CAPITAL AT O
AT NN ) O
) , , O
, DT a O
a NN 'saliva O
'saliva NN threshold O
threshold POS ' O
' NN ( O
( NN CAPITAL Tsa O
Tsa NN ) O
) VBZ does O
does RB indeed O
indeed VB exist O

Tsa NN CAPITAL Tsa O
Tsa VBZ is O
is DT the O
the NN point O
point IN during O
during NN exercise O
exercise IN at O
at WDT which O
which DT the O
the NNS levels O
levels IN of O
of JJ salivary O
salivary NN alpha-amylase O
alpha-amylase CC and O
and NNS electrolytes O
electrolytes NN ( O
( RB especially O
especially NN CAPITAL Na+ O
Na+ NN ) O
) RB also O
also VB begin O
begin TO to O
to NN rise O
rise IN above O
above NN baseline O
baseline NNS levels O

The DT CAPITAL The O
The NN occurrence O
occurrence IN of O
of DT the O
the CD 2 O
2 NNS thresholds O
thresholds NN ( O
( IN CAPITAL AT O
AT CC and O
and NN CAPITAL Tsa O
Tsa NN ) O
) MD might O
might , , O
, IN in O
in VB turn O
turn , , O
, VB be O
be JJ attributable O
attributable TO to O
to DT the O
the JJ same O
same VBG underlying O
underlying NN mechanism O
mechanism , , O
, IN that O
that IN of O
of VBN increased O
increased JJ adrenal O
adrenal JJ sympathetic O
sympathetic NN activity O
activity IN at O
at JJ high O
high NN exercise O
exercise NNS intensities O

Fat NNP CAPITAL Fat O
Fat VBZ is O
is DT an O
an RB extremely O
extremely JJ important O
important JJ substrate O
substrate IN for O
for NN muscle O
muscle NN contraction O
contraction , , O
, DT both O
both IN at O
at NN rest O
rest CC and O
and IN during O
during NN exercise O

Triglycerides NNS CAPITAL Triglycerides O
Triglycerides NN ( O
( NNS CAPITAL TGs O
TGs NN ) O
) , , O
, VBN stored O
stored IN in O
in NN adipose O
adipose NN tissue O
tissue CC and O
and IN within O
within NN muscle O
muscle NNS fibres O
fibres , , O
, VBP are O
are VBN considered O
considered TO to O
to VB be O
be DT the O
the JJ main O
main NN source O
source IN of O
of DT the O
the JJ free O
free JJ fatty O
fatty NNS acids O
acids NN ( O
( NNS CAPITAL FFAs O
FFAs NN ) O
) VBN oxidised O
oxidised IN during O
during NN exercise O

It PRP CAPITAL It O
It VBZ is O
is RB still O
still JJ unclear O
unclear , , O
, RB however O
however , , O
, WRB how O
how DT the O
the NN use O
use IN of O
of DT these O
these NNS substrates O
substrates VBZ is O
is VBN regulated O
regulated IN during O
during NN exercise O

The DT CAPITAL The O
The NN regulation O
regulation VBZ seems O
seems TO to O
to VB be O
be JJ multifactorial O
multifactorial CC and O
and VBZ includes O
includes : : O
: NN ( O
( LS i O
i NN ) O
) JJ dietary O
dietary CC and O
and JJ nutritional O
nutritional NN status O
status : ; O
; NN ( O
( LS ii O
ii NN ) O
) JJ hormonal O
hormonal NN milieu O
milieu : ; O
; NN ( O
( LS iii O
iii NN ) O
) NN exercise O
exercise NN mode O
mode , , O
, NN intensity O
intensity CC and O
and NN duration O
duration : ; O
; CC and O
and NN ( O
( NN iv O
iv NN ) O
) NN training O
training NN status O

On IN CAPITAL On O
On DT the O
the JJ other O
other NN hand O
hand , , O
, DT the O
the NN mechanism O
mechanism IN for O
for NN CAPITAL FFA O
FFA NN transport O
transport IN from O
from PRP$ its O
its NN storage O
storage IN as O
as NNS triglycerides O
triglycerides IN in O
in NN adipose O
adipose NN tissue O
tissue CC and O
and NN muscle O
muscle TO to O
to PRP$ its O
its NN place O
place IN of O
of NN utilisation O
utilisation IN in O
in NN heart O
heart , , O
, JJ skeletal O
skeletal NN muscle O
muscle , , O
, NN kidney O
kidney CC and O
and NN liver O
liver VBZ is O
is RBR more O
more RB clearly O
clearly VBN understood O

It PRP CAPITAL It O
It VBZ has O
has VBN been O
been VBN determined O
determined IN that O
that DT the O
the NN plasma O
plasma NN CAPITAL FFA O
FFA NN turnover O
turnover NN rate O
rate VBZ is O
is RB sufficiently O
sufficiently JJ rapid O
rapid TO to O
to NN account O
account IN for O
for JJS most O
most IN of O
of DT the O
the JJ fat O
fat VBN metabolised O
metabolised IN during O
during JJ low O
low NN intensity O
intensity NN exercise O
exercise NN ( O
( CD 25 O
25 TO to O
to CD 40 O
40 NN % O
% NN CAPITAL VO2max O
VO2max NN ) O

However RB CAPITAL However O
However , , O
, DT an O
an NN exercise O
exercise NN intensity O
intensity IN of O
of CD 65 O
65 NN % O
% NN CAPITAL VO2max O
VO2max NNS results O
results IN in O
in DT a O
a JJ slight O
slight NN decrease O
decrease IN in O
in DT the O
the NN amount O
amount IN of O
of NN plasma O
plasma NN CAPITAL FFA O
FFA NN uptake O
uptake IN by O
by NN muscle O
muscle NN tissue O

Other JJ CAPITAL Other O
Other NNS studies O
studies VB have O
have VBN found O
found IN that O
that IN during O
during JJ prolonged O
prolonged NN exercise O
exercise , , O
, NN muscle O
muscle NNS CAPITAL TGs O
TGs VBN become O
become DT the O
the JJ predominant O
predominant NN source O
source IN of O
of NN energy O
energy VBN obtained O
obtained IN from O
from JJ fat O

Furthermore RB CAPITAL Furthermore O
Furthermore , , O
, PRP it O
it VBZ is O
is RB widely O
widely VBN documented O
documented IN that O
that JJ endurance O
endurance NNS activities O
activities NN increase O
increase DT the O
the NN energy O
energy NN utilisation O
utilisation IN from O
from JJ fat O
fat IN while O
while VBG sparing O
sparing NN carbohydrate O
carbohydrate NNS sources O

For IN CAPITAL For O
For NN example O
example , , O
, IN during O
during NN exercise O
exercise IN on O
on DT a O
a NN cycle O
cycle NN ergometer O
ergometer , , O
, JJ nonplasma O
nonplasma NNS CAPITAL FFAs O
FFAs CC and O
and NN plasma O
plasma NNS CAPITAL FFAs O
FFAs VB contribute O
contribute CD 40 O
40 NN % O
% , , O
, CC and O
and NNS carbohydrates O
carbohydrates CD 60 O
60 NN % O
% , , O
, IN of O
of DT the O
the JJ total O
total VBN calculated O
calculated NN amount O
amount IN of O
of NN energy O
energy NN expenditure O
expenditure IN before O
before NN exercise O
exercise CC and O
and NN vice O
vice RB versa O
versa IN after O
after NN exercise O
exercise NN ( O
( CD 60 O
60 NN % O
% JJ nonplasma O
nonplasma CC and O
and NN plasma O
plasma NNS CAPITAL FFAs O
FFAs CC and O
and CD 40 O
40 NN % O
% NNS carbohydrates O
carbohydrates NN ) O

Although IN CAPITAL Although O
Although PRP it O
it VBD was O
was JJ many O
many NNS years O
years IN before O
before PRP it O
it VBD was O
was RB fully O
fully VBD demonstrated O
demonstrated , , O
, JJ fat O
fat VBZ is O
is RB now O
now JJ known O
known TO to O
to VB be O
be VBN transported O
transported IN in O
in DT the O
the NN blood O
blood IN as O
as NN CAPITAL FFA O
FFA VBN bound O
bound TO to O
to DT the O
the NN protein O
protein NN carrier O
carrier NN albumin O

The DT CAPITAL The O
The NN mobilisation O
mobilisation IN of O
of NN CAPITAL FFA O
FFA VBZ is O
is RB primarily O
primarily DT a O
a NN function O
function IN of O
of JJ sympathetic O
sympathetic JJ nervous O
nervous NN activity O
activity VBN directed O
directed IN towards O
towards DT the O
the NNS adipocytes O
adipocytes , , O
, CC or O
or DT the O
the NN 'fat O
'fat NN pad O
pad POS ' O
' . . O
. DT CAPITAL This O
This JJ nervous O
nervous NN activity O
activity MD can O
can VB be O
be JJ direct O
direct CC or O
or MD may O
may VB be O
be DT an O
an NN effect O
effect IN of O
of VBG circulating O
circulating NNS catecholamines O
catecholamines JJ such O
such IN as O
as NN adrenaline O
adrenaline NN ( O
( NN epinephrine O
epinephrine NN ) O

This DT CAPITAL This O
This NN article O
article VBZ summarises O
summarises DT the O
the NN role O
role IN of O
of JJ fat O
fat NN metabolism O
metabolism IN during O
during NN exercise O

As IN CAPITAL As O
As DT the O
the JJ clinical O
clinical NN availability O
availability IN of O
of NN glycohaemoglobin/GHb O
glycohaemoglobin/GHb NN measurement O
measurement NNS increases O
increases , , O
, RB so O
so VBZ does O
does DT the O
the NN need O
need IN for O
for JJ comparable O
comparable CC and O
and JJ accurate O
accurate NNS values O
values IN among O
among JJ different O
different NNS laboratories O
laboratories CC and O
and JJ different O
different NNS methods O

At IN CAPITAL At O
At JJS least O
least RB there O
there MD should O
should VB be O
be NN comparability O
comparability , , O
, NN i.e O
i.e . . O
. , , O
, NN commutability O
commutability CC or O
or NN feasibility O
feasibility IN of O
of VBG providing O
providing JJ comparable O
comparable NNS results O
results IN from O
from JJ different O
different NNS assays O
assays IN in O
in JJ different O
different NNS laboratories O

A DT CAPITAL A O
A JJ clinical O
clinical JJ joint O
joint NN study O
study IN on O
on NN insulin T
insulin NN therapy T
therapy , , O
, DT a O
a NN survey O
survey IN of O
of DT the O
the JJ actual O
actual JJ inter-laboratory O
inter-laboratory NNS differences O
differences IN in O
in NN CAPITAL GHb O
GHb NN measurement O
measurement IN among O
among CD 41 O
41 NNS institutions O
institutions CC and O
and DT an O
an NN assessment O
assessment IN of O
of CD 11 O
11 NN assay O
assay NNS methods O
methods IN for O
for DT the O
the NN determination O
determination IN of O
of NN CAPITAL GHb O
GHb VBD were O
were VBN performed O
performed VBG using O
using JJ commercial O
commercial NNS calibrators O
calibrators CC and O
and JJ fresh O
fresh NN blood O
blood NNS samples O

Data NNS CAPITAL Data O
Data IN on O
on DT the O
the JJ actual O
actual NN state O
state IN of O
of JJ inter-laboratory O
inter-laboratory CC and O
and JJ inter-assay O
inter-assay NNS differences O
differences IN of O
of VBN observed O
observed NNS values O
values VBD were O
were JJ useful O
useful IN for O
for VBG comparing O
comparing NNS results O
results IN among O
among NNS facilities O

The DT CAPITAL The O
The NN recommendation O
recommendation IN of O
of DT the O
the NNP CAPITAL Japan O
Japan NNP CAPITAL Diabetes O
Diabetes NNP CAPITAL Society O
Society TO to O
to NN measure O
measure RB only O
only DT the O
the JJ stable O
stable NN CAPITAL GHb O
GHb NN component O
component CC and O
and TO to O
to JJ correct O
correct DT the O
the NN CAPITAL GHb O
GHb NN percentage O
percentage IN by O
by JJ two-point O
two-point NN calibration O
calibration IN with O
with VBN assigned O
assigned NNS values O
values , , O
, VBD was O
was JJ effective O
effective CC but O
but RB not O
not JJ sufficient O

Even RB CAPITAL Even O
Even IN after O
after NN correction O
correction , , O
, CD 8 O
8 IN out O
out IN of O
of CD 11 O
11 NNS methods O
methods RB still O
still VBD remained O
remained IN of O
of JJ little O
little JJ practical O
practical NN use O
use IN because O
because IN of O
of PRP$ their O
their JJ large O
large JJ relative O
relative NNS errors O

Inter-method JJ CAPITAL Inter-method O
Inter-method NNS differences O
differences IN among O
among CD 11 O
11 JJ available O
available NN assay O
assay NNS methods O
methods VBD were O
were JJ great O
great RB even O
even IN after O
after NN correction O
correction CC and O
and VBD depended O
depended IN on O
on RB not O
not RB only O
only DT the O
the NNS methods O
methods CC but O
but DT the O
the NNS samples O
samples VBN used O
used IN for O
for DT the O
the NN determination O

The DT CAPITAL The O
The NN performance O
performance IN of O
of DT some O
some NNS methods O
methods CC or O
or NNS instruments O
instruments VBN used O
used VBP are O
are RB only O
only JJ poor O
poor IN at O
at VBG distinguishing O
distinguishing DT the O
the JJ stable O
stable VBN glycated O
glycated NN haemoglobin O
haemoglobin PRP itself O

Some DT CAPITAL Some O
Some JJ alternative O
alternative NN measurement O
measurement NN system O
system IN with O
with NN comparability O
comparability , , O
, NN commutability O
commutability CC and O
and NN precision O
precision MD should O
should VB be O
be VBN established O

An DT CAPITAL An O
An JJ urgent O
urgent CC and O
and JJ worldwide O
worldwide NN problem O
problem TO to O
to VB remove O
remove JJ inter-laboratory O
inter-laboratory NNS differences O
differences IN in O
in DT the O
the NN measurement O
measurement IN of O
of NN CAPITAL GHb O
GHb NNS needs O
needs TO to O
to VB be O
be VBD solved O

Users NNS CAPITAL Users O
Users IN in O
in JJ clinical O
clinical NN practice O
practice MD must O
must VB recognize O
recognize DT these O
these NNS problems O
problems , , O
, CC and O
and , , O
, IN before O
before NN supply O
supply , , O
, DT the O
the NNS providers O
providers MD should O
should NN check O
check PRP$ their O
their NN method O
method CC and O
and VB keep O
keep NNS records O
records IN that O
that VBP are O
are RB readily O
readily JJ traceable O

A DT CAPITAL A O
A JJ postal O
postal NN survey O
survey VBD was O
was VBN performed O
performed TO to O
to VB determine O
determine DT the O
the JJ current O
current NNS practices O
practices CC and O
and NNS attitudes O
attitudes IN of O
of NNS radiologists O
radiologists IN towards O
towards DT the O
the NN imaging O
imaging IN of O
of VBN suspected O
suspected JJR lower O
lower NN limb O
limb JJ deep D
deep NN vein D
vein NN thrombosis D
thrombosis NN ( D
( NN CAPITAL DVT D
DVT NN ) D

One CD CAPITAL One O
One CD hundred O
hundred CC and O
and CD twenty-seven O
twenty-seven NNS departments O
departments VBD responded O
responded TO to O
to DT a O
a NN questionnaire O
questionnaire VBN sent O
sent IN in O
in NNP CAPITAL March O
March CD 1996 O

The DT CAPITAL The O
The NNS results O
results NN show O
show IN that O
that CD 87 O
87 NN % O
% IN of O
of NNS hospitals O
hospitals VB possess O
possess NN colour O
colour NNP CAPITAL Doppler O
Doppler NN ultrasound O
ultrasound NN ( O
( NN CAPITAL CDUS O
CDUS NN ) O
) NNS machines O
machines CC and O
and IN that O
that CD 46 O
46 NN % O
% IN of O
of NNS departments O
departments VB perform O
perform NN ultrasound O
ultrasound IN as O
as DT the O
the RB first O
first NN line O
line NN investigation O
investigation IN in O
in IN over O
over CD 90 O
90 NN % O
% IN of O
of NNS cases O

Thirty CD CAPITAL Thirty O
Thirty IN per O
per NN cent O
cent IN of O
of NNS departments O
departments VBN considered O
considered NN calf O
calf NN vein O
vein NN visualization O
visualization TO to O
to VB be O
be RB generally O
generally JJ adequate O
adequate CC and O
and CD 34 O
34 NN % O
% VBN thought O
thought IN that O
that NNS clinicians O
clinicians IN in O
in PRP$ their O
their NNS hospitals O
hospitals RB invariably O
invariably JJ anticoagulated O
anticoagulated NNS patients O
patients IN with O
with VBN isolated T
isolated NN calf T
calf NN thrombus T

In IN CAPITAL In O
In NNS hospitals O
hospitals WRB where O
where NN venography O
venography VBD was O
was RB routinely O
routinely VBN used O
used IN as O
as DT the O
the RB first O
first NN line O
line NN investigation O
investigation , , O
, DT the O
the JJS most O
most JJ common O
common NNS reasons O
reasons VBD were O
were : : O
: DT the O
the VBN perceived O
perceived NN inferiority O
inferiority IN of O
of NN ultrasound O
ultrasound NN ( O
( NNP CAPITAL US O
US NN ) O
) IN in O
in VBG demonstrating O
demonstrating JJ below-knee O
below-knee NN clot D
clot , , O
, PRP$ its O
its JJ time-consuming O
time-consuming NN nature O
nature CC and O
and DT the O
the JJ limited O
limited NN access O
access TO to O
to JJ suitable O
suitable NN ultrasound O
ultrasound NNS machines O

The DT CAPITAL The O
The JJ widespread O
widespread NN use O
use IN of O
of NN ultrasound O
ultrasound VBZ is O
is JJ encouraging O
encouraging , , O
, RB however O
however , , O
, RB there O
there VBP are O
are RB clearly O
clearly JJ diverse O
diverse NNS views O

A DT CAPITAL A O
A JJ significant O
significant NN minority O
minority IN of O
of NNS departments O
departments VB depend O
depend RB principally O
principally IN upon O
upon NN venography O
venography IN in O
in DT the O
the NN diagnosis O
diagnosis IN of O
of NN CAPITAL DVT D

Existential JJ CAPITAL Existential O
Existential NN phenomenology O
phenomenology CC and O
and DT the O
the JJ sociological O
sociological NN tradition O

Dual JJ CAPITAL Dual O
Dual NN leadership O
leadership IN in O
in JJ complex O
complex NNS organizations O

Scientists NNS CAPITAL Scientists O
Scientists IN at O
at JJ major O
major CC and O
and JJ minor O
minor NNS universities O
universities : : O
: DT a O
a NN study O
study IN of O
of NN productivity O
productivity CC and O
and NN recognition O

Demotion NN CAPITAL Demotion O
Demotion IN in O
in JJ industrial O
industrial NN management O

Career NNP CAPITAL Career O
Career NN anchorage O
anchorage : : O
: JJ managerial O
managerial NN mobility O
mobility NNS motivations O

Social NNP CAPITAL Social O
Social NN class O
class CC and O
and JJ premarital O
premarital JJ sexual O
sexual NN permissiveness O
permissiveness : : O
: DT a O
a NN re-examination O

A DT CAPITAL A O
A NN comment O
comment IN on O
on `` `` O
`` NN anomy O
anomy '' '' O

A DT CAPITAL A O
A NN factor O
factor JJ analytic O
analytic NN exploration O
exploration IN of O
of DT the O
the NN alienation O
alienation , , O
, NN anomia O
anomia CC and O
and NN authoritarianism O
authoritarianism NN domain O

Technical NNP CAPITAL Technical O
Technical NN note O
note IN on O
on CD two O
two NNS rates O
rates IN of O
of JJ mixed O
mixed NN marriage O

Some DT CAPITAL Some O
Some NNS comments O
comments IN on O
on NN awareness O

On IN CAPITAL On O
On JJ experimental O
experimental NN design O

Observations NNS CAPITAL Observations O
Observations IN on O
on DT the O
the NN incidence O
incidence IN of O
of VBG following O
following IN of O
of JJ visual O
visual CC and O
and JJ auditory O
auditory NNS stimuli O
stimuli IN in O
in JJ naive O
naive NN mallard O
mallard NNS ducklings O
ducklings NN ( O
( NNP CAPITAL Anas O
Anas NNS platyrhynchos O
platyrhynchos NN ) O

The DT CAPITAL The O
The NN comfort O
comfort NNS movements O
movements IN of O
of FW CAPITAL Anatidae O

Potential JJ CAPITAL Potential O
Potential JJ ethological O
ethological VBG isolating O
isolating NNS mechanisms O
mechanisms CC and O
and JJ assortative O
assortative VBG mating O
mating IN in O
in DT the O
the JJ domestic O
domestic NN fowl O

An DT CAPITAL An O
An JJ experimental O
experimental NN study O
study IN of O
of NN conflict O
conflict CC and O
and NN fear O
fear : : O
: DT an O
an NN analysis O
analysis IN of O
of NN behavior O
behavior IN of O
of JJ young O
young NNS chicks O
chicks IN toward O
toward DT a O
a NN mealworm O

I PRP CAPITAL I O
I . . O
. DT CAPITAL The O
The NN behavior O
behavior IN of O
of NNS chicks O
chicks WDT which O
which VB do O
do RB not O
not VB eat O
eat DT the O
the NN mealworm O

The DT CAPITAL The O
The VBG measuring O
measuring NN function O
function IN of O
of DT the O
the RB first O
first NNS legs O
legs IN of O
of FW CAPITAL Araneus O
Araneus NN diadematus O
diadematus NN CAPITAL Cl O

The DT CAPITAL The O
The NN transport O
transport IN of O
of NN prey O
prey IN by O
by NNS ants O

Courtship NN CAPITAL Courtship O
Courtship NN behaviour O
behaviour IN in O
in DT the O
the FW CAPITAL Drosophila O
Drosophila NN obscura O
obscura NN group O

II NNP CAPITAL II O

Comparative JJ CAPITAL Comparative O
Comparative NNS studies O

Vision NNP CAPITAL Vision O
Vision CC versus O
versus NN touch O
touch IN in O
in NN form O
form NN discrimination O

Short-term JJ CAPITAL Short-term O
Short-term NN retention O
retention IN as O
as DT a O
a NN function O
function IN of O
of NN method O
method IN of O
of NN measurement O
measurement , , O
, VBG recording O
recording NN time O
time , , O
, CC and O
and NN meaningfulness O
meaningfulness IN of O
of DT the O
the NN material O

The DT CAPITAL The O
The NN conservation O
conservation IN of O
of DT a O
a NN shape O
shape NN property O
property CC and O
and DT a O
a NN proposal O
proposal IN about O
about DT the O
the NN origin O
origin IN of O
of DT the O
the NNS conservations O

Persisting VBG CAPITAL Persisting O
Persisting VBZ odours O
odours IN as O
as DT a O
a VBG biasing O
biasing NN factor O
factor IN in O
in JJ open-field O
open-field NN research O
research IN with O
with NNS mice O

The DT CAPITAL The O
The NN display O
display IN of O
of NN information O
information CC and O
and DT the O
the NN judgment O
judgment IN of O
of NN contingency O

Vividness NN CAPITAL Vividness O
Vividness IN of O
of NNS words O
words CC and O
and VBG learning O
learning TO to O
to VB learn O
learn IN in O
in JJ free-recall O
free-recall VBG learning O

Genetic JJ CAPITAL Genetic O
Genetic NN study O
study IN of O
of DT the O
the NN memorization O
memorization IN of O
of NNS words O
words CC and O
and NNS pictures O

Amylase NN CAPITAL Amylase O
Amylase NN production O
production IN by O
by FW CAPITAL Streptomyces O
Streptomyces NNS species O

Physico-chemical JJ CAPITAL Physico-chemical O
Physico-chemical NNS studies O
studies IN on O
on DT the O
the NN stability O
stability IN of O
of NN penicillin T
penicillin NNS salts T

IV CD CAPITAL IV O

A DT CAPITAL A O
A JJ statistical O
statistical NN evaluation O

Studies NNS CAPITAL Studies O
Studies IN on O
on NN nitrogen O
nitrogen NN metabolism O
metabolism IN of O
of NNP CAPITAL Penicillium O
Penicillium NN chrysogenum O
chrysogenum NNP CAPITAL Thom O
Thom . . O
. PRP CAPITAL I O
I . . O
. NNS CAPITAL Effects O
Effects IN of O
of NN lactose O
lactose CC and O
and NN sucrose O
sucrose NNS additions O
additions IN on O
on NN nitrogen O
nitrogen NN metabolism O

Studies NNS CAPITAL Studies O
Studies IN on O
on NN nitrogen O
nitrogen NN metabolism O
metabolism IN of O
of NNP CAPITAL Penicillium O
Penicillium NN chrysogenum O
chrysogenum NNP CAPITAL Thom O
Thom . . O
. NNP CAPITAL II O

Amino NN CAPITAL Amino O
Amino NN acid O
acid NN metabolism O
metabolism CC and O
and PRP$ its O
its NN relation O
relation TO to O
to DT the O
the NN biosynthesis O
biosynthesis IN of O
of NN penicillin T

The DT CAPITAL The O
The NN contribution O
contribution IN of O
of JJ thoracic T
thoracic NN surgery T
surgery TO to O
to PRP$ our O
our NN discipline O

Research NNP CAPITAL Research O
Research JJ past O
past CC and O
and JJ present O
present , , O
, IN with O
with JJ particular O
particular NN reference O
reference TO to O
to DT the O
the NN application O
application IN of O
of DT the O
the NNS techniques O
techniques IN of O
of JJ basic O
basic NN science O
science TO to O
to DT the O
the NNS problems O
problems IN of O
of JJ adrenal O
adrenal NN pathology O

Some DT CAPITAL Some O
Some JJ inflammatory D
inflammatory NNS disorders D
disorders IN of O
of DT the O
the JJ large O
large NN intestine O

Coexistence NN CAPITAL Coexistence O
Coexistence IN of O
of JJ subdural O
subdural CC and O
and JJ archnoidal O
archnoidal NNS collections O
collections IN of O
of NN fluid O
fluid : : O
: DT an O
an JJ unusual O
unusual NN case O

The DT CAPITAL The O
The NN scope O
scope IN of O
of NN sphincterotomy T
sphincterotomy IN in O
in JJ biliary T
biliary CC and T
and JJ pancreatic T
pancreatic NN surgery T

Sarcoidosis NN CAPITAL Sarcoidosis T
Sarcoidosis VBG involving O
involving DT the O
the NN veriform O
veriform NN appendix O

`` `` `` O
`` JJ CAPITAL Chronic D
Chronic NN pancreatitis D
pancreatitis `` `` O
`` CC and O
and NN carcinoma D
carcinoma IN of D
of DT the D
the NN pancreas D

A DT CAPITAL A O
A NN method O
method TO to O
to NN aid O
aid JJ correct O
correct NN diagnosis O

Control NN CAPITAL Control O
Control IN of O
of JJ post-haemorrhoidectomy D
post-haemorrhoidectomy NN bleeding D
bleeding IN with O
with DT a T
a NNP CAPITAL Foley T
Foley NN catheter T
catheter CC and T
and DT a T
a NN pack T

Diagnosis NN CAPITAL Diagnosis O
Diagnosis CC and O
and NN therapy O
therapy IN of O
of JJ chronic D
chronic JJ aspecific D
aspecific NN pancreatitis D

Behavior NN CAPITAL Behavior O
Behavior IN of O
of DT the O
the NN tetanus D
tetanus NN patient O
patient VBN subjected O
subjected TO to O
to NN resuscitation T
resuscitation NN treatment T

Further JJ CAPITAL Further O
Further NNS data O
data IN on O
on JJ mediastinal D
mediastinal CC and D
and JJ pulmonary D
pulmonary NNS tumors D
tumors IN of O
of DT the O
the NN child O

Review NN CAPITAL Review O
Review CC and O
and JJ personal O
personal NNS cases O

Dextran NN CAPITAL Dextran O
Dextran IN of O
of JJ low O
low JJ molecular O
molecular NN weight O
weight IN in O
in JJ peripheral D
peripheral JJ arterial D
arterial NN insufficiency D

Clinico-statistical JJ CAPITAL Clinico-statistical O
Clinico-statistical NNS considerations O
considerations IN on O
on JJ vescicular D
vescicular NN mole D

On IN CAPITAL On O
On DT the O
the NN significance O
significance IN of O
of JJ histologic O
histologic NNS findings O
findings IN in O
in NNS neoplasms D
neoplasms IN of O
of DT the O
the NN trophoblast O
trophoblast NN ( O
( NN case O
case NNS contributions O
contributions NN ) O

Diagnostic JJ CAPITAL Diagnostic O
Diagnostic NN evaluation O
evaluation IN of O
of DT the O
the NN patient O
patient IN with O
with JJ high D
high NN blood D
blood NN pressure D

Epidemiology NNP CAPITAL Epidemiology O
Epidemiology IN of O
of NN hypertension D

Renal JJ CAPITAL Renal D
Renal JJ vascular D
vascular NN hypertension D
hypertension : ; O
; NN diagnosis O
diagnosis CC and O
and NN treatment O

The DT CAPITAL The O
The NN use O
use IN of O
of JJ radioactive O
radioactive NNS isotopes O
isotopes IN in O
in DT the O
the NN diagnosis O
diagnosis IN of O
of NN hypertension D

The DT CAPITAL The O
The NN angiogram O
angiogram IN in O
in DT the O
the NN study O
study IN of O
of NN hypertension D

Guanethidine NN CAPITAL Guanethidine O

Hepatocerebral JJ CAPITAL Hepatocerebral D
Hepatocerebral NN degeneration D
degeneration NN ( D
( NN portal D
portal JJ systemic D
systemic NN encephalopathy D
encephalopathy NN ) D

The DT CAPITAL The O
The NN relationship O
relationship TO to O
to JJ fatty O
fatty NNS acids O

Oviposition NN CAPITAL Oviposition O
Oviposition CC and O
and PRP$ its O
its NN regulation O
regulation IN in O
in DT the O
the JJ polygynous O
polygynous NN society O
society IN of O
of NNS CAPITAL Polistes O
Polistes NN gallicus O
gallicus NNP CAPITAL L. O

Interaction NN CAPITAL Interaction O
Interaction IN of O
of JJ aggressive O
aggressive CC and O
and JJ sexual O
sexual NN behavior O
behavior IN in O
in JJ male O
male NNS mice O

Conflict NN CAPITAL Conflict O
Conflict CC and O
and VBN conditioned O
conditioned JJ aversive O
aversive NNS stimuli O
stimuli IN in O
in DT the O
the NN development O
development IN of O
of JJ experimental O
experimental NNS neuroses O

Study NNP CAPITAL Study O
Study IN of O
of DT the O
the NN effect O
effect IN of O
of JJR newer O
newer JJ analeptic O
analeptic NN ( O
( JJ CAPITAL Micoren O
Micoren NN ) O
) IN in O
in NN hypoventilation O
hypoventilation NN syndrome O

Treatment NN CAPITAL Treatment O
Treatment IN of O
of DT a D
a NN disorder D
disorder IN of D
of NN perception D
perception CC and D
and NN concept D
concept NN formation D
formation IN in O
in DT a O
a NN case O
case IN of O
of NN school O
school NN failure O

Rorschach JJ CAPITAL Rorschach O
Rorschach VBZ correlates O
correlates IN of O
of NN time O
time NN estimation O

Use NNP CAPITAL Use O
Use IN of O
of NN food O
food IN in O
in NN child T
child NN psychotherapy T

About IN CAPITAL About O
About JJ genital O
genital NN discharge O
discharge IN with O
with JJ special O
special NN consideration O
consideration IN of O
of PRP$ its O
its JJ cervical O
cervical NN manifestation O

Auto-uro NN CAPITAL Auto-uro T
Auto-uro NN therapy T
therapy : : O
: NN status O
status CC and O
and JJ future O
future NNS prospects O

Clinical JJ CAPITAL Clinical O
Clinical NN experience O
experience IN with O
with DT the O
the NN surface T
surface JJ anesthetic T
anesthetic NN xylocaine T
xylocaine IN in O
in NNS obstetrics O

The DT CAPITAL The O
The NN problem O
problem IN of O
of JJ medicinal O
medicinal NN management O
management IN of O
of NN labor O

Conglutination NN CAPITAL Conglutination O
Conglutination IN of O
of DT the O
the NN labia O
labia NN minora O

The DT CAPITAL The O
The NN fight O
fight IN against O
against JJ hemolytic D
hemolytic NN disease D
disease IN of O
of DT the O
the JJ newborn O
newborn IN in O
in JJ general O
general NN practice O

Long JJ CAPITAL Long O
Long NN term O
term NNS results O
results IN in O
in DT the O
the CD 300 O
300 JJS most O
most JJ grave O
grave NNS cases O
cases IN out O
out IN of O
of CD 4000 O
4000 JJ hyperthyroid D
hyperthyroid NNS patients D
patients VBN treated O
treated IN with O
with NN iodine T
iodine NN CAPITAL I-131 T
I-131 IN at O
at DT the O
the NN center O
center IN of O
of NNP CAPITAL Ancona O

On IN CAPITAL On O
On JJ socalled O
socalled JJ nervous O
nervous NN exhaustion O

Examination NN CAPITAL Examination O
Examination IN of O
of JJ neonatal O
neonatal JJ archaic O
archaic NN ( O
( JJ primitive O
primitive NN ) O
) NNS reflexes O
reflexes IN in O
in NN icterus D
icterus NN gravis D

Urologic JJ CAPITAL Urologic O
Urologic NNS complications O
complications IN in O
in JJ non-recurrent D
non-recurrent NN cancer D
cancer IN of O
of DT the O
the NN cervix O

Prolonged JJ CAPITAL Prolonged T
Prolonged NN cortisone T
cortisone NN therapy T
therapy IN in O
in NN treatment O
treatment IN of O
of JJ allergic D
allergic NNS diseases D

The DT CAPITAL The O
The VBG complexing O
complexing IN of O
of NN calcium O
calcium IN by O
by NN citrate O
citrate , , O
, JJ ortho- O
ortho- CC and O
and NNS polyphosphates O

A DT CAPITAL A O
A NN method O
method IN of O
of VBG determining O
determining DT the O
the NN patency O
patency IN of O
of DT the O
the JJ nasolacrimal O
nasolacrimal NN apparatus O

Intra-arterial JJ CAPITAL Intra-arterial O
Intra-arterial NN infusion O
infusion IN of O
of DT the O
the NN head O
head CC and O
and NN neck O

Anatomic JJ CAPITAL Anatomic O
Anatomic CC and O
and JJ distributional O
distributional NNS problems O

Lymphatics NNS CAPITAL Lymphatics O
Lymphatics IN of O
of DT the O
the NN mouth O
mouth CC and O
and NN neck O

Effect NN CAPITAL Effect O
Effect IN of O
of NN sodium O
sodium NNS ions O
ions IN on O
on DT the O
the NN behavior O
behavior IN of O
of NN rest O
rest CC and O
and NN action O
action NNS potentials O
potentials IN of O
of DT the O
the NN cell O
cell NN membrane O
membrane IN of O
of DT the O
the NN rat O
rat NN myometrium O

Studies NNS CAPITAL Studies O
Studies IN on O
on NN contractile O
contractile NNS properties O
properties IN of O
of DT the O
the NN blood O
blood NN serum O

Twin JJ CAPITAL Twin O
Twin NN pregnancy O
pregnancy CC and O
and JJ fetal O
fetal CC and O
and JJ infantile O
infantile JJ perinatal D
perinatal NN mortality D

Fate NNP CAPITAL Fate O
Fate IN of O
of DT the O
the JJ 2d O
2d JJ twin O

Differential JJ CAPITAL Differential O
Differential NN diagnosis O
diagnosis IN of O
of JJ infectious D
infectious NN hepatitis D
hepatitis IN in O
in NN pregnancy O

Epithelial JJ CAPITAL Epithelial O
Epithelial NN metaplasia D
metaplasia IN of O
of DT the O
the NN endometrium O

Leukoplakia NN CAPITAL Leukoplakia D
Leukoplakia IN of O
of DT the O
the JJ vaginal O
vaginal NN portion O
portion IN of O
of DT the O
the NN uterus O
uterus CC and O
and PRP$ its O
its JJ clinical O
clinical NN evaluation O

Blood NN CAPITAL Blood O
Blood NN loss O
loss IN in O
in JJ artificial O
artificial NN interruption O
interruption IN of O
of NN pregnancy O

Modified VBN CAPITAL Modified T
Modified NN bra T
bra IN in O
in DT the O
the NN prevention O
prevention IN of O
of NN mastitis D
mastitis IN in O
in NN nursing O
nursing NNS mothers O

Hormonal JJ CAPITAL Hormonal O
Hormonal NN phenomenon O
phenomenon IN after O
after DT the O
the NN excision O
excision IN of O
of NN hydatiform O
hydatiform NN mole O

Fetal JJ CAPITAL Fetal O
Fetal NN chondrodystrophy O

Malignant JJ CAPITAL Malignant D
Malignant JJ mesodermal D
mesodermal JJ mixed D
mixed NN tumor D
tumor IN of O
of DT the O
the NN uterus O
uterus VBG following O
following NN irradiation T

Supportive JJ CAPITAL Supportive O
Supportive NN role O
role IN of O
of NN nurse O
nurse IN in O
in RB first O
first NN stage O
stage IN of O
of NN labor O
labor `` `` O
`` MD can O
can RB not O
not VB be O
be VBN emphasized O
emphasized RB enough O
enough '' '' O
'' , , O
, VBG according O
according TO to O
to NN patient O

Toxemia NN CAPITAL Toxemia D
Toxemia IN of O
of NN pregnancy O

Outpatient NN CAPITAL Outpatient O
Outpatient NN care O
care : -- O
-- DT the O
the NN role O
role IN of O
of DT the O
the NN nurse O

Abandonment NN CAPITAL Abandonment O
Abandonment : : O
: JJS deepest O
deepest NN fear O
fear IN of O
of VBN hospitalized O
hospitalized NNS children O

Support NN CAPITAL Support O
Support IN in O
in RB first O
first NN stage O
stage IN of O
of NN labor O

The DT CAPITAL The O
The NN family O
family NN physician O
physician CC and O
and JJ cervical D
cervical NN carcinoma D
carcinoma : -- O
-- NN challenge O
challenge CC and O
and NN opportunity O

Purposeful JJ CAPITAL Purposeful O
Purposeful `` `` O
`` JJ heroic O
heroic '' '' O
'' NN heart O
heart NN treatment O

Skilled JJ CAPITAL Skilled O
Skilled NNS workers O
workers VBP are O
are JJ vital O
vital TO to O
to NN maintenance O
maintenance NN cost O
cost NNS cuts O

Karen NNP CAPITAL Karen O
Karen : : O
: DT the O
the JJ other O
other NN side O
side IN of O
of DT the O
the NN picture O

Rhesus NN CAPITAL Rhesus D
Rhesus JJ haemolytic D
haemolytic NN disease D
disease : ; O
; DT an O
an NN approach O
approach TO to O
to NN prevention O

Tumours NNP CAPITAL Tumours D
Tumours IN of O
of DT the O
the NN uterus O

2 CD 2 O

Malignancy NN CAPITAL Malignancy O

Cancer NN CAPITAL Cancer D
Cancer IN of O
of DT the O
the NN vulva O

Effects NNS CAPITAL Effects O
Effects IN of O
of NN smoking O
smoking IN on O
on VBN selected O
selected JJ clinical O
clinical JJ obstetric O
obstetric NNS factors O

Amniotic JJ CAPITAL Amniotic D
Amniotic NN fluid D
fluid NN embolism D

A DT CAPITAL A O
A NN review O
review IN of O
of DT the O
the NN syndrome O
syndrome IN with O
with DT a O
a NN report O
report IN of O
of CD 4 O
4 NNS cases O

Chronic JJ CAPITAL Chronic D
Chronic NN histiocytosis D
histiocytosis NN CAPITAL X D
X VBN associated O
associated IN with O
with NN pregnancy O

Disseminated VBN CAPITAL Disseminated D
Disseminated NN lupus D
lupus NN erythematosus D
erythematosus IN in O
in NN pregnancy O

Intralesional JJ CAPITAL Intralesional T
Intralesional NN therapy T
therapy IN with T
with NN betamethasone T

Strucutre NNP CAPITAL Strucutre O
Strucutre IN of O
of DT the O
the NN influenza D
influenza NN virus D

2 CD 2 O
2 NNS students O
students IN at O
at NN CAPITAL Quo O
Quo NNP CAPITAL Vadis O

Double JJ CAPITAL Double O
Double JJ aortic O
aortic JJ arch O
arch VBN associated O
associated IN with O
with NN tetralogy O
tetralogy IN of O
of NNP CAPITAL Fallot O
Fallot IN in O
in NNS infants O
infants : ; O
; NN report O
report IN of O
of CD two O
two NNS cases O

Tested VBN CAPITAL Tested O
Tested NNS questionnaires O
questionnaires NN help O
help NN administration O
administration VB learn O
learn IN if O
if NNS programs O
programs VBP are O
are DT a O
a NN success O
success , , O
, CC and O
and WRB why O

Dumping VBG CAPITAL Dumping D
Dumping NN syndrome D
syndrome VBG following O
following JJ pyloroplasty T
pyloroplasty . . O

Measured VBN CAPITAL Measured O
Measured JJ subtotal O
subtotal NN gastrectomy O
gastrectomy IN for O
for JJ duodenal O
duodenal NN ulcer O

The DT CAPITAL The O
The NNS lesions O
lesions IN in O
in JJ bovine O
bovine NNS udders O
udders VBG shedding O
shedding JJ nonhemolytic O
nonhemolytic JJ coagulase-negative O
coagulase-negative NNS staphylococci O

Repository JJ CAPITAL Repository O
Repository NN vitamin O
vitamin NN CAPITAL B O
B CD 12 O
12 NNS preparations O

Mass JJ CAPITAL Mass O
Mass NN spectrometry O
spectrometry IN in O
in JJ structural O
structural CC and O
and JJ stereochemical O
stereochemical NNS problems O

93 CD 93 O

Further JJ CAPITAL Further O
Further NNS observations O
observations IN on O
on DT the O
the NN importance O
importance IN of O
of JJ interatomic O
interatomic NN distance O
distance IN in O
in DT the O
the NN CAPITAL McLafferty O
McLafferty NN rearrangement O

Synthesis NN CAPITAL Synthesis O
Synthesis CC and O
and NN fragmentation O
fragmentation NN behavior O
behavior IN of O
of JJ deuterium-labeled O
deuterium-labeled JJ 12-keto O
12-keto NNS steroids O

Treatment NN CAPITAL Treatment O
Treatment IN of O
of NN childhood D
childhood NN schizophrenia D

A DT CAPITAL A O
A JJ three-year O
three-year NN comparison O
comparison IN of O
of NN day O
day CC and O
and JJ residental O
residental NN treatment O

Polycystic JJ CAPITAL Polycystic O
Polycystic NNS ovaries O
ovaries VBN associated O
associated IN with O
with JJ congenital D
congenital JJ adrenal D
adrenal NN hyperplasia D

Beta-propiolactone JJ CAPITAL Beta-propiolactone T
Beta-propiolactone IN as O
as VBN used O
used IN in O
in NN sterilization O
sterilization IN of O
of NNS homografts O
homografts RB not O
not JJ carcinogenic O
carcinogenic IN for O
for NNS mice O

New NNP CAPITAL New O
New NNS operations O
operations IN in O
in NNS children O
children POS 's O
's JJ cardiac O
cardiac NN disease O

Effect NN CAPITAL Effect O
Effect IN of O
of NN diabetes D
diabetes CC and O
and NN starvation O
starvation IN on O
on JJ myocardial O
myocardial NN triglyceride O
triglyceride CC and O
and JJ free O
free JJ fatty O
fatty NN acid O
acid NN utilization O

Effect NN CAPITAL Effect O
Effect IN of O
of NN epinephrine O
epinephrine IN on O
on JJ myocardial O
myocardial NN triglyceride O
triglyceride CC and O
and JJ free O
free JJ fatty O
fatty NN acid O
acid NN utilization O

Diurnal JJ CAPITAL Diurnal O
Diurnal NN periodicity O
periodicity IN in O
in DT the O
the JJ metabolic O
metabolic NN activity O
activity IN of O
of NN bone O
bone NN tissue O

Fine JJ CAPITAL Fine O
Fine NN structure O
structure IN of O
of NNS desmosomes O

, , , O
, NNS hemidesmosomes O
hemidesmosomes , , O
, CC and O
and DT an O
an JJ adepidermal O
adepidermal JJ globular O
globular NN layer O
layer IN in O
in VBG developing O
developing NN newt O
newt NN epidermis O

Redundant JJ CAPITAL Redundant O
Redundant JJ myelin O
myelin NNS sheaths O
sheaths CC and O
and JJ other O
other JJ ultrastructural O
ultrastructural NNS features O
features IN of O
of DT the O
the NN toad O
toad NN cerebellum O

A DT CAPITAL A O
A JJ radioautographic O
radioautographic NN study O
study IN with O
with NN CAPITAL H3-thymidine O
H3-thymidine IN on O
on JJ adrenal O
adrenal NN medulla O
medulla NNS nuclei O
nuclei IN of O
of NNS rats O
rats RB intermittently O
intermittently VBN exposed O
exposed TO to O
to JJ cold O

A DT CAPITAL A O
A JJ fine O
fine JJ structural O
structural NN analysis O
analysis IN of O
of DT the O
the NN epidermis O
epidermis IN of O
of DT the O
the NN earthworm O
earthworm , , O
, NN CAPITAL Lumbricus O
Lumbricus NN terrestris O
terrestris NNP CAPITAL L. O

Effect NN CAPITAL Effect O
Effect IN of O
of JJ thoracic O
thoracic NN cava O
cava NN obstruction O
obstruction IN on O
on NN response O
response IN of O
of JJ proximal O
proximal NN tubule O
tubule NN sodium O
sodium NN reabsorption O
reabsorption TO to O
to NN saline O
saline NN infusion O

The DT CAPITAL The O
The NN metabolism O
metabolism IN of O
of RB intravenously O
intravenously VBN injected O
injected JJ isotopic O
isotopic JJ cholic O
cholic NN acid O
acid IN in O
in NNP CAPITAL Laennec D
Laennec POS 's D
's NN cirrhosis D

The DT CAPITAL The O
The NN origin O
origin CC and O
and NN glyceride O
glyceride NN distribution O
distribution IN of O
of JJ fatty O
fatty NNS acids O
acids IN in O
in NN rat O
rat NN adipose O
adipose NN tissue O

Absorption NN CAPITAL Absorption O
Absorption IN of O
of NN medium O
medium CC and O
and RB long O
long NN chain O
chain NNS triglycerides O
triglycerides : : O
: NNS factors O
factors VBG influencing O
influencing PRP$ their O
their NN hydrolysis O
hydrolysis CC and O
and NN transport O

The DT CAPITAL The O
The NN effect O
effect IN of O
of NN epinephrine O
epinephrine IN on O
on JJ immunoreactive O
immunoreactive NN insulin O
insulin NNS levels O
levels IN in O
in NN man O

The DT CAPITAL The O
The NN role O
role IN of O
of DT the O
the NN liver O
liver IN in O
in JJ serum-induced O
serum-induced NN hypercoagulability D

Comparative JJ CAPITAL Comparative O
Comparative NNS fates O
fates IN of O
of RB intravenously O
intravenously CC and O
and RB orally O
orally VBN administered O
administered NN aldosterone O
aldosterone : : O
: NN evidence O
evidence IN for O
for JJ extrahepatic O
extrahepatic NN formation O
formation IN of O
of JJ acid-hydrolyzable O
acid-hydrolyzable NN conjugate O
conjugate IN in O
in NN man O

Binding NN CAPITAL Binding O
Binding IN of O
of NN sulfobromophthalein O
sulfobromophthalein NN ( O
( NN CAPITAL BSP O
BSP NN ) O
) NN sodium O
sodium IN by O
by NN plasma O
plasma NN albumin O

Its PRP$ CAPITAL Its O
Its NN role O
role IN in O
in JJ hepatic O
hepatic NN CAPITAL BSP O
BSP NN extraction O

The DT CAPITAL The O
The NN rationale O
rationale IN of O
of VBN extended T
extended NN resection T
resection IN for O
for JJ complicated D
complicated NN cancer D
cancer IN of D
of DT the D
the JJ large D
large NN bowel D

Etiology NN CAPITAL Etiology O
Etiology CC and O
and NN incidence O
incidence IN of O
of JJ renal D
renal NNS stones D

Diagnosis NN CAPITAL Diagnosis O
Diagnosis IN of O
of NN stone D
stone NN disease D

Medical JJ CAPITAL Medical T
Medical NN treatment T
treatment IN of O
of NN stone D
stone NN disease D

Surgical NNP CAPITAL Surgical T
Surgical NN treatment T
treatment IN of O
of JJ urinary D
urinary NNS stones D

Prevention NNP CAPITAL Prevention O
Prevention IN of O
of NN stone D
stone NN formation D

Urinary JJ CAPITAL Urinary O
Urinary JJ calculi O

Is VBZ CAPITAL Is O
Is DT the O
the NN task O
task JJ hopeless O
hopeless . ? O

The DT CAPITAL The O
The NN family O
family NN medicine O
medicine NN program O
program IN of O
of DT the O
the NNP CAPITAL University O
University IN of O
of NNP CAPITAL Miami O

Electron NN CAPITAL Electron O
Electron JJ microscopic O
microscopic NNS studies O
studies IN of O
of NN CAPITAL Mycoplasma O
Mycoplasma NN ( O
( NN CAPITAL PPLO O
PPLO NN strain O
strain CD 880 O
880 NN ) O
) IN in O
in JJ artificial O
artificial NN medium O
medium CC and O
and IN in O
in NN tissue O
tissue NN culture O

Chemotherapeutic JJ CAPITAL Chemotherapeutic O
Chemotherapeutic NNS effects O
effects IN on O
on JJ mammalian D
mammalian NN tumor D
tumor NNS cells D

3 CD 3 O

Modification NN CAPITAL Modification O
Modification IN of O
of NN leukemia O
leukemia NN CAPITAL L1210 O
L1210 NN growth O
growth NNS kinetics O
kinetics IN with O
with DT an O
an JJ antimetabolite O

Comparison NN CAPITAL Comparison O
Comparison IN of O
of DT the O
the NN sensitivity O
sensitivity IN of O
of JJ normal O
normal JJ hematopoietic O
hematopoietic CC and O
and VBN transplanted O
transplanted NN lymphoma O
lymphoma JJ colony-forming O
colony-forming NNS cells O
cells IN of O
of NNS mice O
mice TO to O
to NN vinblastine O
vinblastine VBN administered O
administered IN in O
in FW vivo O

Evidence NN CAPITAL Evidence O
Evidence IN for O
for DT an O
an JJ immunological O
immunological NN reaction O
reaction IN of O
of DT the O
the NN host O
host VBN directed O
directed IN against O
against PRP$ its O
its JJ own O
own RB actively O
actively VBG growing O
growing JJ primary D
primary NN tumor D

Hyperbaric JJ CAPITAL Hyperbaric T
Hyperbaric NN oxygen T
oxygen , , T
, JJ whole-body T
whole-body NN CAPITAL X T
X NN irradiation T
irradiation , , T
, CC and T
and NN cyclophosphamide T
cyclophosphamide NN combination T
combination NN therapy T
therapy IN in O
in NN mouse D
mouse NN leukemia D
leukemia NN CAPITAL L1210 D

Clinical JJ CAPITAL Clinical O
Clinical NN staging O
staging IN in O
in NN cancer D
cancer IN of D
of DT the D
the NN larynx D
larynx : : O
: DT a O
a NN report O
report IN on O
on CD 788 O
788 NNS cases O
cases VBG using O
using DT the O
the JJ CAPITAL American O
American NNP CAPITAL Joint O
Joint NNP CAPITAL Committee O
Committee POS 's O
's NN method O
method IN of O
of NN stage O
stage NN classification O

Comparison NN CAPITAL Comparison O
Comparison IN of O
of DT the O
the JJ international O
international CC and O
and JJ CAPITAL American O
American NNS systems O
systems IN for O
for DT the O
the NN staging O
staging IN of O
of NN breast D
breast NN cancer D

Effects NNS CAPITAL Effects O
Effects IN of O
of NN tryptophan O
tryptophan NN mustard O
mustard IN on O
on NN incorporation O
incorporation IN of O
of NN amino O
amino NNS acids O
acids IN into O
into NNS proteins O
proteins IN in O
in JJ tumor-bearing O
tumor-bearing NNS rats O

An DT CAPITAL An O
An NN electron O
electron NN microscope O
microscope NN study O
study IN of O
of NN plant D
plant NN neoplasia D
neoplasia VBN induced O
induced IN by O
by NN wound D
wound NN tumor D
tumor NN virus D

Possibilities NNS CAPITAL Possibilities O
Possibilities IN of O
of JJ surgical T
surgical NN correction T
correction IN of O
of NNS malformations D
malformations IN of D
of DT the D
the NNS bones D
bones IN of D
of DT the D
the NN foot D

The DT CAPITAL The O
The JJ postprandial O
postprandial NN period O
period IN of O
of DT the O
the VBN gastrectomized O
gastrectomized NN patient O

Radiocinematographic JJ CAPITAL Radiocinematographic O
Radiocinematographic CC and O
and JJ clinical O
clinical NN correlation O

Muscle NN CAPITAL Muscle O
Muscle NN pathology O
pathology : ; O
; NN contribution O
contribution IN of O
of NN experimentation O

Origin NN CAPITAL Origin O
Origin IN of O
of NN milk O
milk NN cholesterol O
cholesterol IN in O
in DT the O
the NN rat O
rat : : O
: JJ dietary O
dietary CC versus O
versus JJ endogenous O
endogenous NNS sources O

Comparative JJ CAPITAL Comparative O
Comparative NNS effects O
effects IN of O
of CD two O
two NN benzodiazepine O
benzodiazepine NNS compounds O
compounds IN on O
on VBN isolated O
isolated JJ human O
human NN myometrium O

Histochemistry NN CAPITAL Histochemistry O
Histochemistry IN of O
of JJ hydrolytic O
hydrolytic CC and O
and JJ oxidative O
oxidative NNS enzymes O
enzymes IN in O
in DT the O
the JJ human O
human CC and O
and RB experimentally O
experimentally VBN induced O
induced NN adenocarcinoma D
adenocarcinoma IN of O
of DT the O
the NN endometrium O

Cardiac JJ CAPITAL Cardiac O
Cardiac NNS monitors O
monitors NN work O
work : -- O
-- CC but O
but PRP they O
they MD should O
should NN report O
report RBR more O
more IN than O
than PRP they O
they VB do O

Delivery NN CAPITAL Delivery O
Delivery NN room O
room NNS pediatrics O

The DT CAPITAL The O
The NNS responsibilities O
responsibilities IN of O
of DT the O
the NN obstetrician O

A DT CAPITAL A O
A NN pediatrician O
pediatrician POS 's O
's NN checklist O
checklist IN for O
for NNS adolescents O

Community NNP CAPITAL Community O
Community NN clinic O
clinic NN treatment O
treatment IN for O
for JJ back-ward O
back-ward NNS patients O

Studies NNS CAPITAL Studies O
Studies IN in O
in JJ infantile D
infantile NN malnutrition D

V NN CAPITAL V O

The DT CAPITAL The O
The NN effect O
effect IN of O
of JJ dietary O
dietary NN protein O
protein NN source O
source IN on O
on NN serum O
serum NNS proteins O

Fish NN CAPITAL Fish T
Fish NN protein T
protein VBZ concentrates T
concentrates IN in O
in DT the O
the NN treatment O
treatment IN of O
of NN kwashiorkor D

athyrism NN athyrism D
athyrism IN in O
in DT the O
the JJ fetal O
fetal NN rat O

Evidence NN CAPITAL Evidence O
Evidence IN for O
for NN impairment O
impairment IN of O
of NN elastin O
elastin NN formation O

Familial JJ CAPITAL Familial D
Familial NN vitamin D
vitamin NN CAPITAL D D
D JJ resistant D
resistant NN rickets D
rickets IN in O
in JJ untreated O
untreated JJ adult O

Bony JJ CAPITAL Bony O
Bony NN proliferation O
proliferation IN of O
of JJ neural O
neural NNS arches O
arches IN with O
with NN cord O
cord NN compression O

Amyloidosis NN CAPITAL Amyloidosis D
Amyloidosis IN of O
of DT the O
the NN cornea O

Report NNP CAPITAL Report O
Report IN of O
of DT a O
a NN case O
case IN without O
without JJ conjunctival O
conjunctival NN involvement O

Effect NN CAPITAL Effect O
Effect IN of O
of VBG tranquilizing T
tranquilizing NNS drugs T
drugs IN on O
on JJ postnatal O
postnatal NN behavior O

Fathers NNS CAPITAL Fathers O
Fathers IN in O
in DT the O
the NN delivery O
delivery NN room O
room : -- O
-- DT an O
an NN opposition O
opposition NN standpoint O

Fathers NNS CAPITAL Fathers O
Fathers IN in O
in DT the O
the NN delivery O
delivery : -- O
-- '' '' O
'' JJ helpful O
helpful CC and O
and JJ supportive O
supportive '' '' O

`` `` `` O
`` NN CAPITAL Return O
Return DT the O
the NN joy O
joy IN of O
of NN home O
home NN delivery O
delivery '' '' O
'' IN with O
with NNS fathers O
fathers IN in O
in DT the O
the NN delivery O
delivery NN room O

Fathers NNS CAPITAL Fathers O
Fathers IN in O
in DT the O
the NN delivery O
delivery NN room O
room : -- O
-- RB long O
long NN experience O
experience NNS molds O
molds CD one O
one NN viewpoint O

Doctors NNS CAPITAL Doctors O
Doctors : -- O
-- PRP we O
we NN need O
need PRP you O

Pharmacological JJ CAPITAL Pharmacological O
Pharmacological NN blockade O
blockade IN of O
of NN ovulation O
ovulation IN in O
in DT the O
the NN ewe O

Some DT CAPITAL Some O
Some NNS factors O
factors VBG affecting O
affecting DT the O
the NN response O
response IN of O
of DT the O
the JJ immature O
immature NN mouse O
mouse TO to O
to JJ pregnant O
pregnant NN mare O
mare NN serum O
serum NN gonadotrophin O
gonadotrophin CC and O
and JJ human O
human JJ chorionic O
chorionic NN gonadotrophin O

The DT CAPITAL The O
The NN metabolism O
metabolism IN of O
of NN cortisol O
cortisol IN by O
by JJ human O
human JJ extra-hepatic O
extra-hepatic NNS tissues O

Aromatization NN CAPITAL Aromatization O
Aromatization IN of O
of NN 7-alpha-hydroxydehydroepiandrosterone O
7-alpha-hydroxydehydroepiandrosterone CC and O
and IN of O
of PRP$ its O
its JJ 3-sulphate O
3-sulphate IN by O
by JJ ovarian O
ovarian CC and O
and JJ placental O
placental NN tissue O
tissue NNS cultures O

Metabolic JJ CAPITAL Metabolic O
Metabolic CC and O
and JJ endocrine O
endocrine NNS effects O
effects IN of O
of JJ lysergic O
lysergic NN acid O
acid NN diethylamide O
diethylamide NN ( O
( CD CAPITAL LSD-25 O
LSD-25 NN ) O
) IN on O
on JJ male O
male NNS rats O

Mutation NN CAPITAL Mutation O
Mutation NNS frequencies O
frequencies VBN detected O
detected VBG following O
following NN irradiation T
irradiation IN of O
of JJ virgin O
virgin CC and O
and VBN inseminated O
inseminated FW CAPITAL Drosophila O
Drosophila FW melanogaster O
melanogaster NNS females O

Relationship NN CAPITAL Relationship O
Relationship IN of O
of NNS fractons O
fractons IN of O
of NNS soybeans O
soybeans CC and O
and DT a O
a JJ crystalline O
crystalline NN soybean O
soybean NN trypsin O
trypsin NN inhibitor O
inhibitor TO to O
to DT the O
the NNS effects O
effects IN of O
of VBG feeding O
feeding JJ unheated O
unheated NN soybean O
soybean NN meal O
meal TO to O
to NNS chicks O

Metabolism NN CAPITAL Metabolism O
Metabolism IN of O
of JJ polyunsaturated O
polyunsaturated JJ fatty O
fatty NNS acids O
acids CC and O
and NN serum O
serum NN cholesterol O
cholesterol NNS levels O
levels IN in O
in DT the O
the NN rat O

Comparison NN CAPITAL Comparison O
Comparison IN of O
of JJ neutral O
neutral JJ fat O
fat CC and O
and JJ free O
free JJ fatty O
fatty NNS acids O
acids IN in O
in JJ high O
high JJ lipid-low O
lipid-low NN carbohydrate O
carbohydrate NNS diets O
diets IN for O
for DT the O
the VBG growing O
growing NN chicken O

An DT CAPITAL An O
An NN approach O
approach TO to O
to JJ quantitative O
quantitative NN analysis O
analysis IN of O
of JJ intrauterine O
intrauterine NN pressure O
pressure NNS data O

Intracranial JJ CAPITAL Intracranial D
Intracranial NNS teratomas D
teratomas IN in O
in JJ fetal O
fetal NN life O
life CC and O
and NN infancy O

Twinning VBG CAPITAL Twinning O
Twinning IN in O
in NN relation O
relation TO to O
to NN birth O
birth NN weight O
weight , , O
, NN mortality O
mortality , , O
, CC and O
and JJ congenital D
congenital NNS anomalies D

Breast NN CAPITAL Breast O
Breast NN engorgement O
engorgement CC and O
and NN postpartum D
postpartum NN fever D

Evolution NN CAPITAL Evolution O
Evolution IN of O
of DT a O
a NN placenta O
placenta NN circumvallata O

Sequential JJ CAPITAL Sequential O
Sequential JJ estrogen-progestogen T
estrogen-progestogen NN therapy T
therapy IN in O
in NN gynecology O

Ovarian JJ CAPITAL Ovarian D
Ovarian NN carcinoma D

The DT CAPITAL The O
The NNS problems O
problems IN of O
of NN staging O
staging CC and O
and VBG grading O

Oxytocin NN CAPITAL Oxytocin O
Oxytocin NN induction O
induction IN in O
in JJ pregnant O
pregnant NNS rabbits O
rabbits , , O
, IN with O
with JJ special O
special NN reference O
reference TO to O
to DT the O
the NN stillbirth O
stillbirth NN rate O

Significance NN CAPITAL Significance O
Significance IN of O
of DT a O
a JJ single O
single JJ umbilical O
umbilical NN artery O

Report NNP CAPITAL Report O
Report IN from O
from DT the O
the JJ collaborative O
collaborative NN study O
study IN of O
of JJ cerebral O
cerebral NN palsy O

Perforated JJ CAPITAL Perforated D
Perforated JJ peptic D
peptic NN ulcer D
ulcer IN in O
in NN pregnancy O

Poverty NN CAPITAL Poverty O
Poverty IN as O
as DT an O
an VBN isolated O
isolated NN factor O
factor IN in O
in NN relation O
relation TO to O
to JJ perinatal D
perinatal NN asphyxia D

Perforation NN CAPITAL Perforation D
Perforation IN of D
of DT the D
the NN postpartum D
postpartum NN uterus D
uterus IN with O
with DT an O
an JJ intrauterine O
intrauterine JJ contraceptive O
contraceptive NN device O

Congenital JJ CAPITAL Congenital D
Congenital NN heart D
heart NN disease D
disease , , O
, NN deaf-mutism D
deaf-mutism CC and O
and VBN associated D
associated JJ somatic D
somatic NNS malformations D
malformations VBG occurring O
occurring IN in O
in JJ several O
several NNS members O
members IN of O
of CD one O
one NN family O

Toward IN CAPITAL Toward O
Toward DT a O
a NN community O
community NN alcoholism O
alcoholism NN program O

Cases NNS CAPITAL Cases O
Cases CD 8 O
8 CC and O
and CD 9 O

Anesthesia NNP CAPITAL Anesthesia T
Anesthesia NNS accidents O

Gynaecological JJ CAPITAL Gynaecological O
Gynaecological NN pain O

Profileplasty JJ CAPITAL Profileplasty T

Hypertrophic JJ CAPITAL Hypertrophic O
Hypertrophic JJ obstructive O
obstructive NN cardiomyopathy D

Oral JJ CAPITAL Oral T
Oral NNS contraceptives T
contraceptives , , O
, NN thrombosis D
thrombosis , , O
, CC and O
and JJ cyclical O
cyclical NNS factors O
factors VBG affecting O
affecting NNS veins O
veins . . O

On IN CAPITAL On O
On DT the O
the NN influence O
influence IN of O
of JJ cytostatic O
cytostatic NNS agents O
agents CC and O
and JJ immune O
immune NNS bodies O
bodies IN on O
on NN choriocarcinoma O
choriocarcinoma NNS cells O
cells IN in O
in NN tissue O
tissue NN culture O

Fat NNP CAPITAL Fat O
Fat NN absorption O
absorption : : O
: DT a O
a NN transport O
transport NN problem O

Corpora NNP CAPITAL Corpora D
Corpora NN lutea D
lutea IN in O
in JJ proven O
proven NNS mules O

Reconstructive JJ CAPITAL Reconstructive O
Reconstructive JJ tubal T
tubal NN surgery T

Studies NNS CAPITAL Studies O
Studies IN on O
on DT the O
the JJ natural O
natural JJ posterior O
posterior JJ pituitary O
pituitary NNS hormones O

II NNP CAPITAL II O

On IN CAPITAL On O
On DT the O
the JJ official O
official NN inspection O
inspection IN of O
of JJ coal-tar O
coal-tar NNS dyes O
dyes IN in O
in CD 1969 O

3 CD 3 O

Analysis NN CAPITAL Analysis O
Analysis IN of O
of NN CAPITAL Cr O
Cr , , O
, NN CAPITAL Zn O
Zn , , O
, NNP CAPITAL Fe O
Fe CC and O
and NN CAPITAL Pb O
Pb NNS contaminants O
contaminants IN in O
in NN food O
food JJ coal-tar O
coal-tar NNS dyes O
dyes CC and O
and PRP$ their O
their NN aluminium O
aluminium NN lakes O
lakes IN by O
by JJ atomic O
atomic NN absorption O
absorption NN spectrophotometry O

Radiosterilization NN CAPITAL Radiosterilization O
Radiosterilization IN of O
of JJ medical O
medical NNS products O

I PRP CAPITAL I O
I . . O
. NNS CAPITAL Effects O
Effects IN of O
of NN radiation O
radiation IN on O
on JJ physical O
physical CC and O
and NN chemical O
chemical NNS properties O
properties IN of O
of NN injection O
injection NNS needles O

Screening VBG CAPITAL Screening O
Screening NNS tests O
tests IN of O
of NNS microorganisms O
microorganisms IN for O
for DT the O
the JJ microbial O
microbial NN transformation O
transformation IN of O
of NN griseophenone O
griseophenone DT CAPITAL A O
A , , O
, NN CAPITAL N-methylcoclaurine O
N-methylcoclaurine CC and O
and NN sparteine O

Gas NN CAPITAL Gas O
Gas JJ chromatographic O
chromatographic NNS studies O
studies IN on O
on JJ organic O
organic NNS mercurials O

Application NN CAPITAL Application O
Application IN of O
of JJ infra-red O
infra-red NN absorption O
absorption NN spectroscopy O
spectroscopy TO to O
to NN examination O
examination IN of O
of NNS drugs O
drugs CC and O
and PRP$ their O
their NN preparation O

XIX NNP CAPITAL XIX O

Determination NN CAPITAL Determination O
Determination IN of O
of NN silicone O
silicone NN oil O
oil IN in O
in JJ disposable O
disposable JJ plastic O
plastic NNS syringes O

Observation NN CAPITAL Observation O
Observation IN of O
of NN air O
air NN pollution O
pollution IN with O
with DT the O
the NN aid O
aid IN of O
of JJ continuous O
continuous NNS analysers O

3 CD 3 O

Correlation NN CAPITAL Correlation O
Correlation IN between O
between DT the O
the NN concentration O
concentration IN of O
of JJ various O
various NNS kinds O
kinds IN of O
of NNS pollutants O
pollutants IN in O
in NN atmosphere O
atmosphere CC and O
and NN wind O
wind NN direction O
direction CC and O
and NN velocity O
velocity IN at O
at NNP CAPITAL Kasumigaseki O
Kasumigaseki , , O
, JJ central O
central NN district O
district IN of O
of NNP CAPITAL Tokyo O

Ultramicro-analysis JJ CAPITAL Ultramicro-analysis O
Ultramicro-analysis IN of O
of NN cyclohexylamine O
cyclohexylamine CC and O
and JJ low O
low JJ fatty O
fatty NNS amines O
amines IN by O
by NN gas O
gas NN chromatography O

Some DT CAPITAL Some O
Some NNS knowledges O
knowledges IN on O
on DT the O
the NN potency O
potency IN of O
of NN heparin O
heparin NNS fractions O
fractions VBN obtained O
obtained IN by O
by NN gel O
gel NN filtration O

On IN CAPITAL On O
On DT the O
the JJ peripheral O
peripheral NNS effects O
effects IN of O
of NN endotoxin O
endotoxin CC and O
and NN leucocyte O
leucocyte NN pyrogen O
pyrogen IN in O
in NN rabbit O

A DT CAPITAL A O
A JJ tentative O
tentative NN draft O
draft IN of O
of JJ qualitative O
qualitative NN test O
test IN of O
of NN fluoride O
fluoride IN for O
for NN adoption O
adoption TO to O
to DT the O
the JJ general O
general NNS tests O
tests IN of O
of JJ eighth O
eighth VBN revised O
revised NN edition O
edition IN of O
of DT the O
the NNP CAPITAL Pharmacopoeia O
Pharmacopoeia IN of O
of NNP CAPITAL Japan O

Identification NN CAPITAL Identification O
Identification IN of O
of NNS tranquillizers T
tranquillizers IN by O
by JJ thin-layer O
thin-layer NN chromatography O

Analysis NN CAPITAL Analysis O
Analysis IN of O
of NNS steroids O

II NNP CAPITAL II O

A DT CAPITAL A O
A NN note O
note IN on O
on DT the O
the NN assay O
assay IN of O
of NN corticoid O
corticoid NNS preparations O
preparations IN by O
by NN tetrazolium O
tetrazolium NN salt O

Analysis NN CAPITAL Analysis O
Analysis IN of O
of NNS steroids O

3 CD 3 O

Colorimetric JJ CAPITAL Colorimetric O
Colorimetric NN assay O
assay IN of O
of NN thiomesterone O

Studies NNS CAPITAL Studies O
Studies IN on O
on DT the O
the NN radioimmunoassay O
radioimmunoassay IN of O
of NN insulin T

I PRP CAPITAL I O
I . . O
. DT CAPITAL The O
The NN production O
production CC and O
and NN detection O
detection IN of O
of JJ anti-insulin O
anti-insulin NN serum O
serum CC and O
and JJ anti-guinea-pig O
anti-guinea-pig NN globulin O
globulin NN rabbit O
rabbit NN serum O

Synthesis NN CAPITAL Synthesis O
Synthesis IN of O
of JJ lysergic O
lysergic NN acid O
acid NN diethylamide O
diethylamide NN ( O
( NN CAPITAL LSD O
LSD NN ) O

Studies NNS CAPITAL Studies O
Studies IN on O
on DT the O
the JJ anti-microbial O
anti-microbial NN activity O
activity IN of O
of JJ nonionic O
nonionic CC and O
and JJ anionic O
anionic NNS surfactants O

On IN CAPITAL On O
On DT the O
the NNP CAPITAL National O
National NNP CAPITAL Institute O
Institute IN of O
of JJ CAPITAL Hygienic O
Hygienic NNPS CAPITAL Sciences O
Sciences JJ CAPITAL Standard O
Standard `` `` O
`` NN lysozyme O
lysozyme JJ standard O
standard '' '' O

On IN CAPITAL On O
On DT the O
the NN examination O
examination IN of O
of NN ginseng O
ginseng CC and O
and JJ powdered O
powdered NN ginseng O
ginseng IN in O
in CD 1969 O

On IN CAPITAL On O
On DT the O
the NN standardization O
standardization IN of O
of JJ plastic T
plastic NN suture T

Undergraduate JJ CAPITAL Undergraduate O
Undergraduate NN research O
research NNS assistants O
assistants IN in O
in DT the O
the NN CAPITAL Faculty O
Faculty IN of O
of NNP CAPITAL Medicine O

University NNP CAPITAL University O
University NNP CAPITAL College O
College IN of O
of NNP CAPITAL Rhodesia O

Congenital JJ CAPITAL Congenital D
Congenital JJ aortic D
aortic NN stenosis D

Sodium NN CAPITAL Sodium O
Sodium IN in O
in NN heart D
heart NN failure D

Potassium NN CAPITAL Potassium O
Potassium IN in O
in NN heart D
heart NN failure D

Hydrogen NN CAPITAL Hydrogen O
Hydrogen NN ion O
ion NN equilibrium O
equilibrium IN in O
in NN heart D
heart NN failure D

Various JJ CAPITAL Various O
Various NNS aspects O
aspects IN of O
of JJ water-salt O
water-salt NN metabolism O
metabolism IN in O
in NN heart D
heart JJ congestive D
congestive NN failure D

Clinical JJ CAPITAL Clinical O
Clinical NN physiopathology O
physiopathology IN of O
of DT the O
the NN patency O
patency IN of O
of DT the O
the JJ interatrial O
interatrial NN septum O

Various JJ CAPITAL Various O
Various NNS aspects O
aspects IN of O
of NN diuresis D
diuresis IN in O
in NN heart D
heart JJ congestive D
congestive NN failure D

Changes NNS CAPITAL Changes O
Changes IN in O
in DT the O
the NN mechanism O
mechanism IN of O
of JJ renal O
renal NN acidification O
acidification IN in O
in JJ congestive D
congestive NN heart D
heart NN failure D
failure : : O
: NNS effects O
effects IN of O
of JJ diuretic T
diuretic NN treatment T
treatment IN on O
on DT the O
the NN acid-base O
acid-base NN equilibrium O

Defects NNS CAPITAL Defects O
Defects IN of O
of DT the O
the JJ interventricular O
interventricular NN septum O
septum RB not O
not VBN associated O
associated IN with O
with JJ other O
other NNS malformations O

Clinical JJ CAPITAL Clinical O
Clinical NN physiopathology O
physiopathology IN of O
of DT the O
the NN patency O
patency IN of O
of NN CAPITAL Botallo D
Botallo POS 's D
's NN ductus D
ductus NN arteriosus D

Clinical JJ CAPITAL Clinical O
Clinical NN physiopathology O
physiopathology IN of O
of JJ congenital D
congenital JJ cyanogenic D
cyanogenic NNS cardiopathies D

Electronic JJ CAPITAL Electronic O
Electronic NNS computers O
computers IN in O
in JJ medical O
medical NN education O
education IN of O
of DT the O
the JJ future O

Anesthesiology NNP CAPITAL Anesthesiology O
Anesthesiology CC and O
and NNS computers O

Immediate NNP CAPITAL Immediate O
Immediate NN outcome O
outcome CC and O
and JJ long-term O
long-term NNS results O
results IN of O
of CD 108 O
108 NNS sphincterotomies O
sphincterotomies IN of O
of NNP CAPITAL Oddi O
Oddi POS 's O
's NN sphincter O
sphincter IN of O
of JJ biliary O
biliary NN indication O

Neuraminic JJ CAPITAL Neuraminic O
Neuraminic JJ acid-containing O
acid-containing NNS oligosaccharides O
oligosaccharides IN of O
of JJ human O
human NN urine O
urine : : O
: NN isolation O
isolation CC and O
and NN identification O
identification IN of O
of NN di-N-acetylneuraminyl-3-galactosyl-N-acetylgalactosamine O
di-N-acetylneuraminyl-3-galactosyl-N-acetylgalactosamine , , O
, JJ 6-2-Nacetylneuraminyl-lactose O
6-2-Nacetylneuraminyl-lactose , , O
, JJ 6-2-N-acetylneuraminyl-N-acetyllactosamine O
6-2-N-acetylneuraminyl-N-acetyllactosamine CC and O
and JJ 3-2-N-acetylneuraminyl-lactose O

Determination NN CAPITAL Determination O
Determination IN of O
of NN serum O
serum NN oxytocinase O
oxytocinase NN ( O
( JJ 1-cystine-aminopeptidase O
1-cystine-aminopeptidase NN ) O
) NN activity O

Intolerance NN CAPITAL Intolerance O
Intolerance TO to O
to NN milk O
milk IN in O
in JJ ulcerative D
ulcerative NN colitis D

A DT CAPITAL A O
A JJ preliminary O
preliminary NN report O

Rhinitis NN CAPITAL Rhinitis D
Rhinitis IN in O
in NNS herds O
herds IN with O
with NN piglet D
piglet NN influenza D

Research NNP CAPITAL Research O
Research IN on O
on VBG breeding O
breeding NN hygiene O
hygiene IN in O
in NNS pigs O
pigs CC and O
and NNS piglets O
piglets JJ free O
free IN from O
from JJ epidemic D
epidemic NNS diseases D

The DT CAPITAL The O
The JJ stimulatory O
stimulatory NN effect O
effect IN of O
of VBG luteinizing O
luteinizing NN hormone O
hormone IN on O
on NN adenosine O
adenosine CD 3 O
3 POS ' O
' , , O
, JJ 5'-monophosphate O
5'-monophosphate NN accumulation O
accumulation IN in O
in NN corpus O
corpus NN luteum O
luteum NNS slices O

Electrolyte NN CAPITAL Electrolyte O
Electrolyte CC and O
and NN acid-base O
acid-base NN balance O
balance IN in O
in JJ fetal O
fetal CC and O
and JJ maternal O
maternal NN blood O

An DT CAPITAL An O
An JJ experimental O
experimental CC and O
and DT a O
a JJ clinical O
clinical NN study O

Q NNP CAPITAL Q D
Q NN fever D
fever IN at O
at DT a O
a JJ combined O
combined NN meat O
meat CC and O
and NN poultry O
poultry NN abattoir O

Some DT CAPITAL Some O
Some JJ functional O
functional CC and O
and JJ morphological O
morphological NNS alterations O
alterations VBG occurring O
occurring IN during O
during CC and O
and IN after O
after DT the O
the NN adaptation O
adaptation IN of O
of NNP CAPITAL BHK O
BHK CD 21 O
21 NN clone O
clone CD 13 O
13 NNS cells O
cells TO to O
to NN suspension O
suspension NN culture O

Asbestos NN CAPITAL Asbestos O
Asbestos IN as O
as DT an O
an JJ urban O
urban NN air O
air NN contaminant O

Gas NN CAPITAL Gas O
Gas NN permeability O
permeability IN of O
of JJ plastic O
plastic NNS membranes O
membranes IN for O
for JJ artificial T
artificial NNS lungs T

Technoogy JJ CAPITAL Technoogy O
Technoogy , , O
, NN automation O
automation CC and O
and JJ human O
human NN welfare O

A DT CAPITAL A O
A NN radium O
radium NN accident O
accident IN in O
in DT a O
a NN hospital O

High JJ CAPITAL High O
High NN energy O
energy NN roentgen O
roentgen NN ray O
ray NN contamination O
contamination IN of O
of DT the O
the NN electron O
electron NN beam O
beam IN from O
from DT a O
a JJ medical O
medical NN betatron O

The DT CAPITAL The O
The RB genetically O
genetically JJ significant O
significant NN dose O
dose IN from O
from NN roentgen O
roentgen NNS examinations O
examinations IN in O
in NNP CAPITAL Finland O
Finland IN in O
in CD 1963 O

Differential JJ CAPITAL Differential O
Differential NN expression O
expression IN of O
of NN fibroblast O
fibroblast NN growth O
growth NN factor-2 O
factor-2 CC and O
and NN receptor O
receptor IN by O
by JJ glial O
glial NNS cells O
cells IN in O
in JJ experimental O
experimental JJ autoimmune D
autoimmune NN encephalomelitis D
encephalomelitis NN ( D
( NN CAPITAL EAE D
EAE NN ) D

Cesarean JJ CAPITAL Cesarean O
Cesarean NNS deliveries O
deliveries IN at O
at DT a O
a NN university O
university NN hospital O
hospital : : O
: NN analysis O
analysis IN of O
of NNS rates O
rates CC and O
and NNS indications O

Increase NN CAPITAL Increase O
Increase IN in O
in JJ ambient O
ambient NN temperature O
temperature MD may O
may VB explain O
explain NN decrease O
decrease IN in O
in JJ amniotic O
amniotic NN fluid O
fluid NN index O

Early RB CAPITAL Early O
Early NN treatment O
treatment IN of O
of JJ gestational D
gestational NN diabetes D
diabetes VBZ reduces O
reduces DT the O
the NN rate O
rate IN of O
of JJ fetal D
fetal NN macrosomia D

Antenatally RB CAPITAL Antenatally O
Antenatally JJ detectable O
detectable NNS markers O
markers IN for O
for DT the O
the NN diagnosis O
diagnosis IN of O
of RB autosomally D
autosomally JJ trisomic D
trisomic NNS fetuses D
fetuses IN in O
in JJ at-risk O
at-risk NNS pregnancies O

The DT CAPITAL The O
The NN rate O
rate IN of O
of JJ severe O
severe NN preeclampsia D
preeclampsia VBZ is O
is VBN increased O
increased IN in O
in NN triplet O
triplet IN as O
as VBN compared O
compared TO to O
to JJ twin O
twin NNS gestations O

Thermal JJ CAPITAL Thermal O
Thermal NN equipment O
equipment NN usage O
usage NNS patterns O
patterns IN in O
in JJ neonatal O
neonatal JJ intensive O
intensive NN care O
care NNS units O
units : : O
: NN interunit O
interunit NN variability O
variability CC and O
and JJ intraunit O
intraunit NN consistency O

Massive JJ CAPITAL Massive O
Massive JJ fetomaternal D
fetomaternal NN hemorrhage D

Perinatal JJ CAPITAL Perinatal O
Perinatal NNS features O
features IN of O
of JJ omphalocele-exstrophy-imperforate D
omphalocele-exstrophy-imperforate JJ anus-spinal D
anus-spinal NNS defects D
defects NN ( D
( NN CAPITAL OEIS D
OEIS NN complex D
complex NN ) D
) VBN associated O
associated IN with O
with JJ large O
large NNS meningomyeloceles D
meningomyeloceles CC and O
and JJ severe D
severe NN limb D
limb NNS defects D

Subchorial JJ CAPITAL Subchorial D
Subchorial NN hematoma D
hematoma : : O
: DT a O
a JJ probable O
probable NN cause O
cause IN of O
of JJ reversible O
reversible JJ nonimmune O
nonimmune NNS hydrops O
hydrops NN fetalis D

Pregnancy NN CAPITAL Pregnancy O
Pregnancy IN in O
in JJ chronic O
chronic JJ progressive O
progressive JJ external O
external NN ophthalmoplegia D
ophthalmoplegia : : O
: DT a O
a NN case O
case NN report O

Effect NN CAPITAL Effect O
Effect IN of O
of NN magnesium O
magnesium NN sulfate O
sulfate IN on O
on DT the O
the NN development O
development IN of O
of JJ cystic O
cystic JJ periventricular O
periventricular NN leukomalacia D
leukomalacia IN in O
in NN preterm O
preterm NNS infants O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> JJ CAPITAL Repeated O
Repeated NNS courses O
courses IN of O
of NNS steroids O
steroids IN in O
in NN preterm O
preterm NN membrane O
membrane NN rupture O
rupture VB do O
do RB not O
not NN increase O
increase DT the O
the NN risk O
risk IN of O
of JJ histologic O
histologic NN chorioamnionitis O

Intrapartum NNP CAPITAL Intrapartum O
Intrapartum NN sonography O
sonography IN of O
of DT the O
the JJR lower O
lower JJ uterine O
uterine NN segment O
segment IN in O
in NNS patients O
patients IN with O
with JJ breech-presenting O
breech-presenting NNS fetuses O

Isolated VBN CAPITAL Isolated O
Isolated JJ persistent O
persistent JJ fetal O
fetal NN bradycardia O
bradycardia IN in O
in JJ complete O
complete NN CAPITAL A-V O
A-V NN block O
block : : O
: DT a O
a JJ conservative O
conservative NN approach O
approach VBZ is O
is JJ appropriate O

A DT CAPITAL A O
A NN case O
case NN report O
report CC and O
and DT a O
a NN review O
review IN of O
of DT the O
the NN literature O

Spontaneous JJ CAPITAL Spontaneous O
Spontaneous NN rectus D
rectus NN sheath D
sheath NN hematoma D
hematoma IN during O
during NN pregnancy O
pregnancy VBG mimicking O
mimicking NN abruptio D
abruptio NN placenta D

Amnioinfusion NN CAPITAL Amnioinfusion T
Amnioinfusion IN for O
for NN prevention O
prevention IN of O
of JJ pulmonary D
pulmonary NN hypoplasia D
hypoplasia IN in O
in NN second-trimester O
second-trimester NN rupture O
rupture IN of O
of NNS membranes O

Trauma FW CAPITAL Trauma O
Trauma CC and O
and NN pregnancy O

Fetal JJ CAPITAL Fetal O
Fetal VBG breathing O
breathing NNS movements O
movements IN within O
within CD 24 O
24 NNS hours O
hours IN of O
of NN delivery O
delivery IN in O
in NN prematurity O
prematurity VBP are O
are JJ related O
related TO to O
to JJ histologic O
histologic CC and O
and JJ clinical O
clinical NN evidence O
evidence IN of O
of NN amnionitis D

Laerdal JJ CAPITAL Laerdal O
Laerdal NN infant O
infant NNS resuscitators O
resuscitators VBP are O
are JJ unreliable O
unreliable IN as O
as JJ free-flow O
free-flow NN oxygen O
oxygen NN delivery O
delivery NNS devices O

Laryngeal NN CAPITAL Laryngeal D
Laryngeal NN obstruction D
obstruction VBN caused O
caused IN by O
by NN lingual D
lingual NN thyroglossal D
thyroglossal NN duct D
duct NN cyst D
cyst VBG presenting O
presenting IN at O
at NN birth O

Oligohydramnios JJ CAPITAL Oligohydramnios O
Oligohydramnios CC and O
and DT the O
the RB appropriately O
appropriately VBN grown O
grown NN fetus O

Ultrastructure NN CAPITAL Ultrastructure O
Ultrastructure IN of O
of JJ human O
human JJ colostral O
colostral NNS cells O

Dubowitz NNP CAPITAL Dubowitz O
Dubowitz NN assessment O
assessment IN of O
of JJ gestational O
gestational NN age O
age CC and O
and NN agreement O
agreement IN with O
with JJ prenatal O
prenatal NNS methods O

Low JJ CAPITAL Low O
Low JJ prenatal O
prenatal NN weight O
weight NN gain O
gain IN among O
among JJ low-income O
low-income NNS women O
women : : O
: WDT what O
what VBP are O
are DT the O
the NN risk O
risk NNS factors O
factors . ? O

Depression NN CAPITAL Depression D
Depression IN after O
after NN childbirth O
childbirth : : O
: DT the O
the NNS views O
views IN of O
of JJ medical O
medical NNS students O
students CC and O
and NNS women O
women VBN compared O

Breastfeeding VBG CAPITAL Breastfeeding O
Breastfeeding CC and O
and DT the O
the NN use O
use IN of O
of NNS pacifiers O

Care NNP CAPITAL Care O
Care IN in O
in JJ normal O
normal NN birth O
birth : : O
: DT a O
a JJ practical O
practical NN guide O

Technical NNP CAPITAL Technical O
Technical VBG CAPITAL Working O
Working NNP CAPITAL Group O
Group , , O
, NNP CAPITAL World O
World NNP CAPITAL Health O
Health NNP CAPITAL Organization O

Cesarean JJ CAPITAL Cesarean O
Cesarean NNS sections O
sections : : O
: NNS women O
women POS 's O
's NN choice O
choice IN for O
for VBG giving O
giving NN birth O
birth . ? O

Epidurals NNS CAPITAL Epidurals T
Epidurals CC and O
and VBG breastfeeding O

Lamaze NN CAPITAL Lamaze O
Lamaze CC and O
and NNP CAPITAL Bradley O
Bradley NN childbirth O
childbirth NNS classes O

Concerns NNS CAPITAL Concerns O
Concerns IN about O
about DT the O
the NN institutionalization O
institutionalization IN of O
of NN childbirth O
childbirth NN education O

Index NNP CAPITAL Index O
Index TO to O
to JJ current O
current NN literature O

A DT CAPITAL A O
A VBN randomized O
randomized NN trial O
trial IN of O
of JJ one-to-one O
one-to-one NN nurse O
nurse NN support O
support IN of O
of NNS women O
women IN in O
in NN labor O

Commentary JJ CAPITAL Commentary O
Commentary : : O
: VBP are O
are NNS nurses O
nurses JJ effective O
effective NNS providers O
providers IN of O
of NN labor O
labor NN support O
support . ? O
? MD CAPITAL Should O
Should PRP they O
they VB be O
be . ? O
? MD CAPITAL Can O
Can PRP they O
they VB be O
be . ? O

Women NNS CAPITAL Women O
Women POS 's O
's NNS views O
views IN of O
of JJ different O
different NNS models O
models IN of O
of JJ antenatal O
antenatal NN care O
care IN in O
in NNP CAPITAL Victoria O
Victoria , , O
, NNP CAPITAL Australia O

The DT CAPITAL The O
The NN effect O
effect IN of O
of NN discharge O
discharge NN pack O
pack NN formula O
formula CC and O
and NN breast O
breast NNS pumps O
pumps IN on O
on VBG breastfeeding O
breastfeeding NN duration O
duration CC and O
and NN choice O
choice IN of O
of NN infant O
infant VBG feeding O
feeding NN method O

Commentary JJ CAPITAL Commentary O
Commentary : : O
: NN discharge O
discharge NNS packs O
packs : : O
: WRB how O
how RB much O
much VB do O
do PRP they O
they NN matter O
matter . ? O

Quality JJ CAPITAL Quality O
Quality NN framework O
framework IN for O
for NN force O
force NN plate O
plate NN testing O

Bone NN CAPITAL Bone O
Bone NN registration O
registration NN method O
method IN for O
for NN robot T
robot VBN assisted T
assisted NN surgery T
surgery : : O
: NN pedicle O
pedicle VB screw O
screw NN insertion O

Parameter NN CAPITAL Parameter O
Parameter NN sensitivity O
sensitivity IN of O
of DT a O
a JJ mathematical O
mathematical NN model O
model IN of O
of DT the O
the JJ anterior O
anterior JJ cruciate O
cruciate NN ligament O

Simultaneous JJ CAPITAL Simultaneous O
Simultaneous NN measurement O
measurement IN of O
of NN stiffness O
stiffness CC and O
and NN energy O
energy JJ absorptive O
absorptive NNS properties O
properties IN of O
of JJ articular O
articular NN cartilage O
cartilage CC and O
and JJ subchondral O
subchondral JJ trabecular O
trabecular NN bone O

Estimation NN CAPITAL Estimation O
Estimation IN of O
of NNS loads O
loads CC and O
and NNS stresses O
stresses IN in O
in JJ abdominal O
abdominal NNS muscles O
muscles IN during O
during JJ slow O
slow NNS lifts O

Contralateral JJ CAPITAL Contralateral O
Contralateral NN modification O
modification IN of O
of JJ transitory O
transitory VBN evoked O
evoked JJ otoacoustic O
otoacoustic NNS emissions O

Treatment NN CAPITAL Treatment O
Treatment IN of O
of JJ cavernous D
cavernous NN hemangiomas D
hemangiomas IN with O
with DT the O
the NN neodymium T
neodymium : : T
: NN CAPITAL YAG T
YAG NN laser T

Mucous JJ CAPITAL Mucous D
Mucous NN membrane D
membrane NNS melanomas D
melanomas IN of O
of DT the O
the JJ upper O
upper JJ aerodigestive O
aerodigestive NN tract O

An DT CAPITAL An O
An NN analysis O
analysis IN of O
of CD 34 O
34 NNS cases O

Are VBP CAPITAL Are O
Are DT the O
the NNS products O
products IN of O
of NN CAPITAL CD44 O
CD44 NNS exons O
exons NN v5 O
v5 CC and O
and NN v6 O
v6 NNS markers O
markers IN for O
for NN metastasis O
metastasis IN of O
of NN laryngeal D
laryngeal NNS carcinomas D
carcinomas . ? O

Detection NN CAPITAL Detection O
Detection IN of O
of RB differentially O
differentially VBN expressed O
expressed NNS genes O
genes IN in O
in NN head-neck D
head-neck NNS carcinomas D

Tuberculosis NN CAPITAL Tuberculosis D
Tuberculosis IN of O
of DT the O
the NN parotid O
parotid NN gland O
gland : : O
: DT a O
a JJ rare O
rare JJ differential O
differential NN diagnosis O
diagnosis IN of O
of NN parotid D
parotid NN tumor D

A DT CAPITAL A O
A NN case O
case IN of O
of NN sarcoidosis D
sarcoidosis IN of O
of DT the O
the JJ mastoid O

Genomic JJ CAPITAL Genomic O
Genomic NN medicine O

Internet NN CAPITAL Internet O
Internet NNS resources O
resources IN for O
for JJ medical O
medical NNS genetics O

Genetics NNP CAPITAL Genetics O

A DT CAPITAL A O
A NN piece O
piece IN of O
of PRP$ my O
my NN mind O

A DT CAPITAL A O
A JJ 'normal O
'normal POS ' O
' NN practice O

Predisposition NN CAPITAL Predisposition O
Predisposition JJ genetic O
genetic NN testing O
testing IN for O
for NN late-onset D
late-onset NNS disorders D
disorders IN in O
in NNS adults O

A DT CAPITAL A O
A NN position O
position NN paper O
paper IN of O
of DT the O
the NNP CAPITAL National O
National NNP CAPITAL Society O
Society IN of O
of JJ CAPITAL Genetic O
Genetic NNS CAPITAL Counselors O

Scientists NNS CAPITAL Scientists O
Scientists VB revel O
revel IN in O
in JJ new O
new NN research O
research NN tool O
tool : : O
: DT an O
an JJ online O
online NN index O
index IN of O
of NN cancer O
cancer NNS genes O

Center NNP CAPITAL Center O
Center IN for O
for JJ genetic O
genetic NN research O
research IN on O
on NN scleroderma D

As IN CAPITAL As O
As NNS discoveries O
discoveries VB unfold O
unfold , , O
, DT a O
a JJ new O
new NN urgency O
urgency TO to O
to VB bring O
bring JJ genetic O
genetic NN literacy O
literacy TO to O
to NNS physicians O

> JJR > O
> IN CAPITAL From O
From DT the O
the NNPS CAPITAL Centers O
Centers IN for O
for NN CAPITAL Disease O
Disease NN CAPITAL Control O
Control CC and O
and NNP CAPITAL Prevention O

Gonorrhea NN CAPITAL Gonorrhea D
Gonorrhea IN among O
among NNS men O
men WP who O
who VB have O
have NN sex O
sex IN with O
with NNS men O
men : -- O
-- VBN selected O
selected RB sexually O
sexually JJ transmitted O
transmitted NNS diseases O
diseases NNS clinics O
clinics , , O
, CD 1993-1996 O

> JJR > O
> IN CAPITAL From O
From DT the O
the NNPS CAPITAL Centers O
Centers IN for O
for NN CAPITAL Disease O
Disease NN CAPITAL Control O
Control CC and O
and NNP CAPITAL Prevention O

Chlamydia NN CAPITAL Chlamydia D
Chlamydia VBG screening O
screening NNS practices O
practices IN of O
of JJ primary-care O
primary-care NNS providers O
providers : -- O
-- VB CAPITAL Wake O
Wake NNP CAPITAL County O
County , , O
, NNP CAPITAL North O
North NNP CAPITAL Carolina O
Carolina , , O
, CD 1996 O

Social NNP CAPITAL Social O
Social NNS ties O
ties CC and O
and NN susceptibility O
susceptibility TO to O
to DT the O
the JJ common D
common JJ cold D

Prevention NNP CAPITAL Prevention O
Prevention IN of O
of JJ bacterial D
bacterial NN endocarditis D
endocarditis : : O
: JJ CAPITAL American O
American NNP CAPITAL Heart O
Heart NNP CAPITAL Association O
Association NNS recommendations O

Issues NNS CAPITAL Issues O
Issues VBG regarding O
regarding JJ antiretroviral T
antiretroviral NN treatment T
treatment IN for O
for NNS patients O
patients IN with O
with NN CAPITAL HIV-1 D
HIV-1 NN infection D

Prescribing VBG CAPITAL Prescribing O
Prescribing NN protease T
protease NNS inhibitors T
inhibitors IN for O
for DT the O
the JJ homeless O

Treatment NN CAPITAL Treatment O
Treatment IN of O
of NN verruca D
verruca NN vulgaris D
vulgaris IN with O
with JJ topical T
topical NN cidofovir T

Complete JJ CAPITAL Complete O
Complete JJ genomic O
genomic NN screen O
screen IN in O
in JJ late-onset O
late-onset JJ familial O
familial NN CAPITAL Alzheimer D
Alzheimer NN disease D

Evidence NN CAPITAL Evidence O
Evidence IN for O
for DT a O
a JJ new O
new NN locus O
locus IN on O
on NN chromosome O
chromosome CD 12 O

BRCA1 NN CAPITAL BRCA1 O
BRCA1 NN sequence O
sequence NN analysis O
analysis IN in O
in NNS women O
women IN at O
at JJ high O
high NN risk O
risk IN for O
for NN susceptibility O
susceptibility NNS mutations O

Risk NN CAPITAL Risk O
Risk NN factor O
factor NN analysis O
analysis CC and O
and NNS implications O
implications IN for O
for JJ genetic O
genetic NN testing O

Characteristics NNS CAPITAL Characteristics O
Characteristics IN of O
of NN prostate D
prostate NN cancer D
cancer IN in O
in NNS families O
families RB potentially O
potentially VBN linked O
linked TO to O
to DT the O
the JJ hereditary O
hereditary NN prostate O
prostate NN cancer O
cancer CD 1 O
1 NN ( O
( NN CAPITAL HPC1 O
HPC1 NN ) O
) NN locus O

Chromosome NN CAPITAL Chromosome O
Chromosome CD 19 O
19 NN single-locus O
single-locus CC and O
and NN multilocus O
multilocus NN haplotype O
haplotype NNS associations O
associations IN with O
with JJ multiple D
multiple NN sclerosis D

Evidence NN CAPITAL Evidence O
Evidence IN of O
of DT a O
a JJ new O
new NN susceptibility O
susceptibility NN locus O
locus IN in O
in JJ CAPITAL Caucasian O
Caucasian CC and O
and JJ CAPITAL Chinese O
Chinese NNS patients O

Cancer NN CAPITAL Cancer D
Cancer NN incidence O
incidence IN after O
after NN retinoblastoma D

Radiation NNP CAPITAL Radiation O
Radiation NN dose O
dose CC and O
and NN sarcoma O
sarcoma NN risk O

Genetic JJ CAPITAL Genetic O
Genetic NN testing O
testing IN in O
in JJ hereditary O
hereditary JJ colorectal D
colorectal NN cancer D

Molecular JJ CAPITAL Molecular O
Molecular NNS neurogenetics O
neurogenetics : : O
: DT the O
the NN genome O
genome VBZ is O
is VBG settling O
settling DT the O
the NN issue O

Family NNP CAPITAL Family O
Family NN history O
history CC and O
and JJ genetic O
genetic NN risk O
risk NNS factors O
factors : : O
: RB forward O
forward TO to O
to DT the O
the JJ future O

Preparing VBG CAPITAL Preparing O
Preparing NN health O
health NNS professionals O
professionals IN for O
for DT the O
the JJ genetic O
genetic NN revolution O

Preterm NNP CAPITAL Preterm O
Preterm JJ premature O
premature NN rupture D
rupture IN of D
of DT the D
the NNS membranes D
membranes VBN associated O
associated IN with O
with JJ recent O
recent NN cocaine O
cocaine NN use O

Attitudes NNS CAPITAL Attitudes O
Attitudes IN toward O
toward NN health-care O
health-care , , O
, NN CAPITAL HIV D
HIV NN infection D
infection , , O
, CC and O
and JJ perinatal O
perinatal NN transmission O
transmission NNS interventions O
interventions IN in O
in DT a O
a NN cohort O
cohort IN of O
of JJ inner-city O
inner-city , , O
, JJ pregnant O
pregnant NNS women O

Association NNP CAPITAL Association O
Association IN of O
of NN parvovirus D
parvovirus NN infection D
infection IN with O
with VBN isolated O
isolated JJ fetal O
fetal NNS effusions O

Early RB CAPITAL Early O
Early CC and O
and JJ long-term O
long-term NNS results O
results IN of O
of NN rehabilitation O
rehabilitation IN of O
of JJ cochlear T
cochlear VB implant T
implant NNS patients O
patients NN ) O

Principles NNS CAPITAL Principles O
Principles IN of O
of NN signal O
signal NN detection O
detection IN in O
in NN pharmacovigilance O

Homology NN CAPITAL Homology O
Homology NN modeling O
modeling IN of O
of JJ adenylosuccinate O
adenylosuccinate NN synthetase O
synthetase IN from O
from FW CAPITAL Saccharomyces O
Saccharomyces FW cerevisiae O
cerevisiae VBZ reveals O
reveals DT a O
a JJ possible O
possible VBG binding O
binding NN region O
region IN for O
for JJ single-stranded O
single-stranded NN CAPITAL ARS O
ARS NNS sequences O

Deletion NN CAPITAL Deletion O
Deletion NN analysis O
analysis IN of O
of DT the O
the NN p16/CDKN2 O
p16/CDKN2 NN gene O
gene IN in O
in NN head O
head CC and O
and NN neck O
neck JJ squamous O
squamous NN cell O
cell NN carcinoma D
carcinoma VBG using O
using JJ quantitative O
quantitative NN polymerase O
polymerase NN chain O
chain NN reaction O
reaction NN method O

Ribosomal JJ CAPITAL Ribosomal O
Ribosomal NN CAPITAL S6 O
S6 NN kinase O
kinase NN p90rsk O
p90rsk CC and O
and NN mRNA O
mRNA JJ cap-binding O
cap-binding NN protein O
protein NN eIF4E O
eIF4E NNS phosphorylations O
phosphorylations VB correlate O
correlate IN with O
with NN CAPITAL MAP O
MAP NN kinase O
kinase NN activation O
activation IN during O
during JJ meiotic O
meiotic NN reinitiation O
reinitiation IN of O
of NN mouse O
mouse NNS oocytes O

Hyaluronidase NN CAPITAL Hyaluronidase O
Hyaluronidase NN activity O
activity IN of O
of JJ macaque O
macaque NN sperm O
sperm VBN assessed O
assessed IN by O
by DT an O
an IN in O
in FW vitro O
vitro JJ cumulus O
cumulus NN penetration O
penetration NN assay O

The DT CAPITAL The O
The NN comparison O
comparison IN of O
of DT the O
the NN responsiveness O
responsiveness IN of O
of JJ human O
human VBN isolated O
isolated JJ internal O
internal JJ mammary O
mammary CC and O
and JJ gastroepiploic O
gastroepiploic NNS arteries O
arteries TO to O
to NN levcromakalim O
levcromakalim : : O
: DT an O
an JJ alternative O
alternative NN approach O
approach TO to O
to DT the O
the NN management O
management IN of O
of NN graft O
graft NN spasm O

Single-dose JJ CAPITAL Single-dose O
Single-dose NNS pharmacokinetics O
pharmacokinetics IN of O
of NN felbamate O
felbamate IN in O
in NNS patients O
patients IN with O
with JJ renal O
renal NN dysfunction O

Reporting NNP CAPITAL Reporting O
Reporting IN of O
of JJ adverse O
adverse NN drug O
drug NNS reactions O
reactions IN by O
by NN hospital O
hospital NNS doctors O
doctors CC and O
and DT the O
the NN response O
response TO to O
to NN intervention O

Glutamate JJ CAPITAL Glutamate O
Glutamate NNS receptors O
receptors CC and O
and NN gene O
gene NN induction O
induction : : O
: NN signalling O
signalling IN from O
from NN receptor O
receptor TO to O
to NN nucleus O

Role NN CAPITAL Role O
Role IN of O
of NN phosphatidylinositol O
phosphatidylinositol NN 3-kinase O
3-kinase IN in O
in NN degranulation O
degranulation VBN induced O
induced IN by O
by JJ CAPITAL IgE-dependent O
IgE-dependent CC and O
and JJ -independent O
-independent NNS mechanisms O
mechanisms IN in O
in NN rat O
rat JJ basophilic O
basophilic NN CAPITAL RBL-2H3 O
RBL-2H3 NN ( O
( NN ml O
ml NN ) O
) NNS cells O

Platelet-derived JJ CAPITAL Platelet-derived O
Platelet-derived NN growth O
growth NN factor O
factor VBZ activates O
activates DT a O
a JJ mammalian O
mammalian NN CAPITAL Ste20 O
Ste20 VBN coupled O
coupled JJ mitogen-activated O
mitogen-activated NN protein O
protein NN kinase O
kinase IN in O
in NN airway O
airway JJ smooth O
smooth NN muscle O

Cyclic JJ CAPITAL Cyclic O
Cyclic NN CAPITAL AMP O
AMP NNS inhibitors O
inhibitors VBZ inhibits O
inhibits JJ CAPITAL PDGF-stimulated O
PDGF-stimulated JJ mitogen-activated O
mitogen-activated NN protein O
protein NN kinase O
kinase NN activity O
activity IN in O
in NN rat O
rat JJ aortic O
aortic JJ smooth O
smooth NN muscle O
muscle NNS cells O
cells IN via O
via NN inactivation O
inactivation IN of O
of NN c-Raf-1 O
c-Raf-1 NN kinase O
kinase CC and O
and NN induction O
induction IN of O
of NN CAPITAL MAP O
MAP NN kinase O
kinase NN phosphatase-1 O

Mitochondrial JJ CAPITAL Mitochondrial O
Mitochondrial NNS cytopathies O
cytopathies CC and O
and JJ renal D
renal JJ tubular D
tubular NN acidosis D

Elective JJ CAPITAL Elective T
Elective NN surgery T
surgery IN for O
for JJ colorectal D
colorectal NN cancer D
cancer IN in O
in DT the O
the JJ aged O
aged : : O
: DT a O
a JJ clinical-economical O
clinical-economical NN evaluation O

Leukaemia NN CAPITAL Leukaemia D
Leukaemia CC and O
and JJ non-Hodgkin D
non-Hodgkin POS 's D
's NN lymphoma D
lymphoma IN in O
in NNS children O
children CC and O
and JJ young O
young NNS adults O
adults : : O
: VBP are O
are JJ prenatal O
prenatal CC and O
and JJ neonatal O
neonatal NNS factors O
factors JJ important O
important NNS determinants O
determinants IN of O
of NN disease O
disease . ? O

Inverse JJ CAPITAL Inverse O
Inverse NN correlation O
correlation IN between O
between NN loss O
loss IN of O
of NN heterozygosity O
heterozygosity IN of O
of DT the O
the JJ short O
short NN arm O
arm IN of O
of NN chromosome O
chromosome CD 12 O
12 CC and O
and NN p15ink4B/p16ink4 O
p15ink4B/p16ink4 NN gene O
gene NN inactivation O
inactivation IN in O
in NN childhood D
childhood JJ acute D
acute JJ lymphoblastic D
lymphoblastic NN leukaemia D

Drug NN CAPITAL Drug O
Drug NN resistance O
resistance NNS markers O
markers : : O
: VBP are O
are PRP they O
they JJ bad O
bad CC or O
or JJ good O
good . ? O

Elective JJ CAPITAL Elective T
Elective NN surgery T
surgery IN for O
for JJ gastrointestinal D
gastrointestinal NNS tumours D
tumours IN in O
in DT the O
the JJ elderly O

Folate NNP CAPITAL Folate T
Folate CC and O
and NN heart D
heart NN disease D
disease : : O
: JJ theoretical O
theoretical NN link O
link NNS needs O
needs NN study O
study . . O

A DT CAPITAL A O
A NN call O
call IN for O
for JJ stepped-up O
stepped-up NN melanoma D
melanoma VBG screening O

New NNP CAPITAL New O
New NNS approaches O
approaches TO to O
to NN stroke D
stroke VB require O
require JJ immediate O
immediate NN action O

The DT CAPITAL The O
The NN focus O
focus VBZ is O
is RB now O
now IN on O
on NNS standards O
standards CC and O
and NN privacy O
privacy IN in O
in JJ electronic O
electronic NN patient O
patient NNS records O

Osteopathic JJ CAPITAL Osteopathic O
Osteopathic NN manifesto O

I PRP CAPITAL I O
I . . O
. NN CAPITAL Introduction O

II NNP CAPITAL II O

The DT CAPITAL The O
The NNS roots O

1981 CD 1981 O

Treatment NN CAPITAL Treatment O
Treatment NNS uncertainties O
uncertainties VB surround O
surround RB early O
early NN diagnosis O
diagnosis IN of O
of NN breast D
breast NN cancer D

Depression NN CAPITAL Depression D
Depression IN in O
in DT the O
the RB chronically O
chronically RB ill O
ill NNS needs O
needs JJ separate O
separate NN treatment O

Medical JJ CAPITAL Medical O
Medical NNS centers O
centers VB tackle O
tackle NNS delays O
delays , , O
, VB reduce O
reduce VB wait O
wait NNS times O

Epilepsy NNP CAPITAL Epilepsy O
Epilepsy CC and O
and NN attention O
attention NN deficit O
deficit NN hyperactivity O
hyperactivity NN disorder O
disorder : : O
: VBZ is O
is NN methylphenidate O
methylphenidate JJ safe O
safe CC and O
and JJ effective O
effective . ? O

Applying VBG CAPITAL Applying O
Applying DT the O
the NN CAPITAL AIDS D
AIDS NN paradigm O
paradigm TO to O
to NN hepatitis D

New NNP CAPITAL New O
New NN asthma D
asthma NNS guidelines O
guidelines VB emphasize O
emphasize JJR better O
better NN diagnosis O
diagnosis , , O
, JJR stricter O
stricter NN control O

Osteopathic JJ CAPITAL Osteopathic O
Osteopathic NN manifesto O

IV CD CAPITAL IV O

The DT CAPITAL The O
The NN search O

1981 CD 1981 O

Researchers NNP CAPITAL Researchers O
Researchers NN puzzle O
puzzle IN over O
over NN origin O
origin IN of O
of NN type O
type CD 2 O
2 NN diabetes D

Ovarian JJ CAPITAL Ovarian D
Ovarian NN cancer D
cancer : : O
: JJ diagnostic O
diagnostic NNS limitations O
limitations , , O
, NN treatment O
treatment NNS obstacles O

Osteopathic JJ CAPITAL Osteopathic O
Osteopathic NN manifesto O

V NN CAPITAL V O

Legislative JJ CAPITAL Legislative O
Legislative CC and O
and JJ legal O
legal NN vigilance O

1981 CD 1981 O

Osteopathic JJ CAPITAL Osteopathic O
Osteopathic NN manifesto O

VI NNP CAPITAL VI O

The DT CAPITAL The O
The JJ light O
light IN of O
of DT the O
the NN profession O

1981 CD 1981 O

Electrophysiological JJ CAPITAL Electrophysiological O
Electrophysiological NN evidence O
evidence IN on O
on DT the O
the NN time O
time NN course O
course IN of O
of JJ semantic O
semantic CC and O
and JJ phonological O
phonological NNS processes O
processes IN in O
in NN speech O
speech NN production O

Effects NNS CAPITAL Effects O
Effects IN of O
of NN alanine O
alanine CC and O
and NN glycine O
glycine NN substitution O
substitution IN for O
for NN tryptophan O
tryptophan IN on O
on DT the O
the NN heterogeneity O
heterogeneity IN of O
of NN gramicidin O
gramicidin DT CAPITAL A O
A NNS analogs O
analogs IN in O
in NNS micelles O

Torsion-angle JJ CAPITAL Torsion-angle O
Torsion-angle JJ molecular O
molecular NNS dynamics O
dynamics IN as O
as DT a O
a JJ new O
new JJ efficient O
efficient NN tool O
tool IN for O
for NN CAPITAL NMR O
NMR NN structure O
structure NN calculation O

Time-domain JJ CAPITAL Time-domain O
Time-domain NN quanification O
quanification IN of O
of NN amplitude O
amplitude , , O
, NN chemical O
chemical NN shift O
shift , , O
, JJ apparent O
apparent NN relaxation O
relaxation NN time O
time NN CAPITAL T2 O
T2 , , O
, CC and O
and NN phase O
phase IN by O
by JJ wavelet-transform O
wavelet-transform NN analysis O

Application NN CAPITAL Application O
Application TO to O
to JJ biomedical O
biomedical JJ magnetic O
magnetic NN resonance O
resonance NN spectroscopy O

Investigation NNP CAPITAL Investigation O
Investigation IN of O
of NNS uncertainties O
uncertainties IN in O
in NN relaxation O
relaxation NN analysis O
analysis IN of O
of NN 2D O
2D NNP CAPITAL NOE O
NOE WDT which O
which VB arise O
arise IN from O
from JJ spectral O
spectral NN noise O

An DT CAPITAL An O
An JJ efficient O
efficient NN CAPITAL HN O
HN NN ( O
( NNP CAPITAL CA O
CA NN ) O
) NNP CAPITAL NH O
NH NN pluse O
pluse NN scheme O
scheme IN for O
for JJ triple-resonance O
triple-resonance NN 4D O
4D NN correlation O
correlation IN of O
of JJ sequential O
sequential NN amide O
amide NNS protons O
protons CC and O
and JJ nitrogens-15 O
nitrogens-15 IN in O
in VBN deuterated O
deuterated NNS proteins O

Optimal JJ CAPITAL Optimal O
Optimal NN detection O
detection IN of O
of JJ weak O
weak NN nJ O
nJ NN ( O
( CD 1H- O
1H- NN 119Sn O
119Sn NN ) O
) NNS couplings O
couplings IN by O
by JJ gradient-enhanced O
gradient-enhanced NN 1D O
1D CC and O
and NN 2D O
2D JJ heteronuclear O
heteronuclear JJ multiple-quantum O
multiple-quantum NN correlation O
correlation NN spectroscopy O

Application NN CAPITAL Application O
Application TO to O
to DT a O
a JJ novel O
novel NN tin O
tin JJ derivative O
derivative IN of O
of NN erythromycin O
erythromycin DT CAPITAL A O

Thermoelectric NNP CAPITAL Thermoelectric O
Thermoelectric VBG cooling O
cooling IN for O
for NN CAPITAL NMR O
NMR NN sample O
sample NN temperature O
temperature NN control O

H2NCO-E.COSY NN CAPITAL H2NCO-E.COSY O
H2NCO-E.COSY , , O
, DT a O
a JJ simple O
simple NN method O
method IN for O
for DT the O
the JJ sterospecific O
sterospecific NN assignment O
assignment IN of O
of JJ side-chain O
side-chain NN amide O
amide NNS protons O
protons IN in O
in NNS proteins O

Applying VBG CAPITAL Applying O
Applying NN excitation O
excitation VBG sculpting O
sculpting TO to O
to NN construct O
construct RB singly O
singly CC and O
and RB doubly O
doubly JJ selective O
selective NN 1D O
1D NN CAPITAL NMR O
NMR NNS experiments O

Radiation NNP CAPITAL Radiation O
Radiation NN dosimetry O
dosimetry IN by O
by JJ localized O
localized JJ magnetic O
magnetic NN resonance O
resonance NN spectroscopy O

The DT CAPITAL The O
The NN 2D O
2D NN CAPITAL NMR O
NMR NNS experiments O
experiments NN CAPITAL H O
H NN ( O
( NN CAPITAL C O
C NN ) O
) NN CAPITAL CO2 O
CO2 CC and O
and NN CAPITAL HCCO2 O
HCCO2 IN for O
for NN assignment O
assignment CC and O
and NN pH O
pH NN titration O
titration IN of O
of NN carboxylate O
carboxylate NNS groups O
groups IN in O
in RB uniformly O
uniformly JJ 15N/13C-labeled O
15N/13C-labeled NNS proteins O

Post-acquisition NN CAPITAL Post-acquisition O
Post-acquisition JJ solvent O
solvent NN suppression O
suppression IN by O
by JJ singular-value O
singular-value NN decomposition O

Osteopathic JJ CAPITAL Osteopathic O
Osteopathic NN manifesto O

IX CD CAPITAL IX O

What WDT CAPITAL What O
What IN about O
about PRP$ our O
our NN distinctiveness O
distinctiveness . ? O
? CD 1981 O

Preparing VBG CAPITAL Preparing O
Preparing IN for O
for NN thalidomide T
thalidomide POS 's T
's NN comeback O

Heart NNP CAPITAL Heart D
Heart NN disease D
disease : : O
: NNS women O
women POS 's O
's JJ unique O
unique NNS risks O
risks NN demand O
demand NN attention O

Resolution NNP CAPITAL Resolution O
Resolution JJ due O
due IN in O
in JJ medical O
medical NN software O
software NN regulation O

Osteopathic JJ CAPITAL Osteopathic O
Osteopathic NN manifesto O

VII NN CAPITAL VII O

Shadows NNS CAPITAL Shadows O
Shadows CC and O
and NNS images O

1981 CD 1981 O

The DT CAPITAL The O
The JJ practical O
practical NN use O
use IN of O
of NN CAPITAL PCR O
PCR IN for O
for JJ rapid O
rapid NN detection O
detection IN of O
of NN methicillin T
methicillin NN resistance O
resistance IN among O
among JJ staphylococcal O
staphylococcal JJ clinical O
clinical NNS isolates O
isolates IN from O
from JJ CAPITAL Turkish O
Turkish NNS hospitals O

Randomised VBN CAPITAL Randomised O
Randomised JJ double-blind O
double-blind NN trial O
trial IN of O
of VBN fixed O
fixed JJ low-dose O
low-dose NN warfarin T
warfarin IN with T
with NN aspirin T
aspirin IN after O
after JJ myocardial D
myocardial NN infarction D

Coumadin NNP CAPITAL Coumadin O
Coumadin NN CAPITAL Aspirin O
Aspirin NN CAPITAL Reinfarction O
Reinfarction NNP CAPITAL Study O
Study NN ( O
( NNS CAPITAL CARS O
CARS NN ) O
) NNS CAPITAL Investigators O

Randomised VBN CAPITAL Randomised O
Randomised NN trial O
trial IN of O
of NN roxithromycin T
roxithromycin IN in O
in JJ non-Q-wave D
non-Q-wave JJ coronary D
coronary NNS syndromes D
syndromes : : O
: NN CAPITAL ROXIS O
ROXIS NN CAPITAL Pilot O
Pilot NNP CAPITAL Study O

ROXIS NN CAPITAL ROXIS O
ROXIS NNP CAPITAL Study O
Study NNP CAPITAL Group O

Association NNP CAPITAL Association O
Association IN between O
between NN 5-HT2A O
5-HT2A NN gene O
gene NN promoter O
promoter NN polymorphism O
polymorphism CC and O
and NN anorexia D
anorexia NN nervosa D

Randomised VBN CAPITAL Randomised O
Randomised NN study O
study IN of O
of JJ radical T
radical NN surgery T
surgery CC versus T
versus NN radiotherapy T
radiotherapy IN for O
for NN stage D
stage NN CAPITAL Ib-IIa D
Ib-IIa JJ cervical D
cervical NN cancer D

State NNP CAPITAL State O
State NN regulation O
regulation IN in O
in DT a O
a NN world O
world IN of O
of `` `` O
`` JJ boundary-less O
boundary-less '' '' O
'' NN technology O

Screening VBG CAPITAL Screening O
Screening IN for O
for NN CAPITAL Chlamydia D
Chlamydia NN trachomatis D
trachomatis . ? O

Physician-assisted JJ CAPITAL Physician-assisted O
Physician-assisted NN suicide O
suicide IN in O
in NNP CAPITAL Oregon O

Common JJ CAPITAL Common O
Common JJ nutritional O
nutritional NNS issues O
issues IN in O
in JJ pediatric O
pediatric CC and O
and JJ adult O
adult JJ critical O
critical NN care O
care NN medicine O

A DT CAPITAL A O
A JJ multifactorial O
multifactorial NN analysis O
analysis IN of O
of JJ facial O
facial NN nerve O
nerve NNS results O
results IN in O
in NN surgery O
surgery IN for O
for NN cerebellopontine O
cerebellopontine NN angle O
angle NNS tumors O

Osteopathic JJ CAPITAL Osteopathic O
Osteopathic NN manifesto O

VIII CD CAPITAL VIII O

Our PRP$ CAPITAL Our O
Our JJ distinct O
distinct NN image O

1981 CD 1981 O

Quality JJ CAPITAL Quality O
Quality IN in O
in JJ general O
general NN practice O

Winning VBG CAPITAL Winning O
Winning DT the O
the NN war O
war IN on O
on NN cancer D

Clinical JJ CAPITAL Clinical O
Clinical JJ problem-solving O
problem-solving : -- O
-- WRB where O
where VBD did O
did JJ good O
good JJ old O
old JJ clinical O
clinical NN diagnosis O
diagnosis VB go O
go . ? O

The DT CAPITAL The O
The VBN named O
named NN nurse O
nurse : : O
: NN patient O
patient CC and O
and NN nurse O
nurse NNS expectations O

Genetic JJ CAPITAL Genetic O
Genetic NN testing O
testing VBZ opens O
opens VB brave O
brave JJ new O
new NN world O

Heterologous JJ CAPITAL Heterologous O
Heterologous NNS vaccines T
vaccines : : O
: NN proponent O
proponent VBZ sparks O
sparks DT some O
some NN interest O

Steps NNS CAPITAL Steps O
Steps RB still O
still VBG being O
being VBN taken O
taken TO to O
to VB undo O
undo NN damage O
damage IN of O
of `` `` O
`` NNP CAPITAL America O
America POS 's O
's NNP CAPITAL Nuremberg O
Nuremberg '' '' O

Patient-centered JJ CAPITAL Patient-centered O
Patient-centered NNS ethics O
ethics VBG reclaiming O
reclaiming NN center O
center NN stage O

Social NNP CAPITAL Social O
Social NNS ties O
ties CC and O
and NN susceptibility O
susceptibility TO to O
to DT the O
the JJ common D
common JJ cold D

Connecting VBG CAPITAL Connecting O
Connecting NN peptide O
peptide , , O
, VBG correcting O
correcting NN peptide O
peptide . ? O

Winning VBG CAPITAL Winning O
Winning NN health O
health NNS victories O
victories IN with O
with NN community O
community NN commitment O

Telemedicine NN CAPITAL Telemedicine O
Telemedicine VBZ gets O
gets DT a O
a NN chance O
chance TO to O
to VB prove O
prove PRP itself O

Additional JJ CAPITAL Additional O
Additional NNS opinions O
opinions IN on O
on DT the O
the NN mortality O
mortality IN of O
of NN animal O
animal NN research O

Recurrent JJ CAPITAL Recurrent D
Recurrent NNS strokes D
strokes IN in O
in DT a O
a JJ 34-year-old O
34-year-old NN man O

A DT CAPITAL A O
A NN plan O
plan IN for O
for VBG improving O
improving NNS outcomes O
outcomes IN for O
for NNS patients O
patients IN with O
with JJ chronic D
chronic JJ renal D
renal NN failure D

Scientific NNP CAPITAL Scientific O
Scientific NN evidence O
evidence IN in O
in NN family O
family CC and O
and NN community O
community NN medicine O

Evidence NN CAPITAL Evidence O
Evidence IN that O
that DT the O
the NN expression O
expression IN of O
of JJ progesterone-induced O
progesterone-induced VBG blocking O
blocking NN factor O
factor IN by O
by JJ maternal O
maternal NNS CAPITAL T-lymphocytes O
T-lymphocytes VBZ is O
is RB positively O
positively VBD correlated O
correlated IN with O
with NN conception O

Another DT CAPITAL Another O
Another NN use O
use IN of O
of NNS androgens T
androgens : : O
: NN treatment O
treatment IN of O
of NN anemia D
anemia IN of D
of NN end-stage D
end-stage JJ renal D
renal NN disease D

Isotopic JJ CAPITAL Isotopic O
Isotopic NN evidence O
evidence IN for O
for JJ extraterrestrial O
extraterrestrial JJ non-racemic O
non-racemic NN amino O
amino NNS acids O
acids IN in O
in DT the O
the NNP CAPITAL Murchison O
Murchison NN meteorite O

The DT CAPITAL The O
The JJ CAPITAL American O
American JJ CAPITAL Medical O
Medical NNP CAPITAL Association O
Association NNS CAPITAL Guidelines O
Guidelines IN for O
for JJ CAPITAL Adolescent O
Adolescent JJ CAPITAL Preventive O
Preventive NNP CAPITAL Services O

Classification NN CAPITAL Classification O
Classification IN of O
of JJ malignant D
malignant NNS lymphomas D
lymphomas : : O
: DT the O
the VBN updated O
updated NNP CAPITAL Kiel O
Kiel NN classification O

Rethink VB CAPITAL Rethink O
Rethink IN on O
on VBG screening O
screening IN for O
for NN breast D
breast NN cancer D

Sports-related JJ CAPITAL Sports-related O
Sports-related JJ ocular D
ocular NNS injuries D

Fruit NNP CAPITAL Fruit O
Fruit NN juice O
juice NN consumption O

The DT CAPITAL The O
The NN case O
case IN of O
of DT the O
the VBG missing O
missing NN methylphenidate T

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> JJ CAPITAL Intensive T
Intensive NN insulin T
insulin NN treatment T
treatment IN after O
after JJ acute D
acute JJ myocardial D
myocardial NN infarction D
infarction IN in O
in NN diabetes D
diabetes NN mellitus D

Intensive JJ CAPITAL Intensive O
Intensive NN insulin O
insulin NNS regimens O
regimens IN in O
in JJ primary O
primary NN prevention O
prevention MD should O
should VB be O
be VBN assessed O

GPs NNS CAPITAL GPs O
GPs POS ' O
' NNS perceptions O
perceptions IN of O
of NN tolerability O
tolerability IN of O
of JJ selective O
selective NN serotonin O
serotonin NN reuptake O
reuptake NNS inhibitors O
inhibitors CC and O
and JJ tricyclic O
tricyclic NNS antidepressants T

Research NNP CAPITAL Research O
Research IN into O
into RB long O
long NN term O
term NN use O
use VBZ is O
is VBN needed O

Diagnosing VBG CAPITAL Diagnosing O
Diagnosing CC and O
and VBG managing O
managing NN polymyalgia D
polymyalgia NN rheumatica D
rheumatica CC and O
and JJ temporal D
temporal NN arteritis D

Sensitivity NN CAPITAL Sensitivity O
Sensitivity IN of O
of JJ temporal O
temporal NN artery O
artery NN biopsy O
biopsy VBZ varies O
varies IN with O
with NN biopsy O
biopsy NN length O
length CC and O
and NN sectioning O
sectioning NN strategy O

Obstructive JJ CAPITAL Obstructive O
Obstructive NN sleep D
sleep NN apnoea D

Authors NNS CAPITAL Authors O
Authors POS ' O
' NN reply O

Impact NN CAPITAL Impact O
Impact IN of O
of JJ postmenopausal O
postmenopausal NN hormone T
hormone NN therapy T
therapy IN on O
on JJ cardiovascular O
cardiovascular NNS events O
events CC and O
and NN cancer D
cancer . . O

Search VB CAPITAL Search O
Search IN for O
for NNS studies O
studies VBD was O
was JJ limited O

Treating VBG CAPITAL Treating O
Treating NN shoulder O
shoulder NNS complaints O
complaints IN in O
in JJ general O
general NN practice O

Diagnostic JJ CAPITAL Diagnostic O
Diagnostic NNS criteria O
criteria MD must O
must VB be O
be VBN used O
used CC and O
and JJ therapeutic O
therapeutic NNS regimens O
regimens JJ standardised O

Authorship NN CAPITAL Authorship O

System NNP CAPITAL System O
System VBG acknowledging O
acknowledging NNS roles O
roles IN of O
of NNS contributors O
contributors VBZ is O
is RB best O

Authorship NN CAPITAL Authorship O

New NNP CAPITAL New O
New NN authorship O
authorship NNS practices O
practices VBP are O
are VBN needed O
needed IN in O
in VBG developing O
developing NNS countries O

Authorship NN CAPITAL Authorship O

Researchers NNP CAPITAL Researchers O
Researchers POS ' O
' JJ objective O
objective VBZ is O
is TO to O
to VB get O
get DT the O
the NN job O
job VBN done O

Quality JJ CAPITAL Quality O
Quality CC and O
and JJ clinical O
clinical NN audit O

Transurethral JJ CAPITAL Transurethral T
Transurethral NN microwave T
microwave JJ thermotherapy T

Management NNP CAPITAL Management O
Management IN of O
of NN ileosigmoid D
ileosigmoid VBG knotting D

Epitome NNP CAPITAL Epitome O
Epitome IN of O
of NN myocarditis D

Producing NNP CAPITAL Producing O
Producing JJ consistent O
consistent NNS estimates O
estimates IN of O
of DT the O
the NN power O
power JJ spectral O
spectral NN density O
density IN of O
of NNP CAPITAL NN O
NN NNS sequences O

Environmental JJ CAPITAL Environmental O
Environmental NN tobacco O
tobacco NN smoke O
smoke CC and O
and JJ coronary D
coronary NN heart D
heart NN disease D

Long-term JJ CAPITAL Long-term O
Long-term NN benefit O
benefit IN of O
of CD one O
one JJ thrombolytic T
thrombolytic IN over O
over DT another O

Coupling NN CAPITAL Coupling O
Coupling IN of O
of JJ hemodynamic O
hemodynamic NNS measurements O
measurements IN with O
with NN oxygen O
oxygen IN during O
during NN exercise O
exercise VBZ does O
does RB not O
not VB improve O
improve NN risk O
risk NN stratification O
stratification IN in O
in NNS patients O
patients IN with O
with NN heart D
heart NN failure D

Smoking NN CAPITAL Smoking O
Smoking : -- O
-- JJ good O
good CC or O
or JJ bad O
bad IN for O
for NN semen O
semen . ? O

The DT CAPITAL The O
The NN pruning O
pruning IN of O
of NN CAPITAL Doctor O
Doctor NNP CAPITAL McDonough O
McDonough CC and O
and DT the O
the `` `` O
`` VBG humanizing O
humanizing '' '' O
'' IN of O
of NNS statistics O

Violence NN CAPITAL Violence O

Prevention NNP CAPITAL Prevention O
Prevention IN in O
in DT the O
the NN home O
home NN health O
health VBG setting O

Contempo NNP CAPITAL Contempo O
Contempo CD 1997 O
1997 : : O
: NNS obstetrics O
obstetrics CC and O
and NN gynecology O

Mortality NN CAPITAL Mortality O
Mortality CC and O
and NN refusal O
refusal IN of O
of NN CAPITAL ICU O
ICU NN admission O

Extracorporeal JJ CAPITAL Extracorporeal O
Extracorporeal NN photopheresis O
photopheresis IN in O
in CAPITAL S O
S NN ( O
( NN c O
c NN ) O
) JJ zary O
zary NN syndrome O

Attacks NNS CAPITAL Attacks O
Attacks IN on O
on NN tobacco O
tobacco NN industry O

Does VBZ CAPITAL Does O
Does VBG blinding O
blinding IN of O
of NNS readers O
readers VB affect O
affect NNS results O
results IN of O
of NNS meta-analyses O
meta-analyses . ? O

Consumption NN CAPITAL Consumption O
Consumption IN of O
of NN alcohol O
alcohol CC and O
and NN mortality O
mortality IN in O
in NNP CAPITAL Russia O

Presenilin NNP CAPITAL Presenilin O
Presenilin NNS polymorphisms O
polymorphisms IN in O
in NN CAPITAL Alzheimer D
Alzheimer POS 's D
's NN disease D

Autoimmune NN CAPITAL Autoimmune D
Autoimmune NN enteropathy D
enteropathy IN in O
in NNS adults O

Cyclosporiasis NN CAPITAL Cyclosporiasis D
Cyclosporiasis CC and O
and NNS raspberries O

Protean JJ CAPITAL Protean O
Protean NNS agonists O

Keys NNP CAPITAL Keys O
Keys TO to O
to NN receptor O
receptor JJ active O
active NNS states O
states . ? O

Kinetic JJ CAPITAL Kinetic O
Kinetic NNS models O
models IN of O
of NN ion O
ion NNS channels O

Agonist NN CAPITAL Agonist O
Agonist NN efficacy O
efficacy CC and O
and JJ allosteric O
allosteric NNS models O
models IN of O
of NN receptor O
receptor NN action O

Receptor NN CAPITAL Receptor O
Receptor NN CAPITAL Classification O
Classification : : O
: DT CAPITAL The O
The NN CAPITAL Integration O
Integration IN of O
of JJ CAPITAL Operational O
Operational , , O
, JJ CAPITAL Structural O
Structural , , O
, CC and O
and JJ CAPITAL Transductional O
Transductional NN CAPITAL Information O

Conference NN CAPITAL Conference O
Conference NNS proceedings O

Verona NNP CAPITAL Verona O
Verona , , O
, NNP CAPITAL Italy O
Italy , , O
, NNP CAPITAL September O
September CD 21-22 O
21-22 , , O
, CD 1995 O

Policies NNS CAPITAL Policies O
Policies IN for O
for VBG posting O
posting JJ biomedical O
biomedical NN journal O
journal NN information O
information IN on O
on DT the O
the NN CAPITAL Internet O

International NNP CAPITAL International O
International NNP CAPITAL Committee O
Committee IN of O
of JJ CAPITAL Medical O
Medical NNP CAPITAL Journal O
Journal NNS CAPITAL Editors O

Who WP CAPITAL Who O
Who VBZ understands O
understands DT the O
the NN menopause O
menopause . ? O

Comparison NN CAPITAL Comparison O
Comparison IN of O
of CD two O
two NNS methods O
methods IN of O
of VBG screening O
screening IN for O
for JJ genital O
genital JJ chlamydial D
chlamydial NN infection D
infection IN in O
in NNS women O
women VBG attending O
attending IN in O
in JJ general O
general NN practice O
practice : : O
: JJ cross O
cross JJ sectional O
sectional NN survey O

Antimicrobial JJ CAPITAL Antimicrobial T
Antimicrobial NN therapy T
therapy IN in O
in NN neutropenia D

M1/4llerian CAPITAL M1/4llerian O
M1/4llerian NN agenesis O
agenesis : : O
: DT an O
an VB update O

The DT CAPITAL The O
The NNP CAPITAL US O
US NN attack O
attack IN on O
on NNP CAPITAL Cuba O
Cuba POS 's O
's NN health O

Patient NN CAPITAL Patient O
Patient NN consent O
consent IN for O
for NN publication O
publication CC and O
and DT the O
the NN health O
health IN of O
of DT the O
the JJ public O

Brain NN CAPITAL Brain D
Brain NN serotonin D
serotonin NN neurotoxicity D
neurotoxicity CC and O
and JJ primary D
primary JJ pulmonary D
pulmonary NN hypertension D
hypertension IN from O
from NN fenfluramine T
fenfluramine CC and O
and NN dexfenfluramine T

Battling VBG CAPITAL Battling O
Battling NN CAPITAL HI D
HI IN on O
on JJ many O
many NNS fronts O

Medical JJ CAPITAL Medical O
Medical NNP CAPITAL Injury O
Injury NNP CAPITAL Compensation O
Compensation NNP CAPITAL Reform O
Reform NNP CAPITAL Act O
Act : : O
: JJ good O
good CC or O
or JJ bad O
bad . ? O

Fever NN CAPITAL Fever O
Fever IN of O
of JJ unknown O
unknown NN origin O

Moxonidine NN CAPITAL Moxonidine T
Moxonidine IN for O
for NN hypertension D

Researchers NNP CAPITAL Researchers O
Researchers VB make O
make JJ slow O
slow NN headway O
headway IN in O
in VBG managing O
managing JJ dry D
dry NN mouth D

A DT CAPITAL A O
A JJR kinder O
kinder , , O
, JJR gentler O
gentler NN approach O

Putting VBG CAPITAL Putting O
Putting NNS patients O
patients RB first O
first . ? O

Managing VBG CAPITAL Managing O
Managing DT the O
the JJ anxious O
anxious CC and O
and JJ phobic O
phobic JJ dental O
dental NN patient O

Do VB CAPITAL Do O
Do PRP it O
it CC or O
or VB lose O
lose PRP it O

Assessment NNP CAPITAL Assessment O
Assessment IN of O
of JJ fetal O
fetal JJ nuchal O
nuchal NN translucency O
translucency NN test O
test IN for O
for NN CAPITAL Down D
Down POS 's D
's NN syndrome D

Amiodarone NNP CAPITAL Amiodarone T
Amiodarone CC and O
and NN thyroid O
thyroid NN function O

Chemotherapy NN CAPITAL Chemotherapy T
Chemotherapy IN with T
with NN praziquantel T
praziquantel VBZ has O
has DT the O
the JJ potential O
potential TO to O
to VB reduce O
reduce DT the O
the NN prevalence O
prevalence IN of O
of NN CAPITAL Echinococcus D
Echinococcus NN multilocularis D
multilocularis IN in O
in JJ wild O
wild NNS foxes O
foxes NN ( O
( NNP CAPITAL Vulpes O
Vulpes NNS vulpes O
vulpes NN ) O

Death NN CAPITAL Death O
Death NNS rates O
rates IN from O
from NN childhood D
childhood NN leukaemia D
leukaemia IN near O
near JJ nuclear O
nuclear NNS sites O

Other JJ CAPITAL Other O
Other NNS studies O
studies VBD showed O
showed IN that O
that NN radiation O
radiation NNS levels O
levels IN in O
in NNP CAPITAL Newbury O
Newbury NN area O
area VBD were O
were JJ low O

Haemoptysis NN CAPITAL Haemoptysis D
Haemoptysis : : O
: DT a O
a JJ rare O
rare NN cause O

Human JJ CAPITAL Human D
Human NN papillomavirus D
papillomavirus NNS types O
types CD 52 O
52 CC and O
and CD 58 O
58 VBP are O
are JJ prevalent O
prevalent IN in O
in JJ cervical D
cervical NN cancer D
cancer IN from O
from JJ CAPITAL Chinese O
Chinese NNS women O

Breastfeeding VBG CAPITAL Breastfeeding O
Breastfeeding IN after O
after RB early O
early NN discharge O

Malnutrition NN CAPITAL Malnutrition D
Malnutrition CC and O
and NN microcephaly D
microcephaly IN in O
in JJ CAPITAL Australian O
Australian JJ aboriginal O
aboriginal NNS children O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NN CAPITAL Probucol T
Probucol CC and T
and NNS multivitamins T
multivitamins IN in O
in DT the O
the NN prevention O
prevention IN of O
of NN restenosis D
restenosis IN after O
after JJ coronary O
coronary NN angioplasty O

Generalised JJ CAPITAL Generalised O
Generalised JJ caseous D
caseous NN lymphadenitis D

Public NNP CAPITAL Public O
Public NN health O
health NN approach O
approach TO to O
to VBN activated O
activated NN protein O
protein NN CAPITAL C O
C NN resistance O
resistance NN assay O

Hormone NN CAPITAL Hormone T
Hormone NN replacement T
replacement NN therapy T

Dose-volume JJ CAPITAL Dose-volume O
Dose-volume NN histograms O
histograms MD can O
can VB be O
be VBN interpreted O
interpreted IN in O
in JJ different O
different NNS ways O

Addressing VBG CAPITAL Addressing O
Addressing JJ needle-stick O
needle-stick NNS concerns O

Cervical JJ CAPITAL Cervical D
Cervical NN cancer D
cancer VBG screening O

CyberCHEST NN CAPITAL CyberCHEST O

An DT CAPITAL An O
An JJ open O
open JJ future O

Keeping VBG CAPITAL Keeping O
Keeping PRP us O
us IN on O
on PRP$ our O
our NNS toes O
toes . ! O

Thalidomide NNP CAPITAL Thalidomide O
Thalidomide IN in O
in JJ oral O
oral NN CAPITAL Crohn O
Crohn POS 's O
's NN disease O
disease JJ refractory O
refractory TO to O
to JJ conventional O
conventional JJ medical O
medical NN treatment O

Mortality NN CAPITAL Mortality O
Mortality CC and O
and NN length O
length IN of O
of VB stay O
stay IN in O
in NN teaching O
teaching CC vs O
vs JJ nonteaching O
nonteaching NNS hospitals O

Early RB CAPITAL Early O
Early NN discharge O
discharge IN of O
of NNS newborns O

Patient NN CAPITAL Patient O
Patient NN consent O
consent IN for O
for NN publication O

Flucticasone NN CAPITAL Flucticasone T
Flucticasone NN propionate T
propionate VBZ is O
is JJ safe O
safe IN in O
in VBN recommended O
recommended NNS doses O

Fetal JJ CAPITAL Fetal O
Fetal JJ nuchal O
nuchal NN translucency O
translucency NN test O
test IN for O
for NN CAPITAL Down D
Down POS 's D
's NN syndrome D

Treatment NN CAPITAL Treatment O
Treatment IN of O
of NN hypertension D
hypertension IN in O
in JJ elderly O
elderly NNS patients O

Meta-analyses NNS CAPITAL Meta-analyses O
Meta-analyses CC and O
and JJ large O
large VBN randomized O
randomized , , O
, JJ controlled O
controlled NNS trials O

Low-fat JJ CAPITAL Low-fat O
Low-fat NNS diets O

Ultrasonographic JJ CAPITAL Ultrasonographic O
Ultrasonographic NN evaluation O
evaluation IN of O
of JJ parathyroid D
parathyroid NN hyperplasia D

Misconceptions NNS CAPITAL Misconceptions O
Misconceptions IN about O
about NN mosaicism D

Are VBP CAPITAL Are O
Are JJ normal O
normal VBG hearing O
hearing NNS thresholds O
thresholds DT a O
a JJ sufficient O
sufficient NN condition O
condition IN for O
for JJ click-evoked O
click-evoked JJ otoacoustic O
otoacoustic NNS emissions O
emissions . ? O

Structure NN CAPITAL Structure O
Structure CC and O
and IN in O
in FW vitro O
vitro JJ substrate O
substrate NN specificity O
specificity IN of O
of DT the O
the JJ murine O
murine JJ multidrug O
multidrug JJ resistance-associated O
resistance-associated NN protein O

ATP-dependent JJ CAPITAL ATP-dependent O
ATP-dependent NN transport O
transport IN of O
of JJ lipophilic O
lipophilic JJ cytotoxic O
cytotoxic NNS drugs O
drugs IN by O
by NN membrane O
membrane NNS vesicles O
vesicles JJ prepared O
prepared IN from O
from JJ CAPITAL MRP-overexpressing O
MRP-overexpressing NN CAPITAL HL60/ADR O
HL60/ADR NNS cells O

Cellular JJ CAPITAL Cellular O
Cellular CC and O
and IN in O
in FW vitro O
vitro NN transport O
transport IN of O
of NN glutathione O
glutathione NNS conjugates O
conjugates IN by O
by NN CAPITAL MRP O

Dominant JJ CAPITAL Dominant O
Dominant JJ negative O
negative CC and O
and JJ cooperative O
cooperative NNS effects O
effects IN of O
of JJ mutant O
mutant NNS forms O
forms IN of O
of NN prolactin O
prolactin NN receptor O

Effect NN CAPITAL Effect O
Effect IN of O
of NN calcium O
calcium CC and O
and NN vitamin O
vitamin NN CAPITAL D O
D NN supplementation O
supplementation IN on O
on NN bone O
bone NN density O
density IN in O
in NNS men O
men CC and O
and NNS women O
women CD 65 O
65 NNS years O
years IN of O
of NN age O
age CC or O
or JJR older O

Infection NN CAPITAL Infection O
Infection NN control O
control CC and O
and VBN contaminated O
contaminated NN waste O
waste NN disposal O
disposal NNS practices O
practices IN in O
in NNP CAPITAL Southern O
Southern NNP CAPITAL Sydney O
Sydney NNP CAPITAL Area O
Area NNP CAPITAL Health O
Health NNP CAPITAL Service O
Service JJ CAPITAL Dental O
Dental NNS CAPITAL Clinics O

Vitamins NNS CAPITAL Vitamins O
Vitamins CC and O
and NNS minerals O
minerals : : O
: NN efficacy O
efficacy CC and O
and NN safety O

Joint NNP CAPITAL Joint O
Joint NNP CAPITAL Commission O
Commission IN on O
on NN CAPITAL Accreditation O
Accreditation IN of O
of NNP CAPITAL Healthcare O
Healthcare NNP CAPITAL Organizations O
Organizations POS ' O
' NN infection O
infection NN control O
control NNS requirements O
requirements : : O
: NN fact O
fact CC or O
or NN fiction O
fiction . ? O

Poppy NNP CAPITAL Poppy O
Poppy NN tea O
tea CC and O
and DT the O
the NN baker O
baker POS 's O
's RB first O
first NN seizure D

ABC NNP CAPITAL ABC O
ABC IN of O
of JJ mental O
mental NN health O

Mental JJ CAPITAL Mental O
Mental NN health O
health CC and O
and DT the O
the NN law O

Female JJ CAPITAL Female O
Female JJ embryonic O
embryonic NN lethality O
lethality IN in O
in NNS mice O
mice JJ nullizygous O
nullizygous IN for O
for DT both O
both NN CAPITAL Msh2 O
Msh2 CC and O
and NN p53 O

Tests NNS CAPITAL Tests O
Tests IN of O
of DT the O
the JJ double-strand O
double-strand NN break O
break , , O
, RB lethal-potentially O
lethal-potentially JJ lethal O
lethal CC and O
and JJ repair-misrepair O
repair-misrepair NNS models O
models IN for O
for JJ mammalian O
mammalian NN cell O
cell NN survival O
survival VBG using O
using NNS data O
data IN for O
for NN survival O
survival IN as O
as DT a O
a NN function O
function IN of O
of JJ delayed-plating O
delayed-plating NN interval O
interval IN for O
for JJ log-phase O
log-phase JJ CAPITAL Chinese O
Chinese NN hamster O
hamster NN CAPITAL V79 O
V79 NNS cells O

Influence NN CAPITAL Influence O
Influence IN of O
of NN physician O
physician NN confidentiality O
confidentiality NNS assurances O
assurances IN on O
on NNS adolescents O
adolescents POS ' O
' NN willingness O
willingness TO to O
to VB disclose O
disclose NN information O
information CC and O
and VB seek O
seek JJ future O
future NN health O
health NN care O

A DT CAPITAL A O
A VBN randomized O
randomized JJ controlled O
controlled NN trial O

Fever NN CAPITAL Fever D
Fever IN in O
in NNP CAPITAL Africa O
Africa : : O
: VB do O
do NNS patients O
patients VB know O
know WRB when O
when PRP they O
they VBP are O
are JJ hot O
hot . ? O

Randomised VBN CAPITAL Randomised O
Randomised JJ placebo-controlled O
placebo-controlled NN trial O
trial IN of O
of JJ granulocyte-colony T
granulocyte-colony VBG stimulating T
stimulating NN factor T
factor IN in O
in JJ diabetic D
diabetic NN foot D
foot NN infection D

Systemic JJ CAPITAL Systemic O
Systemic NN absorption O
absorption IN of O
of NN sunscreen O
sunscreen IN after O
after JJ topical O
topical NN application O

A DT CAPITAL A O
A NN comparison O
comparison IN of O
of JJ continuous T
continuous NN infusion T
infusion IN of T
of RB alteplase T
alteplase IN with T
with JJ double-bolus T
double-bolus NN administration T
administration IN for O
for JJ acute D
acute JJ myocardial D
myocardial NN infarction D

The DT CAPITAL The O
The JJ CAPITAL Continuous O
Continuous NN CAPITAL Infusion O
Infusion CC versus O
versus JJ CAPITAL Double-Bolus O
Double-Bolus NNP CAPITAL Administration O
Administration IN of O
of RB CAPITAL Alteplase O
Alteplase NN ( O
( NNP CAPITAL COBALT O
COBALT NN ) O
) NNS CAPITAL Investigators O

Evaluation NN CAPITAL Evaluation O
Evaluation CC and O
and NN management O
management IN of O
of JJ traumatic D
traumatic NNS lacerations D

Atrial JJ CAPITAL Atrial D
Atrial NN fibrillation D
fibrillation VBZ begets O
begets NN trouble O

Ethics NNS CAPITAL Ethics O
Ethics IN of O
of NN CAPITAL HIV O
HIV NNS trials O

The DT CAPITAL The O
The NNS ethics O
ethics NN industry O

Fever NN CAPITAL Fever D
Fever IN in O
in NNP CAPITAL Africa O
Africa CC and O
and WP CAPITAL WHO O
WHO NN recommendation O

`` `` `` D
`` NN CAPITAL Whiplash D
Whiplash '' '' D
'' NN injury D
injury IN of O
of DT the O
the JJ cervical O
cervical NN spine O
spine : : O
: NN value O
value IN of O
of JJ modern O
modern JJ diagnostic O
diagnostic NN imaging O

Guidelines NNS CAPITAL Guidelines O
Guidelines CC and O
and JJ cardiac O
cardiac NNS anaesthetists O

Antibiotic JJ CAPITAL Antibiotic T
Antibiotic NN management T
management IN of O
of JJ sore D
sore NN throat D

Lansoprazole JJ CAPITAL Lansoprazole T
Lansoprazole , , O
, NNP CAPITAL H. O
H. NN pylori O
pylori , , O
, CC and O
and JJ atrophic D
atrophic NN gastritis D
gastritis . . O

Help VB CAPITAL Help O
Help VBD wanted O
wanted : : O
: NNS ultrasonographers O

`` `` `` O
`` NNS CAPITAL Children O
Children VBP are O
are RB not O
not VBN supposed O
supposed TO to O
to VB die O

'' '' '' O
'' VBN CAPITAL Combined O
Combined JJ pediatric O
pediatric CC and O
and NN radiation O
radiation NN oncology O
oncology JJ grand O
grand NNS rounds O
rounds NNS addresses O
addresses JJ severe O
severe NN illness O
illness CC and O
and NN death O

Structure-activity JJ CAPITAL Structure-activity O
Structure-activity CC and O
and NN mechanism O
mechanism NNS studies O
studies IN on O
on NN silicon O
silicon NNS phthalocyanines O
phthalocyanines IN with O
with NN CAPITAL Plasmodium O
Plasmodium NN falciparum O
falciparum IN in O
in DT the O
the JJ dark O
dark CC and O
and IN under O
under JJ red O
red JJ light O

The DT CAPITAL The O
The NN importance O
importance IN of O
of VBG being O
being WRB where O
where . ? O
? VBG CAPITAL Balancing O
Balancing DT the O
the NN perspective O
perspective IN on O
on NN practice O
practice NN coverage O

Effects NNS CAPITAL Effects O
Effects IN of O
of NN dobutamine T
dobutamine IN at O
at RB maximally O
maximally VBN tolerated O
tolerated NN dose O
dose IN on O
on JJ myocardial O
myocardial NN blood O
blood NN flow O
flow IN in O
in NNS humans O
humans IN with O
with JJ ischemic D
ischemic NN heart D
heart NN disease D
disease . . O

Cholesterol-lowering JJ CAPITAL Cholesterol-lowering T
Cholesterol-lowering NN therapy T

Ion NN CAPITAL Ion O
Ion NN composition O
composition IN of O
of NN airway O
airway NN surface O
surface JJ liquid O
liquid IN of O
of NNS patients O
patients IN with O
with JJ cystic D
cystic NN fibrosis D
fibrosis IN as O
as VBN compared O
compared IN with O
with JJ normal O
normal CC and O
and JJ disease-control O
disease-control NNS subjects O

Research NNP CAPITAL Research O
Research IN in O
in NNP CAPITAL Copenhagen O
Copenhagen NNS hospitals O
hospitals : -- O
-- DT a O
a JJ bibliometric O
bibliometric NN evaluation O

More RBR CAPITAL More O
More IN on O
on NN infertility D

Dermatobia NN CAPITAL Dermatobia O
Dermatobia : -- O
-- JJ tropical D
tropical NN myiasis D

Progressive JJ CAPITAL Progressive O
Progressive JJ sensorineural O
sensorineural NN hearing D
hearing NN loss D
loss , , O
, JJ subjective O
subjective NN tinnitus D
tinnitus CC and O
and NN vertigo D
vertigo VBN caused O
caused IN by O
by JJ elevated O
elevated NN blood O
blood NNS lipids O

Chronic JJ CAPITAL Chronic O
Chronic NN telogen D
telogen NN effluvium D
effluvium : : O
: JJ potential O
potential NN complication O
complication IN for O
for JJ clinical O
clinical NNS trials O
trials IN in O
in JJ female O
female JJ androgenetic D
androgenetic NN alopecia D
alopecia . ? O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NNP CAPITAL Measles D
Measles NN vaccination T
vaccination CC and O
and JJ inflammatory O
inflammatory NN bowel O
bowel NN disease O

Treatment NN CAPITAL Treatment O
Treatment IN of O
of JJ suicidal O
suicidal NNS patients O

The DT CAPITAL The O
The JJ systemic O
systemic NNS amyloidoses T

Cancer NN CAPITAL Cancer D
Cancer NN therapy T
therapy CC and O
and NN tumor O
tumor NN physiology O

Mutual JJ CAPITAL Mutual O
Mutual NNS relationships O
relationships VBN based O
based IN on O
on NN equality O

Specialists NNS CAPITAL Specialists O
Specialists CC and O
and NNS nurses O
nurses : : O
: DT the O
the NNS pillars O
pillars IN of O
of NN hospital O
hospital NN care O

Disability NN CAPITAL Disability O
Disability NNS models O
models IN in O
in NNS geriatrics O
geriatrics : : O
: JJ comprehensive O
comprehensive RB rather O
rather IN than O
than VBG competing O
competing NNS models O
models MD should O
should VB be O
be VBN promoted O

Ethical JJ CAPITAL Ethical O
Ethical NNS issues O
issues IN in O
in JJ interventional T
interventional NN radiology T

Taking VBG CAPITAL Taking O
Taking NN issue O
issue IN with O
with NNP CAPITAL UK O
UK VBG funding O
funding NNS priorities O

Phototherapeutic JJ CAPITAL Phototherapeutic T
Phototherapeutic NN keratectomy T
keratectomy IN in O
in JJ recurrent D
recurrent NN corneal D
corneal NNS erosions D
erosions JJ refractory O
refractory TO to O
to JJ other O
other NNS forms O
forms IN of O
of NN treatment O

Wegener NNP CAPITAL Wegener D
Wegener POS 's D
's NN granulomatosis D
granulomatosis IN from O
from NN infancy O
infancy TO to O
to NN adolescence O

Hormonal JJ CAPITAL Hormonal O
Hormonal NNS responses O
responses TO to O
to NN restraint O
restraint IN in O
in NN rhesus O
rhesus NNS monkeys O

Planned NNP CAPITAL Planned O
Planned NN parenthood O
parenthood CC and O
and JJ artifical O
artifical NN selection O

Valvular JJ CAPITAL Valvular D
Valvular NN heart D
heart NN disease D
disease VBN associated O
associated IN with O
with JJ fenfluramine-phentermine T

The DT CAPITAL The O
The NN role O
role IN of O
of NNS procedures O
procedures IN in O
in NN family O
family NN practice O
practice : : O
: VBZ is O
is RB there O
there DT a O
a RB right O
right NN answer O
answer . ? O

Arthrodesis FW CAPITAL Arthrodesis T
Arthrodesis IN of T
of DT the T
the RB first T
first JJ metatarsophalangeal T
metatarsophalangeal JJ joint T
joint TO to O
to NN salvage O
salvage VBD failed D
failed NN silicone D
silicone VB implant D
implant NN arthroplasty D

Methadone NNP CAPITAL Methadone T
Methadone NN maintenance T
maintenance NN treatment T
treatment : : O
: DT a O
a JJ CAPITAL Canadian O
Canadian NN perspective O

Survey NN CAPITAL Survey O
Survey IN on O
on NN rotavirus D
rotavirus NNS infections D
infections IN in O
in DT a O
a JJ CAPITAL German O
German JJ pediatric O
pediatric NN hospital O

Stroke NN CAPITAL Stroke D
Stroke NN incidence O
incidence NNS rates O
rates IN among O
among JJ black O
black NNS residents O
residents IN of O
of NNP CAPITAL Harare O
Harare : -- O
-- DT a O
a JJ prospective O
prospective JJ community-based O
community-based NN study O

Long-term JJ CAPITAL Long-term O
Long-term NN effect O
effect IN of O
of NN calcium O
calcium NN supplementation O
supplementation IN during O
during NN pregnancy O
pregnancy IN on O
on DT the O
the NN blood O
blood NN pressure O
pressure IN of O
of NN offspring O
offspring : : O
: VB follow O
follow RB up O
up IN of O
of DT a O
a VBN randomised O
randomised JJ controlled O
controlled NN trial O

The DT CAPITAL The O
The JJ catalytic O
catalytic NN role O
role IN of O
of NN carbon O
carbon NN dioxide O
dioxide IN in O
in DT the O
the NN decomposition O
decomposition IN of O
of NN peroxynitrite O

Unethical JJ CAPITAL Unethical O
Unethical NNS trials O
trials IN of O
of NNS interventions O
interventions TO to O
to VB reduce O
reduce JJ perinatal O
perinatal NN transmission O
transmission IN of O
of DT the O
the JJ human O
human NN immunodeficiency O
immunodeficiency NN virus O
virus IN in O
in VBG developing O
developing NNS countries O

Ropinirole NNP CAPITAL Ropinirole T
Ropinirole IN for O
for DT the O
the NN treatment O
treatment IN of O
of RB early D
early NNP CAPITAL Parkinson D
Parkinson POS 's D
's NN disease D

The DT CAPITAL The O
The NNP CAPITAL Ropinirole O
Ropinirole NNP CAPITAL Study O
Study NNP CAPITAL Group O

DOTS NNS CAPITAL DOTS O
DOTS : -- O
-- VBP are O
are PRP we O
we JJ over-optimistic O
over-optimistic . ? O

Activation NN CAPITAL Activation O
Activation IN at O
at DT the O
the JJ germinal O
germinal NN vesicle O
vesicle NN stage O
stage IN of O
of NN starfish O
starfish NNS oocytes O
oocytes VBZ produces O
produces JJ parthenogenetic O
parthenogenetic NN development O
development IN through O
through DT the O
the NN failure O
failure IN of O
of JJ polar O
polar NN body O
body NN extrusion O

Female JJ CAPITAL Female O
Female JJ genital O
genital NN mutilation O
mutilation : : O
: DT a O
a JJ contemporary O
contemporary NN issue O
issue , , O
, CC and O
and DT a O
a JJ CAPITAL Victorian O
Victorian NN obsession O

Early RB CAPITAL Early O
Early NN death O
death IN amongst O
amongst NNS anaesthetists O

Fluoride NN CAPITAL Fluoride T
Fluoride NN treatment T
treatment VBN increased O
increased NN serum O
serum NN CAPITAL IGF-1 O
IGF-1 , , O
, NN bone O
bone NN turnover O
turnover , , O
, CC and O
and NN bone O
bone NN mass O
mass , , O
, CC but O
but RB not O
not NN bone O
bone NN strength O
strength , , O
, IN in O
in NNS rabbits O

Retrospective JJ CAPITAL Retrospective O
Retrospective NN comparison O
comparison IN of O
of NNS techniques O
techniques TO to O
to VB prevent O
prevent JJ secondary D
secondary NN cataract D
cataract NN formation D
formation IN after O
after JJ posterior O
posterior NN chamber O
chamber JJ intraocular O
intraocular NN lens T
lens NN implantation T
implantation IN in O
in NNS infants O
infants CC and O
and NNS children O

Serotonin NN CAPITAL Serotonin O
Serotonin IN as O
as DT a O
a NN regulator O
regulator IN of O
of JJ hypothalamic-pituitary-interrenal O
hypothalamic-pituitary-interrenal NN activity O
activity IN in O
in NN teleost O
teleost NN fish O

Predicting VBG CAPITAL Predicting O
Predicting JJ functional O
functional NN appliance O
appliance NN treatment O
treatment NN outcome O
outcome IN in O
in NNP CAPITAL Class O
Class NNP CAPITAL II O
II NNS malocclusions D
malocclusions : -- O
-- DT a O
a NN review O

Effect NN CAPITAL Effect O
Effect IN of O
of NN cereal O
cereal NN fibre O
fibre NN source O
source CC and O
and VBG processing O
processing IN on O
on JJ rectal O
rectal JJ epithelial O
epithelial NN cell O
cell NN proliferation O

Update NNP CAPITAL Update O
Update : : O
: NN influenza D
influenza NN activity O
activity : -- O
-- JJ worldwide O
worldwide , , O
, NNP CAPITAL March-August O
March-August CD 1997 O

A DT CAPITAL A O
A NN drop O
drop IN in O
in JJ pediatric O
pediatric JJ subject O
subject NN examination O
examination NNS scores O
scores IN after O
after NN curriculum O
curriculum NNS changes O
changes IN that O
that VB emphasize O
emphasize JJ general O
general JJ pediatric O
pediatric NNS topics O

Paradigms NNPS CAPITAL Paradigms O
Paradigms CC and O
and DT the O
the NN rise O
rise NN ( O
( CC or O
or NN fall O
fall . ? O
? NN ) O
) IN of O
of JJ molecular O
molecular NN biology O

Water NN CAPITAL Water O
Water NN fluoridation O
fluoridation , , O
, NN tooth D
tooth NN decay D
decay IN in O
in CD 5 O
5 NN year O
year NNS olds O
olds , , O
, CC and O
and JJ social O
social NN deprivation O
deprivation VBN measured O
measured IN by O
by DT the O
the NNP CAPITAL Jarman O
Jarman NN score O
score : : O
: NN analysis O
analysis IN of O
of NNS data O
data IN from O
from JJ CAPITAL British O
British JJ dental O
dental NNS surveys O

The DT CAPITAL The O
The NN diabetes D
diabetes NN audit O
audit CC and O
and NN research O
research IN in O
in NN CAPITAL Tayside O
Tayside NNP CAPITAL Scotland O
Scotland NN ( O
( NN CAPITAL DARTS O
DARTS NN ) O
) NN study O
study : : O
: JJ electronic O
electronic NN record O
record NN linkage O
linkage TO to O
to VB create O
create DT a O
a NN diabetes O
diabetes NN register O

DARTS/MEMO NN CAPITAL DARTS/MEMO O
DARTS/MEMO NN CAPITAL Collaboration O

Pharmaceutical NNP CAPITAL Pharmaceutical O
Pharmaceutical NN industry O
industry VBZ is O
is VBN invited O
invited TO to O
to NN respond O
respond TO to O
to NN amnesty O
amnesty IN for O
for JJ unreported O
unreported NNS trials O

Should MD CAPITAL Should O
Should PRP we O
we NN screen O
screen IN for O
for JJ gestational D
gestational NN diabetes D
diabetes . ? O

Vesico-uterine JJ CAPITAL Vesico-uterine D
Vesico-uterine NN fistula D
fistula : -- O
-- DT a O
a JJ rare O
rare NN complication O
complication IN of O
of NN vacuum T
vacuum NN extraction T
extraction IN in O
in DT a O
a NN patient O
patient IN with O
with JJ previous O
previous NN caesarean T
caesarean NN section T

Managing VBG CAPITAL Managing O
Managing NN endophthalmitis D

The DT CAPITAL The O
The NN plug O
plug CC and O
and NN patch O
patch NN repair O
repair IN for O
for VBG managing O
managing DT the O
the JJ inguinal O
inguinal NN hernia O
hernia IN of O
of DT the O
the JJ adult O

Human JJ CAPITAL Human O
Human NN herpesvirus O
herpesvirus CD 8 O
8 NNS variants O
variants IN in O
in NN sarcoid O
sarcoid NNS tissues O

Practice NN CAPITAL Practice O
Practice NNS parameters O
parameters IN for O
for DT the O
the NN assessment O
assessment CC and O
and NN treatment O
treatment IN of O
of NNS children O
children CC and O
and NNS adolescents O
adolescents IN with O
with NN schizophrenia D

American JJ CAPITAL American O
American NNP CAPITAL Academy O
Academy IN of O
of NN CAPITAL Child O
Child CC and O
and JJ CAPITAL Adolescent O
Adolescent NNP CAPITAL Psychiatry O

Practice NN CAPITAL Practice O
Practice NNS parameters O
parameters IN for O
for DT the O
the JJ psychiatric O
psychiatric NN assessment O
assessment IN of O
of NNS infants O
infants CC and O
and NNS toddlers O
toddlers NN ( O
( CD 0-36 O
0-36 NNS months O
months NN ) O

American JJ CAPITAL American O
American NNP CAPITAL Academy O
Academy IN of O
of NN CAPITAL Child O
Child CC and O
and JJ CAPITAL Adolescent O
Adolescent NNP CAPITAL Psychiatry O

Practice NN CAPITAL Practice O
Practice NNS parameters O
parameters IN for O
for DT the O
the JJ forensic O
forensic NN evaluation O
evaluation IN of O
of NNS children O
children CC and O
and NNS adolescents O
adolescents WP who O
who MD may O
may VB have O
have VBN been O
been RB physically O
physically CC or O
or RB sexually O
sexually JJ abused O

American JJ CAPITAL American O
American NNP CAPITAL Academy O
Academy IN of O
of NN CAPITAL Child O
Child CC and O
and JJ CAPITAL Adolescent O
Adolescent NNP CAPITAL Psychiatry O

Practice NN CAPITAL Practice O
Practice NNS parameters O
parameters IN for O
for DT the O
the JJ psychiatric O
psychiatric NN assessment O
assessment IN of O
of NNS children O
children CC and O
and NNS adolescents O

American JJ CAPITAL American O
American NNP CAPITAL Academy O
Academy IN of O
of NN CAPITAL Child O
Child CC and O
and JJ CAPITAL Adolescent O
Adolescent NNP CAPITAL Psychiatry O

Alternative JJ CAPITAL Alternative O
Alternative NN medicine O

Leprosy NN CAPITAL Leprosy D
Leprosy IN beyond O
beyond DT the O
the NN year O
year CD 2000 O

Effect NN CAPITAL Effect O
Effect IN of O
of JJ danaparoid T
danaparoid NN sodium T
sodium IN on O
on RB hard O
hard VBZ exudates O
exudates IN in O
in JJ diabetic D
diabetic NN retinopathy D
retinopathy . . O

Lead JJ CAPITAL Lead O
Lead VBN based O
based NN paint O
paint NNS hazards O
hazards IN in O
in RB early O
early NN childhood O
childhood NNS centres O
centres IN in O
in DT the O
the NNP CAPITAL Wellington O
Wellington NN region O

Gene NNP CAPITAL Gene O
Gene NN technology O
technology CC and O
and NN democracy O

Use NNP CAPITAL Use O
Use IN of O
of NNS statins T

Adequacy NN CAPITAL Adequacy O
Adequacy IN of O
of NN CAPITAL SMAC O
SMAC POS 's O
's NN statement O
statement MD should O
should VB be O
be VBN judged O
judged IN by O
by NNS clinicians O
clinicians , , O
, RB not O
not NN health O
health NNS economists O

Glasgow NNP CAPITAL Glasgow O
Glasgow VBZ has O
has RB already O
already VBN produced O
produced NN strategy O
strategy IN for O
for NN treatment O

Evidence NN CAPITAL Evidence O
Evidence IN on O
on NN effectiveness O
effectiveness VBZ is O
is JJR stronger O
stronger IN for O
for NNS statins T
statins IN than O
than IN for O
for JJ other O
other NNS treatments O

Evidence NN CAPITAL Evidence O
Evidence VBN based O
based NN advertising O
advertising . ? O
? NN CAPITAL Half O
Half IN of O
of NN drug O
drug NNS advertisements O
advertisements IN in O
in NNP CAPITAL BMJ O
BMJ IN over O
over CD six O
six NNS months O
months VBN cited O
cited DT no O
no VBG supporting O
supporting NN evidence O

Non-steroidal JJ CAPITAL Non-steroidal T
Non-steroidal JJ anti-inflammatory T
anti-inflammatory NN therapy T
therapy IN for O
for JJ bronchial D
bronchial NN asthma D

Drugs NNS CAPITAL Drugs O
Drugs IN for O
for DT the O
the JJ CAPITAL Third O
Third NNP CAPITAL World O

Getting VBG CAPITAL Getting O
Getting DT a O
a VB handle O
handle IN on O
on DT the O
the NNS molecules O
molecules IN that O
that NN guide O
guide NNS axons O

The DT CAPITAL The O
The JJ functional O
functional NN neuroanatomy O
neuroanatomy IN of O
of JJ episodic O
episodic NN memory O
memory NN retrieval O

Re NNP CAPITAL Re O
Re : : O
: `` `` O
`` JJ CAPITAL Biologic O
Biologic NN synergism O
synergism CC and O
and NN parallelism O
parallelism '' '' O

Shifting VBG CAPITAL Shifting O
Shifting JJ medical O
medical NN education O
education IN from O
from DT the O
the NN icebox O
icebox TO to O
to DT the O
the NN refrigerator O

Reattendance NN CAPITAL Reattendance O
Reattendance CC and O
and NNS complications O
complications IN in O
in DT a O
a VBN randomised O
randomised NN trial O
trial IN of O
of VBG prescribing O
prescribing NNS strategies O
strategies IN for O
for JJ sore O
sore NN throat O
throat : : O
: DT the O
the VBG medicalising O
medicalising NN effect O
effect IN of O
of VBG prescribing O
prescribing NNS antibiotics O

Pure JJ CAPITAL Pure D
Pure NN alexia D
alexia MD could O
could RB not O
not VB be O
be DT a O
a NN disconnection O
disconnection NN syndrome O

A DT CAPITAL A O
A VBN randomized O
randomized , , O
, JJ double-blind O
double-blind , , O
, JJ dose-response O
dose-response NN comparison O
comparison IN of O
of JJ epidural T
epidural NN fentanyl T
fentanyl CC versus O
versus NN sufentanil T
sufentanil NN analgesia T
analgesia IN after O
after NN cesarean T
cesarean NN section T

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> JJ CAPITAL Coronary O
Coronary NN artery O
artery NNS problems O
problems IN during O
during NN homograft O
homograft JJ aortic O
aortic NN valve O
valve NN replacement O
replacement : : O
: NN role O
role IN of O
of NN transesophageal O
transesophageal NN echocardiography O

Spontaneous JJ CAPITAL Spontaneous O
Spontaneous JJ splenic D
splenic NN rupture D
rupture VBG following O
following NN administration O
administration IN of O
of NN granulocyte T
granulocyte JJ colony-stimulating T
colony-stimulating NN factor T
factor NN ( T
( NN CAPITAL G-CSF T
G-CSF NN ) T
) : : O
: NN occurrence O
occurrence IN in O
in DT an O
an JJ allogeneic O
allogeneic NN donor O
donor IN of O
of JJ peripheral O
peripheral NN blood O
blood NN stem O
stem NNS cells O

Evidence-based JJ CAPITAL Evidence-based O
Evidence-based NN medicine O
medicine CC and O
and JJ general O
general NN practice O

Koch NNP CAPITAL Koch O
Koch POS 's O
's CC or O
or NN CAPITAL Crohn O
Crohn POS 's O
's . ? O

Female JJ CAPITAL Female O
Female NN CAPITAL Stress O
Stress JJ CAPITAL Urinary O
Urinary NN CAPITAL Incontinence O
Incontinence JJ CAPITAL Clinical O
Clinical NNS CAPITAL Guidelines O
Guidelines NN CAPITAL Panel O
Panel NN summary O
summary NN report O
report IN on O
on JJ surgical T
surgical NN management T
management IN of O
of JJ female D
female NN stress D
stress JJ urinary D
urinary NN incontinence D

The DT CAPITAL The O
The JJ CAPITAL American O
American JJ CAPITAL Urological O
Urological NNP CAPITAL Association O

Haemodynamic JJ CAPITAL Haemodynamic O
Haemodynamic NN performance O
performance IN of O
of DT a O
a JJ 16-mm O
16-mm NNS CAPITAL Carbomedics O
Carbomedics JJ aortic O
aortic NN prosthesis O

Case NNP CAPITAL Case O
Case NNS records O
records IN of O
of DT the O
the NNP CAPITAL Massachusetts O
Massachusetts NNP CAPITAL General O
General NNP CAPITAL Hospital O

Weekly NNP CAPITAL Weekly O
Weekly JJ clinicopathological O
clinicopathological NNS exercises O

Case NNP CAPITAL Case O
Case CD 30-1997 O

A DT CAPITAL A O
A NN preterm O
preterm JJ newborn O
newborn JJ female O
female NN triplet O
triplet IN with O
with JJ diffuse O
diffuse JJ cystic O
cystic NNS changes O
changes IN in O
in DT the O
the RB left O
left NN lung O

Cure VB CAPITAL Cure O
Cure IN of O
of NN CAPITAL Helicobacter D
Helicobacter NN pylori D
pylori NN infection D
infection VBZ improves O
improves JJ gastric O
gastric NN acid O
acid NN secretion O
secretion IN in O
in NNS patients O
patients IN with O
with NN corpus D
corpus NN gastritis D

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> VBN CAPITAL Increased O
Increased NN incidence O
incidence IN of O
of NN preeclampsia D
preeclampsia IN in O
in NNS women O
women VBG conceiving O
conceiving IN by O
by JJ intrauterine T
intrauterine NN insemination T
insemination IN with T
with NN donor T
donor CC versus T
versus NN partner T
partner NN sperm T
sperm IN for O
for NN treatment O
treatment IN of O
of JJ primary D
primary NN infertility D

Pediatric NNP CAPITAL Pediatric D
Pediatric JJ cervical D
cervical NN spine D
spine NN injury D
injury JJ sustained O
sustained IN in O
in VBZ falls O
falls IN from O
from JJ low O
low NNS heights O

Prophylaxis NNP CAPITAL Prophylaxis O
Prophylaxis IN after O
after JJ occupational O
occupational NN exposure O
exposure TO to O
to NN CAPITAL HIV O

How WRB CAPITAL How O
How JJ critical O
critical VBP are O
are JJ critical O
critical NNS values O
values . ? O

Back RB CAPITAL Back O
Back IN from O
from DT the O
the JJ dead O
dead : : O
: JJ extracorporeal T
extracorporeal VBG rewarming T
rewarming IN of O
of JJ severe D
severe JJ accidental D
accidental NN hypothermia D
hypothermia NNS victims O
victims IN in O
in NN accident O
accident CC and O
and NN emergency O

A DT CAPITAL A O
A NN classification O
classification IN of O
of JJ nucleotide-diphospho-sugar O
nucleotide-diphospho-sugar NNS glycosyltransferases O
glycosyltransferases VBN based O
based IN on O
on NN amino O
amino NN acid O
acid NN sequence O
sequence NNS similarities O

EU NNP CAPITAL EU O
EU NN directive O
directive IN on O
on JJ bovine D
bovine NN spongiform D
spongiform NN encephalopathy D
encephalopathy MD will O
will RB not O
not VB affect O
affect NNS drugs O

Management NNP CAPITAL Management O
Management IN of O
of NNS patients O
patients IN with O
with NN CAPITAL HIV/AIDS D

Who WP CAPITAL Who O
Who MD should O
should NN care O
care . ? O

Anesthesiology NNP CAPITAL Anesthesiology O

Second JJ CAPITAL Second O
Second IN of O
of CD two O
two NNS parts O

Overdrugging VBG CAPITAL Overdrugging O
Overdrugging CC and O
and NN undertreatment O
undertreatment IN in O
in JJ primary O
primary NN health O
health NN care O

Transesophageal JJ CAPITAL Transesophageal O
Transesophageal NN echocardiography O
echocardiography NN probe O
probe NN holder O

Pregnancy NN CAPITAL Pregnancy O
Pregnancy NNS outcomes O
outcomes IN in O
in NNS women O
women IN with O
with JJ gestational D
gestational NN diabetes D
diabetes VBN compared O
compared IN with O
with DT the O
the JJ general O
general JJ obstetric O
obstetric NN population O

Confidentiality NN CAPITAL Confidentiality O
Confidentiality IN as O
as DT a O
a NN barrier O
barrier TO to O
to NN treatment O

Recombinant JJ CAPITAL Recombinant O
Recombinant JJ human O
human NN CAPITAL DNase O
DNase NN ( O
( NN rhDNase O
rhDNase NN ) O
) VBZ influences O
influences JJ phospholipid O
phospholipid NN composition O
composition , , O
, NN surface O
surface NN activity O
activity , , O
, NN rheology O
rheology CC and O
and RB consecutively O
consecutively NN clearance O
clearance NNS indices O
indices IN of O
of JJ cystic D
cystic NN fibrosis D
fibrosis NN sputum O

Palliative JJ CAPITAL Palliative O
Palliative NNS options O
options IN of O
of JJ last O
last NN resort O
resort : : O
: DT a O
a NN comparison O
comparison IN of O
of RB voluntarily O
voluntarily VBG stopping O
stopping VBG eating O
eating CC and O
and NN drinking O
drinking , , O
, JJ terminal O
terminal NN sedation O
sedation , , O
, JJ physician-assisted O
physician-assisted NN suicide O
suicide , , O
, CC and O
and JJ voluntary O
voluntary JJ active O
active NN euthanasia O

Automation NN CAPITAL Automation O
Automation IN in O
in JJ cervical O
cervical NN cytology O
cytology : : O
: WP$ whose O
whose NN cost O
cost CC and O
and WP$ whose O
whose NN benefit O
benefit . ? O

Losing VBG CAPITAL Losing O
Losing NN weight O
weight : -- O
-- DT an O
an JJ ill-fated O
ill-fated NNP CAPITAL New O
New NN CAPITAL Year O
Year POS 's O
's NN resolution O

Lumbar JJ CAPITAL Lumbar D
Lumbar NN puncture D
puncture NN need O
need RB n't O
n't VB be O
be DT a O
a NN headache O

Profiting VBG CAPITAL Profiting O
Profiting IN from O
from NN closure O
closure : : O
: DT the O
the JJ private O
private NN finance O
finance NN initiative O
initiative CC and O
and DT the O
the NN CAPITAL NHS O

Incidence NN CAPITAL Incidence O
Incidence IN of O
of NN dog D
dog NN bite D
bite NNS injuries D
injuries VBN treated O
treated IN in O
in NN emergency O
emergency NNS departments O

Use NNP CAPITAL Use O
Use IN of O
of JJ rotational O
rotational NNS movements O
movements TO to O
to VB remove O
remove JJ mandibular O
mandibular NNS molars O

Comparison NN CAPITAL Comparison O
Comparison IN of O
of CD three O
three NNS methods O
methods VBN used O
used IN for O
for NN assessment O
assessment IN of O
of NN pain D
pain IN in O
in NNS dogs O

Randomised VBN CAPITAL Randomised O
Randomised JJ controlled O
controlled NN trial O
trial IN of O
of JJ magnetic-resonance T
magnetic-resonance NN pelvimetry T
pelvimetry IN in O
in NN breech D
breech NN presentation D
presentation IN at D
at NN term D

Single-breath JJ CAPITAL Single-breath O
Single-breath VBG diffusing O
diffusing NNS capacities O
capacities IN for O
for NN CAPITAL NO O
NO , , O
, NNP CAPITAL CO O
CO CC and O
and NN CAPITAL C18O2 O
C18O2 IN in O
in NNS rabbits O

Improved VBN CAPITAL Improved O
Improved NN control O
control MD will O
will VB provide O
provide JJR better O
better NN quality O

Interview NN CAPITAL Interview O
Interview IN by O
by NNP CAPITAL Tom O
Tom NNP CAPITAL Heinemann O

Case NNP CAPITAL Case O
Case IN of O
of DT the O
the NN month O

Autopsy NN CAPITAL Autopsy O
Autopsy NNP CAPITAL Committee O
Committee IN of O
of DT the O
the NNP CAPITAL College O
College IN of O
of JJ CAPITAL American O
American NNPS CAPITAL Pathologists O

Cor NNP CAPITAL Cor O
Cor JJ pulmonale O

Human JJ CAPITAL Human O
Human NN papillomavirus O
papillomavirus IN in O
in DT the O
the NN woman O
woman IN with O
with NN CAPITAL HIV O

Reducing VBG CAPITAL Reducing O
Reducing NN risk O
risk VBZ is O
is RB best O
best NN strategy O

The DT CAPITAL The O
The NN realpolitik O
realpolitik IN of O
of DT a O
a JJ new O
new NNP CAPITAL National O
National NNP CAPITAL Health O
Health NNP CAPITAL Service O
Service IN for O
for DT the O
the NNP CAPITAL UK O

What WDT CAPITAL What O
What VBZ is O
is PRP$ your O
your NN diagnosis O
diagnosis . ? O
? JJ CAPITAL Foreign O
Foreign NN body O
body IN in O
in DT the O
the NN abdomen O

Septic JJ CAPITAL Septic D
Septic NN arthritis D

Brain NN CAPITAL Brain D
Brain NNS tumours D
tumours CC and O
and JJ mobile O
mobile NNS phones O
phones . ? O

Lung NN CAPITAL Lung D
Lung NN cancer D
cancer , , O
, NN tobacco O
tobacco NN smoking O
smoking CC and O
and JJ environmental O
environmental NNS factors O
factors IN in O
in NNP CAPITAL Denmark O

Emergency NN CAPITAL Emergency O
Emergency NN department O
department NN use O
use IN as O
as DT a O
a NN component O
component IN of O
of JJ total O
total JJ ambulatory O
ambulatory NN care O
care : : O
: DT a O
a NN population O
population NN perspective O

Occupational JJ CAPITAL Occupational T
Occupational NN therapy T
therapy CC and O
and NNS outcomes O
outcomes IN for O
for JJR older O
older NNS adults O

Anesthesiology NNP CAPITAL Anesthesiology O

Low-molecular-weight JJ CAPITAL Low-molecular-weight O
Low-molecular-weight NNS heparins O

Case NNP CAPITAL Case O
Case CD 30-1997 O
30-1997 : : O
: JJ pulmonary D
pulmonary JJ interstitial D
interstitial NN emphysema D
emphysema IN in O
in NN infancy O

The DT CAPITAL The O
The NN tobacco O
tobacco NN settlement O

Two CD CAPITAL Two O
Two NNS actions O
actions VBP are O
are JJ possible O
possible IN for O
for NNS doctors O
doctors VBG wanting O
wanting TO to O
to VB promote O
promote JJ human O
human NN welfare O
welfare IN in O
in NNP CAPITAL Africa O

Carcinogenesis NN CAPITAL Carcinogenesis O
Carcinogenesis IN in O
in JJ transgenic O
transgenic NN mouse O
mouse NNS models O

Trouble NN CAPITAL Trouble O
Trouble IN in O
in NN paradise O

Atomic JJ CAPITAL Atomic O
Atomic NN legacy O
legacy IN in O
in DT the O
the NNP CAPITAL Marshall O
Marshall NNP CAPITAL Islands O

The DT CAPITAL The O
The NN road O
road TO to O
to NN justice O

Solvent JJ CAPITAL Solvent O
Solvent NN solution O

Role NN CAPITAL Role O
Role IN of O
of JJ free O
free NNS radicals O
radicals , , O
, NNS telomeres O
telomeres , , O
, CC and O
and NNS telomerases O
telomerases IN in O
in VBG aging O
aging CC and O
and NN cancerogenesis O

The DT CAPITAL The O
The NN effect O
effect IN of O
of NN ephedrine O
ephedrine IN on O
on DT the O
the NN onset O
onset NN time O
time IN of O
of NN rocuronium O

Antibody NN CAPITAL Antibody O
Antibody NN class O
class NN switch O
switch NN recombinase O
recombinase NN activity O
activity VBZ is O
is NN CAPITAL B O
B NN cell O
cell NN stage O
stage JJ specific O
specific CC and O
and NNS functions O
functions RB stochastically O
stochastically IN in O
in DT the O
the NN absence O
absence IN of O
of VBN 'targeted O
'targeted NN accessibility O
accessibility POS ' O
' NN control O

Systematic JJ CAPITAL Systematic O
Systematic NN review O
review IN of O
of NN prophylactic O
prophylactic CC vs O
vs NN rescue O
rescue JJ surfactant O

The DT CAPITAL The O
The NN safety-net O
safety-net NN role O
role IN of O
of JJ international O
international JJ medical O
medical NNS graduates O

The DT CAPITAL The O
The NN prevalence O
prevalence IN of O
of NN chemical O
chemical NN substance O
substance CC and O
and NN alcohol O
alcohol NN abuse O
abuse IN in O
in DT an O
an JJ obstetric O
obstetric NN population O
population IN in O
in NNP CAPITAL Dublin O

schizophrenia NN schizophrenia D
schizophrenia IN as O
as NN failure O
failure IN of O
of JJ hemispheric O
hemispheric NN dominance O
dominance IN for O
for NN language O

Late RB CAPITAL Late O
Late JJ prenatal O
prenatal NN ultrasound O
ultrasound NNS features O
features IN of O
of NNS hydrometrocolpos O
hydrometrocolpos JJ secondary O
secondary TO to O
to JJ cloacal D
cloacal NN anomaly D
anomaly : : O
: NN case O
case NNS reports O
reports CC and O
and NN review O
review IN of O
of DT the O
the NN literature O

Familial JJ CAPITAL Familial O
Familial CC and O
and JJ primary O
primary NN ( O
( NNP CAPITAL AL O
AL NN ) O
) JJ cardiac D
cardiac NN amyloidosis D
amyloidosis : : O
: RB echocardiographically O
echocardiographically JJ similar O
similar NNS diseases O
diseases IN with O
with RB distinctly O
distinctly JJ different O
different JJ clinical O
clinical NNS outcomes O

Diabetic NNP CAPITAL Diabetic O
Diabetic NN retinopathy O
retinopathy , , O
, NN promoter O
promoter NN ( O
( NN 4G/5G O
4G/5G NN ) O
) NN polymorphism O
polymorphism IN of O
of NN CAPITAL PAI-1 O
PAI-1 NN gene O
gene , , O
, CC and O
and NN CAPITAL PAI-1 O
PAI-1 NN activity O
activity IN in O
in NNP CAPITAL Pima O
Pima NNPS CAPITAL Indians O
Indians IN with O
with NN type O
type CD 2 O
2 NN diabetes D

Evaluation NN CAPITAL Evaluation O
Evaluation IN of O
of JJ diagnostic O
diagnostic JJ peritoneal O
peritoneal NN lavage O
lavage IN in O
in JJ stable O
stable NNS patients O
patients IN with O
with NN gunshot D
gunshot NNS wounds D
wounds TO to O
to DT the O
the NN abdomen O

Cerebral JJ CAPITAL Cerebral D
Cerebral NNS abscesses D
abscesses IN in O
in DT a O
a NN patient O
patient IN with O
with NN CAPITAL AIDS D
AIDS VBN caused O
caused IN by O
by JJ methicillin-resistant O
methicillin-resistant FW CAPITAL Staphylococcus O
Staphylococcus NN aureus O
aureus NN ( O
( NNP CAPITAL MRSA O
MRSA NN ) O

A DT CAPITAL A O
A VBN randomised O
randomised NN comparison O
comparison IN of O
of DT the O
the NN CAPITAL EuroQol O
EuroQol CC and O
and JJ CAPITAL Short O
Short NN CAPITAL Form-36 O
Form-36 IN after O
after NN stroke D

United NNP CAPITAL United O
United NNP CAPITAL Kingdom O
Kingdom NNS collaborators O
collaborators IN in O
in DT the O
the NNP CAPITAL International O
International NN CAPITAL Stroke O
Stroke NN CAPITAL Trial O

Clinical JJ CAPITAL Clinical O
Clinical NN significance O
significance IN of O
of NN CAPITAL Blastocystis D
Blastocystis NN hominis D
hominis NN infection D
infection : : O
: JJ epidemiologic O
epidemiologic NN study O

Karolinska FW CAPITAL Karolinska O
Karolinska NNP CAPITAL Institute O
Institute VBD rocked O
rocked IN by O
by NN research O
research NN misconduct O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> JJ CAPITAL Hepatic O
Hepatic NN glutamine O
glutamine NN synthetase O
synthetase NN deficiency O
deficiency IN in O
in JJ fatal O
fatal NN hyperammonemia O
hyperammonemia IN after O
after NN lung O
lung NN transplantation O

Where WRB CAPITAL Where O
Where JJ next O
next IN in O
in DT the O
the NN treatment O
treatment IN of O
of JJ rectal D
rectal NN cancer D
cancer . ? O

GAPS NNS CAPITAL GAPS O
GAPS NN ( O
( NNP CAPITAL AMA O
AMA NNS CAPITAL Guidelines O
Guidelines IN for O
for JJ CAPITAL Adolescent O
Adolescent JJ CAPITAL Preventive O
Preventive NNP CAPITAL Services O
Services NN ) O

Protocols NNS CAPITAL Protocols O
Protocols IN for O
for NN wound O
wound NN management O

Chronic JJ CAPITAL Chronic O
Chronic NN leg D
leg NNS ulcers D
ulcers : : O
: NN beware O
beware DT the O
the NN 'wolf O
'wolf IN in O
in NN sheep O
sheep POS 's O
's NN clothing O
clothing . ! O
! POS ' O
' . . O

Role NN CAPITAL Role O
Role IN of O
of JJ fine T
fine NN needle T
needle NN aspiration T
aspiration NN cytology T
cytology IN in O
in DT the O
the NN management O
management IN of O
of DT the O
the JJ discrete D
discrete NN parotid D
parotid NN lump D

More RBR CAPITAL More O
More IN than O
than CD 20 O
20 NNS years O
years JJ second-look O
second-look NN surgery T
surgery IN in O
in JJ advanced D
advanced JJ epithelial D
epithelial JJ ovarian D
ovarian NN cancer D
cancer : : O
: WDT what O
what VBD did O
did PRP we O
we VB learn O
learn . ? O

Evaluating VBG CAPITAL Evaluating O
Evaluating NN prostate T
prostate NN needle T
needle NN biopsy T
biopsy : : O
: JJ therapeutic O
therapeutic CC and O
and JJ prognostic O
prognostic NN importance O

Sudden JJ CAPITAL Sudden O
Sudden JJ cryptococcal D
cryptococcal NN deafness D

Methicillin-resistant JJ CAPITAL Methicillin-resistant O
Methicillin-resistant FW CAPITAL Staphylococcus O
Staphylococcus NN aureus O
aureus JJ clinical O
clinical NN strain O
strain IN with O
with VBN reduced O
reduced NN vancomycin T
vancomycin NN susceptibility O

HIV NN CAPITAL HIV O
HIV CC and O
and NN CAPITAL AIDS D
AIDS NN awareness O
awareness : : O
: DT an O
an NN evaluation O
evaluation IN of O
of DT a O
a JJ short O
short NN training O
training NN programme O
programme IN for O
for NNS midwives O

What WDT CAPITAL What O
What NNS investigations O
investigations CC and O
and NNS procedures O
procedures VB do O
do NNS patients O
patients IN in O
in NNS hospices O
hospices VB want O
want . ? O
? NN CAPITAL Interview O
Interview VBN based O
based NN survey O
survey IN of O
of NNS patients O
patients CC and O
and PRP$ their O
their NNS nurses O

Occupational JJ CAPITAL Occupational O
Occupational NN asthma D
asthma JJ due O
due TO to O
to NN porcine O
porcine JJ pancreatic O
pancreatic NN amylase O

Double-blind JJ CAPITAL Double-blind O
Double-blind NN study O
study IN of O
of VBG pulsing T
pulsing JJ magnetic T
magnetic NN field T
field NNS effects O
effects IN on O
on JJ multiple D
multiple NN sclerosis D
sclerosis . . O

CDA NNP CAPITAL CDA O
CDA VBZ opposes O
opposes VBN proposed O
proposed NN CAPITAL HBV O
HBV NNS recommendations O

The DT CAPITAL The O
The NN influence O
influence IN of O
of NN allergy D
allergy CC and O
and NN smoking O
smoking IN on O
on DT the O
the NN sulphation O
sulphation IN of O
of JJ nasal O
nasal NNS mucins O

Clinical JJ CAPITAL Clinical O
Clinical JJ problem-solving O

A DT CAPITAL A O
A JJ hidden O
hidden NN agenda O

A DT CAPITAL A O
A NN comparison O
comparison IN of O
of DT the O
the RB early O
early NN outcome O
outcome IN of O
of JJ acute O
acute JJ myocardial D
myocardial NN infarction D
infarction IN in O
in NNS women O
women CC and O
and NNS men O

The DT CAPITAL The O
The JJ CAPITAL Third O
Third NNP CAPITAL International O
International NNP CAPITAL Study O
Study IN of O
of JJ CAPITAL Infarct O
Infarct NN CAPITAL Survival O
Survival JJ CAPITAL Collaborative O
Collaborative NNP CAPITAL Group O

Management NNP CAPITAL Management O
Management IN of O
of JJ life-threatening O
life-threatening NN acid-base D
acid-base NNS disorders D

Second JJ CAPITAL Second O
Second IN of O
of CD two O
two NNS parts O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> JJ CAPITAL Freeze-dried O
Freeze-dried JJ cortical O
cortical NN allograft O
allograft IN in O
in JJ posterior O
posterior JJ spinal O
spinal NN arthrodesis O
arthrodesis : : O
: NN use O
use IN with O
with JJ segmental O
segmental NN instrumentation O
instrumentation IN for O
for JJ idiopathic O
idiopathic JJ adolescent O
adolescent NN scoliosis O

Removal NN CAPITAL Removal O
Removal IN of O
of DT a O
a JJ broken O
broken NN solid-core O
solid-core JJ intramedullary O
intramedullary JJ femoral O
femoral NN nail O
nail VBG using O
using DT both O
both NN antegrade O
antegrade CC and O
and JJ retrograde O
retrograde VBG starting O
starting NNS points O

Do VB CAPITAL Do O
Do DT no O
no NN harm O

Thalidomide NNP CAPITAL Thalidomide T
Thalidomide , , O
, NN laser O
laser NN cavity O
cavity NN preparation O
preparation CC and O
and JJ oral O
oral NN hydrogen O
hydrogen NN peroxide O

Emergency NN CAPITAL Emergency O
Emergency . ! O
! JJ CAPITAL Meningococcal D
Meningococcal NN disease D

First NNP CAPITAL First O
First DT the O
the JJ bad O
bad NN news O
news : ... O

Does VBZ CAPITAL Does O
Does NN hyperglycemia D
hyperglycemia RB really O
really NN cause O
cause JJ coronary D
coronary NN heart D
heart NN disease D
disease . ? O

Diagnosis NN CAPITAL Diagnosis O
Diagnosis CC and O
and NN therapy O
therapy IN of O
of JJ primary O
primary NN stomach D
stomach NN lymphoma D

Consensus NN CAPITAL Consensus O
Consensus IN of O
of DT the O
the NNP CAPITAL Surgical O
Surgical VBG CAPITAL Working O
Working NNP CAPITAL Group O
Group IN for O
for NNP CAPITAL Oncology O
Oncology , , O
, DT the O
the VBG CAPITAL Working O
Working NNP CAPITAL Group O
Group IN for O
for JJ CAPITAL Medical O
Medical NNP CAPITAL Oncology O
Oncology CC and O
and DT the O
the VBG CAPITAL Working O
Working NNP CAPITAL Group O
Group IN for O
for JJ CAPITAL Radiologic O
Radiologic NNP CAPITAL Oncology O

Rate NN CAPITAL Rate O
Rate IN of O
of NN CAPITAL RhD O
RhD NN sensitisation O
sensitisation IN before O
before CC and O
and IN after O
after NN implementation O
implementation IN of O
of DT a O
a NN community O
community VBN based O
based JJ antenatal O
antenatal NN prophylaxis O
prophylaxis NN programme O

Ovine JJ CAPITAL Ovine D
Ovine NN CAPITAL Johne D
Johne POS 's D
's NN disease D

Effect NN CAPITAL Effect O
Effect IN of O
of JJ CAPITAL HAART O
HAART IN on O
on JJ natural O
natural NN history O
history IN of O
of JJ CAPITAL AIDS-related D
AIDS-related JJ opportunistic D
opportunistic NNS disorders D

Psoas NN CAPITAL Psoas D
Psoas NN abscess D

Diagnosed VBN CAPITAL Diagnosed O
Diagnosed IN if O
if VBN suspected O

Breastfeeding VBG CAPITAL Breastfeeding O
Breastfeeding CC and O
and NN catch-up O
catch-up NN growth O
growth IN in O
in NNS infants O
infants VBN born O
born JJ small O
small IN for O
for JJ gestational O
gestational NN age O

Health NNP CAPITAL Health O
Health NNS practices O
practices IN of O
of JJ critical O
critical NN care O
care NNS nurses O
nurses : : O
: VBP are O
are DT these O
these NNS nurses O
nurses JJ good O
good NN role O
role NNS models O
models IN for O
for NNS patients O
patients . ? O

Testing VBG CAPITAL Testing O
Testing IN for O
for NN CAPITAL Helicobacter D
Helicobacter NN pylori D
pylori NN infection D
infection IN after O
after JJ antibiotic T
antibiotic NN treatment T
treatment . . O

Bullous JJ CAPITAL Bullous O
Bullous NN eruption O
eruption IN in O
in DT a O
a NN patient O
patient IN with O
with JJ systemic D
systemic NN lupus D
lupus NN erythematosus D
erythematosus : : O
: JJ mite D
mite NN dermatitis D
dermatitis VBN caused O
caused IN by O
by NN CAPITAL Cheyletiella O
Cheyletiella FW blakei O

A DT CAPITAL A O
A JJ case-control O
case-control NN study O
study IN of O
of NN cytochrome O
cytochrome NN CAPITAL P450 O
P450 NN 1A1 O
1A1 , , O
, NN glutathione O
glutathione NN CAPITAL S-transferase O
S-transferase NN CAPITAL M1 O
M1 , , O
, NN cigarette O
cigarette NN smoking O
smoking CC and O
and NN lung O
lung NN cancer O
cancer NN susceptibility O
susceptibility NN ( O
( NNP CAPITAL Massachusetts O
Massachusetts , , O
, NNP CAPITAL United O
United NNPS CAPITAL States O
States NN ) O

Association NNP CAPITAL Association O
Association IN between O
between JJ thrombolytic T
thrombolytic NN treatment T
treatment CC and O
and DT the O
the NN prognosis O
prognosis IN of O
of RB hemodynamically O
hemodynamically JJ stable O
stable NNS patients O
patients IN with O
with JJ major D
major JJ pulmonary D
pulmonary NN embolism D
embolism : : O
: NNS results O
results IN of O
of DT a O
a JJ multicenter O
multicenter NN registry O
registry . . O

Metastatic JJ CAPITAL Metastatic D
Metastatic JJ malignant D
malignant NN mesothelioma D
mesothelioma VBG presenting O
presenting IN as O
as JJ colonic O
colonic NNS polyps O

Microelectrode-guided JJ CAPITAL Microelectrode-guided T
Microelectrode-guided JJ posteroventral T
posteroventral NN pallidotomy T
pallidotomy IN for O
for NN treatment O
treatment IN of O
of NNP CAPITAL Parkinson D
Parkinson POS 's D
's NN disease D
disease : : O
: JJ postoperative O
postoperative JJ magnetic O
magnetic NN resonance O
resonance NN imaging O
imaging NN analysis O

A DT CAPITAL A O
A JJ positive O
positive NNS cannabinoids O
cannabinoids NN workplace O
workplace NN drug O
drug NN test O
test VBG following O
following DT the O
the NN ingestion O
ingestion IN of O
of RB commercially O
commercially JJ available O
available NN hemp O
hemp NN seed O
seed NN oil O

Congenital JJ CAPITAL Congenital D
Congenital NN diaphragmatic D
diaphragmatic NN hernia D
hernia : : O
: WDT what O
what VBZ happens O
happens IN after O
after NN discharge O
discharge . ? O

Goldilocks NNP CAPITAL Goldilocks O
Goldilocks CC and O
and NNP CAPITAL Mrs O

Ilych NN CAPITAL Ilych O
Ilych : : O
: DT a O
a JJ critical O
critical NN look O
look IN at O
at DT the O
the `` `` O
`` NN philosophy O
philosophy IN of O
of NN hospice O
hospice '' '' O

Sensitivity NN CAPITAL Sensitivity O
Sensitivity CC and O
and NN specificity O
specificity IN of O
of DT the O
the JJ neonatal O
neonatal NN brain-stem O
brain-stem JJ auditory O
auditory VBN evoked O
evoked JJ potential O
potential IN for O
for VBG hearing O
hearing CC and O
and NN language O
language NNS deficits O
deficits IN in O
in NNS survivors O
survivors IN of O
of JJ extracorporeal O
extracorporeal NN membrane O
membrane NN oxygenation O

The DT CAPITAL The O
The NNP CAPITAL Federated O
Federated NNP CAPITAL Council O
Council IN of O
of JJ CAPITAL Internal O
Internal NNP CAPITAL Medicine O
Medicine POS 's O
's NN resource O
resource NN guide O
guide IN for O
for NN residency O
residency NN education O
education : : O
: DT an O
an NN instrument O
instrument IN for O
for JJ curricular O
curricular NN change O

A DT CAPITAL A O
A JJ reluctant O
reluctant NN doctor O
doctor NN shopper O

Frequent JJ CAPITAL Frequent O
Frequent NNS users O
users IN of O
of NN emergency O
emergency NNS services O

Localized JJ CAPITAL Localized O
Localized NN CAPITAL Darier D
Darier NN disease D

Implications NNS CAPITAL Implications O
Implications IN for O
for JJ genetic O
genetic NNS studies O

Follow VB CAPITAL Follow O
Follow RB up O
up IN after O
after JJ potential O
potential JJ curative O
curative NN surgery T
surgery IN of O
of JJ colorectal D
colorectal NN cancer D

Guidelines NNS CAPITAL Guidelines O
Guidelines IN from O
from DT the O
the JJ CAPITAL Norwegian O
Norwegian JJ CAPITAL Gastrointestinal O
Gastrointestinal NN CAPITAL Cancer O
Cancer NNP CAPITAL Group O

The DT CAPITAL The O
The NN prison O
prison NN patient O

Fulminant JJ CAPITAL Fulminant O
Fulminant JJ hepatic D
hepatic NN failure D
failure IN in O
in JJ murine D
murine NN hepatitis D
hepatitis NN virus D
virus NN strain D
strain LS 3 D
3 NN infection D
infection : : O
: JJ tissue-specific O
tissue-specific NN expression O
expression IN of O
of DT a O
a JJ novel O
novel NN fgl2 O
fgl2 NN prothrombinase O

Lung NN CAPITAL Lung T
Lung NN volume T
volume NN reduction T
reduction NN surgery T
surgery IN for O
for NN emphysema D

The DT CAPITAL The O
The NN use O
use CC and O
and NNS effects O
effects IN of O
of JJ postcoital O
postcoital NN contraception O

Vancomycin-resistant JJ CAPITAL Vancomycin-resistant O
Vancomycin-resistant FW CAPITAL Staphylococcus O
Staphylococcus NN aureus O
aureus : : O
: NN apocalypse O
apocalypse RB now O
now . ? O

Reflex NN CAPITAL Reflex D
Reflex JJ sympathetic D
sympathetic NN dystrophy D
dystrophy : : O
: NN fact O
fact CC and O
and NN fiction O

Acute JJ CAPITAL Acute D
Acute NN hydrocephalus D
hydrocephalus CC and O
and NN brain D
brain NN abscess D
abscess IN in O
in NN CAPITAL Listeria D
Listeria NNS monocytogenes D
monocytogenes NN meningitis D

Antisense JJ CAPITAL Antisense O
Antisense NN suppression O
suppression IN of O
of JJ 4-coumarate O
4-coumarate : : O
: NN coenzyme O
coenzyme DT CAPITAL A O
A NN ligase O
ligase NN activity O
activity IN in O
in NNP CAPITAL Arabidopsis O
Arabidopsis VBZ leads O
leads TO to O
to JJ altered O
altered NN lignin O
lignin NN subunit O
subunit NN composition O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NNP CAPITAL Alopecia O
Alopecia IN as O
as DT a O
a NN consequence O
consequence IN of O
of NN tacrolimus O
tacrolimus NN therapy O
therapy IN in O
in JJ renal O
renal NN transplantation O
transplantation . ? O

Implementation NN CAPITAL Implementation O
Implementation IN of O
of JJ pharmaceutical O
pharmaceutical NN practice O
practice NNS guidelines O

In IN CAPITAL In O
In FW vitro O
vitro NNS interactions O
interactions IN of O
of RB oxidatively O
oxidatively VBN modified O
modified NN CAPITAL LDL O
LDL IN with O
with NN type O
type PRP CAPITAL I O
I , , O
, NNP CAPITAL II O
II , , O
, NNP CAPITAL III O
III , , O
, CD CAPITAL IV O
IV , , O
, CC and O
and NN CAPITAL V O
V NN collagen O
collagen , , O
, NN laminin O
laminin , , O
, NN fibronectin O
fibronectin , , O
, CC and O
and JJ poly-D-lysine O

Factors NNS CAPITAL Factors O
Factors VBG influencing O
influencing NN blood O
blood NN flow O
flow IN in O
in DT the O
the JJ optic O
optic NN nerve O
nerve NN head O

Mutations NNS CAPITAL Mutations O
Mutations IN of O
of DT the O
the FW CAPITAL Drosophila O
Drosophila NN dDP O
dDP , , O
, NN dE2F O
dE2F , , O
, CC and O
and NN cyclin O
cyclin NN CAPITAL E O
E NNS genes O
genes VB reveal O
reveal JJ distinct O
distinct NNS roles O
roles IN for O
for DT the O
the NN CAPITAL E2F-DP O
E2F-DP NN transcription O
transcription NN factor O
factor CC and O
and NN cyclin O
cyclin NN CAPITAL E O
E IN during O
during DT the O
the NN CAPITAL G1-S O
G1-S NN transition O

SYT-SSX NN CAPITAL SYT-SSX O
SYT-SSX NN gene O
gene NN fusion O
fusion IN as O
as DT a O
a NN determinant O
determinant IN of O
of NN morphology O
morphology CC and O
and NN prognosis O
prognosis IN in O
in JJ synovial O
synovial NN sarcoma O

A DT CAPITAL A O
A JJ rapid O
rapid JJ molecular O
molecular NN method O
method NN ( O
( NN polymerase O
polymerase NN chain O
chain NN reaction O
reaction IN with O
with JJ sequence-specific O
sequence-specific NNS primers O
primers NN ) O
) TO to O
to NN genotype O
genotype IN for O
for NN CAPITAL ABO O
ABO NN blood O
blood NN group O
group CC and O
and NN secretor O
secretor NN status O
status CC and O
and PRP$ its O
its JJ potential O
potential IN for O
for NN organ T
organ NNS transplants T

A DT CAPITAL A O
A JJ population-based O
population-based NN registry O
registry IN on O
on NN paraproteinaemia D
paraproteinaemia IN in O
in DT CAPITAL The O
The NNP CAPITAL Netherlands O

Comprehensive NNP CAPITAL Comprehensive O
Comprehensive NN CAPITAL Cancer O
Cancer NNP CAPITAL Centre O
Centre NNP CAPITAL West O
West , , O
, JJ CAPITAL Leiden O
Leiden , , O
, DT CAPITAL The O
The NNP CAPITAL Netherlands O

Intra- JJ CAPITAL Intra- O
Intra- CC and O
and JJ inter-individual O
inter-individual JJ biological O
biological NN variability O
variability NNS data O
data NN bank O

Genetic JJ CAPITAL Genetic O
Genetic NN testing O
testing IN for O
for NN cancer D
cancer NN risk O
risk : : O
: WRB how O
how TO to O
to VB reconcile O
reconcile DT the O
the NNS conflicts O

Run-in NN CAPITAL Run-in O
Run-in NNS periods O
periods IN in O
in VBN randomized O
randomized NNS trials O
trials : : O
: NNS implications O
implications IN for O
for DT the O
the NN application O
application IN of O
of NNS results O
results IN in O
in JJ clinical O
clinical NN practice O

Rapid JJ CAPITAL Rapid O
Rapid CC and O
and NN ultrarapid O
ultrarapid JJ opioid T
opioid NN detoxification T
detoxification NNS techniques O

Fulminant JJ CAPITAL Fulminant O
Fulminant NN hepatitis T
hepatitis VBN associated O
associated IN with O
with NN hepatitis T
hepatitis DT CAPITAL A T
A NN virus T
virus NN superinfection T
superinfection IN in O
in NNS patients O
patients IN with O
with JJ chronic O
chronic NN hepatitis T
hepatitis NN CAPITAL C T

The DT CAPITAL The O
The JJ CAPITAL Overactive T
Overactive NN CAPITAL Bladder T
Bladder : : O
: IN CAPITAL From O
From JJ CAPITAL Basic O
Basic NNP CAPITAL Science O
Science TO to O
to JJ CAPITAL Clinical O
Clinical NNP CAPITAL Management O
Management NN CAPITAL Consensus O
Consensus NN CAPITAL Conference O

Proceedings NNP CAPITAL Proceedings O

London NNP CAPITAL London O
London , , O
, NNP CAPITAL England O
England , , O
, NNP CAPITAL June O
June CD 29 O
29 , , O
, CD 1997 O

Techniques NNS CAPITAL Techniques O
Techniques IN for O
for NN erbium T
erbium : : T
: NN CAPITAL YAG T
YAG NN laser T
laser NN skin T
skin VBG resurfacing T
resurfacing : : O
: JJ initial O
initial NNS pearls O
pearls IN from O
from DT the O
the RB first O
first CD 100 O
100 NNS patients O

Predicting VBG CAPITAL Predicting O
Predicting NNS changes O
changes IN in O
in DT the O
the NN distribution O
distribution IN of O
of NN sweating D
sweating VBG following O
following JJ thoracoscopic T
thoracoscopic NN sympathectomy T
sympathectomy . . O

The DT CAPITAL The O
The NN CAPITAL AACC O
AACC NN CAPITAL Lectureship O
Lectureship NN CAPITAL Award O
Award NN CAPITAL Address O

The DT CAPITAL The O
The NN market O
market IN for O
for NN health O
health NN care O
care : : O
: WRB where O
where VBZ is O
is DT the O
the NN patient O
patient . ? O

Human JJ CAPITAL Human O
Human JJ fetal O
fetal JJ pituitary O
pituitary VBZ expresses O
expresses JJ functional O
functional NN growth O
growth NN hormone-releasing O
hormone-releasing NN peptide O
peptide NNS receptors O

The DT CAPITAL The O
The NNP CAPITAL Bizarro O
Bizarro NN world O
world IN of O
of NN osteodistraction T

A DT CAPITAL A O
A NN piece O
piece IN of O
of PRP$ my O
my NN mind O

Leaders NNS CAPITAL Leaders O
Leaders CC or O
or NNS lemmings O
lemmings . ? O

Sales NNS CAPITAL Sales O
Sales IN of O
of NN food O
food NN aid O
aid IN as O
as NN sign O
sign IN of O
of NN distress O
distress , , O
, RB not O
not JJ excess O

Gastrointestinal JJ CAPITAL Gastrointestinal O
Gastrointestinal NN absorption O
absorption IN of O
of NNS metals O

Embryonic JJ CAPITAL Embryonic O
Embryonic NN stem O
stem NNS cells O
cells CC and O
and JJ hematopoietic O
hematopoietic NN stem O
stem NN cell O
cell NN biology O

Shark NN CAPITAL Shark T
Shark NN cartilage T
cartilage IN for O
for NN cancer D
cancer . ? O

The DT CAPITAL The O
The NN role O
role IN of O
of DT the O
the NN school O
school IN in O
in DT the O
the NN management O
management IN of O
of NN attention D
attention NN deficit D
deficit NN hyperactivity D
hyperactivity NN disorder D

Photorepair NN CAPITAL Photorepair O
Photorepair NNS mutants O
mutants IN of O
of NNP CAPITAL Arabidopsis O

Toxic JJ CAPITAL Toxic D
Toxic NN shock D
shock NN syndrome D
syndrome IN without O
without NN rash D
rash IN in O
in DT a O
a JJ young O
young NN child O
child : : O
: NN link O
link IN with O
with NN syndrome O
syndrome IN of O
of JJ hemorrhagic D
hemorrhagic NN shock D
shock CC and O
and NN encephalopathy D
encephalopathy . ? O

Mediastinal JJ CAPITAL Mediastinal O
Mediastinal VBG growing O
growing NN teratoma D
teratoma NN syndrome D

Structure NN CAPITAL Structure O
Structure CC and O
and NN expression O
expression IN of O
of DT the O
the NN chicken O
chicken NN calmodulin O
calmodulin PRP CAPITAL I O
I NN gene O

Fibromyalgia NN CAPITAL Fibromyalgia D
Fibromyalgia : -- O
-- IN out O
out IN of O
of NN control O
control . ? O

Fibromyalgia NN CAPITAL Fibromyalgia D
Fibromyalgia : : O
: NNP CAPITAL La O
La NNP CAPITAL Maladie O
Maladie NN est O
est NNP CAPITAL Morte O

Vive JJ CAPITAL Vive O
Vive DT le O
le VB CAPITAL Malade O
Malade . ! O

Electron NN CAPITAL Electron O
Electron NN beam O
beam VBN computed O
computed JJ tomographic O
tomographic JJ coronary O
coronary NN calcium O
calcium IN as O
as DT a O
a NN predictor O
predictor IN of O
of JJ coronary O
coronary NNS events O
events : : O
: NN comparison O
comparison IN of O
of CD two O
two NNS protocols O

The DT CAPITAL The O
The NNS ethics O
ethics IN of O
of JJ genetic O
genetic NN research O
research IN on O
on JJ sexual O
sexual NN orientation O

Testicular JJ CAPITAL Testicular T
Testicular NN sperm T
sperm NN retrieval T
retrieval IN by T
by JJ percutaneous T
percutaneous JJ fine T
fine NN needle T
needle NN sperm T
sperm NN aspiration T
aspiration VBN compared O
compared IN with O
with JJ testicular T
testicular NN sperm T
sperm NN extraction T
extraction IN by T
by JJ open T
open NN biopsy T
biopsy IN in O
in NNS men O
men IN with O
with JJ non-obstructive D
non-obstructive NN azoospermia D

Cyclin NN CAPITAL Cyclin O
Cyclin NN CAPITAL D1 O
D1 NN overexpression O
overexpression IN in O
in JJ malignant D
malignant NNS lymphomas D

Patient NN CAPITAL Patient O
Patient NN safety O
safety CC and O
and JJ scented O
scented JJ pediatric O
pediatric NN anesthesia O
anesthesia NNS facemasks O

Ion NN CAPITAL Ion O
Ion NNS channels O

SHARPs NNS CAPITAL SHARPs O
SHARPs : : O
: JJ mammalian O
mammalian JJ enhancer-of-split- O
enhancer-of-split- CC and O
and JJ hairy-related O
hairy-related NNS proteins O
proteins VBN coupled O
coupled TO to O
to JJ neuronal O
neuronal NN stimulation O

Complementary JJ CAPITAL Complementary O
Complementary CC and O
and JJ alternative O
alternative NN medicine O
medicine : : O
: NN friend O
friend , , O
, NN foe O
foe , , O
, CC or O
or NNP CAPITAL OWA O
OWA . ? O

Ondansetron NN CAPITAL Ondansetron T
Ondansetron VBZ is O
is RB not O
not DT a O
a NN panacea O

Masking VBG CAPITAL Masking O
Masking , , O
, VBG blinding O
blinding , , O
, CC and O
and VB peer O
peer NN review O
review : : O
: DT the O
the JJ blind O
blind VBG leading O
leading DT the O
the VBN blinded O

Human JJ CAPITAL Human O
Human JJ cervico-facial O
cervico-facial NN morphogenesis O

Evaluation NN CAPITAL Evaluation O
Evaluation IN of O
of VBN acquired O
acquired NNS data O
data CC and O
and JJ current O
current NN outlook O

( NN ( O
( NNP CAPITAL Part O
Part CD 1 O
1 : : O
: JJ facial O
facial NN morphogenesis O
morphogenesis NN ) O

The DT CAPITAL The O
The NN effect O
effect IN of O
of NN CAPITAL TRK-530 T
TRK-530 IN on O
on JJ experimental O
experimental NN arthritis D
arthritis IN in O
in NNS mice O

Spontaneous JJ CAPITAL Spontaneous O
Spontaneous NN exfoliation O
exfoliation IN of O
of NNS teeth O
teeth VBG following O
following JJ severe O
severe JJ elemental O
elemental NN mercury D
mercury NN poisoning D
poisoning : : O
: NN case O
case NN report O
report CC and O
and JJ histological O
histological NN investigation O
investigation IN for O
for NN mechanism O

Small JJ CAPITAL Small D
Small NN cell D
cell NN lung D
lung NN cancer D
cancer MD can O
can VB express O
express NN CAPITAL CD34 O
CD34 NN antigen O

X NN CAPITAL X O
X NN inactivation O
inactivation IN in O
in NNS females O
females IN with O
with JJ CAPITAL X-linked D
X-linked NN disease D

Report NNP CAPITAL Report O
Report IN of O
of NNS spores O
spores IN of O
of NN CAPITAL Henneguya O
Henneguya NN salminicola O
salminicola NN ( O
( NN CAPITAL Myxozoa O
Myxozoa NN ) O
) IN in O
in JJ human O
human NN stool O
stool NNS specimens O
specimens : : O
: JJ possible O
possible NN source O
source IN of O
of NN confusion O
confusion IN with O
with JJ human O
human NN spermatozoa O

Evaluation NN CAPITAL Evaluation O
Evaluation IN of O
of DT a O
a NN ventilation T
ventilation NN strategy T
strategy TO to O
to VB prevent O
prevent NN barotrauma D
barotrauma IN in O
in NNS patients O
patients IN at O
at JJ high O
high NN risk O
risk IN for O
for JJ acute D
acute JJ respiratory D
respiratory NN distress D
distress NN syndrome D

Pressure- NN CAPITAL Pressure- O
Pressure- CC and O
and JJ CAPITAL Volume-Limited O
Volume-Limited NN CAPITAL Ventilation O
Ventilation NN CAPITAL Strategy O
Strategy NNP CAPITAL Group O

Audit NNP CAPITAL Audit O
Audit NN commission O
commission VBZ tackles O
tackles JJ anaesthetic O
anaesthetic NNS services O

Abdominal JJ CAPITAL Abdominal D
Abdominal NN tuberculosis D
tuberculosis VBG involving O
involving JJ hepatic O
hepatic JJ hilar O
hilar NN lymph O
lymph NNS nodes O

A DT CAPITAL A O
A NN cause O
cause IN of O
of NN portal D
portal NN vein D
vein NN thrombosis D
thrombosis CC and O
and NN portal D
portal NN hypertension D

Treatment NN CAPITAL Treatment O
Treatment IN of O
of NNS men O
men IN with O
with NN paraphilia D
paraphilia IN with O
with DT a O
a JJ long-acting O
long-acting NN analogue T
analogue IN of T
of JJ gonadotropin-releasing T
gonadotropin-releasing NN hormone T

Analgesic JJ CAPITAL Analgesic D
Analgesic NN nephropathy D

Translocations NNS CAPITAL Translocations O
Translocations IN of O
of NN 11q13 O
11q13 IN in O
in NN mantle D
mantle NN cell D
cell NN lymphoma D
lymphoma VB fail O
fail TO to O
to VB disrupt O
disrupt DT the O
the NN CAPITAL S O
S NN mu O
mu NN bp-2 O
bp-2 NN gene O

Variation NN CAPITAL Variation O
Variation IN in O
in NN proficiency O
proficiency NN testing O
testing NN performance O
performance IN by O
by NN testing O
testing NN site O

The DT CAPITAL The T
The `` `` T
`` NN CAPITAL H T
H '' '' T
'' NN graft T
graft : : O
: DT an O
an JJ alternative O
alternative NN approach O
approach IN for O
for VBG performing O
performing RB minimally O
minimally JJ invasive O
invasive JJ direct T
direct JJ coronary T
coronary NN artery T
artery NN bypass T

Effect NN CAPITAL Effect O
Effect IN of O
of NN interferon T
interferon IN on O
on NN hepatitis D
hepatitis NN CAPITAL B D
B . . O

Health NNP CAPITAL Health O
Health NN insurance O
insurance IN for O
for NNS children O
children : -- O
-- DT a O
a NN model O
model IN for O
for JJ incremental O
incremental NN health O
health NN reform O
reform . ? O

Distinction NN CAPITAL Distinction O
Distinction NNS awards O
awards CC and O
and JJ racial O
racial NN discrimination O

Potential JJ CAPITAL Potential O
Potential NNS biases O
biases VBD were O
were RB not O
not VBN taken O
taken IN into O
into NN account O
account IN in O
in NN study O
study IN of O
of VBG waiting O
waiting NNS times O

Factors NNS CAPITAL Factors O
Factors VBG affecting O
affecting NN uptake O
uptake IN of O
of JJ antenatal O
antenatal NN CAPITAL HIV O
HIV NN testing O
testing IN in O
in NNP CAPITAL London O
London : : O
: NNS results O
results IN of O
of DT a O
a JJ multicentre O
multicentre NN study O

Coronary JJ CAPITAL Coronary O
Coronary JJ arterioluminal O
arterioluminal NNS communications O
communications IN in O
in JJ routine O
routine NN angiography O

Peptide NN CAPITAL Peptide O
Peptide JJ nucleic O
nucleic NN acid O
acid NN ( O
( NN CAPITAL PNA O
PNA NN ) O
) IN from O
from NN CAPITAL DNA O
DNA NN recognition O
recognition TO to O
to JJ antisense O
antisense CC and O
and NN CAPITAL DNA O
DNA NN structure O

Homeopathy NNP CAPITAL Homeopathy T
Homeopathy IN for O
for JJ postoperative D
postoperative NN ileus D
ileus . ? O
? DT CAPITAL A O
A NN meta-analysis O

Treatment NN CAPITAL Treatment O
Treatment IN of O
of JJ postmenopausal D
postmenopausal NN osteoporosis D

Fascioloidiasis NN CAPITAL Fascioloidiasis D
Fascioloidiasis IN in O
in JJ game-ranched O
game-ranched NN elk O
elk IN from O
from NNP CAPITAL Montana O

Connexin-26 NN CAPITAL Connexin-26 O
Connexin-26 NNS mutations O
mutations IN in O
in JJ sporadic O
sporadic JJ non-syndromal D
non-syndromal NN sensorineural D
sensorineural NN deafness D

Lyme NN CAPITAL Lyme D
Lyme NN disease D
disease VBG presenting O
presenting IN as O
as NN CAPITAL Tourette D
Tourette POS 's D
's NN syndrome D

The DT CAPITAL The O
The VBG screening O
screening VB muddle O

Treatment NN CAPITAL Treatment O
Treatment IN of O
of JJ hypertensive O
hypertensive NNS patients O
patients IN with O
with NN diabetes D

China NNP CAPITAL China O
China POS 's O
's JJ human-organ O
human-organ NN trade O
trade VBN highlighted O
highlighted IN by O
by NNP CAPITAL US O
US NN arrest O
arrest IN of O
of `` `` O
`` NN salesman O
salesman '' '' O

Dimension NN CAPITAL Dimension O
Dimension IN in O
in VBG defining O
defining NN tumor D
tumor NN response O

Administration NNP CAPITAL Administration O
Administration IN of O
of NN dexamethasone T
dexamethasone VBZ induces O
induces NN proteinuria D
proteinuria IN of O
of JJ glomerular O
glomerular NN origin O
origin IN in O
in NNS mice O

Preoperative JJ CAPITAL Preoperative O
Preoperative NN thromboxane O
thromboxane NN CAPITAL A2/prostaglandin O
A2/prostaglandin NN CAPITAL H2 O
H2 NN receptor O
receptor NN activity O
activity VBZ predicts O
predicts RB early O
early NN graft D
graft NN thrombosis D

Hypertension NN CAPITAL Hypertension D
Hypertension NN treatment O
treatment CC and O
and NN control O
control IN in O
in JJ sub-Saharan O
sub-Saharan NNP CAPITAL Africa O
Africa : : O
: DT the O
the JJ epidemiological O
epidemiological NN basis O
basis IN for O
for NN policy O

Needle-exchange JJ CAPITAL Needle-exchange O
Needle-exchange NNS programmes O
programmes IN in O
in DT the O
the NNP CAPITAL USA O

A DT CAPITAL A O
A JJ discriminant O
discriminant NN function O
function IN for O
for NN preeclampsia D
preeclampsia : : O
: JJ case-control O
case-control NN study O
study IN of O
of JJ minor O
minor NNS hemoglobins O
hemoglobins , , O
, JJ red O
red NN cell O
cell NNS enzymes O
enzymes , , O
, CC and O
and JJ clinical O
clinical NN laboratory O
laboratory NNS values O

Patterning NN CAPITAL Patterning O
Patterning IN of O
of VBN immobilized O
immobilized NN antibody O
antibody NNS layers O
layers IN via O
via NN photolithography O
photolithography CC and O
and NN oxygen O
oxygen NN plasma O
plasma NN exposure O

A DT CAPITAL A O
A JJ cell-based O
cell-based NN immunobiosensor O
immunobiosensor IN with O
with VBN engineered O
engineered JJ molecular O
molecular NN recognition O
recognition : -- O
-- NNP CAPITAL Part O
Part NNP CAPITAL II O
II : : O
: NN CAPITAL Enzyme O
Enzyme NN amplification O
amplification NNS systems O

Evanescent JJ CAPITAL Evanescent O
Evanescent NN wave O
wave NN fibre O
fibre JJ optic O
optic NN sensor O
sensor IN for O
for NN detection O
detection IN of O
of NNP CAPITAL L. O
L. JJ donovani O
donovani JJ specific O
specific NNS antibodies O
antibodies IN in O
in NNS sera O
sera IN of O
of FW kala O
kala NN azar O
azar NNS patients O

Multianalyte JJ CAPITAL Multianalyte O
Multianalyte NNS biosensors O
biosensors IN on O
on JJ optical O
optical NN imaging O
imaging NNS bundles O

Specific JJ CAPITAL Specific O
Specific VBG binding O
binding IN of O
of JJ low O
low JJ molecular O
molecular NN weight O
weight NNS ligands O
ligands IN with O
with JJ direct O
direct JJ optical O
optical NN detection O

Amperometric JJ CAPITAL Amperometric O
Amperometric NN lactate O
lactate NN oxidase O
oxidase NN catheter O
catheter IN for O
for JJ real-time O
real-time NN lactate O
lactate VBG monitoring O
monitoring VBN based O
based IN on O
on JJ thin O
thin NN film O
film NN technology O

Dual-fractal JJ CAPITAL Dual-fractal O
Dual-fractal NN analysis O
analysis IN for O
for NN antigen O
antigen : -- O
-- NN antibody O
antibody VBG binding O
binding NNS kinetics O
kinetics IN for O
for NN biosensor O
biosensor NNS applications O

Dipstick NN CAPITAL Dipstick O
Dipstick RB only O
only NN urinalysis O
urinalysis NN screen O
screen IN for O
for DT the O
the JJ pediatric O
pediatric NN emergency O
emergency NN room O

Cytoplasmic JJ CAPITAL Cytoplasmic O
Cytoplasmic NN transport O
transport IN in O
in FW CAPITAL Drosophila O
Drosophila JJ ovarian O
ovarian NNS follicles O
follicles : : O
: DT the O
the NN migration O
migration IN of O
of VBN microinjected O
microinjected JJ fluorescent O
fluorescent NNS probes O
probes IN through O
through JJ intercellular O
intercellular NNS bridges O
bridges VBZ depends O
depends DT neither O
neither IN on O
on JJ electrical O
electrical NN charge O
charge CC nor O
nor IN on O
on JJ external O
external NN osmolarity O

Further JJ CAPITAL Further O
Further NN evidence O
evidence IN for O
for DT the O
the NN importance O
importance IN of O
of DT an O
an NN androgen O
androgen NN response O
response NN element O
element IN in O
in DT the O
the NN factor O
factor CD CAPITAL IX O
IX NN promoter O

The DT CAPITAL The O
The JJ obstetric O
obstetric NN experience O
experience IN of O
of NNS carriers O
carriers IN of O
of NN haemophilia D

Acquired VBN CAPITAL Acquired O
Acquired NN haemophilia D
haemophilia , , O
, DT an O
an JJ unusual O
unusual NN cause O
cause IN of O
of JJ severe O
severe NN postpartum D
postpartum NN haemorrhage D

Zoonotic JJ CAPITAL Zoonotic O
Zoonotic CC and O
and JJ viral D
viral NN infection D
infection IN in O
in JJ fetal O
fetal NN loss O
loss IN after O
after CD 12 O
12 NNS weeks O

High-affinity JJ CAPITAL High-affinity O
High-affinity VBG binding O
binding IN of O
of DT the O
the JJ neonatal O
neonatal NN CAPITAL Fc O
Fc NN receptor O
receptor TO to O
to PRP$ its O
its NN CAPITAL IgG O
IgG NN ligand O
ligand VBZ requires O
requires NN receptor O
receptor NN immobilization O

Molecular JJ CAPITAL Molecular O
Molecular NNS distances O
distances IN from O
from JJ dipolar O
dipolar VBN coupled O
coupled NNS spin-labels O
spin-labels : : O
: DT the O
the JJ global O
global NN analysis O
analysis IN of O
of NN multifrequency O
multifrequency JJ continuous O
continuous NN wave O
wave NN electron O
electron JJ paramagnetic O
paramagnetic NN resonance O
resonance NNS data O

Computer NN CAPITAL Computer O
Computer NN science O
science CC and O
and NN biology O
biology : -- O
-- DT the O
the JJ CAPITAL German O
German NN CAPITAL Conference O
Conference IN on O
on NNS CAPITAL Bioinformatics O
Bioinformatics NN ( O
( NN CAPITAL GCB'96 O
GCB'96 NN ) O

Surface NN CAPITAL Surface O
Surface NN plasmon O
plasmon NN resonance O
resonance NN analysis O
analysis IN of O
of NN topoisomerase O
topoisomerase JJ CAPITAL I-DNA O
I-DNA VBG binding O
binding : : O
: NN effect O
effect IN of O
of NN CAPITAL Mg2+ O
Mg2+ CC and O
and NN CAPITAL DNA O
DNA NN sequence O

The DT CAPITAL The O
The CD 1996 O
1996 NN list O

Proposed VBN CAPITAL Proposed O
Proposed JJ new O
new JJ bacterial O
bacterial NN taxa O
taxa CC and O
and VBN proposed O
proposed NNS changes O
changes IN of O
of JJ bacterial O
bacterial NNS names O
names VBN published O
published IN during O
during CD 1996 O
1996 CC and O
and VBN considered O
considered TO to O
to VB be O
be IN of O
of NN interest O
interest TO to O
to JJ medical O
medical CC or O
or JJ veterinary O
veterinary NN bacteriology O

An DT CAPITAL An O
An JJ informational O
informational NN note O

The DT CAPITAL The O
The CD 1995 O
1995 NN list O

Proposed VBN CAPITAL Proposed O
Proposed JJ new O
new JJ bacterial O
bacterial NN taxa O
taxa CC and O
and VBN proposed O
proposed NNS changes O
changes IN of O
of JJ bacterial O
bacterial NNS names O
names VBN published O
published IN during O
during CD 1995 O
1995 CC and O
and VBN considered O
considered TO to O
to VB be O
be IN of O
of NN interest O
interest TO to O
to JJ medical O
medical CC or O
or JJ veterinary O
veterinary NN bacteriology O

An DT CAPITAL An O
An JJ informational O
informational NN note O

Biobehavioral JJ CAPITAL Biobehavioral O
Biobehavioral NN pain D
pain NN research O
research : : O
: DT a O
a JJ multi-institute O
multi-institute NN assessment O
assessment IN of O
of NN cross-cutting O
cross-cutting NNS issues O
issues CC and O
and NN research O
research NNS needs O

Use NNP CAPITAL Use O
Use IN of O
of NN surface O
surface NN plasmon O
plasmon NN resonance O
resonance TO to O
to NN probe O
probe DT the O
the NN equilibrium O
equilibrium CC and O
and JJ dynamic O
dynamic NNS aspects O
aspects IN of O
of NNS interactions O
interactions IN between O
between JJ biological O
biological NNS macromolecules O

ABC NNP CAPITAL ABC O
ABC IN of O
of JJ mental O
mental NN health O

Psychosexual JJ CAPITAL Psychosexual D
Psychosexual NNS problems D

Hazards NNS CAPITAL Hazards O
Hazards IN of O
of VBG running O
running DT a O
a NN marathon O

Troponin-T JJ CAPITAL Troponin-T O
Troponin-T NNS concentrations O
concentrations MD should O
should VB be O
be VBN measured O

Second JJ CAPITAL Second O
Second NNP CAPITAL Strang O
Strang NNP CAPITAL International O
International NN CAPITAL Cancer O
Cancer NN CAPITAL Conference O
Conference : : O
: NNS genetics O
genetics CC and O
and DT the O
the NN environment O
environment NNP CAPITAL New O
New NNP CAPITAL York O
York , , O
, NNP CAPITAL USA O
USA , , O
, CD 15-16 O
15-16 NNP CAPITAL November O
November CD 1996 O

Use NNP CAPITAL Use O
Use IN of O
of DT a O
a VBN modified O
modified NN version O
version IN of O
of DT the O
the JJ CAPITAL Overt O
Overt NNP CAPITAL Aggression O
Aggression NNP CAPITAL Scale O
Scale IN in O
in DT the O
the NN measurement O
measurement CC and O
and NN assessment O
assessment IN of O
of JJ aggressive O
aggressive NNS behaviours O
behaviours VBG following O
following NN brain D
brain NN injury D

Ectopic JJ CAPITAL Ectopic D
Ectopic NN pregnancy D
pregnancy NN recurrence O
recurrence : : O
: NN role O
role IN of O
of JJ gynecologic O
gynecologic , , O
, JJ obstetric O
obstetric , , O
, JJ contraceptive O
contraceptive CC and O
and NN smoking O
smoking NN history O

AIDS NNP CAPITAL AIDS O
AIDS : : O
: DT a O
a NN world O
world , , O
, DT a O
a NN desire O

Urogynaecology NN CAPITAL Urogynaecology O
Urogynaecology NNS proceedings O
proceedings IN of O
of DT the O
the JJ joint O
joint NN CAPITAL RCOG/BAUS O
RCOG/BAUS NN urogynaecology O
urogynaecology NN meeting O

19 CD 19 O
19 NNP CAPITAL September O
September CD 1996 O

The DT CAPITAL The O
The VBG naming O
naming IN of O
of DT a O
a NN syndrome O

The DT CAPITAL The O
The NN use O
use IN of O
of JJ implantable O
implantable JJ venous O
venous NN access O
access NNS devices O
devices NN ( O
( NNS CAPITAL IVADs O
IVADs NN ) O
) IN in O
in NNS children O
children IN with O
with NN hemophilia D

Nephrotic JJ CAPITAL Nephrotic D
Nephrotic NN syndrome D
syndrome VBN associated O
associated IN with O
with NN hypocomplementemia D
hypocomplementemia IN in O
in DT a O
a JJ 4-year-old O
4-year-old NN boy O
boy IN with O
with NN hemophilia D
hemophilia NN CAPITAL B D

Growth NN CAPITAL Growth O
Growth NN hormone O
hormone NN secretion O
secretion IN in O
in JJ CAPITAL HIV-positive O
HIV-positive CC versus O
versus JJ CAPITAL HIV-negative O
HIV-negative JJ hemophilic O
hemophilic NNS males O
males IN with O
with JJ abnormal O
abnormal NN growth O
growth CC and O
and JJ pubertal O
pubertal NN development O

The DT CAPITAL The O
The NNP CAPITAL Hemophilia O
Hemophilia NN CAPITAL Growth O
Growth CC and O
and NNP CAPITAL Development O
Development NNP CAPITAL Study O

Trends NNS CAPITAL Trends O
Trends IN in O
in NN CAPITAL HIV O
HIV VBG counseling O
counseling CC and O
and NN testing O
testing IN of O
of NNS clients O
clients VBG attending O
attending DT a O
a JJ public O
public RB sexually O
sexually JJ transmitted O
transmitted NN disease O
disease NN clinic O
clinic IN in O
in NNP CAPITAL Portland O
Portland , , O
, NNP CAPITAL Oregon O
Oregon , , O
, CD 1989-1995 O

Risk NN CAPITAL Risk O
Risk NNS factors O
factors IN for O
for NN CAPITAL HIV-1 D
HIV-1 NN infection D
infection IN among O
among JJ pregnant O
pregnant NNS women O
women IN in O
in JJ CAPITAL French O
French NNP CAPITAL Guiana O

Angiogenesis NN CAPITAL Angiogenesis O
Angiogenesis IN in O
in JJ inflammatory D
inflammatory NN disease D

Epidemiology NNP CAPITAL Epidemiology O
Epidemiology CC and O
and NN association O
association IN with O
with JJ extra-gastrointestinal D
extra-gastrointestinal NNS diseases D

Extra-gastrointestinal JJ CAPITAL Extra-gastrointestinal D
Extra-gastrointestinal NNS diseases D
diseases CC and O
and NNP CAPITAL Helicobacter O
Helicobacter NN pylori O

Update NNP CAPITAL Update O
Update IN on O
on NNP CAPITAL Helicobacter O
Helicobacter NN pylori O
pylori NN research O

Diagnosis NN CAPITAL Diagnosis O

Uptake NN CAPITAL Uptake O
Uptake IN on O
on NNP CAPITAL Helicobacter O
Helicobacter NN pylori O
pylori NN research O

Pathogenesis NN CAPITAL Pathogenesis O
Pathogenesis CC and O
and NN host O
host NN response O

Update NNP CAPITAL Update O
Update IN on O
on NNP CAPITAL Helicobacter O
Helicobacter NN pylori O
pylori NN research O

Malignancies NNS CAPITAL Malignancies O

Update NNP CAPITAL Update O
Update IN on O
on NNP CAPITAL Helicobacter O
Helicobacter NN pylori O
pylori NN research O

Dyspepsia NN CAPITAL Dyspepsia D

Update NNP CAPITAL Update O
Update IN on O
on NNP CAPITAL Helicobacter O
Helicobacter NN pylori O
pylori NN research O

Eradication NN CAPITAL Eradication O

Sequence NN CAPITAL Sequence O
Sequence NN analysis O
analysis IN of O
of DT the O
the JJ 36-kb O
36-kb NN region O
region IN between O
between NN gntZ O
gntZ CC and O
and NN trnY O
trnY NNS genes O
genes IN of O
of NN CAPITAL Bacillus O
Bacillus NNS subtilis O
subtilis NN genome O

A DT CAPITAL A O
A NN review O
review IN of O
of NN interferon O
interferon NN immunogenicity O

Based VBN CAPITAL Based O
Based IN on O
on DT a O
a JJ roundtable O
roundtable NN workshop O
workshop VBN held O
held IN in O
in NNP CAPITAL London O
London , , O
, NNP CAPITAL United O
United NNP CAPITAL Kingdom O
Kingdom , , O
, CD 9 O
9 NNP CAPITAL February O
February CD 1996 O

Histologic JJ CAPITAL Histologic O
Histologic NN diagnosis O
diagnosis IN of O
of JJ chronic D
chronic NN hepatitis D
hepatitis , , O
, VBG grading O
grading CC and O
and NN staging O

Inositol NN CAPITAL Inositol T
Inositol NN treatment O
treatment IN of O
of NN autism D

Current JJ CAPITAL Current O
Current NN progress O
progress IN in O
in RB early O
early NN pregnancy O
pregnancy NN investigation O

Truncated-gene JJ CAPITAL Truncated-gene O
Truncated-gene NN reporter O
reporter NN system O
system IN for O
for VBG studying O
studying DT the O
the NN regulation O
regulation IN of O
of NN manganese O
manganese NN peroxidase O
peroxidase NN expression O

Disparate JJ CAPITAL Disparate O
Disparate NN sequence O
sequence NNS characteristics O
characteristics IN of O
of DT the O
the NN CAPITAL Erysiphe O
Erysiphe NN graminis O
graminis NN f.sp O

hordei NN hordei O
hordei NN glyceraldehyde-3-phosphate O
glyceraldehyde-3-phosphate NN dehydrogenase O
dehydrogenase NN gene O

The DT CAPITAL The O
The JJ CAPITAL Integrative O
Integrative NNP CAPITAL Neurobiology O
Neurobiology IN of O
of NN CAPITAL Affiliation O

Proceedings NNP CAPITAL Proceedings O
Proceedings IN of O
of DT a O
a NN conference O

Washington NNP CAPITAL Washington O
Washington , , O
, NN CAPITAL DC O
DC , , O
, NNP CAPITAL USA O

March NNP CAPITAL March O
March CD 14-17 O
14-17 , , O
, CD 1996 O

Proceedings NNP CAPITAL Proceedings O
Proceedings IN of O
of DT the O
the JJ 10th O
10th NNP CAPITAL International O
International NNP CAPITAL Symposium O
Symposium IN on O
on DT the O
the NN CAPITAL Pharmacology O
Pharmacology IN of O
of NN CAPITAL Thermoregulation O

Memphis NNP CAPITAL Memphis O
Memphis , , O
, NNP CAPITAL Tennessee O
Tennessee , , O
, NNP CAPITAL USA O

August NNP CAPITAL August O
August CD 17-22 O
17-22 , , O
, CD 1996 O

Neuropeptides NNS CAPITAL Neuropeptides O
Neuropeptides IN in O
in NNP CAPITAL Development O
Development CC and O
and NN CAPITAL Aging O

Proceedings NNP CAPITAL Proceedings O
Proceedings IN of O
of DT a O
a NN conference O

Breckenridge NNP CAPITAL Breckenridge O
Breckenridge , , O
, NNP CAPITAL Colorado O
Colorado , , O
, NNP CAPITAL USA O

February NNP CAPITAL February O
February CD 3-6 O
3-6 , , O
, CD 1996 O

Receptor NN CAPITAL Receptor O
Receptor NN CAPITAL Classification O
Classification : : O
: DT CAPITAL The O
The NN CAPITAL Integration O
Integration IN of O
of JJ CAPITAL Operational O
Operational , , O
, JJ CAPITAL Structural O
Structural , , O
, CC and O
and JJ CAPITAL Transductional O
Transductional NN CAPITAL Information O

Proceedings NNP CAPITAL Proceedings O
Proceedings IN of O
of DT a O
a NN conference O

Verona NNP CAPITAL Verona O
Verona , , O
, NNP CAPITAL Italy O
Italy , , O
, NNP CAPITAL September O
September CD 21-22 O
21-22 , , O
, CD 1995 O

Psychobiology NN CAPITAL Psychobiology O
Psychobiology IN of O
of JJ CAPITAL Postraumatic D
Postraumatic NN CAPITAL Stress D
Stress NN CAPITAL Disorder D

Proceedings NNP CAPITAL Proceedings O
Proceedings IN of O
of DT a O
a NN conference O

New NNP CAPITAL New O
New NNP CAPITAL York O
York , , O
, NNP CAPITAL New O
New NNP CAPITAL York O
York , , O
, NNP CAPITAL USA O

September NNP CAPITAL September O
September CD 7-10 O
7-10 , , O
, CD 1996 O

Adolescent JJ CAPITAL Adolescent O
Adolescent NNP CAPITAL Gynecology O
Gynecology CC and O
and NNP CAPITAL Endocrinology O
Endocrinology : : O
: JJ CAPITAL Basic O
Basic CC and O
and JJ CAPITAL Clinical O
Clinical NNS CAPITAL Aspects O

Proceedings NNP CAPITAL Proceedings O
Proceedings IN of O
of DT the O
the JJ 3rd O
3rd NNP CAPITAL International O
International NNP CAPITAL Congress O

Athens NNP CAPITAL Athens O
Athens , , O
, NNP CAPITAL Greece O
Greece , , O
, NNP CAPITAL December O
December CD 6-9 O
6-9 , , O
, CD 1995 O

Proceedings NNP CAPITAL Proceedings O
Proceedings IN of O
of DT the O
the JJ 3rd O
3rd NNP CAPITAL International O
International NN CAPITAL Conference O
Conference IN on O
on JJ CAPITAL Neuroprotective O
Neuroprotective NNS CAPITAL Agents O
Agents : : O
: JJ CAPITAL Clinical O
Clinical CC and O
and JJ CAPITAL Experimental O
Experimental NNS CAPITAL Aspects O

Lake NNP CAPITAL Lake O
Lake NN CAPITAL Como O
Como , , O
, NNP CAPITAL Italy O
Italy , , O
, NNP CAPITAL September O
September CD 9-12 O
9-12 , , O
, CD 1996 O

Exon/intron NN CAPITAL Exon/intron O
Exon/intron NN structure O
structure IN of O
of DT the O
the JJ human O
human NN CAPITAL AF-4 O
AF-4 NN gene O
gene , , O
, DT a O
a NN member O
member IN of O
of DT the O
the NN CAPITAL AF-4/LAF-4/FMR-2 O
AF-4/LAF-4/FMR-2 NN gene O
gene NN family O
family VBG coding O
coding IN for O
for DT a O
a JJ nuclear O
nuclear NN protein O
protein IN with O
with JJ structural O
structural NNS alterations O
alterations IN in O
in JJ acute O
acute NN leukaemia D

Cloning NN CAPITAL Cloning O
Cloning CC and O
and NN characterization O
characterization IN of O
of DT a O
a JJ neural O
neural NN cell O
cell NN recognition O
recognition NN molecule O
molecule IN on O
on NNS axons O
axons IN of O
of DT the O
the JJ retinotectal O
retinotectal NN system O
system CC and O
and JJ spinal O
spinal NN cord O

Identification NN CAPITAL Identification O
Identification , , O
, NN localization O
localization , , O
, CC and O
and NN expression O
expression IN of O
of CD two O
two JJ novel O
novel JJ human O
human NNS genes O
genes JJ similar O
similar TO to O
to NN deoxyribonuclease O
deoxyribonuclease PRP CAPITAL I O
I . . O

Drug NN CAPITAL Drug O
Drug NN resistance O
resistance IN during O
during NN indinavir T
indinavir NN therapy T
therapy VBZ is O
is VBN caused O
caused IN by O
by NNS mutations O
mutations IN in O
in DT the O
the NN protease O
protease NN gene O
gene CC and O
and IN in O
in PRP$ its O
its NN CAPITAL Gag O
Gag JJ substrate O
substrate NN cleavage O
cleavage NNS sites O

A DT CAPITAL A O
A NN protein O
protein IN with O
with DT a O
a JJ novel O
novel JJ calcium-binding O
calcium-binding NN domain O
domain VBN associated O
associated IN with O
with JJ calcareous O
calcareous NNS corpuscles O
corpuscles IN in O
in NN CAPITAL Echinococcus D
Echinococcus NN granulosus D

Oncogenic JJ CAPITAL Oncogenic O
Oncogenic NN raf-1 O
raf-1 VBZ induces O
induces DT the O
the NN expression O
expression IN of O
of JJ non-histone O
non-histone JJ chromosomal O
chromosomal JJ architectural O
architectural NN protein O
protein NN CAPITAL HMGI-C O
HMGI-C IN via O
via DT a O
a NN p44/p42 O
p44/p42 JJ mitogen-activated O
mitogen-activated NN protein O
protein JJ kinase-dependent O
kinase-dependent NN pathway O
pathway IN in O
in JJ salivary O
salivary JJ epithelial O
epithelial NNS cells O

Pendred VBN CAPITAL Pendred D
Pendred NN syndrome D
syndrome VBZ is O
is VBN caused O
caused IN by O
by NNS mutations O
mutations IN in O
in DT a O
a JJ putative O
putative NN sulphate O
sulphate NN transporter O
transporter NN gene O
gene NN ( O
( NN CAPITAL PDS O
PDS NN ) O

Meis2 NN CAPITAL Meis2 O
Meis2 , , O
, DT a O
a JJ novel O
novel NN mouse O
mouse JJ CAPITAL Pbx-related O
Pbx-related NN homeobox O
homeobox NN gene O
gene VBN induced O
induced IN by O
by JJ retinoic O
retinoic NN acid O
acid IN during O
during NN differentiation O
differentiation IN of O
of NN CAPITAL P19 O
P19 JJ embryonal O
embryonal NN carcinoma O
carcinoma NNS cells O

Proceedings NNP CAPITAL Proceedings O
Proceedings IN of O
of DT the O
the NN CAPITAL VIIIth O
VIIIth NNP CAPITAL International O
International NN CAPITAL Conference O
Conference IN on O
on DT the O
the NN CAPITAL Na/K-ATPase O
Na/K-ATPase CC and O
and JJ CAPITAL Related O
Related NN CAPITAL Transport O
Transport NNS CAPITAL ATPases O

Mar NNP CAPITAL Mar O
Mar DT del O
del NNP CAPITAL Plata O
Plata , , O
, NNP CAPITAL Argentina O
Argentina , , O
, NNP CAPITAL August O
August CD 26-30 O
26-30 , , O
, CD 1996 O

Targeted VBN CAPITAL Targeted O
Targeted NN development O
development IN of O
of NN microsatellite O
microsatellite NNS markers O
markers IN from O
from DT the O
the VBN defined O
defined NN region O
region IN of O
of JJ bovine O
bovine NN chromosome O
chromosome JJ 6q21-31 O

Genetic JJ CAPITAL Genetic O
Genetic NN population O
population NN structure O
structure IN in O
in DT the O
the JJ yellow O
yellow NN mongoose O
mongoose , , O
, NN CAPITAL Cynictis O
Cynictis NN penicillata O

ETTIN NN CAPITAL ETTIN O
ETTIN NNS patterns O
patterns DT the O
the NNP CAPITAL Arabidopsis O
Arabidopsis JJ floral O
floral NN meristem O
meristem CC and O
and JJ reproductive O
reproductive NNS organs O

Ancient JJ CAPITAL Ancient O
Ancient NN CAPITAL DNA O
DNA IN from O
from NN amber O
amber JJ fossil O
fossil NNS bees O
bees . ? O

The DT CAPITAL The O
The NN histone O
histone NN CAPITAL H1 O
H1 NNS genes O
genes IN of O
of DT the O
the NN dipteran O
dipteran NN insect O
insect , , O
, NNP CAPITAL Chironomus O
Chironomus NN thummi O
thummi , , O
, NN fall O
fall IN under O
under CD two O
two JJ divergent O
divergent NNS classes O
classes CC and O
and VBP encode O
encode NNS proteins O
proteins IN with O
with JJ distinct O
distinct JJ intranuclear O
intranuclear NN distribution O
distribution CC and O
and RB potentially O
potentially JJ different O
different NNS functions O

Characterization NN CAPITAL Characterization O
Characterization IN of O
of DT the O
the NN orf31-petG O
orf31-petG NN gene O
gene NN cluster O
cluster IN from O
from DT the O
the NN plastid O
plastid NN genome O
genome IN of O
of JJ CAPITAL Populus O
Populus NNS deltoides O

Xenopus NN CAPITAL Xenopus O
Xenopus NN CAPITAL Pax-2 O
Pax-2 NNS displays O
displays JJ multiple O
multiple NN splice O
splice NNS forms O
forms IN during O
during NN embryogenesis O
embryogenesis CC and O
and JJ pronephric O
pronephric NN kidney O
kidney NN development O

International NNP CAPITAL International O
International NNP CAPITAL Workshop O
Workshop IN on O
on NN CAPITAL Bone O
Bone NNP CAPITAL Research O
Research IN in O
in NN CAPITAL Space O

Tokyo NNP CAPITAL Tokyo O
Tokyo , , O
, NNP CAPITAL Japan O
Japan , , O
, NNP CAPITAL November O
November CD 11-13 O
11-13 , , O
, CD 1996 O

Proceedings NNP CAPITAL Proceedings O

Joint NNP CAPITAL Joint O
Joint NN meeting O
meeting IN of O
of DT the O
the NNP CAPITAL Benelux O
Benelux NNP CAPITAL Society O
Society IN for O
for NN CAPITAL Microcirculation O
Microcirculation CC and O
and DT the O
the NN CAPITAL Gesellschaft O
Gesellschaft f1/4r O
f1/4r NN CAPITAL Mikrozirkulation O
Mikrozirkulation NN e.V O

Mainz NNP CAPITAL Mainz O
Mainz , , O
, NNP CAPITAL Germany O
Germany , , O
, NNP CAPITAL October O
October CD 23-25 O
23-25 , , O
, CD 1997 O

Abstracts NNS CAPITAL Abstracts O

3rd JJ 3rd O
3rd NNP CAPITAL Congress O
Congress IN of O
of DT the O
the JJ CAPITAL French O
French NNP CAPITAL Society O
Society IN of O
of NN CAPITAL Blood T
Blood NN CAPITAL Transfusion T

Marseille NNP CAPITAL Marseille O
Marseille , , O
, NNP CAPITAL France O
France , , O
, CD 28-30 O
28-30 NNP CAPITAL April O
April CD 1998 O

Central NNP CAPITAL Central O
Central CC and O
and NNP CAPITAL East O
East JJ CAPITAL European O
European NNP CAPITAL Regional O
Regional NN CAPITAL INTERASMA O
INTERASMA NN CAPITAL Conference O

Budapest NNP CAPITAL Budapest O
Budapest , , O
, NNP CAPITAL Hungary O
Hungary , , O
, NNP CAPITAL August O
August CD 24-27 O
24-27 , , O
, CD 1997 O

Summary NN CAPITAL Summary O
Summary IN of O
of NN symposium O
symposium , , O
, JJ antisense O
antisense NNS oligonucleotides O
oligonucleotides : : O
: NNS strategies O
strategies CC and O
and NNS successes O

Sarasota NNP CAPITAL Sarasota O
Sarasota , , O
, NNP CAPITAL Florida O
Florida , , O
, NNP CAPITAL USA O

April NNP CAPITAL April O
April CD 21 O
21 , , O
, CD 1995 O

International NNP CAPITAL International O
International JJ forensic O
forensic NN science O
science CC and O
and NN justice O

Proceedings NNP CAPITAL Proceedings O
Proceedings IN of O
of DT the O
the JJ 6th O
6th NNP CAPITAL Congress O
Congress IN of O
of DT the O
the CAPITAL Soci O
Soci NN ( O
( NN c O
c NN ) O
) t O
t NN ( O
( NN c O
c NN ) O
) IN de O
de NN CAPITAL Pharmaco-Toxicologie O
Pharmaco-Toxicologie JJ CAPITAL Cellulaire O
Cellulaire CC and O
and DT the O
the CAPITAL Soci O
Soci NN ( O
( NN c O
c NN ) O
) t O
t NN ( O
( NN c O
c NN ) O
) JJ CAPITAL Franaise O
Franaise IN de O
de NN CAPITAL Toxicologie O
Toxicologie CAPITAL G O
G NN ( O
( NN c O
c NN ) O
) n O
n NN ( O
( NN c O
c NN ) O
) NN tique O

Paris NNP CAPITAL Paris O
Paris , , O
, NNP CAPITAL France O
France , , O
, NNP CAPITAL March O
March CD 6-7 O
6-7 , , O
, CD 1997 O

The DT CAPITAL The O
The JJ CAPITAL Italian O
Italian NNP CAPITAL Association O
Association IN for O
for DT the O
the NNP CAPITAL Study O
Study IN of O
of NN CAPITAL Glaucoma D

Proceedings NNP CAPITAL Proceedings O
Proceedings IN of O
of DT the O
the JJ 12th O
12th JJ annual O
annual JJ general O
general NN meeting O

Rapallo NNP CAPITAL Rapallo O
Rapallo , , O
, NNP CAPITAL Italy O
Italy , , O
, CD 14-15 O
14-15 NNP CAPITAL March O
March CD 1997 O

Report NNP CAPITAL Report O
Report IN of O
of DT the O
the JJ 61st O
61st NNP CAPITAL National O
National NNP CAPITAL Scientific O
Scientific VBG CAPITAL Meeting O
Meeting IN of O
of DT the O
the JJ CAPITAL American O
American NNP CAPITAL College O
College IN of O
of NNP CAPITAL Rheumatology O
Rheumatology , , O
, NNP CAPITAL Washington O
Washington NN CAPITAL DC O
DC , , O
, CD 8-12 O
8-12 NNP CAPITAL November O
November CD 1997 O

Topical JJ CAPITAL Topical O
Topical NN dictionary O

USAN NNP CAPITAL USAN O
USAN NNP CAPITAL Council O

List NN CAPITAL List O
List DT CAPITAL No O

404 CD 404 O

New NNP CAPITAL New O
New NNS names O

Nagrestipen NN CAPITAL Nagrestipen O

Proposed VBN CAPITAL Proposed O
Proposed JJ genetic O
genetic NN nomenclature O
nomenclature NNS rules O
rules IN for O
for NNP CAPITAL Tetrahymena O
Tetrahymena NN thermophila O
thermophila , , O
, NN CAPITAL Paramecium O
Paramecium NN primaurelia O
primaurelia CC and O
and NN CAPITAL Paramecium O
Paramecium NN tetraurelia O

The DT CAPITAL The O
The NNP CAPITAL Seventh O
Seventh NNP CAPITAL International O
International VBG CAPITAL Meeting O
Meeting IN on O
on VB CAPITAL Ciliate O
Ciliate JJ CAPITAL Molecular O
Molecular NN CAPITAL Biology O
Biology NNP CAPITAL Genetics O
Genetics JJ CAPITAL Nomenclature O

Joint NNP CAPITAL Joint O
Joint JJ annual O
annual NN session O
session IN of O
of DT the O
the NNP CAPITAL North O
North JJ CAPITAL German O
German NNP CAPITAL Society O
Society IN of O
of NN CAPITAL Radiology O
Radiology CC and O
and DT the O
the NN CAPITAL Radiology O
Radiology NNP CAPITAL Society O
Society IN of O
of JJR CAPITAL Lower O
Lower NNP CAPITAL Saxony O
Saxony CC and O
and FW CAPITAL Sachsen O
Sachsen NNP CAPITAL Anhalt O

Kiel NNP CAPITAL Kiel O
Kiel , , O
, NN 20-21 O
20-21 NNP CAPITAL February O
February CD 1998 O

Abstracts NNS CAPITAL Abstracts O

Neurone NN CAPITAL Neurone O
Neurone NN development O
development CC and O
and NN death O
death , , O
, IN from O
from DT a O
a NN cell O
cell NN biologist O
biologist POS 's O
's NN perspective O

3rd JJ 3rd O
3rd NN CAPITAL Neurotrauma/Polytrauma O
Neurotrauma/Polytrauma NNP CAPITAL Symposium O

Cologne NNP CAPITAL Cologne O
Cologne , , O
, NNP CAPITAL Germany O
Germany , , O
, NNP CAPITAL March O
March CD 14-15 O
14-15 , , O
, CD 1998 O

Abstracts NNS CAPITAL Abstracts O

Neuroimmunomodulation NN CAPITAL Neuroimmunomodulation O
Neuroimmunomodulation : : O
: JJ CAPITAL Molecular O
Molecular NNS CAPITAL Aspects O
Aspects , , O
, JJ CAPITAL Integrative O
Integrative NNP CAPITAL Systems O
Systems , , O
, CC and O
and JJ CAPITAL Clinical O
Clinical NNS CAPITAL Advances O

Proceedings NNP CAPITAL Proceedings O
Proceedings IN of O
of DT the O
the JJ 3rd O
3rd NNP CAPITAL Congress O
Congress IN of O
of DT the O
the NNP CAPITAL International O
International NNP CAPITAL Society O
Society IN of O
of NN CAPITAL NeuroImmunoModulation O
NeuroImmunoModulation NN ( O
( NN CAPITAL ISNIM O
ISNIM NN ) O

Bethesda NNP CAPITAL Bethesda O
Bethesda , , O
, NNP CAPITAL Maryland O
Maryland , , O
, NNP CAPITAL USA O

November NNP CAPITAL November O
November CD 13-15 O
13-15 , , O
, CD 1996 O

8th JJ 8th O
8th JJ CAPITAL European O
European VBG CAPITAL Meeting O
Meeting IN on O
on NN CAPITAL Dysmorphology O

Strasbourg NNP CAPITAL Strasbourg O
Strasbourg , , O
, NNP CAPITAL France O
France , , O
, CD 3-6 O
3-6 NNP CAPITAL September O
September CD 1997 O

Abstracts NNS CAPITAL Abstracts O

EU NNP CAPITAL EU O
EU VBG CAPITAL Working O
Working NNP CAPITAL Group O
Group IN on O
on NN CAPITAL Tobacco O
Tobacco CC and O
and JJ CAPITAL Oral O
Oral NNP CAPITAL Health O
Health NN CAPITAL Consensus O
Consensus VBG CAPITAL Meeting O

Copenhagen NNP CAPITAL Copenhagen O
Copenhagen , , O
, CD 23-26 O
23-26 NNP CAPITAL October O
October CD 1997 O

Abstracts NNS CAPITAL Abstracts O

Presentations NNS CAPITAL Presentations O
Presentations IN from O
from DT the O
the JJ 2nd O
2nd NNP CAPITAL NIH O
NIH NNP CAPITAL Symposium O
Symposium IN on O
on JJ CAPITAL Therapeutic O
Therapeutic NNS CAPITAL Oligonucleotides O
Oligonucleotides : : O
: NN CAPITAL Targeting O
Targeting NN CAPITAL Transcription O
Transcription NNS CAPITAL Factors O
Factors CC and O
and NN CAPITAL Signaling O
Signaling NNS CAPITAL Pathways O

Bethesda NNP CAPITAL Bethesda O
Bethesda , , O
, NNP CAPITAL Maryland O
Maryland , , O
, NNP CAPITAL USA O

December NNP CAPITAL December O
December CD 5 O
5 , , O
, CD 1997 O

Infectious JJ CAPITAL Infectious D
Infectious NNS diseases D
diseases : : O
: PRP$ their O
their NN impact O
impact IN on O
on NN dentistry O

What WDT CAPITAL What O
What POS 's O
's JJ new O
new IN in O
in NN protein O
protein JJ folding O
folding . ? O
? NNP CAPITAL EMBO O
EMBO NN workshop O
workshop : : O
: NN protein O
protein JJ folding O
folding CC and O
and VBG misfolding O
misfolding IN inside O
inside CC and O
and IN outside O
outside DT the O
the NN cell O

Meeting VBG CAPITAL Meeting O
Meeting IN of O
of DT the O
the JJ CAPITAL European O
European NN forum O
forum IN of O
of NNS nurses O

17th JJ 17th O
17th JJ CAPITAL European O
European NNP CAPITAL Workshop O
Workshop IN on O
on DT the O
the NN CAPITAL Cell O
Cell NN CAPITAL Biology O
Biology IN of O
of NNS CAPITAL Phagocytes O

Catania NNP CAPITAL Catania O
Catania , , O
, NNP CAPITAL Italy O
Italy , , O
, NNP CAPITAL May O
May CD 27-31 O
27-31 , , O
, CD 1998 O

Abstracts NNS CAPITAL Abstracts O

Onset NN CAPITAL Onset O
Onset IN of O
of DT the O
the JJ preovulatory O
preovulatory VBG luteinizing O
luteinizing NN hormone O
hormone NN surge O
surge : : O
: JJ diurnal O
diurnal VBG timing O
timing CC and O
and JJ critical O
critical JJ follicular O
follicular NNS prerequisites O

Municipal JJ CAPITAL Municipal O
Municipal NN animal O
animal NN control O
control NNS ordinances O
ordinances : -- O
-- DT some O
some JJ legal O
legal NNS issues O

Psychosexual JJ CAPITAL Psychosexual O
Psychosexual NN care O
care IN in O
in DT a O
a JJ multi-ethnic O
multi-ethnic NN society O

Serologic JJ CAPITAL Serologic O
Serologic NN evidence O
evidence IN for O
for JJ mother-to-child O
mother-to-child NN transmission O
transmission IN of O
of NN CAPITAL Kaposi D
Kaposi JJ sarcoma-associated D
sarcoma-associated NN herpesvirus D
herpesvirus NN infection D

Brandon/Hill NNP CAPITAL Brandon/Hill O
Brandon/Hill VBN selected O
selected NN list O
list IN of O
of NN nursing O
nursing NNS books O
books CC and O
and NNS journals O

Retraction NN CAPITAL Retraction O

The DT CAPITAL The O
The NN CAPITAL TSG101 O
TSG101 NN tumor O
tumor NN susceptibility O
susceptibility NN gene O
gene VBZ is O
is JJ located O
located IN in O
in NN chromosome O
chromosome CD 11 O
11 NN band O
band NN p15 O
p15 CC and O
and VBZ is O
is VBN mutated O
mutated IN in O
in JJ human O
human NN breast D
breast NN cancer D

An DT CAPITAL An O
An NN omission O

Indoor JJ CAPITAL Indoor O
Indoor NN pollution O
pollution CC and O
and NN health O

Dioxins NNS CAPITAL Dioxins O
Dioxins : : O
: JJ current O
current NN knowledge O
knowledge IN about O
about NN health O
health NNS effects O

Influence NN CAPITAL Influence O
Influence IN of O
of JJ environmental O
environmental NNS factors O
factors IN on O
on NN fertility O
fertility : : O
: NN example O
example IN of O
of DT the O
the NN diminution O
diminution IN of O
of NN sperm O
sperm NN quality O

New NNP CAPITAL New O
New NNS developments O
developments IN in O
in DT the O
the NN treatment O
treatment IN of O
of NN diabetes D
diabetes CC and O
and NN hyperlipidemias D

Role NN CAPITAL Role O
Role IN of O
of NNS beta-blockers T
beta-blockers IN in O
in DT the O
the NN treatment O
treatment IN of O
of JJ cardiac D
cardiac NN insufficiency D

Which WDT CAPITAL Which O
Which NN calcium T
calcium NNS antagonists T
antagonists IN for O
for NN hypertension D
hypertension . ? O

Correct JJ CAPITAL Correct O
Correct NN use O
use IN of O
of NN serotonin T
serotonin NNS agonists T
agonists IN in O
in NN migraine D
migraine : : O
: JJ oral O
oral CC or O
or JJ injectable O
injectable NN form O
form . ? O

Overtraining VBG CAPITAL Overtraining O
Overtraining CC and O
and NN recovery O

A DT CAPITAL A O
A JJ conceptual O
conceptual NN model O

Saliva FW CAPITAL Saliva O
Saliva NN composition O
composition CC and O
and NN exercise O

Lipid NN CAPITAL Lipid O
Lipid NN metabolism O
metabolism IN during O
during NN exercise O

Golf NNP CAPITAL Golf D
Golf NNS injuries D

An DT CAPITAL An O
An NN overview O

Prevention NNP CAPITAL Prevention O
Prevention IN of O
of NN ankle D
ankle NNS injuries D

Academic NNP CAPITAL Academic O
Academic NN medicine O
medicine : -- O
-- JJ alternative O
alternative NN medicine O
medicine IN from O
from DT the O
the NN viewpoint O
viewpoint IN of O
of JJ public O
public NN health O
health JJ public O
public NN health O
health NNS directors O

Academic NNP CAPITAL Academic O
Academic NN medicine O
medicine CC and O
and JJ complementary O
complementary NN medicine O
medicine : -- O
-- NN campaign O
campaign IN for O
for DT the O
the NN truth O
truth IN in O
in JJ medical O
medical NNS theories O

The DT CAPITAL The O
The JJ academic O
academic NN medicine O
medicine : -- O
-- JJ alternative O
alternative NN medicine O
medicine NN tension O
tension NN field O

Are VBP CAPITAL Are O
Are JJ academic O
academic JJ medicine-alternative O
medicine-alternative NN medicine O
medicine JJ incompatible O
incompatible , , O
, JJ compatible O
compatible , , O
, JJ complementary O
complementary . ? O

Research NNP CAPITAL Research O
Research IN in O
in JJ complementary O
complementary NN medicine O
medicine : : O
: NNS results O
results CC and O
and NNS problems O

Subcutaneous JJ CAPITAL Subcutaneous D
Subcutaneous NNS hematomas D
hematomas , , O
, VBN reduced O
reduced RB CAPITAL Quick O
Quick NN value O

Factor NN CAPITAL Factor D
Factor NN CAPITAL VII D
VII NN deficiency D

Mononucleosis NN CAPITAL Mononucleosis D
Mononucleosis NN infectiosa D
infectiosa NN ( O
( JJ CAPITAL Epstein-Barr D
Epstein-Barr NN virus D
virus NN infection D

Morphology NN CAPITAL Morphology O
Morphology CC and O
and JJ molecular O
molecular NN biology O
biology IN of O
of JJ malignant O
malignant JJ soft D
soft NN tissue D
tissue NNS sarcomas D

Surgical NNP CAPITAL Surgical O
Surgical NNS aspects O
aspects IN in O
in DT the O
the JJ multidisciplinary O
multidisciplinary NN treatment O
treatment IN of O
of JJ soft D
soft NN tissue D
tissue NNS sarcomas D

Surgical NNP CAPITAL Surgical T
Surgical NN management T
management IN of O
of JJ soft D
soft NN tissue D
tissue NNS sarcomas D
sarcomas : : O
: NNS principles O
principles IN of O
of NN resection T
resection CC and O
and JJ reconstructive O
reconstructive JJ plastic O
plastic NNS procedures O

Adjuvant JJ CAPITAL Adjuvant T
Adjuvant NN chemotherapy T
chemotherapy IN in O
in RB early O
early JJ soft D
soft NN tissue D
tissue NN sarcoma D
sarcoma CC and O
and JJ palliative T
palliative NN chemotherapy T
chemotherapy IN in O
in JJ advanced O
advanced JJ soft D
soft NN tissue D
tissue NN sarcoma D
sarcoma IN in O
in NNS adults O

Radiotherapy NN CAPITAL Radiotherapy T
Radiotherapy IN of O
of JJ soft D
soft NN tissue D
tissue NNS sarcomas D

Spinal JJ CAPITAL Spinal D
Spinal JJ muscular D
muscular NN atrophy D
atrophy : : O
: WRB where O
where VBP are O
are PRP we O
we IN in O
in CD 1998 O
1998 . ? O

Diseases NNS CAPITAL Diseases O
Diseases JJ transmitted O
transmitted IN by O
by JJ non-conventional O
non-conventional NNS agents O
agents NN ( O
( `` `` O
`` NNS prions O
prions '' '' O
'' NN ) O
) : : O
: JJ nosology O
nosology CC and O
and NN diagnosis O

A DT CAPITAL A O
A NN note O
note IN on O
on DT the O
the NN epidemiology O
epidemiology IN of O
of NN CAPITAL Creutzfeldt-Jakob D
Creutzfeldt-Jakob NN syndrome D

Biology NN CAPITAL Biology O
Biology IN of O
of JJ non-conventional O
non-conventional JJ transmissible O
transmissible NNS agents O
agents CC or O
or NNS prions O

Cerebral JJ CAPITAL Cerebral D
Cerebral NN hemosiderosis D
hemosiderosis JJ related O
related TO to O
to JJ hereditary O
hereditary NN ceruloplasmin D
ceruloplasmin NN deficiency D

Clinical JJ CAPITAL Clinical O
Clinical JJ familial O
familial NN case O
case NN study O

Intramedullary JJ CAPITAL Intramedullary O
Intramedullary NNS metastases O
metastases IN of O
of JJ bronchogenic D
bronchogenic NN carcinoma D

Two CD CAPITAL Two O
Two NNS cases O

Nervous JJ CAPITAL Nervous D
Nervous NN system D
system NN borreliosis D
borreliosis IN with O
with NN pseudo-lymphoma O
pseudo-lymphoma NNS cells O
cells IN in O
in JJ cerebrospinal O
cerebrospinal NN fluid O

Epidural JJ CAPITAL Epidural O
Epidural CC and O
and JJ intramedullary O
intramedullary NN abscess O
abscess IN of O
of JJ acute O
acute NN onset O

Cranial JJ CAPITAL Cranial D
Cranial NN nerve D
nerve NNS injuries D
injuries IN during O
during JJ multifocal O
multifocal NNS neuropathies O
neuropathies IN with O
with JJ persistent O
persistent NN conduction O
conduction NNS blocks O

Cytokines NNS CAPITAL Cytokines O
Cytokines CC and O
and JJ peripheral O
peripheral NNS neuropathies O

Clinical JJ CAPITAL Clinical O
Clinical NN diagnosis O
diagnosis IN of O
of NN frontotemporal D
frontotemporal NN dementia D

Study NNP CAPITAL Study O
Study IN of O
of JJ cortical D
cortical NN atrophy D
atrophy IN with O
with JJ magnetic O
magnetic NN resonance O
resonance NN imaging O
imaging IN in O
in NN corticobasal D
corticobasal NN degeneration D

Autosomal JJ CAPITAL Autosomal O
Autosomal JJ dominant O
dominant JJ nocturnal O
nocturnal JJ frontal O
frontal NN lobe O
lobe NN epilepsy D

Eosinophilic JJ CAPITAL Eosinophilic D
Eosinophilic NN meningitis D
meningitis JJ due O
due TO to O
to JJ CAPITAL Angiostrongylus O
Angiostrongylus NN cantonensis O

Case NNP CAPITAL Case O
Case IN of O
of JJ superficial D
superficial NN hemosiderosis D
hemosiderosis IN of D
of DT the D
the JJ central D
central JJ nervous D
nervous NN system D
system VBN treated O
treated IN with O
with NN trientine T

Germinal JJ CAPITAL Germinal D
Germinal NN tumor D
tumor NNS metastases D

Case NNP CAPITAL Case O
Case NN report O

Bradycardia NN CAPITAL Bradycardia D
Bradycardia : : O
: DT an O
an JJ unrecognized O
unrecognized NN complication O
complication IN of O
of DT some O
some JJ epileptic O
epileptic NNS crises O

Facial JJ CAPITAL Facial D
Facial NN palsy O
palsy JJ relevant O
relevant TO to O
to NN CAPITAL HIV O
HIV NN seropositivity O

Pneumosinus NN CAPITAL Pneumosinus O
Pneumosinus NNS dilatans O
dilatans : : O
: DT a O
a JJ little-known O
little-known JJ diagnostic O
diagnostic NN tool O

Current JJ CAPITAL Current O
Current NN status O
status IN of O
of JJ mitochondrial D
mitochondrial NNS diseases D

Vascular JJ CAPITAL Vascular D
Vascular NNP CAPITAL Parkinson D
Parkinson NNS syndromes D
syndromes : : O
: DT a O
a JJ controversial O
controversial NN concept O

Epilepsy NNP CAPITAL Epilepsy D
Epilepsy CC and O
and JJ psychiatric D
psychiatric NNS disorders D
disorders : : O
: JJ epidemiological O
epidemiological NNS data O

Auditory JJ CAPITAL Auditory D
Auditory NN perception D
perception NNS disorders D
disorders JJ due O
due TO to O
to JJ bilateral D
bilateral JJ cortical D
cortical NNS lesions D

An DT CAPITAL An O
An NN electrophysiology O
electrophysiology NN study O

Zinc NN CAPITAL Zinc T
Zinc NN gluconate T
gluconate NNS lozenges T
lozenges IN for O
for VBG treating O
treating DT the O
the JJ common D
common JJ cold D

Body NN CAPITAL Body O
Body NN weight O
weight CC and O
and NN mortality O
mortality IN among O
among NNS women O

Survey NN CAPITAL Survey O
Survey CC and O
and NN assessment O
assessment IN of O
of DT the O
the JJ actual O
actual NN state O
state IN of O
of JJ routine O
routine NN measurement O
measurement IN of O
of NN glycohaemoglobin/GHb O
glycohaemoglobin/GHb IN by O
by JJ commercial O
commercial NNS methods O
methods : : O
: VBG warning O
warning TO to O
to DT the O
the NNS users O
users CC and O
and DT the O
the NNS providers O

The DT CAPITAL The O
The JJ radiological O
radiological NN investigation O
investigation IN of O
of VBN suspected O
suspected JJR lower O
lower NN limb O
limb JJ deep D
deep NN vein D
vein NN thrombosis D

p53 NN p53 O
p53 NNS mutations O
mutations IN in O
in JJ CAPITAL BRCA1-associated O
BRCA1-associated JJ familial O
familial NN breast D
breast NN cancer D

Metronidazole NNP CAPITAL Metronidazole T
Metronidazole NN ( O
( NNP CAPITAL Flagyl O
Flagyl NN ) O

The DT CAPITAL The O
The NNP CAPITAL Preterm O
Preterm NN CAPITAL Prediction O
Prediction NNP CAPITAL Study O
Study : : O
: NN association O
association IN of O
of NN cesarean T
cesarean NN delivery T
delivery IN with O
with NNS increases O
increases IN in O
in JJ maternal O
maternal NN weight O
weight CC and O
and NN body O
body NN mass O
mass NN index O

Controversies NNS CAPITAL Controversies O
Controversies IN in O
in VBG hydrating O
hydrating DT the O
the RB terminally O
terminally RB ill O
ill NN patient O

Frequency NN CAPITAL Frequency O
Frequency CC and O
and NN significance O
significance IN of O
of JJ antinuclear O
antinuclear NNS antibodies O
antibodies IN in O
in JJ multiple D
multiple NN sclerosis D

Magnetic JJ CAPITAL Magnetic O
Magnetic NN resonance O
resonance NN imaging O
imaging IN of O
of DT the O
the NN bone O
bone NN marrow O
marrow IN in O
in JJ hematologic D
hematologic NNS malignancies D

Generation NN CAPITAL Generation O
Generation IN of O
of NN diversity O
diversity IN in O
in JJ mammalian O
mammalian JJ gut-associated O
gut-associated JJ lymphoid O
lymphoid NNS tissues O
tissues : : O
: JJ restricted O
restricted NN CAPITAL V O
V NN gene O
gene NN usage O
usage VBZ does O
does RB not O
not VB preclude O
preclude JJ complex O
complex NN CAPITAL V O
V NN gene O
gene NN organization O

A DT CAPITAL A O
A JJ major O
major JJ non-LTR O
non-LTR NN retrotransposon O
retrotransposon IN of O
of NN CAPITAL Bombyx O
Bombyx NN mori O
mori , , O
, NN CAPITAL L1Bm O

Algae NNP CAPITAL Algae O
Algae CC or O
or NN protozoa O
protozoa : : O
: JJ phylogenetic O
phylogenetic NN position O
position IN of O
of NNS euglenophytes O
euglenophytes CC and O
and NNS dinoflagellates O
dinoflagellates IN as O
as VBN inferred O
inferred IN from O
from JJ mitochondrial O
mitochondrial NNS sequences O

Structure NN CAPITAL Structure O
Structure CC and O
and NN function O
function IN of O
of DT the O
the RB long O
long JJ terminal O
terminal NNS repeats O
repeats IN of O
of JJ feline O
feline NN leukemia O
leukemia NNS viruses O
viruses VBN derived O
derived IN from O
from RB naturally O
naturally VBG occurring O
occurring JJ acute D
acute JJ myeloid D
myeloid NNS leukemias D
leukemias IN in O
in NNS cats O

Use NNP CAPITAL Use O
Use IN of O
of JJ protein-C T
protein-C NN concentrate T
concentrate , , T
, NN heparin T
heparin , , T
, CC and T
and NN haemodiafiltration T
haemodiafiltration IN in O
in JJ meningococcus-induced D
meningococcus-induced NN purpura D
purpura NNS fulminans D

Satellite NNP CAPITAL Satellite O
Satellite NN CAPITAL DNA O
DNA NN repeat O
repeat NN sequence O
sequence NN variation O
variation VBZ is O
is JJ low O
low IN in O
in CD three O
three NNS species O
species IN of O
of VBG burying O
burying NNS beetles O
beetles IN in O
in DT the O
the NN genus O
genus NN CAPITAL Nicrophorus O
Nicrophorus NN ( O
( NNP CAPITAL Coleoptera O
Coleoptera : : O
: FW CAPITAL Silphidae O
Silphidae NN ) O

The DT CAPITAL The O
The NN importance O
importance IN of O
of NN patient O
patient NN registration O
registration CC and O
and VBG processing O

Dose-dependent JJ CAPITAL Dose-dependent O
Dose-dependent NNS effects O
effects IN of O
of JJ recombinant O
recombinant JJ human O
human NN interleukin-6 O
interleukin-6 IN on O
on NN glucose O
glucose NN regulation O

Genomic JJ CAPITAL Genomic O
Genomic NN sequence O
sequence IN of O
of DT a O
a NN CAPITAL Lyme D
Lyme NN disease D
disease NN spirochaete O
spirochaete , , O
, FW CAPITAL Borrelia O
Borrelia FW burgdorferi O

Interaction NN CAPITAL Interaction O
Interaction IN between O
between JJ electronic O
electronic NN article O
article NN surveillance O
surveillance NNS systems O
systems CC and O
and JJ implantable O
implantable NNS defibrillators O
defibrillators : : O
: NNS insights O
insights IN from O
from DT a O
a JJ fourth O
fourth NN generation O
generation NN CAPITAL ICD O

Human JJ CAPITAL Human O
Human JJ bodily O
bodily NN health O
health CC and O
and DT the O
the JJ common O
common JJ good O

Proposals NNS CAPITAL Proposals O
Proposals IN for O
for NN action O
action IN by O
by NNS individuals O
individuals CC and O
and DT the O
the JJ CAPITAL Catholic O
Catholic NNP CAPITAL Church O

Invited VBN CAPITAL Invited O
Invited NN commentary O
commentary : : O
: DT le O
le NN mystre O
mystre IN de O
de CAPITAL Montr O
Montr NN ( O
( NN c O
c NN ) O
) NNP al O
al . . O

Why WRB CAPITAL Why O
Why NNP CAPITAL Oedipus O
Oedipus CC and O
and RB not O
not NNP CAPITAL Christ O
Christ . ? O
? : : O
: DT a O
a JJ psychoanalytic O
psychoanalytic NN inquiry O
inquiry IN into O
into NN innocence O
innocence , , O
, JJ human O
human NN sacrifice O
sacrifice , , O
, CC and O
and DT the O
the JJ sacred O
sacred : -- O
-- NNP CAPITAL Part O
Part PRP CAPITAL I O
I : : O
: NN CAPITAL Innocence O
Innocence , , O
, NN spirituality O
spirituality , , O
, CC and O
and JJ human O
human NN sacrifice O

Equine NN CAPITAL Equine O
Equine NN dinucleotide O
dinucleotide NN repeat O
repeat NNS loci O
loci NN CAPITAL LEX049-LEX063 O

Molecular JJ CAPITAL Molecular O
Molecular NNS systematics O
systematics IN of O
of NNS tanagers O
tanagers NN ( O
( FW CAPITAL Thraupinae O
Thraupinae NN ) O
) : : O
: NN evolution O
evolution CC and O
and NN biogeography O
biogeography IN of O
of DT a O
a JJ diverse O
diverse NN radiation O
radiation IN of O
of JJ neotropical O
neotropical NNS birds O

Expression NN CAPITAL Expression O
Expression IN of O
of NN cytokeratin O
cytokeratin CD 20 O
20 IN in O
in JJ urinary O
urinary NN cytology O
cytology IN of O
of NNS patients O
patients IN with O
with NN bladder D
bladder NN carcinoma D

A DT CAPITAL A O
A NN family O
family IN of O
of RB highly O
highly JJ repetitive O
repetitive NNS CAPITAL DNAs O
DNAs IN from O
from `` `` O
`` NN ginbuna O
ginbuna '' '' O
'' NN ( O
( NNP CAPITAL Carassius O
Carassius NN auratus O
auratus NN langsdorfi O
langsdorfi NN ) O
) NN genome O
genome JJ common O
common TO to O
to NNP CAPITAL Carassius O
Carassius NN auratus O
auratus NNS populations O

Characterization NN CAPITAL Characterization O
Characterization IN of O
of NN cDNA O
cDNA NNS clones O
clones IN in O
in JJ size-fractionated O
size-fractionated NN cDNA O
cDNA NNS libraries O
libraries IN from O
from JJ human O
human NN brain O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> JJ CAPITAL Respiratory O
Respiratory NN arrest O
arrest VBG following O
following JJ peribulbar O
peribulbar NN anesthesia O
anesthesia IN for O
for NN cataract O
cataract NN surgery O
surgery : : O
: NN case O
case NN report O
report CC and O
and NN review O
review IN of O
of DT the O
the NN literature O

Mouse NN CAPITAL Mouse O
Mouse NN CAPITAL LIM-kinase O
LIM-kinase CD 2 O
2 NN gene O
gene : : O
: NN cDNA O
cDNA VBG cloning O
cloning , , O
, JJ genomic O
genomic NN organization O
organization , , O
, CC and O
and JJ tissue-specific O
tissue-specific NN expression O
expression IN of O
of CD two O
two RB alternatively O
alternatively VBN initiated O
initiated NNS transcripts O

A DT CAPITAL A O
A JJ gross O
gross CC and O
and JJ microscopic O
microscopic NN study O
study IN of O
of JJ cerebral D
cerebral NNS injuries D
injuries VBG accompanying O
accompanying JJ maxillofacial O
maxillofacial JJ high-velocity O
high-velocity NN projectile D
projectile VBG wounding D
wounding IN in O
in NNS dogs O

Does VBZ CAPITAL Does O
Does DT this O
this NN patient O
patient VB have O
have DT a O
a NN mole O
mole CC or O
or DT a O
a NN melanoma D
melanoma . ? O

Methotrexate NNP CAPITAL Methotrexate T
Methotrexate CC and O
and NN trimethoprim T
trimethoprim : : O
: DT a O
a JJ fatal O
fatal NN interaction O

Pellagra NN CAPITAL Pellagra D
Pellagra CC and O
and DT the O
the NN origin O
origin IN of O
of DT a O
a NN myth O
myth : : O
: NN evidence O
evidence IN from O
from JJ CAPITAL European O
European NN literature O
literature CC and O
and NN folklore O

Absorbable JJ CAPITAL Absorbable T
Absorbable NN suture T
suture NN technique T
technique : : O
: NN solution O
solution TO to O
to DT the O
the NN growth O
growth NN problem O
problem IN in O
in JJ pediatric O
pediatric NN pacing O
pacing IN with O
with JJ endocardial O
endocardial VBZ leads O

Undergraduate JJ CAPITAL Undergraduate O
Undergraduate JJ orthodontic O
orthodontic NN education O
education : : O
: WDT what O
what MD should O
should PRP we O
we VB teach O
teach RB rather O
rather IN than O
than WDT what O
what MD can O
can PRP we O
we VB teach O
teach . ? O

Genetic JJ CAPITAL Genetic O
Genetic NN variation O
variation IN in O
in DT the O
the JJ dimorphic O
dimorphic NNS regions O
regions IN of O
of NN CAPITAL RAP-1 O
RAP-1 NNS genes O
genes CC and O
and NN rap-1 O
rap-1 NNS loci O
loci IN of O
of NN CAPITAL Babesia D
Babesia NN bigemina D

History NN CAPITAL History O
History : -- O
-- DT a O
a VBG living O
living NN museum O

Interview NN CAPITAL Interview O
Interview IN by O
by NNP CAPITAL Grethe O
Grethe NNP CAPITAL Kjaergaard O

Gastric JJ CAPITAL Gastric O
Gastric NN site O
site IN of O
of NN epidermoid D
epidermoid NN carcinoma D

Hypodermic JJ CAPITAL Hypodermic O
Hypodermic NNS needles O
needles IN in O
in DT the O
the JJ neuropathic O
neuropathic NN foot O
foot IN of O
of DT a O
a NN patient O
patient IN with O
with NN diabetes D

Helicobacter NNP CAPITAL Helicobacter O
Helicobacter NN pylori O
pylori : -- O
-- RBR more O
more JJ light O
light , , O
, JJR less O
less NN heat O

A DT CAPITAL A O
A JJ national O
national NN survey O
survey IN of O
of JJ physician-assisted O
physician-assisted NN suicide O
suicide CC and O
and NN euthanasia O
euthanasia IN in O
in DT the O
the NNP CAPITAL United O
United NNPS CAPITAL States O

Death NN CAPITAL Death O
Death VBZ is O
is DT a O
a NN journey O
journey TO to O
to VB be O
be VBN undertaken O

Replicated VBN CAPITAL Replicated O
Replicated NNS declines O
declines IN in O
in NN assault O
assault NNS rates O
rates IN after O
after NN implementation O
implementation IN of O
of DT the O
the VBN CAPITAL Assaulted O
Assaulted NNP CAPITAL Staff O
Staff NNP CAPITAL Action O
Action NN CAPITAL Program O

Positive JJ CAPITAL Positive O
Positive NN patch O
patch NN test O
test TO to O
to NN cocamidopropyl O
cocamidopropyl NN betaine O
betaine IN in O
in DT a O
a NN hairdresser O

Management NNP CAPITAL Management O
Management IN of O
of NN dyslipidemia D
dyslipidemia IN in O
in NNS adults O
adults IN with O
with NN diabetes D

American JJ CAPITAL American O
American NNP CAPITAL Diabetes O
Diabetes NNP CAPITAL Association O

Acute JJ CAPITAL Acute D
Acute NN diverticulitis D

Investigation NNP CAPITAL Investigation O
Investigation IN of O
of DT the O
the NN yeast O
yeast JJ mitochondrial O
mitochondrial JJ unselective O
unselective NN channel O
channel IN in O
in JJ intact O
intact CC and O
and JJ permeabilized O
permeabilized NNS spheroplasts O

Acute JJ CAPITAL Acute D
Acute NN sciatica D
sciatica IN with O
with DT an O
an JJ infective O
infective NN cause O

An DT CAPITAL An O
An JJ ecologic O
ecologic NN analysis O
analysis IN of O
of JJ psychosocial D
psychosocial NN stress D
stress CC and O
and NN heart D
heart NN disease D
disease IN in O
in JJ CAPITAL British O
British NNP CAPITAL Columbia O

Human JJ CAPITAL Human O
Human NN leukocyte O
leukocyte NN antigen O
antigen NNS frequencies O
frequencies IN in O
in DT a O
a VBN selected O
selected NN group O
group IN of O
of JJ CAPITAL Lebanese O
Lebanese JJ CAPITAL Greek O
Greek JJ CAPITAL Orthodox O

Alcohol NN CAPITAL Alcohol O
Alcohol CC and O
and DT the O
the NN heart O

Spontaneous JJ CAPITAL Spontaneous D
Spontaneous JJ ovarian D
ovarian NN hyperstimulation D
hyperstimulation NN syndrome D
syndrome IN with O
with NN pregnancy O

Will MD CAPITAL Will O
Will DT the O
the JJ real O
real JJ plastic O
plastic NN surgeon O
surgeon VB please O
please VB stand O
stand RB up O
up . ? O

Modulation NN CAPITAL Modulation O
Modulation IN of O
of JJ ultraviolet O
ultraviolet JJ light-induced O
light-induced JJ epidermal D
epidermal NN damage D
damage : : O
: JJ beneficial O
beneficial NNS effects O
effects IN of O
of NN tocopherol T

A DT CAPITAL A O
A NN survey O
survey IN of O
of DT the O
the NNS attitudes O
attitudes IN of O
of JJ chronic O
chronic JJ psychiatric O
psychiatric NNS patients O
patients VBG living O
living IN in O
in DT the O
the NN community O
community IN toward O
toward PRP$ their O
their NN medication O

Alterations NNS CAPITAL Alterations O
Alterations IN in O
in DT the O
the VBG developing O
developing JJ immune O
immune NN system O
system IN of O
of DT the O
the NN CAPITAL F344 O
F344 NN rat O
rat IN after O
after JJ perinatal O
perinatal NN exposure O
exposure TO to O
to CD 2 O
2 , , O
, CD 3 O
3 , , O
, CD 7 O
7 , , O
, NN 8-tetrachlorodibenzo-p-dioxin O
8-tetrachlorodibenzo-p-dioxin : : O
: NNP CAPITAL II O

Effects NNS CAPITAL Effects O
Effects IN on O
on DT the O
the NN pup O
pup CC and O
and DT the O
the JJ adult O

Renal JJ CAPITAL Renal O
Renal NN ultrasonography O
ultrasonography : : O
: DT a O
a NN procedure O
procedure IN for O
for NNS nephrologists O

Use NNP CAPITAL Use O
Use IN of O
of NN cisapride T
cisapride IN in O
in NN treatment O
treatment IN of O
of NN constipation D
constipation IN in O
in NNS children O

Bilateral JJ CAPITAL Bilateral O
Bilateral NN sampling O
sampling IN of O
of DT the O
the JJ internal O
internal JJ jugular O
jugular NN vein O
vein TO to O
to VB distinguish O
distinguish IN between O
between NNS mechanisms O
mechanisms IN of O
of JJ adrenocorticotropic O
adrenocorticotropic JJ hormone-dependent O
hormone-dependent NN CAPITAL Cushing D
Cushing NN syndrome D

The DT CAPITAL The O
The NN influence O
influence IN of O
of NNS patients O
patients POS ' O
' NNS hopes O
hopes IN of O
of VBG receiving O
receiving DT a O
a NN prescription O
prescription IN on O
on NNS doctors O
doctors POS ' O
' NNS perceptions O
perceptions CC and O
and DT the O
the NN decision O
decision TO to O
to VB prescribe O
prescribe : : O
: DT a O
a NN questionnaire O
questionnaire NN survey O

Coronary JJ CAPITAL Coronary D
Coronary JJ endothelial D
endothelial NN dysfunction D
dysfunction IN in O
in NNS humans O
humans VBZ is O
is VBN associated O
associated IN with O
with JJ myocardial D
myocardial NN perfusion D
perfusion NNS defects D

Medical JJ CAPITAL Medical O
Medical NNS devices O
devices CC and O
and DT the O
the NN year O
year CD 2000 O
2000 NN problem O

Internists NNPS CAPITAL Internists O
Internists POS ' O
' CC and O
and NNS surgeons O
surgeons POS ' O
' NNS attitudes O
attitudes IN toward O
toward NNS guns O
guns CC and O
and NN firearm O
firearm NN injury O
injury NN prevention O

Firearm NN CAPITAL Firearm O
Firearm NN injury O
injury NN prevention O

American JJ CAPITAL American O
American NNP CAPITAL College O
College IN of O
of NNP CAPITAL Physicians O

Management NNP CAPITAL Management O
Management IN of O
of JJ vaginal D
vaginal NN vault D
vault NN prolapse D

Death NN CAPITAL Death O
Death NNS rates O
rates IN of O
of NNS characters O
characters IN in O
in NN soap O
soap NNS operas O
operas IN on O
on JJ CAPITAL British O
British NN television O
television : : O
: VBZ is O
is DT a O
a NN government O
government NN health O
health VBG warning O
warning VBN required O
required . ? O

Child NN CAPITAL Child O
Child JJ sexual O
sexual NN abuse O
abuse : : O
: WRB when O
when DT a O
a NN doctor O
doctor POS 's O
's NN duty O
duty TO to O
to NN report O
report NN abuse O
abuse NNS conflicts O
conflicts IN with O
with DT a O
a NN duty O
duty IN of O
of NN confidentiality O
confidentiality TO to O
to DT the O
the NN victim O

Tissue NN CAPITAL Tissue O
Tissue NNS adhesives O
adhesives : -- O
-- VBN revisited O

Racial JJ CAPITAL Racial O
Racial NN discrimination O
discrimination IN in O
in DT the O
the NN allocation O
allocation IN of O
of NN distinction O
distinction NNS awards O
awards . ? O
? NN CAPITAL Analysis O
Analysis IN of O
of NN list O
list IN of O
of NN award O
award NNS holders O
holders IN by O
by NN type O
type IN of O
of NN award O
award , , O
, NN specialty O
specialty CC and O
and NN region O

Multicenter JJ CAPITAL Multicenter O
Multicenter NN study O
study IN of O
of JJ surfactant T
surfactant NN ( T
( JJ beractant T
beractant NN ) T
) NN use O
use IN in O
in DT the O
the NN treatment O
treatment IN of O
of NN term O
term NNS infants O
infants IN with O
with JJ severe D
severe JJ respiratory D
respiratory NN failure D

Survanta NN CAPITAL Survanta O
Survanta IN in O
in NN CAPITAL Term O
Term NNS CAPITAL Infants O
Infants NNP CAPITAL Study O
Study NNP CAPITAL Group O

Consultation NN CAPITAL Consultation O
Consultation NN section O

Cataract NN CAPITAL Cataract D
Cataract JJ surgical O
surgical NN problem O

Changing VBG CAPITAL Changing O
Changing DT the O
the NN law O
law IN on O
on NN decision O
decision VBG making O
making IN for O
for RB mentally O
mentally JJ incapacitated O
incapacitated NNS adults O

The DT CAPITAL The O
The VBG coding O
coding NN audit O

Providing VBG CAPITAL Providing O
Providing JJ primary O
primary NN care O
care IN in O
in DT the O
the NN accident O
accident CC and O
and NN emergency O
emergency NN department O

Challenges NNS CAPITAL Challenges O
Challenges TO to O
to JJ CAPITAL Native O
Native JJ CAPITAL American O
American NN health O
health NN care O

Federal NNP CAPITAL Federal O
Federal NNS programs O
programs CC and O
and JJ CAPITAL Indian O
Indian NN country O
country : : O
: DT a O
a NN time O
time IN for O
for NN reinvention O

Chicago NNP CAPITAL Chicago O
Chicago NN report O
report NNS profiles O

Big JJ CAPITAL Big O
Big NN city O
city NN health O

College-age JJ CAPITAL College-age O
College-age NN drinking O
drinking NNS problems O

Using VBG CAPITAL Using O
Using NN CAPITAL YPLL O
YPLL IN in O
in NN health O
health VBG planning O

WHO WP CAPITAL WHO O
WHO VBZ decides O
decides : : O
: NN food O
food NN irradiation O
irradiation JJ safe O
safe IN at O
at DT any O
any NN level O

Genetic JJ CAPITAL Genetic O
Genetic NN sampling O
sampling : : O
: JJ big O
big NN brother O
brother CC or O
or JJ big O
big NN science O
science . ? O

Physician NN CAPITAL Physician O
Physician NNS assistants O
assistants CC and O
and NN nurse O
nurse NNS practitioners O
practitioners IN in O
in NN hospital O
hospital NN outpatient O
outpatient NNS departments O
departments , , O
, CD 1993-1994 O

Laying VBG CAPITAL Laying O
Laying DT the O
the NN foundation O
foundation IN for O
for JJ CAPITAL Healthy O
Healthy NNS CAPITAL People O
People CD 2010 O

The DT CAPITAL The O
The RB first O
first NN year O
year IN of O
of NN consultation O

The DT CAPITAL The O
The JJ veracious O
veracious NN etiology O
etiology IN of O
of JJ ectopic D
ectopic NN pregnancy D

Is VBZ CAPITAL Is O
Is JJ dietary O
dietary JJ fat O
fat DT a O
a JJ major O
major NN determinant O
determinant IN of O
of NN body O
body JJ fat O
fat . ? O

Factors NNS CAPITAL Factors O
Factors VBN involved O
involved IN in O
in DT the O
the NN rate O
rate IN of O
of NN fall O
fall IN of O
of NN thyroid O
thyroid VBG stimulating O
stimulating NN hormone O
hormone IN in O
in VBN treated O
treated NN hypothyroidism D

Case NNP CAPITAL Case O
Case NN complexity O

Imaging NNP CAPITAL Imaging O
Imaging JJ pulmonary D
pulmonary NN embolism D

Early RB CAPITAL Early O
Early JJ inpatient O
inpatient NN rehabilitation O
rehabilitation IN after O
after JJ elective O
elective NN hip O
hip CC and O
and NN knee O
knee NN arthroplasty T

Inpatient JJ CAPITAL Inpatient O
Inpatient NN rehabilitation O
rehabilitation IN after O
after JJ total O
total JJ joint T
joint NN replacement T

Delayed VBN CAPITAL Delayed O
Delayed NN healing O
healing IN of O
of NN rhytidectomy T
rhytidectomy NN flap O
flap VBD resurfaced O
resurfaced IN with O
with NN CAPITAL CO2 O
CO2 NN laser O

The DT CAPITAL The O
The NN CAPITAL SAPHO D
SAPHO NN syndrome D
syndrome : : O
: DT an O
an VBG evolving O
evolving NN concept O
concept IN for O
for JJ unifying O
unifying JJ several O
several JJ idiopathic O
idiopathic NNS disorders O
disorders IN of O
of NN bone O
bone CC and O
and NN skin O

Beverage NNP CAPITAL Beverage O
Beverage NN use O
use CC and O
and NN risk O
risk IN for O
for NN kidney D
kidney NNS stones D
stones IN in O
in NNS women O

Use NNP CAPITAL Use O
Use IN of O
of DT a O
a NNP CAPITAL Foley O
Foley NN catheter O
catheter IN in O
in DT the O
the NN removal O
removal IN of O
of DT a O
a JJ substernal D
substernal NN goiter D

Early RB CAPITAL Early O
Early NN identification O
identification IN of O
of JJ variant O
variant NN CAPITAL Creutzfeldt-Jakob D
Creutzfeldt-Jakob NN disease D

Slater NNP CAPITAL Slater O
Slater VBN revisited O
revisited : : O
: CD 6 O
6 NN year O
year VB follow O
follow RB up O
up NN study O
study IN of O
of NNS patients O
patients IN with O
with RB medically O
medically JJ unexplained O
unexplained NN motor D
motor NNS symptoms D

Re NNP CAPITAL Re O
Re : : O
: NNP CAPITAL Intermediate O
Intermediate NN term O
term NN assessment O
assessment IN of O
of DT the O
the NN reliability O
reliability , , O
, NN function O
function CC and O
and NN patient O
patient NN satisfaction O
satisfaction IN with O
with DT the O
the NN CAPITAL AMS700 O
AMS700 NN ultrex O
ultrex NN penile O
penile NN prosthesis O

Reduced VBN CAPITAL Reduced O
Reduced NN ratio O
ratio IN of O
of JJ male O
male TO to O
to JJ female O
female NNS births O
births IN in O
in JJ several O
several JJ industrial O
industrial NNS countries O
countries : : O
: DT a O
a NN sentinel O
sentinel NN health O
health NN indicator O
indicator . ? O

Should MD CAPITAL Should O
Should PRP we O
we VB accept O
accept NN mediocrity O
mediocrity . ? O

Resolution NNP CAPITAL Resolution O
Resolution IN of O
of JJ recalcitrant D
recalcitrant NN molluscum D
molluscum NN contagiosum D
contagiosum NN virus D
virus NNS lesions D
lesions IN in O
in JJ human O
human NN immunodeficiency O
immunodeficiency JJ virus-infected O
virus-infected NNS patients O
patients VBN treated O
treated IN with O
with NN cidofovir T

Colonoscopic JJ CAPITAL Colonoscopic O
Colonoscopic NN removal O
removal IN of O
of NN chicken O
chicken NNS bones O
bones VBN impacted O
impacted IN in O
in DT the O
the NN sigmoid O
sigmoid IN in O
in CD two O
two NNS patients O

`` `` `` O
`` VB CAPITAL Pull O
Pull '' '' O
'' CC or O
or `` `` O
`` NN push O
push '' '' O
'' NN CAPITAL PEG O
PEG : : O
: DT the O
the NN reinsertion O
reinsertion IN of O
of DT the O
the NN gastroscope O
gastroscope VBZ is O
is RB often O
often JJ unnecessary O

Clear JJ CAPITAL Clear D
Clear NN cell D
cell NN papulosis D
papulosis : : O
: NN case O
case NN report O
report CC and O
and NN literature O
literature NN review O

Malignant JJ CAPITAL Malignant D
Malignant NN melanoma D
melanoma IN in O
in FW situ O
situ : : O
: DT an O
an NN oxymoron O
oxymoron WP$ whose O
whose NN time O
time VBZ has O
has VBN come O

External JJ CAPITAL External T
External NN beam T
beam NN radiation T
radiation NN therapy T
therapy IN for O
for NN choroidal D
choroidal NN neovascularization D

Somatic JJ CAPITAL Somatic O
Somatic NN mesoderm O
mesoderm NN differentiation O
differentiation CC and O
and DT the O
the NN development O
development IN of O
of DT a O
a NN subset O
subset IN of O
of JJ pericardial O
pericardial NNS cells O
cells VB depend O
depend IN on O
on DT the O
the RB not O
not RB enough O
enough NNS muscles O
muscles NN ( O
( NN nem O
nem NN ) O
) NN locus O
locus , , O
, WDT which O
which VBZ contains O
contains DT the O
the JJ inscuteable O
inscuteable NN gene O
gene CC and O
and DT the O
the NN intron O
intron JJ located O
located NN gene O
gene , , O
, NNS skittles O

Hemodynamic JJ CAPITAL Hemodynamic O
Hemodynamic NNS effects O
effects IN of O
of JJ acute O
acute NN tetrandrine O
tetrandrine CC and O
and NN terlipressin O
terlipressin NN administration O
administration IN on O
on JJ portal O
portal JJ hypertensive O
hypertensive NNS rats O

Nonneoplastic JJ CAPITAL Nonneoplastic D
Nonneoplastic NNS disorders D
disorders IN of D
of DT the D
the NN eccrine D
eccrine NNS glands D

Cerebrospinal JJ CAPITAL Cerebrospinal O
Cerebrospinal NN fluid O
fluid CC and O
and NN plasma O
plasma NN insulin O
insulin NNS levels O
levels IN in O
in NN CAPITAL Alzheimer D
Alzheimer POS 's D
's NN disease D
disease : : O
: NN relationship O
relationship TO to O
to NN severity O
severity IN of O
of NN dementia D
dementia CC and O
and NN apolipoprotein O
apolipoprotein NN CAPITAL E O
E NN genotype O

Isolated VBN CAPITAL Isolated O
Isolated JJ internal D
internal NN ophthalmoplegia D
ophthalmoplegia VBN associated O
associated IN with O
with NN CAPITAL IgG O
IgG JJ anti-GQ1b O
anti-GQ1b NN antibody O

Bolus NN CAPITAL Bolus T
Bolus JJ thrombolytic T
thrombolytic NNS infusions T
infusions IN during O
during NNP CAPITAL CPR O
CPR IN for O
for NNS patients O
patients IN with O
with JJ refractory D
refractory NN arrest D
arrest NNS rhythms D
rhythms : : O
: NN outcome O
outcome IN of O
of DT a O
a NN case O
case NN series O

Enthesopathy NN CAPITAL Enthesopathy D
Enthesopathy IN in O
in DT a O
a NN case O
case IN of O
of JJ primary D
primary JJ biliary D
biliary NN cirrhosis D
cirrhosis IN with O
with JJ positive O
positive NN CAPITAL HLA-B27 O

Remifentanil NN CAPITAL Remifentanil T
Remifentanil IN in O
in DT the O
the RB critically O
critically RB ill O

Hyponatremia NN CAPITAL Hyponatremia D
Hyponatremia IN with O
with NN venlafaxine T
venlafaxine . . O

Use NNP CAPITAL Use O
Use IN of O
of DT a O
a NN nerve T
nerve NN stimulator T
stimulator IN for O
for JJ phrenic D
phrenic NN nerve D
nerve NN block D
block IN in O
in NN treatment O
treatment IN of O
of NNS hiccups D

Anaesthesia NNP CAPITAL Anaesthesia O
Anaesthesia IN for O
for JJ laparoscopic T
laparoscopic NN cholecystectomy T
cholecystectomy IN in O
in DT a O
a NN patient O
patient IN with O
with NN CAPITAL Eisenmenger D
Eisenmenger POS 's D
's NN syndrome D

Micronutrients NNS CAPITAL Micronutrients T
Micronutrients CC and O
and JJ human O
human NN cancer D
cancer NNS risks D
risks : -- O
-- NNS prospects O
prospects IN for O
for NN prevention O

Joint NNP CAPITAL Joint O
Joint NNP CAPITAL International O
International NNP CAPITAL Symposium O
Symposium IN of O
of DT the O
the JJ CAPITAL Danish O
Danish NN CAPITAL Cancer O
Cancer NNP CAPITAL Society O
Society , , O
, JJ CAPITAL European O
European NN CAPITAL Cancer O
Cancer NNP CAPITAL Prevention O
Prevention NNP CAPITAL Organization O
Organization CC and O
and NNP CAPITAL National O
National NNP CAPITAL Food O
Food NNP CAPITAL Agency O
Agency IN of O
of NNP CAPITAL Denmark O

Aarhus NNP CAPITAL Aarhus O
Aarhus , , O
, NNP CAPITAL Denmark O
Denmark , , O
, CD 21-24 O
21-24 NNP CAPITAL May O
May CD 1997 O

Abstracts NNS CAPITAL Abstracts O

Vitamin NN CAPITAL Vitamin O
Vitamin NN CAPITAL K2 O
K2 CC and O
and NN serum O
serum NN cholesterol O
cholesterol IN in O
in NNS patients O
patients IN on O
on JJ continuous O
continuous JJ ambulatory O
ambulatory JJ peritoneal T
peritoneal NN dialysis T

Income NN CAPITAL Income O
Income NN inequality O
inequality CC and O
and NN population O
population NN health O

Naloxone NN CAPITAL Naloxone T
Naloxone JJ -precipitated O
-precipitated JJ acute D
acute NN opioid D
opioid NN withdrawal D
withdrawal NN syndrome D
syndrome IN after O
after JJ epidural T
epidural NN morphine T

Idiopathic JJ CAPITAL Idiopathic D
Idiopathic NN atrial D
atrial NN flutter D

Munchausen NN CAPITAL Munchausen D
Munchausen POS 's D
's NN syndrome D

Clinical JJ CAPITAL Clinical O
Clinical NN evaluation O
evaluation IN of O
of JJ adjuvant T
adjuvant JJ chemoradiotherapy T
chemoradiotherapy IN with T
with JJ CAPITAL CDDP T
CDDP , , T
, JJ 5-FU T
5-FU , , T
, CC and T
and NN CAPITAL VP-16 T
VP-16 IN for O
for JJ advanced D
advanced NN esophageal D
esophageal NN cancer D

New JJ CAPITAL New T
New NN drug T
drug NN treatment T
treatment IN for O
for NN CAPITAL Alzheimer D
Alzheimer POS 's D
's NN disease D
disease : : O
: NNS lessons O
lessons IN for O
for NN healthcare O
healthcare NN policy O

Development NNP CAPITAL Development O
Development IN of O
of NN neurosurgery T
neurosurgery IN in O
in NNP CAPITAL Greece O
Greece : : O
: JJ past O
past , , O
, JJ present O
present , , O
, CC and O
and JJ future O

Intravascular-catheter-related JJ CAPITAL Intravascular-catheter-related D
Intravascular-catheter-related NNS infections D

The DT CAPITAL The O
The NN effect O
effect IN of O
of DT a O
a JJ social O
social NN support O
support VBG boosting O
boosting NN intervention O
intervention IN on O
on NN stress O
stress , , O
, VBG coping O
coping , , O
, CC and O
and JJ social O
social NN support O
support IN in O
in NNS caregivers O
caregivers IN of O
of NNS children O
children IN with O
with NN CAPITAL HIV/AIDS D

Point-counterpoint JJ CAPITAL Point-counterpoint O

Mass JJ CAPITAL Mass O
Mass NN population O
population NN skin D
skin NN cancer D
cancer VBG screening O
screening VBZ is O
is RB not O
not JJ worthwhile O

Persons NNS CAPITAL Persons O
Persons JJ successful O
successful IN at O
at JJ long-term O
long-term NN weight O
weight NN loss O
loss CC and O
and NN maintenance O
maintenance VB continue O
continue TO to O
to VB consume O
consume DT a O
a JJ low-energy O
low-energy , , O
, JJ low-fat O
low-fat NN diet O

Ultrasound NN CAPITAL Ultrasound O
Ultrasound NNS measurements O
measurements IN of O
of DT the O
the JJ newborn O
newborn NN hip O

Comparison NN CAPITAL Comparison O
Comparison IN of O
of CD two O
two NNS methods O
methods IN in O
in CD 657 O
657 NNS newborns O

Inferences NNS CAPITAL Inferences O
Inferences IN from O
from NN symphysiotomy T
symphysiotomy NN experience O

1995 CD 1995 O
1995 JJ coronary T
coronary NN artery T
artery NN bypass T
bypass NN risk O
risk NN model O
model : : O
: DT CAPITAL The O
The NNP CAPITAL Society O
Society IN of O
of JJ CAPITAL Thoracic O
Thoracic NNPS CAPITAL Surgeons O
Surgeons JJ CAPITAL Adult O
Adult JJ CAPITAL Cardiac O
Cardiac NNP CAPITAL National O
National NN CAPITAL Database O

Informed JJ CAPITAL Informed O
Informed NN consent O
consent : : O
: VBG edging O
edging RB forwards O
forwards NN ( O
( CC and O
and RB backwards O
backwards NN ) O

Online JJ CAPITAL Online O
Online JJ medical O
medical NNS surveys O
surveys : : O
: VBG using O
using DT the O
the NN CAPITAL Internet O
Internet IN as O
as DT a O
a NN research O
research NN tool O

US-guided JJ CAPITAL US-guided O
US-guided NN puncture O
puncture IN of O
of DT the O
the JJ internal O
internal JJ jugular O
jugular NN vein O
vein : : O
: NNS complications O
complications CC and O
and JJ anatomic O
anatomic NNS considerations O

Mouth NN CAPITAL Mouth O
Mouth NN care O
care CC and O
and NN skin O
skin NN care O
care IN in O
in JJ palliative O
palliative NN medicine O

Simple JJ CAPITAL Simple O
Simple JJ antiseptic T
antiseptic NNS mouthwashes T
mouthwashes VBP are O
are RB best O
best IN for O
for NN infection D

The DT CAPITAL The O
The NN effect O
effect IN of O
of NN melatonin O
melatonin NN administration O
administration IN on O
on JJ ethanol-induced O
ethanol-induced NN lipid O
lipid NN peroxidation O
peroxidation IN in O
in NNS rats O

A DT CAPITAL A O
A NN comparison O
comparison IN of O
of NN aspirin T
aspirin CC plus T
plus JJ tirofiban T
tirofiban IN with O
with NN aspirin T
aspirin CC plus T
plus NN heparin T
heparin IN for O
for JJ unstable D
unstable NN angina D

Platelet NN CAPITAL Platelet O
Platelet NN CAPITAL Receptor O
Receptor NN CAPITAL Inhibition O
Inhibition IN in O
in JJ CAPITAL Ischemic O
Ischemic NN CAPITAL Syndrome O
Syndrome NNP CAPITAL Management O
Management NN ( O
( NN CAPITAL PRISM O
PRISM NN ) O
) NNP CAPITAL Study O
Study NNS CAPITAL Investigators O

Mike NNP CAPITAL Mike O
Mike NNP CAPITAL Grace O
Grace NNS talks O
talks TO to O
to NNP CAPITAL Mike O
Mike NNP CAPITAL Joy O

Interview NN CAPITAL Interview O
Interview IN by O
by NNP CAPITAL Mike O
Mike NNP CAPITAL Grace O

Multivalent JJ CAPITAL Multivalent O
Multivalent NNS cations O
cations VB depress O
depress NN ligand O
ligand NN affinity O
affinity IN of O
of JJ insulin-like O
insulin-like NN growth O
growth JJ factor-binding O
factor-binding NN proteins-3 O
proteins-3 CC and O
and CD -5 O
-5 IN on O
on JJ human O
human NN CAPITAL GM-10 O
GM-10 NN fibroblast O
fibroblast NN cell O
cell NNS surfaces O

Effect NN CAPITAL Effect O
Effect IN of O
of JJ continuous O
continuous JJ spinal O
spinal NN remifentanil O
remifentanil NN infusion O
infusion IN on O
on NN behaviour O
behaviour CC and O
and JJ spinal O
spinal NN glutamate O
glutamate NN release O
release VBN evoked O
evoked IN by O
by JJ subcutaneous O
subcutaneous NN formalin O
formalin IN in O
in DT the O
the NN rat O

How WRB CAPITAL How O
How RB long O
long MD should O
should NN suction O
suction VBZ drains O
drains VB stay O
stay IN in O
in IN after O
after NN breast T
breast NN surgery T
surgery IN with O
with JJ axillary T
axillary NN dissection T
dissection . ? O

Physicians NNP CAPITAL Physicians O
Physicians JJ disciplined O
disciplined IN for O
for JJ sex-related O
sex-related NNS offenses O

Something NN CAPITAL Something O
Something IN from O
from NN nothing O
nothing : : O
: DT the O
the NN evolution O
evolution CC and O
and NN utility O
utility IN of O
of NN satellite O
satellite NNS repeats O

Sudden JJ CAPITAL Sudden O
Sudden NN death O
death IN in O
in JJ young O
young NNS athletes O
athletes : : O
: VBG screening O
screening IN for O
for DT the O
the NN needle O
needle IN in O
in DT a O
a NN haystack O

Chemotherapy NN CAPITAL Chemotherapy T
Chemotherapy RB alone T
alone VBN compared O
compared IN with O
with NN chemotherapy T
chemotherapy CC plus T
plus NN radiotherapy T
radiotherapy IN for O
for JJ localized O
localized NN intermediate- O
intermediate- CC and O
and JJ high-grade O
high-grade JJ non-Hodgkin D
non-Hodgkin POS 's D
's NN lymphoma D

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NNP CAPITAL Prevention O
Prevention IN of O
of DT a O
a RB first O
first NN stroke D
stroke IN by O
by NNS transfusions T
transfusions IN in O
in NNS children O
children IN with O
with JJ sickle O
sickle NN cell O
cell NN anemia O
anemia CC and O
and JJ abnormal O
abnormal NNS results O
results IN on O
on JJ transcranial O
transcranial NNP CAPITAL Doppler O
Doppler NN ultrasonography O

HIV NN CAPITAL HIV T
HIV NNS vaccines T
vaccines : : O
: NNS prospects O
prospects CC and O
and NNS challenges O

Occupation NN CAPITAL Occupation O
Occupation : : O
: DT the O
the NN keystone O
keystone IN of O
of DT a O
a NN curriculum O
curriculum IN for O
for DT a O
a JJ self-defined O
self-defined NN profession O

Touch VB CAPITAL Touch O
Touch NN sensibility O
sensibility IN in O
in DT the O
the NN breast O
breast IN after O
after JJ subcutaneous T
subcutaneous NN mastectomy T
mastectomy CC and O
and JJ immediate O
immediate NN reconstruction O
reconstruction IN with O
with DT a O
a NN prosthesis O

Iatrogenic JJ CAPITAL Iatrogenic T
Iatrogenic NNS ruptures T
ruptures IN of O
of DT the O
the JJ tracheobronchial O
tracheobronchial NN tree O

Endoscopic JJ CAPITAL Endoscopic T
Endoscopic NN hemostasis T
hemostasis IN of O
of NN bleeding D
bleeding JJ duodenal D
duodenal NN ulcer D
ulcer IN in O
in DT a O
a NN child O
child IN with O
with NN CAPITAL Henoch-Schnlein D
Henoch-Schnlein NN purpura D

Classification NN CAPITAL Classification O
Classification IN of O
of JJ primary O
primary JJ gastric D
gastric NNS lymphomas D
lymphomas VBG according O
according TO to O
to JJ histologic O
histologic NNS features O

SCIM NN CAPITAL SCIM O
SCIM : -- O
-- JJ spinal O
spinal NN cord O
cord NN independence O
independence NN measure O
measure : : O
: DT a O
a JJ new O
new NN disability O
disability NN scale O
scale IN for O
for NNS patients O
patients IN with O
with JJ spinal D
spinal NN cord D
cord NNS lesions D

Molecular JJ CAPITAL Molecular O
Molecular NN analysis O
analysis IN of O
of NN cellulose O
cellulose NN biosynthesis O
biosynthesis IN in O
in NNP CAPITAL Arabidopsis O

Users NNS CAPITAL Users O
Users POS ' O
' NNS guides O
guides TO to O
to DT the O
the JJ medical O
medical NN literature O
literature : : O
: NNP CAPITAL XIV O

How WRB CAPITAL How O
How TO to O
to VB decide O
decide IN on O
on DT the O
the NN applicability O
applicability IN of O
of JJ clinical O
clinical NN trial O
trial NNS results O
results TO to O
to PRP$ your O
your NN patient O

Evidence-Based JJ CAPITAL Evidence-Based O
Evidence-Based NNP CAPITAL Medicine O
Medicine VBG CAPITAL Working O
Working NNP CAPITAL Group O

Hemispheric NNP CAPITAL Hemispheric O
Hemispheric NN difference O
difference IN in O
in JJ human O
human NN skin O
skin NN color O

Limitations NNPS CAPITAL Limitations O
Limitations IN of O
of JJ diagnostic O
diagnostic NNS criteria O
criteria CC and O
and NN assessment O
assessment NNS instruments O
instruments IN for O
for JJ mental D
mental NNS disorders D

Implications NNS CAPITAL Implications O
Implications IN for O
for NN research O
research CC and O
and NN policy O

Causing VBG CAPITAL Causing O
Causing NN death O
death CC or O
or VBG allowing O
allowing TO to O
to VB die O
die . ? O
? NNP CAPITAL Developments O
Developments IN in O
in DT the O
the NN law O

Albumin NN CAPITAL Albumin O
Albumin NN synthesis O
synthesis NNS rates O
rates VBP are O
are RB not O
not VBN decreased O
decreased IN in O
in JJ hypoalbuminemic D
hypoalbuminemic NN cachectic D
cachectic NN cancer D
cancer NNS patients O
patients IN with O
with DT an O
an JJ ongoing O
ongoing NN acute-phase O
acute-phase NN protein O
protein NN response O

Brain-gut JJ CAPITAL Brain-gut O
Brain-gut NN axis O
axis IN in O
in NN health O
health CC and O
and NN disease O

Pins NNS CAPITAL Pins O
Pins CC and O
and NNS CAPITAL Rubbers O
Rubbers NN CAPITAL Traction O
Traction NNP CAPITAL System O

A DT CAPITAL A O
A NN specialist O
specialist NN nurse O
nurse MD can O
can VB replace O
replace JJ pre-registration O
pre-registration NN house O
house NNS officers O
officers IN in O
in DT the O
the JJ surgical O
surgical JJ pre-admission O
pre-admission NN clinic O

Voluntary JJ CAPITAL Voluntary O
Voluntary NN death O
death : : O
: DT a O
a NN comparison O
comparison IN of O
of JJ terminal O
terminal NN dehydration D
dehydration CC and O
and JJ physician-assisted O
physician-assisted NN suicide O

Ionized VBN CAPITAL Ionized O
Ionized NN magnesium O
magnesium IN in O
in NN serum O
serum CC and O
and JJ ultrafiltrate O
ultrafiltrate : : O
: NN pH O
pH CC and O
and NN bicarbonate O
bicarbonate NN effect O
effect IN on O
on NNS measurements O
measurements IN with O
with DT the O
the NN CAPITAL AVL O
AVL CD 988-4 O
988-4 NN electrolyte O
electrolyte NN analyzer O

Anterior NNP CAPITAL Anterior D
Anterior NN glenohumeral D
glenohumeral NNS dislocations D
dislocations : : O
: WDT what O
what TO to O
to VB do O
do CC and O
and WRB how O
how TO to O
to VB do O
do PRP it O

Relationship NN CAPITAL Relationship O
Relationship IN between O
between NN topotecan T
topotecan JJ systemic O
systemic NN exposure O
exposure CC and O
and NN tumor O
tumor NN response O
response IN in O
in JJ human O
human NN neuroblastoma D
neuroblastoma NNS xenografts D

Cerebral JJ CAPITAL Cerebral D
Cerebral NN infarct D
infarct VBG following O
following JJ central T
central JJ venous T
venous NN cannulation T

The DT CAPITAL The O
The NN CAPITAL Gram O
Gram VB stain O

Heavy JJ CAPITAL Heavy O
Heavy NN caffeine O
caffeine NN intake O
intake IN in O
in NN pregnancy O
pregnancy CC and O
and JJ sudden D
sudden NN infant D
infant NN death D
death NN syndrome D

New NNP CAPITAL New O
New NNP CAPITAL Zealand O
Zealand NN CAPITAL Cot O
Cot NN CAPITAL Death O
Death NNP CAPITAL Study O
Study NNP CAPITAL Group O

When WRB CAPITAL When O
When MD can O
can NNS odds O
odds NNS ratios O
ratios NN mislead O
mislead . ? O

Treatment NN CAPITAL Treatment O
Treatment IN of O
of JJ renal D
renal NN failure D
failure IN in O
in JJ idiopathic D
idiopathic JJ membranous D
membranous NN nephropathy D
nephropathy IN with O
with NN azathioprine T
azathioprine CC and T
and JJ prednisolone T

Enzyme NN CAPITAL Enzyme O
Enzyme NN structure O
structure IN with O
with CD two O
two JJ catalytic O
catalytic NNS sites O
sites IN for O
for JJ double-sieve O
double-sieve NN selection O
selection IN of O
of JJ substrate O

Role NN CAPITAL Role O
Role IN of O
of DT the O
the JJ ketogenic T
ketogenic NN diet T
diet IN in O
in NNS children O
children IN with O
with JJ intractable D
intractable NNS seizures D
seizures . . O

Building-associated JJ CAPITAL Building-associated O
Building-associated JJ pulmonary D
pulmonary NN disease D
disease IN from O
from NN exposure O
exposure TO to O
to NNP CAPITAL Stachybotrys O
Stachybotrys NN chartarum O
chartarum CC and O
and JJ CAPITAL Aspergillus O
Aspergillus NN versicolor O

Interleukin-8 NN CAPITAL Interleukin-8 O
Interleukin-8 VBZ participates O
participates IN in O
in NN angiogenesis O
angiogenesis IN in O
in JJ non-small O
non-small NN cell O
cell , , O
, CC but O
but RB not O
not JJ small O
small NN cell O
cell NN carcinoma D
carcinoma IN of O
of DT the O
the NN lung O

Antenatal JJ CAPITAL Antenatal T
Antenatal NN indomethacin T
indomethacin : -- O
-- JJ adverse O
adverse JJ fetal O
fetal NNS effects O
effects VBN confirmed O

Evaluation NN CAPITAL Evaluation O
Evaluation IN of O
of DT the O
the NN microparticle O
microparticle NN enzyme O
enzyme NN immunoassay O
immunoassay NNP CAPITAL Abbott O
Abbott NN CAPITAL IMx O
IMx NNP CAPITAL Select O
Select NN CAPITAL Chlamydia O
Chlamydia CC and O
and DT the O
the NN importance O
importance IN of O
of JJ urethral O
urethral NN site O
site NN sampling O
sampling TO to O
to VB detect O
detect NN CAPITAL Chlamydia D
Chlamydia NN trachomatis D
trachomatis IN in O
in NNS women O

The DT CAPITAL The O
The JJ persistent O
persistent JJ vegetative O
vegetative NN state O
state IN after O
after JJ closed D
closed NN head D
head NN injury D
injury : : O
: JJ clinical O
clinical CC and O
and JJ magnetic O
magnetic NN resonance O
resonance NN imaging O
imaging NNS findings O
findings IN in O
in CD 42 O
42 NNS patients O

Wegener NNP CAPITAL Wegener D
Wegener POS 's D
's NN granulomatosis D
granulomatosis IN of O
of DT the O
the NN head O
head CC and O
and NN neck O

Chromosomal JJ CAPITAL Chromosomal O
Chromosomal NNS abnormalities O
abnormalities IN of O
of DT a O
a JJ new O
new NN nasopharyngeal D
nasopharyngeal NN carcinoma D
carcinoma NN cell O
cell NN line O
line NN ( O
( NN CAPITAL NPC-BM1 O
NPC-BM1 NN ) O
) VBN derived O
derived IN from O
from DT a O
a NN bone D
bone NN marrow D
marrow JJ metastatic D
metastatic NN lesion D

Relation NN CAPITAL Relation O
Relation IN between O
between JJ intellectual D
intellectual VBG dysfunctioning D
dysfunctioning CC and O
and NN mortality O
mortality IN in O
in JJ community-residing O
community-residing JJR older O
older NNS people O

Anxiety NN CAPITAL Anxiety O
Anxiety CC and O
and JJ autonomic O
autonomic NN flexibility O
flexibility : : O
: DT a O
a JJ cardiovascular O
cardiovascular NN approach O

Cross-reactivity NN CAPITAL Cross-reactivity O
Cross-reactivity IN of O
of JJ specific O
specific NNS antibodies O
antibodies VBN directed O
directed TO to O
to NN heat O
heat NN shock O
shock NNS proteins O
proteins IN from O
from JJ periodontopathogenic O
periodontopathogenic NNS bacteria O
bacteria CC and O
and IN of O
of JJ human O
human NN origin O
origin NN ( O
( VBN corrected O
corrected NN ) O

Immunogenicity NN CAPITAL Immunogenicity O
Immunogenicity IN of O
of NN hepatitis D
hepatitis NN CAPITAL B D
B NN vaccine T
vaccine IN in O
in NN term O
term CC and O
and NN preterm O
preterm NNS infants O

Secondary JJ CAPITAL Secondary O
Secondary NN prevention O
prevention IN for O
for NN stroke D
stroke IN after O
after JJ CAPITAL CAPRIE T
CAPRIE CC and T
and NN CAPITAL ESPS-2 T

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> JJ CAPITAL New-onset O
New-onset NN angina O
angina VBG preceding O
preceding JJ acute O
acute JJ myocardial O
myocardial NN infarction O
infarction VBZ is O
is VBN associated O
associated IN with O
with VBN improved O
improved NN contractile O
contractile NN recovery O
recovery IN after O
after NN thrombolysis O

Magnetic JJ CAPITAL Magnetic O
Magnetic NN resonance O
resonance NN imaging O
imaging IN in O
in JJ focal D
focal NN myositis D

Concomitant JJ CAPITAL Concomitant D
Concomitant NN alveolitis D
alveolitis CC and O
and NN asthma D
asthma VBG following O
following NN exposure O
exposure TO to O
to NN triphenylmethane O
triphenylmethane NN triisocyanate O

Gorlin NNP CAPITAL Gorlin D
Gorlin NN syndrome D
syndrome : : O
: NN identification O
identification IN of O
of CD 4 O
4 JJ novel O
novel NN germ-line O
germ-line NNS mutations O
mutations IN of O
of DT the O
the JJ human O
human VBN patched O
patched NN ( O
( NN CAPITAL PTCH O
PTCH NN ) O
) NN gene O

Mutations NNS CAPITAL Mutations O
Mutations IN in O
in JJ brief O
brief DT no O

137 CD 137 O

Online JJ CAPITAL Online O

Genetic JJ CAPITAL Genetic O
Genetic NNS findings O
findings IN in O
in JJ congenital D
congenital JJ bilateral D
bilateral NN aplasia D
aplasia IN of O
of FW vas O
vas NNS deferens O
deferens NNS patients O
patients CC and O
and NN identification O
identification IN of O
of CD six O
six JJ novel O
novel NNS mutatations O

Mutations NNS CAPITAL Mutations O
Mutations IN in O
in JJ brief O
brief DT no O

138 CD 138 O

Online JJ CAPITAL Online O

A DT CAPITAL A O
A JJ novel O
novel NN point O
point NN mutation O
mutation IN in O
in DT a O
a NN splice O
splice NN acceptor O
acceptor NN site O
site IN of O
of NN intron O
intron CD 1 O
1 IN of O
of DT the O
the JJ human O
human JJ low O
low NN density O
density NN lipoprotein O
lipoprotein NN receptor O
receptor NN gene O
gene WDT which O
which NNS causes O
causes JJ severe O
severe NN hypercholesterolemia D
hypercholesterolemia : : O
: DT an O
an JJ unexpected O
unexpected NN absence O
absence IN of O
of NN exon O
exon VBG skipping O

Mutations NNS CAPITAL Mutations O
Mutations IN in O
in JJ brief O
brief DT no O

139 CD 139 O

Online JJ CAPITAL Online O

A DT CAPITAL A O
A IN de O
de FW novo O
novo NN missense O
missense NN mutation O
mutation NN ( O
( NN CAPITAL R1623Q O
R1623Q NN ) O
) IN of O
of DT the O
the NN CAPITAL SCN5A O
SCN5A NN gene O
gene IN in O
in DT a O
a JJ CAPITAL Japanese O
Japanese NN girl O
girl IN with O
with JJ sporadic D
sporadic RB long D
long NN CAPITAL QT D
QT NN sydrome D

Mutations NNS CAPITAL Mutations O
Mutations IN in O
in JJ brief O
brief DT no O

140 CD 140 O

Online JJ CAPITAL Online O

Missense NN CAPITAL Missense O
Missense NN mutation O
mutation IN in O
in NN exon O
exon CD 11 O
11 NN ( O
( NN CAPITAL Codon O
Codon CD 378 O
378 NN ) O
) IN of O
of DT the O
the NN presenilin-1 O
presenilin-1 NN gene O
gene IN in O
in DT a O
a JJ CAPITAL French O
French NN family O
family IN with O
with JJ early-onset O
early-onset NN CAPITAL Alzheimer D
Alzheimer POS 's D
's NN disease D
disease CC and O
and NN transmission O
transmission NN study O
study IN by O
by NN mismatch O
mismatch VBN enhanced O
enhanced NN allele O
allele JJ specific O
specific NN amplification O

Mutations NNS CAPITAL Mutations O
Mutations IN in O
in JJ brief O
brief DT no O

141 CD 141 O

Online JJ CAPITAL Online O

besancon NN besancon O
besancon IN @ O
@ NN rockefeller1.univ.lyon1.fr O

Mutation NN CAPITAL Mutation O
Mutation VBG sharing O
sharing , , O
, JJ predominant O
predominant NN involvement O
involvement IN of O
of DT the O
the NN CAPITAL MLH1 O
MLH1 NN gene O
gene CC and O
and NN description O
description IN of O
of CD four O
four JJ novel O
novel NNS mutations O
mutations IN in O
in JJ hereditary D
hereditary NN nonpolyposis D
nonpolyposis JJ colorectal D
colorectal NN cancer D

Mutations NNS CAPITAL Mutations O
Mutations IN in O
in JJ brief O
brief DT no O

144 CD 144 O

Online JJ CAPITAL Online O

A DT CAPITAL A O
A JJ new O
new JJ informative O
informative NN CAPITAL Alw O
Alw CD 26 O
26 PRP CAPITAL I O
I NN polymorphism O
polymorphism IN in O
in NN exon O
exon CD 10 O
10 IN of O
of DT the O
the JJ human O
human JJ low O
low NN density O
density NN lipoprotein O
lipoprotein NN receptor O
receptor NN gene O

Application NN CAPITAL Application O
Application TO to O
to JJ prenatal O
prenatal NN diagnosis O

Mutations NNS CAPITAL Mutations O
Mutations IN in O
in JJ brief O
brief DT no O

145 CD 145 O

Online JJ CAPITAL Online O

Novel JJ CAPITAL Novel O
Novel NN acceptor O
acceptor NN splice O
splice NN site O
site NN mutation O
mutation IN in O
in DT the O
the JJ invariant O
invariant NNP CAPITAL AG O
AG IN of O
of NN intron O
intron CD 6 O
6 IN of O
of NN alpha-galactosidase O
alpha-galactosidase DT CAPITAL A O
A NN gene O
gene , , O
, VBG causing O
causing NN CAPITAL Fabry D
Fabry NN disease D

Mutations NNS CAPITAL Mutations O
Mutations IN in O
in JJ brief O
brief DT no O

146 CD 146 O

Online JJ CAPITAL Online O

Meta-analysis NN CAPITAL Meta-analysis O
Meta-analysis IN of O
of NNS trials O
trials VBG comparing O
comparing NNS antidepressants T
antidepressants IN with O
with JJ active O
active NNS placebos O

Evidence-based JJ CAPITAL Evidence-based O
Evidence-based NNS guidelines O
guidelines IN for O
for JJ universal O
universal VBG counselling O
counselling CC and O
and VBG offering O
offering IN of O
of NN CAPITAL HIV O
HIV NN testing O
testing IN in O
in NN pregnancy O
pregnancy IN in O
in NNP CAPITAL Canada O

Chelation NN CAPITAL Chelation T
Chelation NN therapy T
therapy IN for O
for JJ peripheral D
peripheral JJ arterial D
arterial NN occlusive D
occlusive NN disease D
disease : : O
: DT a O
a JJ systematic O
systematic NN review O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NN CAPITAL Sodium T
Sodium NN channel T
channel NN block T
block IN with T
with NN mexiletine T
mexiletine VBZ is O
is JJ effective O
effective IN in O
in VBG reducing O
reducing NN dispersion O
dispersion IN of O
of NN repolarization O
repolarization CC and O
and VBG preventing O
preventing NN torsade D
torsade FW des D
des NNS pointes D
pointes IN in O
in NN CAPITAL LQT2 O
LQT2 CC and O
and NN CAPITAL LQT3 O
LQT3 NNS models O
models IN of O
of DT the O
the JJ long-QT O
long-QT NN syndrome O

Simultaneous JJ CAPITAL Simultaneous O
Simultaneous JJ microsurgical T
microsurgical JJ vasal T
vasal NN reconstruction T
reconstruction CC and O
and NN varicocele T
varicocele NN ligation T
ligation : : O
: NN safety O
safety NN profile O
profile CC and O
and NNS outcomes O

A DT CAPITAL A O
A VBN predetermined O
predetermined NN design O
design IN for O
for JJR easier O
easier JJ aesthetic T
aesthetic JJ abdominoplasty T

Significance NN CAPITAL Significance O
Significance IN of O
of NN revision O
revision IN of O
of DT the O
the JJ occupational O
occupational NN illness O
illness NN legislation O
legislation IN for O
for VBG evaluating O
evaluating NN intervertebral D
intervertebral NN disk D
disk NN damage D

Serum NN CAPITAL Serum O
Serum NN urate O
urate IN during O
during NNS bouts O
bouts IN of O
of JJ acute D
acute JJ gouty D
gouty NN arthritis D

Isolated VBN CAPITAL Isolated O
Isolated JJ axial O
axial JJ lateral O
lateral NN pulse O
pulse IN as O
as DT a O
a NN sign O
sign IN of O
of JJ latero-bulbar D
latero-bulbar NN ischemia D
ischemia : : O
: JJ clinical O
clinical JJ topographic O
topographic NN correlation O

Microalbuminuria NN CAPITAL Microalbuminuria D
Microalbuminuria VBZ is O
is RB positively O
positively VBN associated O
associated IN with O
with JJ usual O
usual JJ dietary O
dietary JJ saturated O
saturated JJ fat O
fat NN intake O
intake CC and O
and RB negatively O
negatively VBN associated O
associated IN with O
with JJ usual O
usual JJ dietary O
dietary NN protein O
protein NN intake O
intake IN in O
in NNS people O
people IN with O
with JJ insulin-dependent D
insulin-dependent NN diabetes D
diabetes NN mellitus D

Endoscopic JJ CAPITAL Endoscopic T
Endoscopic NN ultrasound T
ultrasound JJ miniprobe-guided T
miniprobe-guided NN steroid T
steroid NN injection T
injection IN for O
for NN treatment O
treatment IN of O
of JJ refractory D
refractory NN esophageal D
esophageal NNS strictures D

Purification NN CAPITAL Purification O
Purification CC and O
and NN characterization O
characterization IN of O
of DT an O
an NN acetyl O
acetyl NN xylan O
xylan NN esterase O
esterase IN from O
from NN CAPITAL Bacillus O
Bacillus NN pumilus O

The DT CAPITAL The O
The NN CAPITAL Stresst'er O
Stresst'er NN ergometer O
ergometer IN as O
as DT an O
an JJ alternative O
alternative TO to O
to NN treadmill O
treadmill NN testing O
testing IN in O
in NNS patients O
patients IN with O
with NN claudication D

Renal JJ CAPITAL Renal D
Renal NN trauma D
trauma CC and O
and DT the O
the NN risk O
risk IN of O
of JJ long-term O
long-term NNS complications O
complications IN in O
in NN shock T
shock NN wave T
wave NN lithotripsy T

Current JJ CAPITAL Current O
Current NN management O
management IN of O
of NN corneal D
corneal NNS abrasions D
abrasions : : O
: NN evidence O
evidence VBN based O
based NN practice O
practice . ? O

Placebo NN CAPITAL Placebo O
Placebo IN in O
in NN drug O
drug JJ clinical O
clinical NNS trials O

Chromosome NN CAPITAL Chromosome O
Chromosome NN 22qII O
22qII NNS deletions O

An DT CAPITAL An O
An JJ under-recognised O
under-recognised NN cause O
cause IN of O
of JJ idiopathic D
idiopathic VBG learning D
learning NN disability D

Serial JJ CAPITAL Serial O
Serial JJ magnetic O
magnetic NN resonance O
resonance NN imaging O
imaging NNS findings O
findings IN for O
for DT a O
a RB spontaneously O
spontaneously VBG resolving O
resolving JJ spinal D
spinal JJ subdural D
subdural NN hematoma D
hematoma : : O
: NN case O
case NN report O

A DT CAPITAL A O
A JJ simple O
simple NN technique O
technique IN for O
for NN correction O
correction IN of O
of JJ mucosal D
mucosal NNS irregularities D
irregularities IN of D
of DT the D
the NN lip D

Cancer NN CAPITAL Cancer D
Cancer NN risk O
risk IN in O
in DT the O
the NN rubber O
rubber NN industry O
industry : : O
: DT a O
a NN review O
review IN of O
of DT the O
the JJ recent O
recent JJ epidemiological O
epidemiological NN evidence O

HIV NN CAPITAL HIV O
HIV NN treatment O
treatment NNS strategies O
strategies : : O
: VBG planning O
planning IN for O
for DT the O
the RB long O
long NN term O

The DT CAPITAL The O
The NN project O
project IN of O
of DT a O
a JJ national O
national NN control O
control NN program O
program IN for O
for NN tuberculosis D
tuberculosis IN in O
in NNP CAPITAL Spain O

Decrease NN CAPITAL Decrease O
Decrease IN in O
in JJ antibiotic O
antibiotic NN susceptibility O
susceptibility CC or O
or NN increase O
increase IN in O
in NN resistance O
resistance . ? O

Helicobacter NNP CAPITAL Helicobacter O
Helicobacter NN pylori O
pylori CC and O
and JJ abdominal O
abdominal NNS symptoms O
symptoms : : O
: DT a O
a JJ population-based O
population-based NN study O
study IN among O
among JJ preschool O
preschool NNS children O
children IN in O
in JJ southern O
southern NNP CAPITAL Germany O

Have VBP CAPITAL Have O
Have PRP we O
we VBN treated O
treated NN CAPITAL AIDS D
AIDS RB too O
too RB well O
well . ? O
? VBG CAPITAL Rationing O
Rationing CC and O
and DT the O
the JJ future O
future IN of O
of NNP CAPITAL AIDS O
AIDS NN exceptionalism O

Recommendations NNS CAPITAL Recommendations O
Recommendations IN on O
on JJ antiretroviral T
antiretroviral NN treatment T

The DT CAPITAL The O
The NNP CAPITAL AIDS O
AIDS NNP CAPITAL Study O
Study NNP CAPITAL Group O
Group IN of O
of DT the O
the JJ CAPITAL Spanish O
Spanish NNP CAPITAL Society O
Society IN of O
of JJ CAPITAL Infectious O
Infectious NNS CAPITAL Diseases O
Diseases CC and O
and JJ CAPITAL Clinical O
Clinical NNP CAPITAL Microbiology O

Requirements NNS CAPITAL Requirements O
Requirements IN for O
for NN training O
training TO to O
to VB ensure O
ensure NN competence O
competence IN of O
of NNS endoscopists O
endoscopists VBG performing O
performing JJ invasive O
invasive NNS procedures O
procedures IN in O
in NNS children O

Safe NN CAPITAL Safe O
Safe NN motherhood O
motherhood : : O
: MD can O
can PRP we O
we VB make O
make DT a O
a NN difference O
difference . ? O

Lumbar JJ CAPITAL Lumbar D
Lumbar NN spine D
spine NN stenosis D
stenosis : : O
: DT a O
a JJ common O
common NN cause O
cause IN of O
of RB back O
back CC and O
and NN leg O
leg NN pain D

Myoepithelial JJ CAPITAL Myoepithelial D
Myoepithelial NN carcinoma D
carcinoma IN with O
with NN predominance O
predominance IN of O
of NN plasmacytoid O
plasmacytoid NNS cells O
cells VBG arising O
arising IN in O
in DT a O
a JJ pleomorphic D
pleomorphic NN adenoma D
adenoma IN of O
of DT the O
the NN parotid O
parotid NN gland O

Lonomia NN CAPITAL Lonomia O
Lonomia NN obliqua O
obliqua NN caterpillar O
caterpillar NNS spicules O
spicules NN trigger O
trigger JJ human O
human NN blood O
blood NN coagulation O
coagulation IN via O
via NN activation O
activation IN of O
of NN factor O
factor NN CAPITAL X O
X CC and O
and NN prothrombin O

Doing VBG CAPITAL Doing O
Doing NN everything O

Successful JJ CAPITAL Successful O
Successful NN replantation O
replantation IN of O
of DT an O
an VBN amputated O
amputated NN tongue O

Morbidity NN CAPITAL Morbidity O
Morbidity CC and O
and NN healthcare O
healthcare NN utilisation O
utilisation IN of O
of NNS children O
children IN in O
in NNS households O
households IN with O
with CD one O
one JJ adult O
adult : : O
: JJ comparative O
comparative JJ observational O
observational NN study O

A DT CAPITAL A O
A JJ novel O
novel NN frameshift O
frameshift NN mutation O
mutation NN 840delA O
840delA CC and O
and DT a O
a JJ novel O
novel NN polymorphism O
polymorphism NN CAPITAL D203A O
D203A IN in O
in DT the O
the JJ steroidogenic O
steroidogenic JJ acute O
acute JJ regulatory O
regulatory NN protein O
protein NN gene O
gene IN in O
in DT a O
a JJ CAPITAL Japanese O
Japanese NN patient O
patient IN with O
with JJ congenital D
congenital NN lipoid D
lipoid JJ adrenal D
adrenal NN hyperplasia D

Mutations NNS CAPITAL Mutations O
Mutations IN in O
in JJ brief O
brief DT no O

117 CD 117 O

Online JJ CAPITAL Online O

Identification NN CAPITAL Identification O
Identification IN of O
of CD five O
five JJ new O
new NNS mutations O
mutations CC and O
and CD three O
three JJ novel O
novel NNS polymorphisms O
polymorphisms IN in O
in DT the O
the NN muscle O
muscle NN chloride O
chloride NN channel O
channel NN gene O
gene NN ( O
( NN CAPITAL CLCN1 O
CLCN1 NN ) O
) IN in O
in CD 20 O
20 JJ CAPITAL Italian O
Italian NNS patients O
patients IN with O
with JJ dominant O
dominant CC and O
and JJ recessive O
recessive NN myotonia D
myotonia NN congenita D

Mutations NNS CAPITAL Mutations O
Mutations IN in O
in JJ brief O
brief DT no O

118 CD 118 O

Online JJ CAPITAL Online O

Identification NN CAPITAL Identification O
Identification IN of O
of DT a O
a JJ large O
large NN insertion O
insertion CC and O
and CD two O
two JJ novel O
novel NN point O
point NNS mutations O
mutations NN ( O
( NN 3671del8 O
3671del8 CC and O
and NN CAPITAL S1221X O
S1221X NN ) O
) IN in O
in JJ tuberous D
tuberous NN sclerosis D
sclerosis NN complex D
complex NN ( D
( NN CAPITAL TSC D
TSC NN ) D
) NNS patients O

Mutations NNS CAPITAL Mutations O
Mutations IN in O
in JJ brief O
brief DT no O

119 CD 119 O

Online JJ CAPITAL Online O

Mutational JJ CAPITAL Mutational O
Mutational NN analysis O
analysis IN of O
of DT the O
the NN cystathionine O
cystathionine NN beta-synthase O
beta-synthase NN gene O
gene : : O
: DT a O
a NN splicing O
splicing NN mutation O
mutation , , O
, CD two O
two NN missense O
missense NNS mutations O
mutations CC and O
and DT an O
an NN insertion O
insertion IN in O
in NNS patients O
patients IN with O
with NN homocystinuria D

Mutations NNS CAPITAL Mutations O
Mutations IN in O
in JJ brief O
brief DT no O

120 CD 120 O

Online JJ CAPITAL Online O

Analysis NN CAPITAL Analysis O
Analysis IN of O
of CD five O
five NNS mutations O
mutations IN in O
in CD 20 O
20 NN mucopolysaccharidois D
mucopolysaccharidois NN type O
type CD 1 O
1 NNS patients O
patients : : O
: JJ high O
high NN prevalence O
prevalence IN of O
of DT the O
the NN CAPITAL W402X O
W402X NN mutation O

Mutations NNS CAPITAL Mutations O
Mutations IN in O
in JJ brief O
brief DT no O

121 CD 121 O

Online JJ CAPITAL Online O

A DT CAPITAL A O
A JJ novel O
novel NN missense O
missense NN mutation O
mutation NN CAPITAL Ile538Val O
Ile538Val IN in O
in DT the O
the NN fibroblast O
fibroblast NN growth O
growth NN factor O
factor NN receptor O
receptor CD 3 O
3 IN in O
in NN hypochondroplasia D

Mutations NNS CAPITAL Mutations O
Mutations IN in O
in JJ brief O
brief DT no O

122 CD 122 O

Online JJ CAPITAL Online O

Detection NN CAPITAL Detection O
Detection IN of O
of CD four O
four JJ novel O
novel NNS mutations O
mutations IN in O
in DT the O
the NN iduronate-2-sulfatase O
iduronate-2-sulfatase NN gene O

Mutations NNS CAPITAL Mutations O
Mutations IN in O
in JJ brief O
brief DT no O

123 CD 123 O

Online JJ CAPITAL Online O

Polymorphisms NNS CAPITAL Polymorphisms O
Polymorphisms IN in O
in DT the O
the VBG coding O
coding NNS exons O
exons IN of O
of DT the O
the JJ human O
human VBG luteinizing O
luteinizing NN hormone O
hormone NN receptor O
receptor NN gene O

Mutations NNS CAPITAL Mutations O
Mutations IN in O
in JJ brief O
brief DT no O

124 CD 124 O

Online JJ CAPITAL Online O

Independent NNP CAPITAL Independent O
Independent NN occurrence O
occurrence IN of O
of DT the O
the JJ novel O
novel NN CAPITAL Arg2163 O
Arg2163 TO to O
to PRP$ CAPITAL His O
His NN mutation O
mutation IN in O
in DT the O
the NN factor O
factor CD CAPITAL VIII O
VIII NN gene O
gene IN in O
in CD three O
three JJ unrelated O
unrelated NNS families O
families IN with O
with NN haemophila D
haemophila DT CAPITAL A D
A IN with O
with JJ different O
different NNS phenotypes O

Mutations NNS CAPITAL Mutations O
Mutations IN in O
in JJ brief O
brief DT no O

126 CD 126 O

Online JJ CAPITAL Online O

Are VBP CAPITAL Are O
Are JJ CAPITAL Japanese O
Japanese NNS researchers O
researchers VBG exploiting O
exploiting NNP CAPITAL Thai O
Thai NN CAPITAL HIV O
HIV NNS patients O
patients . ? O

Underutilization NN CAPITAL Underutilization O
Underutilization IN of O
of NN aspirin T
aspirin IN in O
in JJR older O
older NNS patients O
patients IN with O
with RB prior D
prior JJ myocardial D
myocardial NN infarction D
infarction IN at O
at DT the O
the NN time O
time IN of O
of NN admission O
admission TO to O
to DT a O
a NN nursing O
nursing NN home O
home . . O

Distinguishing VBG CAPITAL Distinguishing O
Distinguishing JJ silent D
silent NN lacunar D
lacunar NN infarction D
infarction IN from O
from JJ enlarged D
enlarged NN CAPITAL Virchow-Robin D
Virchow-Robin NNS spaces D
spaces : : O
: DT a O
a JJ magnetic O
magnetic NN resonance O
resonance NN imaging O
imaging CC and O
and JJ pathological O
pathological NN study O

Correlation NN CAPITAL Correlation O
Correlation VBZ is O
is RB not O
not NN causation O

Inhalation NN CAPITAL Inhalation O
Inhalation IN of O
of NN ammonium O
ammonium JJ nitrate O
nitrate NN fuel O
fuel NN oil O
oil JJ explosive O
explosive NN ( O
( NNP CAPITAL ANFO O
ANFO NN ) O

Management NNP CAPITAL Management O
Management IN of O
of NN polycythaemia D
polycythaemia IN in O
in NNS adults O
adults IN with O
with JJ cyanotic D
cyanotic JJ congenital D
congenital NN heart D
heart NN disease D

Bolstering VBG CAPITAL Bolstering O
Bolstering NNP CAPITAL Sisyphus O

Use NNP CAPITAL Use O
Use IN of O
of JJ public O
public NN performance O
performance NNS reports O
reports : : O
: DT a O
a NN survey O
survey IN of O
of NNS patients O
patients VBG undergoing O
undergoing JJ cardiac T
cardiac NN surgery T

Role NN CAPITAL Role O
Role IN of O
of DT a O
a NN p53 O
p53 NN polymorphism O
polymorphism IN in O
in DT the O
the NN development O
development IN of O
of JJ human D
human JJ papillomavirus-associated D
papillomavirus-associated NN cancer D

The DT CAPITAL The O
The NN use O
use IN of O
of NNS nurses O
nurses IN in O
in JJ alternative O
alternative NN dispute O
dispute NN resolution O

Re NNP CAPITAL Re O
Re : : O
: NNP CAPITAL Friday O
Friday NN afternoon O
afternoon JJ pulmonary T
pulmonary NN arteriography T
arteriography NN ( T
( NN CAPITAL FAPA T
FAPA NN ) T
) : : O
: VBP are O
are NNS CAPITAL Fridays O
Fridays JJ good O
good IN for O
for PRP$ your O
your NN health O
health . ? O

Hormone NN CAPITAL Hormone T
Hormone NN replacement T
replacement NN therapy T
therapy CC and O
and NN breast D
breast NN cancer D
cancer . . O

Physician NN CAPITAL Physician O
Physician VB heal O
heal RB thyself O
thyself : : O
: VBP are O
are NNS antibiotics T
antibiotics DT the O
the NN cure O
cure CC or O
or DT the O
the NN disease O
disease . ? O

Primary JJ CAPITAL Primary D
Primary JJ biliary D
biliary NN cirrhosis D

Polymorphism NN CAPITAL Polymorphism O
Polymorphism IN in O
in NN promoter O
promoter NN region O
region IN of O
of JJ inducible O
inducible JJ nitric O
nitric NN oxide O
oxide NN synthase O
synthase NN gene O
gene CC and O
and NN protection O
protection IN against O
against NN malaria D

Ventilatory JJ CAPITAL Ventilatory O
Ventilatory NNS responses O
responses TO to O
to JJ acute O
acute CC and O
and JJ sustained O
sustained NN hypoxia O
hypoxia IN during O
during NN isoflurane O
isoflurane NN anesthesia O

Leprosy NN CAPITAL Leprosy D
Leprosy NN type D
type LS 1 D
1 NN reaction O
reaction IN as O
as DT the O
the RB first O
first NN manifestation O
manifestation IN of O
of JJ borderline O
borderline JJ lepromatous D
lepromatous NNP leprosy D
leprosy IN in O
in DT a O
a JJ young O
young JJ native O
native JJ CAPITAL German O

A DT CAPITAL A O
A JJ systematic O
systematic NN review O
review IN of O
of CD five O
five JJ systemic T
systemic NNS treatments T
treatments IN for O
for JJ severe D
severe NN psoriasis D

Trisomy NNP CAPITAL Trisomy O
Trisomy CD 10 O
10 IN in O
in NN leukemia D

Receptive JJ CAPITAL Receptive O
Receptive NNS properties O
properties IN of O
of JJ primary O
primary JJ afferent O
afferent NNS fibres O
fibres IN from O
from NN rabbit O
rabbit NN pleura O
pleura , , O
, IN in O
in FW vitro O

Congenital JJ CAPITAL Congenital D
Congenital NNS anomalies D
anomalies IN of D
of JJ tracheobronchial D
tracheobronchial VBG branching D
branching NNS patterns D
patterns : : O
: NN spiral O
spiral NN CAPITAL CT O
CT NNS aspects O
aspects IN in O
in NNS adults O

American JJ CAPITAL American O
American NNP CAPITAL Heart O
Heart NNP CAPITAL Association O
Association VBZ urges O
urges NN caution O
caution IN on O
on JJ new O
new NN diet O
diet NN drug O

Absence NN CAPITAL Absence O
Absence IN of O
of JJ renal O
renal CC and O
and JJ hepatic O
hepatic NN toxicity O
toxicity IN after O
after CD four O
four NNS hours O
hours IN of O
of CD 1.25 O
1.25 JJ minimum O
minimum JJ alveolar O
alveolar JJ anesthetic O
anesthetic NN concentration O
concentration NN sevoflurane O
sevoflurane NN anesthesia O
anesthesia IN in O
in NNS volunteers O

Linear JJ CAPITAL Linear D
Linear NN lichen D
lichen NN planopilaris D
planopilaris IN of O
of DT the O
the NN face O

Electrolyte NN CAPITAL Electrolyte O
Electrolyte NNS abnormalities O
abnormalities IN in O
in NNS patients O
patients IN with O
with JJ chronic D
chronic JJ renal D
renal NN failure D
failure VBG receiving O
receiving JJ parenteral O
parenteral NN nutrition O

Risk NN CAPITAL Risk O
Risk NNS factors O
factors IN for O
for JJ hemiretinal D
hemiretinal NN vein D
vein NN occlusion D
occlusion : : O
: NN comparison O
comparison IN with O
with NN risk O
risk NNS factors O
factors IN for O
for JJ central D
central CC and D
and NN branch D
branch JJ retinal D
retinal NN vein D
vein NN occlusion D
occlusion : : O
: DT the O
the NN eye O
eye NN disease O
disease JJ case-control O
case-control NN study O

The DT CAPITAL The O
The JJ psychological O
psychological NNS profiles O
profiles IN of O
of NNS patients O
patients IN with O
with JJ whiplash-associated D
whiplash-associated NN headache D

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> JJ CAPITAL Fatal O
Fatal JJ spontaneous O
spontaneous JJ spinal O
spinal JJ epidural O
epidural NN hematoma O
hematoma VBG following O
following NN thrombolysis O
thrombolysis IN for O
for JJ myocardial O
myocardial NN infarction O

Bifid JJ CAPITAL Bifid O
Bifid NN CAPITAL T O
T NNS waves O
waves VBN induced O
induced IN by O
by NN isoprenaline T
isoprenaline IN in O
in DT a O
a NN patient O
patient IN with O
with NN CAPITAL Brugada D
Brugada NN syndrome D
syndrome . . O

Quo NN CAPITAL Quo O
Quo NN vadis O
vadis `` `` O
`` NN suprema O
suprema NN lex O
lex '' '' O
'' . ? O

Death NN CAPITAL Death O
Death IN in O
in NN springtime O

Clinical JJ CAPITAL Clinical T
Clinical NN management T
management CC and O
and NN treatment O
treatment NNS outcomes O
outcomes IN of O
of NN CAPITAL Merkel D
Merkel NN cell D
cell NN carcinoma D

Relatives NNS CAPITAL Relatives O
Relatives IN in O
in DT the O
the NN resuscitation O
resuscitation NN room O
room : : O
: PRP$ their O
their NN point O
point IN of O
of NN view O

Large JJ CAPITAL Large D
Large NN airway D
airway NN disease D
disease VBN associated O
associated IN with O
with JJ inflammatory D
inflammatory NN bowel D
bowel NN disease D

Autonomy NN CAPITAL Autonomy O
Autonomy IN in O
in DT the O
the NN face O
face IN of O
of DT a O
a VBG devastating O
devastating NN diagnosis O

Advanced NNP CAPITAL Advanced O
Advanced NN practice O
practice NN nursing O
nursing : : O
: VBZ is O
is DT the O
the NN physician O
physician POS 's O
's JJ assistant O
assistant DT an O
an NN accident O
accident IN of O
of NN history O
history CC or O
or DT a O
a NN failure O
failure TO to O
to NN act O
act . ? O

Acute JJ CAPITAL Acute D
Acute JJ obstructive D
obstructive NN hydrocephalus D
hydrocephalus VBG complicating O
complicating JJ bacterial D
bacterial NN meningitis D
meningitis IN in O
in NN childhood O

Subcutaneous JJ CAPITAL Subcutaneous O
Subcutaneous JJ autologous O
autologous JJ ovarian O
ovarian NN transplantation O
transplantation IN in O
in JJ CAPITAL Wistar O
Wistar NNS rats O
rats VBZ maintains O
maintains NN hormone O
hormone NN secretion O

Teaching VBG CAPITAL Teaching O
Teaching JJ irritable D
irritable NN bowel D
bowel NN syndrome D
syndrome NNS patients O
patients TO to O
to NN care O
care IN for O
for PRP themselves O

Nonanesthetic JJ CAPITAL Nonanesthetic O
Nonanesthetic JJ volatile O
volatile NNS drugs O
drugs VB obey O
obey DT the O
the NNP CAPITAL Meyer-Overton O
Meyer-Overton NN correlation O
correlation IN in O
in CD two O
two JJ molecular O
molecular NN protein O
protein NN site O
site NNS models O

Inhaled VBN CAPITAL Inhaled T
Inhaled NN sodium T
sodium NN cromoglycate T
cromoglycate IN in O
in JJ young O
young NNS children O
children IN with O
with JJ moderate O
moderate NN asthma D

Directly RB CAPITAL Directly O
Directly VBN observed O
observed NN therapy O
therapy CC and O
and NN treatment O
treatment NN completion O
completion IN for O
for NN tuberculosis D
tuberculosis IN in O
in DT the O
the NNP CAPITAL United O
United NNPS CAPITAL States O
States : : O
: VBZ is O
is JJ universal O
universal VBN supervised O
supervised NN therapy O
therapy JJ necessary O
necessary . ? O

Investigation NNP CAPITAL Investigation O
Investigation IN of O
of JJ antibiotic T
antibiotic NN prophylaxis T
prophylaxis NN usage O
usage IN for O
for JJ vascular O
vascular CC and O
and JJ nonvascular O
nonvascular JJ interventional O
interventional NNS procedures O

Effect NN CAPITAL Effect O
Effect IN of O
of NN protein O
protein NN kinase O
kinase NN CAPITAL C O
C NNS inhibitors O
inhibitors IN on O
on NN cardioprotection O
cardioprotection IN by O
by JJ ischemic O
ischemic VBG preconditioning O
preconditioning VBZ depends O
depends IN on O
on DT the O
the NN number O
number IN of O
of VBG preconditioning O
preconditioning NNS episodes O

How WRB CAPITAL How O
How VB do O
do PRP you O
you VB treat O
treat JJ refractory D
refractory NN pouchitis D
pouchitis CC and O
and WRB when O
when VB do O
do PRP you O
you VB decide O
decide TO to O
to VB remove O
remove DT the O
the NN pouch O
pouch . ? O

Filter NNP CAPITAL Filter O
Filter NN paper O
paper NN blood O
blood NN spot O
spot NN assay O
assay IN of O
of JJ human O
human JJ insulin-like O
insulin-like NN growth O
growth NN factor O
factor PRP CAPITAL I O
I NN ( O
( NN CAPITAL IGF-I O
IGF-I NN ) O
) CC and O
and JJ CAPITAL IGF-binding O
IGF-binding JJ protein-3 O
protein-3 CC and O
and JJ preliminary O
preliminary NN application O
application IN in O
in DT the O
the NN evaluation O
evaluation IN of O
of NN growth O
growth NN hormone O
hormone NN status O

Effect NN CAPITAL Effect O
Effect IN of O
of NN iodixanol D
iodixanol IN on O
on JJ renal O
renal NN function O
function RB immediately O
immediately IN after O
after JJ abdominal T
abdominal NN angiography T
angiography . . O

Clinical JJ CAPITAL Clinical O
Clinical NN comparison O
comparison IN with O
with NN iomeprol D
iomeprol CC and O
and NN ioxaglate D

A DT CAPITAL A O
A JJ new O
new VBN modified O
modified NN technique O
technique IN for O
for NN harvest O
harvest IN of O
of NN calcaneal O
calcaneal NN bone O
bone NNS grafts O
grafts IN in O
in NN surgery T
surgery IN on O
on DT the O
the NN foot O
foot CC and O
and NN ankle O

Is VBZ CAPITAL Is O
Is NN prevaccination O
prevaccination VBG screening O
screening IN for O
for NN hepatitis D
hepatitis NN CAPITAL B D
B IN among O
among RB sexually O
sexually JJ active O
active NNS adolescents O
adolescents JJ cost-effective O
cost-effective . ? O

Epilepsy NNP CAPITAL Epilepsy D
Epilepsy : -- O
-- DT a O
a NN guide O
guide TO to O
to JJ medical O
medical NN treatment O

1 CD 1 O
1 : : O
: JJ CAPITAL Antiepileptic T
Antiepileptic NNS drugs T

Adolescent JJ CAPITAL Adolescent O
Adolescent NN pregnancy O
pregnancy CC and O
and JJ sexual O
sexual NN abuse O

Normoxic JJ CAPITAL Normoxic T
Normoxic JJ cardiopulmonary T
cardiopulmonary NN bypass T
bypass VBZ reduces O
reduces JJ oxidative D
oxidative JJ myocardial D
myocardial NN damage D
damage CC and D
and JJ nitric D
nitric NN oxide D
oxide IN during O
during JJ cardiac O
cardiac NNS operations O
operations IN in O
in DT the O
the JJ adult O

A DT CAPITAL A O
A JJ multidimensional O
multidimensional NN study O
study IN of O
of NN preference O
preference NNS judgements O
judgements IN for O
for NNS excerpts O
excerpts IN of O
of NN music O

Extending VBG CAPITAL Extending O
Extending DT the O
the NNS benefits O
benefits IN of O
of NN breast D
breast NN cancer D
cancer VBG screening O

Still RB CAPITAL Still O
Still RB hard O
hard TO to O
to VB know O
know WRB how O
how JJ large O
large DT the O
the NNS benefits O
benefits MD will O
will RB really O
really VB be O

Rhabdomyolysis NNP CAPITAL Rhabdomyolysis D
Rhabdomyolysis CC and O
and NN carbon D
carbon NN monoxide D
monoxide NN poisoning D

Effect NN CAPITAL Effect O
Effect IN of O
of JJ dental T
dental NN treatment T
treatment IN on O
on DT the O
the NN lung O
lung NN function O
function IN of O
of NNS children O
children IN with O
with NN asthma D
asthma . . O

conclusions NNS conclusions O
conclusions : : O
: NN apc T
apc VBZ is O
is JJ effective O
effective IN for O
for DT the O
the NN treatment O
treatment IN of O
of JJ endoluminal D
endoluminal NN hemoptysis D
hemoptysis CC and O
and NN airway D
airway NN obstruction D

induction NN induction T
induction NN chemotherapy T
chemotherapy NN ( T
( NN cisplatin T
cisplatin CC + T
+ NN vinorelbine T
vinorelbine NN ) T
) VBZ is O
is VBN found O
found TO to O
to VB be O
be RB markedly O
markedly JJ effective O
effective IN for O
for JJ squamous D
squamous NN cell D
cell NN lung D
lung NN carcinoma D
carcinoma IN with D
with NN sarcoidosis D
sarcoidosis : -- O
-- DT a O
a NN case O
case NN report O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> IN in O
in NN conclusion O
conclusion , , O
, NN 3d O
3d JJ computer-assisted O
computer-assisted NN analysis O
analysis IN of O
of DT the O
the JJ internal O
internal NN structure O
structure IN of O
of JJ small O
small JJ pulmonary O
pulmonary NNS nodules O
nodules VBG using O
using JJ contrast-enhanced O
contrast-enhanced JJ dh-ct O
dh-ct VBD was O
was VBN found O
found TO to O
to VB be O
be JJ effective O
effective IN for O
for VBG differentiating O
differentiating IN between O
between JJ benign O
benign CC and O
and JJ malignant O
malignant NNS nodules O

the DT the O
the NN patient O
patient VBD was O
was DT a O
a JJ 62-year-old O
62-year-old NN man O
man IN with O
with JJ squamous D
squamous NN cell D
cell NN lung D
lung NN cancer D
cancer , , O
, WDT which O
which VBD was O
was RB first O
first RB successfully O
successfully VBN treated O
treated IN by O
by DT a O
a NN combination T
combination IN of T
of NN radiation T
radiation NN therapy T
therapy CC and T
and NN chemotherapy T
chemotherapy , , O
, CC but O
but VBD showed O
showed JJ local O
local NN recurrence O
recurrence IN after O
after CD 8 O
8 NNS months O

the DT the O
the NN combination T
combination IN of T
of NN txt T
txt , , T
, NN gem T
gem CC and T
and NN cddp T
cddp MD may O
may VB be O
be JJ effective O
effective IN for O
for JJ recurrent D
recurrent JJ non-small-cell D
non-small-cell NN lung D
lung NN carcinoma D
carcinoma , , O
, RB even O
even IN in O
in NNS patients O
patients IN that O
that VB have O
have VBD failed O
failed TO to O
to NN respond O
respond TO to O
to RBR more O
more IN than O
than CD one O
one NN chemotherapy O
chemotherapy NN regimen O

the DT the O
the NN aim O
aim IN of O
of DT the O
the JJ current O
current NN study O
study VBD was O
was TO to O
to VB compare O
compare DT the O
the JJ objective O
objective NN response O
response CC and O
and NN survival O
survival NNS rates O
rates IN of O
of NNS patients O
patients IN with O
with NN mrcc D
mrcc VBN treated O
treated IN with O
with JJ il-2 T
il-2 VBN administered O
administered DT either O
either RB systemically O
systemically NN ( O
( NN syst O
syst , , O
, RB subcutaneously O
subcutaneously NN ) O
) CC or O
or IN via O
via NN inhalation O
inhalation NN ( O
( NN inh O
inh NN ) O
) , , O
, VBG using O
using RB relatively O
relatively JJ large O
large NN sample O
sample NNS sizes O
sizes TO to O
to VB afford O
afford DT a O
a RBR more O
more JJ meaningful O
meaningful NN comparison O

conclusion NN conclusion O
conclusion : : O
: IN as O
as VBN expected O
expected , , O
, DT the O
the NN type O
type IN of O
of NN chemotherapy T
chemotherapy PRP we O
we VBN used O
used , , O
, TO to O
to VB treat O
treat JJ non-seminomatous D
non-seminomatous NN germ-cell D
germ-cell NNS tumors D
tumors VBN proved O
proved TO to O
to VB be O
be RB highly O
highly JJ effective O
effective IN for O
for JJ seminomatous D
seminomatous NNS types D
types , , O
, IN as O
as RB well O

carboplatin NN carboplatin T
carboplatin CC and T
and NN ifosfamide T
ifosfamide VBN performed O
performed RB well O
well CC and O
and JJ safe O
safe , , O
, IN in O
in DT the O
the NN treatment O
treatment IN of O
of JJ non-bulky D
non-bulky JJ metastatic D
metastatic NN seminoma D

these DT these O
these NNS results O
results VBN suggested O
suggested IN that O
that DT the O
the NN sp1 T
sp1 NN decoy T
decoy NN strategy T
strategy MD would O
would VB be O
be JJ effective O
effective IN for O
for VBG regulating O
regulating NN tumor D
tumor NN growth D
growth IN by O
by RB simultaneously O
simultaneously VBG reducing O
reducing NN cancer O
cancer NN cell O
cell NN ( O
( DT a O
a NN ) O
) JJ angiogenic O
angiogenic NN growth O
growth NN factor O
factor NN expression O
expression , , O
, NN ( O
( NN b O
b NN ) O
) NN proliferation O
proliferation , , O
, CC and O
and NN ( O
( NN c O
c NN ) O
) NN invasiveness O

considering VBG considering O
considering IN that O
that NNS hamsters O
hamsters VBD had O
had DT a O
a NN lung O
lung NN metastasis O
metastasis NN rate O
rate IN of O
of CD 50 O
50 NN % O
% IN before O
before JJ mdp-lys O
mdp-lys NN treatment O
treatment , , O
, JJ liposomal T
liposomal JJ mdp-lys T
mdp-lys VBN given O
given IN at O
at DT a O
a NN dose O
dose IN of O
of CD 20 O
20 NN microg O
microg NN twice/week O
twice/week VBD was O
was JJ effective O
effective IN for O
for VBG inhibiting O
inhibiting NN lung D
lung NN metastasis D
metastasis IN at O
at DT a O
a RB far O
far JJR lower O
lower NN dose O
dose IN of O
of JJ mdp-lys O
mdp-lys IN than O
than IN that O
that VBN given O
given IN as O
as DT a O
a NN solution O
solution NN ( O
( CD 40 O
40 NN microg O
microg CC vs. O
vs. CD 350 O
350 NN microg O
microg IN per O
per NN week O
week NN ) O

we PRP we O
we VB have O
have VBN documented O
documented RB previously O
previously IN that O
that JJ adenovirus-mediated T
adenovirus-mediated NN interleukin T
interleukin CD 12 T
12 NN ( T
( JJ il-12 T
il-12 NN ) T
) NN gene T
gene NN therapy T
therapy VBZ is O
is JJ effective O
effective IN for O
for JJ orthotopic D
orthotopic NN tumor D
tumor NN control O
control CC and O
and NN suppression O
suppression IN of O
of JJ pre-established D
pre-established NNS metastases D
metastases IN in D
in DT a D
a JJ preclinical D
preclinical NN prostate D
prostate NN cancer D
cancer NN model D
model NN ( O
( NN y. O
y. NN nasu O
nasu FW et O
et NNP al O
al . . O
. , , O
, NN gene O
gene IN ther O

we PRP we O
we RB further O
further VBN developed O
developed DT a O
a NN vaccine O
vaccine NN model O
model VBN based O
based IN on O
on NN s.c.injection O
s.c.injection IN of O
of JJ infected O
infected , , O
, JJ irradiated O
irradiated NN rm-9 O
rm-9 NNS cells O
cells CC and O
and VBN found O
found IN that O
that DT both O
both JJ admil-12 T
admil-12 CC and T
and JJ admil-12/b7 T
admil-12/b7 VBP are O
are JJ effective O
effective IN at O
at VBG suppressing O
suppressing DT the O
the NN development O
development CC and O
and NN growth O
growth IN of O
of NN challenge D
challenge JJ orthotopic D
orthotopic NNS tumors D
tumors VBG using O
using DT this O
this NN protocol O

despite IN despite O
despite DT the O
the JJ marked O
marked NN toxicity O
toxicity IN of O
of DT the O
the JJ initial O
initial JJ intensive T
intensive NN chemotherapy T
chemotherapy , , O
, DT the O
the NNS treatments O
treatments VBP are O
are JJ tolerable O
tolerable CC and O
and JJ effective O
effective IN in O
in DT the O
the NN control O
control IN of O
of JJ extra-thoracic D
extra-thoracic NNS micrometastases D
micrometastases , , O
, IN whereas O
whereas PRP they O
they VBP are O
are JJR less O
less JJ effective O
effective IN for O
for JJ thoracic O
thoracic JJ primary O
primary NN tumor O

radiotherapy NN radiotherapy T
radiotherapy VBZ is O
is JJ effective O
effective IN for O
for NN palliation O
palliation IN of O
of NNS symptoms D
symptoms VBN associated D
associated IN with D
with NN sblc D

clinically RB clinically O
clinically , , O
, JJ oral T
oral NN administration T
administration IN of T
of NN uft T
uft VBZ has O
has VBN proved O
proved TO to O
to VB be O
be JJ effective O
effective IN as O
as DT an O
an JJ adjuvant T
adjuvant NN therapy T
therapy IN after O
after NN surgery O
surgery IN for O
for DT some O
some JJ malignant D
malignant NNS tumors D
tumors JJ such D
such IN as D
as JJ non-small D
non-small NN cell D
cell NN lung D
lung NN cancer D

moreover RB moreover O
moreover , , O
, NN uft T
uft VBZ has O
has VBN proved O
proved TO to O
to VB be O
be JJ effective O
effective IN for O
for JJ inoperable D
inoperable JJ advanced D
advanced NNS malignancies D
malignancies JJ such D
such IN as D
as JJ colorectal D
colorectal NN cancer D
cancer , , O
, RB especially O
especially IN in O
in NN combination O
combination IN with O
with NN leucovorin T
leucovorin CC or T
or NN cisplatin T

a DT a O
a NN phase O
phase LS ii O
ii NN study O
study IN of O
of VBN fractionated O
fractionated NN administration O
administration IN of O
of JJ irinotecan T
irinotecan NN ( T
( NN cpt-11 T
cpt-11 NN ) T
) CC and T
and NN cisplatin T
cisplatin NN ( T
( NN cddp T
cddp NN ) T
) IN in O
in NNS patients O
patients IN with O
with JJ non-small-cell D
non-small-cell NN lung D
lung NN cancer D
cancer NN ( D
( NN nsclc D
nsclc NN ) D
) VBD was O
was VBN conducted O

in IN in O
in NN conclusion O
conclusion , , O
, VBN fractionated O
fractionated NN administration O
administration IN of O
of NN cpt-11 T
cpt-11 CC and T
and NN cddp T
cddp VBD was O
was RB highly O
highly JJ effective O
effective IN for O
for JJ advanced D
advanced NN nsclc D
nsclc IN with O
with JJ manageable O
manageable NNS toxicities O

we PRP we O
we NN report O
report DT the O
the NN use O
use IN of O
of NN paclitaxel T
paclitaxel IN in O
in DT the O
the JJ successful O
successful NN treatment O
treatment IN of O
of DT a O
a NN patient O
patient IN with O
with JJ recurrent D
recurrent NN adenocarcinoma D
adenocarcinoma IN of D
of DT the D
the NN cervix D

weekly JJ weekly O
weekly NN paclitaxel T
paclitaxel VBD was O
was RB very O
very RB well O
well VBN tolerated O
tolerated , , O
, RB yet O
yet VBD was O
was JJ effective O
effective IN for O
for JJ recurrent D
recurrent JJ cervical D
cervical NN adenocarcinoma D

conclusion NN conclusion O
conclusion : : O
: PRP$ our O
our NNS results O
results VBP suggest O
suggest IN that O
that NN pseudoephedrine T
pseudoephedrine CC plus T
plus NN acetaminophen T
acetaminophen VBZ is O
is JJ effective O
effective IN for O
for NN relief O
relief IN of O
of NNS symptoms D
symptoms JJ attributable D
attributable TO to D
to DT the D
the NN paranasal D
paranasal NNS sinuses D
sinuses IN that O
that MD may O
may VB develop O
develop RB early O
early IN in O
in DT the O
the NN course O
course IN of O
of DT a O
a JJ cold O

reviewer NN reviewer O
reviewer POS 's O
's NNS conclusions O
conclusions : : O
: DT a O
a JJ single O
single NN dose O
dose IN of O
of JJ nasal T
nasal NN decongestant T
decongestant IN in O
in DT the O
the JJ common O
common JJ cold O
cold VBZ is O
is RB moderately O
moderately JJ effective O
effective IN for O
for DT the O
the JJ short O
short NN term O
term NN relief O
relief IN of O
of NN congestion D
congestion IN in O
in NNS adults O
adults , , O
, IN while O
while RB there O
there VBZ is O
is DT no O
no NN evidence O
evidence JJ available O
available TO to O
to NN show O
show NN benefit O
benefit IN after O
after VBN repeated O
repeated NN use O
use IN over O
over JJ several O
several NNS days O

conclusions NNS conclusions O
conclusions : : O
: NNS members O
members IN of O
of DT an O
an RB ethnically O
ethnically JJ diverse O
diverse NN community O
community VB believe O
believe NNS antibiotics T
antibiotics VBP are O
are JJ effective O
effective IN for O
for NNS colds D
colds , , O
, VBP are O
are RB very O
very JJ likely O
likely TO to O
to VB seek O
seek NN care O
care IN for O
for NNS colds O
colds , , O
, CC and O
and RB often O
often VB obtain O
obtain NNS antibiotics O
antibiotics IN without O
without DT a O
a NN prescription O

the DT the O
the JJ available O
available VBN inactivated O
inactivated NN vaccine T
vaccine VBZ is O
is JJ effective O
effective IN for O
for VBG preventing O
preventing NN influenza D
influenza CC and O
and DT the O
the JJ serious O
serious NN disease O
disease CC and O
and NN death O
death IN that O
that MD can O
can VB accompany O
accompany PRP it O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NN amantadine T
amantadine , , O
, NN rimantadine T
rimantadine , , O
, CC and O
and DT the O
the RB newly O
newly JJ available O
available NNS drugs O
drugs NN zanamivir T
zanamivir CC and O
and NN oseltamivir T
oseltamivir VBP are O
are JJ effective O
effective IN for O
for NN influenza D
influenza NN prevention D
prevention CC and D
and NN treatment D
treatment NN ( O
( DT the O
the JJ former O
former CD two O
two IN for O
for NN influenza O
influenza DT a O
a RB only O
only NN ) O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> DT the O
the NN availability O
availability IN of O
of CD four O
four JJ antiviral T
antiviral NNS agents T
agents IN that O
that RB effectively O
effectively VB prevent O
prevent CC and O
and VB treat O
treat NN influenza D
influenza VBZ provides O
provides DT the O
the NN physician O
physician IN with O
with JJ considerable O
considerable NN flexibility O
flexibility IN for O
for PRP$ their O
their NN use O
use IN in O
in NN influenza O
influenza NN control O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> RB thus O
thus NN influenza D
influenza NN vaccination T
vaccination VBZ is O
is JJ effective O
effective IN for O
for VBG preventing O
preventing NN influenza D
influenza NN disease D
disease IN in O
in NNS persons O
persons JJ aged O
aged CD 65 O
65 NNS years O
years CC and O
and IN over O
over , , O
, CC and O
and MD should O
should VB be O
be DT an O
an JJ integral O
integral NN part O
part IN of O
of DT the O
the NN care O
care IN of O
of DT this O
this NN population O
population VBG residing O
residing IN in O
in NN nursing O
nursing NNS homes O

intravenous JJ intravenous T
intravenous NN injection T
injection IN of T
of JJ pb2-as T
pb2-as , , T
, IN as T
as DT a T
a JJ complex T
complex IN with T
with JJ dmrie-c T
dmrie-c , , T
, DT a T
a JJ cationic T
cationic JJ liposome T
liposome , , O
, VBD was O
was JJS most O
most JJ effective O
effective IN for O
for VBG prolonging O
prolonging DT the O
the VB mean O
mean NN survival O
survival NN time O
time IN in O
in NNS days O
days NN ( O
( NNS msds O
msds NN ) O
) CC and O
and VBG increasing O
increasing DT the O
the NN survival O
survival NNS rates O
rates IN of O
of NNS mice O
mice JJ infected O
infected IN with O
with DT the O
the NN influenza D
influenza DT a D
a NN virus D

background NN background O
background CC and O
and NNS objectives O
objectives : : O
: JJ thoracic T
thoracic JJ paravertebral T
paravertebral NN block T
block NN ( T
( NN tpvb T
tpvb NN ) T
) VBZ is O
is DT a O
a JJ unilateral O
unilateral JJ analgesic O
analgesic NN technique O
technique IN that O
that VBZ has O
has VBN been O
been VBN advocated O
advocated IN in O
in DT both O
both JJ acute D
acute CC and D
and JJ chronic D
chronic JJ thoracic D
thoracic CC and D
and JJ abdominal D
abdominal NN pain D

other JJ other T
other NNS blocks T
blocks JJ such T
such IN as T
as JJ interpleural T
interpleural CC and T
and JJ epidural T
epidural MD can O
can VB be O
be RB effectively O
effectively VBN used O
used IN in O
in JJ pleuritic D
pleuritic NN pain D

this DT this O
this NN report O
report VBZ illustrates O
illustrates IN that O
that NN tpvb T
tpvb MD could O
could RB also O
also VB be O
be JJ effective O
effective IN for O
for DT this O
this RB kind O
kind IN of O
of NN pain D

conclusions NNS conclusions O
conclusions : : O
: DT this O
this NN case O
case NN report O
report VBZ supports O
supports DT the O
the NN notion O
notion IN that O
that , , O
, IN in O
in NN practice O
practice , , O
, DT the T
the JJ paravertebral T
paravertebral NN block T
block MD could O
could VB be O
be DT an O
an JJ effective O
effective CC and O
and JJ safe O
safe JJ alternative O
alternative TO to O
to NN relief O
relief IN of O
of JJ pleuritic D
pleuritic NN pain D

conclusion NN conclusion O
conclusion : : O
: JJ mr-guided T
mr-guided NN rfa T
rfa VBG using T
using JJ single T
single VBN cooled T
cooled NN tip T
tip NNS electrodes T
electrodes VBZ is O
is JJ safe O
safe CC and O
and RB technically O
technically JJ effective O
effective IN for O
for NN treatment O
treatment IN of O
of JJ hepatic D
hepatic NNS neoplasms D
neoplasms RB up O
up TO to O
to CD 3 O
3 NN cm O
cm IN in O
in NN size O
size , , O
, RB however O
however RB further O
further NNS improvements O
improvements VBP are O
are JJ necessary O

a DT a O
a JJ 68-year-old O
68-year-old NN man O
man VBD underwent O
underwent JJ curative T
curative NN pancreaticoduodenectomy T
pancreaticoduodenectomy IN for O
for NN bile D
bile NN duct D
duct NN cancer D

one CD one O
one NN course O
course IN of O
of JJ chronochemotherapy T
chronochemotherapy VBD was O
was JJ effective O
effective IN for O
for NN lymph D
lymph NN node D
node CC and D
and NN peritoneum D
peritoneum NNS metastases D

the DT the O
the RB only O
only JJ specific O
specific NN antidote O
antidote IN for O
for JJ dosage-dependent D
dosage-dependent NN hepatotoxicity D
hepatotoxicity VBZ is O
is NN n-acetylcysteine T
n-acetylcysteine NN ( T
( CC and T
and DT some T
some JJ other T
other NN sulfhydryl T
sulfhydryl NNS donors T
donors NN ) T
) , , O
, WDT which O
which VBZ is O
is RB highly O
highly JJ effective O
effective IN for O
for DT the O
the NN prevention O
prevention IN of O
of JJ significant O
significant NN hepatotoxicity O
hepatotoxicity IN after O
after NN acetaminophen O
acetaminophen NN overdose O

corticosteroids NNS corticosteroids T
corticosteroids MD can O
can VB be O
be VBN considered O
considered IN for O
for NNS cases O
cases IN of O
of JJ drug-induced D
drug-induced NN hepatitis D
hepatitis , , O
, RB especially O
especially DT those O
those IN with O
with NN evidence O
evidence IN of O
of JJ immune O
immune NN hypersensitivity O
hypersensitivity , , O
, IN if O
if DT no O
no NN improvement O
improvement VBZ is O
is VBN seen O
seen IN in O
in CD 8 O
8 TO to O
to CD 12 O
12 NNS weeks O

our PRP$ our O
our NN conclusion O
conclusion VBD was O
was IN that O
that DT the O
the JJ covered-ems T
covered-ems MD can O
can VB be O
be JJ effective O
effective IN for O
for DT the O
the NN palliation O
palliation IN of O
of JJ esophagorespiratory D
esophagorespiratory NN fistulas D

the DT the O
the NN food O
food CC and O
and NN drug O
drug NN administration O
administration NN ( O
( NN fda O
fda NN ) O
) RB recently O
recently VBN approved O
approved DT the O
the RB first O
first JJ protein-polysaccharide T
protein-polysaccharide NN conjugate T
conjugate NN vaccine T
vaccine TO to O
to VB prevent O
prevent JJ invasive D
invasive JJ pneumococcal D
pneumococcal NNS diseases D
diseases IN in O
in NNS infants O
infants CC and O
and NNS toddlers O
toddlers JJR < O
< CD 2 O
2 NNS years O
years IN of O
of NN age O

this DT this O
this VBN conjugated T
conjugated NN vaccine T
vaccine IN against O
against NN pneumococcus D
pneumococcus NNS uses O
uses DT the O
the JJ same O
same NN technology O
technology IN as O
as DT the O
the JJ successful O
successful NN vaccine T
vaccine IN against O
against NN haemophilus D
haemophilus NN influenzae D
influenzae NN type D
type NN b D

the DT the O
the JJS most O
most JJ recent O
recent NN study O
study , , O
, VBG involving O
involving IN over O
over CD 37 O
37 , , O
, CD 000 O
000 JJ young O
young NNS children O
children , , O
, RB also O
also VBN evaluated O
evaluated DT the O
the NN vaccine O
vaccine POS 's O
's NN efficacy O
efficacy , , O
, CC and O
and VBN reported O
reported IN that O
that DT the O
the NN vaccine T
vaccine VBZ is O
is RB highly O
highly JJ effective O
effective IN in O
in VBG preventing O
preventing JJ invasive D
invasive NN disease D
disease CC and O
and VBZ has O
has VBD had O
had DT an O
an NN impact O
impact IN on O
on NN otitis D
otitis NNS media D

conclusions NNS conclusions O
conclusions : : O
: DT the O
the JJ heptavalent T
heptavalent JJ pneumococcal T
pneumococcal NN conjugate T
conjugate NN vaccine T
vaccine VBZ is O
is JJ safe O
safe CC and O
and RB highly O
highly JJ effective O
effective IN in O
in VBG preventing O
preventing JJ pneumococcal D
pneumococcal NN meningitis D
meningitis CC and D
and JJ bacteremic D
bacteremic NN pneumonia D
pneumonia IN in O
in JJ young O
young NNS children O
children JJR < O
< CD 2 O
2 NNS years O
years IN of O
of NN age O
age : ; O
; PRP it O
it VBZ is O
is JJR less O
less JJ effective O
effective IN in O
in VBG preventing O
preventing NN otitis O
otitis NNS media O

based VBN based O
based IN on O
on DT the O
the NNS results O
results IN of O
of CD three O
three JJ well-designed O
well-designed NNS studies O
studies VBG demonstrating O
demonstrating DT the O
the NN vaccine O
vaccine POS 's O
's NN safety O
safety , , O
, NN immunogenicity O
immunogenicity , , O
, CC and O
and NN efficacy O
efficacy , , O
, DT the O
the NN vaccine T
vaccine VBZ is O
is JJ safe O
safe CC and O
and JJ effective O
effective IN for O
for JJ active O
active NN immunization O
immunization IN of O
of NNS children O
children JJR < O
< CD 2 O
2 NNS years O
years IN of O
of NN age O
age IN against O
against JJ invasive D
invasive NN disease D
disease VBN caused D
caused IN by D
by CD seven D
seven NN streptococcus D
streptococcus FW pneumoniae D
pneumoniae NNS serotypes D
serotypes VBN included O
included IN in O
in DT the O
the NN vaccine O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> LS i O
i VBD concluded O
concluded IN that O
that JJ 6-month O
6-month NN regimen O
regimen VBG containing O
containing NN pyrazinamide T
pyrazinamide VBD was O
was JJ effective O
effective IN for O
for DT the O
the NNS patients O
patients IN with O
with NN isoniazid-rifampicin D
isoniazid-rifampicin JJ susceptible D
susceptible NN tuberculosis D
tuberculosis NNS patients O
patients IN except O
except DT the O
the NNS patients O
patients JJ complicated O
complicated IN with O
with NN diabetes D
diabetes NN mellitus D

only RB only O
only DT the O
the NN combination T
combination IN of T
of DT a T
a NN cell T
cell JJ wall-active T
wall-active JJ antibiotic T
antibiotic TO to T
to WDT which T
which DT the T
the NN enterococcus T
enterococcus VBZ is T
is JJ susceptible T
susceptible NN ( T
( FW ie T
ie , , T
, JJ certain T
certain JJ beta-lactams T
beta-lactams CC or T
or NN vancomycin T
vancomycin NN ) T
) CC plus T
plus DT an T
an NN aminoglycoside T
aminoglycoside NN ( T
( FW ie T
ie , , T
, NN gentamicin T
gentamicin CC or T
or NN streptomycin T
streptomycin NN ) T
) VBZ is O
is JJ bactericidal O
bactericidal , , O
, CC and O
and VBZ is O
is VBN required O
required IN for O
for NN cure O
cure IN of O
of NN endocarditis D
endocarditis , , D
, NN meningitis D
meningitis CC and D
and RB probably D
probably NN infection D
infection IN in D
in NN neutropenic D
neutropenic NNS patients D
patients : ; O
; JJ bacteriostatic O
bacteriostatic NN activity O
activity VBZ is O
is JJ sufficient O
sufficient TO to O
to VB treat O
treat JJS most O
most JJ other O
other NNS infections O

two CD two T
two NN triazole T
triazole JJ antifungal T
antifungal NNS agents T
agents , , T
, NN fluconazole T
fluconazole CC and T
and NN itraconazole T
itraconazole , , O
, VBD were O
were VBN introduced O
introduced IN over O
over DT a O
a NN decade O
decade IN ago O
ago CC and O
and IN since O
since RB then O
then VB have O
have VBN been O
been VBN used O
used RB extensively O
extensively IN for O
for DT the O
the NN prophylaxis O
prophylaxis CC and O
and NN treatment O
treatment IN of O
of DT a O
a NN variety O
variety IN of O
of JJ fungal D
fungal NNS infections D

the DT the O
the NN use O
use IN of O
of JJ topical T
topical NNS corticosteroids T
corticosteroids VBZ has O
has VBN revolutionised O
revolutionised DT the O
the NN treatment O
treatment IN of O
of JJ inflammatory D
inflammatory NN skin D
skin NNS diseases D

in IN in O
in JJ particular O
particular , , O
, NN tacrolimus T
tacrolimus CC and T
and NN ascomycin T
ascomycin NNS derivatives T
derivatives VB have O
have VBN been O
been VBN shown O
shown TO to O
to VB be O
be JJ effective O
effective IN for O
for VBG treating O
treating JJ atopic D
atopic NN dermatitism D
dermatitism IN with O
with DT a O
a JJ surprising O
surprising NN lack O
lack IN of O
of NN side O
side NNS effects O

cyclophosphamide NN cyclophosphamide T
cyclophosphamide NN therapy T
therapy VBZ is O
is JJ effective O
effective IN for O
for NN bronchiolitis D
bronchiolitis NNS obliterans D
obliterans VBG occurring D
occurring IN as D
as DT a D
a RB late D
late NN manifestation D
manifestation IN of D
of NN lupus D
lupus NN erythematosus D
erythematosus NN ( O
( NN letter O
letter NN ) O

in IN in O
in NN summary O
summary , , O
, NN gemifloxacin T
gemifloxacin VBD was O
was VBN found O
found TO to O
to VB be O
be RB well O
well VBN tolerated O
tolerated CC and O
and JJ effective O
effective IN for O
for DT the O
the NN treatment O
treatment IN of O
of NN aecb D
aecb , , O
, VBG suggesting O
suggesting PRP it O
it VBZ is O
is RB well O
well VBN suited O
suited IN for O
for JJ empirical O
empirical NN treatment O
treatment IN of O
of DT this O
this JJ common O
common JJ respiratory O
respiratory NN condition O
condition IN in O
in DT the O
the JJ current O
current JJ clinical O
clinical NN environment O

d-penicillamine NN d-penicillamine T
d-penicillamine NN ( T
( JJ 2-amino-3-mercapto-3-methylbutanoic T
2-amino-3-mercapto-3-methylbutanoic NN acid T
acid NN ) T
) , , T
, DT a T
a JJ well-known T
well-known JJ heavy T
heavy NN metal T
metal NN chelator T
chelator , , O
, VBZ is O
is DT the O
the NN drug O
drug IN of O
of NN choice O
choice IN in O
in DT the O
the NN treatment O
treatment IN of O
of NN wilson D
wilson POS 's D
's NN disease D
disease CC and O
and VBZ is O
is RB also O
also JJ effective O
effective IN for O
for DT the O
the NN treatment O
treatment IN of O
of JJ several D
several NNS disorders D
disorders VBG including D
including JJ rheumatoid D
rheumatoid NN arthritis D
arthritis , , D
, JJ primary D
primary JJ biliary D
biliary NN cirrhosis D
cirrhosis , , D
, NN scleroderma D
scleroderma , , D
, JJ fibrotic D
fibrotic NN lung D
lung NNS diseases D
diseases CC and D
and JJ progressive D
progressive JJ systemic D
systemic NN sclerosis D

stages NNS stages O
stages IN of O
of JJ non-small D
non-small NN cell D
cell NN lung D
lung NN cancer D
cancer NN ( D
( NN nsclc D
nsclc NN ) D
) IN that O
that VBP are O
are JJ potential O
potential NNS candidates O
candidates IN for O
for JJ surgical T
surgical NN resection T
resection VB have O
have VBN been O
been VBN treated O
treated IN in O
in JJ several O
several NNS ways O
ways : : O
: NN surgery T
surgery RB alone O
alone VBZ is O
is JJ curative O
curative IN in O
in RB only O
only NNS two-thirds O
two-thirds IN of O
of NNS cases O
cases CC and O
and JJ post-operative T
post-operative NN radiotherapy T
radiotherapy NN ( T
( NN rt T
rt NN ) T
) VBZ provides O
provides RB only O
only JJ weak O
weak NN control O
control IN of O
of JJ advanced-stage O
advanced-stage NN disease O

among IN among O
among DT these O
these , , O
, DT the O
the NN gemcitabine/cisplatin T
gemcitabine/cisplatin NN study O
study NN protocol O
protocol NN ( O
( NN gc O
gc NN ) O
) , , O
, VBN set O
set RB up O
up IN in O
in DT a O
a NN phase O
phase LS ii O
ii NN study O
study IN for O
for NNS patients O
patients IN with O
with NN stage D
stage NN iiia D
iiia NN n2 D
n2 NN nsclc D
nsclc , , O
, VBD was O
was RB very O
very JJ effective O
effective NN ( O
( JJ objective O
objective NN response O
response NN ( O
( CC or O
or NN ) O
) : : O
: CD 70.2 O
70.2 NN % O
% : ; O
; JJ median O
median NN survival O
survival : : O
: CD 19 O
19 NNS months O
months NN ) O
) CC and O
and MD should O
should VB be O
be JJ promising O
promising IN for O
for NNS stages O
stages NN ib O
ib CC and O
and LS ii O

several JJ several O
several NNS studies O
studies VB have O
have VBN suggested O
suggested IN that O
that JJ non-small D
non-small NN cell D
cell NN lung D
lung NN cancer D
cancer NN ( D
( NN nsclc D
nsclc NN ) D
) NNS patients O
patients WP$ whose O
whose NNS tumors O
tumors VB have O
have NN neuroendocrine O
neuroendocrine NN ( O
( NN ne O
ne NN ) O
) NNS features O
features MD may O
may VB be O
be RBR more O
more JJ responsive O
responsive TO to O
to NN chemotherapy T
chemotherapy IN in O
in NN addition O
addition , , O
, VBN increased O
increased NN expression O
expression IN of O
of NN p53 O
p53 CC and O
and NN her2 O
her2 MD may O
may VB confer O
confer JJ relative O
relative NN chemotherapy O
chemotherapy NN resistance O
resistance CC and O
and VBD shortened O
shortened NN survival O

the DT the O
the NN cancer O
cancer CC and O
and NN leukemia O
leukemia NN group O
group NN b O
b VBN performed O
performed DT a O
a NN series O
series IN of O
of NNS studies O
studies VBG involving O
involving JJ sequential T
sequential NN chemotherapy T
chemotherapy VBN followed T
followed IN by T
by NN radiation T
radiation IN for O
for NNS patients O
patients IN with O
with JJ unresectable D
unresectable NN stage D
stage LS iii D
iii NN nsclc D

this DT this O
this NN london O
london NN lung O
lung NN cancer O
cancer NN group O
group NN trial O
trial IN of O
of NN gemcitabine/carboplatin T
gemcitabine/carboplatin MD may O
may VB define O
define DT an O
an JJ active O
active , , O
, JJ safe O
safe , , O
, CC and O
and JJ acceptable O
acceptable NN treatment O
treatment IN for O
for NNS patients O
patients IN with O
with JJ extensive-stage O
extensive-stage CC and O
and NN poor-prognosis O
poor-prognosis JJ small D
small NN cell D
cell NN lung D
lung NN cancer D

gemcitabine NN gemcitabine T
gemcitabine CC and T
and NN carboplatin T
carboplatin IN for O
for NNS patients O
patients IN with O
with JJ advanced D
advanced JJ non-small D
non-small NN cell D
cell NN lung D
lung NN cancer D

an DT an T
an JJ aggressive T
aggressive JJ surgical T
surgical NN approach T
approach VBZ is O
is JJ justified O
justified IN in O
in NNS patients O
patients IN with O
with NN mplc D
mplc CC and O
and NNS offers O
offers DT the O
the JJS greatest O
greatest NN chance O
chance IN for O
for JJ long-term O
long-term NN survival O
survival RB even O
even IN in O
in DT the O
the NN case O
case IN of O
of JJ limited O
limited NN resection O

methods NNS methods O
methods CC and O
and NNS materials O
materials : : O
: NNS eleven O
eleven NNS patients O
patients IN with O
with JJ small D
small NN cell D
cell NN lung D
lung NN cancer D
cancer NN ( D
( NN sclc D
sclc NN ) D
) , , O
, WP who O
who VBD had O
had VBN presented O
presented JJ complete O
complete NN response O
response IN of O
of NN disease O
disease IN after O
after NN chemotherapy T
chemotherapy CC and O
and JJ radical T
radical NN radiotherapy T
radiotherapy IN in T
in DT the T
the NN lung T
lung , , O
, VBD were O
were VBN prescribed O
prescribed TO to O
to VB receive O
receive DT a O
a VBG prophylacting O
prophylacting JJ cranial O
cranial NN irradiation O
irradiation NN ( O
( NN pci O
pci NN ) O
) IN with O
with DT a O
a CD 6 O
6 NN mev O
mev JJ linear O
linear NN accelerator O

only RB only O
only CD 22 O
22 NNS patients O
patients NN ( O
( CD 10 O
10 NN % O
% NN ) O
) VBD were O
were JJ alive O
alive IN at O
at CD five O
five NNS years O
years : : O
: CD 19 O
19 NNS patients O
patients IN with O
with NN nsclc D
nsclc WP who O
who VBD had O
had VBD got O
got JJ surgical T
surgical NN treatment T
treatment , , O
, CD one O
one NN patient O
patient IN with O
with NN nsclc D
nsclc NN ( D
( NN stage D
stage NN iiib D
iiib NN ) D
) WP who O
who VBD had O
had VBN recieved O
recieved NN radiotherapy T
radiotherapy , , O
, CC and O
and CD two O
two NNS patients O
patients IN with O
with NN sclc D
sclc , , D
, JJ limited D
limited NN disease D
disease , , O
, VBN treated O
treated IN with O
with JJ chemo- T
chemo- CC and T
and NN radiotherapy T

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> DT the O
the JJ standard O
standard NN care O
care IN for O
for NNS patients O
patients IN with O
with JJ non-small-cell D
non-small-cell NN lung D
lung NN cancer D
cancer VBZ is O
is NN chemotherapy T
chemotherapy IN of T
of JJ supportive T
supportive NN care T
care , , O
, IN with O
with NN surgery T
surgery VBG being O
being VBN reserved O
reserved IN for O
for NN palliation O
palliation IN of O
of NNS symptoms O
symptoms : ; O
; RB however O
however , , O
, RB there O
there VBZ is O
is DT a O
a JJ small O
small NN group O
group IN of O
of NNS patients O
patients IN with O
with DT a O
a JJ finite O
finite NN number O
number IN of O
of JJ extrathoracic D
extrathoracic NNS metastases D
metastases NN ( D
( NNS oligometastases D
oligometastases NN ) D
) WP who O
who MD may O
may NN experience O
experience VBN improved O
improved NN survival O
survival IN by O
by NN resection T
resection IN of T
of PRP$ their T
their NNS metastases T
metastases CC and T
and DT the T
the JJ primary T
primary NN site T
site , , O
, IN with O
with CC or O
or IN without O
without JJ systemic O
systemic NN treatment O

five CD five O
five JJ new O
new NNS agents O
agents , , O
, NN paclitaxel T
paclitaxel , , O
, NN docetaxel T
docetaxel , , O
, NN vinorelbine T
vinorelbine , , O
, NN gemcitabine T
gemcitabine CC and O
and JJ irinotecan T
irinotecan , , O
, VB have O
have VBN been O
been VBN introduced O
introduced IN for O
for DT the O
the NN treatment O
treatment IN of O
of NN nsclc D
nsclc CC and O
and VBN investigated O
investigated RB extensively O
extensively DT both O
both RB preclinically O
preclinically CC and O
and RB clinically O

whether IN whether O
whether DT the O
the NN era O
era IN of O
of JJ platinum-based T
platinum-based NN chemotherapy T
chemotherapy IN in O
in DT the O
the NN treatment O
treatment IN of O
of NN nsclc D
nsclc MD should O
should VB continue O
continue CC or O
or RB not O
not MD must O
must VB be O
be VBN determined O
determined IN by O
by NN phase O
phase LS iii O
iii NNS trials O
trials , , O
, VBG evaluating O
evaluating DT the O
the NN use O
use IN of O
of DT a O
a NN platinum O
platinum NN agent O
agent IN with O
with CD one O
one IN of O
of DT the O
the JJ new O
new NN agent O
agent NNS combinations O

these DT these O
these JJ aggressive T
aggressive JJ chemotherapeutic T
chemotherapeutic NNS combinations T
combinations MD will O
will RB hopefully O
hopefully VB improve O
improve NN survival O
survival CC and O
and NN quality O
quality IN of O
of NN life O
life IN for O
for NNS patients O
patients IN with O
with JJ advanced D
advanced NN nsclc D

results NNS results O
results : : O
: PRP we O
we VB have O
have VBN performed O
performed CD 60 O
60 JJ carinal T
carinal NNS resections T
resections IN for O
for JJ bronchogenic D
bronchogenic NN carcinoma D
carcinoma : : O
: CD 18 O
18 VBN isolated T
isolated JJ carinal T
carinal NNS resections T
resections IN for O
for NN tumor D
tumor VBN confined D
confined TO to D
to DT the D
the NN carinal D
carinal CC or D
or JJ proximal D
proximal JJ main D
main NN stem D
stem NN bronchus D
bronchus : ; O
; CD 35 O
35 JJ carinal T
carinal NNS pneumonectomies T
pneumonectomies : ; O
; CD 5 O
5 JJ carinal T
carinal CC plus T
plus JJ lobar T
lobar NNS resections T
resections , , O
, CC and O
and CD 2 O
2 JJ carinal T
carinal NNS resections T
resections IN for O
for NN stump D
stump NN recurrence D
recurrence IN after D
after RB prior D
prior NN pneumonectomy D

conclusions NNS conclusions O
conclusions : : O
: DT this O
this VBZ constitutes O
constitutes CD one O
one IN of O
of DT the O
the JJS largest O
largest JJ single-institution O
single-institution NNS reports O
reports IN on O
on JJ carinal T
carinal NN resection T
resection IN for O
for JJ bronchogenic D
bronchogenic NN carcinoma D
carcinoma VBG involving D
involving DT the D
the NN carina D

extracorporeal JJ extracorporeal T
extracorporeal NN photopheresis T
photopheresis VBZ has O
has VBD evolved O
evolved IN as O
as DT a O
a JJ possible O
possible NN therapy O
therapy IN for O
for NNS patients O
patients IN with O
with JJ acute D
acute NN nd D
nd JJ chronic D
chronic NN lung D
lung NN allograft D
allograft NN rejection D

methods NNS methods O
methods : : O
: PRP we O
we RB retrospectively O
retrospectively VBN reviewed O
reviewed CD 14 O
14 NNS patients O
patients VBN diagnosed O
diagnosed IN with O
with NN bos D
bos WP who O
who VBD underwent O
underwent NN therapy T
therapy IN with T
with JJ extracorporeal T
extracorporeal NN photopheresis T

in IN in O
in CD three O
three NNS patients O
patients IN with O
with NN bos D
bos CC and D
and JJ concurrent D
concurrent JJ acute D
acute NN rejection D
rejection , , O
, NN therapy T
therapy IN with T
with JJ extracorporeal T
extracorporeal NN photopheresis T
photopheresis VBD led O
led TO to O
to DT the O
the NN resolution O
resolution IN of O
of DT the O
the JJ acute O
acute NN rejection O
rejection NN episode O

conclusion NN conclusion O
conclusion : : O
: JJ extracorporeal T
extracorporeal NN photopheresis T
photopheresis VBZ appears O
appears TO to O
to VB be O
be DT a O
a JJ promising O
promising NN therapy O
therapy IN for O
for NNS patients O
patients IN with O
with RB early D
early NN bos D

purpose NN purpose O
purpose : : O
: JJ many O
many NNS patients O
patients IN with O
with RB locally D
locally JJ advanced D
advanced JJ non-small-cell D
non-small-cell NN lung D
lung NN cancer D
cancer NN ( D
( NN la-nsclc D
la-nsclc NN ) D
) VBP are O
are JJ eligible O
eligible IN for O
for JJ combined-modality T
combined-modality NN therapy T
therapy NN ( T
( NN cmt T
cmt : ; T
; NN chemotherapy T
chemotherapy CC and T
and NN radiotherapy T
radiotherapy NN ) T

over IN over O
over DT the O
the JJ past O
past CD twenty O
twenty NNS years O
years NN combination T
combination NN chemotherapy T
chemotherapy VBZ has O
has VBN continued O
continued TO to O
to VB produce O
produce JJ small O
small NN survival O
survival NNS gains O
gains IN for O
for NNS patients O
patients IN with O
with NN sclc D

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NN purpose O
purpose : : O
: DT the O
the NN benefit O
benefit IN of O
of JJ whole-lung T
whole-lung NN irradiation T
irradiation NN ( T
( NN wli T
wli NN ) T
) IN for O
for NNS patients O
patients WP who O
who VB have O
have JJ pulmonary D
pulmonary NNS metastases D
metastases NN ( D
( NN pm D
pm NN ) D
) IN of D
of NN ewing D
ewing NN sarcoma D
sarcoma NN family D
family NNS tumors D
tumors NN ( D
( NN esft D
esft NN ) D
) VBZ is O
is JJ unclear O

extent NN extent O
extent IN of O
of JJ pulmonary O
pulmonary NN involvement O
involvement IN at O
at NN diagnosis O
diagnosis , , O
, NN response O
response IN of O
of NN pm D
pm IN after O
after NN induction T
induction NN chemotherapy T
chemotherapy , , O
, JJ local O
local NN treatment O
treatment IN of O
of NN pm O
pm RB thereafter O
thereafter , , O
, CC and O
and JJ clinical O
clinical NN outcome O
outcome VBD were O
were VBN recorded O

conclusions NNS conclusions O
conclusions : : O
: DT the O
the JJ comparable O
comparable NN survival O
survival IN of O
of NNS patients O
patients IN with O
with JJ poor O
poor CC and O
and JJ good O
good NN response O
response IN of O
of NN pm D
pm TO to O
to NN induction T
induction NN chemotherapy T
chemotherapy VBZ suggests O
suggests IN that O
that NN wli T
wli MD may O
may NN benefit O
benefit JJ poor O
poor NNS responders O

objective JJ objective O
objective : : O
: TO to O
to NN report O
report DT the O
the NN use O
use IN of O
of NN heparin T
heparin CC and O
and NN enoxaparin T
enoxaparin IN for O
for JJ radiation-induced D
radiation-induced NN myelopathy D

therefore RB therefore O
therefore , , O
, NNS patients O
patients IN with O
with JJ radiation-induced D
radiation-induced JJ spinal D
spinal NN cord D
cord NN injury D
injury MD may O
may NN benefit O
benefit IN from O
from JJ anticoagulant T
anticoagulant NN therapy T

conclusions NNS conclusions O
conclusions : : O
: NN heparin T
heparin CC and/or T
and/or NN enoxaparin T
enoxaparin MD may O
may VB be O
be VBN considered O
considered IN as O
as JJ potential O
potential NNS treatments O
treatments IN for O
for NNS patients O
patients IN with O
with JJ radiation-induced D
radiation-induced NN myelopathy D

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NN tracheal O
tracheal NN stent O
stent NN insertion O
insertion VBZ is O
is DT a O
a JJ useful O
useful NN method O
method IN for O
for NNS patients O
patients IN with O
with JJ malignant O
malignant NN tracheal O
tracheal NN stenosis O

expandable JJ expandable T
expandable NN metal T
metal NNS stents T
stents VBD were O
were VBN inserted O
inserted IN in O
in CD two O
two NNS patients O
patients IN with O
with JJ severe D
severe NN dyspnea D
dyspnea JJ due D
due TO to D
to NN tracheal D
tracheal NN stenosis D
stenosis VBN caused D
caused IN by D
by NN lung D
lung NN cancer D
cancer CC and D
and NN esophageal D
esophageal NN cancer D

thus RB thus O
thus , , O
, PRP we O
we MD should O
should VB recognize O
recognize DT this O
this JJ immanent O
immanent NN risk O
risk CC and O
and VB perform O
perform JJ peri- T
peri- CC and T
and JJ postoperative T
postoperative NN management T
management IN for O
for NNS patients O
patients IN with O
with JJ gh-producing D
gh-producing NNS tumors D

background NN background O
background : : O
: IN at O
at JJ present O
present DT the O
the NN addition T
addition IN of T
of JJ thoracic T
thoracic NN irradiation T
irradiation TO to T
to NN combination T
combination NN chemotherapy T
chemotherapy VBZ is O
is DT a O
a JJ standard O
standard NN treatment O
treatment IN for O
for JJ limited D
limited VBD staged D
staged JJ small D
small NN cell D
cell NN lung D
lung NN cancer D

we PRP we O
we VBN conducted O
conducted DT a O
a NN phase O
phase LS ii O
ii NN study O
study IN of O
of NN etoposide T
etoposide NN ( T
( JJ vp-16 T
vp-16 NN ) T
) JJ -ifosfamide-cisplatin T
-ifosfamide-cisplatin NN ( T
( NN vip T
vip NN ) T
) NN combination T
combination NN chemotherapy T
chemotherapy CC plus T
plus JJ early T
early JJ concurrent T
concurrent JJ thoracic T
thoracic NN irradiation T
irradiation IN for O
for DT the O
the NNS patients O
patients IN with O
with RB previously O
previously JJ untreated D
untreated JJ limited D
limited JJ small D
small NN cell D
cell NN lung D
lung NN cancer D
cancer IN in O
in NN order O
order TO to O
to VB assess O
assess IN if O
if DT the O
the NN treatment O
treatment NN modality O
modality MD could O
could VB improve O
improve DT the O
the NN response O
response NN rate O
rate CC and O
and DT the O
the NN toxicity O

methods NNS methods O
methods : : O
: CD forty-four O
forty-four NNS patients O
patients IN with O
with JJ limited D
limited JJ small D
small NN cell D
cell NN lung D
lung NN cancer D
cancer VBD were O
were VBN treated O
treated IN with O
with NN etoposide-ifosfamide-cisplatin T
etoposide-ifosfamide-cisplatin CC and T
and JJ concurrent T
concurrent JJ thoracic T
thoracic NN irradiation T

conclusion NN conclusion O
conclusion : : O
: NN vip T
vip NN combination T
combination NN chemotherapy T
chemotherapy CC and T
and JJ early T
early JJ concurrent T
concurrent JJ thoracic T
thoracic NN irradiation T
irradiation IN for O
for NNS patients O
patients IN with O
with JJ limited D
limited NN stage D
stage JJ small D
small NN cell D
cell NN lung D
lung NN cancer D
cancer VBD revealed O
revealed JJ excellent O
excellent JJ antitumor O
antitumor NN response O
response IN with O
with JJ tolerable O
tolerable NN toxicity O

in IN in O
in DT this O
this NN study O
study PRP we O
we VBN analyzed O
analyzed CD 33 O
33 NNS cases O
cases WDT which O
which VBD underwent O
underwent JJ complete T
complete JJ surgical T
surgical NN resection T
resection TO to O
to VB assess O
assess DT the O
the NN role O
role IN of O
of NN surgery O
surgery IN in O
in DT the O
the NN treatment O
treatment IN of O
of NNS patients O
patients IN with O
with NN n D
n LS 2 D
2 NN nsclc D

we PRP we O
we RB thereby O
thereby VB recommend O
recommend IN that O
that NN surgery T
surgery MD should O
should RB only O
only VB be O
be VBN performed O
performed IN for O
for DT those O
those NN n D
n LS 2 D
2 NN nsclc D
nsclc NNS patients O
patients VBN diagnosed O
diagnosed IN as O
as NN t O
t CD 1 O
1 CC or O
or NN t O
t CD 2 O
2 IN with O
with DT a O
a NN classification O
classification IN of O
of NN p1 O
p1 CC or O
or JJR less O

inhaled VBN inhaled T
inhaled NN corticosteroid T
corticosteroid NN therapy T
therapy VBZ is O
is VBN recommended O
recommended IN for O
for NNS patients O
patients IN with O
with JJ persistent D
persistent NN disease D
disease , , O
, CC and O
and JJ careful O
careful NN instruction O
instruction IN in O
in DT the O
the NN use O
use IN of O
of JJ metered-dose O
metered-dose NNS inhalers O
inhalers VBZ is O
is RB particularly O
particularly JJ important O
important IN for O
for DT the O
the JJ elderly O

background NN background O
background : : O
: DT the O
the NN role O
role IN of O
of JJ surgical T
surgical VBG staging T
staging IN of O
of NNS patients O
patients IN with O
with JJ non-small D
non-small NN cell D
cell NN lung D
lung NN cancer D
cancer NN ( D
( NN nsclc D
nsclc NN ) D
) VBZ continues O
continues TO to O
to VB evolve O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> DT this O
this NN report O
report VBZ describes O
describes PRP$ our O
our NNS findings O
findings VBG utilizing O
utilizing JJ routine O
routine JJ cervical O
cervical JJ mediastinoscopy O
mediastinoscopy IN in O
in DT the O
the NN evaluation O
evaluation IN of O
of JJ peripheral O
peripheral NN t1 O
t1 NN ( O
( JJR < O
< CD 3 O
3 NN cm O
cm NN ) O
) NN lung O
lung NNS tumors O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> JJ mediastinoscopy O
mediastinoscopy VBZ facilitates O
facilitates NN identification O
identification IN of O
of NNS patients O
patients IN with O
with RB regionally D
regionally JJ advanced D
advanced NN disease D
disease RB prior D
prior TO to D
to NN resection D
resection , , O
, VBG allowing O
allowing JJ neoadjuvant T
neoadjuvant NN therapy T
therapy CC and O
and VBG avoiding O
avoiding JJ unnecessary O
unnecessary NNS resections O

purpose NN purpose O
purpose : : O
: VBN given O
given DT the O
the JJ cisplatin-related O
cisplatin-related NN myelotoxicity O
myelotoxicity CC and O
and JJ nonhematologic O
nonhematologic NNS toxicities O
toxicities , , O
, PRP we O
we VBD were O
were VBD prompted O
prompted TO to O
to VB undertake O
undertake DT a O
a NN study O
study IN of O
of DT the O
the JJ noncisplatin T
noncisplatin NN combination T
combination IN of T
of NN paclitaxel T
paclitaxel CC plus T
plus NN gemcitabine T
gemcitabine TO to O
to VB evaluate O
evaluate DT the O
the NN efficacy O
efficacy , , O
, NN tolerance O
tolerance , , O
, CC and O
and NN survival O
survival IN of O
of DT this O
this NN combination O
combination IN in O
in NNS patients O
patients IN with O
with RB locally D
locally JJ advanced D
advanced CC and D
and JJ metastatic D
metastatic JJ non-small-cell D
non-small-cell NN lung D
lung NN cancer D
cancer NN ( D
( NN nsclc D
nsclc NN ) D

we PRP we O
we VBN evaluated O
evaluated DT the O
the NN role O
role IN of O
of JJ systemic T
systemic NN chemotherapy T
chemotherapy IN for O
for NNS patients O
patients IN with O
with JJ malignant D
malignant JJ pleural D
pleural NNS effusions D
effusions IN from D
from NN nsclc D

methods NNS methods O
methods : : O
: PRP we O
we VBN analyzed O
analyzed CD 34 O
34 NNS patients O
patients WP who O
who VBD were O
were VBN found O
found TO to O
to VB have O
have JJ malignant D
malignant JJ pleural D
pleural NNS effusions D
effusions IN in O
in DT the O
the NN course O
course IN of O
of NN diagnosis O
diagnosis IN of O
of CD 118 O
118 NNS patients O
patients VBN enrolled O
enrolled IN in O
in CD three O
three JJ consecutive O
consecutive JJ clinical O
clinical NNS trials O
trials IN on O
on JJ advanced O
advanced NN nsclc D
nsclc VBG assessing O
assessing NN combination T
combination NN chemotherapy T
chemotherapy IN of T
of NN cisplatin T
cisplatin , , T
, NN ifosfamide T
ifosfamide , , T
, CC and T
and JJ irinotecan T
irinotecan IN with T
with JJ recombinant T
recombinant JJ human T
human NN granulocyte T
granulocyte JJ colony-stimulating T
colony-stimulating NN factor T
factor NN support T

conclusions NNS conclusions O
conclusions : : O
: DT both O
both DT the O
the NN response O
response NN rate O
rate CC and O
and NN survival O
survival NNS data O
data IN in O
in DT this O
this JJ retrospective O
retrospective NN study O
study VBP suggest O
suggest DT a O
a JJ high O
high NN degree O
degree IN of O
of NN activity O
activity IN of O
of DT this O
this NN combination T
combination NN chemotherapy T
chemotherapy IN in O
in NNS patients O
patients IN with O
with JJ malignant D
malignant JJ pleural D
pleural NNS effusions D
effusions IN from D
from NN nsclc D

in IN in O
in NN contrast O
contrast , , O
, DT the O
the NN introduction O
introduction CC and O
and NN improvement O
improvement IN of O
of NN chemotherapy T
chemotherapy IN since O
since DT the O
the NNS 1970s O
1970s VBD gave O
gave NN rise O
rise TO to O
to DT an O
an NN improvement O
improvement IN in O
in : - O
- RB only O
only JJ short-term O
short-term NN ( O
( JJR < O
< CD 2 O
2 NNS years O
years NN ) O
) : - O
- NN survival O
survival IN for O
for NNS patients O
patients IN with O
with NN small-cell D
small-cell NN lung D
lung NN cancer D

between IN between O
between NNP july O
july CD 1992 O
1992 CC and O
and NNP december O
december CD 1997 O
1997 , , O
, CD 1799 O
1799 NNS patients O
patients VBD were O
were VBN diagnosed O
diagnosed IN as O
as VBG having O
having NN lung D
lung NN cancer D
cancer IN in O
in PRP$ our O
our NN hospital O
hospital CC and O
and CD 926 O
926 NNS patients O
patients VBN received O
received NN chemotherapy T
chemotherapy CC and/or T
and/or JJ thoracic T
thoracic NN radiotherapy T

the DT the O
the NN administration O
administration IN of O
of NN mitomycin T
mitomycin NN c T
c IN in O
in NN addition O
addition TO to O
to JJ cisplatin-based T
cisplatin-based NNS regimens T
regimens IN for O
for NNS patients O
patients IN with O
with NN lung D
lung NN cancer D
cancer MD should O
should VB be O
be RB carefully O
carefully VBN considered O

570 CD 570 O
570 NNS patients O
patients IN with O
with NN osteosarcoma D
osteosarcoma IN of D
of DT the D
the NNS extremities D
extremities VBD were O
were VBN treated O
treated IN with O
with CD five O
five JJ different O
different NNS protocols O
protocols IN of O
of JJ neoadjuvant T
neoadjuvant NN chemotherapy T
chemotherapy IN at O
at JJ rizzoli O
rizzoli NN institute O
institute IN between O
between CD 1983 O
1983 CC and O
and CD 1995 O

we PRP we O
we VBP conclude O
conclude IN that O
that IN for O
for NNS patients O
patients IN with O
with NN osteosarcoma D
osteosarcoma IN of D
of DT the D
the NNS extremities D
extremities VBN treated O
treated IN with O
with JJ neoadjuvant T
neoadjuvant NN chemotherapy T
chemotherapy : : O
: NN ( O
( DT a O
a NN ) O
) DT the O
the NN pattern O
pattern IN of O
of JJ systemic O
systemic NN relapse O
relapse NNS changes O
changes VBG according O
according TO to O
to DT the O
the NN efficacy O
efficacy IN of O
of DT the O
the NN protocol O
protocol IN of O
of NN chemotherapy O
chemotherapy VBN used O

the DT the O
the NN degree O
degree IN of O
of NN healing O
healing CC and O
and NN damage O
damage IN of O
of DT the O
the JJ bronchial O
bronchial NN wall O
wall IN after O
after JJ photodynamic T
photodynamic NN therapy T
therapy , , T
, NN nd-yag T
nd-yag NN laser T
laser CC and T
and JJ electrocautery T
electrocautery IN for O
for JJ intraluminal D
intraluminal JJ early-stage D
early-stage NN cancer D
cancer VB have O
have VBN been O
been VBN analysed O

to TO to O
to VB examine O
examine IN whether O
whether NN efficacy O
efficacy IN of O
of JJ postoperative O
postoperative JJ oral O
oral NN administration O
administration IN of O
of NN uft T
uft , , T
, DT a T
a NN 5-fluorouracil T
5-fluorouracil JJ derivative T
derivative JJ chemotherapeutic T
chemotherapeutic NN agent T
agent , , O
, MD may O
may VB be O
be VBN influenced O
influenced IN by O
by NN incidence O
incidence IN of O
of NN apoptosis O
apoptosis NN ( O
( NN apoptosis O
apoptosis NN index O
index NN ) O
) CC or O
or JJ apoptosis-related O
apoptosis-related NN gene O
gene NN status O
status NN ( O
( NN p53 O
p53 CC and O
and NN bcl-2 O
bcl-2 NN ) O
) IN of O
of DT the O
the NN tumour O
tumour , , O
, DT a O
a JJ total O
total IN of O
of CD 162 O
162 NNS patients O
patients IN with O
with JJ pathologic D
pathologic NN stage D
stage LS i D
i JJ non-small D
non-small NN cell D
cell NN lung D
lung NN cancer D
cancer VBD were O
were RB retrospectively O
retrospectively VBN reviewed O

objectives NNS objectives O
objectives : : O
: DT the O
the NN purpose O
purpose IN of O
of DT this O
this NN study O
study VBZ is O
is TO to O
to NN review O
review PRP$ our O
our NN experience O
experience IN with O
with DT the O
the NN spectrum O
spectrum IN of O
of NN neuroendocrine D
neuroendocrine NNS neoplasms D
neoplasms IN of D
of DT the D
the NN lung D
lung IN with O
with NN emphasis O
emphasis IN on O
on DT the O
the JJ histopathologic O
histopathologic NN classification O
classification CC and O
and JJ surgical T
surgical NN therapy T
therapy IN of O
of DT each O
each NN class O
class IN of O
of NN neoplasm O

patients NNS patients O
patients : : O
: IN during O
during DT this O
this NN period O
period , , O
, DT a O
a JJ total O
total IN of O
of CD 77 O
77 NNS patients O
patients VBD underwent O
underwent NN lung T
lung NN resection T
resection IN for O
for DT the O
the VBG following O
following NN neuroendocrine D
neuroendocrine NNS neoplasms D
neoplasms : : O
: JJ typical D
typical NN carcinoid D
carcinoid NN ( D
( NN tc D
tc NN ) D
) , , O
, CD 50 O
50 NNS patients O
patients : ; O
; JJ atypical D
atypical NN carcinoid D
carcinoid NN ( D
( NN ac D
ac NN ) D
) , , O
, CD 5 O
5 NNS patients O
patients : ; O
; JJ large D
large NN cell D
cell NN neuroendocrine D
neuroendocrine NN carcinoma D
carcinoma NN ( D
( NN lcnec D
lcnec NN ) D
) , , O
, CD 9 O
9 NNS patients O
patients : ; O
; JJ mixed D
mixed NN large-small D
large-small NN cell D
cell NN neuroendocrine D
neuroendocrine NN carcinoma D
carcinoma NN ( D
( NN lsnec D
lsnec NN ) D
) , , O
, CD 4 O
4 NNS patients O
patients : ; O
; CC or O
or JJ small D
small NN cell D
cell NN neuroendocrine D
neuroendocrine NN carcinoma D
carcinoma NN ( D
( NN scc D
scc NN ) D
) , , O
, CD 9 O
9 NNS patients O

despite IN despite O
despite DT the O
the JJ poor O
poor JJ overall O
overall NN prognosis O
prognosis IN in O
in JJ high-grade O
high-grade NN neuroendocrine D
neuroendocrine NNS tumors D
tumors IN of D
of DT the D
the NN lung D
lung , , O
, NN surgery T
surgery VBZ remains O
remains DT a O
a JJ viable O
viable NN adjunct O
adjunct IN in O
in DT the O
the RB early O
early NNS stages O
stages IN of O
of DT this O
this NN disease O

urpose NN urpose O
urpose : : O
: TO to O
to VB assess O
assess NNS results O
results IN with O
with JJ twice-daily O
twice-daily JJ high-dose O
high-dose NN radiotherapy T
radiotherapy NN ( T
( NN rt T
rt NN ) T
) IN for O
for JJ non-small-cell D
non-small-cell NN lung D
lung NN cancer D
cancer NN ( D
( NN nsclc D
nsclc NN ) D

is VBZ is O
is JJ prolonged O
prolonged NN survival O
survival JJ possible O
possible IN for O
for NNS patients O
patients IN with O
with JJ supraclavicular D
supraclavicular NN node D
node NNS metastases D
metastases IN in D
in NN nsclc D
nsclc VBN treated O
treated IN with O
with JJ chemoradiotherapy T
chemoradiotherapy . ? O
? NN ijrobp O
ijrobp CD 1999 O
1999 : ; O
; CD 44 O
44 NN ( O
( CD 4 O
4 NN ) O
) : : O
: CD 847-853 O

we PRP we O
we VBN aimed O
aimed TO to O
to VB investigate O
investigate IN whether O
whether JJ biological O
biological NNS factors O
factors JJ related O
related TO to O
to NN radiosensitivity O
radiosensitivity CC and O
and NN chemosensitivity O
chemosensitivity VB have O
have JJ prognostic O
prognostic NN significance O
significance IN in O
in JJ non-small-cell-lung-cancer D
non-small-cell-lung-cancer NN ( D
( NN nsclc D
nsclc NN ) D
) NNS patients O
patients VBN treated O
treated IN with O
with RB daily O
daily JJ low O
low NNS doses O
doses IN of O
of NN cisplatin T
cisplatin CC and T
and NN radiotherapy T

we PRP we O
we VBN treated O
treated CD 27 O
27 NN nsclcm D
nsclcm NNS patients O
patients IN with O
with JJ concomitant O
concomitant RB daily O
daily JJ low-dose O
low-dose NN cisplatin T
cisplatin CC and T
and NN radiotherapy T
radiotherapy IN between O
between CD 1993 O
1993 CC and O
and CD 1995 O

background NN background O
background : : O
: PRP we O
we VBN examined O
examined DT the O
the NNS complications O
complications CC and O
and NNS outcomes O
outcomes IN of O
of VBG placing O
placing NNS stents T
stents IN for O
for DT both O
both NN esophageal D
esophageal CC and D
and JJ tracheobronchial D
tracheobronchial NNS stenoses D

methods NNS methods O
methods : : O
: PRP we O
we VBN placed O
placed NNS stents T
stents IN for O
for DT both O
both NN esophageal D
esophageal CC and D
and JJ tracheobronchial D
tracheobronchial NNS stenoses D
stenoses IN in O
in CD 8 O
8 NNS patients O
patients NN ( O
( CD 7 O
7 IN with O
with NN esophageal O
esophageal NN cancer O
cancer CC and O
and CD 1 O
1 IN with O
with NN lung O
lung NN cancer O
cancer NN ) O

covered VBN covered O
covered CC or O
or JJ noncovered O
noncovered JJ metallic T
metallic NNS stents T
stents VBD were O
were VBN used O
used IN for O
for DT the O
the NN esophageal D
esophageal NNS stenoses D
stenoses , , O
, IN except O
except IN in O
in CD 1 O
1 NN patient O
patient VBN treated O
treated IN with O
with DT a O
a NN silicone O
silicone NN stent O

silicone NN silicone T
silicone NNS stents T
stents VBD were O
were VBN used O
used IN for O
for DT the O
the JJ tracheobronchial D
tracheobronchial NNS stenoses D

results NNS results O
results : : O
: DT all O
all NNS patients O
patients JJ experienced O
experienced NN improvement O
improvement IN of O
of NNS grades O
grades IN of O
of DT both O
both NN dysphagia D
dysphagia CC and D
and JJ respiratory D
respiratory NNS symptoms D
symptoms IN after O
after JJ stent T
stent NN therapy T

conclusions NNS conclusions O
conclusions : : O
: IN for O
for NNS patients O
patients IN with O
with DT both O
both NN esophageal D
esophageal CC and D
and JJ tracheobronchial D
tracheobronchial NNS stenoses D
stenoses , , O
, DT a O
a JJ stent T
stent MD should O
should VB be O
be VBN introduced O
introduced IN into O
into DT the O
the NN tracheobronchus O
tracheobronchus RB first O

because IN because O
because NN placement O
placement IN of O
of NNS stents O
stents IN in O
in DT both O
both DT the O
the NN esophagus O
esophagus CC and O
and NN tracheobronchus O
tracheobronchus VBZ has O
has DT a O
a JJ high O
high NN risk O
risk IN of O
of NN enlargement O
enlargement IN of O
of DT the O
the NN fistula O
fistula , , O
, DT a O
a VBN covered T
covered JJ metallic T
metallic JJ stent T
stent VBZ is O
is JJ preferable O
preferable IN for O
for NN esophageal D
esophageal NN cancer D
cancer VBG involving D
involving DT the D
the NN tracheobronchus D

a DT a O
a JJ retrospective O
retrospective JJ immunohistochemical O
immunohistochemical NN study O
study VBD was O
was VBN performed O
performed IN on O
on NN material O
material IN from O
from NNS patients O
patients WP who O
who VBD were O
were RB newly O
newly VBN diagnosed O
diagnosed IN with O
with JJ osteogenic D
osteogenic NN sarcoma D
sarcoma WP who O
who VBD were O
were VBN treated O
treated VBG according O
according TO to O
to DT the O
the NN t12 T
t12 NN protocol T
protocol IN from O
from DT the O
the NNS authors O
authors POS ' O
' NN institution O
institution IN between O
between CD 1986 O
1986 TO to O
to CD 1993 O

these DT these O
these NNS data O
data VBP suggest O
suggest IN that O
that NN her2/erbb-2 O
her2/erbb-2 MD should O
should VB be O
be VBN evaluated O
evaluated RB prospectively O
prospectively IN as O
as DT a O
a JJ prognostic O
prognostic NN indicator O
indicator CC and O
and JJ clinical O
clinical NNS trials O
trials VBG using O
using NNS antibodies T
antibodies IN that O
that NN target O
target DT this O
this NN receptor O
receptor MD should O
should VB be O
be VBN considered O
considered IN for O
for DT the O
the NN treatment O
treatment IN of O
of NNS patients O
patients IN with O
with JJ osteogenic D
osteogenic NN sarcoma D

objective JJ objective O
objective : : O
: TO to O
to VB examine O
examine DT the O
the NN effectiveness O
effectiveness IN of O
of JJ ninjin T
ninjin NN yoei T
yoei TO to T
to NN ( T
( NN nyt T
nyt : ; T
; JJ ren-shen-yang-rong-tang T
ren-shen-yang-rong-tang IN in T
in JJ chinese T
chinese NN medicine T
medicine : ; T
; NN kotaro T
kotaro JJ pharmaceutical T
pharmaceutical NN co. T
co. , , T
, NN ltd. T
ltd. , , T
, NN osaka T
osaka , , T
, NN japan T
japan NN ) T
) , , T
, CD one T
one IN of T
of DT the T
the JJ traditional T
traditional JJ herbal T
herbal NNS medicines T
medicines , , O
, IN against O
against NN lung D
lung NN carcinoma D

setting VBG setting O
setting : : O
: DT the O
the NN nursing O
nursing NN center O
center NN himawari O
himawari NN design O
design , , O
, NN patient O
patient , , O
, CC and O
and NN preparation O
preparation : : O
: DT the O
the JJ regular O
regular NN dosage O
dosage IN of O
of NN nyt T
nyt NN ( O
( CD 15 O
15 NN g/d O
g/d NN ) O
) VBD was O
was VBN prescribed O
prescribed IN for O
for CD 7 O
7 NNS weeks O
weeks TO to O
to CD one O
one JJ elderly O
elderly NN patient O
patient IN with O
with NN lung D
lung NN carcinoma D

conclusion NN conclusion O
conclusion : : O
: NN nyt T
nyt VBZ has O
has DT a O
a JJ positive O
positive NN effect O
effect IN on O
on NN life O
life NN expectancy O
expectancy IN for O
for NNS patients O
patients IN with O
with NN malignancy D

background NN background O
background : : O
: DT the O
the NNS costs O
costs IN of O
of JJ videothoracoscopic T
videothoracoscopic NNS procedures T
procedures IN for O
for NNS patients O
patients IN with O
with NN lung D
lung NN carcinoma D
carcinoma VBD were O
were VBN compared O
compared IN with O
with DT those O
those IN of O
of NNS patients O
patients WP who O
who VBD underwent O
underwent JJ open T
open NN thoracotomy T
thoracotomy IN in O
in NN japan O

methods NNS methods O
methods : : O
: DT the O
the NN cost O
cost IN of O
of JJ surgical T
surgical NN treatment T
treatment IN in O
in CD 1997 O
1997 CC and O
and CD 1998 O
1998 IN for O
for NNS patients O
patients IN with O
with JJ resectable D
resectable JJ primary D
primary CC or D
or JJ metastatic D
metastatic NN lung D
lung NN carcinoma D
carcinoma VBD was O
was VBN analyzed O
analyzed IN from O
from VBN itemized O
itemized NNS statements O
statements IN of O
of NN hospital O
hospital NNS charges O

for IN for O
for NNS patients O
patients IN with O
with NN lung D
lung NN carcinoma D
carcinoma WP who O
who VBP are O
are IN in O
in RB relatively O
relatively JJ poor O
poor NN health O
health , , O
, DT the O
the NNS authors O
authors VBD chose O
chose JJ videothoracoscopic T
videothoracoscopic JJ lobectomy T
lobectomy CC or T
or JJ partial T
partial NN resection T
resection IN of T
of DT the T
the NN lung T
lung RB instead O
instead IN of O
of DT an O
an JJ open O
open NN thoracotomy O

for IN for O
for NNS patients O
patients IN with O
with JJ solitary D
solitary JJ pulmonary D
pulmonary NN metastasis D
metastasis , , O
, DT the O
the NNS authors O
authors RB routinely O
routinely VBN performed O
performed JJ thoracoscopic T
thoracoscopic JJ partial T
partial NN resection T
resection IN of T
of DT the T
the NN lung T

background NN background O
background : : O
: JJ curative T
curative NN therapy T
therapy VBZ is O
is JJ available O
available IN for O
for NNS patients O
patients IN with O
with NN stage D
stage CD 0 D
0 NN lung D
lung NN carcinoma D
carcinoma , , O
, IN with O
with DT a O
a JJR > O
> CD 90 O
90 NN % O
% JJ 5-year O
5-year NN survival O
survival NN rate O

promising JJ promising O
promising JJ chemopreventive T
chemopreventive NNS agents T
agents RB also O
also VBP are O
are IN under O
under NN investigation O
investigation RB currently O
currently TO to O
to VB reduce O
reduce DT the O
the NN risk O
risk IN of O
of NN lung D
lung NN carcinoma D
carcinoma IN in O
in JJ high O
high NN risk O
risk NNS populations O

object NN object O
object : : O
: DT the O
the NN purpose O
purpose IN of O
of DT this O
this JJ retrospective O
retrospective NN study O
study VBD was O
was TO to O
to VB compare O
compare DT the O
the NN effectiveness O
effectiveness IN of O
of NN gamma T
gamma NN knife T
knife NN radiosurgery T
radiosurgery NN ( T
( NNS gks T
gks NN ) T
) IN for O
for JJ multiple D
multiple JJ cerebral D
cerebral NNS metastases D
metastases IN with O
with IN that O
that IN of O
of JJ whole-brain T
whole-brain NN radiation T
radiation NN therapy T
therapy NN ( T
( NN wbrt T
wbrt NN ) T

in IN in O
in DT the O
the NNS gks O
gks NN group O
group , , O
, JJ large O
large NNS lesions O
lesions NN ( O
( JJR > O
> CD 30 O
30 NN mm O
mm NN ) O
) VBD were O
were VBN removed O
removed RB surgically O
surgically CC and O
and DT all O
all JJ other O
other JJ small D
small NNS lesions D
lesions NN ( O
( JJR < O
< CC or O
or JJ = O
= CD 30 O
30 NN mm O
mm NN ) O
) VBD were O
were VBN treated O
treated IN by O
by NNS gks T

new JJ new O
new JJ distant D
distant NNS lesions D
lesions VBD were O
were VBN treated O
treated IN by O
by VBN repeated O
repeated NNS gks T
gks IN without O
without NN prophylactic O
prophylactic NN wbrt O

conclusions NNS conclusions O
conclusions : : O
: NN gamma T
gamma NN knife T
knife NN radiosurgery T
radiosurgery IN without O
without NN prophylactic O
prophylactic NN wbrt O
wbrt MD could O
could VB be O
be DT a O
a JJ primary O
primary NN choice O
choice IN of O
of NN treatment O
treatment IN for O
for NNS patients O
patients IN with O
with IN as O
as JJ many O
many IN as O
as CD 10 O
10 JJ cerebral D
cerebral NNS metastases D
metastases IN from D
from NN nonsmall D
nonsmall NN cell D
cell NN cancer D

the DT the O
the JJ notable O
notable NN exception O
exception VBZ has O
has VBN been O
been NN docetaxel T
docetaxel , , O
, WDT which O
which VBZ has O
has VBN been O
been RB extensively O
extensively VBN studied O
studied IN as O
as DT a O
a JJ second-line O
second-line NN therapy O
therapy IN for O
for NN nsclc D

object NN object O
object : : O
: DT the O
the NN purpose O
purpose IN of O
of DT this O
this JJ retrospective O
retrospective NN study O
study VBD was O
was TO to O
to VB compare O
compare DT the O
the NN effectiveness O
effectiveness IN of O
of NN gamma T
gamma NN knife T
knife NN radiosurgery T
radiosurgery NN ( T
( NNS gks T
gks NN ) T
) IN for O
for JJ multiple D
multiple JJ cerebral D
cerebral NNS metastases D
metastases IN with O
with IN that O
that IN of O
of JJ whole-brain T
whole-brain NN radiation T
radiation NN therapy T
therapy NN ( T
( NN wbrt T
wbrt NN ) T

patients NNS patients O
patients IN with O
with DT a O
a JJ single D
single JJ non-sclc D
non-sclc , , D
, NN breast D
breast , , D
, NN melanoma D
melanoma , , D
, JJ renal D
renal NN cell D
cell , , D
, CC and D
and JJ ovarian D
ovarian NN carcinoma D
carcinoma NN brain D
brain NN metastasis D
metastasis VB have O
have DT the O
the RB best O
best NN chance O
chance IN for O
for JJ long-term O
long-term NN survival O
survival IN if O
if VBN treated O
treated IN with O
with JJ surgical T
surgical NN resection T
resection CC and T
and NN wbrt T

objective JJ objective O
objective : : O
: JJ careful O
careful NN patient O
patient NN selection O
selection VBZ is O
is JJ vital O
vital WRB when O
when JJ video-assisted T
video-assisted JJ thoracoscopic T
thoracoscopic JJ surgical T
surgical NN ( T
( NNS vats T
vats NN ) T
) JJ therapeutic T
therapeutic JJ pulmonary T
pulmonary NN metastasectomy T
metastasectomy IN of O
of JJ colorectal D
colorectal NN carcinoma D
carcinoma VBZ is O
is VBN considered O

we PRP we O
we VBN reviewed O
reviewed PRP$ our O
our NNS vats O
vats NN experience O
experience IN for O
for JJ therapeutic T
therapeutic NN metastasectomy T
metastasectomy IN of O
of JJ peripheral D
peripheral JJ colorectal D
colorectal JJ pulmonary D
pulmonary NNS metastases D

methods NNS methods O
methods : : O
: IN over O
over CD 90 O
90 NNS months O
months , , O
, JJ therapeutic T
therapeutic NNS vats T
vats NN metastasectomy T
metastasectomy VBD was O
was JJ accomplished O
accomplished IN upon O
upon CD 80 O
80 NNS patients O
patients IN with O
with JJ colorectal D
colorectal NNS metastases D

conclusions NNS conclusions O
conclusions : : O
: JJ therapeutic T
therapeutic NNS vats T
vats NN resection T
resection IN of O
of JJ colorectal D
colorectal NNS metastases D
metastases VBZ appears O
appears JJ efficacious O

objectives NNS objectives O
objectives : : O
: TO to O
to NN review O
review DT the O
the NN spectrum O
spectrum IN of O
of NN presentation O
presentation CC and O
and DT the O
the JJ surgical T
surgical NN management T
management IN of O
of JJ non D
non JJ small D
small NN cell D
cell NN lung D
lung NN cancer D
cancer NN ( D
( NN nsclc D
nsclc NN ) D
) CC and O
and DT the O
the NN role O
role IN of O
of JJ various O
various JJ diagnostic O
diagnostic NNS modalities O
modalities IN in O
in VBG predicting O
predicting DT the O
the JJ post-operative O
post-operative NN stage O
stage CC and O
and DT the O
the NN correlation O
correlation IN of O
of DT the O
the JJ post-operative O
post-operative NN stage O
stage IN with O
with DT the O
the NNS chances O
chances IN of O
of NN recurrence O

patients NNS patients O
patients IN with O
with NN limited-stage D
limited-stage NN small-cell D
small-cell NN carcinoma D
carcinoma IN of D
of DT the D
the NN lung D
lung VBP are O
are VBN treated O
treated IN with O
with JJ combined-modality T
combined-modality NN therapy T
therapy IN with O
with DT the O
the NN intent O
intent TO to O
to NN cure O

in IN in O
in DT the O
the JJ past O
past JJ several O
several NNS years O
years , , O
, JJ new T
new JJ chemotherapeutic T
chemotherapeutic NNS agents T
agents , , T
, VBG including T
including DT the T
the NNS taxanes T
taxanes CC and T
and DT the T
the NN topoisomerase T
topoisomerase LS i T
i NNS inhibitors T
inhibitors , , O
, VB have O
have VBD demonstrated O
demonstrated JJ substantial O
substantial NN activity O
activity IN against O
against NN small-cell D
small-cell NN carcinoma D

we PRP we O
we VBN evaluated O
evaluated DT the O
the NN role O
role IN of O
of NN chemotherapy T
chemotherapy IN for O
for NNS patients O
patients IN with O
with NN brain D
brain NNS metastases D
metastases IN from D
from NN nsclc D

methods NNS methods O
methods : : O
: PRP we O
we VBN analyzed O
analyzed CD 30 O
30 NNS patients O
patients WP who O
who VBD were O
were VBN discovered O
discovered TO to O
to VB have O
have NN brain O
brain NNS metastases O
metastases IN during O
during DT the O
the NN diagnosis O
diagnosis IN of O
of CD 121 O
121 NNS patients O
patients VBN enrolled O
enrolled IN in O
in CD three O
three JJ consecutive O
consecutive JJ clinical O
clinical NNS trials O
trials IN on O
on JJ advanced D
advanced NN nsclc D
nsclc VBG assessing O
assessing NN combination T
combination NN chemotherapy T
chemotherapy IN of T
of NN cisplatin T
cisplatin , , T
, NN ifosfamide T
ifosfamide CC and T
and JJ irinotecan T
irinotecan IN with T
with JJ rhg-csf T
rhg-csf NN support T

conclusions NNS conclusions O
conclusions : : O
: DT both O
both DT the O
the NN response O
response NN rate O
rate CC and O
and NN survival O
survival NNS data O
data IN in O
in DT this O
this JJ retrospective O
retrospective NN study O
study VBP suggest O
suggest DT a O
a JJ high O
high NN degree O
degree IN of O
of NN activity O
activity IN of O
of DT this O
this NN combination T
combination NN chemotherapy T
chemotherapy IN in O
in NNS patients O
patients IN with O
with NN brain D
brain NNS metastases D
metastases IN from D
from NN nsclc D

the DT the O
the NN aim O
aim IN of O
of DT this O
this NN study O
study VBD was O
was DT the O
the NN evaluation O
evaluation IN of O
of DT both O
both DT the O
the JJ antitumour O
antitumour NN activity O
activity CC and O
and NN toxicity O
toxicity IN of O
of DT an O
an JJ immunochemotherapeutic T
immunochemotherapeutic NN regimen T
regimen VBG consisting T
consisting IN of T
of JJ interferon-alpha2b T
interferon-alpha2b CC and T
and NN interleukin-2 T
interleukin-2 IN in T
in NN combination T
combination IN with T
with NN fotemustine T
fotemustine IN for O
for NNS patients O
patients IN with O
with JJ metastatic D
metastatic NN melanoma D

to TO to O
to VB explore O
explore DT the O
the NN induction O
induction IN of O
of NN chemotherapy T
chemotherapy NN ( T
( NN ct T
ct NN ) T
) NN dna O
dna NN damage O
damage CC and O
and PRP$ its O
its NN correlation O
correlation IN with O
with NN tumor O
tumor NN response O
response CC and O
and NN patient O
patient NN survival O
survival , , O
, PRP we O
we VBD undertook O
undertook DT the O
the JJ present O
present NN study O
study IN in O
in CD 20 O
20 JJ small D
small NN cell D
cell NN lung D
lung NN cancer D
cancer NN ( D
( NN sclc D
sclc NN ) D
) NNS patients O

in IN in O
in NNS patients O
patients IN with O
with JJ metastatic D
metastatic JJ colorectal D
colorectal NN cancer D
cancer , , O
, JJ intravenous T
intravenous NN oxaliplatin T
oxaliplatin VBZ has O
has VBN been O
been VBN trialled O
trialled IN as O
as DT a O
a NN monotherapy O
monotherapy CC and O
and IN in O
in NN combination O
combination IN with O
with JJ other O
other NNS agents O

neoadjuvant JJ neoadjuvant T
neoadjuvant NN therapy T
therapy IN with T
with JJ oxaliplatin/fluorouracil/folinic T
oxaliplatin/fluorouracil/folinic NN acid T
acid VBZ has O
has JJ proven O
proven JJ beneficial O
beneficial IN in O
in VBG enabling O
enabling JJ surgical O
surgical NN removal O
removal IN of O
of RB previously O
previously JJ unresectable D
unresectable NN liver D
liver NNS metastases D

in IN in O
in CD 2 O
2 NNS studies O
studies , , O
, NN surgery T
surgery IN with O
with JJ curative O
curative NN intent O
intent VBD was O
was VBN performed O
performed IN in O
in CD 16 O
16 CC and O
and CD 51 O
51 NN % O
% IN of O
of NNS patients O
patients IN with O
with RB initially O
initially JJ unresectable D
unresectable NN liver D
liver NNS metastases D
metastases VBG following O
following JJ oxaliplatin/fluorouracil/folinic T
oxaliplatin/fluorouracil/folinic NN acid T
acid NN therapy T
therapy : ; O
; DT the O
the JJ 5-year O
5-year NN survival O
survival NNS rates O
rates VBD were O
were CD 40 O
40 CC and O
and CD 50 O
50 NN % O
% , , O
, RB respectively O

in IN in O
in NNS patients O
patients IN with O
with JJ advanced D
advanced JJ ovarian D
ovarian NN cancer D
cancer , , O
, JJ first-line O
first-line NN therapy O
therapy IN with O
with NN oxaliplatin/cyclophosphamide T
oxaliplatin/cyclophosphamide VBN achieved O
achieved DT an O
an JJ objective O
objective NN response O
response NN rate O
rate WDT which O
which VBD did O
did RB not O
not VBP differ O
differ RB significantly O
significantly IN from O
from IN that O
that IN of O
of NN cisplatin/cyclophosphamide T
cisplatin/cyclophosphamide NN ( O
( CD 33 O
33 CC vs O
vs CD 42 O
42 NN % O
% NN ) O

in IN in O
in NN addition O
addition , , O
, NN oxaliplatin T
oxaliplatin VBZ has O
has VBN shown O
shown NN efficacy O
efficacy IN in O
in NNS patients O
patients IN with O
with JJ platinum-pretreated D
platinum-pretreated JJ ovarian D
ovarian NN cancer D
cancer CC and O
and VBN achieved O
achieved JJ objective O
objective NN response O
response NNS rates O
rates JJ similar O
similar TO to O
to NN paclitaxel O
paclitaxel IN in O
in DT this O
this VBG setting O
setting NN ( O
( CD 16 O
16 CC vs O
vs CD 17 O
17 NN % O
% NN ) O

promising JJ promising O
promising NNS results O
results VB have O
have RB also O
also VBN been O
been VBN found O
found IN with O
with NN oxaliplatin T
oxaliplatin IN in O
in NNS patients O
patients IN with O
with JJ non-hodgkin D
non-hodgkin POS 's D
's NN lymphoma D
lymphoma , , D
, NN breast D
breast NN cancer D
cancer , , D
, NN mesothelioma D
mesothelioma CC and D
and JJ non-small D
non-small NN cell D
cell NN lung D
lung NN cancer D

conclusion NN conclusion O
conclusion : : O
: NN oxaliplatin T
oxaliplatin IN in T
in NN combination T
combination IN with T
with JJ fluorouracil/folinic T
fluorouracil/folinic NN acid T
acid VBZ is O
is DT an O
an JJ effective O
effective NN treatment O
treatment NN option O
option IN for O
for NNS patients O
patients IN with O
with JJ metastatic D
metastatic JJ colorectal D
colorectal NN cancer D
cancer , , O
, DT both O
both IN as O
as DT a O
a JJ first-line O
first-line NN therapy O
therapy CC and O
and IN in O
in NNS patients O
patients JJ refractory O
refractory TO to O
to JJ previous O
previous NN chemotherapy O

additional JJ additional O
additional JJ clinical O
clinical NN investigation O
investigation IN of O
of NN oxaliplatin T
oxaliplatin IN in O
in NNS patients O
patients IN with O
with JJ other O
other NNS cancers D
cancers VBZ is O
is VBN warranted O
warranted VBN given O
given DT the O
the JJ promising O
promising NNS results O
results VBN achieved O
achieved IN in O
in RB early O
early NNS trials O
trials , , O
, JJS most O
most RB notably O
notably IN in O
in NNS patients O
patients IN with O
with JJ platinum-pretreated O
platinum-pretreated JJ ovarian O
ovarian NN cancer O

combined VBN combined T
combined NN modality T
modality NN treatment T
treatment VBZ has O
has NN 'come O
'come IN out O
out IN of O
of NN age O
age POS ' O
' CC and O
and RB increasingly O
increasingly VBZ represents O
represents JJ standard O
standard IN of O
of NN care O
care IN for O
for DT a O
a RB rapidly O
rapidly VBG growing O
growing NN number O
number IN of O
of NNS patients O
patients IN in O
in RB locally O
locally JJ advanced O
advanced NNS stages O
stages IN of O
of NN nsclc D

the DT the O
the JJ current O
current NN study O
study VBD was O
was VBN designed O
designed TO to O
to VB assess O
assess DT the O
the JJ prognostic O
prognostic NN value O
value IN of O
of JJ immunomorphologic O
immunomorphologic NNS changes O
changes IN in O
in JJ locoregional O
locoregional NN lymph O
lymph NNS nodes O
nodes CC and O
and JJ lymphocytic O
lymphocytic NN infiltration O
infiltration IN of O
of JJ primary O
primary NN tumor O
tumor NN ( O
( NN li O
li NN ) O
) IN in O
in NNS patients O
patients WP who O
who VB undergo O
undergo NN resection T
resection IN for O
for JJ bronchogenic D
bronchogenic NN carcinoma D

conclusions NNS conclusions O
conclusions : : O
: NN lymph O
lymph NN node O
node NN immunoreactivity O
immunoreactivity CC and O
and NN li O
li RB significantly O
significantly NN influence O
influence RB long O
long NN term O
term NN survival O
survival IN after O
after JJ curative T
curative NN surgery T
surgery IN for O
for NNS patients O
patients IN with O
with NN carcinoma D
carcinoma IN of D
of DT the D
the NN lung D
lung CC and O
and MD may O
may VB be O
be JJ useful O
useful IN in O
in VBG stratifying O
stratifying NNS patients O
patients IN for O
for JJ prospective O
prospective NNS trials O
trials IN of O
of JJ adjuvant O
adjuvant NN treatment O
treatment , , O
, VBG including O
including NN immunotherapy O

the DT the O
the NN drug O
drug VBZ is O
is RB currently O
currently IN in O
in NN phase O
phase LS iii O
iii JJ clinical O
clinical NNS trials O
trials IN for O
for NNS patients O
patients IN with O
with JJ non-small D
non-small NN cell D
cell NN lung D
lung NN cancer D
cancer IN in O
in NN combination O
combination IN with O
with NN paclitaxel T
paclitaxel CC and T
and NN carboplatin T
carboplatin , , O
, IN as O
as RB well O
well IN as O
as IN in O
in JJ advanced D
advanced NN hormone D
hormone JJ refractory D
refractory NN prostate D
prostate NN cancer D
cancer IN in O
in NN combination O
combination IN with O
with NN mitoxantrone T

standard JJ standard O
standard NN treatment O
treatment IN of O
of NN sclc D
sclc VBZ consists O
consists IN of O
of JJ platinum-based T
platinum-based NN combination T
combination NN chemotherapy T
chemotherapy , , O
, IN with O
with JJ thoracic O
thoracic NN irradiation O
irradiation VBN added O
added IN for O
for NNS patients O
patients IN with O
with JJ limited-stage O
limited-stage NN disease O

several JJ several O
several JJR newer O
newer JJ chemotherapeutic T
chemotherapeutic NNS drugs T
drugs VB have O
have RB recently O
recently VBN been O
been VBN shown O
shown TO to O
to VB have O
have JJ significant O
significant NN activity O
activity IN in O
in NNS patients O
patients IN with O
with JJ untreated D
untreated CC or D
or VBD relapsed D
relapsed NN sclc D

we PRP we O
we RB recently O
recently VBN performed O
performed NN completion T
completion NN pneumonectomy T
pneumonectomy IN of T
of DT the T
the VBN left T
left NN lung T
lung IN in O
in DT a O
a JJ 70-year-old O
70-year-old NN man O
man IN with O
with NN hemophilia O
hemophilia DT a O
a , , O
, IN for O
for JJ squamous D
squamous NN cell D
cell NN carcinoma D
carcinoma IN in O
in DT the O
the JJ residual O
residual RB left O
left NN lung O

objective JJ objective O
objective : : O
: JJ several O
several NNS reports O
reports VB emphasize O
emphasize DT the O
the NN importance O
importance IN of O
of JJ en-bloc T
en-bloc NN resection T
resection IN as O
as DT the O
the JJ optimal O
optimal JJ surgical O
surgical NN treatment O
treatment IN of O
of NN lung D
lung NN cancer D
cancer IN with O
with NN chest O
chest NN wall O
wall NN invasion O

methods NNS methods O
methods : : O
: IN between O
between CD 1981 O
1981 CC and O
and CD 1998 O
1998 , , O
, CD 100 O
100 NNS patients O
patients NN ( O
( CD 90 O
90 JJ male O
male : ; O
; CD ten O
ten JJ female O
female NN ) O
) , , O
, IN with O
with DT a O
a JJ median O
median NN age O
age IN of O
of CD 60 O
60 NNS years O
years NN ( O
( CD 36-84 O
36-84 NN ) O
) , , O
, VBD underwent O
underwent JJ radical T
radical JJ en-bloc T
en-bloc NN resection T
resection IN of O
of JJ non-small D
non-small NN cell D
cell NN lung D
lung NN cancer D
cancer NN ( D
( NN nsclc D
nsclc NN ) D
) IN with O
with NN chest O
chest NN wall O
wall NN involvement O

over IN over O
over DT the O
the JJ past O
past CD 17 O
17 NNS years O
years NN ( O
( CD 1981 O
1981 TO to O
to CD 1997 O
1997 NN ) O
) , , O
, CD 29 O
29 NNS patients O
patients VBD underwent O
underwent JJ complete T
complete JJ pulmonary T
pulmonary NN resection T
resection IN for O
for JJ primary D
primary NN lung D
lung NN cancer D
cancer VBN accompanied O
accompanied IN by O
by NN satellite O
satellite NNS nodules O
nodules IN in O
in DT the O
the JJ same O
same NN lobe O
lobe IN as O
as DT the O
the JJ primary O

of IN of O
of CD 1 O
1 , , O
, CD 042 O
042 NNS patients O
patients IN with O
with JJ primary D
primary NN lung D
lung NN cancer D
cancer WP who O
who VBD underwent O
underwent NN resection T
resection IN from O
from CD 1982 O
1982 TO to O
to CD 1995 O
1995 , , O
, CD 549 O
549 NNS patients O
patients IN with O
with NN adenocarcinoma O
adenocarcinoma NN ( O
( NN ad O
ad NN ) O
) CC and O
and CD 363 O
363 IN with O
with JJ squamous O
squamous NN cell O
cell NN carcinoma O
carcinoma NN ( O
( NN sq O
sq NN ) O
) VBD were O
were VBN included O
included IN in O
in DT this O
this NN study O

for IN for O
for JJ small D
small NN cell D
cell NN lung D
lung NN cancer D
cancer NN ( D
( NN sclc D
sclc NN ) D
) , , O
, WDT which O
which NNS accounts O
accounts IN for O
for RB approximately O
approximately CD 20 O
20 NN % O
% IN of O
of NNS cases O
cases IN of O
of NN lung O
lung NN cancer O
cancer , , O
, DT the O
the JJ primary O
primary NN treatment O
treatment VBZ is O
is NN chemotherapy T
chemotherapy CC and O
and IN in O
in DT the O
the NN majority O
majority IN of O
of NNS cases O
cases DT the O
the JJ primary O
primary NN aim O
aim VBZ is O
is TO to O
to NN control O
control DT the O
the NN disease O
disease WDT which O
which RB generally O
generally MD would O
would VB have O
have NN spread O
spread IN beyond O
beyond DT the O
the NNS lungs O
lungs IN at O
at DT the O
the NN time O
time IN of O
of NN presentation O

a DT a O
a VBG growing O
growing NN body O
body IN of O
of NN evidence O
evidence VBZ suggests O
suggests IN that O
that JJ postoperative T
postoperative NN irradiation T
irradiation IN for O
for JJ non-small D
non-small NN cell D
cell NN lung D
lung NN cancer D
cancer MD may O
may NN cause O
cause JJ life-threatening O
life-threatening NN toxicity O
toxicity CC and O
and , , O
, WRB when O
when DT the O
the NN risk O
risk IN of O
of JJ local-regional O
local-regional NN recurrence O
recurrence VBZ is O
is JJ low O
low , , O
, DT the O
the NN toxicity O
toxicity IN of O
of NN irradiation O
irradiation MD may O
may VB outweight O
outweight DT the O
the NN benefit O

as IN as O
as DT a O
a JJ best-case O
best-case NN scenario O
scenario , , O
, JJ postoperative T
postoperative NN irradiation T
irradiation MD may O
may VB improve O
improve DT the O
the NN chance O
chance IN for O
for JJ long-term O
long-term NN survival O
survival IN in O
in NNS patients O
patients IN with O
with NN n2 D
n2 NNS tumors D

for IN for O
for NNS patients O
patients IN with O
with NN stage D
stage LS i D
i CC or D
or LS ii D
ii JJ non-small D
non-small NN cell D
cell NN lung D
lung NN cancer D
cancer NN ( D
( NN nsclc D
nsclc NN ) D
) , , O
, JJ surgical T
surgical NN resection T
resection VBZ is O
is VBN considered O
considered DT the O
the JJ standard O
standard IN of O
of NN care O

efforts NNS efforts O
efforts IN at O
at VBG improving O
improving NN survival O
survival IN for O
for JJ early-stage D
early-stage NN nsclc D
nsclc NNS patients O
patients VB have O
have VBN focused O
focused IN on O
on DT the O
the NN use O
use IN of O
of NN chemotherapy T
chemotherapy VBN administered O
administered RB postoperatively O
postoperatively NN ( O
( JJ adjuvant O
adjuvant NN ) O
) CC or O
or RB preoperatively O
preoperatively NN ( O
( JJ neoadjuvant O
neoadjuvant CC or O
or NN induction O
induction NN ) O
) TO to O
to VB eradicate O
eradicate JJ micrometastatic D
micrometastatic NN disease D

chemotherapy NN chemotherapy T
chemotherapy VBN administered O
administered IN before O
before NN surgery O
surgery CC or O
or JJ definitive O
definitive NN irradiation O
irradiation VBZ has O
has VBN improved O
improved NN survival O
survival NNS rates O
rates IN in O
in NNS patients O
patients IN with O
with NN stage D
stage LS iii D
iii NN nsclc D

patients NNS patients O
patients : : O
: NNS patients O
patients IN with O
with DT a O
a JJ single O
single NN ( O
( NN n O
n JJ = O
= CD 2 O
2 , , O
, CD 764 O
764 NN ) O
) CC and O
and JJ synchronous O
synchronous NN nsclc D
nsclc NN ( O
( NN n O
n JJ = O
= CD 85 O
85 NN ) O
) WP who O
who VBD underwent O
underwent JJ pulmonary T
pulmonary NN resection T

background NN background O
background : : O
: NN prophylactic T
prophylactic JJ cranial T
cranial NN irradiation T
irradiation NNS halves O
halves DT the O
the NN rate O
rate IN of O
of NN brain O
brain NNS metastases O
metastases IN in O
in NNS patients O
patients IN with O
with JJ small D
small NN cell D
cell NN lung D
lung NN cancer D

objectives NNS objectives O
objectives : : O
: DT this O
this NN study O
study NNS aims O
aims TO to O
to NN test O
test IN whether O
whether NN prophylactic T
prophylactic JJ cranial T
cranial NN irradiation T
irradiation VBZ prolongs O
prolongs NN survival O
survival IN of O
of NNS patients O
patients IN with O
with JJ small D
small NN cell D
cell NN lung D
lung NN cancer D
cancer IN in O
in JJ complete O
complete NN remission O

reviewer NN reviewer O
reviewer POS 's O
's NNS conclusions O
conclusions : : O
: NN prophylactic T
prophylactic JJ cranial T
cranial NN irradiation T
irradiation RB significantly O
significantly VBZ improves O
improves NN survival O
survival CC and O
and JJ disease-free O
disease-free NN survival O
survival IN for O
for NNS patients O
patients IN with O
with JJ small D
small NN cell D
cell NN lung D
lung NN cancer D
cancer IN in O
in JJ complete O
complete NN remission O

methods NNS methods O
methods : : O
: JJ non-small D
non-small NN cell D
cell NN lung D
lung NN cancer D
cancer NNS cells O
cells VBD were O
were VBN treated O
treated IN with O
with NN gemcitabine T
gemcitabine , , O
, VBN harvested O
harvested , , O
, CC and O
and JJ nuclear O
nuclear NNS extracts O
extracts VBN analyzed O
analyzed IN for O
for JJ nf-kappab O
nf-kappab NN dna O
dna VBG binding O
binding IN by O
by JJ electrophoretic O
electrophoretic NN mobility O
mobility NN shift O
shift NNS assays O

novel JJ novel O
novel NN treatment O
treatment NNS strategies O
strategies IN for O
for NNS patients O
patients IN with O
with JJ advanced D
advanced NN nsclc D
nsclc MD may O
may VB involve O
involve NN chemotherapy T
chemotherapy JJ combined O
combined IN with O
with NN inhibition O
inhibition IN of O
of JJ nf-kappab-dependent O
nf-kappab-dependent JJ cell-survival O
cell-survival NNS pathways O

combination NN combination T
combination NN chemotherapy T
chemotherapy VBZ is O
is DT the O
the NN cornerstone O
cornerstone IN of O
of NN treatment O
treatment IN that O
that VBZ confers O
confers DT a O
a JJ meaningful O
meaningful NN survival O
survival NN benefit O
benefit IN for O
for NNS patients O
patients IN with O
with NN small-cell D
small-cell NN lung D
lung NN cancer D

in IN in O
in JJ single-agent O
single-agent NN phase O
phase LS ii O
ii NNS studies O
studies , , O
, JJ irinotecan T
irinotecan VBD yielded O
yielded NN response O
response NNS rates O
rates IN between O
between CD 16 O
16 NN % O
% CC and O
and CD 47 O
47 NN % O
% IN in O
in NNS patients O
patients IN with O
with RB previously O
previously VBN treated O
treated NN small-cell D
small-cell NN lung D
lung NN cancer D

a DT a O
a NN phase O
phase LS ii O
ii NN study O
study IN of O
of JJ irinotecan T
irinotecan IN in T
in NN combination T
combination IN with T
with NN cisplatin T
cisplatin NN ( T
( NN platinol T
platinol NN ) T
) VBD resulted O
resulted IN in O
in DT a O
a NN response O
response NN rate O
rate IN of O
of CD 86 O
86 NN % O
% CC and O
and DT a O
a JJ median O
median NN survival O
survival IN of O
of CD 13.0 O
13.0 NNS months O
months IN in O
in NNS patients O
patients IN with O
with NN extensive-disease D
extensive-disease NN small-cell D
small-cell NN lung D
lung NN cancer D

based VBN based O
based IN on O
on DT these O
these NNS results O
results , , O
, DT the O
the JJ irinotecan T
irinotecan CC and T
and NN cisplatin T
cisplatin NN combination T
combination VBZ is O
is DT a O
a JJ new O
new JJ standard O
standard NN regimen O
regimen IN in O
in DT the O
the NN treatment O
treatment IN of O
of NN extensive-disease D
extensive-disease NN small-cell D
small-cell NN lung D
lung NN cancer D

background NN background O
background : : O
: DT both O
both NN gemcitabine T
gemcitabine CC and T
and NN etoposide T
etoposide VBP are O
are JJ active O
active IN in O
in DT the O
the NN treatment O
treatment IN of O
of NN small-cell D
small-cell NN lung D
lung NN cancer D
cancer NN ( D
( NN sclc D
sclc NN ) D
) , , O
, CC and O
and VBP are O
are VBN characterised O
characterised IN by O
by JJ mild O
mild NN toxicity O
toxicity NNS profiles O

patients NNS patients O
patients CC and O
and NNS methods O
methods : : O
: CD forty-two O
forty-two JJ chemo-naive O
chemo-naive JJ extensive O
extensive NN disease O
disease NN sclc D
sclc NNS patients O
patients VBD were O
were VBN enrolled O
enrolled TO to O
to VB receive O
receive NN gemcitabine T
gemcitabine CD 1000 O
1000 NN mg/m2 O
mg/m2 , , O
, NNS days O
days CD 1 O
1 , , O
, CD 8 O
8 CC and O
and CD 15 O
15 , , O
, CC and O
and NN etoposide T
etoposide CD 80 O
80 NN mg/m2 O
mg/m2 , , O
, NNS days O
days CD 8 O
8 , , O
, CD 9 O
9 CC and O
and CD 10 O
10 IN of O
of DT a O
a JJ 28-day O
28-day NN cycle O

background NN background O
background : : O
: TO to O
to VB find O
find DT the O
the NN maximum O
maximum VBN tolerated O
tolerated NN dose O
dose IN for O
for NN ifosfamide T
ifosfamide IN in T
in NN combination T
combination IN with T
with NN paclitaxel T
paclitaxel CC and T
and NN carboplatin T
carboplatin IN in O
in NN small-cell D
small-cell NN lung D
lung NN cancer D
cancer NNS patients O
patients NN ( O
( NN sclc O
sclc NN ) O
) , , O
, WP who O
who VBP are O
are JJ resistant O
resistant TO to O
to NN cyclophosphamide O
cyclophosphamide , , O
, NN doxorubicin O
doxorubicin CC and O
and NN etoposide O
etoposide NN ( O
( NN cde O
cde NN ) O

conclusions NNS conclusions O
conclusions : : O
: DT the O
the NN maximum O
maximum VBN tolerated O
tolerated NN dose O
dose IN of O
of DT this O
this NN combination O
combination IN for O
for NNS patients O
patients IN with O
with JJ resistant D
resistant NN sclc D
sclc VBZ is O
is NN ifosfamide T
ifosfamide CD 2000 O
2000 NN mg/m2 O
mg/m2 IN in O
in NN combination O
combination IN with O
with NN paclitaxel T
paclitaxel CD 175 O
175 NN mg/m2 O
mg/m2 CC and O
and NN carboplatin T
carboplatin NN auc O
auc CD 6 O
6 NN mg/ml O
mg/ml NN min O
min VBN administered O
administered IN on O
on DT the O
the RB first O
first NN day O
day IN of O
of DT a O
a JJ 21-day O
21-day NN cycle O

many JJ many O
many JJ endobronchial T
endobronchial NN treatment T
treatment NNS modalities T
modalities VBP are O
are JJ available O
available TO to O
to NN supplement O
supplement JJ traditional O
traditional NNS therapies O
therapies IN for O
for JJ advanced D
advanced NN lung D
lung NN cancer D

methods NNS methods O
methods : : O
: DT the O
the NN author O
author NNS reviews O
reviews DT the O
the NN use O
use IN of O
of JJ several O
several JJ endobronchial T
endobronchial NN treatment T
treatment NNS modalities T
modalities IN that T
that MD can T
can VBP augment T
augment JJ standard T
standard JJ antitumor T
antitumor NNS therapies T
therapies IN for O
for JJ advanced O
advanced NN lung D
lung NN cancer D
cancer , , O
, VBG including O
including JJ rigid O
rigid CC and O
and JJ flexible O
flexible NN bronchoscopy O
bronchoscopy , , O
, NN laser O
laser NN therapy O
therapy , , O
, JJ endobronchial O
endobronchial NN prosthesis O
prosthesis , , O
, CC and O
and JJ photodynamic O
photodynamic NN therapy O

conclusions NNS conclusions O
conclusions : : O
: JJ endobronchial T
endobronchial NNS interventions T
interventions VBP are O
are JJ important O
important NNS adjuncts O
adjuncts IN in O
in DT the O
the NN multimodality O
multimodality NN management O
management IN of O
of NN lung D
lung NN cancer D
cancer CC and O
and MD should O
should VBN become O
become JJ standard O
standard NNS considerations O
considerations IN in O
in DT the O
the NN management O
management IN of O
of NNS patients O
patients IN with O
with JJ advanced O
advanced NN lung O
lung NN cancer O

standard JJ standard O
standard NNS operations O
operations IN for O
for NN lung D
lung NN cancer D
cancer NNS patients O
patients VBP are O
are RB generally O
generally VBN accepted O
accepted IN as O
as VBG performing O
performing JJ lobectomy T
lobectomy CC or T
or NN pneumonectomy T
pneumonectomy IN on O
on DT the O
the NN tumor O
tumor VBG baring O
baring NN lung O
lung CC and O
and JJ ipsilateral O
ipsilateral JJ hilar O
hilar CC and O
and JJ mediastinal O
mediastinal NN lymphadenectomy O
lymphadenectomy VBG including O
including JJ subcarinal O
subcarinal NN lymph O
lymph NNS nodes O

small JJ small D
small NN cell D
cell NN lung D
lung NN cancer D
cancer VBZ is O
is DT a O
a RB frequently O
frequently VBG relapsing O
relapsing NN tumor O
tumor IN despite O
despite DT a O
a JJ high O
high NN rate O
rate IN of O
of NN response O
response IN after O
after JJ first-line O
first-line NN chemotherapy T

for IN for O
for JJ symptomatic D
symptomatic NNS metastases D
metastases IN in D
in NN bone D
bone CC or D
or NN brain D
brain , , O
, NN radiotherapy T
radiotherapy RB usually O
usually VBZ gives O
gives JJ temporary O
temporary NN palliation O

for IN for O
for JJ intrathoracic D
intrathoracic NN relapse D
relapse CC and D
and JJ severe D
severe NN obstruction D
obstruction IN of D
of JJ main D
main NN bronchus D
bronchus CC and/or D
and/or JJ superior D
superior NN caval D
caval NN vein D
vein , , O
, NN radiotherapy T
radiotherapy VBZ is O
is DT a O
a NN possibility O
possibility IN if O
if RB not O
not VBN given O
given IN as O
as NN part O
part IN of O
of JJ first-line O
first-line NN treatment O

tumor NN tumor T
tumor NNS vaccines T
vaccines IN against O
against NNS gangliosides O
gangliosides IN that O
that VBP are O
are VBN expressed O
expressed IN on O
on RB almost O
almost DT all O
all JJ human O
human NN sclc D
sclc NNS cells O
cells VB have O
have VBN been O
been RB recently O
recently VBN developed O

an DT an O
an JJ anti-idiotypic T
anti-idiotypic JJ monoclonal T
monoclonal NN antibody T
antibody IN against O
against DT the O
the NN gd3 O
gd3 NN ganglioside O
ganglioside , , O
, NN bec-2 O
bec-2 , , O
, VBZ is O
is VBG being O
being VBN evaluated O
evaluated IN after O
after NN chemotherapy O
chemotherapy IN in O
in NN sclc D
sclc NNS patients O
patients IN in O
in DT a O
a JJ european O
european NN study O

the DT the O
the NN matrix T
matrix NN metalloproteinase T
metalloproteinase NNS inhibitors T
inhibitors NN marimastat T
marimastat CC and T
and NN bms-275291 T
bms-275291 VBP are O
are IN under O
under NN evaluation O
evaluation IN in O
in NN sclc D

we PRP we O
we VBN attempted O
attempted DT a O
a JJ new O
new NN regimen O
regimen IN of O
of JJ intermittent O
intermittent NN administration O
administration IN of O
of JJ 5-fu T
5-fu CC and T
and JJ low-dose T
low-dose NN isovorin T
isovorin NN ( T
( JJ f.i T
f.i NN ) T
) TO to O
to CD four O
four NNS patients O
patients IN with O
with JJ advanced O
advanced CC and O
and JJ recurrent O
recurrent NN colon D
colon NN cancer D

purpose/objectives NNS purpose/objectives O
purpose/objectives : : O
: TO to O
to VBP describe O
describe DT the O
the NN relationship O
relationship IN between O
between NN fatigue O
fatigue CC and O
and JJ nutritional O
nutritional NN status O
status IN in O
in NNS patients O
patients VBG receiving O
receiving NN radiation T
radiation NN therapy T
therapy IN for O
for NN lung D
lung NN cancer D

sample NN sample O
sample : : O
: CD 45 O
45 NNS adults O
adults IN with O
with JJ primary O
primary NN cancer D
cancer IN of D
of DT the D
the NN lung D
lung VBG receiving O
receiving JJR < O
< NN outpatient O
outpatient JJ primary O
primary CC or O
or JJ adjuvant O
adjuvant NN radiation T
radiation NN therapy T

we PRP we O
we JJ present O
present DT the O
the NN case O
case IN of O
of DT a O
a NN patient O
patient IN with O
with JJ metastatic D
metastatic JJ transitional D
transitional NN cell D
cell NN carcinoma D
carcinoma IN of D
of DT the D
the NN bladder D
bladder CC and D
and JJ renal D
renal NN failure D
failure WP who O
who VBD underwent O
underwent JJ successful O
successful JJ systemic T
systemic NN chemotherapy T
chemotherapy IN with T
with NN paclitaxel T
paclitaxel CC and T
and NN carboplatin T

background NN background O
background : : O
: DT the O
the JJ objective O
objective IN of O
of DT this O
this NN phase O
phase LS ii O
ii NN study O
study VBD was O
was TO to O
to VB evaluate O
evaluate DT the O
the NN concept O
concept IN of O
of JJ sequential T
sequential NN chemotherapy T
chemotherapy IN in O
in DT the O
the NN treatment O
treatment IN of O
of NNS patients O
patients IN with O
with JJ advanced D
advanced NN nonsmall D
nonsmall NN cell D
cell NN lung D
lung NN carcinoma D
carcinoma NN ( D
( NN nsclc D
nsclc NN ) D
) IN by O
by DT the O
the NN administration O
administration IN of O
of NN carboplatin T
carboplatin CC plus T
plus NN gemcitabine T
gemcitabine VBN followed T
followed IN by T
by IN of T
of NN paclitaxel T

conclusions NNS conclusions O
conclusions : : O
: DT this O
this NN study O
study VBZ is O
is DT the O
the RB first O
first TO to O
to VB evaluate O
evaluate VBN planned T
planned JJ sequential T
sequential NN chemotherapy T
chemotherapy IN in O
in NNS patients O
patients IN with O
with NN nsclc D

patients NNS patients O
patients WP who O
who NN benefit O
benefit IN from O
from DT a O
a JJ surgical T
surgical NN resection T
resection IN for O
for JJ non-small-cell D
non-small-cell NN lung D
lung NN cancer D
cancer IN with O
with NN aneuploid O
aneuploid NN dna O
dna JJ content O
content VB prove O
prove TO to O
to VB have O
have DT a O
a JJR higher O
higher NN risk O
risk IN of O
of NN death O

purpose NN purpose O
purpose : : O
: DT this O
this VBN randomized O
randomized NN trial O
trial VBD was O
was VBN designed O
designed TO to O
to VB determine O
determine IN whether O
whether NN paclitaxel T
paclitaxel CC plus T
plus NN carboplatin T
carboplatin NN ( T
( NN pc T
pc NN ) T
) VBN offered O
offered DT a O
a NN survival O
survival NN advantage O
advantage IN over O
over NN vinorelbine T
vinorelbine CC plus T
plus NN cisplatin T
cisplatin NN ( T
( NN vc T
vc NN ) T
) IN for O
for NNS patients O
patients IN with O
with JJ advanced D
advanced JJ non D
non : -- D
-- NN small-cell D
small-cell NN lung D
lung NN cancer D

conclusion NN conclusion O
conclusion : : O
: NN pc T
pc VBZ is O
is RB equally O
equally JJ efficacious O
efficacious IN as O
as NN vc T
vc IN for O
for DT the O
the NN treatment O
treatment IN of O
of JJ advanced D
advanced JJ non D
non : -- D
-- NN small-cell D
small-cell NN lung D
lung NN cancer D

purpose NN purpose O
purpose : : O
: DT a O
a JJ prospective O
prospective VBN randomized O
randomized NN trial O
trial IN in O
in NN small-cell O
small-cell NN lung O
lung NN cancer O
cancer NN ( O
( NN sclc O
sclc NN ) O
) VBD was O
was VBN performed O
performed TO to O
to VB determine O
determine IN if O
if NN intensification O
intensification IN of O
of DT the O
the NN platinum O
platinum NN dose O
dose IN by O
by VBG giving O
giving NN cisplatin T
cisplatin CC and T
and NN carboplatin T
carboplatin IN in O
in NN combination O
combination TO to O
to NNS patients O
patients IN with O
with NN sclc D
sclc NNS yields O
yields JJR higher O
higher NN response O
response NNS rates O
rates CC and O
and NN survival O
survival , , O
, IN than O
than NN carboplatin T
carboplatin RB alone T
alone IN in T
in DT a T
a NN combination T
combination NN chemotherapy T
chemotherapy NN regimen T

conclusions NNS conclusions O
conclusions : : O
: DT the O
the NN intensification T
intensification IN of T
of NN platinum T
platinum NN dose T
dose NN ( T
( NN cisplatin T
cisplatin CC plus T
plus NN carboplatin T
carboplatin NN ) T
) IN in T
in NN combination T
combination NN chemotherapy T
chemotherapy RB significantly O
significantly VBN increased O
increased DT the O
the JJ complete O
complete NN response O
response NN rate O
rate , , O
, JJ overall O
overall NN survival O
survival CC and O
and NN number O
number IN of O
of JJ two-year O
two-year NNS survivors O
survivors IN among O
among NN sclc D
sclc NNS patients O
patients IN with O
with JJ limited O
limited NN disease O
disease VBN compared O
compared TO to O
to NN combination T
combination NN therapy T
therapy IN with T
with NN carboplatin T
carboplatin RB alone T
alone , , O
, VBG suggesting O
suggesting IN that O
that DT a O
a RBR more O
more JJ aggressive O
aggressive NN treatment O
treatment TO to O
to DT this O
this NN category O
category IN of O
of NNS patients O
patients VBZ is O
is JJ worthwhile O
worthwhile , , O
, IN while O
while DT no O
no NN difference O
difference IN in O
in NN treatment O
treatment NN outcome O
outcome VBD was O
was VBN observed O
observed IN for O
for NNS patients O
patients IN with O
with JJ extensive O
extensive NN disease O

the DT the O
the NN aim O
aim IN of O
of DT this O
this NN study O
study VBD was O
was TO to O
to VB investigate O
investigate DT the O
the NNS relationships O
relationships IN among O
among NN technetium-99m O
technetium-99m JJ tetrofosmin O
tetrofosmin NN ( O
( JJ tc-tf O
tc-tf NN ) O
) NN accumulation O
accumulation IN in O
in JJ untreated O
untreated JJ small O
small NN cell O
cell NN lung O
lung NN cancer O
cancer NN ( O
( NN sclc O
sclc NN ) O
) , , O
, DT the O
the NN expression O
expression IN of O
of NN p-glycoprotein O
p-glycoprotein NN ( O
( NN pgp O
pgp NN ) O
) CC and O
and JJ multidrug O
multidrug NN resistance O
resistance JJ related O
related NN protein-1 O
protein-1 NN ( O
( NN mrp1 O
mrp1 NN ) O
) , , O
, CC and O
and DT the O
the NN response O
response TO to O
to NN chemotherapy T
chemotherapy IN in O
in NNS patients O
patients IN with O
with JJ untreated D
untreated NN sclc D

tc-tf JJ tc-tf O
tc-tf NN chest O
chest NN scintigraphy O
scintigraphy VBD correlated O
correlated RB well O
well IN with O
with NN pgp O
pgp CC or O
or NN mrp1 O
mrp1 NN expression O
expression CC and O
and RB accurately O
accurately VBN predicted O
predicted DT the O
the NN response O
response TO to O
to NN chemotherapy T
chemotherapy IN in O
in NNS patients O
patients IN with O
with NN sclc D

exploratory JJ exploratory T
exploratory NNS interventions T
interventions , , T
, JJ partial T
partial NN tumor T
tumor NNS resections T
resections CC and T
and NN lung T
lung NNS resections T
resections IN for O
for NN metastasis D
metastasis VBD were O
were RBR more O
more RB frequently O
frequently VBN performed O
performed IN in O
in JJ young O
young NNS patients O
patients IN than O
than IN in O
in JJR older O
older NNS patients O

in IN in O
in DT the O
the JJ present O
present NN report O
report , , O
, PRP we O
we VBN reviewed O
reviewed NNS articles O
articles IN on O
on JJ pulmonary T
pulmonary NN angiography T
angiography IN for O
for NNS patients O
patients IN with O
with JJ pulmonary D
pulmonary NN hypertension D

prophylactic NN prophylactic T
prophylactic JJ cranial T
cranial NN irradiation T
irradiation NN ( T
( NN pci T
pci NN ) T
) VBZ has O
has VBN been O
been VBD demonstrated O
demonstrated TO to O
to RB significantly O
significantly VB reduce O
reduce DT the O
the NN incidence O
incidence IN of O
of NN brain O
brain NN relapse O
relapse IN from O
from JJ limited D
limited NN disease D
disease NN small-cell D
small-cell NN lung D
lung NN cancer D
cancer NN ( D
( NN ld D
ld NN sclc D
sclc NN ) D
) , , O
, CC but O
but NNS concerns O
concerns IN about O
about JJ neurologic O
neurologic NN toxicity O
toxicity VBP remain O

thus RB thus O
thus , , O
, JJ twice-daily O
twice-daily NN pci T
pci MD should O
should VB be O
be VBN considered O
considered IN for O
for NNS patients O
patients IN with O
with NN ld D
ld NN sclc D
sclc WP who O
who VB achieve O
achieve DT a O
a JJ complete O
complete NN response O
response TO to O
to NN chemoirradiation O

animal NN animal O
animal NNS studies O
studies VBP suggest O
suggest IN that O
that DT the O
the NN kidney O
kidney VBZ is O
is VBN involved O
involved IN in O
in DT the O
the NN elimination O
elimination IN of O
of JJ recombinant T
recombinant JJ human T
human NN granulocyte T
granulocyte JJ colony-stimulating T
colony-stimulating NN factor T
factor NN ( T
( JJ rhg-csf T
rhg-csf NN ) T
) , , O
, WDT which O
which VBZ is O
is VBN used O
used IN for O
for NNS patients O
patients IN with O
with NN neutropenia D
neutropenia IN during O
during NN cancer D
cancer NN chemotherapy T

amifostine NN amifostine T
amifostine NN ( T
( NN wr-2721 T
wr-2721 NN ) T
) VBZ is O
is DT a O
a JJ cytoprotective O
cytoprotective NN agent O
agent IN that O
that VBZ protects O
protects DT a O
a JJ broad O
broad NN range O
range IN of O
of JJ normal O
normal NNS tissues O
tissues IN from O
from DT the O
the JJ toxic D
toxic NNS effects D
effects IN of D
of NN chemotherapy D
chemotherapy CC and D
and NN radiotherapy D
radiotherapy IN without O
without VBG attenuating O
attenuating NN tumour O
tumour NN response O

in IN in O
in DT a O
a JJ pivotal O
pivotal NN phase O
phase LS iii O
iii NN trial O
trial , , O
, CD 242 O
242 NNS patients O
patients IN with O
with JJ advanced D
advanced JJ ovarian D
ovarian NN cancer D
cancer VBD were O
were VBN randomised O
randomised TO to O
to VB receive O
receive NN treatment O
treatment IN with O
with NN cisplatin T
cisplatin CD 100 O
100 NN mg/m2 O
mg/m2 CC and O
and NN cyclophosphamide T
cyclophosphamide CD 1000 O
1000 NN mg/m2 O
mg/m2 DT every O
every CD 3 O
3 NNS weeks O
weeks IN with O
with CC or O
or IN without O
without NN pretreatment O
pretreatment IN with O
with JJ intravenous O
intravenous NN amifostine O
amifostine CD 910 O
910 NN mg/m2 O

over IN over O
over CD 6 O
6 NNS cycles O
cycles IN of O
of NN therapy O
therapy , , O
, NN amifostine T
amifostine RB significantly O
significantly VBN reduced O
reduced JJ haematological D
haematological , , D
, JJ renal D
renal CC and D
and JJ neurological D
neurological NNS toxicities D
toxicities : : O
: NN treatment O
treatment NNS delays O
delays , , O
, NN treatment O
treatment NN discontinuation O
discontinuation CC and O
and NNS days O
days IN in O
in NN hospital O
hospital JJ related O
related TO to O
to DT these O
these JJ adverse O
adverse NNS events O
events VBD were O
were RB also O
also RB significantly O
significantly VBN reduced O
reduced IN in O
in NNS patients O
patients VBG receiving O
receiving NN amifostine O
amifostine CC versus O
versus NNS patients O
patients VBG receiving O
receiving NN chemotherapy O
chemotherapy RB alone O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> IN in O
in DT another O
another VBN randomised O
randomised NN phase O
phase LS iii O
iii NN trial O
trial IN in O
in CD 303 O
303 NNS patients O
patients IN with O
with NN head D
head CC and D
and NN neck D
neck NN cancer D
cancer VBG undergoing O
undergoing NN irradiation T
irradiation NN therapy T
therapy NN ( O
( JJ total O
total NN dose O
dose CD 50 O
50 TO to O
to JJ 70gy O
70gy NN ) O
) , , O
, NN pretreatment O
pretreatment IN with O
with JJ intravenous O
intravenous NN amifostine T
amifostine CD 200 O
200 NN mg/m2 O
mg/m2 RB significantly O
significantly VBN reduced O
reduced DT the O
the NN incidence O
incidence IN of O
of JJ acute O
acute CC and O
and RB late O
late NN grade O
grade JJR > O
> CC or O
or NN =2 O
=2 NN xerostomia D

amifostine NN amifostine T
amifostine NN ( O
( CD 340 O
340 NN mg/m2 O
mg/m2 NN ) O
) RB also O
also VBN provided O
provided JJ significant O
significant NN protection O
protection IN against O
against NN pneumonitis D
pneumonitis CC and D
and NN oesophagitis D
oesophagitis IN in O
in NNS patients O
patients IN with O
with NN lung D
lung NN cancer D
cancer VBG receiving O
receiving JJ thoracic T
thoracic NN irradiation T
irradiation IN in O
in DT a O
a JJ preliminary O
preliminary NN report O
report IN from O
from DT a O
a NN phase O
phase LS iii O
iii NN trial O
trial NN ( O
( NN n O
n JJ = O
= CD 144 O
144 NN ) O

amifostine NN amifostine T
amifostine VBZ has O
has RB also O
also VBN been O
been VBN shown O
shown TO to O
to VB stimulate O
stimulate JJ haematopoietic O
haematopoietic NN stem O
stem NNS cells O
cells CC and O
and VBZ has O
has VBN been O
been VBN investigated O
investigated IN as O
as DT a O
a NN therapy O
therapy IN for O
for NNS patients O
patients IN with O
with JJ myelodysplastic D
myelodysplastic NN syndrome D
syndrome IN in O
in NN number O
number IN of O
of JJ small O
small JJ preliminary O
preliminary NNS studies O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NN conclusion O
conclusion : : O
: DT the O
the NNS results O
results IN of O
of NN phase O
phase LS iii O
iii NNS trials O
trials VB have O
have VBN confirmed O
confirmed DT the O
the NN safety O
safety CC and O
and NN efficacy O
efficacy IN of O
of NN amifostine T
amifostine IN as O
as DT a O
a JJ cytoprotectant O
cytoprotectant TO to O
to VB ameliorate O
ameliorate JJ cisplatin-induced D
cisplatin-induced JJ cumulative D
cumulative JJ renal D
renal NN toxicity D
toxicity , , O
, IN for O
for WDT which O
which PRP it O
it VBZ is O
is DT the O
the RB only O
only NN agent O
agent JJ proven O
proven TO to O
to VB be O
be JJ effective O
effective , , O
, CC and O
and NN neutropenia D
neutropenia IN in O
in NNS patients O
patients IN with O
with JJ advanced O
advanced JJ ovarian O
ovarian NN cancer O
cancer , , O
, CC and O
and TO to O
to VB reduce O
reduce NN xerostomia D
xerostomia IN in O
in NNS patients O
patients IN with O
with NN head D
head CC and D
and NN neck D
neck NN cancer D
cancer VBG receiving O
receiving NN irradiation T
irradiation NN therapy T

depending VBG depending O
depending IN on O
on DT the O
the NN outcome O
outcome IN of O
of JJ numerous O
numerous JJ ongoing O
ongoing JJ clinical O
clinical NNS trials O
trials , , O
, NN amifostine T
amifostine MD may O
may RB eventually O
eventually VB find O
find JJR broader O
broader JJ clinical O
clinical NNS applications O
applications , , O
, DT both O
both IN as O
as DT a O
a JJ cytoprotectant O
cytoprotectant CC and O
and IN as O
as DT a O
a JJ potential O
potential NN therapy O
therapy IN in O
in JJ myelodysplastic D
myelodysplastic NN syndrome D

to TO to O
to VB perform O
perform DT a O
a JJ curative O
curative NN operation O
operation IN for O
for DT the O
the NN lung D
lung NN cancer D
cancer IN without O
without JJ myocardial O
myocardial NN infarction O
infarction , , O
, RB minimally T
minimally JJ invasive T
invasive JJ direct T
direct JJ coronary T
coronary NN artery T
artery NN bypass T
bypass CC and T
and VBN left T
left JJR lower T
lower JJ lobectomy T
lobectomy IN with T
with JJ video-endoscopic T
video-endoscopic NN assistance T
assistance VBD were O
were VBN performed O
performed RB simultaneously O

A DT CAPITAL A O
A NN review O
review IN of O
of DT the O
the JJ fetal-maternal O
fetal-maternal NN carboxyhemoglobin O
carboxyhemoglobin NNS relationships O
relationships CC and O
and DT the O
the NNS differences O
differences IN in O
in JJ fetal O
fetal NN oxyhemoglobin O
oxyhemoglobin NN physiology O
physiology VBP are O
are VBN used O
used TO to O
to VB explain O
explain DT the O
the NN recommendation O
recommendation IN that O
that JJ pregnant O
pregnant NNS women O
women IN with O
with NN carbon D
carbon NN monoxide D
monoxide NN poisoning D
poisoning MD should O
should VB receive O
receive CD 100 O
100 NN % O
% NN oxygen T
oxygen NN therapy T
therapy IN for O
for RB up O
up TO to O
to CD five O
five NNS times O
times RB longer O
longer IN than O
than VBZ is O
is RB otherwise O
otherwise JJ necessary O

The DT CAPITAL The O
The NNS authors O
authors VBP describe O
describe DT the O
the NN case O
case IN of O
of DT a O
a NN child O
child IN with O
with NN status D
status NN epilepticus D
epilepticus IN in O
in WP whom O
whom NN phenytoin T
phenytoin VBD was O
was VBN administered O
administered IN via O
via DT the O
the JJ intraosseous O
intraosseous NN route O
route , , O
, CC and O
and NN seizure O
seizure NN resolution O
resolution CC and O
and JJ therapeutic O
therapeutic NN serum O
serum NNS levels O
levels VBD were O
were VBN achieved O

A DT CAPITAL A O
A NN patient O
patient VBG suffering O
suffering NN baclofen D
baclofen NN overdose D
overdose RB successfully O
successfully VBN treated O
treated IN with O
with NN atropine T
atropine VBZ is O
is VBN reported O

Atropine NNP CAPITAL Atropine T
Atropine VBZ appears O
appears TO to O
to VB be O
be JJ useful O
useful IN in O
in VBG treating O
treating NNS cases O
cases IN of O
of NN baclofen D
baclofen NN overdose D
overdose JJ complicated O
complicated IN by O
by NN bradycardia O
bradycardia CC and O
and NN hypotension O

Therapeutic JJ CAPITAL Therapeutic O
Therapeutic NN effect O
effect IN of O
of DT a O
a VBN left T
left JJ ventricular T
ventricular VB assist T
assist NN device T
device IN on O
on JJ acute D
acute JJ myocardial D
myocardial NN infarction D
infarction VBN evaluated O
evaluated IN by O
by JJ magnetic O
magnetic NN resonance O
resonance NN imaging O

Continuous JJ CAPITAL Continuous T
Continuous JJ arteriovenous T
arteriovenous NN hemofiltration T
hemofiltration IN for O
for DT the O
the NN treatment O
treatment IN of O
of NN anasarca D
anasarca CC and D
and JJ acute D
acute JJ renal D
renal NN failure D
failure IN in O
in RB severely O
severely VBN burned O
burned NNS patients O

Continuous JJ CAPITAL Continuous T
Continuous JJ renal T
renal NN replacement T
replacement NN therapy T
therapy IN in O
in NNS patients O
patients IN with O
with JJ acute D
acute JJ renal D
renal NN dysfunction D
dysfunction VBG undergoing O
undergoing JJ intraaortic O
intraaortic NN balloon O
balloon NN pump O
pump CC and/or O
and/or RB left O
left JJ ventricular O
ventricular NN device O
device NN support O

Continuous JJ CAPITAL Continuous T
Continuous JJ arterio-venous T
arterio-venous NN hemofiltration T
hemofiltration IN in O
in DT a O
a JJ wearable O
wearable NN device O
device TO to O
to VB treat O
treat NN end-stage D
end-stage JJ renal D
renal NN disease D

The DT CAPITAL The O
The NN effectiveness O
effectiveness IN of O
of NN neostigmine T
neostigmine CD 0.07 T
0.07 NN mg T
mg NN kg-1 T
kg-1 CC and T
and NN edrophonium T
edrophonium CD 0.8 O
0.8 NN mg O
mg NN kg-1 O
kg-1 IN as O
as NNS antagonists O
antagonists IN of O
of JJ profound D
profound JJ neuromuscular D
neuromuscular NN blockade D
blockade VBN induced O
induced IN by O
by NN vecuronium O
vecuronium CD 0.1 O
0.1 NN mg O
mg NN kg-1 O
kg-1 CC or O
or NN atracurium O
atracurium CD 0.5 O
0.5 NN mg O
mg NN kg-1 O
kg-1 VBD was O
was VBN studied O
studied IN in O
in CD 59 O
59 JJ healthy O
healthy NNS patients O

Antagonism NN CAPITAL Antagonism O
Antagonism IN of O
of JJ atracurium-induced O
atracurium-induced JJ neuromuscular D
neuromuscular NN blockade D
blockade IN by O
by NN neostigmine T
neostigmine CC or T
or NN edrophonium T
edrophonium VBZ has O
has VBN been O
been VBN studied O
studied VBG using O
using DT the O
the JJ tetanic O
tetanic NN ( O
( CD 50 O
50 NN CAPITAL Hz O
Hz NN ) O
) CC and O
and JJ train-of-four O
train-of-four NN ( O
( CD 2 O
2 NN CAPITAL Hz O
Hz NN ) O
) CC or O
or JJ single O
single VB twitch O
twitch NNS responses O
responses IN of O
of DT the O
the NN adductor O
adductor NN pollicis O
pollicis NN muscle O
muscle IN in O
in CD 22 O
22 VBN anaesthetized O
anaesthetized NNS patients O

Active JJ CAPITAL Active T
Active NNS forms T
forms IN of T
of NN vitamin T
vitamin NN CAPITAL D3 T
D3 , , T
, CD 1 T
1 JJ alpha-hydroxyvitamin T
alpha-hydroxyvitamin NN CAPITAL D3 T
D3 CC and T
and CD 1 T
1 NN alpha T
alpha , , T
, NN 25-dihydroxyvitamin T
25-dihydroxyvitamin NN CAPITAL D3 T
D3 , , O
, VBD were O
were VBN administered O
administered IN in O
in DT an O
an JJ open-design O
open-design NN study O
study TO to O
to CD 40 O
40 NNS patients O
patients IN with O
with NN psoriasis D
psoriasis NN vulgaris D
vulgaris IN in O
in CD three O
three NNS ways O
ways : : O
: TO to O
to CD 17 O
17 NNS patients O
patients CD 1 O
1 JJ alpha-hydroxyvitamin O
alpha-hydroxyvitamin NN CAPITAL D3 O
D3 VBD was O
was VBN given O
given RB orally O
orally IN at O
at DT a O
a NN dose O
dose IN of O
of CD 1.0 O
1.0 NN micrograms/day O
micrograms/day IN for O
for CD 6 O
6 NNS months O
months , , O
, TO to O
to CD four O
four NNS patients O
patients CD 1 O
1 NN alpha O
alpha , , O
, NN 25-dihydroxyvitamin O
25-dihydroxyvitamin NN CAPITAL D3 O
D3 VBD was O
was VBN given O
given RB orally O
orally IN at O
at DT a O
a NN dose O
dose IN of O
of CD 0.5 O
0.5 NNS microgram/day O
microgram/day IN for O
for CD 6 O
6 NNS months O
months , , O
, CC and O
and CD 19 O
19 NNS patients O
patients VBD were O
were VBN given O
given CD 1 O
1 NN alpha O
alpha , , O
, NN 25-dihydroxyvitamin O
25-dihydroxyvitamin NN CAPITAL D3 O
D3 VBN applied O
applied RB topically O
topically IN at O
at NN concentration O
concentration IN of O
of CD 0.5 O
0.5 NN microgram/g O
microgram/g IN of O
of NN base O
base IN for O
for CD 8 O
8 NNS weeks O

These DT CAPITAL These O
These NNS data O
data VBP suggest O
suggest IN that O
that NN psoriasis D
psoriasis MD may O
may NN respond O
respond TO to O
to JJ active T
active NNS metabolites T
metabolites IN of T
of NN vitamin T
vitamin NN CAPITAL D3 T
D3 CC and O
and IN that O
that NNS abnormalities O
abnormalities IN in O
in NN vitamin O
vitamin NN CAPITAL D O
D NN metabolism O
metabolism CC or O
or IN in O
in NN responsiveness O
responsiveness IN of O
of DT the O
the NN skin O
skin NNS cells O
cells TO to O
to JJ active O
active NNS metabolites O
metabolites IN of O
of NN vitamin O
vitamin NN CAPITAL D O
D MD may O
may VB be O
be VBN involved O
involved IN in O
in DT the O
the NN pathogenesis O
pathogenesis IN of O
of DT this O
this NN skin O
skin NN disease O

Successful JJ CAPITAL Successful O
Successful NN treatment O
treatment IN of O
of NN psoriasis D
psoriasis IN with O
with JJ topical O
topical NN application O
application IN of O
of JJ active T
active NN vitamin T
vitamin NN CAPITAL D3 T
D3 NN analogue T
analogue , , T
, CD 1 T
1 NN alpha T
alpha , , T
, JJ 24-dihydroxycholecalciferol T

We PRP CAPITAL We O
We VBP suggest O
suggest IN that O
that CD 1 T
1 NN alpha T
alpha , , T
, CD 24 T
24 NN ( T
( NN CAPITAL OH T
OH NN ) T
) NN 2D3 T
2D3 NNS merits O
merits RB further O
further NN investigation O
investigation IN as O
as DT a O
a RB potentially O
potentially JJ useful O
useful JJ topical O
topical NN therapy O
therapy IN for O
for NN psoriasis D

When WRB CAPITAL When O
When NN indomethacin T
indomethacin VBD was O
was VBN applied O
applied RB immediately O
immediately IN after O
after NN irradiation O
irradiation , , O
, NN CAPITAL UVR O
UVR NN ( O
( JJ ultraviolet O
ultraviolet NN radiation O
radiation NN ) O
) JJ dose-dependent O
dose-dependent NN suppression O
suppression IN of O
of NN erythema D
erythema VBD was O
was VBD demonstrated O
demonstrated IN for O
for DT both O
both NNS wavelengths O
wavelengths IN until O
until CD 36 O
36 NN h O
h IN after O
after NN irradiation O
irradiation WRB when O
when DT both O
both NN indomethacin O
indomethacin CC and O
and NN control O
control NN gel O
gel JJ base-treated O
base-treated NNS sites O
sites VBD were O
were RB equally O
equally JJ erythematous O

Suppression NN CAPITAL Suppression O
Suppression IN of O
of NN erythema D
erythema RB also O
also VBD occurred O
occurred WRB when O
when NN application O
application IN of O
of NN indomethacin T
indomethacin VBD was O
was VBN delayed O
delayed IN until O
until CD 24 O
24 NN h O
h IN after O
after NN irradiation O
irradiation , , O
, VBG showing O
showing IN that O
that IN for O
for DT both O
both NNS wavelengths O
wavelengths NN prostaglandin O
prostaglandin NN synthesis O
synthesis VBZ remains O
remains VBN increased O
increased IN throughout O
throughout DT this O
this NN period O

There EX CAPITAL There O
There VBD was O
was CD one O
one JJ retinal O
retinal NN dialysis O
dialysis , , O
, CC and O
and CD one O
one NN lens D
lens NN dislocation D
dislocation VBG requiring O
requiring NN extraction T

Rates NNP CAPITAL Rates O
Rates IN of O
of NN superoxide O
superoxide NN ( O
( NNP CAPITAL SA O
SA NN ) O
) NN generation O
generation IN by O
by NN blood O
blood NNS monocytes O
monocytes VBN stimulated O
stimulated FW ex O
ex FW vivo O
vivo VBD were O
were VBN studied O
studied IN before O
before CC and O
and IN during O
during NN corticosteroid T
corticosteroid NN treatment O
treatment IN of O
of JJ rheumatoid D
rheumatoid NN arthritis D
arthritis NN ( D
( NN CAPITAL RA D
RA NN ) D
) NNS patients O
patients , , O
, IN in O
in NN control O
control NNS patients O
patients CC and O
and IN in O
in JJ healthy O
healthy NNS controls O

Significant JJ CAPITAL Significant O
Significant NN inhibition O
inhibition IN of O
of NN monocyte O
monocyte NNP CAPITAL SA O
SA NN output O
output VBN stimulated O
stimulated IN with O
with JJ CAPITAL IgG-treated O
IgG-treated NN zymosan O
zymosan NN ( O
( NN CAPITAL ITZ O
ITZ NN ) O
) CC and O
and NN fluoride O
fluoride NN ion O
ion NN ( O
( NN CAPITAL F O
F NN ) O
) , , O
, CC but O
but RB not O
not JJ serum-treated O
serum-treated NN zymosan O
zymosan NN ( O
( NN CAPITAL STZ O
STZ NN ) O
) VBD was O
was VBD demonstrated O
demonstrated VBG following O
following NN steroid T
steroid NN therapy T
therapy IN in O
in NN CAPITAL RA D

Methotrexate NNP CAPITAL Methotrexate T
Methotrexate NN ( T
( NN CAPITAL MTX T
MTX NN ) T
) VBZ appears O
appears TO to O
to VB be O
be JJ useful O
useful IN in O
in NNS patients O
patients IN with O
with JJ rheumatoid D
rheumatoid NN arthritis D
arthritis NN ( D
( NN CAPITAL RA D
RA NN ) D
) JJ refractory O
refractory TO to O
to JJ other O
other NNS drugs O
drugs CC but O
but PRP$ its O
its JJ long-term O
long-term NN toxicity O
toxicity CC and O
and NN efficacy O
efficacy VBP are O
are JJ uncertain O

MTX NN CAPITAL MTX T
MTX IN in O
in DT a O
a JJ low-dose O
low-dose NN regimen O
regimen VBZ is O
is JJ useful O
useful IN in O
in JJ refractory D
refractory NN CAPITAL RA D
RA CC and O
and JJ superior O
superior TO to O
to JJ low-dose O
low-dose NN purine O
purine NNS analogues O

Twelve CD CAPITAL Twelve O
Twelve NNS patients O
patients IN with O
with JJ intractable D
intractable JJ rheumatoid D
rheumatoid NN arthritis D
arthritis VBD were O
were VBN treated O
treated IN with O
with JJ antilymphocyte T
antilymphocyte NN globulin T
globulin NN ( T
( NN CAPITAL ALG T
ALG NN ) T
) , , T
, JJ prednisolone T
prednisolone CC and T
and DT a T
a JJ cytotoxic T
cytotoxic NN agent T
agent , , T
, RB usually T
usually NN azathioprine T
azathioprine , , O
, CC and O
and VBD were O
were VBN followed O
followed IN for O
for CD 1 O
1 NN year O

Rigid JJ CAPITAL Rigid T
Rigid JJ ureteroscopy T
ureteroscopy IN for O
for DT the O
the NN treatment O
treatment IN of O
of JJ ureteric D
ureteric NN calculi D
calculi : : O
: NN experience O
experience IN in O
in CD 120 O
120 NNS cases O

Over IN CAPITAL Over O
Over DT a O
a JJ 1-year O
1-year NN period O
period , , O
, JJ rigid T
rigid JJ ureteroscopy T
ureteroscopy VBZ has O
has VBN been O
been VBN used O
used TO to O
to VB retrieve O
retrieve JJ ureteric D
ureteric NN calculi D
calculi IN in O
in CD 120 O
120 NNS patients O

Eleven CD CAPITAL Eleven O
Eleven NNS patients O
patients IN with O
with JJ vesicoureteric D
vesicoureteric NN reflux D
reflux JJ secondary O
secondary TO to O
to JJ neuropathic O
neuropathic NN bladder O
bladder VBD were O
were VBN treated O
treated IN by O
by JJ endoscopic T
endoscopic NN injection T
injection IN of T
of VBN pyrolised T
pyrolised NN polytetrafluoroethylene T
polytetrafluoroethylene NN ( T
( NN CAPITAL Polytef T
Polytef NN ) T
) VB paste T

Two CD CAPITAL Two O
Two CD hundred O
hundred CC and O
and CD seventy-seven O
seventy-seven NNS patients O
patients IN with O
with JJ advanced D
advanced JJ prostatic D
prostatic NN cancer D
cancer VBD were O
were VBN treated O
treated IN by O
by DT either O
either NN orchiectomy T
orchiectomy CC or T
or NN oestrogen T

Use NNP CAPITAL Use O
Use IN of O
of VBN scarred O
scarred NNS flaps O
flaps CC and O
and JJ secondary O
secondary NNS flaps O
flaps IN for O
for JJ reconstructive T
reconstructive NN surgery T
surgery IN of O
of JJ extensive D
extensive NNS burns D

A DT CAPITAL A O
A NN patient O
patient IN with O
with DT a O
a JJ vesico-enteric D
vesico-enteric NN fistula D
fistula VBD was O
was RB successfully O
successfully VBN treated O
treated IN with O
with NN resection T
resection IN of T
of DT the T
the JJ small T
small NN intestine T
intestine CC and T
and NN dome T
dome IN of T
of DT the T
the NN bladder T
bladder CC and T
and NN drainage T
drainage IN of T
of DT the T
the VBG intervening T
intervening NN abscess T

Supramaximal JJ CAPITAL Supramaximal T
Supramaximal JJ horizontal T
horizontal NN rectus T
rectus NN surgery T
surgery IN in O
in DT the O
the NN management O
management IN of O
of JJ third D
third CC and D
and JJ sixth D
sixth NN nerve D
nerve NN palsy D

Supramaximal JJ CAPITAL Supramaximal T
Supramaximal JJ medial T
medial CC and T
and JJ lateral T
lateral NN rectus T
rectus NN surgery T
surgery VBD was O
was VBN performed O
performed TO to O
to JJ correct O
correct JJ horizontal D
horizontal NNS deviations D
deviations IN in D
in CD seven D
seven NNS cases D
cases IN of D
of JJ sixth D
sixth NN nerve D
nerve NN palsy D
palsy CC and D
and CD three D
three NNS cases D
cases IN of D
of JJ third D
third NN nerve D
nerve NN palsy D
palsy , , O
, IN with O
with JJ satisfactory O
satisfactory NNS results O
results IN in O
in JJS most O
most NNS cases O

Steroid NN CAPITAL Steroid T
Steroid NN therapy T
therapy VBD was O
was RB also O
also VBN used O
used IN in O
in CD two O
two NNS patients O
patients IN with O
with JJ CAPITAL NSAID-induced D
NSAID-induced NN proteinuria D

Recombinant JJ CAPITAL Recombinant T
Recombinant NN leukocyte T
leukocyte DT CAPITAL A T
A NN interferon T
interferon NN ( T
( NN rIFN-alpha T
rIFN-alpha DT CAPITAL A T
A NN ) T
) IN in O
in DT the O
the NN treatment O
treatment IN of O
of VBN disseminated D
disseminated JJ malignant D
malignant NN melanoma D

Ninety-six CD CAPITAL Ninety-six O
Ninety-six NNS patients O
patients IN with O
with VBN disseminated D
disseminated JJ malignant D
malignant NN melanoma D
melanoma VBN received O
received NN thrice O
thrice JJ weekly O
weekly JJ intramuscular O
intramuscular NNS injections O
injections IN of O
of NN leukocyte T
leukocyte DT CAPITAL A T
A JJ recombinant T
recombinant NN interferon T
interferon NN ( T
( NN rIFN-alpha T
rIFN-alpha DT CAPITAL A T
A , , T
, NN CAPITAL Roferon-A T
Roferon-A , , T
, NNP CAPITAL Hoffmann T
Hoffmann NNP CAPITAL La T
La NNP CAPITAL Roche T
Roche NN ) T
) IN at O
at NNS doses O
doses IN of O
of CD 12 O
12 NN CAPITAL X O
X CD 10 O
10 NN ( O
( CD 6 O
6 NN ) O
) NN CAPITAL U/m2 O
U/m2 CC or O
or CD 50 O
50 NN CAPITAL X O
X CD 10 O
10 NN ( O
( CD 6 O
6 NN ) O
) NN CAPITAL U/m2 O
U/m2 IN with O
with CC or O
or IN without O
without NN cimetidine O
cimetidine IN as O
as DT an O
an JJ immunorestorative O
immunorestorative NN agent O

As IN CAPITAL As O
As VBN noted O
noted RB previously O
previously , , O
, VBG using O
using NN chemotherapy O
chemotherapy , , O
, DT a O
a JJ small O
small NN proportion O
proportion IN of O
of NNS patients O
patients IN with O
with JJ advanced D
advanced JJ malignant D
malignant NN melanoma D
melanoma , , O
, IN despite O
despite RB prior O
prior NN therapy O
therapy , , O
, MD may O
may VB achieve O
achieve JJ prolonged O
prolonged JJ objective O
objective NN regression O
regression IN with O
with NN rIFN-alpha T
rIFN-alpha DT CAPITAL A T

Clinical JJ CAPITAL Clinical O
Clinical NN course O
course IN of O
of NN breast O
breast NN cancer O
cancer NNS patients O
patients IN with O
with JJ osseous D
osseous NN metastasis D
metastasis VBN treated O
treated IN with O
with NN combination T
combination NN chemotherapy T

Between IN CAPITAL Between O
Between NNP CAPITAL July O
July CD 1973 O
1973 CC and O
and NNP CAPITAL December O
December CD 1979 O
1979 , , O
, CD 1171 O
1171 NNS patients O
patients IN with O
with JJ metastatic D
metastatic NN breast D
breast NN cancer D
cancer VBD were O
were VBN treated O
treated IN with O
with JJ doxorubicin-containing T
doxorubicin-containing NN chemotherapy T

Two CD CAPITAL Two O
Two NNS patients O
patients IN with O
with JJ metastatic D
metastatic NN dysgerminoma D
dysgerminoma IN of D
of DT the D
the NN ovary D
ovary VBD were O
were VBN treated O
treated IN with O
with DT a T
a NN combination T
combination IN of T
of NN etoposide T
etoposide , , T
, NN bleomycin T
bleomycin , , T
, CC and T
and NN cisplatin T
cisplatin IN at O
at DT CAPITAL The O
The NNP CAPITAL University O
University IN of O
of NNP CAPITAL Texas O
Texas NN CAPITAL M.D O

Chemotherapy NN CAPITAL Chemotherapy T
Chemotherapy MD may O
may VB be O
be DT an O
an JJ alternative O
alternative TO to O
to NN radiotherapy O
radiotherapy IN for O
for DT the O
the NN treatment O
treatment IN of O
of JJ metastatic D
metastatic NN dysgerminoma D
dysgerminoma CC and O
and MD should O
should RB also O
also VB be O
be VBN considered O
considered IN for O
for VBN selected O
selected NNS patients O
patients IN with O
with NN CAPITAL Stage O
Stage PRP CAPITAL I O
I NN disease O

Long-term JJ CAPITAL Long-term O
Long-term NN survival O
survival CC and O
and NN morbidity O
morbidity IN in O
in NNS patients O
patients IN with O
with JJ metastatic D
metastatic JJ malignant D
malignant NN germ D
germ NN cell D
cell NNS tumors D
tumors VBN treated O
treated IN with O
with JJ cisplatin-based T
cisplatin-based NN combination T
combination NN chemotherapy T

Treatment NN CAPITAL Treatment O
Treatment IN of O
of JJ advanced D
advanced NN stage D
stage NN mycosis D
mycosis NNS fungoides D
fungoides IN with O
with NN bleomycin T
bleomycin , , T
, NN doxorubicin T
doxorubicin , , T
, CC and T
and NN methotrexate T
methotrexate IN with T
with JJ topical T
topical NN nitrogen T
nitrogen NN mustard T
mustard NN ( T
( NN CAPITAL BAM-M T
BAM-M NN ) T

Ten CD CAPITAL Ten O
Ten NNS patients O
patients IN with O
with JJ advanced D
advanced NN stage D
stage NN ( D
( NN CAPITAL TNM D
TNM NN CAPITAL IIB-IVB D
IIB-IVB NN ) D
) NN mycosis D
mycosis NNS fungoides D
fungoides VBD were O
were VBN treated O
treated IN with O
with DT a O
a NN combination T
combination NN chemotherapy T
chemotherapy NN program T
program VBG consisting T
consisting IN of T
of NN bleomycin T
bleomycin CC and T
and NN methotrexate T
methotrexate JJ weekly T
weekly , , T
, NN doxorubicin T
doxorubicin DT every T
every CD 3 T
3 NNS weeks T
weeks , , T
, CC and T
and JJ topical T
topical NN nitrogen T
nitrogen NN mustard T
mustard JJ daily T
daily NN ( T
( NN CAPITAL BAM-M T
BAM-M NN ) T

Three CD CAPITAL Three O
Three NNS patients O
patients IN in O
in WP whom O
whom NN splenomegaly D
splenomegaly VBD was O
was VBN detected O
detected IN during O
during PRP$ their O
their NN staging O
staging NN evaluation O
evaluation VBD underwent O
underwent NN splenectomy T

This DT CAPITAL This O
This NN study O
study VBZ indicates O
indicates IN that O
that NN CAPITAL BAM-M T
BAM-M VBZ is O
is JJ effective O
effective NN therapy O
therapy IN for O
for JJ advanced D
advanced NN stage D
stage NN mycosis D
mycosis NNS fungoides D
fungoides CC and O
and VBZ suggests O
suggests IN that O
that DT the O
the JJ therapeutic O
therapeutic NN role O
role IN of O
of NN splenectomy O
splenectomy MD should O
should VB be O
be VBN evaluated O
evaluated RB further O

Only RB CAPITAL Only O
Only NNS patients O
patients WP$ whose O
whose JJ primary D
primary NN head D
head CC and D
and NN neck D
neck NN tumor D
tumor NNS shows O
shows DT a O
a NN response O
response TO to O
to JJ systemic O
systemic NN therapy O
therapy VB undergo O
undergo NNP CAPITAL Ommaya T
Ommaya NN placement T

Additional JJ CAPITAL Additional O
Additional NN chemotherapy T
chemotherapy MD may O
may RB thus O
thus VB have O
have VBN eradicated O
eradicated DT these O
these NNS micrometastases D
micrometastases IN in O
in DT the O
the JJR older O
older NNS children O
children , , O
, IN since O
since DT the O
the NN age O
age NN influence O
influence IN on O
on NN CAPITAL Stage O
Stage NNP CAPITAL II O
II NN disease O
disease VBD disappeared O
disappeared WRB when O
when JJ multimodal O
multimodal NN treatment O
treatment VBD was O
was VBN given O
given IN in O
in DT this O
this NN study O

Traditional JJ CAPITAL Traditional O
Traditional NN therapy O
therapy IN for O
for JJ malignant D
malignant JJ pleural D
pleural NNS effusions D
effusions VBZ includes O
includes NN thoracentesis T
thoracentesis CC or T
or NN tube T
tube NN drainage T
drainage IN with O
with NN instillation O
instillation IN of O
of NNS irritants O
irritants TO to O
to VB achieve O
achieve NN pleurodesis O

We PRP CAPITAL We O
We VB feel O
feel IN that O
that NN pleuroperitoneal T
pleuroperitoneal VBG shunting T
shunting VBZ is O
is DT a O
a JJ valid O
valid JJ new O
new NN method O
method IN for O
for NN treatment O
treatment IN of O
of JJ malignant D
malignant JJ pleural D
pleural NNS effusions D
effusions WDT which O
which MD can O
can RB effectively O
effectively VB palliate O
palliate JJ respiratory O
respiratory NNS symptoms O
symptoms IN with O
with JJ low O
low NN morbidity O

When WRB CAPITAL When O
When NN right D
right JJ ventricular D
ventricular NN failure D
failure VBZ prohibits O
prohibits NN separation O
separation IN from O
from JJ cardiopulmonary O
cardiopulmonary NN bypass O
bypass , , O
, JJ standard T
standard NNS methods T
methods IN of T
of VBG increasing T
increasing JJ pulmonary T
pulmonary NN blood T
blood NN flow T
flow MD should O
should VB be O
be VBN employed O
employed , , O
, VBG including O
including NN correction O
correction IN of O
of NN hypoxia O
hypoxia CC and O
and NN acidosis O
acidosis , , O
, NN volume O
volume VBG loading O
loading , , O
, CC and O
and JJ inotropic O
inotropic NN support O
support IN of O
of DT the O
the RB right O
right NN ventricle O

For IN CAPITAL For O
For JJ refractory D
refractory NN right D
right JJ ventricular D
ventricular NN failure D
failure VBG following O
following DT the O
the JJ surgical O
surgical NN repair O
repair IN of O
of JJ congenital O
congenital JJ cardiac O
cardiac NNS defects O
defects IN in O
in WDT which O
which DT the O
the NN placement O
placement IN of O
of RB right O
right JJ atrial O
atrial CC and O
and JJ pulmonary O
pulmonary NN artery O
artery FW cannulae O
cannulae VBZ is O
is RB not O
not RB technically O
technically JJ feasible O
feasible , , O
, NN use T
use IN of T
of VB high-frequency T
high-frequency JJ high-volume T
high-volume NN ventilation T
ventilation VBZ appears O
appears TO to O
to VB be O
be RB quite O
quite JJ promising O

Current JJ CAPITAL Current O
Current NNS results O
results VBP suggest O
suggest IN that O
that NN CAPITAL RHBP T
RHBP VBZ remains O
remains DT the O
the NN gold O
gold JJ standard O
standard IN for O
for JJ severe D
severe NN CAPITAL RV D
RV NN failure D
failure , , O
, CC but O
but RB further O
further JJ clinical O
clinical NN experience O
experience IN with O
with NN CAPITAL PABC O
PABC MD may O
may RBR more O
more RB clearly O
clearly VB define O
define PRP$ its O
its NN role O
role IN in O
in DT the O
the NN management O
management IN of O
of NN CAPITAL RV O
RV NN failure O

Guiding VBG CAPITAL Guiding O
Guiding JJ surgical T
surgical NN therapy T
therapy IN of O
of JJ ventricular D
ventricular NN tachycardia D
tachycardia IN by O
by JJ preoperative O
preoperative JJ endocardial O
endocardial NN catheter O
catheter VBG mapping O
mapping VBZ necessitates O
necessitates NN improvement O
improvement IN of O
of DT the O
the NN accuracy O
accuracy IN of O
of NN localization O
localization IN of O
of DT the O
the JJ arrhythmogenic O
arrhythmogenic NN site O

However RB CAPITAL However O
However , , O
, DT the O
the NNS results O
results IN of O
of DT this O
this NN study O
study VBP indicate O
indicate IN that O
that NN procainamide T
procainamide MD may O
may VB be O
be JJ effective O
effective IN in O
in VBG suppressing O
suppressing DT the O
the NN induction O
induction IN of O
of JJ sustained O
sustained JJ ventricular D
ventricular NN tachycardia D
tachycardia IN at O
at DT a O
a RB relatively O
relatively JJ low O
low NN plasma O
plasma NN concentration O
concentration , , O
, CC but O
but RB not O
not IN at O
at DT a O
a JJR higher O
higher NN plasma O
plasma NN concentration O

Coronary JJ CAPITAL Coronary T
Coronary JJ angioplasty T
angioplasty IN for O
for RB early D
early NN postinfarction D
postinfarction JJ unstable D
unstable NN angina D

Coronary JJ CAPITAL Coronary T
Coronary JJ angioplasty T
angioplasty VBD was O
was VBN performed O
performed IN in O
in CD 53 O
53 NNS patients O
patients IN in O
in WP whom O
whom JJ unstable D
unstable NN angina D
angina VBD had O
had VBD reoccurred O
reoccurred IN after O
after CD 48 O
48 NN hr O
hr CC and O
and IN within O
within CD 30 O
30 NNS days O
days IN after O
after JJ sustained O
sustained JJ myocardial O
myocardial NN infarction O

At IN CAPITAL At O
At CD 6 O
6 NNS months O
months JJ follow-up O
follow-up CD 26 O
26 NN % O
% NN ( O
( CD 14/53 O
14/53 NN ) O
) IN of O
of DT all O
all DT the O
the NNS patients O
patients WP who O
who VBD underwent O
underwent JJ angioplasty T
angioplasty VBD had O
had NN recurrence O
recurrence IN of O
of NN angina D
angina , , O
, WDT which O
which VBD was O
was RB successfully O
successfully VBN treated O
treated IN with O
with NN repeat T
repeat JJ angioplasty T
angioplasty , , T
, NN bypass T
bypass NN surgery T
surgery , , T
, CC or T
or JJ medical T
medical NN therapy T

Coronary JJ CAPITAL Coronary D
Coronary NN dissection D
dissection CC and D
and JJ total D
total JJ coronary D
coronary NN occlusion D
occlusion VBG leading O
leading TO to O
to NN emergency T
emergency JJ coronary T
coronary NN surgery T
surgery VBP are O
are DT the O
the JJS most O
most JJ frequent O
frequent NNS complications O
complications IN of O
of JJ percutaneous O
percutaneous JJ transluminal O
transluminal JJ coronary O
coronary NN angioplasty O
angioplasty NN ( O
( NN CAPITAL PTCA O
PTCA NN ) O
) CC and O
and PRP$ their O
their NN occurrence O
occurrence RB usually O
usually VBZ is O
is JJ unpredictable O

Effect NN CAPITAL Effect O
Effect IN of O
of NN zanamivir T
zanamivir IN on O
on NN duration O
duration CC and O
and NN resolution O
resolution IN of O
of NN influenza D
influenza NNS symptoms O

A DT CAPITAL A O
A NN comparison O
comparison IN of O
of DT a O
a JJ five-day O
five-day NN regimen O
regimen IN of O
of NN cefdinir T
cefdinir IN with O
with DT a O
a JJ seven-day O
seven-day NN regimen O
regimen IN of O
of NN loracarbef T
loracarbef IN for O
for DT the O
the NN treatment O
treatment IN of O
of JJ acute O
acute NNS exacerbations O
exacerbations IN of O
of JJ chronic D
chronic NN bronchitis D

Initial JJ CAPITAL Initial O
Initial JJ empiric O
empiric NN therapy O
therapy IN for O
for JJ community-acquired O
community-acquired JJ bacterial D
bacterial NN meningitis D
meningitis MD should O
should VB be O
be VBN based O
based IN on O
on DT the O
the NN possibility O
possibility IN that O
that JJ penicillin-resistant O
penicillin-resistant NN pneumococci O
pneumococci MD may O
may VB be O
be DT the O
the JJ etiologic O
etiologic NNS organisms O
organisms CC and O
and , , O
, RB hence O
hence , , O
, MD should O
should VBP include O
include DT a O
a NN combination O
combination IN of O
of JJ third-generation O
third-generation NN cephalosporin T
cephalosporin NN ( T
( NN cefotaxime T
cefotaxime CC or T
or NN ceftriaxone T
ceftriaxone NN ) T
) CC and T
and NN vancomycin T

Ampicillin NNP CAPITAL Ampicillin T
Ampicillin MD should O
should VB be O
be VBN included O
included IN if O
if DT the O
the NN patient O
patient VBZ has O
has VBG predisposing O
predisposing NNS factors O
factors IN that O
that VBP are O
are VBN associated O
associated IN with O
with DT a O
a NN risk O
risk IN for O
for NN infection D
infection IN with D
with NN CAPITAL Listeria D
Listeria NNS monocytogenes D

Results NNS CAPITAL Results O
Results IN of O
of JJ clinical O
clinical NNS trials O
trials CC and O
and NN meta-analysis O
meta-analysis VBP suggest O
suggest IN that O
that NN dexamethasone T
dexamethasone NN therapy T
therapy VBZ improves O
improves DT the O
the NN outcome O
outcome IN for O
for NNS patients O
patients IN with O
with JJ bacterial D
bacterial NN meningitis D

Placebo-controlled JJ CAPITAL Placebo-controlled O
Placebo-controlled NNS trials O
trials VB have O
have VBN shown O
shown IN that O
that NN vitamin T
vitamin NN CAPITAL C T
C NN supplementation O
supplementation NNS decreases O
decreases DT the O
the NN duration O
duration CC and O
and NN severity O
severity IN of O
of JJ common D
common JJ cold D
cold NNS infections D

Since IN CAPITAL Since O
Since JJ few O
few NNS trials O
trials VB have O
have VBN examined O
examined DT the O
the NNS effects O
effects IN of O
of JJ therapeutic O
therapeutic NN supplementation O
supplementation CC and O
and PRP$ their O
their NNS results O
results VB have O
have VBN been O
been JJ variable O
variable , , O
, RB further O
further JJ therapeutic O
therapeutic NNS trials O
trials VBP are O
are VBN required O
required TO to O
to VB examine O
examine DT the O
the NN role O
role IN of O
of NN vitamin T
vitamin NN CAPITAL C T
C IN in O
in DT the O
the NN treatment O
treatment IN of O
of NNS colds D

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> JJ CAPITAL Progressive D
Progressive JJ multifocal D
multifocal NN leukoencephalopathy D
leukoencephalopathy VBG following O
following JJ oral T
oral NN fludarabine T
fludarabine NN treatment O
treatment IN of O
of JJ chronic D
chronic JJ lymphocytic D
lymphocytic NN leukemia D

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NN CAPITAL PURPOSE O
PURPOSE : : O
: TO CAPITAL To O
To NN review O
review VBN reported O
reported JJ inflammatory D
inflammatory NNS reactions D
reactions VBG occurring O
occurring IN after O
after NN initiation O
initiation IN of O
of RB highly O
highly JJ active O
active JJ antiretroviral T
antiretroviral NN therapy T
therapy NN ( T
( JJ CAPITAL HAART T
HAART NN ) T
) IN in O
in NNS persons O
persons JJ infected O
infected IN with O
with NN CAPITAL HIV-1 D
HIV-1 CC and O
and TO to O
to VB explore O
explore DT the O
the NNS mechanisms O
mechanisms VBG leading O
leading TO to O
to DT these O
these NNS reactions O

Levofloxacin NN CAPITAL Levofloxacin T
Levofloxacin CC versus T
versus JJ intravenous T
intravenous NN ceftriaxone T
ceftriaxone CC and T
and JJ amoxicillin/clavulanate T
amoxicillin/clavulanate IN in O
in DT the O
the NN treatment O
treatment IN of O
of JJ community-acquired O
community-acquired NN pneumonia D
pneumonia IN that O
that VB require O
require NN hospitalization O

Overall JJ CAPITAL Overall O
Overall CD 1 O
1 NN year O
year NN survival O
survival NN ( O
( JJ operative O
operative NNS deaths O
deaths VBN excluded O
excluded NN ) O
) VBD was O
was CD 68 O
68 NN % O
% IN after O
after NN tumor D
tumor NN resection T
resection VBN compared O
compared TO to O
to CD 31 O
31 NN % O
% IN after O
after JJ palliative O
palliative NN surgery O
surgery NN ( O
( NN CAPITAL P O
P JJR < O
< CD 0.001 O
0.001 NN ) O

The DT CAPITAL The O
The NNS results O
results IN of O
of DT this O
this NN study O
study NN show O
show IN that O
that NN resection T
resection IN of O
of JJ extrahepatic D
extrahepatic NN bile D
bile NN duct D
duct NNS carcinomas D
carcinomas , , O
, RB particularly O
particularly IN in O
in DT an O
an JJ upper-third O
upper-third NN localization O
localization , , O
, VBZ is O
is RB often O
often VBN associated O
associated IN with O
with JJ worthwhile O
worthwhile JJ long-term O
long-term NN survival O

Background NN CAPITAL Background O
Background : : O
: NN CAPITAL N-acetylcysteine T
N-acetylcysteine NN ( T
( NN CAPITAL NAC T
NAC NN ) T
) CC and T
and NN ambroxol T
ambroxol NN ( T
( NNP CAPITAL AMB T
AMB NN ) T
) VB have O
have RB recently O
recently VBN been O
been VBN proposed O
proposed IN as O
as JJ possible O
possible JJ therapeutic O
therapeutic NNS agents O
agents IN in O
in DT the O
the NN treatment O
treatment IN of O
of JJ pulmonary D
pulmonary NNS disorders D

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> JJ CAPITAL Postoperative O
Postoperative NN alkaline D
alkaline NN reflux D
reflux IN after O
after JJ total T
total NN gastrectomy T
gastrectomy IN for O
for NN stomach D
stomach NN cancer D

Antimicrobial JJ CAPITAL Antimicrobial T
Antimicrobial NN therapy T
therapy IN for O
for JJ respiratory D
respiratory NN disease D

Corticosteroids NNS CAPITAL Corticosteroids T
Corticosteroids IN for O
for DT the O
the NN treatment O
treatment IN of O
of NN croup D

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NN CAPITAL BACKGROUND O
BACKGROUND : : O
: IN CAPITAL In O
In DT the O
the JJ present O
present NN study O
study PRP we O
we VBN investigated O
investigated DT the O
the NN efficacy O
efficacy CC and O
and NN tolerability O
tolerability IN of O
of NN i.m T
i.m . . T
. NN octreotide T
octreotide NN acetate T
acetate NN ( T
( NN octreotide T
octreotide NN CAPITAL LAR T
LAR NN ) T
) IN in O
in NNS patients O
patients IN with O
with JJ metastatic D
metastatic NN neuroendocrine D
neuroendocrine NNS tumors D
tumors NN ( D
( NNS CAPITAL NETs D
NETs NN ) D
) RB previously O
previously VBN treated O
treated CC and O
and VBD failed O
failed IN on O
on NN i.m T
i.m . . T
. NN lanreotide T

The DT CAPITAL The O
The NN CAPITAL PR O
PR VBD was O
was VBN observed O
observed IN in O
in CD one O
one NN patient O
patient IN with O
with JJ non-functioning D
non-functioning NN endocrine D
endocrine JJ pancreatic D
pancreatic NN tumor D
tumor IN with D
with JJ progressive D
progressive NN liver D
liver CC and D
and NN lymph D
lymph NN node D
node NNS metastases D
metastases IN after O
after CD 16 O
16 NNS months O
months IN of O
of NN i.m T
i.m . . T
. NN lanreotide T
lanreotide NN therapy T

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: NN CAPITAL Octreotide T
Octreotide NN CAPITAL LAR T
LAR CD 20 O
20 NN mg O
mg NNS shows O
shows JJ significant O
significant NN efficacy O
efficacy IN in O
in NNS terms O
terms IN of O
of JJ objective O
objective NN response O
response NN rate O
rate NN ( O
( NN CAPITAL PR O
PR CC + O
+ NN CAPITAL SD O
SD NN ) O
) , , O
, JJ biochemical O
biochemical CC and O
and JJ symptomatic O
symptomatic NN control O
control IN in O
in NNS patients O
patients IN with O
with JJ metastatic D
metastatic NNS CAPITAL NETs D
NETs IN of O
of DT the O
the NN CAPITAL GEP O
GEP NN system O
system JJ pretreated O
pretreated CC and O
and VBG progressing O
progressing IN on O
on JJ slow O
slow NN release O
release NN lanreotide O

Inchinko-to JJ CAPITAL Inchinko-to T
Inchinko-to NN ( T
( NN CAPITAL TJ-135 T
TJ-135 NN ) T
) VBZ is O
is DT a O
a JJ herbal O
herbal NN medicine O
medicine VBG consisting O
consisting IN of O
of CD three O
three NNS kinds O
kinds IN of O
of JJ crude O
crude NNS drugs O
drugs , , O
, CC and O
and IN in O
in NNP CAPITAL Japan O
Japan PRP it O
it VBZ is O
is VBN administered O
administered RB mainly O
mainly TO to O
to NNS patients O
patients IN with O
with NN cholestasis D

The DT CAPITAL The O
The JJ present O
present NN study O
study VBN evaluated O
evaluated DT the O
the NNS effects O
effects IN of O
of NN CAPITAL TJ-135 T
TJ-135 IN on O
on NN concanavalin D
concanavalin DT CAPITAL A D
A NN ( D
( NN con D
con DT CAPITAL A D
A NN ) D
) JJ -induced D
-induced NN hepatitis D
hepatitis IN in O
in NNS mice O
mice IN in O
in FW vivo O
vivo CC and O
and RB con O
con JJ CAPITAL A-induced O
A-induced NN cytokine O
cytokine NN production O
production IN in O
in FW vitro O

These DT CAPITAL These O
These NNS results O
results VBP suggest O
suggest IN that O
that NN con D
con JJ CAPITAL A-induced D
A-induced NN hepatitis D
hepatitis VBD was O
was VBN ameliorated O
ameliorated IN by O
by NN pretreatment O
pretreatment IN with O
with NN CAPITAL TJ-135 T

Therefore RB CAPITAL Therefore O
Therefore NN administration O
administration IN of O
of NN CAPITAL TJ-135 T
TJ-135 MD may O
may VB be O
be JJ useful O
useful IN in O
in NNS patients O
patients IN with O
with JJ severe O
severe JJ acute O
acute NN hepatitis D
hepatitis VBG accompanying D
accompanying NN cholestasis D
cholestasis CC or O
or IN in O
in DT those O
those IN with O
with JJ autoimmune D
autoimmune NN hepatitis D

Zinc NN CAPITAL Zinc T
Zinc NNS lozenges T
lozenges : -- O
-- DT a O
a NN cure O
cure IN for O
for JJ common D
common NNS colds D
colds . ? O

T-helper NN CAPITAL T-helper T
T-helper NN type T
type CD 2 T
2 JJ cell-directed T
cell-directed NN therapy T
therapy IN for O
for NN asthma D

Effects NNS CAPITAL Effects O
Effects IN of O
of DT the O
the JJ CAPITAL Japanese T
Japanese JJ herbal T
herbal NN medicine T
medicine JJ 'Inchinko-to T
'Inchinko-to '' ' T
' NN ( T
( NN CAPITAL TJ-135 T
TJ-135 NN ) T
) IN on O
on NN concanavalin D
concanavalin JJ CAPITAL A-induced D
A-induced NN hepatitis D
hepatitis IN in O
in NNS mice O

Presumed VBN CAPITAL Presumed O
Presumed NNS cavernomas O
cavernomas VB have O
have VBN been O
been VBN documented O
documented VBG following O
following NN radiation T
radiation IN for O
for NN malignancy D
malignancy NN ( O
( CD 5-6 O
5-6 NN ) O
) , , O
, CC and O
and JJ sterotactic O
sterotactic JJ cerebral O
cerebral NN biopsy O
biopsy NN ( O
( CD 7 O
7 NN ) O

Surgical NNP CAPITAL Surgical T
Surgical NN management T
management IN of O
of NN syringomyelia D
syringomyelia VBN associated D
associated IN with D
with JJ spinal D
spinal JJ adhesive D
adhesive NN arachnoiditis D

Discontinuation NN CAPITAL Discontinuation O
Discontinuation IN of O
of JJ secondary O
secondary NN prophylaxis O
prophylaxis IN for O
for JJ cryptococcal D
cryptococcal NN meningitis D
meningitis IN in O
in JJ CAPITAL HIV-infected O
HIV-infected NNS patients O
patients VBG responding O
responding TO to O
to RB highly O
highly JJ active O
active JJ antiretroviral T
antiretroviral NN therapy T

Hepatectomy JJ CAPITAL Hepatectomy T
Hepatectomy IN for O
for NN cholangiocarcinoma D
cholangiocarcinoma JJ complicated O
complicated IN with O
with RB right O
right JJ umbilical O
umbilical NN portion O
portion : : O
: JJ anomalous O
anomalous NN configuration O
configuration IN of O
of DT the O
the JJ intrahepatic O
intrahepatic JJ biliary O
biliary NN tree O

Traditionally RB CAPITAL Traditionally O
Traditionally , , O
, DT the O
the NN therapy O
therapy IN of O
of JJ symptomatic D
symptomatic NN bronchiectasis D
bronchiectasis VBZ is O
is VBN based O
based IN on O
on NNS antibiotics T
antibiotics , , T
, JJ antibronchoobstructive T
antibronchoobstructive NN medication T
medication , , T
, CC and T
and NN chest T
chest JJ physical T
physical NN therapy T

Bilateral JJ CAPITAL Bilateral T
Bilateral NN lung T
lung NN transplantation T
transplantation MD should O
should VB be O
be VBN considered O
considered IN in O
in JJR younger O
younger NNS patients O
patients IN with O
with JJ severe O
severe , , O
, VBN generalized O
generalized NN bronchiectasis D
bronchiectasis CC and D
and JJ respiratory D
respiratory NN failure D

Prospective JJ CAPITAL Prospective O
Prospective , , O
, VBN randomized O
randomized , , O
, JJ largescale O
largescale NNS trials O
trials VBG supporting O
supporting DT any O
any IN of O
of DT the O
the JJ different O
different NN treatment O
treatment NNS strategies O
strategies VBP are O
are RB not O
not JJ available O
available , , O
, CC but O
but NNS antibiotics T
antibiotics CC and T
and NN surgery T
surgery RB probably O
probably VB have O
have VBN improved O
improved DT the O
the JJ long-term O
long-term NN outcome O
outcome IN of O
of JJ many O
many NNS patients O
patients IN with O
with NN bronchiectasis D

OBJECTIVES NNS CAPITAL OBJECTIVES O
OBJECTIVES : : O
: NN CAPITAL Interest O
Interest IN in O
in NN zinc T
zinc IN as O
as DT a O
a NN treatment O
treatment IN for O
for DT the O
the JJ common D
common JJ cold D
cold VBZ has O
has VBN grown O
grown VBG following O
following DT the O
the JJ recent O
recent NN publication O
publication IN of O
of JJ several O
several JJ controlled O
controlled NNS trials O

The DT CAPITAL The O
The JJ objective O
objective IN of O
of DT this O
this NN review O
review VBD was O
was TO to O
to VB assess O
assess DT the O
the NNS effects O
effects IN of O
of NN zinc T
zinc NNS lozenges T
lozenges IN for O
for JJ cold D
cold NNS symptoms D

Results NNS CAPITAL Results O
Results IN from O
from CD two O
two NNS trials O
trials NN ( O
( NN 04 O
04 : - O
- NNP CAPITAL Mossad O
Mossad : ; O
; CD 08 O
08 : - O
- NNP CAPITAL Smith O
Smith NN ) O
) VBN suggested O
suggested NN zinc T
zinc NNS lozenges T
lozenges VBN reduced O
reduced DT the O
the NN severity O
severity CC and O
and NN duration O
duration IN of O
of JJ cold D
cold NNS symptoms D

Given VBN CAPITAL Given O
Given DT the O
the JJ potential O
potential IN for O
for NN treatment O
treatment TO to O
to VB produce O
produce NN side O
side NNS effects O
effects , , O
, DT the O
the NN use O
use IN of O
of NN zinc T
zinc NNS lozenges T
lozenges TO to O
to VB treat O
treat JJ cold D
cold NNS symptoms D
symptoms VBZ deserves O
deserves RB further O
further NN study O

Randomized VBN CAPITAL Randomized O
Randomized NN trial O
trial IN of O
of NN interferon-alpha T
interferon-alpha CC plus T
plus JJ ursodeoxycholic T
ursodeoxycholic NN acid T
acid CC versus O
versus NN interferon T
interferon CC plus T
plus NN placebo T
placebo IN in O
in NNS patients O
patients IN with O
with JJ chronic D
chronic NN hepatitis D
hepatitis NN CAPITAL C D
C JJ resistant D
resistant TO to D
to NN interferon D

We PRP CAPITAL We O
We VBP describe O
describe DT a O
a JJ rare O
rare NN case O
case IN of O
of JJ spontaneous D
spontaneous NN rupture D
rupture IN of D
of DT a D
a JJ hepatic D
hepatic NN metastasis D
metastasis IN from D
from JJ renal D
renal NN cell D
cell NN carcinoma D
carcinoma IN that O
that VBD was O
was VBN treated O
treated RB successfully O
successfully IN by O
by JJ hepatic T
hepatic JJ arterial T
arterial NN embolization T

A DT CAPITAL A O
A JJ 65-year-old O
65-year-old NN woman O
woman , , O
, WP who O
who VBD had O
had VBN been O
been VBG undergoing O
undergoing NN immunotherapy T
immunotherapy IN for O
for RB inoperably D
inoperably VBN disseminated D
disseminated JJ renal D
renal NN carcinoma D
carcinoma CC and D
and NN lung D
lung NNS metastases D
metastases , , O
, VBN presented O
presented IN with O
with JJ severe O
severe JJ abdominal O
abdominal NN pain O
pain IN in O
in DT a O
a NN state O
state IN of O
of JJ hypovolemic O
hypovolemic NN shock O

Although IN CAPITAL Although O
Although JJ hepatic O
hepatic NN rupture O
rupture JJ due O
due TO to O
to JJ metastatic O
metastatic NN cancer O
cancer VBZ is O
is RB extremely O
extremely JJ rare O
rare , , O
, NN transcatheter T
transcatheter JJ arterial T
arterial NN embolization T
embolization NN ( T
( NN CAPITAL TAE T
TAE NN ) T
) VBZ is O
is DT an O
an JJ appropriate O
appropriate CC and O
and JJ useful O
useful NN treatment O
treatment IN for O
for JJ massive D
massive NN hemorrhage D
hemorrhage VBN caused D
caused IN by D
by JJ spontaneous D
spontaneous NN rupture D
rupture IN of D
of NN liver D
liver NN metastasis D

Patients NNS CAPITAL Patients O
Patients IN with O
with JJ classical O
classical NNS symptoms O
symptoms JJ such O
such IN as O
as NN heartburn D
heartburn CC and D
and NN regurgitation D
regurgitation MD may O
may VB be O
be VBN treated O
treated RB pharmaceutically T
pharmaceutically VBN combined T
combined IN with T
with NN life T
life NN style T
style VBG counselling T

Surgical NNP CAPITAL Surgical T
Surgical NN treatment T
treatment VBZ is O
is DT a O
a JJ good O
good JJ alternative O
alternative IN for O
for NNS patients O
patients IN with O
with JJ persistent D
persistent JJ severe D
severe NN regurgitation D
regurgitation IN during O
during JJ medical O
medical NN therapy O
therapy CC and O
and IN for O
for JJ young O
young NNS patients O
patients WP who O
who VBP prefer O
prefer NN surgery O
surgery TO to O
to JJ lifelong O
lifelong NN medication O

The DT CAPITAL The O
The JJ surgical T
surgical NN treatment T
treatment IN of O
of NN lung D
lung NNS lacerations D
lacerations CC and D
and JJ major D
major JJ bronchial D
bronchial NNS disruptions D
disruptions VBN caused O
caused IN by O
by JJ blunt O
blunt JJ thoracic O
thoracic NN trauma O

BACKGROUND NN CAPITAL BACKGROUND O
BACKGROUND : : O
: DT CAPITAL An O
An VBG increasing O
increasing NN number O
number IN of O
of NNS reports O
reports VBP indicate O
indicate JJ symptomatic O
symptomatic NN relief O
relief IN of O
of JJ biliary O
biliary JJ colic O
colic NNS symptoms O
symptoms IN after O
after NN cholecystectomy T
cholecystectomy IN for O
for JJ biliary D
biliary NN dyskinesia D

Despite IN CAPITAL Despite O
Despite DT this O
this , , O
, NN cholecystectomy T
cholecystectomy IN as O
as DT a O
a NN treatment O
treatment IN for O
for JJ biliary D
biliary NN dyskinesia D
dyskinesia VBZ remains O
remains JJ controversial O

Our PRP$ CAPITAL Our O
Our NN aim O
aim VBD was O
was TO to O
to VB determine O
determine NN efficacy O
efficacy IN of O
of NN cholecystectomy T
cholecystectomy IN in O
in VBG alleviating O
alleviating JJ biliary D
biliary NN dyskinesia D
dyskinesia NNS symptoms D
symptoms CC and O
and DT the O
the NN correlation O
correlation IN with O
with JJ histologic O
histologic NNS findings O

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: JJ CAPITAL Biliary D
Biliary NN dyskinesia D
dyskinesia NNS patients O
patients WP who O
who VBD underwent O
underwent NN cholecystectomy T
cholecystectomy VBD had O
had RB significantly O
significantly JJR greater O
greater NN symptom O
symptom NN improvement O
improvement VBN compared O
compared IN with O
with JJ nonsurgical O
nonsurgical NNS patients O

Cholecystectomy NN CAPITAL Cholecystectomy T
Cholecystectomy MD should O
should VB be O
be DT a O
a JJ first-line O
first-line NN therapy O
therapy IN for O
for JJ biliary D
biliary NN dyskinesia D
dyskinesia NNS patients O

Transbronchial JJ CAPITAL Transbronchial O
Transbronchial NN biopsy O
biopsy VBD revealed O
revealed JJ inflammatory D
inflammatory JJ nonspecific D
nonspecific JJ alveolar D
alveolar NNS lesions D
lesions JJ suggestive D
suggestive IN of D
of NN bronchiolitis D
bronchiolitis NNS obliterans D
obliterans VBG organizing D
organizing NN pneumonia D
pneumonia , , O
, WDT which O
which VBD responded O
responded RB well O
well RB clinically O
clinically CC and O
and RB radiologically O
radiologically TO to O
to JJ oral T
oral NNS corticosteroids T

Novel JJ CAPITAL Novel O
Novel NN treatment O
treatment NNS strategies O
strategies IN for O
for NNS patients O
patients IN with O
with JJ advanced D
advanced NN CAPITAL NSCLC D
NSCLC MD may O
may VB involve O
involve NN chemotherapy T
chemotherapy JJ combined O
combined IN with O
with NN inhibition O
inhibition IN of O
of JJ CAPITAL NF-kappaB-dependent O
NF-kappaB-dependent JJ cell-survival O
cell-survival NNS pathways O

Effectiveness NN CAPITAL Effectiveness O
Effectiveness IN of O
of NN pseudoephedrine T
pseudoephedrine CC plus T
plus NN acetaminophen T
acetaminophen IN for O
for NN treatment O
treatment IN of O
of NNS symptoms O
symptoms VBN attributed O
attributed TO to O
to DT the O
the JJ paranasal O
paranasal NNS sinuses O
sinuses VBN associated O
associated IN with O
with DT the O
the JJ common D
common JJ cold D

OBJECTIVE NN CAPITAL OBJECTIVE O
OBJECTIVE : : O
: DT CAPITAL This O
This JJ retrospective O
retrospective NN study O
study VBD was O
was VBN designed O
designed TO to O
to VBP confirm O
confirm IN that O
that JJ aggressive T
aggressive JJ pulmonary T
pulmonary NN resection T
resection MD can O
can VB provide O
provide JJ effective O
effective JJ long-term O
long-term NN palliation O
palliation IN of O
of NN disease O
disease IN for O
for NNS patients O
patients IN with O
with JJ pulmonary D
pulmonary NN aspergilloma D

METHODS NNS CAPITAL METHODS O
METHODS CC CAPITAL AND O
AND NNS CAPITAL RESULTS O
RESULTS : : O
: IN CAPITAL From O
From CD 1959 O
1959 TO to O
to CD 1998 O
1998 , , O
, CD 84 O
84 NNS patients O
patients VBD underwent O
underwent DT a O
a JJ total O
total IN of O
of CD 90 O
90 NNS operations T
operations IN for O
for NN treatment O
treatment IN of O
of JJ pulmonary D
pulmonary NN aspergilloma D
aspergilloma IN in O
in DT the O
the JJ CAPITAL Marie-Lannelongue O
Marie-Lannelongue NNP CAPITAL Hospital O

The DT CAPITAL The O
The NN lesion D
lesion VBD was O
was JJ resected O
resected IN by O
by JJ video-assisted T
video-assisted JJ thoracoscopic T
thoracoscopic NN surgery T
surgery IN because O
because PRP it O
it VBD was O
was VBN suspected O
suspected IN of O
of VBG being O
being DT a O
a NN lung O
lung NN abscess O
abscess IN that O
that VBD had O
had VBN caused O
caused VBN repeated O
repeated NNS episodes O
episodes IN of O
of NN inflammation O

In IN CAPITAL In O
In DT this O
this NN study O
study , , O
, PRP we O
we VBN investigated O
investigated DT the O
the NN expression O
expression CC and O
and JJ therapeutic O
therapeutic JJ potential O
potential IN of O
of NN CAPITAL TRAIL T
TRAIL IN in O
in NN cholangiocarcinoma D
cholangiocarcinoma , , O
, CD one O
one IN of O
of DT the O
the JJS most O
most VBG devastating O
devastating JJ human O
human JJ hepatic O
hepatic NNS malignancies O

Finally RB CAPITAL Finally O
Finally , , O
, IN in O
in FW vivo O
vivo NN administration O
administration IN of O
of JJ recombinant O
recombinant NN CAPITAL TRAIL T
TRAIL RB substantially O
substantially VBD inhibited O
inhibited JJ subcutaneous O
subcutaneous NN tumor O
tumor NN growth O
growth IN of O
of JJ human O
human NN cholangiocarcinoma D
cholangiocarcinoma NNS cells O

Induction NN CAPITAL Induction O
Induction IN of O
of NN apoptosis O
apoptosis IN in O
in NN tumor O
tumor NNS cells O
cells VBZ is O
is JJ possible O
possible IN with O
with DT a O
a RB biologically O
biologically JJ active O
active NN CAPITAL TRAIL T
TRAIL , , O
, CC and O
and VBZ suggests O
suggests IN that O
that DT this O
this NN cytokine O
cytokine VBZ is O
is DT a O
a JJ promising O
promising JJ antitumor O
antitumor NN agent O
agent IN against O
against JJ human D
human NN cholangiocarcinoma D

Interferon NN CAPITAL Interferon T
Interferon NNS plays O
plays DT a O
a JJ critical O
critical NN role O
role IN in O
in DT the O
the NN host O
host POS 's O
's JJ natural O
natural NN defense O
defense IN against O
against JJ viral D
viral NNS infections D
infections CC and O
and IN in O
in PRP$ their O
their NN treatment O

This DT CAPITAL This O
This NN study O
study VBN investigated O
investigated IN whether O
whether JJ intensive O
intensive NN chemotherapy T
chemotherapy MD might O
might VB have O
have DT a O
a JJ positive O
positive NN effect O
effect IN on O
on NN asthma D
asthma IN in O
in DT these O
these JJ special O
special NNS cases O
cases CC and O
and IN whether O
whether NN asthma O
asthma RB generally O
generally NNS relapses O
relapses IN after O
after NN completion O
completion IN of O
of NN chemotherapy O

The DT CAPITAL The O
The NNS authors O
authors VBN monitored O
monitored JJ clinical O
clinical NN outcome O
outcome CC and O
and NN lung O
lung NN function O
function IN of O
of CD 43 O
43 NNS children O
children IN with O
with JJ acute D
acute JJ lymphoblastic D
lymphoblastic NN leukemia D
leukemia CC and D
and JJ non-Hodgkin D
non-Hodgkin NN lymphoma D
lymphoma WP who O
who VBN received O
received NN chemotherapy T
chemotherapy IN at O
at DT the O
the NNP CAPITAL University O
University NNS CAPITAL Children O
Children POS 's O
's NNP CAPITAL Hospital O
Hospital IN of O
of NNP CAPITAL Greifswald O
Greifswald IN between O
between CD 1993 O
1993 CC and O
and CD 1998 O

She PRP CAPITAL She O
She VBD was O
was VBN diagnosed O
diagnosed IN as O
as JJ miliary D
miliary NN tuberculosis D
tuberculosis CC and O
and VBN treated O
treated IN with O
with JJ antituberculous T
antituberculous NNS drugs T

The DT CAPITAL The O
The NN hemorrhage D
hemorrhage VBD was O
was RB successfully O
successfully VBD stopped O
stopped IN by O
by NN microcoil T
microcoil NN embolization T

Immunomodulatory JJ CAPITAL Immunomodulatory O
Immunomodulatory NNS effects O
effects IN of O
of NN acupuncture T
acupuncture IN in O
in DT the O
the NN treatment O
treatment IN of O
of JJ allergic D
allergic NN asthma D
asthma : : O
: DT a O
a VBN randomized O
randomized JJ controlled O
controlled NN study O

An DT CAPITAL An O
An JJ open-label O
open-label NN study O
study IN of O
of NN lamivudine T
lamivudine IN for O
for JJ chronic D
chronic NN hepatitis D
hepatitis NN CAPITAL B D
B IN in O
in CD six O
six NNS patients O
patients IN with O
with JJ chronic O
chronic JJ renal O
renal NN failure O
failure IN before O
before CC and O
and IN after O
after NN kidney O
kidney NN transplantation O

CONCLUSION NN CAPITAL CONCLUSION O
CONCLUSION : : O
: DT CAPITAL The O
The NN CAPITAL WDTA O
WDTA VBZ is O
is DT an O
an RB intrinsically O
intrinsically VBG motivating O
motivating JJ educational O
educational NN program O
program IN that O
that VBZ has O
has DT the O
the NN ability O
ability TO to O
to NN effect O
effect NNS determinants O
determinants IN of O
of NN asthma D
asthma NN self-management T
self-management NN behavior O
behavior IN in O
in CD 9- O
9- TO to O
to JJ 13-year-old O
13-year-old NNS children O
children IN with O
with NN asthma O

Usefulness NN CAPITAL Usefulness O
Usefulness IN of O
of JJ percutaneous T
percutaneous JJ transhepatic T
transhepatic JJ biliary T
biliary NN drainage T
drainage IN in O
in NNS patients O
patients IN with O
with JJ surgical D
surgical NN jaundice D
jaundice : -- O
-- DT a O
a JJ prospective O
prospective VBN randomised O
randomised NN study O

Neutralization NN CAPITAL Neutralization O
Neutralization IN of O
of NN hepatitis D
hepatitis DT CAPITAL A D
A NN virus D
virus NN ( D
( NN CAPITAL HAV D
HAV NN ) D
) IN by O
by DT an O
an NN immunoadhesin T
immunoadhesin VBG containing T
containing DT the T
the JJ cysteine-rich T
cysteine-rich NN region T
region IN of T
of NN CAPITAL HAV T
HAV JJ cellular T
cellular JJ receptor-1 T

To TO CAPITAL To O
To VB ascertain O
ascertain DT the O
the NNS results O
results IN of O
of JJ standard T
standard NN CAPITAL ABVD T
ABVD NN chemotherapy T
chemotherapy NN ( T
( NN doxorubicin T
doxorubicin , , T
, NN bleomycin T
bleomycin , , T
, NN vinblastine T
vinblastine , , T
, NN dacarbazine T
dacarbazine NN ) T
) IN in O
in JJ CAPITAL HIV-infected O
HIV-infected NNS patients O
patients IN with O
with RB newly D
newly VBN diagnosed D
diagnosed NN CAPITAL Hodgkin D
Hodgkin POS 's D
's NN disease D
disease NN ( D
( NN CAPITAL HD D
HD NN ) D
) , , O
, DT a O
a JJ nonrandomized O
nonrandomized , , O
, JJ prospective O
prospective , , O
, JJ multiinstitutional O
multiinstitutional JJ clinical O
clinical NN trial O
trial VBD was O
was VBN conducted O
conducted IN by O
by DT the O
the NNP CAPITAL AIDS O
AIDS JJ CAPITAL Clinical O
Clinical NNS CAPITAL Trials O
Trials NNP CAPITAL Group O
Group NN ( O
( NN CAPITAL ACTG O
ACTG NN ) O
) , , O
, IN in O
in JJ CAPITAL HIV-infected O
HIV-infected NNS patients O
patients IN with O
with NN CAPITAL Hodgkin O
Hodgkin POS 's O
's NN disease O

The DT CAPITAL The O
The NN effectiveness O
effectiveness IN of O
of NNS glucocorticoids T
glucocorticoids IN in O
in VBG treating O
treating NN croup D
croup : : O
: NN meta-analysis O
meta-analysis NN ( O
( VB see O
see NNS comments O
comments NN ) O

PURPOSE NN CAPITAL PURPOSE O
PURPOSE : : O
: VBN CAPITAL Inhaled O
Inhaled NNS corticosteroids T
corticosteroids VB have O
have JJ beneficial O
beneficial NNS effects O
effects IN on O
on JJ pulmonary O
pulmonary NN function O
function CC and O
and NN inflammation O
inflammation IN in O
in NNS patients O
patients IN with O
with NN asthma D
asthma , , O
, CC but O
but PRP they O
they RB also O
also NN cause O
cause JJ systemic O
systemic JJ adverse O
adverse NNS effects O
effects , , O
, JJ such O
such IN as O
as JJ adrenal O
adrenal NN suppression O

Second JJ CAPITAL Second O
Second , , O
, NNS children O
children IN in O
in DT the O
the RB first O
first NN year O
year IN of O
of NN life O
life VBP are O
are IN at O
at JJS highest O
highest NN risk O
risk IN of O
of NN progression O
progression CC and O
and MD should O
should VB be O
be VBN treated O
treated IN with O
with JJ trimethoprim-sulfamethoxazole T
trimethoprim-sulfamethoxazole TO to O
to VB prevent O
prevent NN CAPITAL Pneumocystis D
Pneumocystis NN carinii D
carinii NN pneumonia D
pneumonia , , O
, CC and O
and VBN targeted O
targeted IN for O
for VBG receiving O
receiving NNS antiretrovirals O

Effectiveness NN CAPITAL Effectiveness O
Effectiveness IN of O
of NN casein T
casein NN hydrolysate T
hydrolysate NNS feedings O
feedings IN in O
in NNS infants O
infants IN with O
with JJ colic D
colic NN ( O
( VB see O
see NNS comments O
comments NN ) O

We PRP CAPITAL We O
We VBP conclude O
conclude IN that O
that JJ antimicrobial/ T
antimicrobial/ JJ antituberculous T
antituberculous NNS agents T
agents VB have O
have RB only O
only DT a O
a JJ minor O
minor JJ short-term O
short-term NN effect O
effect IN in O
in JJ long-lasting O
long-lasting NN CAPITAL CGM D
CGM IN of O
of JJ undetermined O
undetermined NN cause O

The DT CAPITAL The O
The NN patient O
patient VBD had O
had RB previously O
previously VBN been O
been VBN immunized O
immunized IN with O
with CD two O
two NNS doses O
doses IN of O
of NN CAPITAL Hib D
Hib NN conjugate O
conjugate NN vaccine T
vaccine NN ( O
( NN CAPITAL PRP-T O
PRP-T NN ) O

Thus RB CAPITAL Thus O
Thus , , O
, NN s-ECP O
s-ECP VBZ appears O
appears TO to O
to VB be O
be DT a O
a JJ useful O
useful NN marker O
marker IN for O
for VBG determining O
determining WRB when O
when DT a O
a JJ step-down O
step-down IN in O
in NN iBDP T
iBDP NN therapy T
therapy VBZ is O
is VBD indicated O
indicated , , O
, CC and O
and RB thus O
thus MD may O
may VB contribute O
contribute TO to O
to JJ successful O
successful JJ long-term O
long-term NN management O
management IN of O
of JJ chronic D
chronic NN asthma D

Twinrix JJ CAPITAL Twinrix T
Twinrix NN ( O
( NNP CAPITAL SmithKline O
SmithKline NNP CAPITAL Beecham O
Beecham NNS CAPITAL Biologicals O
Biologicals NN ) O
) VBZ is O
is DT a O
a JJ combined O
combined NN hepatitis D
hepatitis DT CAPITAL A D
A CC and D
and NN CAPITAL B D
B NN vaccine T
vaccine JJ licensed O
licensed IN with O
with DT a O
a JJ three-dose O
three-dose NN schedule O

A DT CAPITAL A O
A JJ two-dose O
two-dose JJ combined O
combined NN hepatitis D
hepatitis DT CAPITAL A D
A CC and D
and NN CAPITAL B D
B NN vaccine T
vaccine MD would O
would VB facilitate O
facilitate NN immunisation O
immunisation NNS programs O

Therefore RB CAPITAL Therefore O
Therefore , , O
, PRP it O
it MD can O
can VB be O
be VBD concluded O
concluded IN that O
that IN with O
with CD two O
two NNS injections O
injections IN of O
of DT the O
the JJ high-dose O
high-dose NN hepatitis D
hepatitis DT CAPITAL A D
A CC and D
and NN CAPITAL B D
B NN vaccine T
vaccine , , O
, CD 6 O
6 NNS months O
months RB apart O
apart , , O
, DT a O
a JJ similar O
similar JJ immune O
immune NN response O
response MD can O
can VB be O
be VBN obtained O
obtained IN as O
as VBN induced O
induced IN with O
with CD three O
three NNS doses O
doses IN of O
of JJ CAPITAL Twinrix T
Twinrix IN at O
at NNS months O
months CD 0 O
0 , , O
, CD 1 O
1 CC and O
and CD 6 O

AIM NN CAPITAL AIM O
AIM : : O
: TO CAPITAL To O
To VB assess O
assess DT the O
the NN impact O
impact IN on O
on JJ community-based O
community-based NNS pediatricians O
pediatricians IN of O
of DT the O
the NNS conclusions O
conclusions IN of O
of DT the O
the JJ 10th O
10th NN CAPITAL Conference O
Conference IN de O
de NN CAPITAL Consensus O
Consensus IN en O
en NN CAPITAL Therapeutique O
Therapeutique JJ CAPITAL Anti-Infectieuse O
Anti-Infectieuse NN ( O
( NN CAPITAL CCTAI O
CCTAI NN ) O
) IN on O
on DT the O
the JJ antibiotic T
antibiotic NN treatment T
treatment IN in O
in JJ acute D
acute NN nasopharyngitis D
nasopharyngitis NN ( D
( NN CAPITAL ANP D
ANP NN ) D

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: DT CAPITAL These O
These NNS data O
data , , O
, DT the O
the RB first O
first NN evidence O
evidence IN that O
that JJ chronic O
chronic NN stress O
stress MD can O
can VB inhibit O
inhibit DT the O
the NN stability O
stability IN of O
of DT the O
the NN CAPITAL IgG O
IgG NN antibody O
antibody NN response O
response TO to O
to DT a O
a JJ bacterial T
bacterial NN vaccine T
vaccine IN for O
for NN pneumonia D
pneumonia , , O
, VB provide O
provide JJ additional O
additional NN evidence O
evidence IN of O
of NN health O
health NNS risks O
risks VBN associated O
associated IN with O
with NN dementia O
dementia VBG caregiving O

We PRP CAPITAL We O
We VBN assessed O
assessed DT the O
the NN prevalence O
prevalence IN of O
of NN head O
head NN louse O
louse NN infestation O
infestation CC and O
and DT the O
the NN effectiveness O
effectiveness IN of O
of CD 1 T
1 NN % T
% NN permethrin T
permethrin IN against O
against NN head D
head NN lice D
lice IN in O
in JJ CAPITAL Kosovar O
Kosovar NNS refugees O

Refugees NNS CAPITAL Refugees O
Refugees IN with O
with VBG crawling D
crawling NN lice D
lice VBD were O
were VBN treated O
treated IN with O
with DT a O
a NN pediculicide T
pediculicide VBG containing T
containing CD 1 T
1 NN % T
% NN permethrin T

We PRP CAPITAL We O
We VBP conclude O
conclude IN that O
that CD 1 T
1 NN % T
% NN permethrin T
permethrin NN treatment T
treatment VBD was O
was JJ effective O
effective IN in O
in NN louse D
louse NN control O
control IN in O
in DT this O
this NN refugee O
refugee NN population O

Antibiotics NNS CAPITAL Antibiotics T
Antibiotics IN for O
for FW CAPITAL Salmonella D
Salmonella NN meningitis D
meningitis IN in O
in NNS children O

Four CD CAPITAL Four O
Four NNS patients O
patients VBN developed O
developed JJ mild O
mild NN pancreatitis D
pancreatitis , , O
, CD one O
one VBD had O
had JJ moderate O
moderate NN pancreatitis D
pancreatitis CC and O
and CD one O
one VBD had O
had NN leak O
leak IN of O
of NN contrast O
contrast , , O
, WDT which O
which VBD was O
was VBN treated O
treated IN by O
by NN administration T
administration IN of T
of JJ clear T
clear NNS fluids T
fluids RB orally O
orally IN for O
for CD one O
one NN day O

We PRP CAPITAL We O
We VBN treated O
treated CD two O
two NNS children O
children IN with O
with JJ influenza-associated D
influenza-associated JJ acute D
acute NN encephalopathy D
encephalopathy IN by O
by DT a O
a NN combination T
combination IN of T
of JJ mild T
mild NN hypothermia T
hypothermia CC and T
and NN steroid T
steroid NN pulse T
pulse NN therapy T

Successful JJ CAPITAL Successful O
Successful NN treatment O
treatment IN of O
of JJ anaerobic D
anaerobic JJ pleuropulmonary D
pleuropulmonary NNS infections D
infections VBZ requires O
requires DT a O
a NN combination T
combination IN of T
of JJ antibiotic T
antibiotic NN therapy T
therapy CC and T
and JJ surgical T
surgical NNS interventions T

Treatment NN CAPITAL Treatment O
Treatment IN of O
of JJ spontaneous D
spontaneous JJ carotid-cavernous D
carotid-cavernous NN fistula D
fistula IN in D
in NN CAPITAL Ehlers-Danlos D
Ehlers-Danlos NN syndrome D
syndrome IN by O
by JJ transvenous T
transvenous NN occlusion T
occlusion IN with T
with NNP CAPITAL Guglielmi T
Guglielmi JJ detachable T
detachable NNS coils T

PURPOSE NN CAPITAL PURPOSE O
PURPOSE : : O
: NN CAPITAL Macrolide T
Macrolide NNS antibiotics T
antibiotics VBP are O
are RB frequently O
frequently VBN prescribed O
prescribed TO to O
to NNS patients O
patients IN with O
with NNS symptoms D
symptoms IN of D
of DT a D
a JJ common D
common JJ cold D

Because IN CAPITAL Because O
Because DT the O
the NNS symptoms O
symptoms IN of O
of NN rhinovirus O
rhinovirus NNS colds O
colds VBP are O
are VBN attributed O
attributed TO to O
to DT the O
the JJ inflammatory O
inflammatory NN response O
response TO to O
to NN infection O
infection , , O
, PRP we O
we VBN studied O
studied DT the O
the NNS effects O
effects IN of O
of NN treatment O
treatment IN with O
with NN clarithromycin T
clarithromycin IN on O
on DT the O
the JJ symptomatic O
symptomatic CC and O
and JJ inflammatory O
inflammatory NN response O
response TO to O
to JJ nasal O
nasal NN inoculation O
inoculation IN with O
with NN rhinovirus D

Therapeutic JJ CAPITAL Therapeutic T
Therapeutic NN pneumothorax T
pneumothorax NN ( T
( NN CAPITAL TP T
TP NN ) T
) VBN proved O
proved PRP$ its O
its NN efficacy O
efficacy IN in O
in JJ pre-antibiotic O
pre-antibiotic NN era O
era , , O
, RB so O
so CD one O
one MD can O
can VB assume O
assume IN that O
that PRP it O
it MD can O
can VB be O
be VBN applied O
applied IN with O
with DT the O
the JJ same O
same NN success O
success IN in O
in JJ multidrug D
multidrug JJ resistant D
resistant NN CAPITAL TB D

In IN CAPITAL In O
In NN conclusion O
conclusion , , O
, IN in O
in DT some O
some NNS cases O
cases IN of O
of NN CAPITAL MDR D
MDR NN CAPITAL TB D
TB , , O
, DT the O
the NN CAPITAL TP T
TP NN ( O
( IN if O
if RB there O
there VBP are O
are DT no O
no JJ pleural O
pleural NNS adherences O
adherences NN ) O
) MD may O
may JJ lead O
lead TO to O
to JJ good O
good NNS results O

Acupuncture NN CAPITAL Acupuncture T
Acupuncture NN treatment O
treatment IN of O
of JJ common D
common JJ cold D

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: DT CAPITAL These O
These NNS data O
data , , O
, DT the O
the RB first O
first NN evidence O
evidence IN that O
that JJ chronic O
chronic NN stress O
stress MD can O
can VB inhibit O
inhibit DT the O
the NN stability O
stability IN of O
of DT the O
the NN CAPITAL IgG O
IgG NN antibody O
antibody NN response O
response TO to O
to DT a O
a JJ bacterial T
bacterial NN vaccine T
vaccine IN for O
for NN pneumonia D
pneumonia , , O
, VB provide O
provide JJ additional O
additional NN evidence O
evidence IN of O
of NN health O
health NNS risks O
risks VBN associated O
associated IN with O
with NN dementia O
dementia VBG caregiving O

When WRB CAPITAL When O
When NN bleeding D
bleeding VBZ is O
is VBD stopped O
stopped IN via O
via JJ surgical T
surgical CC or T
or JJ radiological T
radiological NNS methods T
methods , , O
, DT the O
the JJ clinical O
clinical NN course O
course IN of O
of JJ hemobilia-associated O
hemobilia-associated NN pancreatitis O
pancreatitis VBZ appears O
appears TO to O
to VB be O
be JJ benign O

A DT CAPITAL A O
A NN case O
case IN of O
of JJ biliary D
biliary NN stenosis D
stenosis IN in O
in JJ polycystic O
polycystic NN liver O
liver VBN improved O
improved IN by O
by NN injection T
injection IN of T
of NN minocycline T
minocycline NN hydrochloride T
hydrochloride TO to O
to DT a O
a JJ hepatic O
hepatic NN cyst O

The DT CAPITAL The O
The VBN ruptured D
ruptured NN horn D
horn VBD was O
was VBN excised O
excised IN by O
by NN laparotomy T

Therapy NN CAPITAL Therapy O
Therapy VBN designed O
designed TO to O
to NN control O
control DT the O
the NN efferent D
efferent NN phase D
phase IN of D
of VBN established D
established NN asthma D
asthma IN by O
by VBG augmenting T
augmenting JJ down-regulatory T
down-regulatory NN CAPITAL Th1 T
Th1 VBG counterbalancing T
counterbalancing NNS mechanisms T
mechanisms MD should O
should VB be O
be JJ effective O

All DT CAPITAL All O
All NNS children O
children IN with O
with NN croup D
croup NNS symptoms O
symptoms WP who O
who VB demonstrate O
demonstrate VBN increased O
increased NN work O
work IN of O
of VBG breathing O
breathing IN in O
in DT the O
the NNS clinics O
clinics CC or O
or NN emergency O
emergency NNS departments O
departments MD should O
should VB be O
be VBN treated O
treated IN with O
with NNS glucocorticoids T

Increasing VBG CAPITAL Increasing O
Increasing NN resistance O
resistance IN among O
among DT the O
the JJ common D
common JJ respiratory D
respiratory NNS pathogens D
pathogens VBZ has O
has JJ encouraged O
encouraged NN assessment O
assessment IN of O
of JJ alternative O
alternative NNS agents O
agents , , O
, IN for O
for NN example O
example , , O
, NN levofloxacin T

Unlike IN CAPITAL Unlike O
Unlike JJR earlier O
earlier NNS quinolones O
quinolones , , O
, NN levofloxacin T
levofloxacin VBZ has O
has JJ excellent O
excellent NN activity O
activity IN against O
against NN CAPITAL Streptococcus D
Streptococcus FW pneumoniae D
pneumoniae , , O
, VBG including O
including NNS strains O
strains JJ resistant O
resistant TO to O
to NN penicillin O

Clinical JJ CAPITAL Clinical O
Clinical NNS trials O
trials NN show O
show NN levofloxacin T
levofloxacin TO to O
to VB be O
be IN as O
as JJ effective O
effective IN as O
as NNS cephalosporins O
cephalosporins IN in O
in JJ acute O
acute NN exacerbation O
exacerbation IN of O
of JJ chronic D
chronic NN bronchitis D
bronchitis CC and O
and IN as O
as JJ effective O
effective IN as O
as NN co-amoxiclav O
co-amoxiclav , , O
, NNS cephalosporins O
cephalosporins CC or O
or NN amoxycillin O
amoxycillin IN in O
in JJ community-acquired D
community-acquired NN pneumonia D

Additionally RB CAPITAL Additionally O
Additionally , , O
, JJ epidemiologic O
epidemiologic NN evidence O
evidence IN of O
of DT a O
a JJ marked O
marked NN decline O
decline IN in O
in JJ new O
new NN CAPITAL KS D
KS IN since O
since DT the O
the JJ widespread O
widespread NN use O
use IN of O
of RB highly T
highly JJ active T
active JJ antiretroviral T
antiretroviral NN therapy T
therapy NN ( T
( JJ CAPITAL HAART T
HAART NN ) T
) NNS advocates O
advocates PRP$ its O
its NN use O

A DT CAPITAL A O
A NN field O
field NN study O
study VBD was O
was VBD carried O
carried IN out O
out TO to O
to VB evaluate O
evaluate DT the O
the NN effect O
effect IN of O
of NN vaccination T
vaccination IN against O
against NNS swine D
swine JJ enzootic D
enzootic NN pneumonia D
pneumonia IN in O
in JJ different O
different NN production O
production NNS systems O
systems NN ( O
( JJ closed O
closed CC or O
or JJ one-site O
one-site , , O
, CC and O
and JJ open O
open , , O
, CD two- O
two- CC or O
or JJ three-site O
three-site , , O
, NNS systems O
systems NN ) O

Humoral JJ CAPITAL Humoral O
Humoral JJ immune O
immune NN response O
response IN after O
after NN vaccination T
vaccination IN against O
against NN influenza D
influenza IN in O
in NNS patients O
patients IN with O
with NN breast O
breast NN cancer O

Gingyo-san JJ CAPITAL Gingyo-san T
Gingyo-san CC and O
and PRP$ its O
its NNS components O
components VBD were O
were VBN administered O
administered RB orally O
orally TO to O
to NNS mice O
mice CD 1 O
1 NN day O
day IN before O
before , , O
, RB then O
then CD 1 O
1 CC and O
and CD 4 O
4 NNS days O
days IN after O
after DT the O
the NN inhalation O
inhalation IN of O
of DT a O
a JJ mouse-adopted D
mouse-adopted NN strain D
strain IN of D
of NN influenza D
influenza NN CAPITAL A2 D
A2 NN ( D
( NN CAPITAL H2N2 D
H2N2 NN ) D
) NN virus D

From IN CAPITAL From O
From DT these O
these NNS results O
results JJ CAPITAL Gingyo-san T
Gingyo-san VBD was O
was VBN shown O
shown TO to O
to VB be O
be DT an O
an JJ antiviral O
antiviral NN agent O
agent IN in O
in NNS mice O
mice JJ infected O
infected IN with O
with DT a O
a JJ lethal O
lethal NN amount O
amount IN of O
of DT a O
a JJ mouse-adopted D
mouse-adopted NN strain D
strain IN of D
of NN influenza D
influenza NN CAPITAL A2 D
A2 NN virus D

The DT CAPITAL The O
The NN purpose O
purpose IN of O
of DT the O
the JJ present O
present NN study O
study VBD was O
was TO to O
to VB analyze O
analyze DT the O
the NN association O
association IN of O
of JJ recurrent O
recurrent JJ abdominal O
abdominal NN pain O
pain CC and O
and NNP CAPITAL H. O
H. NN pylori O
pylori NN infection O
infection IN in O
in NNS children O
children CC and O
and TO to O
to VB evaluate O
evaluate DT the O
the NN efficacy O
efficacy IN of O
of JJ antimicrobial T
antimicrobial NN treatment T
treatment IN in O
in NNS patients O
patients IN with O
with NN evidence O
evidence IN of O
of NN infection D

Patients NNS CAPITAL Patients O
Patients IN with O
with NN evidence O
evidence IN of O
of NN infection D
infection IN with D
with NN CAPITAL H. D
H. NN pylori D
pylori VBD were O
were VBN treated O
treated IN with O
with DT a O
a NN combination T
combination IN of T
of NN omeprazole T
omeprazole , , T
, NNP amoxicillin T
amoxicillin , , T
, CC and T
and NN clarithromycin T

Treatment NN CAPITAL Treatment O
Treatment IN with O
with NN omeprazole T
omeprazole , , T
, NNP amoxicillin T
amoxicillin , , T
, CC and T
and NN clarithromycin T
clarithromycin VBD resulted O
resulted IN in O
in NN eradication O
eradication IN of O
of DT the O
the NN infection D
infection IN in O
in DT all O
all CC and O
and IN in O
in NN resolution O
resolution IN of O
of DT the O
the JJ clinical O
clinical NNS symptoms O
symptoms IN in O
in CD 15 O
15 NN ( O
( CD 80 O
80 NN % O
% NN ) O
) IN of O
of CD 19 O
19 NNS patients O
patients WP who O
who VBD had O
had DT a O
a JJ follow-up O
follow-up NN examination O

A DT CAPITAL A O
A VBN combined T
combined NN therapy T
therapy NNS results O
results IN in O
in NN eradication O
eradication IN of O
of DT the O
the NN bacterium D
bacterium CC and O
and IN in O
in NN improvement O
improvement IN of O
of DT the O
the JJ clinical O
clinical NNS symptoms O
symptoms IN in O
in DT a O
a JJ significant O
significant NN majority O
majority IN of O
of DT the O
the NNS patients O

In IN CAPITAL In O
In JJ certain O
certain JJ clinical O
clinical NNS settings O
settings , , O
, JJ interventional T
interventional JJ radiologic T
radiologic NNS procedures T
procedures VB have O
have VBN become O
become DT an O
an JJ important O
important JJ alternative O
alternative TO to O
to NN surgery O
surgery IN in O
in DT the O
the NN treatment O
treatment IN of O
of NNS gallstones D
gallstones CC and O
and PRP$ their O
their NNS complications O
complications : ; O
; NNS techniques O
techniques VBP include O
include JJ percutaneous T
percutaneous NN cholecystostomy T
cholecystostomy CC and T
and NN gallstone T
gallstone NN removal T

BACKGROUND NN CAPITAL BACKGROUND O
BACKGROUND : : O
: DT CAPITAL The O
The NN administration O
administration IN of O
of NN salbutamol T
salbutamol VBZ is O
is VBN permitted O
permitted RB only O
only IN by O
by NN inhalation O
inhalation IN by O
by DT the O
the NNP CAPITAL International O
International NNP CAPITAL Olympic O
Olympic NNP CAPITAL Committee O
Committee NN ( O
( NNP CAPITAL IOC O
IOC NN ) O
) IN for O
for DT the O
the NN management O
management IN of O
of NN asthma D
asthma CC and D
and JJ exercise-induced D
exercise-induced NN asthma D
asthma IN in O
in NNS athletes O

Urine NN CAPITAL Urine O
Urine VBD was O
was RB also O
also VBN obtained O
obtained IN from O
from NNS subjects O
subjects WP who O
who VBD had O
had VBN received O
received DT the O
the NN maximum O
maximum NN dosage O
dosage IN of O
of VBN inhaled O
inhaled NN salbutamol T
salbutamol JJ advisable O
advisable IN for O
for VBG competing O
competing NNS athletes O
athletes TO to O
to VB provide O
provide NN protection O
protection IN from O
from JJ exercise-induced O
exercise-induced NN asthma O
asthma CC and O
and NN treatment O
treatment IN of O
of NN asthma D
asthma NN ( O
( CD 1600 O
1600 NN microg O
microg IN in O
in CD 24 O
24 NN h O
h , , O
, CD 800 O
800 NN microg O
microg VBG being O
being IN in O
in DT the O
the JJ last O
last CD 4 O
4 NN h O
h NN ) O

Antimicrobials NNS CAPITAL Antimicrobials T
Antimicrobials VBD were O
were VBN prescribed O
prescribed TO to O
to CD 175 O
175 NN ( O
( CD 83.73 O
83.73 IN per O
per NN cent O
cent NN ) O
) NNS patients O
patients IN with O
with JJ common D
common JJ cold D
cold CC and O
and CD 78 O
78 NN ( O
( CD 82.11 O
82.11 IN per O
per NN cent O
cent NN ) O
) NNS patients O
patients IN with O
with NN diarrhea D

OBJECTIVE NN CAPITAL OBJECTIVE O
OBJECTIVE : : O
: TO to O
to VB evaluate O
evaluate DT the O
the JJ possible O
possible NN existence O
existence IN of O
of DT the O
the JJ so-called O
so-called JJR < O
< NN CAPITAL Roux-en-Y O
Roux-en-Y NN syndrome O
syndrome JJR > O
> IN in O
in DT a O
a NN group O
group IN of O
of CD 21 O
21 NNS patients O
patients WP who O
who VBD underwent O
underwent NN surgery T
surgery TO to O
to JJ correct O
correct JJ postoperative D
postoperative NN alkaline D
alkaline NN reflux D
reflux NN gastritis D

All DT CAPITAL All O
All VBD had O
had VBN undergone O
undergone JJ CAPITAL Billroth T
Billroth NNP CAPITAL II T
II JJ subtotal T
subtotal NN gastrectomy T
gastrectomy NN ( O
( CD 20 O
20 IN for O
for NN ulcer D
ulcer CC and O
and CD 1 O
1 IN for O
for JJ gastric D
gastric NN cancer D
cancer NN ) O

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: PRP we O
we VBN found O
found DT no O
no NN evidence O
evidence IN of O
of NNS disturbances O
disturbances IN in O
in JJ gastric O
gastric NN remnant O
remnant VBG emptying O
emptying IN after O
after JJ CAPITAL Roux-en-Y T
Roux-en-Y NN gastrojejunostomy T
gastrojejunostomy TO to O
to VB treat O
treat JJ postoperative D
postoperative NN alkaline D
alkaline JJ gastric D
gastric NN reflux D

BACKGROUND NN CAPITAL BACKGROUND O
BACKGROUND : : O
: NN CAPITAL Drainage O
Drainage NNS methods O
methods IN for O
for DT the O
the JJ gastric O
gastric NN conduit O
conduit IN after O
after NN esophagectomy T
esophagectomy IN for O
for NN carcinoma D
carcinoma VB have O
have VBN been O
been JJ controversial O

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: DT CAPITAL This O
This NN study O
study VBZ indicates O
indicates IN that O
that DT the O
the NN use O
use IN of O
of DT a O
a JJ computerized O
computerized NN physician O
physician NN reminder O
reminder CC and O
and DT a O
a VBN mailed O
mailed NN patient O
patient NN reminder O
reminder VBD had O
had DT a O
a JJ positive O
positive NN impact O
impact IN on O
on NN influenza D
influenza NNS immunizations T
immunizations IN for O
for JJR older O
older NNS adults O
adults IN in O
in DT a O
a JJ large O
large NN family O
family NN practice O
practice NN office O

Contemporary NNP CAPITAL Contemporary O
Contemporary NN asthma O
asthma NN management O
management NNS guidelines O
guidelines NN list O
list VBN inhaled T
inhaled NNS corticosteroids T
corticosteroids IN as O
as DT the O
the VBN preferred O
preferred NN controller O
controller NN medication O
medication IN for O
for NNS patients O
patients IN with O
with JJ persistent D
persistent NN asthma D

Fluticasone NN CAPITAL Fluticasone T
Fluticasone NN propionate T
propionate VBZ is O
is CD one O
one IN of O
of JJ several O
several VBN inhaled O
inhaled NNS corticosteroids O
corticosteroids VBN used O
used IN for O
for DT the O
the NN treatment O
treatment IN of O
of NN asthma D

A DT CAPITAL A O
A NN series O
series IN of O
of JJ comparative O
comparative NNS analyses O
analyses NN show O
show IN that O
that VBN inhaled T
inhaled NN fluticasone T
fluticasone NN propionate T
propionate VBZ is O
is RBR more O
more NN cost O
cost JJ effective O
effective IN than O
than JJ oral O
oral NN zafirlukast O
zafirlukast CC and O
and NN triamcinolone O
triamcinolone NN acetonide O
acetonide CC and O
and RB slightly O
slightly RBR more O
more NN cost O
cost JJ effective O
effective IN than O
than NN flunisolide O
flunisolide IN in O
in JJ adult O
adult NNS patients O
patients IN with O
with NN asthma D

Quality-of-life JJ CAPITAL Quality-of-life O
Quality-of-life NNS assessments O
assessments IN in O
in NNS patients O
patients IN with O
with JJ mild O
mild TO to O
to JJ moderate O
moderate NN disease O
disease NN show O
show IN that O
that VBN inhaled T
inhaled NN fluticasone T
fluticasone NN propionate T
propionate VBN achieved O
achieved NNS improvements O
improvements WDT which O
which VBD were O
were VBD deemed O
deemed TO to O
to VB be O
be RB clinically O
clinically JJ meaningful O
meaningful IN in O
in NNS patients O
patients IN with O
with JJ mild O
mild TO to O
to JJ moderate O
moderate NN asthma D
asthma : ; O
; DT these O
these NNS changes O
changes VBD were O
were RB significantly O
significantly JJR greater O
greater IN than O
than DT those O
those VBN achieved O
achieved IN with O
with JJ oral O
oral NN zafirlukast O
zafirlukast , , O
, VBN inhaled O
inhaled NN triamcinolone O
triamcinolone NN acetonide O
acetonide CC or O
or NN placebo O

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: IN CAPITAL In O
In NN addition O
addition TO to O
to DT the O
the JJ considerable O
considerable NN body O
body IN of O
of JJ clinical O
clinical NN evidence O
evidence VBG supporting O
supporting DT the O
the NN use O
use IN of O
of VBN inhaled T
inhaled NN fluticasone T
fluticasone NN propionate T
propionate IN in O
in NNS patients O
patients IN with O
with NN asthma D
asthma , , O
, VBG accumulating O
accumulating JJ short O
short NN term O
term NN cost-effectiveness O
cost-effectiveness NNS data O
data RB also O
also VBP suggest O
suggest IN that O
that DT this O
this NN agent O
agent MD can O
can VB be O
be VBN administered O
administered IN for O
for DT a O
a JJ similar O
similar CC or O
or JJR lower O
lower NN cost O
cost IN per O
per NN outcome O
outcome IN than O
than JJ other O
other VBN inhaled O
inhaled NNS corticosteroids O
corticosteroids CC or O
or JJ oral O
oral NN zafirlukast O

Importantly RB CAPITAL Importantly O
Importantly , , O
, DT the O
the JJ clinical O
clinical NNS benefits O
benefits VBN offered O
offered IN by O
by NN fluticasone T
fluticasone NN propionate T
propionate IN in O
in NNS patients O
patients IN with O
with JJ persistent D
persistent NN asthma D
asthma VBP are O
are VBN accompanied O
accompanied IN by O
by RB clinically O
clinically JJ significant O
significant NNS improvements O
improvements IN in O
in NN quality O
quality IN of O
of NN life O

OBJECTIVE NN CAPITAL OBJECTIVE O
OBJECTIVE : : O
: TO CAPITAL To O
To VBP describe O
describe DT the O
the NN effect O
effect IN of O
of NN influenza D
influenza NN vaccination T
vaccination IN on O
on JJ long-term O
long-term NN change O
change IN in O
in NN CAPITAL CD4 O
CD4 NN count O
count CC and O
and NN CAPITAL HIV O
HIV NN CAPITAL RNA O
RNA NN level O
level , , O
, CC and O
and IN on O
on NN progression O
progression TO to O
to NNP CAPITAL AIDS O
AIDS CC or O
or NN death O

Combination NN CAPITAL Combination T
Combination NN therapy T
therapy IN with T
with NN interferon-alpha T
interferon-alpha NN ( T
( NN CAPITAL IFN T
IFN NN alpha T
alpha NN ) T
) CC plus T
plus NNP CAPITAL Ribavirin T
Ribavirin VBZ has O
has VBN been O
been VBN shown O
shown TO to O
to VB improve O
improve DT the O
the NN response O
response NN rate O
rate IN in O
in NNS patients O
patients IN with O
with JJ chronic D
chronic NN hepatitis D
hepatitis NN CAPITAL C D
C IN as O
as VBN compared O
compared TO to O
to NN CAPITAL IFN O
IFN NN alpha O
alpha RB alone O

To TO CAPITAL To O
To VB prove O
prove , , O
, IN whether O
whether NNP CAPITAL Ribavirin T
Ribavirin VBZ has O
has DT any O
any JJ additional O
additional NN effect O
effect IN on O
on DT the O
the NN decline O
decline IN of O
of NN hepatitis D
hepatitis NN CAPITAL C D
C NN viremia D
viremia IN during O
during DT the O
the RB first O
first NNS weeks O
weeks IN of O
of NN treatment O
treatment NNS patients O
patients IN with O
with CC and O
and IN without O
without NN combination O
combination NN therapy O
therapy VBD were O
were VBN compared O

In IN CAPITAL In O
In NNS patients O
patients IN with O
with NN combination T
combination NN therapy T
therapy , , O
, DT a O
a RB further O
further NN reduction O
reduction IN of O
of NN viremia D
viremia NN level O
level MD could O
could VB be O
be VBN observed O
observed , , O
, IN whereas O
whereas NN viremia O
viremia NNS levels O
levels IN in O
in NNS patients O
patients IN with O
with NN CAPITAL IFN O
IFN NN alpha O
alpha RB alone O
alone RB slightly O
slightly VBN increased O

Ribavirin NNP CAPITAL Ribavirin T
Ribavirin IN in T
in NN combination T
combination IN with T
with NN CAPITAL IFN T
IFN NN alpha T
alpha VBZ exerts O
exerts DT an O
an JJ additional O
additional JJ anti-viral/immunmodulatory O
anti-viral/immunmodulatory NN effect O
effect WDT which O
which VBZ manifests O
manifests PRP itself O
itself IN in O
in NN phase O
phase CD 2 O
2 IN of O
of NN hepatitis D
hepatitis NN CAPITAL C D
C NN viremia D
viremia NN decline O

Surgical NNP CAPITAL Surgical T
Surgical NN clearance T
clearance IN of O
of NN CAPITAL CBD D
CBD NNS stones D
stones VBD was O
was VBN achieved O
achieved IN in O
in CD 58 O
58 NNS patients O
patients NN ( O
( CD 93.5 O
93.5 NN % O
% : ; O
; NN group O
group NN CAPITAL Ia O
Ia NN ) O

Use NNP CAPITAL Use O
Use IN of O
of NN CAPITAL ES T
ES TO to O
to VB treat O
treat NN CAPITAL CBD D
CBD NNS stones D
stones IN on O
on DT a O
a JJ routine O
routine NN basis O
basis VBD was O
was RB therefore O
therefore RB not O
not VBN found O
found TO to O
to VB be O
be DT any O
any JJR better O
better IN than O
than JJ one-time O
one-time JJ surgical O
surgical NN exploration O

Effect NN CAPITAL Effect O
Effect IN of O
of NN cholecystectomy T
cholecystectomy IN on O
on NN gastroesophageal D
gastroesophageal CC and D
and JJ duodenogastric D
duodenogastric NN reflux D

It PRP CAPITAL It O
It VBZ is O
is VBN suggested O
suggested IN that O
that VBN damaged D
damaged JJ mucosal D
mucosal NNS tissues D
tissues IN with O
with NN CAPITAL AHF T
AHF MD can O
can VB be O
be RB effectively O
effectively VBN compensated O
compensated IN by O
by VBN enhanced O
enhanced NN regeneration O
regeneration NN response O
response JJ due O
due TO to O
to DT an O
an RB adequately O
adequately JJ high O
high NN dose O
dose NN intensity O
intensity , , O
, VBG suggesting O
suggesting DT a O
a JJ possible O
possible NN tolerability O
tolerability NN advantage O
advantage IN for O
for NN CAPITAL AHF O

Minimally RB CAPITAL Minimally O
Minimally JJ invasive O
invasive NN treatment O
treatment IN of O
of NNS abscesses D
abscesses IN by O
by JJ CAPITAL CT-controlled T
CT-controlled NN drainage T
drainage IN with T
with DT a T
a NN basket T
basket NN catheter T
catheter NN system T

PL NN CAPITAL PL T
PL NN granule T
granule VBZ is O
is CD one O
one IN of O
of DT the O
the JJS most O
most JJ common O
common NNS forms O
forms IN of O
of JJ composite O
composite NN medicine O
medicine IN for O
for NNS colds D
colds IN in O
in NNP CAPITAL Japan O
Japan , , O
, VBG including O
including NN acetaminophen O

A DT CAPITAL A O
A JJ 72-year O
72-year JJ old O
old NN man O
man WP who O
who VBD had O
had VBN been O
been VBN prescribed O
prescribed NN amiodarone T
amiodarone IN for O
for RBR more O
more IN than O
than CD one O
one NN year O
year IN before O
before IN for O
for JJ arrhythmogenic D
arrhythmogenic NN right D
right JJ ventricular D
ventricular NN dystrophy D
dystrophy , , O
, RB repeatedly O
repeatedly VBD took O
took NN CAPITAL PL O
PL NNS granules O
granules IN at O
at JJ one-week O
one-week NNS intervals O
intervals IN because O
because IN of O
of VBG sneezing O
sneezing CC and O
and NN fever O

He PRP CAPITAL He O
He VBN needed O
needed JJ mechanical T
mechanical NN ventilation T
ventilation IN for O
for JJ severe D
severe NN hypoxemia D
hypoxemia , , O
, CC but O
but VBN recovered O
recovered IN with O
with NN glucocorticoid T
glucocorticoid NN pulse T
pulse NN therapy T

In IN CAPITAL In O
In DT a O
a JJ follow-up O
follow-up NN study O
study JJ operative O
operative NN risk O
risk , , O
, JJ postoperative O
postoperative JJ functional O
functional NNS disorders O
disorders CC and O
and NN incidence O
incidence IN of O
of JJ anastomotic O
anastomotic NN ( O
( JJ recurrent O
recurrent NN ) O
) NN ulcer O
ulcer IN after O
after JJ partial T
partial NN gastrectomy T
gastrectomy IN with T
with JJ CAPITAL Roux-en-Y T
Roux-en-Y NN gastrojejunostomy T
gastrojejunostomy IN for O
for NN gastroduodenal D
gastroduodenal NN ulcer D
ulcer VBD were O
were VBN evaluated O
evaluated IN in O
in CD 52 O
52 NNS patients O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> IN CAPITAL With O
With NN regard O
regard TO to O
to DT the O
the JJ high O
high NN rate O
rate IN of O
of JJ recurrent D
recurrent NN ulcer D
ulcer JJ CAPITAL Roux-en-Y T
Roux-en-Y NN reconstruction T
reconstruction IN after O
after JJ partial T
partial NN gastrectomy T
gastrectomy IN for O
for JJ primary D
primary NN ulcer D
ulcer NN surgery D
surgery MD should O
should VB be O
be VBN avoided O
avoided CC and O
and NN reconstruction O
reconstruction NNS procedures O
procedures VBN preferred O
preferred , , O
, WDT which O
which NN guarantee O
guarantee JJ duodenogastric O
duodenogastric NN reflux O

OBJECTIVE NN CAPITAL OBJECTIVE O
OBJECTIVE : : O
: DT CAPITAL The O
The NN aim O
aim IN of O
of DT these O
these NNS studies O
studies VBD was O
was TO to O
to VB compare O
compare DT the O
the NNS pharmacokinetics O
pharmacokinetics IN of O
of VBN inhaled T
inhaled NN fluticasone T
fluticasone NN propionate T
propionate NN ( T
( NN CAPITAL FP T
FP NN ) T
) IN after O
after VBN repeated O
repeated NN administration O
administration IN via O
via DT the O
the NNP CAPITAL Diskus O
Diskus CC or O
or NNP CAPITAL Diskhaler O
Diskhaler JJ dry O
dry NN powder O
powder NNS inhalers O
inhalers NN ( O
( NNS CAPITAL DPIs O
DPIs NN ) O
) TO to O
to NNS patients O
patients IN with O
with JJ mild-to-moderate D
mild-to-moderate NN asthma D

CONCLUSION NN CAPITAL CONCLUSION O
CONCLUSION : : O
: IN CAPITAL In O
In NNS patients O
patients IN with O
with NN asthma D
asthma VBG receiving O
receiving VBN repeated T
repeated VBN inhaled T
inhaled NNS doses T
doses IN of T
of NN CAPITAL FP T
FP , , O
, DT the O
the JJ systemic O
systemic NN exposure O
exposure NN ( O
( NN CAPITAL AUC O
AUC NN ) O
) IN after O
after NN inhalation O
inhalation IN from O
from DT the O
the NNP CAPITAL Diskus O
Diskus VBD was O
was JJ similar O
similar TO to O
to IN that O
that IN from O
from DT the O
the NNP CAPITAL Diskhaler O
Diskhaler , , O
, IN with O
with DT no O
no NN difference O
difference IN between O
between DT the O
the NNS CAPITAL DPIs O
DPIs IN in O
in DT the O
the NNS effects O
effects IN on O
on NN cortisol O
cortisol NN suppression O

DATA NNP CAPITAL DATA O
DATA NN CAPITAL SYNTHESIS O
SYNTHESIS : : O
: RB CAPITAL Recently O
Recently , , O
, DT an O
an NN expert O
expert NN panel O
panel IN of O
of DT the O
the NNPS CAPITAL Centers O
Centers IN for O
for NN CAPITAL Disease O
Disease NN CAPITAL Control O
Control CC and O
and NNP CAPITAL Prevention O
Prevention VBN recommended O
recommended NN use O
use IN of O
of RB only O
only CD three O
three IN of O
of CD 16 O
16 JJ systemic T
systemic NNS antibiotics T
antibiotics VBN approved O
approved IN by O
by DT the O
the NNP CAPITAL Food O
Food CC and O
and NN CAPITAL Drug O
Drug NNP CAPITAL Administration O
Administration IN for O
for NN treatment O
treatment IN of O
of NN CAPITAL AOM D
AOM : : O
: NNP amoxicillin T
amoxicillin , , T
, NN cefuroxime T
cefuroxime NN axetil T
axetil , , T
, CC and T
and NN ceftriaxone T

A DT CAPITAL A O
A JJ three-step O
three-step NN treatment O
treatment NN algorithm O
algorithm IN for O
for JJ refractory D
refractory NN CAPITAL AOM D
AOM IN that O
that VBZ employs O
employs NNP amoxicillin T
amoxicillin , , T
, NN trimethoprim/sulfamethoxazole T
trimethoprim/sulfamethoxazole NN ( T
( NN CAPITAL TMP/SMX T
TMP/SMX NN ) T
) , , T
, CC or T
or JJ high-dose T
high-dose JJ amoxicillin/clavulanate T
amoxicillin/clavulanate NN ( T
( VBG depending T
depending IN on T
on DT the T
the RB prior T
prior NN dose T
dose IN of T
of CC and T
and NN adherence T
adherence TO to T
to NNP amoxicillin T
amoxicillin NN therapy T
therapy NN ) T
) , , T
, CC and T
and NN ceftriaxone T
ceftriaxone CC or T
or NN tympanocentesis T
tympanocentesis IN at O
at NNS steps O
steps CD 1 O
1 , , O
, CD 2 O
2 , , O
, CC and O
and CD 3 O
3 , , O
, RB respectively O
respectively , , O
, VBZ appears O
appears JJ rational O
rational CC and O
and JJ cost-effective O

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: NNP CAPITAL Amoxicillin T
Amoxicillin VBZ remains O
remains DT the O
the JJ antibiotic O
antibiotic IN of O
of NN choice O
choice IN for O
for JJ initial O
initial JJ empiric O
empiric NN treatment O
treatment IN of O
of NN CAPITAL AOM D
AOM , , O
, IN although O
although DT the O
the JJ traditional O
traditional NN dosage O
dosage MD should O
should VB be O
be VBN increased O
increased IN in O
in NNS patients O
patients IN at O
at NN risk O
risk IN for O
for JJ drug-resistant O
drug-resistant NNP CAPITAL S. O
S. FW pneumoniae O

We PRP CAPITAL We O
We NN support O
support DT the O
the NN use O
use IN of O
of NN conjugate T
conjugate JJ pneumococcal T
pneumococcal NN vaccine T
vaccine IN per O
per NNS guidelines O
guidelines IN for O
for NN prevention O
prevention IN of O
of NN CAPITAL Raom D
Raom IN from O
from DT the O
the NNP CAPITAL Advisory O
Advisory NNP CAPITAL Committee O
Committee IN on O
on NN CAPITAL Immunization O
Immunization NN CAPITAL Practice O
Practice IN of O
of DT the O
the NNPS CAPITAL Centers O
Centers IN for O
for NN CAPITAL Disease O
Disease NN CAPITAL Control O
Control CC and O
and NNP CAPITAL Prevention O
Prevention , , O
, IN with O
with NN consideration O
consideration VBN given O
given TO to O
to NN influenza D
influenza NN vaccine T
vaccine IN for O
for NNS cases O
cases IN of O
of NN rAOM O
rAOM IN that O
that RB historically O
historically VB worsen O
worsen IN during O
during DT the O
the NN flu O
flu NN season O

This DT CAPITAL This O
This NN model O
model MD can O
can VB be O
be VBN used O
used TO to O
to NN test O
test DT the O
the NN safety O
safety CC and O
and NN efficacy O
efficacy IN of O
of JJ liver-assist T
liver-assist NNS devices T
devices VBN aimed O
aimed IN at O
at VBG temporizing O
temporizing DT the O
the NN detoxification O
detoxification NNS functions O
functions IN of O
of DT the O
the VBG failing D
failing NN liver D

Recent JJ CAPITAL Recent O
Recent JJ major O
major JJ epidemiologic O
epidemiologic NNS trends O
trends IN in O
in JJ bacterial O
bacterial NN meningitis O
meningitis VBP include O
include DT a O
a JJ dramatic O
dramatic NN decline O
decline IN in O
in DT the O
the NN incidence O
incidence IN of O
of NN CAPITAL Haemophilus D
Haemophilus NN influenzae D
influenzae NN meningitis D
meningitis IN since O
since DT the O
the NN introduction O
introduction IN of O
of DT the O
the JJ protein-conjugated T
protein-conjugated NNP CAPITAL H. T
H. NN influenzae T
influenzae NNS vaccines T
vaccines , , O
, CC and O
and DT a O
a JJ worldwide O
worldwide NN increase O
increase IN in O
in NNS infections O
infections IN with O
with JJ antibiotic-resistant O
antibiotic-resistant NNS strains O
strains IN of O
of JJ bacterial O
bacterial NNS pathogens O

dverse NN dverse O
dverse NNS outcomes O
outcomes CC and O
and JJ opioid T
opioid JJ analgesic T
analgesic NN administration T
administration IN in O
in JJ acute D
acute JJ abdominal D
abdominal NN pain D

We PRP CAPITAL We O
We VBN examined O
examined DT the O
the NN remnant O
remnant NN stomach O
stomach IN for O
for NNP CAPITAL H. O
H. NN pylori O
pylori NN infection O
infection IN after O
after NN gastrectomy T
gastrectomy IN for O
for JJ gastric D
gastric NN cancer D
cancer CC or D
or JJ peptic D
peptic NN ulcer D
ulcer IN between O
between NNP CAPITAL October O
October CD 1992 O
1992 CC and O
and NNP CAPITAL July O
July CD 1997 O

The DT CAPITAL The O
The JJ recent O
recent NN introduction O
introduction IN of O
of NNP ribavirin T
ribavirin , , O
, VBN given O
given IN in O
in NN combination O
combination , , O
, VBZ has O
has VBD led O
led TO to O
to DT a O
a JJ re-appraisal O
re-appraisal IN of O
of DT the O
the NN management O
management IN of O
of JJ chronic D
chronic NN hepatitis D
hepatitis NN CAPITAL C D

The DT CAPITAL The O
The JJ current O
current NN report O
report VBZ considers O
considers DT the O
the JJ additional O
additional NN benefit O
benefit IN of O
of NN combination T
combination NN therapy T
therapy NN ( T
( NN interferon T
interferon NN alfa T
alfa CC and T
and NNP ribavirin T
ribavirin NN ) T
) VBN compared O
compared IN with O
with NN monotherapy O
monotherapy NN ( O
( NN interferon O
interferon NN alfa O
alfa RB alone O
alone NN ) O
) IN for O
for DT the O
the NN treatment O
treatment IN of O
of NNS patients O
patients IN with O
with JJ chronic D
chronic NN hepatitis D
hepatitis NN CAPITAL C D

OBJECTIVE NN CAPITAL OBJECTIVE O
OBJECTIVE : : O
: TO CAPITAL To O
To NN review O
review DT the O
the JJ clinical O
clinical NN effectiveness O
effectiveness CC and O
and NN cost-effectiveness O
cost-effectiveness IN of O
of NN combination T
combination NN therapy T
therapy IN with T
with NN interferon T
interferon NN alfa T
alfa CC and T
and NNP ribavirin T
ribavirin IN in O
in NNS patients O
patients IN with O
with JJ chronic D
chronic NN hepatitis D
hepatitis NN CAPITAL C D

Sida NNP CAPITAL Sida T
Sida NN cordifolia T
cordifolia NNP CAPITAL L. T
L. NN ( T
( JJ CAPITAL Malvaceae T
Malvaceae NN ) T
) VBZ is O
is VBN used O
used IN in O
in NN folk O
folk NN medicine O
medicine IN for O
for DT the O
the NN treatment O
treatment IN of O
of NN inflammation D
inflammation IN of D
of DT the D
the JJ oral D
oral NN mucosa D
mucosa , , D
, NN blenorrhea D
blenorrhea , , D
, JJ asthmatic D
asthmatic NN bronchitis D
bronchitis CC and D
and JJ nasal D
nasal NN congestion D

Double-blind JJ CAPITAL Double-blind O
Double-blind JJ placebo-controlled O
placebo-controlled NN trial O
trial IN of O
of NN CAPITAL Mycobacterium T
Mycobacterium JJ vaccae T
vaccae NN immunotherapy T
immunotherapy IN for O
for NN tuberculosis D
tuberculosis IN in O
in NNP CAPITAL KwaZulu O
KwaZulu , , O
, NNP CAPITAL South O
South NNP CAPITAL Africa O
Africa , , O
, CD 1991-97 O

OBJECTIVE NN CAPITAL OBJECTIVE O
OBJECTIVE : : O
: TO CAPITAL To O
To VB evaluate O
evaluate DT the O
the NN efficacy O
efficacy IN of O
of JJ oral T
oral NN tacrolimus T
tacrolimus IN as O
as DT an O
an NN induction O
induction NN agent O
agent IN in O
in JJ steroid-refractory D
steroid-refractory JJ severe D
severe NN colitis D
colitis JJ .Study O
.Study NN design O
design : : O
: JJ CAPITAL Open-label O
Open-label , , O
, JJ multicenter O
multicenter NN trial O
trial IN of O
of JJ oral O
oral NN tacrolimus O
tacrolimus IN in O
in NNS patients O
patients IN with O
with JJ severe O
severe NN colitis O

CONCLUSION NN CAPITAL CONCLUSION O
CONCLUSION : : O
: IN CAPITAL Although O
Although NN tacrolimus T
tacrolimus VBZ is O
is JJ effective O
effective NN induction O
induction NN therapy O
therapy IN for O
for JJ severe D
severe JJ ulcerative D
ulcerative CC or D
or NN CAPITAL Crohn D
Crohn POS 's D
's NN colitis D
colitis , , O
, JJR fewer O
fewer IN than O
than CD 50 O
50 NN % O
% IN of O
of NNS patients O
patients VBN treated O
treated MD will O
will RB successfully O
successfully VB achieve O
achieve DT a O
a JJ long-term O
long-term NN remission O

Cytomegalovirus NN CAPITAL Cytomegalovirus D
Cytomegalovirus NN ( D
( NN CAPITAL CMV D
CMV NN ) D
) NN infection D
infection VBD was O
was CD one O
one IN of O
of DT the O
the JJS most O
most JJ common O
common JJ opportunistic O
opportunistic NNS infections O
infections IN in O
in NNP CAPITAL AIDS O
AIDS NNS patients O
patients , , O
, VBG leading O
leading TO to O
to NN blindness O
blindness CC or O
or JJ life-threatening O
life-threatening NN disease O
disease IN in O
in IN about O
about CD 40 O
40 NN % O
% IN of O
of NNS patients O
patients IN in O
in DT the O
the RB later O
later NNS stages O
stages IN of O
of NNP CAPITAL AIDS O
AIDS IN before O
before RB highly T
highly JJ active T
active JJ antiretroviral T
antiretroviral NN therapy T
therapy NN ( T
( JJ CAPITAL HAART T
HAART NN ) T

New JJ CAPITAL New T
New NNS vaccines T
vaccines VBP are O
are IN under O
under NN study O
study TO to O
to RB further O
further NN control O
control JJ bacterial D
bacterial NN meningitis D

The DT CAPITAL The O
The NN study O
study VBN involved O
involved CD 117 O
117 NNS infants O
infants NN ( O
( VB mean O
mean NN age O
age CD 2.6 O
2.6 NNS months O
months NN ) O
) , , O
, WP who O
who VBN needed O
needed NN hospital T
hospital NN treatment T
treatment IN because O
because IN of O
of NN CAPITAL RSV D
RSV NN bronchiolitis D

According VBG CAPITAL According O
According TO to O
to DT the O
the JJ present O
present NN study O
study PRP it O
it VBZ seems O
seems IN that O
that VBN inhaled T
inhaled NN corticosteroid T
corticosteroid NN treatment T
treatment IN during O
during CC and O
and IN after O
after DT the O
the JJ acute O
acute NN phase O
phase IN of O
of NN infant D
infant NN CAPITAL RSV D
RSV NN bronchiolitis D
bronchiolitis MD may O
may VB have O
have DT a O
a JJ beneficial O
beneficial NN effect O
effect IN on O
on JJ subsequent O
subsequent JJ bronchial O
bronchial VBG wheezing O
wheezing NN tendency O

OBJECTIVE NN CAPITAL OBJECTIVE O
OBJECTIVE : : O
: DT CAPITAL This O
This NN study O
study VBD was O
was VBN designed O
designed TO to O
to VB evaluate O
evaluate DT the O
the NN safety O
safety CC and O
and NN estimate O
estimate DT the O
the NN efficacy O
efficacy IN of O
of JJ oral T
oral NN budesonide T
budesonide IN in O
in NNS patients O
patients IN with O
with JJ primary D
primary VBG sclerosing D
sclerosing NN cholangitis D
cholangitis NN ( D
( NN CAPITAL PSC D
PSC NN ) D

Combined VBN CAPITAL Combined T
Combined NN interferon T
interferon CC and T
and NN lamivudine T
lamivudine NN therapy T
therapy : : O
: VBZ is O
is DT this O
this DT the O
the NN treatment O
treatment IN of O
of NN choice O
choice IN for O
for NNS patients O
patients IN with O
with JJ chronic D
chronic NN hepatitis D
hepatitis NN CAPITAL B D
B NN virus D
virus NN infection D
infection . ? O

She PRP CAPITAL She O
She VBD had O
had VBN been O
been VBG taking O
taking NNP amitriptyline T
amitriptyline CD 75 O
75 NN mg O
mg IN at O
at NN night O
night IN for O
for NN depression D
depression IN for O
for CD four O
four NNS months O
months IN before O
before PRP$ her O
her NN admission O

Side NN CAPITAL Side O
Side NNS effects O
effects IN from O
from NN influenza D
influenza NN vaccination T
vaccination : : O
: NNS differences O
differences IN between O
between VBD returned O
returned CC and O
and JJ random O
random NNS surveys O

OBJECTIVE NN CAPITAL OBJECTIVE O
OBJECTIVE : : O
: TO CAPITAL To O
To NN study O
study DT the O
the NN relationship O
relationship IN between O
between NN interleukin-2 O
interleukin-2 NN ( O
( NN CAPITAL IL-2 O
IL-2 NN ) O
) , , O
, JJ soluble O
soluble NN interleukin-2 O
interleukin-2 NN receptor O
receptor NN ( O
( NN sIL-2R O
sIL-2R NN ) O
) CC and O
and DT the O
the JJ non-and-hypo-responsiveness O
non-and-hypo-responsiveness TO to O
to NN hepatitis D
hepatitis NN CAPITAL B D
B NN vaccine T

We PRP CAPITAL We O
We VBN assessed O
assessed DT the O
the NNS effects O
effects IN of O
of JJ early T
early NN replacement T
replacement NN therapy T
therapy IN with T
with JJ protein-C T
protein-C NN concentrate T
concentrate RB together T
together IN with T
with JJ continuous T
continuous JJ veno-venous T
veno-venous NN haemodiafiltration T
haemodiafiltration CC and O
and JJ conventional O
conventional NN treatment O
treatment IN in O
in NN meningococcaemia D

The DT CAPITAL The O
The NN purpose O
purpose IN of O
of DT this O
this NN study O
study VBD was O
was TO to O
to VB determine O
determine IN if O
if JJ topical T
topical NN CAPITAL DL-alpha-tocopherol T
DL-alpha-tocopherol NN ( T
( NN vitamin T
vitamin NN CAPITAL E T
E NN ) T
) MD could O
could VB reduce O
reduce JJ ultraviolet-induced D
ultraviolet-induced NN damage D
damage TO to D
to DT the D
the NN epidermis D

We PRP CAPITAL We O
We VBN observed O
observed DT the O
the NNS effects O
effects IN of O
of NN cisapride T
cisapride IN in O
in DT the O
the NN management O
management IN of O
of JJ idiopathic D
idiopathic NN constipation D
constipation IN in O
in NNS children O

METHODS NNS CAPITAL METHODS O
METHODS : : O
: CD CAPITAL Thirty-seven O
Thirty-seven NNS children O
children IN with O
with DT a O
a NN history O
history IN of O
of NN constipation D
constipation NN ( O
( NN i.e O
i.e . . O
. , , O
, NN pain O
pain CC and O
and NN difficulty O
difficulty CC or O
or NN delay O
delay IN in O
in NN defecation O
defecation IN for O
for JJR > O
> CD 3 O
3 NNS months O
months NN ) O
) VBD were O
were VBN recruited O
recruited CC and O
and RB randomly O
randomly VBN assigned O
assigned TO to O
to CD 8 O
8 NNS weeks O
weeks IN of O
of NN treatment O
treatment IN with O
with DT either O
either NN cisapride T
cisapride , , O
, CD 0.2 O
0.2 NN mg/kg O
mg/kg CD three O
three NNS times O
times RB daily O
daily , , O
, CC or O
or VBG matching O
matching NN placebo O
placebo IN after O
after DT a O
a JJ 2-week O
2-week NN run-in O
run-in NN period O
period IN in O
in DT a O
a JJ double-blind O
double-blind , , O
, JJ parallel-group O
parallel-group NN study O
study NN design O

Patient NN CAPITAL Patient O
Patient CD 1 O
1 VBD demonstrated O
demonstrated JJ dramatic O
dramatic VBG clearing O
clearing IN of O
of PRP$ his O
his NN CAPITAL MCV D
MCV NNS lesions D
lesions WRB when O
when JJ intravenous T
intravenous NN cidofovir T
cidofovir NN therapy T
therapy VBD was O
was VBD started O
started IN for O
for PRP$ his O
his JJ treatment-resistant D
treatment-resistant JJ bilateral D
bilateral NN CAPITAL CMV D
CMV NN retinitis D
retinitis CC and O
and IN because O
because IN of O
of NN cidofovir T
cidofovir POS 's T
's JJ possible O
possible NN activity O
activity IN against O
against NN CAPITAL MCV D

In IN CAPITAL In O
In NN case O
case CD 2 O
2 , , O
, NN cidofovir T
cidofovir VBD was O
was VBN compounded O
compounded IN as O
as DT a O
a CD 3 O
3 NN % O
% NN cream O
cream IN in O
in DT a O
a NN combination O
combination NN vehicle O
vehicle NN ( O
( JJ CAPITAL Dermovan O
Dermovan NN ) O
) IN for O
for JJ extensive O
extensive JJ facial O
facial NN involvement O
involvement , , O
, CC and O
and JJ complete O
complete NN resolution O
resolution IN of O
of NN CAPITAL MCV D
MCV VBD was O
was VBN seen O
seen IN after O
after CD 1 O
1 NN month O
month IN of O
of NN therapy O

In IN CAPITAL In O
In NN case O
case CD 3 O
3 , , O
, JJ intravenous T
intravenous NN cidofovir T
cidofovir NN therapy T
therapy VBD was O
was VBD started O
started DT both O
both IN for O
for NN CAPITAL CMV D
CMV NN retinitis D
retinitis CC and O
and IN in O
in DT an O
an NN attempt O
attempt TO to O
to JJ clear O
clear CD 90 O
90 NN % O
% JJ facial O
facial NN CAPITAL MCV D
MCV NN involvement O
involvement : ; O
; IN after O
after CD 1 O
1 NN month O
month IN of O
of NN treatment O
treatment , , O
, DT all O
all JJ clinical O
clinical NN evidence O
evidence IN of O
of NN CAPITAL MCV D
MCV VBD had O
had VBN resolved O

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: NNP CAPITAL Cidofovir T
Cidofovir , , O
, DT a O
a NN nucleotide O
nucleotide NN analog O
analog IN of O
of NN deoxycytidine O
deoxycytidine NN monophosphate O
monophosphate , , O
, VBZ appears O
appears TO to O
to VB have O
have VBD contributed O
contributed TO to O
to VBG clearing O
clearing IN of O
of JJ advanced D
advanced NN CAPITAL MCV D
MCV NNS lesions D
lesions IN in O
in DT these O
these CD 3 O
3 NNS patients O
patients , , O
, RB thus O
thus VBG providing O
providing JJ suggestive O
suggestive NN evidence O
evidence IN of O
of JJ clinical O
clinical NN activity O
activity IN against O
against NN CAPITAL MCV D

Controlled VBN CAPITAL Controlled O
Controlled NNS trials O
trials IN of O
of NN cidofovir T
cidofovir NN therapy T
therapy IN for O
for NN CAPITAL MCV D
MCV IN in O
in NNS persons O
persons JJ infected O
infected IN with O
with JJ human O
human NN immunodeficiency O
immunodeficiency NN virus O
virus VBP are O
are VBN warranted O

OBJECTIVE NN CAPITAL OBJECTIVE O
OBJECTIVE : : O
: DT CAPITAL This O
This NN study O
study VBN aimed O
aimed TO to O
to VB determine O
determine DT the O
the NN effect O
effect IN of O
of JJ external T
external NN beam T
beam NN radiation T
radiation NN therapy T
therapy IN on O
on NN choroidal D
choroidal NN neovascularization D
neovascularization NN ( D
( NN CAPITAL CNV D
CNV NN ) D
) JJ secondary O
secondary TO to O
to JJ age-related D
age-related JJ macular D
macular NN degeneration D
degeneration NN ( D
( NN CAPITAL AMD D
AMD NN ) D

Thrombolytic JJ CAPITAL Thrombolytic T
Thrombolytic NN therapy T
therapy VBZ has O
has VBN been O
been VBN accepted O
accepted IN in O
in DT the O
the NN treatment O
treatment IN of O
of JJ acute D
acute JJ myocardial D
myocardial NN infarction D

A DT CAPITAL A O
A NN bolus O
bolus NN infusion O
infusion IN of O
of NN tissue T
tissue NN plasminogen T
plasminogen NN activator T
activator VBD was O
was VBN administered O
administered IN during O
during NNP CAPITAL CPR T
CPR IN in O
in JJ refractory D
refractory JJ ventricular D
ventricular NN fibrillation D
fibrillation NN ( O
( CD two O
two NNS cases O
cases NN ) O
) CC and O
and JJ pulseless D
pulseless JJ ventricular D
ventricular NN tachycardia D
tachycardia NN ( O
( CD one O
one NN case O
case NN ) O

We PRP CAPITAL We O
We VBP conclude O
conclude IN that O
that NN bolus T
bolus JJ thrombolytic T
thrombolytic NNS infusions T
infusions IN during O
during NNP CAPITAL CPR D
CPR MD may O
may VB facilitate O
facilitate JJ spontaneous O
spontaneous NN return O
return IN of O
of NN circulation O
circulation IN in O
in JJ select O
select NNS patients O
patients IN with O
with VBN confirmed D
confirmed JJ acute D
acute JJ myocardial D
myocardial NN infarction D
infarction , , O
, VBN witnessed O
witnessed JJ cardiac D
cardiac NN arrest D
arrest IN in O
in DT the O
the NNP CAPITAL ED O
ED , , O
, CC and O
and JJ refractory D
refractory JJ ventricular D
ventricular NN fibrillation D
fibrillation CC or O
or NN tachycardia D

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NN CAPITAL CASE O
CASE NN CAPITAL SUMMARY O
SUMMARY : : O
: DT CAPITAL A O
A JJ 92-year O
92-year JJ old O
old JJ white O
white NN woman O
woman WP who O
who VBD was O
was VBG receiving O
receiving NN venlafaxine T
venlafaxine IN for O
for NN management O
management IN of O
of NN depression D
depression VBD was O
was VBN found O
found TO to O
to VB have O
have NN hyponatremia O

Touch VB CAPITAL Touch O
Touch NN sensibility O
sensibility VBD was O
was VBN assessed O
assessed IN with O
with NN von O
von NNP CAPITAL Frey O
Frey POS 's O
's NNS monofilaments O
monofilaments IN in O
in DT the O
the NNS breasts O
breasts IN of O
of CD 10 O
10 JJ healthy O
healthy NNS women O
women NN ( O
( NNS controls O
controls NN ) O
) CC and O
and IN of O
of CD 80 O
80 NNS women O
women IN with O
with NN breast D
breast NN cancer D
cancer WP who O
who IN at O
at JJS least O
least CD 1 O
1 NN year O
year RB previously O
previously VBD had O
had VBN undergone O
undergone JJ subcutaneous T
subcutaneous NN mastectomy T
mastectomy CC and O
and JJ immediate O
immediate NN reconstruction O
reconstruction IN with O
with DT a O
a NN prosthesis O

Although IN CAPITAL Although O
Although VBN improved O
improved JJ glycemic T
glycemic JJ control T
control , , O
, NN maintenance O
maintenance IN of O
of JJ normal O
normal NN blood O
blood NN pressure O
pressure , , O
, CC and O
and NN use O
use IN of O
of JJ angiotensin-converting T
angiotensin-converting NN enzyme T
enzyme NNS inhibitors T
inhibitors VBP are O
are JJ important O
important NNS strategies O
strategies TO to O
to VB avoid O
avoid VBG developing O
developing NN microalbuminuria D
microalbuminuria , , O
, JJ dietary O
dietary JJ macronutrient O
macronutrient NN intake O
intake MD may O
may RB also O
also VB play O
play DT a O
a NN role O

Local JJ CAPITAL Local O
Local NN injection O
injection IN of O
of NNS corticosteroids T
corticosteroids IN into O
into JJ refractory O
refractory NN esophageal O
esophageal NNS strictures O
strictures TO to O
to NN decrease O
decrease DT the O
the NN restenosis D
restenosis NN rate O
rate VBZ has O
has VBN been O
been VBN reported O

We PRP CAPITAL We O
We RB systematically O
systematically VBN reviewed O
reviewed DT the O
the NN evidence O
evidence VBG concerning O
concerning DT the O
the NN ability O
ability IN of O
of CD five O
five JJ systemic T
systemic NNS treatments T
treatments TO to O
to VB induce O
induce NN remission O
remission IN in O
in NNS patients O
patients IN with O
with JJ severe D
severe NN psoriasis D
psoriasis : : O
: JJ ultraviolet T
ultraviolet NN CAPITAL B T
B NN ( T
( NN CAPITAL UVB T
UVB NN ) T
) , , O
, JJ photochemotherapy T
photochemotherapy NN ( T
( NN CAPITAL PUVA T
PUVA NN ) T
) , , O
, NN methotrexate T
methotrexate NN ( T
( NN CAPITAL MTX T
MTX NN ) T
) , , O
, NNS retinoids T
retinoids NN ( T
( NNP CAPITAL RET T
RET NN ) T
) CC and O
and NN cyclosporin T
cyclosporin DT CAPITAL A T
A NN ( T
( NN CAPITAL CYA T
CYA NN ) T

Consequently RB CAPITAL Consequently O
Consequently , , O
, JJ parenteral T
parenteral NN nutrition T
nutrition NN ( T
( NN CAPITAL PN T
PN NN ) T
) NNS solutions T
solutions VBN used O
used TO to O
to VB treat O
treat JJ malnourished O
malnourished NNS patients O
patients IN with O
with JJ chronic D
chronic JJ renal D
renal NN failure D
failure RB usually O
usually VBP are O
are JJ prepared O
prepared IN with O
with JJ little O
little NN supplementation O
supplementation IN of O
of DT these O
these NNS cations O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: JJ CAPITAL Malnourished O
Malnourished NNS patients O
patients IN with O
with JJ chronic D
chronic JJ renal D
renal NN failure D
failure VBG receiving O
receiving NN CAPITAL PN T
PN VBP are O
are IN at O
at NN risk O
risk IN of O
of VBG developing O
developing NN electrolyte D
electrolyte NNS abnormalities D
abnormalities , , O
, RB particularly O
particularly NN hypophosphatemia D

PURPOSE NN CAPITAL PURPOSE O
PURPOSE : : O
: PRP CAPITAL We O
We NN report O
report DT a O
a JJ multicenter O
multicenter NN experience O
experience VBG using O
using VBN tubularized T
tubularized VBN incised T
incised NN plate T
plate NN urethroplastym T
urethroplastym IN for O
for JJ proximal D
proximal NN hypospadias D

MATERIALS NNS CAPITAL MATERIALS O
MATERIALS CC CAPITAL AND O
AND NNS CAPITAL METHODS O
METHODS : : O
: IN CAPITAL From O
From NNP CAPITAL August O
August CD 1993 O
1993 TO to O
to NNP CAPITAL December O
December CD 1996 O
1996 VBN tubularized T
tubularized VBN incised T
incised NN plate T
plate JJ urethroplasty T
urethroplasty VBD was O
was VBN performed O
performed IN in O
in CD 27 O
27 NNS boys O
boys CD 6 O
6 NNS months O
months TO to O
to CD 3 O
3 NNS years O
years JJ old O
old IN with O
with JJ mid D
mid NN shaft D
shaft CC and D
and JJ penoscrotal D
penoscrotal NN hypospadias D

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: VBN CAPITAL Tubularized T
Tubularized VBN incised T
incised NN plate T
plate NN surgery T
surgery VBN created O
created DT a O
a JJ functional O
functional NN neourethra O
neourethra RB even O
even IN in O
in JJ penoscrotal D
penoscrotal NN hypospadias D

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: VBN CAPITAL Tubularized T
Tubularized VBN incised T
incised NN plate T
plate JJ urethroplasty T
urethroplasty VBZ is O
is DT a O
a JJ versatile O
versatile NN operation O
operation IN that O
that VBZ corrects O
corrects JJ proximal D
proximal NN hypospadias D
hypospadias NNS defects D
defects IN with O
with JJ few O
few NNS complications O
complications CC and O
and JJ superior O
superior JJ cosmetic O
cosmetic NNS results O

Aortocoronary JJ CAPITAL Aortocoronary T
Aortocoronary NN bypass T
bypass VBG grafting T
grafting VBZ is O
is DT an O
an VBN accepted O
accepted NN procedure O
procedure IN for O
for JJ ischemic D
ischemic NN heart D
heart NN disease D

Immunotherapy NN CAPITAL Immunotherapy T
Immunotherapy IN of O
of NNS mice O
mice IN with O
with VBG preexisting O
preexisting NNS cancers D
cancers IN with O
with NN heat T
heat NN shock T
shock NN protein T
protein NNS preparations T
preparations VBN derived T
derived IN from T
from JJ autologous T
autologous NN cancer T
cancer VBD resulted O
resulted IN in O
in VBN retarded O
retarded NN progression O
progression IN of O
of DT the O
the JJ primary O
primary NN cancer D
cancer , , O
, DT a O
a VBN reduced O
reduced JJ metastatic O
metastatic NN load O
load , , O
, CC and O
and NN prolongation O
prolongation IN of O
of JJ life-span O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> JJ CAPITAL Intrapleural T
Intrapleural NN injection T
injection IN of T
of JJ irradiated T
irradiated NN CAPITAL LLC-IL2 T
LLC-IL2 VBN cured O
cured JJ pre-existing D
pre-existing NN lung D
lung NN CAPITAL LLC D
LLC NNS tumors D
tumors CC and O
and VBN extended O
extended DT the O
the NN survival O
survival IN of O
of DT the O
the NNS mice O
mice CC but O
but VBD did O
did RB not O
not VB affect O
affect NN survival O
survival IN of O
of NNS mice O
mice IN with O
with JJ pre-existing O
pre-existing NN peritoneal D
peritoneal NNS tumors D
tumors CC nor O
nor VBD did O
did PRP it O
it VB affect O
affect DT the O
the NN growth O
growth IN of O
of NN s.c. D
s.c. NNS tumors D

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> JJ CAPITAL Intraperitoneal T
Intraperitoneal NN injection T
injection IN of T
of JJ irradiated T
irradiated NN CAPITAL LLC-IL2 T
LLC-IL2 VBN cured O
cured JJ pre-existing D
pre-existing NN CAPITAL LLC D
LLC NN peritoneal D
peritoneal NNS tumors D
tumors CC and O
and VBN extended O
extended DT the O
the NN survival O
survival IN of O
of DT the O
the NNS mice O
mice CC but O
but VBD did O
did RB not O
not VB affect O
affect NN survival O
survival IN of O
of NNS mice O
mice VBG bearing O
bearing NN lung D
lung NNS tumors D
tumors CC nor O
nor VBD did O
did PRP it O
it VB affect O
affect DT the O
the NN growth O
growth IN of O
of NN s.c. D
s.c. NNS tumors D

Subcutaneous JJ CAPITAL Subcutaneous T
Subcutaneous NN injection T
injection IN of T
of JJ irradiated T
irradiated NN CAPITAL LLC-IL2 T
LLC-IL2 VBD did O
did RB not O
not VB affect O
affect DT the O
the NN growth O
growth IN of O
of VBG preexisting O
preexisting NN s.c. D
s.c. NNS tumors D
tumors CC and O
and RB also O
also VBD did O
did RB not O
not VB improve O
improve NN survival O
survival IN of O
of NNS mice O
mice VBG bearing O
bearing DT the O
the NN lung D
lung CC or D
or NN peritoneal D
peritoneal NNS tumors D

We PRP CAPITAL We O
We VBP describe O
describe JJ such O
such DT an O
an NN event O
event IN in O
in DT a O
a NN man O
man WP who O
who VBD underwent O
underwent JJ allogeneic T
allogeneic NN CAPITAL BMT T
BMT IN for O
for NN CAPITAL APL D
APL IN in O
in JJ second O
second NN relapse O
relapse CC and O
and CD 4 O
4 NNS years O
years RB later O
later VBN presented O
presented IN with O
with JJ testicular O
testicular NN relapse O

Olanzapine JJ CAPITAL Olanzapine T
Olanzapine VBZ is O
is DT an O
an JJ atypical O
atypical JJ antipsychotic O
antipsychotic JJ effective O
effective IN in O
in DT the O
the NN treatment O
treatment IN of O
of JJ schizophrenic D
schizophrenic NNS patients D

After IN CAPITAL After O
After DT a O
a CD 2- O
2- TO to O
to JJ 9-day O
9-day NN placebo O
placebo NN lead-in O
lead-in , , O
, CD 79 O
79 NNS inpatients O
inpatients IN with O
with NN schizophrenia D
schizophrenia VBG according O
according TO to O
to NN CAPITAL DSM-III-R O
DSM-III-R NNS criteria O
criteria VBD were O
were VBN placed O
placed IN on O
on DT an O
an NN olanzapine T
olanzapine NN dosage O
dosage IN of O
of CD 10 O
10 NN mg/day O
mg/day CC or O
or CD 1 O
1 NN mg/day O
mg/day IN for O
for RB up O
up TO to O
to CD 6 O
6 NNS weeks O

Fludarabine NN CAPITAL Fludarabine T
Fludarabine CC and O
and JJ ara-C T
ara-C RB successfully O
successfully VBN eradicated O
eradicated NN bone D
bone NN marrow D
marrow NN disease D
disease IN in O
in CD 16 O
16 IN of O
of CD 27 O
27 NNS patients O
patients NN ( O
( CD 59 O
59 NN % O
% NN ) O
) , , O
, CD 23 O
23 NNS patients O
patients IN of O
of WDT which O
which VBD had O
had VBN been O
been VBN treated O
treated RB previously O
previously IN with O
with JJ high-dose O
high-dose JJ ara-C T

These DT CAPITAL These O
These NNS results O
results VBN verified O
verified DT the O
the JJ synergistic O
synergistic NN effect O
effect NN fludarabine T
fludarabine VBD exhibited O
exhibited IN in O
in VBG augmenting O
augmenting JJ ara-CTP T
ara-CTP NNS concentrations O
concentrations IN in O
in NNS patients O
patients POS ' O
' JJ leukemic O
leukemic NNS blasts O
blasts , , O
, RB thus O
thus VBG improving O
improving DT the O
the JJ clinical O
clinical NN response O
response IN in O
in VBD relapsed D
relapsed JJ pediatric D
pediatric NNS leukemias D

BACKGROUND NN CAPITAL BACKGROUND O
BACKGROUND : : O
: DT CAPITAL The O
The VBG growing O
growing NN use O
use IN of O
of NN heparin T
heparin IN in O
in JJ acute D
acute JJ thrombotic D
thrombotic NNS disorders D
disorders , , O
, VBN coupled O
coupled IN with O
with DT the O
the NN availability O
availability IN of O
of JJ many O
many JJ new O
new JJ antithrombotic T
antithrombotic NNS agents T
agents , , O
, VBZ emphasizes O
emphasizes DT the O
the NN need O
need IN for O
for JJ adequate O
adequate NN characterization O
characterization IN of O
of DT the O
the NN platelet O
platelet NNS effects O
effects IN of O
of DT the O
the JJ various O
various NNS anticoagulants T

METHODS NNS CAPITAL METHODS O
METHODS CC CAPITAL AND O
AND NNS CAPITAL RESULTS O
RESULTS : : O
: NN CAPITAL Platelet O
Platelet NN CAPITAL P-selectin O
P-selectin NN ( O
( NN CAPITAL CD62 O
CD62 NN ) O
) CC and O
and VBN activated O
activated NN CAPITAL GP O
GP NN CAPITAL IIb/IIIa O
IIb/IIIa NN ( O
( NN CAPITAL PAC-1 O
PAC-1 NN ) O
) NN expression O
expression IN on O
on NN platelet O
platelet NN membrane O
membrane VBD was O
was VBN quantified O
quantified IN in O
in JJ whole O
whole NN blood O
blood IN as O
as RB well O
well IN as O
as NN platelet O
platelet NN aggregation O
aggregation IN in O
in JJ platelet-rich O
platelet-rich NN plasma O
plasma IN in O
in CD 43 O
43 NNS patients O
patients IN with O
with JJ unstable D
unstable NN angina D
angina IN before O
before CC and O
and IN during O
during NN treatment O
treatment IN with O
with NN CAPITAL UFH T
UFH CC or O
or NN enoxaparin T

PURPOSE NN CAPITAL PURPOSE O
PURPOSE : : O
: PRP CAPITAL We O
We NN review O
review PRP$ our O
our JJ initial O
initial NN experience O
experience IN with O
with JJ direct T
direct JJ percutaneous T
percutaneous JJ transluminal T
transluminal JJ angioplasty T
angioplasty NN ( T
( NNP CAPITAL PTA T
PTA NN ) T
) IN as O
as DT a O
a NN reperfusion T
reperfusion NN treatment T
treatment IN for O
for JJ acute D
acute NN occlusion D
occlusion IN of D
of DT the D
the JJ middle D
middle JJ cerebral D
cerebral NN artery D

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NN CAPITAL CONCLUSION O
CONCLUSION : : O
: JJ CAPITAL Direct O
Direct NNP CAPITAL PTA O
PTA MD may O
may VB be O
be VBN performed O
performed RB safely O
safely IN as O
as DT an O
an JJ alternative O
alternative TO to O
to JJ thrombolytic O
thrombolytic NN therapy O
therapy IN in O
in NNS patients O
patients IN with O
with JJ acute O
acute NN occlusion O
occlusion IN of O
of DT the O
the JJ middle O
middle JJ cerebral O
cerebral NN artery O
artery WRB when O
when RB early O
early NN CAPITAL CT O
CT NNS findings O
findings CC and/or O
and/or JJ lenticulostriate O
lenticulostriate NN artery O
artery NN involvement O
involvement VBP are O
are JJ present O
present CC or O
or WRB when O
when JJ superselective O
superselective JJ local O
local NN angiography O
angiography NNS shows O
shows DT the O
the NN presence O
presence IN of O
of DT a O
a JJ large O
large NN embolus O
embolus CC or O
or JJ high-grade O
high-grade NN stenosis O

Women NNS CAPITAL Women O
Women VBN randomised O
randomised TO to O
to NN screen-and-treat O
screen-and-treat VBN received O
received JJ appropriate O
appropriate NNS antibiotics T
antibiotics RB only O
only IN if O
if VBG screening O
screening VBN proved O
proved JJ positive O
positive IN for O
for CD one O
one CC or O
or RBR more O
more NN infection D

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> DT CAPITAL A O
A JJ 71-year-old O
71-year-old NN woman O
woman IN with O
with JJ autoimmune O
autoimmune JJ hemolytic O
hemolytic NN anemia O
anemia VBD underwent O
underwent DT an O
an NN emergency O
emergency JJ endocardial T
endocardial NN patch T
patch NN repair T
repair IN for O
for JJ ventricular D
ventricular JJ septal D
septal NN perforation D
perforation IN after O
after JJ acute O
acute JJ myocardial O
myocardial NN infarction O

Use NNP CAPITAL Use O
Use IN of O
of VBN washed T
washed JJ red T
red NN blood T
blood NNS cells T
cells VBD was O
was JJ effective O
effective IN in O
in VBG averting O
averting JJ hemolytic D
hemolytic NN crisis D
crisis IN throughout O
throughout JJ perioperative O
perioperative NN period O

Therefore RB CAPITAL Therefore O
Therefore , , O
, JJ prudent O
prudent NN management O
management CC and O
and NN use O
use IN of O
of VBN washed T
washed JJ red T
red NN blood T
blood NNS cells T
cells NN transfusion T
transfusion MD would O
would VB prevent O
prevent JJ hemolytic D
hemolytic NN aggravation D
aggravation RB even O
even IN in O
in JJ open O
open NN heart O
heart NN surgery O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> PRP CAPITAL We O
We NN report O
report DT a O
a NN case O
case IN of O
of DT a O
a JJ 29-year-old O
29-year-old JJ male O
male JJ chronic O
chronic NN CAPITAL HBV O
HBV NN carrier O
carrier WP who O
who VBN developed O
developed JJ fulminant D
fulminant VBN reactivated D
reactivated NN CAPITAL HBV D
HBV NN infection D
infection VBG following O
following JJ intensive O
intensive NN chemotherapy T
chemotherapy IN for O
for NN stage D
stage NN CAPITAL IVB D
IVB JJ large D
large NN cell D
cell NN CAPITAL B-cell D
B-cell JJ non-Hodgkin D
non-Hodgkin POS 's D
's NN lymphoma D
lymphoma VBN associated O
associated IN with O
with JJ extensive O
extensive JJ central O
central JJ nervous O
nervous NN system O
system CC and O
and NN bone O
bone NN marrow O
marrow NN involvement O

We PRP CAPITAL We O
We VB advise O
advise IN that O
that NN lamivudine T
lamivudine MD should O
should VB be O
be VBN considered O
considered IN during O
during JJ intensive O
intensive NN chemotherapy T
chemotherapy NN treatment T
treatment IN of O
of JJ chronic O
chronic NNS carriers O
carriers IN of O
of NN CAPITAL HBV D

OBJECTIVES NNS CAPITAL OBJECTIVES O
OBJECTIVES : : O
: DT CAPITAL The O
The NN purpose O
purpose IN of O
of DT this O
this NN analysis O
analysis VBD was O
was TO to O
to VB determine O
determine DT the O
the NN influence O
influence IN of O
of DT an O
an JJ additional O
additional NN treatment O
treatment NN delay O
delay JJ inherent O
inherent IN in O
in NN transfer O
transfer TO to O
to DT an O
an NN angioplasty O
angioplasty NN center O
center IN for O
for JJ primary T
primary JJ angioplasty T
angioplasty IN of O
of NNS patients O
patients IN with O
with JJ acute D
acute JJ myocardial D
myocardial NN infarction D
infarction WP who O
who VBP are O
are RB first O
first VBN admitted O
admitted TO to O
to NNS hospitals O
hospitals IN without O
without NN angioplasty O
angioplasty NNS facilities O

BACKGROUND NN CAPITAL BACKGROUND O
BACKGROUND : : O
: JJ CAPITAL Several O
Several VBN randomized O
randomized NNS trials O
trials VB have O
have VBD demonstrated O
demonstrated DT the O
the NNS benefits O
benefits IN of O
of JJ primary T
primary JJ angioplasty T
angioplasty IN in O
in JJ acute D
acute JJ myocardial D
myocardial NN infarction D

We PRP CAPITAL We O
We NN report O
report DT the O
the RB first O
first NN case O
case NN ( O
( TO to O
to PRP$ our O
our NN knowledge O
knowledge NN ) O
) IN of O
of DT an O
an JJ endoscopic T
endoscopic NN removal T
removal IN of O
of DT a O
a NN forehead D
forehead JJ soft D
soft NN tissue D
tissue NN mass D

As IN CAPITAL As O
As DT the O
the NN overview O
overview NNS shows O
shows , , O
, DT both O
both NNS groups O
groups IN of O
of NNS substances O
substances VBP are O
are JJ useful O
useful IN for O
for JJ individualized O
individualized NN treatment O
treatment IN of O
of JJ benign D
benign JJ prostatic D
prostatic NN hyperplasia D
hyperplasia NN ( D
( NNP CAPITAL BPH D
BPH NN ) D
) , , O
, VBN provided O
provided IN that O
that JJ conservative O
conservative JJ pharmacological T
pharmacological NN treatment T
treatment IN of O
of NNP CAPITAL BPH D
BPH VBZ is O
is RB basically O
basically VBN accepted O
accepted CC and O
and IN that O
that DT the O
the NNS patients O
patients POS ' O
' NN quality O
quality IN of O
of NN life O
life VBZ is O
is RB also O
also VBN considered O

The DT CAPITAL The O
The NNS results O
results IN of O
of JJ several O
several JJ clinical O
clinical NNS investigations O
investigations VBD showed O
showed DT the O
the NN efficacy O
efficacy CC and O
and NN safety O
safety IN of O
of NN artichoke T
artichoke NNS extracts T
extracts NN ( T
( NNP CAPITAL Cynara T
Cynara NN scolymus T
scolymus NNP CAPITAL L. T
L. NN ) T
) IN in O
in DT the O
the NN treatment O
treatment IN of O
of JJ hepato-biliary D
hepato-biliary NN dysfunction D
dysfunction CC and D
and JJ digestive D
digestive NNS complaints D
complaints , , O
, JJ such O
such IN as O
as NN sensation O
sensation IN of O
of NN fullness O
fullness , , O
, NN loss D
loss IN of D
of NN appetite D
appetite , , O
, NN nausea D
nausea CC and O
and JJ abdominal D
abdominal NN pain D

Besides IN CAPITAL Besides O
Besides DT the O
the JJ well-known O
well-known JJ nonsteroidal T
nonsteroidal JJ antiinflammatory T
antiinflammatory NNS drugs T
drugs NN ( T
( NN CAPITAL NSAID T
NSAID NN ) T
) IN for O
for DT the O
the NN treatment O
treatment IN of O
of JJ rheumatic D
rheumatic NN pain D
pain JJ herbal T
herbal NN medicine T
medicine MD can O
can RB also O
also VB be O
be VBN applied O
applied RB successfully O

Extracts NNS CAPITAL Extracts O
Extracts IN of O
of DT the O
the JJ secondary O
secondary NNS tubers O
tubers IN of O
of NNP CAPITAL Devil T
Devil POS 's T
's VB CAPITAL Claw T
Claw NN ( T
( NN CAPITAL Harpagophytum T
Harpagophytum NNS procumbens T
procumbens NN ) T
) VBP are O
are VBN recommended O
recommended IN for O
for DT the O
the JJ supportive O
supportive NN treatment O
treatment IN of O
of JJ degenerative D
degenerative JJ painful D
painful NN rheumatism D

High-dose JJ CAPITAL High-dose T
High-dose JJ intravenous T
intravenous NN immunoglobulin T
immunoglobulin NN ( T
( NN hdIVIg T
hdIVIg NN ) T
) VBZ is O
is RB increasingly O
increasingly VBN used O
used TO to O
to VB treat O
treat DT a O
a NN range O
range IN of O
of JJ inflammatory D
inflammatory CC and D
and JJ autoimmune D
autoimmune NNS diseases D

The DT CAPITAL The O
The JJ current O
current JJ dermatological O
dermatological NNS uses O
uses IN of O
of NN hdIVIg T
hdIVIg VBP include O
include DT the O
the NN treatment O
treatment IN of O
of NN dermatomyositis D
dermatomyositis CC and O
and DT the O
the JJ autoimmune D
autoimmune JJ bullous D
bullous NNS disorders D
disorders , , O
, NN epidermolysis D
epidermolysis NN bullosa D
bullosa NN acquisita D
acquisita , , O
, NN pemphigoid D
pemphigoid , , O
, CC and O
and NN pemphigus D

Unfortunately RB CAPITAL Unfortunately O
Unfortunately , , O
, JJ current O
current JJ dermatological O
dermatological NNS uses O
uses IN of O
of NN hdIVIg O
hdIVIg VB have O
have VBN been O
been JJ limited O
limited TO to O
to DT either O
either JJ uncontrolled O
uncontrolled NNS trials O
trials CC or O
or JJ anecdotal O
anecdotal NN case O
case NNS reports O
reports , , O
, IN except O
except IN for O
for DT a O
a JJ single O
single JJ controlled O
controlled NN trial O
trial IN of O
of NN hdIVIg T
hdIVIg IN as O
as JJ adjunctive O
adjunctive NN therapy O
therapy IN in O
in NNS patients O
patients IN with O
with NN dermatomyositis D
dermatomyositis , , O
, WDT which O
which VBN documented O
documented DT a O
a JJ significant O
significant NN benefit O

We PRP CAPITAL We O
We VBP describe O
describe DT a O
a NN technique O
technique IN that O
that VBZ enables O
enables DT the O
the JJ autologous T
autologous NN repair T
repair IN of O
of JJ large D
large NN midline D
midline JJ incisional D
incisional NN hernias D
hernias IN by O
by VBG restoring O
restoring DT the O
the JJ functional O
functional JJ musculoaponeurotic O
musculoaponeurotic NN support O
support IN of O
of DT the O
the JJ abdominal O
abdominal NN wall O

OBJECTIVE NN CAPITAL OBJECTIVE O
OBJECTIVE CC CAPITAL AND O
AND NN CAPITAL IMPORTANCE O
IMPORTANCE : : O
: DT CAPITAL The O
The NN use O
use IN of O
of JJ chronic T
chronic JJ intrathecal T
intrathecal NN morphine T
morphine IN for O
for DT the O
the NN treatment O
treatment IN of O
of JJ intractable D
intractable , , D
, JJ nonmalignant D
nonmalignant NN pain D
pain VBZ is O
is VBG becoming O
becoming RBR more O
more JJ prevalent O

METHODS NNS CAPITAL METHODS O
METHODS : : O
: IN CAPITAL During O
During DT a O
a JJ 19-month O
19-month NN period O
period , , O
, CD seven O
seven NNS children O
children IN with O
with NN empyema D
empyema VBD underwent O
underwent JJ thoracoscopy T

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> PRP CAPITAL We O
We VBP describe O
describe DT a O
a NN patient O
patient IN with O
with RB left D
left JJ cardiac D
cardiac NN herniation D
herniation VBG presenting O
presenting IN after O
after JJ intrapericardial T
intrapericardial JJ pulmonectomy T
pulmonectomy IN for O
for JJ primary D
primary NN lung D
lung NN cancer D

The DT CAPITAL The O
The VBG growing O
growing NN use O
use IN of O
of VBN automated T
automated JJ night-time T
night-time NN dialysis T
dialysis NN ( T
( NN CAPITAL APD T
APD NN ) T
) IN in O
in NN peritoneal D
peritoneal NN dialysis D
dialysis IN over O
over DT the O
the JJ last O
last JJ few O
few NNS years O
years NNS shows O
shows IN that O
that DT this O
this NN method O
method VBZ represents O
represents DT a O
a JJ valid O
valid JJ alternative O
alternative TO to O
to JJ continuous T
continuous JJ ambulatory T
ambulatory JJ peritoneal T
peritoneal NN dialysis T
dialysis NN ( T
( NN CAPITAL CAPD T
CAPD NN ) T

La NNP CAPITAL La O
La NNP CAPITAL Serna O
Serna FW et O
et NNP al O
al . . O
. NN ( O
( NNP CAPITAL Lancet O
Lancet CD 1987 O
1987 : ; O
; CD 26 O
26 : : O
: CD 1517 O
1517 NN ) O
) VBD were O
were DT the O
the RB first O
first TO to O
to VB treat O
treat NNS adults O
adults IN with O
with JJ recurrent D
recurrent NN pericarditis D
pericarditis IN with O
with NN colchicine T
colchicine , , O
, CC and O
and VBD were O
were VBN followed O
followed IN by O
by JJ other O
other NNS authors O

While IN CAPITAL While O
While DT these O
these NNS findings O
findings VBP are O
are VBN observed O
observed IN for O
for DT all O
all NNS classes O
classes IN of O
of JJ oral O
oral NNS drugs O
drugs , , O
, DT the O
the NN issue O
issue VBZ is O
is RB especially O
especially JJ critical O
critical IN for O
for NN cancer D
cancer NN chemotherapy T
chemotherapy , , O
, IN in O
in WDT which O
which DT a O
a JJ narrow O
narrow JJ therapeutic O
therapeutic NN index O
index VBZ is O
is RB frequently O
frequently VBN observed O

Treatment NN CAPITAL Treatment O
Treatment IN for O
for JJ low-grade D
low-grade NN CAPITAL NHL D
NHL IN during O
during DT the O
the JJ past O
past CD 30 O
30 NN yr O
yr VBZ has O
has VBD consisted O
consisted IN of O
of JJ high-dose T
high-dose NN radiation T
radiation CC and O
and JJ cytotoxic T
cytotoxic NNS agents T
agents , , O
, VBN administered O
administered RB alone O
alone CC or O
or IN in O
in NN combination O
combination , , O
, CC and O
and JJ high-dose T
high-dose NN therapy T
therapy IN with T
with NN stem T
stem NN cell T
cell NN transplant T

However RB CAPITAL However O
However , , O
, JJ recent O
recent JJ clinical O
clinical NN use O
use IN of O
of JJ monoclonal T
monoclonal NNS antibodies T
antibodies NN ( T
( NNS mAbs T
mAbs NN ) T
) IN in O
in NNS patients O
patients IN with O
with JJ low-grade D
low-grade CC or D
or VBN transformed D
transformed JJ low-grade D
low-grade NN CAPITAL NHL D
NHL VBZ has O
has VBD resulted O
resulted IN in O
in JJR less O
less NN toxicity O
toxicity IN than O
than JJ conventional O
conventional NNS treatments O
treatments , , O
, IN as O
as RB well O
well IN as O
as NN response O
response NNS rates O
rates IN that O
that VBP are O
are JJ comparable O
comparable CC or O
or JJ superior O
superior TO to O
to DT those O
those VBN achieved O
achieved IN with O
with NN chemotherapy T

Therefore RB CAPITAL Therefore O
Therefore , , O
, NN interest O
interest VBZ is O
is VBG growing O
growing IN in O
in NNS mAbs T
mAbs IN as O
as JJ therapeutic O
therapeutic NNS alternatives O
alternatives IN for O
for NNS patients O
patients IN with O
with JJ low-grade D
low-grade NN CAPITAL NHL D
NHL CC and O
and DT those O
those IN with O
with VBN transformed O
transformed NN histology O

CONCLUSION NN CAPITAL CONCLUSION O
CONCLUSION : : O
: DT CAPITAL The O
The NN treatment O
treatment NN paradigm O
paradigm IN for O
for NN CAPITAL NHL D
NHL VBZ is O
is VBN expected O
expected TO to O
to NN change O
change IN over O
over DT the O
the JJ next O
next JJ few O
few NNS years O
years TO to O
to VBP include O
include VBN radiolabeled T
radiolabeled NNS mAbs T
mAbs , , O
, VBN administered O
administered RB alone O
alone CC or O
or IN in O
in NN combination O
combination IN with O
with JJ cytotoxic T
cytotoxic NNS agents T

RESULTS NNS CAPITAL RESULTS O
RESULTS : : O
: JJ CAPITAL Clinical O
Clinical NNS trials O
trials IN of O
of NNP CAPITAL UFT T
UFT VBN published O
published IN in O
in DT the O
the JJ CAPITAL Western O
Western NN world O
world VB have O
have VBN included O
included CD 581 O
581 NNS patients O
patients IN with O
with JJ colorectal D
colorectal NN cancer D

The DT CAPITAL The O
The NN activity O
activity IN of O
of JJ oral T
oral NNP CAPITAL UFT T
UFT IN in O
in NN large-bowel D
large-bowel NN cancer D
cancer WRB when O
when VBN administered O
administered IN with O
with JJ oral T
oral NN CAPITAL LV T
LV NN ( O
( RB approximately O
approximately CD 50 O
50 NN mg/dose O
mg/dose NN ) O
) VBZ has O
has VBD resulted O
resulted IN in O
in JJ objective O
objective NN response O
response NNS rates O
rates IN of O
of RB approximately O
approximately CD 40 O
40 NN % O

CONCLUSION NN CAPITAL CONCLUSION O
CONCLUSION : : O
: NNP CAPITAL UFT T
UFT VBZ is O
is DT a O
a NN fluoropyrimidine T
fluoropyrimidine JJ active O
active IN in O
in JJ colorectal D
colorectal NN cancer D

BACKGROUND NN CAPITAL BACKGROUND O
BACKGROUND : : O
: NN CAPITAL Adrenalectomy T
Adrenalectomy VBZ is O
is DT the O
the JJ current O
current NN treatment O
treatment IN for O
for NN phaeochromocytoma D

CONCLUSION NN CAPITAL CONCLUSION O
CONCLUSION : : O
: JJ CAPITAL Adrenal-sparing T
Adrenal-sparing NN surgery T
surgery VBZ is O
is JJ safe O
safe CC and O
and JJ effective O
effective , , O
, CC and O
and MD may O
may VBN become O
become DT the O
the NN treatment O
treatment IN of O
of NN choice O
choice IN in O
in NNS patients O
patients IN with O
with JJ hereditary D
hereditary NN phaeochromocytoma D

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NN CAPITAL PURPOSE O
PURPOSE : : O
: DT CAPITAL The O
The NNS purposes O
purposes IN of O
of DT this O
this JJ descriptive O
descriptive , , O
, JJ longitudinal O
longitudinal NN study O
study VBD were O
were TO to O
to VB evaluate O
evaluate DT the O
the NNP CAPITAL MacDibbs O
MacDibbs NN CAPITAL Mouth O
Mouth NNP CAPITAL Assessment O
Assessment NN instrument O
instrument IN for O
for DT the O
the NN assessment O
assessment IN of O
of NN mucositis O
mucositis IN in O
in DT the O
the NN radiation T
radiation NN therapy T
therapy NN patient O
patient VBG being O
being VBN treated O
treated IN for O
for NN head D
head CC and D
and NN neck D
neck NN cancer D
cancer CC and O
and TO to O
to VBP describe O
describe DT the O
the NN course O
course IN of O
of JJ radiation-induced D
radiation-induced NN mucositis D
mucositis IN in O
in DT these O
these NNS patients O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> IN CAPITAL As O
As JJ concomitant D
concomitant NN thrombocytosis D
thrombocytosis VBD persisted O
persisted IN despite O
despite NN treatment O
treatment IN with O
with NN hydroxyurea T
hydroxyurea , , O
, DT the O
the JJ new O
new NN megakaryocyte T
megakaryocyte NN inhibitor T
inhibitor NN anagrelide T
anagrelide NN ( T
( NN CAPITAL Agrelin T
Agrelin NN ) T
) VBD was O
was VBN administered O
administered CC and O
and VBD led O
led TO to O
to NN normalization O
normalization IN of O
of DT the O
the NN platelet O
platelet NN count O
count IN within O
within CD 11 O
11 NNS days O

Background NN CAPITAL Background O
Background : : O
: NN CAPITAL Troglitazone T
Troglitazone VBZ is O
is DT a O
a JJ new O
new NN drug O
drug IN for O
for DT the O
the NN treatment O
treatment IN of O
of NN type D
type LS 2 D
2 NN diabetes D

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> IN CAPITAL For O
For DT a O
a NN subset O
subset IN of O
of NNS patients O
patients IN with O
with NN CAPITAL Kaposi D
Kaposi POS 's D
's NN sarcoma D
sarcoma WP who O
who VBD were O
were VBN treated O
treated IN with O
with JJ recombinant T
recombinant NN interferon T
interferon JJ alfa-2a T
alfa-2a , , O
, DT the O
the NN disease O
disease VBZ is O
is IN in O
in JJ complete O
complete NN remission O
remission , , O
, IN without O
without JJ opportunistic D
opportunistic NN infection D
infection , , O
, CC and O
and PRP they O
they VB appear O
appear TO to O
to VB be O
be JJ culture-negative O
culture-negative IN for O
for DT the O
the JJ etiologic O
etiologic NN retrovirus O
retrovirus IN that O
that NNS causes O
causes PRP$ their O
their JJ immune D
immune NN deficiency D

Interferon NN CAPITAL Interferon T
Interferon JJ alfa-2a T
alfa-2a VBZ appears O
appears TO to O
to VB have O
have JJ antineoplastic O
antineoplastic NN efficacy O
efficacy , , O
, NN ( O
( CC and O
and MD may O
may VB have O
have JJ antiretroviral O
antiretroviral NN efficacy O
efficacy IN as O
as RB well O
well NN ) O
) IN in O
in DT this O
this JJ epidemic O
epidemic NN neoplasm D

In IN CAPITAL In O
In CD three O
three JJ consecutive O
consecutive NN CAPITAL Phase O
Phase NNP CAPITAL II O
II NNS trials O
trials IN of O
of JJ recombinant T
recombinant NN interferon T
interferon JJ alfa-2a T
alfa-2a NN ( O
( NN rIFN O
rIFN JJ alfa-2a O
alfa-2a : ; O
; NN CAPITAL Roferon-A O
Roferon-A NNP CAPITAL Hoffmann-La O
Hoffmann-La NNP CAPITAL Roche O
Roche , , O
, NNP CAPITAL Nutley O
Nutley , , O
, NNP CAPITAL NJ O
NJ NN ) O
) VBG involving O
involving CD 96 O
96 NNS patients O
patients IN with O
with JJ advanced D
advanced JJ malignant D
malignant NN melanoma D
melanoma , , O
, DT an O
an JJ overall O
overall NN response O
response NN rate O
rate IN of O
of CD 22 O
22 NN % O
% VBD was O
was VBN observed O

As IN CAPITAL As O
As JJ single O
single NN agent O
agent NN therapy O
therapy IN in O
in JJ malignant D
malignant NN melanoma D
melanoma , , O
, NN interferon T
interferon JJ alfa-2a T
alfa-2a VBD was O
was RB only O
only RB marginally O
marginally JJ useful O
useful IN in O
in JJS most O
most NNS patients O

Studies NNS CAPITAL Studies O
Studies IN with O
with JJ various O
various NN interferon T
interferon NN alpha T
alpha NNS preparations T
preparations , , O
, VBG including O
including NNS interferons T
interferons VBN induced O
induced IN in O
in JJ human O
human NNS leukocytes O
leukocytes , , O
, NN interferon T
interferon NN alfa-N1 T
alfa-N1 , , O
, NN interferon T
interferon JJ alfa-2a T
alfa-2a , , O
, CC and O
and NN interferon T
interferon JJ alfa-2b T
alfa-2b , , O
, VB have O
have DT all O
all VBN provided O
provided NN evidence O
evidence IN for O
for JJ modest O
modest CC but O
but JJ reproducible O
reproducible JJ antitumor O
antitumor NN activity O
activity IN in O
in JJ advanced D
advanced JJ renal D
renal NN cell D
cell NN carcinoma D

Preliminary JJ CAPITAL Preliminary O
Preliminary NN evidence O
evidence VBZ suggests O
suggests IN that O
that NNS interferons T
interferons NN beta T
beta CC and T
and NN gamma T
gamma MD may O
may RB also O
also VB induce O
induce NN regression O
regression IN of O
of JJ metastatic D
metastatic JJ renal D
renal NN cell D
cell NN carcinoma D

The DT CAPITAL The O
The NN rationale O
rationale IN for O
for JJ antileukemic T
antileukemic NN therapy T
therapy IN in O
in JJ hairy D
hairy NN cell D
cell NN leukemia D
leukemia VBZ is O
is TO to O
to VB reduce O
reduce DT the O
the JJ significant O
significant NN risk O
risk IN of O
of NN infection O
infection CC and O
and JJ other O
other JJ potential O
potential JJ serious O
serious NNS complications O

Splenectomy NN CAPITAL Splenectomy T
Splenectomy RB presumably O
presumably VBZ alleviates O
alleviates DT the O
the JJ pancytopenic O
pancytopenic NN effect O
effect IN of O
of NN hypersplenism D
hypersplenism IN by O
by VBG removing O
removing DT the O
the VBN preferred O
preferred NN site O
site IN of O
of JJ leukemic O
leukemic NN cell O
cell NN proliferation O

Recombinant JJ CAPITAL Recombinant O
Recombinant CC and O
and JJ natural O
natural NNS forms O
forms IN of O
of NN interferon T
interferon NN alpha T
alpha VB have O
have VBN been O
been VBN shown O
shown TO to O
to VB bring O
bring IN about O
about NN tumor O
tumor NNS regressions O
regressions IN in O
in NNS patients O
patients IN with O
with JJ low-grade D
low-grade JJ non-Hodgkin D
non-Hodgkin POS 's D
's NN lymphoma D

Current JJ CAPITAL Current O
Current NNS studies O
studies VBG using O
using NN interferon T
interferon IN in O
in NNS patients O
patients IN with O
with JJ low-grade D
low-grade JJ non-Hodgkin D
non-Hodgkin POS 's D
's NNS lymphomas D
lymphomas VBP are O
are VBG evaluating O
evaluating JJR lower O
lower , , O
, CC and O
and RB perhaps O
perhaps JJR better O
better VBN tolerated O
tolerated NNS doses O
doses IN of O
of NN interferon T

This DT CAPITAL This O
This NN approach O
approach VBZ is O
is VBG being O
being VBN extended O
extended TO to O
to DT the O
the NN clinic O
clinic , , O
, CC and O
and NNS trials O
trials VBP are O
are RB now O
now NN underway O
underway VBG evaluating O
evaluating NNS combinations O
combinations IN of O
of NN interferon T
interferon CC and O
and JJ various O
various JJ cytotoxic T
cytotoxic NNS drugs T
drugs JJ known O
known IN from O
from JJ previous O
previous NNS studies O
studies TO to O
to VB be O
be JJ active O
active IN in O
in NNS patients O
patients IN with O
with JJ low-grade D
low-grade JJ non-Hodgkin D
non-Hodgkin POS 's D
's NNS lymphomas D

While IN CAPITAL While O
While DT the O
the VBD demonstrated O
demonstrated JJ antiviral O
antiviral , , O
, JJ antiproliferative O
antiproliferative , , O
, CC and O
and JJ immunomodulatory O
immunomodulatory NNS properties O
properties IN of O
of NNS interferons T
interferons VB have O
have VBD led O
led TO to O
to DT a O
a NN number O
number IN of O
of NNS theories O
theories VBG regarding O
regarding PRP$ their O
their JJ potential O
potential NN use O
use IN in O
in VBG treating O
treating NNS individuals O
individuals IN with O
with JJ chronic D
chronic JJ myelogenous D
myelogenous NN leukemia D
leukemia NN ( D
( NN CAPITAL CML D
CML NN ) D
) , , O
, PRP$ their O
their JJ limited O
limited NN availability O
availability VBZ has O
has VBD prevented O
prevented JJ thorough O
thorough JJ clinical O
clinical NN investigation O

The DT CAPITAL The O
The NNS data O
data VBG resulting O
resulting IN from O
from DT these O
these JJ clinical O
clinical NNS trials O
trials VBP indicate O
indicate IN that O
that NN interferon T
interferon JJ alfa-2a T
alfa-2a VBZ is O
is JJ effective O
effective IN in O
in VBG inducing O
inducing JJ hematologic O
hematologic NNS remissions O
remissions IN in O
in DT the O
the NN majority O
majority IN of O
of RB minimally O
minimally VBN treated O
treated , , O
, NN benign-phase D
benign-phase NN CAPITAL CML D
CML , , O
, JJ CAPITAL Ph1-positive O
Ph1-positive NNS patients O

More RBR CAPITAL More O
More IN than O
than CD 1600 O
1600 NNS patients O
patients IN with O
with JJ neoplastic D
neoplastic NNS disorders D
disorders VB have O
have VBN received O
received JJ recombinant T
recombinant JJ human T
human NN interferon T
interferon JJ alfa-2a T
alfa-2a NN ( T
( NN CAPITAL Roferon-A T
Roferon-A , , T
, NNP CAPITAL Hoffmann-La T
Hoffmann-La NNP CAPITAL Roche T
Roche , , T
, NNP CAPITAL Nutley T
Nutley , , T
, NNP CAPITAL NJ T
NJ NN ) T
) IN as O
as NN part O
part IN of O
of JJ ongoing O
ongoing CC or O
or VBN completed O
completed JJ clinical O
clinical NNS trials O

PURPOSE NN CAPITAL PURPOSE O
PURPOSE : : O
: DT CAPITAL A O
A NN phase O
phase CD CAPITAL I/II O
I/II NN trial O
trial IN of O
of NN docetaxel T
docetaxel , , O
, NN cisplatin T
cisplatin , , O
, NN fluorouracil T
fluorouracil NN ( T
( JJ 5-FU T
5-FU NN ) T
) , , O
, CC and O
and NN leucovorin T
leucovorin NN ( T
( NN CAPITAL TPFL5 T
TPFL5 NN ) T
) NN induction T
induction NN chemotherapy T
chemotherapy IN for O
for NNS patients O
patients IN with O
with RB locally D
locally JJ advanced D
advanced JJ squamous D
squamous NN cell D
cell NN carcinoma D
carcinoma IN of D
of DT the D
the NN head D
head CC and D
and NN neck D
neck NN ( D
( NN CAPITAL SCCHN D
SCCHN NN ) D

PATIENTS NNS CAPITAL PATIENTS O
PATIENTS CC CAPITAL AND O
AND NNS CAPITAL METHODS O
METHODS : : O
: CD CAPITAL Twenty-three O
Twenty-three RB previously O
previously JJ untreated O
untreated NNS patients O
patients IN with O
with NN stage D
stage NNP CAPITAL III D
III CC or D
or CD CAPITAL IV D
IV NN CAPITAL SCCHN D
SCCHN CC and O
and NNP CAPITAL Eastern O
Eastern NNP CAPITAL Cooperative O
Cooperative NNP CAPITAL Oncology O
Oncology NNP CAPITAL Group O
Group JJ functional O
functional NN status O
status JJR less O
less IN than O
than CC or O
or JJ equal O
equal TO to O
to CD 2 O
2 VBD were O
were VBN treated O
treated IN with O
with NN CAPITAL TPFL5 T

Intrathecal JJ CAPITAL Intrathecal T
Intrathecal NN sufentanil T
sufentanil VBZ provides O
provides RB approximately O
approximately CD 2 O
2 NN h O
h IN of O
of JJ excellent O
excellent NN labor D
labor NN analgesia O
analgesia IN with O
with JJ minimal O
minimal NN motor O
motor NN blockade O

OBJECTIVE NN CAPITAL OBJECTIVE O
OBJECTIVE : : O
: PRP CAPITAL We O
We NN report O
report DT the O
the NNS results O
results IN of O
of DT a O
a JJ double-blind O
double-blind , , O
, JJ double-dummy O
double-dummy , , O
, JJ active-control O
active-control NN study O
study VBN designed O
designed TO to O
to VB evaluate O
evaluate DT the O
the NN efficacy O
efficacy CC and O
and NN safety O
safety IN of O
of NN lamotrigine T
lamotrigine NN ( T
( NN CAPITAL LTG T
LTG NN ) T
) VBN administered O
administered IN as O
as NN monotherapy O
monotherapy TO to O
to JJ adult O
adult NNS outpatients O
outpatients IN with O
with JJ partial D
partial NNS seizures D

BACKGROUND NN CAPITAL BACKGROUND O
BACKGROUND : : O
: DT CAPITAL The O
The NN effectiveness O
effectiveness IN of O
of NN CAPITAL LTG T
LTG IN as O
as JJ add-on O
add-on NN therapy O
therapy IN for O
for JJ partial D
partial NNS seizures D
seizures IN in O
in NNS adults O
adults VBZ has O
has RB previously O
previously VBN been O
been VBN established O

CONCLUSIONS NNS CAPITAL CONCLUSIONS O
CONCLUSIONS : : O
: PRP CAPITAL We O
We VBP conclude O
conclude IN that O
that NN CAPITAL LTG T
LTG VBZ is O
is JJ effective O
effective CC and O
and RB well O
well VBN tolerated O
tolerated WRB when O
when VBN administered O
administered IN as O
as NN monotherapy O
monotherapy IN in O
in JJ adult O
adult NNS patients O
patients IN with O
with JJ partial D
partial NNS seizures D

BACKGROUND NN CAPITAL BACKGROUND O
BACKGROUND : : O
: NN CAPITAL Omega3 O
Omega3 JJ fatty O
fatty NNS acids O
acids MD may O
may VB inhibit O
inhibit JJ neuronal O
neuronal NN signal O
signal NN transduction O
transduction NNS pathways O
pathways IN in O
in DT a O
a NN manner O
manner JJ similar O
similar TO to O
to IN that O
that IN of O
of NN lithium T
lithium NN carbonate T
carbonate CC and O
and NN valproate T
valproate , , O
, CD 2 O
2 JJ effective O
effective NNS treatments O
treatments IN for O
for JJ bipolar D
bipolar NN disorder D

The DT CAPITAL The O
The JJ present O
present NN study O
study VBD was O
was VBN performed O
performed TO to O
to VB examine O
examine IN whether O
whether NN omega3 T
omega3 JJ fatty T
fatty NNS acids T
acids RB also O
also NN exhibit O
exhibit JJ mood-stabilizing O
mood-stabilizing NNS properties O
properties IN in O
in JJ bipolar D
bipolar NN disorder D

CONCLUSION NN CAPITAL CONCLUSION O
CONCLUSION : : O
: NN CAPITAL Omega3 T
Omega3 JJ fatty T
fatty NNS acids T
acids VBD were O
were RB well O
well VBN tolerated O
tolerated CC and O
and VBN improved O
improved DT the O
the JJ short-term O
short-term NN course O
course IN of O
of NN illness O
illness IN in O
in DT this O
this JJ preliminary O
preliminary NN study O
study IN of O
of NNS patients O
patients IN with O
with JJ bipolar D
bipolar NN disorder D

Several JJ CAPITAL Several O
Several JJ large-scale O
large-scale NNS trials O
trials VB have O
have RB firmly O
firmly VBN established O
established DT the O
the NN effectiveness O
effectiveness IN of O
of JJ thrombolytic T
thrombolytic NN therapy T
therapy , , O
, NN beta T
beta NNS blockers T
blockers , , O
, CC and O
and NN aspirin T
aspirin IN in O
in DT the O
the NN treatment O
treatment IN of O
of NNP CAPITAL AMI D

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> IN CAPITAL While O
While JJ diastolic D
diastolic RB left D
left JJ ventricular D
ventricular NN ( D
( NN CAPITAL LV D
LV NN ) D
) NN dysfunction D
dysfunction VBZ is O
is JJ frequent O
frequent CC and O
and VBN associated O
associated IN with O
with JJ cardiovascular D
cardiovascular NNS complications D
complications IN in O
in NN end-stage D
end-stage JJ renal D
renal NN disease D
disease VBN treated O
treated IN with O
with NN dialysis T
dialysis , , O
, JJ controversial O
controversial NN information O
information VBZ exists O
exists IN on O
on JJ diastolic O
diastolic NN CAPITAL LV O
LV NN function O
function IN after O
after JJ renal O
renal NN transplantation O

METHODS NNS CAPITAL METHODS O
METHODS : : O
: NN CAPITAL Fluvastatin T
Fluvastatin CD 40 O
40 NN mg O
mg RB daily O
daily VBD was O
was VBN administered O
administered TO to O
to CD 25 O
25 NNS patients O
patients IN with O
with NN hypercholesterolaemia D
hypercholesterolaemia IN for O
for RB up O
up TO to O
to CD 24 O
24 NNS weeks O

The DT CAPITAL The O
The JJ inhibitory O
inhibitory NN effect O
effect IN of O
of JJ n-3 T
n-3 JJ polyunsaturated T
polyunsaturated JJ fatty T
fatty NNS acids T
acids IN on O
on JJ human D
human JJ colorectal D
colorectal NN cancer D
cancer VBZ has O
has VBN been O
been VBD speculated O
speculated IN on O
on IN from O
from JJ epidemiological O
epidemiological NNS data O
data CC and O
and NN animal O
animal NNS studies O

We PRP CAPITAL We O
We VBN conducted O
conducted DT a O
a JJ long-term O
long-term NN trial O
trial IN of O
of JJ docosahexanoic T
docosahexanoic NN acid T
acid NN ( T
( NN CAPITAL DHA T
DHA NN ) T
) JJ -concentrated T
-concentrated NN fish T
fish NN oil T
oil NNS capsules T
capsules IN for O
for NNS patients O
patients IN in O
in DT a O
a JJ high-risk O
high-risk NN group O
group IN for O
for JJ colorectal D
colorectal NN cancer D

Three CD CAPITAL Three O
Three NNS patients O
patients IN with O
with NN CAPITAL FAP D
FAP CC and O
and CD two O
two NNS patients O
patients IN with O
with JJ multiple O
multiple NN ( O
( RBR more O
more IN than O
than CD 30 O
30 NN ) O
) JJ colorectal D
colorectal NNS polyps D
polyps VBD were O
were VBN administered O
administered JJ CAPITAL DHA-concentrated T
DHA-concentrated NN fish T
fish NN oil T
oil NN capsules_Hlk427554600 T
capsules_Hlk427554600 NN ( T
( CD 2.2 T
2.2 NN g T
g IN of T
of NN CAPITAL DHA T
DHA CC and T
and CD 0.6 T
0.6 NN g T
g IN of T
of JJ eicosapentanoic T
eicosapentanoic NN acid T
acid NN ( T
( NNP CAPITAL EPA T
EPA NN ) T
) IN per T
per NN day T
day NN ) T
) IN for O
for CD one O
one CC or O
or CD two O
two NNS years O

This DT CAPITAL This O
This NN article O
article NNS reviews O
reviews JJ current O
current NNS trends O
trends IN in O
in NN management O
management IN of O
of NN esophageal D
esophageal NN achalasia D
achalasia , , O
, VBG highlighting O
highlighting JJ short-term O
short-term NN outcome O
outcome CC and O
and NN cost O
cost NNS comparisons O
comparisons IN of O
of CD three O
three NNS treatments O
treatments : : O
: NN botulinum T
botulinum NN toxin T
toxin NN injection T
injection , , O
, JJ pneumatic T
pneumatic NN dilation T
dilation , , O
, CC and O
and JJ laparoscopic T
laparoscopic JJ myotomy T

The DT CAPITAL The O
The JJ clinical O
clinical NN application O
application IN of O
of JJ therapeutic T
therapeutic NN hysteroscopy T
hysteroscopy , , O
, RB mainly O
mainly IN in O
in DT the O
the NN field O
field IN of O
of DT the O
the NN treatment O
treatment IN of O
of JJ abnormal D
abnormal NN uterine D
uterine NN bleeding D
bleeding , , O
, VBD started O
started IN in O
in DT the O
the NNS 1980s O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> IN CAPITAL In O
In DT this O
this NN article O
article , , O
, NN evidence O
evidence IN of O
of NN effectiveness O
effectiveness CC and O
and NN cost-effectiveness O
cost-effectiveness IN of O
of DT the O
the VBG following O
following NNS procedures O
procedures VBZ is O
is VBN reviewed O
reviewed : : O
: NN ( O
( CD 1 O
1 NN ) O
) NN laser T
laser NN treatment T
treatment IN of O
of NN bladder D
bladder NNS tumors D
tumors : ; O
; NN ( O
( CD 2 O
2 NN ) O
) JJ extracorporeal O
extracorporeal NN shock-wave O
shock-wave NN lithotripsy O
lithotripsy CC and O
and JJ percutaneous O
percutaneous NN nephrolithotomy O
nephrolithotomy : ; O
; NN ( O
( CD 3 O
3 NN ) O
) JJ laparoscopic T
laparoscopic NN treatment T
treatment IN of O
of NN endometriosis D
endometriosis : ; O
; NN ( O
( CD 4 O
4 NN ) O
) JJ laparoscopic T
laparoscopic NN removal T
removal IN of O
of JJ ovarian D
ovarian NNS cysts D
cysts : ; O
; NN ( O
( CD 5 O
5 NN ) O
) JJ laparoscopic O
laparoscopic NN cholecystectomy O
cholecystectomy : ; O
; NN ( O
( CD 6 O
6 NN ) O
) JJ laparoscopic O
laparoscopic NN appendectomy O
appendectomy : ; O
; NN ( O
( CD 7 O
7 NN ) O
) NN catheter T
catheter NN treatment T
treatment IN of O
of JJ coronary D
coronary NN artery D
artery NN disease D
disease : ; O
; NN ( O
( CD 8 O
8 NN ) O
) NN palliation O
palliation IN of O
of NN colon O
colon NN cancer O
cancer IN by O
by JJ endoscopic O
endoscopic NN intervention O
intervention : ; O
; NN ( O
( CD 9 O
9 NN ) O
) NN treatment O
treatment IN of O
of JJ upper D
upper JJ gastrointestinal D
gastrointestinal NN ( D
( NNP CAPITAL UGI D
UGI NN ) D
) NN bleeding D
bleeding IN by O
by JJ endoscopic T
endoscopic NN intervention T
intervention : ; O
; CC and O
and NN ( O
( CD 10 O
10 NN ) O
) JJ arthroscopic O
arthroscopic NN knee O
knee NN surgery O

Gene NNP CAPITAL Gene T
Gene NN therapy T
therapy IN of O
of JJ malignant D
malignant NN brain D
brain NNS tumors D

Treatment NN CAPITAL Treatment O
Treatment IN of O
of JJ irritable D
irritable NN bowel D
bowel NN syndrome D
syndrome IN with O
with JJ CAPITAL Chinese T
Chinese JJ herbal T
herbal NN medicine T
medicine : : O
: DT a O
a VBN randomized O
randomized JJ controlled O
controlled NN trial O

Randomised VBN CAPITAL Randomised O
Randomised NN trial O
trial IN of O
of NN interferon T
interferon NN alpha2b T
alpha2b CC plus T
plus NNP ribavirin T
ribavirin IN for O
for CD 48 O
48 NNS weeks O
weeks CC or O
or IN for O
for CD 24 O
24 NNS weeks O
weeks CC versus O
versus NN interferon T
interferon NN alpha2b T
alpha2b CC plus T
plus NN placebo T
placebo IN for O
for CD 48 O
48 NNS weeks O
weeks IN for O
for NN treatment O
treatment IN of O
of JJ chronic D
chronic NN infection D
infection IN with D
with NN hepatitis D
hepatitis NN CAPITAL C D
C NN virus D

Low-molecular-weight JJ CAPITAL Low-molecular-weight T
Low-molecular-weight NN heparin T
heparin IN for O
for JJ immediate O
immediate NN management O
management IN of O
of NN thromboembolic D
thromboembolic NN disease D
disease IN in O
in NN pregnancy O

Tubularized VBN CAPITAL Tubularized T
Tubularized VBN incised T
incised NN plate T
plate NN hypospadias T
hypospadias NN repair T
repair IN for O
for JJ proximal D
proximal NN hypospadias D

Comparison NN CAPITAL Comparison O
Comparison IN of O
of JJ radical T
radical NN prostatectomy T
prostatectomy CC and O
and NN iodine T
iodine CD 125 T
125 JJ interstitial T
interstitial NN radiotherapy T
radiotherapy IN for O
for DT the O
the NN treatment O
treatment IN of O
of RB clinically D
clinically JJ localized D
localized NN prostate D
prostate NN cancer D
cancer : : O
: DT a O
a JJ 7-year O
7-year JJ biochemical O
biochemical NN ( O
( NN CAPITAL PSA O
PSA NN ) O
) NN progression O
progression NN analysis O

The DT CAPITAL The O
The NN effectiveness O
effectiveness IN of O
of NN acupuncture T
acupuncture IN in O
in VBG treating O
treating JJ acute D
acute JJ dental D
dental NN pain D
pain : : O
: DT a O
a JJ systematic O
systematic NN review O

Correction NN CAPITAL Correction O
Correction IN of O
of JJ cardiac D
cardiac NNS defects D
defects IN through O
through DT a O
a JJ right T
right NN thoracotomy T
thoracotomy IN in O
in NNS children O

New NNP CAPITAL New O
New NN technique O
technique IN for O
for NN mesh T
mesh NN repair T
repair IN of O
of NN paracolostomy D
paracolostomy NN hernias D

Immunotherapy NN CAPITAL Immunotherapy T
Immunotherapy IN of O
of NNS tumors D
tumors IN with O
with JJ autologous T
autologous JJ tumor-derived T
tumor-derived NN heat T
heat NN shock T
shock NN protein T
protein NNS preparations T

Comprehensive JJ CAPITAL Comprehensive T
Comprehensive VBN modified T
modified NN diet T
diet VBZ simplifies O
simplifies NN nutrition T
nutrition NN management T
management IN of O
of NNS adults O
adults IN with O
with NN short-bowel D
short-bowel NN syndrome D

Extended VBN CAPITAL Extended O
Extended NN use O
use IN of O
of NN glatiramer T
glatiramer NN acetate T
acetate NN ( T
( NN CAPITAL Copaxone T
Copaxone NN ) T
) VBZ is O
is RB well O
well VBN tolerated O
tolerated CC and O
and VBZ maintains O
maintains PRP$ its O
its JJ clinical O
clinical NN effect O
effect IN on O
on JJ multiple D
multiple NN sclerosis D
sclerosis NN relapse O
relapse NN rate O
rate CC and O
and NN degree O
degree IN of O
of NN disability O

European JJ CAPITAL European O
European NN register O
register IN of O
of NNS patients O
patients IN with O
with NN sickle D
sickle NN cell D
cell NN disease D
disease VBN treated O
treated IN with O
with NN hydroxyurea T
hydroxyurea VBZ is O
is VBG being O
being VBN set O
set RB up O

Understanding VBG CAPITAL Understanding O
Understanding DT the O
the NN culture O
culture IN of O
of VBG prescribing O
prescribing : : O
: JJ qualitative O
qualitative NN study O
study IN of O
of JJ general O
general NNS practitioners O
practitioners POS ' O
' CC and O
and NNS patients O
patients POS ' O
' NNS perceptions O
perceptions IN of O
of NNS antibiotics T
antibiotics IN for O
for JJ sore D
sore NNS throats D

Steroid NN CAPITAL Steroid T
Steroid NN delivery T
delivery IN in O
in NN croup D

Haematoma NN CAPITAL Haematoma T
Haematoma NN block T
block CC versus O
versus JJ intravenous T
intravenous JJ regional T
regional NN anaesthesia T
anaesthesia IN in O
in NNP CAPITAL Colles D
Colles POS ' D
' NNS fractures D

Direct JJ CAPITAL Direct T
Direct JJ percutaneous T
percutaneous JJ transluminal T
transluminal JJ angioplasty T
angioplasty IN for O
for JJ acute D
acute JJ middle D
middle JJ cerebral D
cerebral NN artery D
artery NN occlusion D

Magnesium NN CAPITAL Magnesium T
Magnesium NN sulphate T
sulphate IN for O
for DT the O
the NN control O
control IN of O
of NNS spasms D
spasms IN in D
in JJ severe D
severe NN tetanus D

Protective JJ CAPITAL Protective O
Protective NN effect O
effect IN of O
of NN pralidoxime T
pralidoxime IN on O
on NN muscle D
muscle NN fiber D
fiber NN necrosis D
necrosis VBN induced O
induced IN by O
by NN organophosphate O
organophosphate NNS compounds O

Assessment NNP CAPITAL Assessment O
Assessment IN of O
of JJ atrioventricular T
atrioventricular NN junction T
junction NN ablation T
ablation CC and T
and NN CAPITAL VVIR T
VVIR NN pacemaker T
pacemaker CC versus O
versus JJ pharmacological T
pharmacological NN treatment T
treatment IN in O
in NNS patients O
patients IN with O
with NN heart D
heart NN failure D
failure CC and D
and JJ chronic D
chronic NN atrial D
atrial NN fibrillation D
fibrillation : : O
: DT a O
a VBN randomized O
randomized , , O
, JJ controlled O
controlled NN study O

Statins NNS CAPITAL Statins T
Statins IN for O
for NN prevention O
prevention IN of O
of NN stroke D

Repair JJ CAPITAL Repair O
Repair IN of O
of JJ ventral D
ventral NN hernias D
hernias IN with O
with VBN expanded T
expanded NN polytetrafluoroethylene T
polytetrafluoroethylene NN patch T

Spinal JJ CAPITAL Spinal T
Spinal NN manipulation T
manipulation IN in O
in DT the O
the NN treatment O
treatment IN of O
of JJ episodic D
episodic JJ tension-type D
tension-type NN headache D
headache : : O
: DT a O
a VBN randomized O
randomized JJ controlled O
controlled NN trial O

Successful JJ CAPITAL Successful O
Successful NN treatment O
treatment IN with O
with NN lamivudine T
lamivudine IN for O
for JJ fulminant D
fulminant VBN reactivated D
reactivated NN hepatitis D
hepatitis NN CAPITAL B D
B NN infectioN D
infectioN VBG following O
following JJ intensive T
intensive NN therapy T
therapy IN for O
for JJ high-grade D
high-grade JJ non-Hodgkin D
non-Hodgkin POS 's D
's NN lymphoma D

Influence NN CAPITAL Influence O
Influence IN of O
of NN treatment O
treatment NN delay O
delay IN on O
on NN infarct O
infarct NN size O
size CC and O
and JJ clinical O
clinical NN outcome O
outcome IN in O
in NNS patients O
patients IN with O
with JJ acute D
acute JJ myocardial D
myocardial NN infarction D
infarction VBN treated O
treated IN with O
with JJ primary T
primary JJ angioplasty T

Should MD CAPITAL Should O
Should NNS patients O
patients IN with O
with JJ advanced D
advanced NNS sarcomas D
sarcomas VB be O
be VBN treated O
treated IN with O
with NN chemotherapy T
chemotherapy . ? O

Plasma NN CAPITAL Plasma T
Plasma NN exchange T
exchange CC and T
and JJ tacrolimus-mycophenolate T
tacrolimus-mycophenolate NN rescue T
rescue IN for O
for JJ acute D
acute JJ humoral D
humoral NN rejection D
rejection IN in O
in NN kidney O
kidney NN transplantation O

Hyperbaric JJ CAPITAL Hyperbaric T
Hyperbaric NN oxygen T
oxygen NN therapy T
therapy IN for O
for NNS children O
children IN with O
with JJ cerebral D
cerebral NN palsy D

Endoscopic JJ CAPITAL Endoscopic T
Endoscopic NN excision T
excision IN of O
of DT a D
a NN forehead D
forehead NN mass D

Effect NN CAPITAL Effect O
Effect IN of O
of JJ photodynamic T
photodynamic NN therapy T
therapy IN in T
in NN combination T
combination IN with T
with NN mitomycin T
mitomycin NN CAPITAL C T
C IN on O
on DT a O
a JJ mitomycin-resistant D
mitomycin-resistant NN bladder D
bladder NN cancer D
cancer NN cell O
cell NN line O

Is VBZ CAPITAL Is O
Is JJ conservative T
conservative NN surgery T
surgery IN for O
for JJ tubal D
tubal NN pregnancy D
pregnancy JJ preferable O
preferable TO to O
to NN salpingectomy T
salpingectomy . ? O
? DT CAPITAL An O
An JJ economic O
economic NN analysis O

Laparoscopic JJ CAPITAL Laparoscopic T
Laparoscopic JJ cornuostomy T
cornuostomy IN in O
in DT the O
the NN treatment O
treatment IN of O
of JJ interstitial D
interstitial NN pregnancy D
pregnancy IN with O
with JJ subsequent O
subsequent NN hysterosalpingography O

Experimental JJ CAPITAL Experimental O
Experimental NN evaluation O
evaluation IN of O
of DT the O
the NN use O
use IN of O
of JJ recombinant T
recombinant NN prourokinase T
prourokinase CC and O
and PRP$ its O
its VBN immobilized O
immobilized NNS forms O
forms IN in O
in DT the O
the NN treatment O
treatment IN of O
of JJ postoperative D
postoperative NN fibrinoid D
fibrinoid NN syndrome D
syndrome IN in O
in NN ophthalmology O

In IN CAPITAL In O
In FW vitro O
vitro CC and O
and IN in O
in FW vivo O
vivo NN comparison O
comparison IN between O
between DT the O
the NNS effects O
effects IN of O
of NN treatment O
treatment IN with O
with NN adenosine T
adenosine NN triphosphate T
triphosphate CC and O
and NN treatment O
treatment IN with O
with NN buthionine T
buthionine NN sulfoximine T
sulfoximine IN on O
on NN chemosensitization O
chemosensitization CC and O
and NN tumour O
tumour NN growth O
growth IN of O
of NN CAPITAL B16 D
B16 NN melanoma D

Effects NNS CAPITAL Effects O
Effects IN of O
of JJ transpupillary T
transpupillary JJ thermotherapy T
thermotherapy IN on O
on JJ immunological O
immunological NNS parameters O
parameters CC and O
and NN apoptosis O
apoptosis IN in O
in DT a O
a NN case O
case IN of O
of JJ primary D
primary NN uveal D
uveal NN melanoma D

Is VBZ CAPITAL Is O
Is RB there O
there DT a O
a JJ rational O
rational NN therapy O
therapy IN for O
for JJ symptomatic O
symptomatic NN treatment O
treatment IN of O
of JJ benign D
benign JJ prostatic D
prostatic NN hyperplasia D
hyperplasia IN with O
with JJ phytogenic T
phytogenic NNS drugs T
drugs . ? O
? NNP CAPITAL Illustrated O
Illustrated IN with O
with DT the O
the NN example O
example IN of O
of DT the O
the NN prostate O
prostate NN agent O
agent IN from O
from NN CAPITAL Serenoa O
Serenoa NNS repens O
repens NN ( O
( NNP CAPITAL Sabal O
Sabal NN fructus O
fructus NN ) O

Pharmacological JJ CAPITAL Pharmacological O
Pharmacological CC and O
and JJ clinical O
clinical NN effectiveness O
effectiveness IN of O
of DT a O
a VBN fixed T
fixed JJ phytogenic T
phytogenic NN combination T
combination VBG trembling T
trembling JJ poplar T
poplar NN ( T
( JJ CAPITAL Populus T
Populus NN tremula T
tremula NN ) T
) , , T
, JJ true T
true NN goldenrod T
goldenrod NN ( T
( NNP CAPITAL Solidago T
Solidago NN virgaurea T
virgaurea NN ) T
) CC and T
and JJ ash T
ash NN ( T
( NN CAPITAL Fraxinus T
Fraxinus NN excelsior T
excelsior NN ) T
) IN in O
in JJ mild D
mild TO to D
to JJ moderate D
moderate JJ rheumatic D
rheumatic NNS complaints D

Therapy NN CAPITAL Therapy O
Therapy IN of O
of JJ degenerative D
degenerative NNS diseases D
diseases IN of D
of DT the D
the JJ musculoskeletal D
musculoskeletal NN system D
system IN with O
with NNP CAPITAL South T
South JJ CAPITAL African T
African NNP devil T
devil POS 's T
's VB claw T
claw NN ( T
( NN CAPITAL Harpagophytum T
Harpagophytum NNS procumbens T
procumbens NN CAPITAL DC T
DC NN ) T

Treatment NN CAPITAL Treatment O
Treatment NN strategy O
strategy IN for O
for JJ mucin-producing D
mucin-producing JJ intrahepatic D
intrahepatic NN cholangiocarcinoma D
cholangiocarcinoma : : O
: NN value O
value IN of O
of JJ percutaneous T
percutaneous JJ transhepatic T
transhepatic JJ biliary T
biliary NN drainage T
drainage CC and O
and JJ cholangioscopy T

Strategy NN CAPITAL Strategy O
Strategy IN for O
for JJ surgical T
surgical NN management T
management IN of O
of JJ ileocolonic D
ileocolonic JJ anastomotic D
anastomotic NN recurrence D
recurrence IN in D
in NN CAPITAL Crohn D
Crohn POS 's D
's NN disease D

Nerve-sparing JJ CAPITAL Nerve-sparing T
Nerve-sparing NN surgery T
surgery IN for O
for JJ advanced D
advanced JJ rectal D
rectal NN cancer D
cancer NNS patients O
patients : : O
: JJ special O
special NN reference O
reference TO to O
to NNP CAPITAL Dukes O
Dukes NN CAPITAL C O
C NNS patients O

Prognostic JJ CAPITAL Prognostic O
Prognostic NNS factors O
factors IN in O
in NNS patients O
patients IN with O
with RB locally O
locally JJ advanced O
advanced JJ rectal D
rectal NN adenocarcinoma D
adenocarcinoma VBN treated O
treated IN with O
with JJ preoperative T
preoperative NN radiotherapy T
radiotherapy CC and O
and NN surgery T

Current JJ CAPITAL Current O
Current JJ surgical T
surgical NN therapy T
therapy IN for O
for NN bronchiectasis D

Thoracic JJ CAPITAL Thoracic T
Thoracic NN surgery T
surgery IN for O
for NN hydatid D
hydatid NN disease D

Surgical NNP CAPITAL Surgical T
Surgical NN treatment T
treatment IN of O
of JJ postpneumonic D
postpneumonic NN empyema D

Thoracoscopic JJ CAPITAL Thoracoscopic T
Thoracoscopic NN surgery T
surgery IN for O
for JJ pulmonary D
pulmonary NN tuberculosis D

Thoracoscopic JJ CAPITAL Thoracoscopic T
Thoracoscopic NN surgery T
surgery IN for O
for JJ spontaneous D
spontaneous NN pneumothorax D

Surgery NN CAPITAL Surgery T
Surgery IN for O
for JJ chronic D
chronic NN thromboembolic D
thromboembolic JJ pulmonary D
pulmonary NN hypertension D

Transabdominal JJ CAPITAL Transabdominal T
Transabdominal JJ extensive T
extensive JJ esophagogastric T
esophagogastric NN devascularization T
devascularization IN with T
with NN gastroesophageal T
gastroesophageal VBG stapling T
stapling IN for O
for NN management O
management IN of O
of JJ noncirrhotic D
noncirrhotic NN portal D
portal NN hypertension D
hypertension : : O
: JJ long-term O
long-term NNS results O

Surgical NNP CAPITAL Surgical T
Surgical NN treatment T
treatment IN for O
for NN lung D
lung NN hydatid D
hydatid NN disease D

Sliding VBG CAPITAL Sliding T
Sliding NN door T
door NN technique T
technique IN for O
for DT the O
the NN repair O
repair IN of O
of NN midline D
midline JJ incisional D
incisional NN hernias D

One-lung JJ CAPITAL One-lung T
One-lung NN ventilation T
ventilation IN in O
in NNS patients O
patients IN with O
with JJ difficult D
difficult NNS airways D

Thoracoscopy JJ CAPITAL Thoracoscopy T
Thoracoscopy IN for O
for NN empyema D
empyema IN in O
in NNS children O

Sex NN CAPITAL Sex O
Sex NNS differences O
differences IN in O
in DT the O
the NN use O
use IN of O
of NN asthma D
asthma NNS drugs T
drugs : : O
: JJ cross O
cross JJ sectional O
sectional NN study O

Conventional JJ CAPITAL Conventional T
Conventional NNS treatments T
treatments IN for O
for JJ non-Hodgkin D
non-Hodgkin POS 's D
's NN lymphoma D
lymphoma : : O
: DT the O
the NN need O
need IN for O
for JJ new O
new NNS therapies O

Adrenal-sparing JJ CAPITAL Adrenal-sparing T
Adrenal-sparing NN surgery T
surgery IN for O
for NN phaeochromocytoma D

Antiplatelet JJ CAPITAL Antiplatelet T
Antiplatelet NN therapy T
therapy IN in O
in JJ acute D
acute JJ cerebral D
cerebral NN ischemia D

Laugier-Hunziker NN CAPITAL Laugier-Hunziker D
Laugier-Hunziker NN syndrome D
syndrome : : O
: NN case O
case NN report O
report CC and O
and NN treatment O
treatment IN with O
with DT the O
the JJ CAPITAL Q-switched T
Q-switched NN CAPITAL Nd-Yag T
Nd-Yag NN laser T

Thoracoscopic JJ CAPITAL Thoracoscopic T
Thoracoscopic NN operation T
operation IN for O
for JJ secondary D
secondary NN pneumothorax D
pneumothorax IN under O
under JJ local O
local CC and O
and JJ epidural O
epidural NN anesthesia O
anesthesia IN in O
in JJ high-risk O
high-risk NNS patients O

Troglitazone-induced JJ CAPITAL Troglitazone-induced D
Troglitazone-induced JJ hepatic D
hepatic NN failure D
failure VBG leading O
leading TO to O
to NN liver T
liver NN transplantation T

A DT CAPITAL A O
A VBN modified O
modified NN technique O
technique IN of O
of JJ tubeless O
tubeless NN anaesthesia O
anaesthesia IN for O
for JJ microlaryngoscopy T
microlaryngoscopy CC and T
and NN bronchoscopy T
bronchoscopy IN in O
in JJ young O
young NNS children O
children IN with O
with NN stridor D

A DT CAPITAL A O
A VBN randomized O
randomized NN trial O
trial IN of O
of NN CAPITAL Lactobacillus T
Lactobacillus NN acidophilus T
acidophilus NN CAPITAL BG2FO4 T
BG2FO4 TO to O
to VB treat O
treat NN lactose D
lactose NN intolerance D

Treatment NN CAPITAL Treatment O
Treatment IN of O
of JJ idiopathic D
idiopathic JJ thrombopenic D
thrombopenic NN purpura D
purpura IN in O
in NNS adolescents O
adolescents IN by O
by JJ intravenous T
intravenous NN immunoglobulin T

Azithromycin NN CAPITAL Azithromycin T
Azithromycin NN therapy T
therapy IN for O
for NN scrub D
scrub NN typhus D
typhus IN during O
during NN pregnancy O

Excimer NNP CAPITAL Excimer T
Excimer NN laser T
laser VBN assisted T
assisted IN in T
in FW situ T
situ NN keratomileusis T
keratomileusis IN for O
for NN hyperopia D

Three CD CAPITAL Three O
Three JJ consecutive O
consecutive NN phase O
phase NNP CAPITAL II O
II NNS studies O
studies IN of O
of JJ recombinant T
recombinant NN interferon T
interferon JJ alfa-2a T
alfa-2a IN in O
in JJ advanced D
advanced JJ malignant D
malignant NN melanoma D

Interferon NN CAPITAL Interferon T
Interferon NN treatment T
treatment IN of O
of JJ renal D
renal NN cell D
cell NN carcinoma D

Current JJ CAPITAL Current O
Current CC and O
and JJ future O
future NNS uses O
uses IN of O
of JJ recombinant T
recombinant NN interferon T
interferon NN alpha T
alpha IN in O
in DT the O
the NN treatment O
treatment IN of O
of JJ low-grade D
low-grade JJ non-Hodgkin D
non-Hodgkin POS 's D
's NN lymphoma D

Antimicrobial JJ CAPITAL Antimicrobial T
Antimicrobial NN treatment T
treatment NNS options O
options IN in O
in DT the O
the NN management O
management IN of O
of JJ odontogenic D
odontogenic NNS infections D

Recombinant JJ CAPITAL Recombinant T
Recombinant NN glycoprotein T
glycoprotein NN vaccine T
vaccine IN for O
for DT the O
the NN prevention O
prevention IN of O
of JJ genital D
genital NN CAPITAL HSV-2 D
HSV-2 NN infection D
infection : : O
: CD two O
two VBN randomized O
randomized JJ controlled O
controlled NNS trials O

Induction NN CAPITAL Induction T
Induction NN chemotherapy T
chemotherapy IN with T
with NN docetaxel T
docetaxel , , T
, NN cisplatin T
cisplatin , , T
, NN fluorouracil T
fluorouracil , , T
, CC and T
and NN leucovorin T
leucovorin IN for O
for JJ squamous D
squamous NN cell D
cell NN carcinoma D
carcinoma IN of O
of DT the O
the NN head O
head CC and O
and NN neck O
neck : : O
: DT a O
a NN phase O
phase CD CAPITAL I/II O
I/II NN trial O

Low-dose JJ CAPITAL Low-dose T
Low-dose NNS steroids T
steroids VB reduce O
reduce JJ flu-like D
flu-like NNS symptoms D
symptoms IN at O
at DT the O
the NN initiation O
initiation IN of O
of NN CAPITAL IFNbeta-1b O
IFNbeta-1b IN in O
in JJ relapsing-remitting O
relapsing-remitting NN CAPITAL MS O

Study NNP CAPITAL Study O
Study IN of O
of CD three O
three JJ different O
different NNS doses O
doses IN of O
of JJ epidural T
epidural NN neostigmine T
neostigmine VBN coadministered T
coadministered IN with T
with NN lidocaine T
lidocaine IN for O
for JJ postoperative D
postoperative NN analgesia D

An DT CAPITAL An O
An JJ active-control O
active-control NN trial O
trial IN of O
of NN lamotrigine T
lamotrigine JJ monotherapy T
monotherapy IN for O
for JJ partial D
partial NNS seizures D

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NN CAPITAL Safety O
Safety IN of O
of JJ intrathecal T
intrathecal NN sodium T
sodium JJ nitroprusside T
nitroprusside IN for O
for DT the O
the NN treatment O
treatment CC and O
and NN prevention O
prevention IN of O
of JJ refractory D
refractory JJ cerebral D
cerebral NN vasospasm D
vasospasm CC and D
and NN ischemia D
ischemia IN in O
in NNS humans O

The DT CAPITAL The O
The NN effect O
effect IN of O
of JJ heliox T
heliox IN in O
in JJ acute D
acute JJ severe D
severe NN asthma D
asthma : : O
: DT a O
a VBN randomized O
randomized JJ controlled O
controlled NN trial O
trial . . O

Long-term JJ CAPITAL Long-term O
Long-term NN survival O
survival IN of O
of NNS patients O
patients IN with O
with JJ unresectable D
unresectable JJ colorectal D
colorectal NN cancer D
cancer NN liver D
liver NNS metastases D
metastases VBG following O
following JJ infusional T
infusional NN chemotherapy T
chemotherapy IN with T
with NN 5-fluorouracil T
5-fluorouracil , , T
, NN leucovorin T
leucovorin , , T
, NN oxaliplatin T
oxaliplatin CC and T
and NN surgery T

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> JJ CAPITAL Fatal D
Fatal JJ acute D
acute NN haemolysis D
haemolysis IN in O
in DT an O
an NN CAPITAL AIDS D
AIDS NN patient O
patient VBN treated O
treated IN with O
with NN lindinavir T

A DT CAPITAL A O
A VBN simplified O
simplified JJ laparoscopic T
laparoscopic NN technique T
technique IN for T
for NN mesh T
mesh NN placement T
placement IN in O
in JJ ventral D
ventral NN hernia D
hernia NN repair O

Pharmacological JJ CAPITAL Pharmacological T
Pharmacological NN management T
management IN of O
of JJ acute D
acute JJ myocardial D
myocardial NN infarction D

Mesenteric JJ CAPITAL Mesenteric D
Mesenteric JJ venous D
venous NN thrombosis D
thrombosis : : O
: JJ successful O
successful NN treatment O
treatment IN by O
by JJ intraarterial T
intraarterial JJ lytic T
lytic NN therapy T

Gene NNP CAPITAL Gene T
Gene NN therapy T
therapy IN for O
for JJ myocardial D
myocardial NN angiogenesis D

Dipyridamole NNP CAPITAL Dipyridamole T
Dipyridamole CC plus T
plus NN aspirin T
aspirin IN in O
in JJ cerebrovascular D
cerebrovascular NN disease D

What WDT CAPITAL What O
What VBZ is O
is DT the O
the JJ real O
real NN role O
role IN of O
of NN CAPITAL CD40 O
CD40 IN in O
in NN cancer D
cancer NN immunotherapy T
immunotherapy . ? O

The DT CAPITAL The O
The NNS effects O
effects IN of O
of JJ oral T
oral NN liarozole T
liarozole IN on O
on JJ epidermal O
epidermal NN proliferation O
proliferation CC and O
and NN differentiation O
differentiation IN in O
in JJ severe D
severe NN plaque D
plaque NN psoriasis D
psoriasis VBP are O
are JJ comparable O
comparable IN with O
with DT those O
those IN of O
of NN acitretin T
acitretin . . O

Safety NN CAPITAL Safety O
Safety CC and O
and JJ potential O
potential NN effectiveness O
effectiveness IN of O
of JJ daunorubicin-containing T
daunorubicin-containing NNS liposomes T
liposomes IN in O
in NNS patients O
patients IN with O
with JJ advanced D
advanced JJ recurrent D
recurrent JJ malignant D
malignant NN CAPITAL CNS D
CNS NNS tumors D

An DT CAPITAL An O
An JJ experimental O
experimental NN application O
application IN of O
of NN gene T
gene NN therapy T
therapy IN for O
for JJ human D
human NN retinoblastoma D

Acid NN CAPITAL Acid T
Acid NN suppression T
suppression NN therapy T
therapy IN in O
in NNP CAPITAL Barrett D
Barrett POS 's D
's NN esophagus D
esophagus : : O
: DT the O
the NN importance O
importance IN of O
of NN pH O
pH VBG monitoring O

Surgical NNP CAPITAL Surgical T
Surgical NNS approaches T
approaches TO to O
to JJ pediatric D
pediatric JJ defecatory D
defecatory NNS disorders D

Lutein NN CAPITAL Lutein T
Lutein VBZ improves O
improves JJ visual O
visual NN function O
function IN in O
in DT some O
some NNS patients O
patients IN with O
with JJ retinal D
retinal NN degeneration D
degeneration : : O
: DT a O
a NN pilot O
pilot NN study O
study IN via O
via DT the O
the NN CAPITAL Internet O

Drug NN CAPITAL Drug O
Drug NN information O
information NNS questions O
questions CC and O
and NNS answers O
answers : : O
: JJ new O
new IN for O
for NN psoriasis D
psoriasis : : O
: NN colchicine T

IPPB NN CAPITAL IPPB T
IPPB IN in O
in JJ severe D
severe JJ pulmonary D
pulmonary NN emphysema D
emphysema : : O
: JJ limited O
limited NNS applications O

Long-term JJ CAPITAL Long-term O
Long-term NN mortality O
mortality IN in O
in NNS patients O
patients IN after O
after DT a O
a JJ CAPITAL British O
British NN trial O
trial IN of O
of NNS anticoagulants T
anticoagulants IN in O
in JJ acute D
acute JJ myocardial D
myocardial NN infarction D

Our PRP$ CAPITAL Our O
Our NNS results O
results IN in O
in DT the O
the JJ surgical T
surgical NN treatment T
treatment IN of O
of JJ habitual D
habitual NN shoulder D
shoulder NN dislocation D
dislocation IN with O
with JJ special O
special NN reference O
reference TO to O
to JJ occupational O
occupational NN disability O

Alkaline NN CAPITAL Alkaline O
Alkaline NN phosphatase O
phosphatase IN in O
in NN neutrophil O
neutrophil NNS leukocytes O
leukocytes IN of O
of NNS patients O
patients IN with O
with JJ infectious D
infectious NN mononucleosis D
mononucleosis CC and O
and DT the O
the NN effect O
effect IN of O
of NN corticosteroid T
corticosteroid NN therapy T

Surgical NNP CAPITAL Surgical T
Surgical NN treatment T
treatment IN of O
of NN uterine D
uterine NN cervix D
cervix NN insufficiency D
insufficiency IN during O
during DT the O
the JJ 2d O
2d NN trimester O
trimester IN of O
of NN pregnancy O

Physiologic JJ CAPITAL Physiologic T
Physiologic NN treatment T
treatment IN of O
of JJ depressive D
depressive NNS reactions D
reactions : : O
: DT a O
a NN pilot O
pilot NN study O

The DT CAPITAL The O
The NN use O
use IN of O
of NN quinidine T
quinidine NN sulphate T
sulphate IN for O
for DT the O
the NN treatment O
treatment IN of O
of NN atrial D
atrial NN fibrillation D
fibrillation IN in O
in CD twelve O
twelve NNS horses O

Synergism NN CAPITAL Synergism O
Synergism IN in O
in DT the O
the NN chemotherapy T
chemotherapy IN of O
of NN CAPITAL Eimeria D
Eimeria NNS infections D
infections IN of O
of NNS chicks O

Treatment NN CAPITAL Treatment O
Treatment IN of O
of NN hydrocele D
hydrocele CC and D
and NNS cysts D
cysts IN of D
of DT the D
the NN epididymis D
epididymis IN with O
with VBG sclerosing T
sclerosing NNS injections T
injections IN of T
of NN quinine T
quinine CC and T
and NN urea T
urea NN chlorhydrolactate T
chlorhydrolactate IN in O
in DT a O
a CD 30 O
30 IN per O
per NN cent O
cent NN solution O

The DT CAPITAL The O
The JJ single-place T
single-place NN caisson T
caisson IN in O
in DT the O
the NN treatment O
treatment IN of O
of NN decompression D
decompression NNS accidents D

Blood NN CAPITAL Blood O
Blood NN volume O
volume NNS measurements O
measurements IN in O
in VB burn D
burn NN therapy T

Phenylbutazone NN CAPITAL Phenylbutazone T
Phenylbutazone CC and O
and JJ acute D
acute NN leukemia D
leukemia . . O

The DT CAPITAL The O
The NN place O
place IN of O
of NN surgery T
surgery IN in O
in NN hypertrophic D
hypertrophic JJ obstructive D
obstructive NN cardiomyopathy D
cardiomyopathy NN ( D
( JJ idiopathic D
idiopathic NN hypertrophic D
hypertrophic JJ subaortic D
subaortic NN stenosis D
stenosis NN ) D

The DT CAPITAL The O
The NN treatment O
treatment IN of O
of JJ autoimmune D
autoimmune JJ hemolytic D
hemolytic NN anemia D
anemia IN with O
with NN heparin T

Effects NNS CAPITAL Effects O
Effects IN of O
of NN clomiphene T
clomiphene NN citrate T
citrate IN on O
on JJ endometrial D
endometrial NN hyperplasia D
hyperplasia IN in O
in DT the O
the JJ premenopausal O
premenopausal JJ female O

Prolonged JJ CAPITAL Prolonged O
Prolonged NN use O
use IN of O
of NN methyldopa T
methyldopa IN in O
in JJ severe D
severe NN hypertension D
hypertension IN in O
in NN pregnancy O

The DT CAPITAL The O
The NNS effects O
effects IN of O
of JJ social O
social NN class O
class CC and O
and NNS friends O
friends POS ' O
' NNS expectations O
expectations IN on O
on JJ oral O
oral NNP polio D
polio NN vaccination T
vaccination NN participation O

Glutathione NN CAPITAL Glutathione O
Glutathione NN CAPITAL S-transferase O
S-transferase NN activity O
activity IN in O
in JJ epithelial D
epithelial JJ ovarian D
ovarian NN cancer D
cancer : : O
: NN association O
association IN with O
with NN response O
response TO to O
to NN chemotherapy T
chemotherapy CC and O
and NN disease O
disease NN outcome O

Interferon-alpha-2b JJ CAPITAL Interferon-alpha-2b T
Interferon-alpha-2b IN in O
in DT the O
the NN management O
management IN of O
of NNS patients O
patients IN with O
with VBD relapsed O
relapsed CC and/or O
and/or JJ refractory O
refractory NN CAPITAL Hodgkin D
Hodgkin POS 's D
's NN disease D

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> JJ CAPITAL Frontal D
Frontal NN dysfunction D
dysfunction NNS blocks O
blocks DT the O
the JJ therapeutic O
therapeutic NN effect O
effect IN of O
of NN CAPITAL THA T
THA IN on O
on NN attention O
attention IN in O
in NN CAPITAL Alzheimer D
Alzheimer POS 's D
's NN disease D

Effects NNS CAPITAL Effects O
Effects IN of O
of NN clomipramine T
clomipramine IN on O
on NN plasma O
plasma NN amino O
amino NNS acids O
acids CC and O
and JJ serotonergic O
serotonergic NNS parameters O
parameters IN in O
in NN panic D
panic NN disorder D
disorder CC and D
and NN depression D
depression . . O

Thalidomide NNP CAPITAL Thalidomide T
Thalidomide IN for O
for JJ aphthous D
aphthous NNS ulcers D
ulcers IN in O
in NN CAPITAL HIV D
HIV NN infection D

Aspirin NN CAPITAL Aspirin T
Aspirin NN therapy T
therapy IN in O
in NN diabetes D
diabetes NN mellitus D

Combined VBN CAPITAL Combined T
Combined JJ pancreas-/kidney T
pancreas-/kidney NN transplantation T
transplantation IN as O
as DT a O
a JJ standard O
standard NN procedure O
procedure IN in O
in NN therapy O
therapy IN of O
of NN kidney D
kidney NN failure D
failure IN in D
in NN type D
type PRP CAPITAL I D
I JJ diabetic D
diabetic NNS patients D

Corticosteroid NN CAPITAL Corticosteroid T
Corticosteroid NNS injections T
injections IN for O
for NN sciatica D

Flutamide NN CAPITAL Flutamide T
Flutamide CC plus T
plus NN castration T
castration IN in O
in NNS patients O
patients IN with O
with RB previously O
previously JJ untreated O
untreated NN prostate D
prostate NN cancer D

The DT CAPITAL The O
The JJ immediate O
immediate NN effectiveness O
effectiveness IN of O
of JJ electrical T
electrical NN nerve T
nerve NN stimulation T
stimulation CC and O
and JJ electrical T
electrical NN muscle T
muscle NN stimulation T
stimulation IN on O
on JJ myofascial D
myofascial NN trigger D
trigger NNS points D

In IN CAPITAL In O
In FW vitro O
vitro JJ radiation-induced O
radiation-induced NN apoptosis O
apoptosis CC and O
and NN tumour O
tumour NN response O
response TO to O
to NN radiotherapy T
radiotherapy : : O
: DT a O
a JJ prospective O
prospective NN study O
study IN in O
in NNS patients O
patients IN with O
with JJ non-Hodgkin D
non-Hodgkin NNS lymphomas D
lymphomas VBN treated O
treated IN by O
by JJ low-dose T
low-dose NN irradiation T

Drug NN CAPITAL Drug T
Drug NN therapy T
therapy IN for O
for JJ coronary D
coronary NN heart D
heart NN disease D
disease : : O
: DT the O
the NNP CAPITAL Sheffield O
Sheffield NN table O

Percutaneous JJ CAPITAL Percutaneous T
Percutaneous NN drainage T
drainage IN of O
of NN hydatid D
hydatid NNS cysts D

Surgery NN CAPITAL Surgery T
Surgery IN for O
for NN ectopia D
ectopia NN lentis D

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> JJ CAPITAL Antiplatelet T
Antiplatelet NN therapy T
therapy TO to O
to VB prevent O
prevent NN stroke D
stroke : : O
: NN risk O
risk IN of O
of NN brain D
brain NN hemorrhage D
hemorrhage CC and O
and NN efficacy O
efficacy IN in O
in JJ atrial T
atrial NN fibrillation T

High-dose JJ CAPITAL High-dose T
High-dose NN chemotherapy T
chemotherapy IN with T
with JJ autologous T
autologous JJ hematopoietic T
hematopoietic NN stem-cell T
stem-cell NN support T
support IN for O
for NN breast D
breast NN cancer D
cancer IN in O
in NNP CAPITAL North O
North NNP CAPITAL America O

Is VBZ CAPITAL Is O
Is JJ concomitant T
concomitant NN radiotherapy T
radiotherapy CC and T
and NN chemotherapy T
chemotherapy JJ superior O
superior TO to O
to JJ optimal O
optimal NN radiotherapy T
radiotherapy RB alone O
alone IN in O
in JJ anal D
anal NN cancer D
cancer . ? O

Standard JJ CAPITAL Standard T
Standard CC versus T
versus JJ high-dose T
high-dose NN therapy T
therapy IN in O
in CD 10+ O
10+ NN breast D
breast NN cancer D

Anal JJ CAPITAL Anal O
Anal NN continence O
continence IN after O
after NN surgery T
surgery IN for O
for JJ rectal D
rectal NN prolapse D

Aspirin NN CAPITAL Aspirin T
Aspirin NN therapy T
therapy IN for O
for JJ cardiovascular D
cardiovascular NN disease D

Dosing NN CAPITAL Dosing O
Dosing IN of O
of JJ amoxicillin/clavulanate T
amoxicillin/clavulanate IN for O
for NN treatment O
treatment IN of O
of JJR lower D
lower JJ respiratory D
respiratory NN tract D
tract NN infection D

Pharmacoeconomic JJ CAPITAL Pharmacoeconomic O
Pharmacoeconomic NN analysis O
analysis IN of O
of JJ ampicillin-sulbactam T
ampicillin-sulbactam CC versus O
versus NN cefoxitin T
cefoxitin IN in O
in DT the O
the NN treatment O
treatment IN of O
of JJ intraabdominal D
intraabdominal NNS infections D

New JJ CAPITAL New T
New NNS therapies T
therapies IN for O
for JJ severe D
severe JJ meningococcal D
meningococcal NN disease D

Another DT CAPITAL Another O
Another JJ potential O
potential NN use O
use IN of O
of NN troglitazone T
troglitazone IN in O
in JJ noninsulin-dependent D
noninsulin-dependent NN diabetes D
diabetes NN mellitus D

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NN CAPITAL Jaw D
Jaw VBG clenching D
clenching VBG following O
following NN CAPITAL Gamma T
Gamma NNP CAPITAL Knife T
Knife NN treatment T
treatment IN for O
for JJ trigeminal D
trigeminal NN neuralgia D

The DT CAPITAL The O
The JJ protective O
protective NN effect O
effect IN of O
of NNS condoms T
condoms CC and O
and JJ nonoxynol-9 T
nonoxynol-9 IN against O
against NN CAPITAL HIV D
HIV NN infection D

Evaluation NN CAPITAL Evaluation O
Evaluation IN of O
of JJ adjuvant T
adjuvant JJ psychological T
psychological NN therapy T
therapy IN in O
in NNS patients O
patients IN with O
with JJ testicular D
testicular NN cancer D
cancer : : O
: VBN randomised O
randomised JJ controlled O
controlled NN trial O

The DT CAPITAL The O
The NN effect O
effect IN of O
of DT an O
an JJ endothelin-receptor T
endothelin-receptor NN antagonist T
antagonist , , T
, NN bosentan T
bosentan , , O
, IN on O
on NN blood O
blood NN pressure O
pressure IN in O
in NNS patients O
patients IN with O
with JJ essential D
essential NN hypertension D
hypertension . . O

Guidelines NNS CAPITAL Guidelines O
Guidelines IN for O
for DT the O
the NN use O
use IN of O
of JJ antiretroviral T
antiretroviral NNS agents T
agents IN in O
in NN CAPITAL HIV D
HIV JJ -infected O
-infected NNS adults O
adults CC and O
and NNS adolescents O

Long-term JJ CAPITAL Long-term O
Long-term NN therapy O
therapy IN with O
with JJ long-acting T
long-acting NN octreotide T
octreotide NN ( T
( JJ CAPITAL Sandostatin-LAR T
Sandostatin-LAR NN ) T
) IN for O
for DT the O
the NN management O
management IN of O
of NN acromegaly D

Are VBP CAPITAL Are O
Are NN CAPITAL ABVD T
ABVD CC and O
and NN CAPITAL MOPP/ABV T
MOPP/ABV RB truly O
truly JJ equivalent O
equivalent IN for O
for VBG treating O
treating NN CAPITAL Hodgkin D
Hodgkin POS 's D
's NN disease D
disease IN at O
at JJ advanced O
advanced NNS stages O
stages . ? O

Paclitaxel NN CAPITAL Paclitaxel T
Paclitaxel IN for O
for DT the O
the NN treatment O
treatment IN of O
of NN lymphoma D

Montelukast JJ CAPITAL Montelukast T
Montelukast , , T
, DT a T
a NN leukotriene-receptor T
leukotriene-receptor NN antagonist T
antagonist , , T
, IN for O
for DT the O
the NN treatment O
treatment IN of O
of JJ mild D
mild NN asthma D
asthma CC and D
and JJ exercise-induced D
exercise-induced NN bronchoconstriction D

Atypical JJ CAPITAL Atypical O
Atypical JJ antipsychotic T
antipsychotic NNS agents T
agents IN in O
in DT the O
the NN treatment O
treatment IN of O
of NN CAPITAL Schizophrenia D
Schizophrenia CC and D
and JJ other D
other JJ psychiatric D
psychiatric NNS disorders D

Percutaneous JJ CAPITAL Percutaneous T
Percutaneous JJ transluminal T
transluminal JJ angioplasty T
angioplasty IN in O
in DT the O
the NN treatment O
treatment IN of O
of JJ renovascular D
renovascular NN hypertension D
hypertension : : O
: JJ sequential O
sequential JJ prospective O
prospective NN study O

Esophageal JJ CAPITAL Esophageal T
Esophageal NN intubation T
intubation IN for O
for JJ palliative O
palliative NN treatment O
treatment IN in O
in JJ advanced D
advanced NN carcinoma D
carcinoma IN of D
of DT the D
the NN esophagus D
esophagus CC and D
and NN cardia D

Pathological JJ CAPITAL Pathological O
Pathological NN staging O
staging CC and O
and JJ biochemical O
biochemical NN recurrence O
recurrence IN after O
after JJ neoadjuvant T
neoadjuvant NN androgen T
androgen NN deprivation T
deprivation NN therapy T
therapy IN in O
in NN combination O
combination IN with O
with JJ radical T
radical NN prostatectomy T
prostatectomy IN in O
in RB clinically O
clinically JJ localized O
localized NN prostate D
prostate NN cancer D

How WRB CAPITAL How O
How RB often O
often VBZ does O
does NN surgery T
surgery IN for O
for JJ peptic D
peptic NN ulceration D
ulceration VB eradicate O
eradicate NNP CAPITAL Helicobacter O
Helicobacter NN pylori O
pylori . ? O
? JJ CAPITAL Systematic O
Systematic NN review O
review IN of O
of CD 36 O
36 NNS studies O

A DT CAPITAL A O
A NN comparison O
comparison IN of O
of JJ noninvasive T
noninvasive JJ positive-pressure T
positive-pressure NN ventilation T
ventilation CC and O
and JJ conventional T
conventional JJ mechanical T
mechanical NN ventilation T
ventilation IN in O
in NNS patients O
patients IN with O
with JJ acute D
acute JJ respiratory D
respiratory NN failure D

Long-term JJ CAPITAL Long-term O
Long-term NN safety O
safety CC and O
and NN effectiveness O
effectiveness IN of O
of JJ iron-chelation T
iron-chelation NN therapy T
therapy IN with T
with NN deferiprone T
deferiprone IN for O
for NN thalassemia D
thalassemia JJ major D

Positron NNP CAPITAL Positron O
Positron NN emission O
emission NN tomography O
tomography IN in O
in VBG assessing O
assessing NN response O
response TO to O
to JJ neoadjuvant T
neoadjuvant NN chemotherapy T
chemotherapy IN for O
for JJ non-small-cell D
non-small-cell NN lung D
lung NN cancer D

Reconstruction NN CAPITAL Reconstruction O
Reconstruction IN of O
of JJ thoracic O
thoracic NN wall O
wall NNS defects O
defects IN after O
after NN tumor D
tumor NN resection T
resection VBG using O
using DT a O
a NN polytetrafluoroethylene O
polytetrafluoroethylene JJ soft O
soft NN tissue O
tissue NN ( O
( NNP CAPITAL Gore-Tex O
Gore-Tex NN ) O
) NN patch O

A DT CAPITAL A O
A NN comparison O
comparison IN of O
of JJ rectal T
rectal NN diazepam T
diazepam NN gel T
gel CC and O
and NN placebo O
placebo IN for O
for JJ acute D
acute JJ repetitive D
repetitive NNS seizures D

Effect NN CAPITAL Effect O
Effect IN of O
of JJ long-term O
long-term NN salmeterol T
salmeterol NN treatment T
treatment IN on O
on JJ exercise-induced D
exercise-induced NN asthma D

Randomized VBN CAPITAL Randomized O
Randomized NN trial O
trial IN of O
of JJ intensive T
intensive NN cyclophosphamide T
cyclophosphamide , , T
, NN epirubicin T
epirubicin , , T
, CC and T
and NN fluorouracil T
fluorouracil NN chemotherapy T
chemotherapy VBN compared O
compared IN with O
with NN cyclophosphamide T
cyclophosphamide , , T
, NN methotrexate T
methotrexate , , T
, CC and T
and NN fluorouracil T
fluorouracil IN in O
in JJ premenopausal O
premenopausal NNS women O
women IN with O
with JJ node-positive D
node-positive NN breast D
breast NN cancer D

Acute JJ CAPITAL Acute O
Acute NN effect O
effect IN of O
of NN lorazepam T
lorazepam IN on O
on JJ respiratory O
respiratory NNS muscles O
muscles IN in O
in NNS patients O
patients IN with O
with JJ chronic D
chronic JJ obstructive D
obstructive JJ pulmonary D
pulmonary NN disease D

Low-molecular-weight JJ CAPITAL Low-molecular-weight T
Low-molecular-weight NNS heparins T
heparins IN in O
in DT the O
the NN treatment O
treatment IN of O
of JJ venous D
venous NN thromboembolism D

5-year JJ 5-year O
5-year NN outcome O
outcome IN of O
of JJ surgical T
surgical NN resection T
resection CC and O
and JJ watchful O
watchful VBG waiting O
waiting IN for O
for NNS men O
men IN with O
with RB moderately O
moderately JJ symptomatic O
symptomatic JJ benign D
benign JJ prostatic D
prostatic NN hyperplasia D
hyperplasia : : O
: DT a O
a NNP CAPITAL Department O
Department IN of O
of NNP CAPITAL Veterans O
Veterans NNP CAPITAL Affairs O
Affairs JJ cooperative O
cooperative NN study O

For IN CAPITAL For O
For WRB how O
how RB long O
long MD should O
should JJ antipsychotic T
antipsychotic NN medication T
medication VB be O
be VBN continued O
continued IN after O
after DT the O
the RB first O
first JJ psychotic D
psychotic NN episode D
episode IN in D
in NNS schizophrenics D
schizophrenics . ? O

IDA-FLAG NN CAPITAL IDA-FLAG T
IDA-FLAG NN ( T
( NN idarubicin T
idarubicin , , T
, NN fludarabine T
fludarabine , , T
, NN cytarabine T
cytarabine , , T
, NN CAPITAL G-CSF T
G-CSF NN ) T
) , , O
, DT an O
an JJ effective O
effective NN remission-induction T
remission-induction NN therapy T
therapy IN for O
for NN poor-prognosis D
poor-prognosis NN CAPITAL AML D
AML IN of D
of NN childhood D
childhood RB prior O
prior TO to O
to JJ allogeneic O
allogeneic CC or O
or JJ autologous O
autologous NN bone O
bone NN marrow O
marrow NN transplantation O
transplantation : : O
: NNS experiences O
experiences IN of O
of DT a O
a NN phase O
phase NNP CAPITAL II O
II NN trial O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NNS CAPITAL Effects O
Effects IN of O
of JJ anal T
anal JJ invasive T
invasive NN treatment T
treatment CC and O
and NN incontinence D
incontinence IN on O
on JJ mental O
mental NN health O
health CC and O
and JJ psychosocial O
psychosocial VBG functioning O
functioning IN of O
of NNS adolescents O
adolescents IN with O
with VBG CAPITAL Hirshsprung D
Hirshsprung POS 's D
's NN disease D
disease CC and O
and JJ low O
low JJ anorectal D
anorectal NNS anomalies D

Single JJ CAPITAL Single O
Single CC or O
or JJ double O
double NN lung T
lung NN transplantation T
transplantation IN for O
for JJ pulmonary D
pulmonary NN hypertension D

Interferon NN CAPITAL Interferon T
Interferon NN beta T
beta NN treatment T
treatment IN for O
for JJ multiple D
multiple NN sclerosis D

Ten-year JJ CAPITAL Ten-year O
Ten-year NN disease O
disease JJ free O
free NN survival O
survival IN after O
after JJ transperineal T
transperineal JJ sonography-guided T
sonography-guided NN iodine-125 T
iodine-125 NN brachytherapy T
brachytherapy IN with O
with CC or O
or IN without O
without JJ 45-Gray T
45-Gray JJ external T
external NN beam T
beam NN irradiation T
irradiation IN in O
in DT the O
the NN treatment O
treatment IN of O
of NNS patients O
patients IN with O
with RB clinically O
clinically JJ localized O
localized , , O
, JJ low O
low TO to O
to JJ high O
high NN CAPITAL Gleason D
Gleason NN grade D
grade NN prostate D
prostate NN carcinoma D

Partial JJ CAPITAL Partial O
Partial CC or O
or IN near O
near JJ total O
total NN pancreatectomy T
pancreatectomy IN for O
for JJ persistent D
persistent JJ neonatal D
neonatal JJ hyperinsulinaemic D
hyperinsulinaemic NN hypoglycaemia D
hypoglycaemia : : O
: DT the O
the NN pathologist O
pathologist POS 's O
's NN role O

Radical NNP CAPITAL Radical T
Radical NN prostatectomy T
prostatectomy IN for O
for NN prostate D
prostate NN cancer D
cancer : : O
: DT the O
the NN perineal O
perineal NN approach O
approach NNS increases O
increases DT the O
the NN risk O
risk IN of O
of RB surgically O
surgically VBN induced O
induced JJ positive O
positive NNS margins O
margins CC and O
and JJ capsular O
capsular NNS incisions O

Open VB CAPITAL Open T
Open NN capsulorrhaphy T
capsulorrhaphy IN with T
with NN suture T
suture NNS anchors T
anchors IN for O
for JJ recurrent D
recurrent JJ anterior D
anterior NN dislocation D
dislocation IN of D
of DT the D
the NN shoulder D

Intravenous JJ CAPITAL Intravenous T
Intravenous NN immunoglobulin T
immunoglobulin NN treatment T
treatment IN in O
in JJ multiple D
multiple NN sclerosis D

Randomised VBN CAPITAL Randomised O
Randomised NN trial O
trial IN of O
of JJ irinotecan T
irinotecan CC versus O
versus NN fluorouracil T
fluorouracil IN by O
by JJ continuous O
continuous NN infusion O
infusion IN after O
after NN fluorouracil O
fluorouracil NN failure O
failure IN in O
in NNS patients O
patients IN with O
with JJ metastatic D
metastatic JJ colorectal D
colorectal NN cancer D

The DT CAPITAL The O
The NN effectiveness O
effectiveness IN of O
of JJ intraocular T
intraocular NN pressure T
pressure NN reduction T
reduction IN in O
in DT the O
the NN treatment O
treatment IN of O
of NN normal-tension D
normal-tension NN glaucoma D

Perceived VBN CAPITAL Perceived O
Perceived NNS contraindications O
contraindications TO to O
to JJ thrombolytic T
thrombolytic NN treatment T
treatment IN in O
in JJ acute D
acute JJ myocardial D
myocardial NN infarction D

Lignocaine JJ CAPITAL Lignocaine T
Lignocaine CC or O
or NN bupivacaine T
bupivacaine IN for O
for JJ digital D
digital NN ring D
ring NN block D

Steroids NNS CAPITAL Steroids T
Steroids IN in O
in JJ lateral D
lateral NN epicondylitis D

Steroids NNS CAPITAL Steroids T
Steroids IN in O
in NNP CAPITAL De D
De NN CAPITAL Quervain D
Quervain POS 's D
's NN tenosynovitis D

Antibiotics NNS CAPITAL Antibiotics T
Antibiotics IN after O
after NN dog D
dog NN bite D

Immobilisation NN CAPITAL Immobilisation T
Immobilisation IN after O
after RB first O
first JJ anterior O
anterior NN shoulder D
shoulder NN dislocation D

Stereotactic JJ CAPITAL Stereotactic T
Stereotactic NN radiosurgery T
radiosurgery IN for O
for JJ acoustic D
acoustic NN neuroma D
neuroma : : O
: DT a O
a JJ CAPITAL Canadian O
Canadian NN perspective O

Anticytokine JJ CAPITAL Anticytokine T
Anticytokine NN therapy T
therapy : -- O
-- DT a O
a JJ new O
new NN era O
era IN in O
in DT the O
the NN treatment O
treatment IN of O
of JJ rheumatoid D
rheumatoid NN arthritis D
arthritis . ? O

Control NN CAPITAL Control O
Control IN of O
of DT the O
the JJ malignant D
malignant NN hyperpyrexic D
hyperpyrexic NN syndrome D
syndrome IN in O
in NN CAPITAL MHS O
MHS NNS swine O
swine IN by O
by JJ dantrolene T
dantrolene NN sodium T

Hematopoietic JJ CAPITAL Hematopoietic T
Hematopoietic NN stem-cell T
stem-cell NN transplantation T
transplantation IN for O
for DT the O
the NN treatment O
treatment IN of O
of JJ severe D
severe VBN combined D
combined NN immunodeficiency D

Low-dose JJ CAPITAL Low-dose T
Low-dose NN clozapine T
clozapine IN for O
for DT the O
the NN treatment O
treatment IN of O
of JJ drug-induced D
drug-induced NN psychosis D
psychosis IN in D
in NNP CAPITAL Parkinson D
Parkinson POS 's D
's NN disease D

Comparing VBG CAPITAL Comparing O
Comparing DT the O
the NN efficacy O
efficacy CC and O
and NN safety O
safety IN of O
of NN fluoxetine T
fluoxetine CC and O
and NN venlafaxine T
venlafaxine IN in O
in NN outpatient D
outpatient NN depression D

Cost-effectiveness NN CAPITAL Cost-effectiveness O
Cost-effectiveness IN of O
of NN interferon T
interferon NN treatment T
treatment IN for O
for NN hepatitis D
hepatitis NN CAPITAL C D

Hyperbaric JJ CAPITAL Hyperbaric T
Hyperbaric NN oxygen T
oxygen NN therapy T
therapy IN for O
for NNS children O
children IN with O
with JJ cerebral D
cerebral NN palsy D

Peripheral JJ CAPITAL Peripheral T
Peripheral JJ retinal T
retinal NN cryotherapy T
cryotherapy IN for O
for NN postvitrectomy D
postvitrectomy JJ diabetic D
diabetic JJ vitreous D
vitreous NN hemorrhage D
hemorrhage IN in O
in JJ phakic O
phakic NNS patients O

Hyperbaric JJ CAPITAL Hyperbaric T
Hyperbaric CC or T
or JJ normobaric T
normobaric NN oxygen T
oxygen IN for O
for JJ acute D
acute NN carbon D
carbon NN monoxide D
monoxide NN poisoning D
poisoning : : O
: DT a O
a VBN randomised O
randomised JJ controlled O
controlled JJ clinical O
clinical NN trial O

Multicentre JJ CAPITAL Multicentre O
Multicentre JJ clinical O
clinical NN evaluation O
evaluation IN of O
of NN vigabatrin T
vigabatrin NN ( T
( JJ CAPITAL Sabril T
Sabril NN ) T
) IN in O
in JJ mild D
mild TO to D
to JJ moderate D
moderate JJ partial D
partial NNS epilepsies D

Matrix NNP CAPITAL Matrix T
Matrix NN metalloproteinase T
metalloproteinase NNS inhibitors T
inhibitors IN in O
in DT the O
the NN treatment O
treatment IN of O
of NN cancer D

High JJ CAPITAL High O
High NN dose O
dose NN cyclophosphamide T
cyclophosphamide IN with O
with NN carboplatin T
carboplatin : : O
: DT a O
a JJ tolerable O
tolerable NN regimen O
regimen JJ suitable O
suitable IN for O
for NN dose O
dose NN intensification O
intensification IN in O
in NNS children O
children IN with O
with JJ solid D
solid NNS tumors D

Microsurgical JJ CAPITAL Microsurgical T
Microsurgical NN treatment T
treatment IN of O
of JJ supratentorial D
supratentorial JJ cavernous D
cavernous NNS malformations D

Microsurgical JJ CAPITAL Microsurgical T
Microsurgical NN treatment T
treatment IN of O
of NN infratentorial D
infratentorial NNS malformations D

Stereotactic JJ CAPITAL Stereotactic T
Stereotactic NN radiosurgery T
radiosurgery IN for O
for NN management O
management IN of O
of JJ deep D
deep NN brain D
brain JJ cavernous D
cavernous NNS malformations D

Interferon-antibodies JJ CAPITAL Interferon-antibodies T
Interferon-antibodies CC and O
and DT the O
the NN breakthrough O
breakthrough NN phenomenon O
phenomenon IN during O
during NN ribavirin/interferon-alpha T
ribavirin/interferon-alpha NN combination T
combination NN therapy T
therapy CC and O
and NN interferon-alpha T
interferon-alpha JJ monotherapy T
monotherapy IN of O
of NNS patients O
patients IN with O
with JJ chronic D
chronic NN hepatitis D
hepatitis NN CAPITAL C D

Treatment NN CAPITAL Treatment O
Treatment IN of O
of NNP CAPITAL Barrett D
Barrett NN esophagus D
esophagus IN with O
with NNP argon T
argon NN plasma T
plasma NN coagulation T
coagulation IN with T
with NN acid T
acid NN suppression T
suppression : -- O
-- DT a O
a JJ prospective O
prospective NN study O

Meta-analysis NN CAPITAL Meta-analysis O
Meta-analysis IN of O
of NN typhoid D
typhoid NN vaccine T
vaccine NN efficacy O
efficacy NNS trials O
trials VBD showed O
showed IN that O
that JJ whole O
whole NN cell O
cell NNS vaccines O
vaccines VBP are O
are RBR more O
more JJ effective O
effective IN than O
than DT either O
either DT the O
the JJ oral O
oral , , O
, VBN attenuated O
attenuated NN vaccine O
vaccine CC or O
or DT the O
the NNP CAPITAL Vi O
Vi NN polysaccharide O
polysaccharide NN vaccine O

Experimental JJ CAPITAL Experimental O
Experimental NN vaccination T
vaccination IN against O
against NN CAPITAL Mycoplasma D
Mycoplasma NN agalactiae D
agalactiae VBG using O
using JJ different O
different VBN inactivated O
inactivated NNS vaccines O

A DT CAPITAL A O
A VBN randomized O
randomized , , O
, JJ controlled O
controlled NN study O
study IN in O
in NNS adults O
adults IN of O
of DT the O
the NN immunogenicity O
immunogenicity IN of O
of DT a O
a JJ novel O
novel NN hepatitis D
hepatitis NN CAPITAL B D
B NN vaccine T
vaccine VBG containing O
containing NN CAPITAL MF59 O
MF59 JJ adjuvant O

Immunogenicity NN CAPITAL Immunogenicity O
Immunogenicity IN of O
of CD three O
three NN CAPITAL Haemophilus D
Haemophilus NN influenzae D
influenzae NN type D
type NN b D
b NN protein O
protein NN conjugate O
conjugate NNS vaccines T
vaccines IN in O
in NN CAPITAL HIV O
HIV JJ seropositive O
seropositive NNS adults O
adults CC and O
and NN analysis O
analysis IN of O
of NNS predictors O
predictors IN of O
of NN vaccine O
vaccine NN response O

Vaccination NN CAPITAL Vaccination T
Vaccination IN against O
against NN CAPITAL Schistosoma D
Schistosoma NN mansoni D
mansoni NN infection D
infection VBG using O
using CD 74 O
74 NN kDa O
kDa NN CAPITAL Schistosoma O
Schistosoma NN protein O
protein NN antigen O

Phase NN CAPITAL Phase O
Phase CD 1 O
1 NN safety O
safety CC and O
and JJ immune O
immune NN response O
response NNS studies O
studies IN of O
of DT a O
a NN CAPITAL DNA T
DNA NN vaccine T
vaccine VBG encoding O
encoding NN hepatitis D
hepatitis NN CAPITAL B D
B NN surface O
surface NN antigen O
antigen VBN delivered O
delivered IN by O
by DT a O
a NN gene O
gene NN delivery O
delivery NN device O

Protection NNP CAPITAL Protection O
Protection IN of O
of NNS swine O
swine IN from O
from NN foot-and-mouth D
foot-and-mouth NN disease D
disease IN with O
with CD one O
one NN dose O
dose IN of O
of DT an O
an JJ all-D T
all-D NN retro T
retro NN peptide T

Intranasal JJ CAPITAL Intranasal T
Intranasal NN immunization T
immunization IN with O
with NN CAPITAL Chlamydia D
Chlamydia NN trachomatis D
trachomatis , , D
, NN serovar D
serovar NN CAPITAL E D
E , , O
, VBZ protects O
protects IN from O
from DT a O
a JJ subsequent O
subsequent JJ vaginal O
vaginal NN challenge O
challenge IN with O
with DT the O
the JJ homologous O
homologous NN serovar O

Mutants NNS CAPITAL Mutants O
Mutants IN of O
of NN cholera O
cholera NN toxin O
toxin IN as O
as DT an O
an JJ effective O
effective CC and O
and JJ safe O
safe JJ adjuvant O
adjuvant IN for O
for JJ nasal D
nasal NN influenza D
influenza NN vaccine T

Field NN CAPITAL Field O
Field NN evaluation O
evaluation IN of O
of DT the O
the JJ clinical O
clinical NN effectiveness O
effectiveness IN of O
of NNS vaccines T
vaccines IN against O
against NN pertussis D
pertussis , , D
, NNS measles D
measles , , D
, NN rubella D
rubella CC and D
and NNS mumps D
mumps : : O
: NNS comments O

Transmural JJ CAPITAL Transmural T
Transmural NN drainage T
drainage IN of O
of JJ pancreatic D
pancreatic NN fluid D
fluid NNS collections D
collections IN without O
without NN electrocautery O
electrocautery VBG using O
using DT the O
the NN CAPITAL Seldinger O
Seldinger NN technique O

Echocardiography-guided JJ CAPITAL Echocardiography-guided T
Echocardiography-guided NN ethanol T
ethanol JJ septal T
septal NN reduction T
reduction IN for O
for NN hypertrophic D
hypertrophic JJ obstructive D
obstructive NN cardiomyopathy D

Alterations NNS CAPITAL Alterations O
Alterations IN of O
of NN monocyte O
monocyte NN function O
function IN in O
in NNS patients O
patients IN with O
with NN growth D
growth NN hormone D
hormone NN ( D
( NN CAPITAL GH D
GH NN ) D
) NN deficiency D
deficiency : : O
: NN effect O
effect IN of O
of JJ substitutive O
substitutive NN CAPITAL GH T
GH NN therapy T

Comparison NN CAPITAL Comparison O
Comparison IN of O
of DT the O
the NNS effects O
effects IN of O
of NN salmeterol T
salmeterol CC and O
and NN ipratropium T
ipratropium NN bromide T
bromide IN on O
on NN exercise O
exercise NN performance O
performance CC and O
and NN breathlessness O
breathlessness IN in O
in NNS patients O
patients IN with O
with JJ stable D
stable JJ chronic D
chronic JJ obstructive D
obstructive JJ pulmonary D
pulmonary NN disease D
disease . . O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NN CAPITAL Safety O
Safety NN trial O
trial IN with O
with DT the O
the NN 5HT1B/1D T
5HT1B/1D NN agonist T
agonist NN avitriptan T
avitriptan NN ( O
( NN CAPITAL BMS-180048 O
BMS-180048 NN ) O
) IN in O
in NNS patients O
patients IN with O
with NN migraine D
migraine WP who O
who VB have O
have JJ experienced O
experienced NN pressure D
pressure , , D
, NN tightness D
tightness , , D
, CC and/or D
and/or NN pain D
pain IN in O
in DT the O
the NN chest O
chest , , O
, NN neck O
neck , , O
, CC and/or O
and/or NN throat O
throat VBG following O
following NN sumatriptan T

Double JJ CAPITAL Double O
Double JJ blind O
blind , , O
, NN cluster O
cluster VBN randomised O
randomised NN trial O
trial IN of O
of JJ low O
low NN dose O
dose NN supplementation O
supplementation IN with O
with NN vitamin T
vitamin DT CAPITAL A T
A CC or O
or NN beta T
beta NN carotene T
carotene IN on O
on NN mortality D
mortality JJ related D
related TO to D
to NN pregnancy D
pregnancy IN in O
in NNP CAPITAL Nepal O
Nepal . . O

Medical JJ CAPITAL Medical T
Medical NNS treatments T
treatments IN for O
for NN balding D
balding IN in O
in NNS men O

Carbon NNP CAPITAL Carbon D
Carbon NN monoxide D
monoxide NN poisoning D
poisoning VBN treated O
treated IN with O
with JJ hyperbaric T
hyperbaric NN oxygen T
oxygen : : O
: JJ metabolic O
metabolic NN acidosis O
acidosis IN as O
as DT a O
a NN predictor O
predictor IN of O
of NN treatment O
treatment NNS requirements O

Medication NN CAPITAL Medication T
Medication VBN received O
received IN by O
by NNS patients O
patients IN with O
with NN depression D
depression VBG following O
following DT the O
the JJ acute O
acute NN episode O
episode : : O
: NN adequacy O
adequacy CC and O
and NN relation O
relation TO to O
to NN outcome O

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> VBN CAPITAL Reduced D
Reduced NN bone D
bone NN density D
density IN at O
at NN completion O
completion IN of O
of NN chemotherapy T
chemotherapy IN for O
for DT a O
a NN malignancy D

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NN CAPITAL Surgical-site D
Surgical-site NNS complications D
complications VBN associated O
associated IN with O
with DT a O
a NN morphine T
morphine NN nerve T
nerve VB paste T
paste VBN used O
used IN for O
for JJ postoperative D
postoperative NN pain D
pain NN control D
control IN after D
after NN laminectomy D

Splenectomy NN CAPITAL Splenectomy T
Splenectomy IN during O
during NN pregnancy O
pregnancy : : O
: DT an O
an NN option O
option IN in O
in DT the O
the NN treatment O
treatment IN of O
of JJ autoimmune D
autoimmune JJ thrombocytopenic D
thrombocytopenic NN purpura D

Melatonin NN CAPITAL Melatonin T
Melatonin NN treatment T
treatment IN of O
of NN sleep-wake D
sleep-wake NN cycle D
cycle NNS disorders D
disorders IN in O
in NNS children O
children CC and O
and NNS adolescents O

Randomized VBN CAPITAL Randomized O
Randomized NN phase O
phase NNP CAPITAL II O
II NN study O
study IN of O
of DT the O
the NN neurokinin T
neurokinin CD 1 T
1 NN receptor T
receptor NN antagonist T
antagonist NN CAPITAL CJ-11 T
CJ-11 , , T
, CD 974 T
974 IN in O
in DT the O
the NN control O
control IN of O
of JJ cisplatin-induced D
cisplatin-induced NN emesis D

Cataract NN CAPITAL Cataract D
Cataract NN surgery T
surgery CC and O
and PRP$ its O
its NN effect O
effect IN on O
on JJ intraocular O
intraocular NN pressure O

The DT CAPITAL The O
The NN outcome O
outcome IN of O
of JJ arthroscopic T
arthroscopic NN treatment T
treatment IN of O
of JJ temporomandibular D
temporomandibular JJ joint D
joint NN arthropathy D

Neostigmine NN CAPITAL Neostigmine T
Neostigmine IN for O
for JJ acute D
acute JJ colonic D
colonic NN pseudo-obstruction D

New NNP CAPITAL New O
New NN vaccine T
vaccine NNS targets O
targets NN childhood D
childhood NN pneumonia D

A DT CAPITAL A O
A NN comparison O
comparison IN of O
of NN botulinum T
botulinum NN toxin T
toxin CC and O
and NN nitroglycerin T
nitroglycerin NN ointment T
ointment IN for O
for JJ chronic D
chronic JJ anal D
anal NN fissure D

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> DT CAPITAL The O
The NN effect O
effect IN of O
of NN bisoprolol T
bisoprolol IN on O
on NN perioperative D
perioperative NN mortality D
mortality CC and O
and JJ myocardial D
myocardial NN infarction D
infarction IN in O
in JJ high-risk O
high-risk NNS patients O
patients VBG undergoing O
undergoing JJ vascular T
vascular NN surgery T

Surgical NNP CAPITAL Surgical T
Surgical NN management T
management IN of O
of JJ severe D
severe JJ secondary D
secondary NN peritonitis D

Early JJ CAPITAL Early T
Early JJ surgical T
surgical NN treatment T
treatment IN for O
for JJ supratentorial D
supratentorial JJ intracerebral D
intracerebral NN hemorrhage D
hemorrhage : : O
: DT a O
a VBN randomized O
randomized NN feasibility O
feasibility NN study O

Evaluation NN CAPITAL Evaluation O
Evaluation IN of O
of NN clomipramine T
clomipramine IN as O
as DT an O
an NN adjunct O
adjunct TO to O
to JJ behavioural T
behavioural NN therapy T
therapy IN in O
in DT the O
the NN treatment O
treatment IN of O
of JJ separation-related D
separation-related NNS problems D
problems IN in O
in NNS dogs O

NICE JJ CAPITAL NICE O
NICE TO to O
to NN rule O
rule IN on O
on NN influenza D
influenza NN flu D
flu NN drug O
drug NN zanamivir T

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> JJ CAPITAL Longitudinal D
Longitudinal NN melanonychia D
melanonychia VBN associated O
associated IN with O
with NN hydroxyurea T
hydroxyurea NN therapy T
therapy IN in O
in DT a O
a NN patient O
patient IN with O
with JJ essential D
essential NN thrombocytosis D

Biologic JJ CAPITAL Biologic O
Biologic NNS markers O
markers IN as O
as NNS predictors O
predictors IN of O
of JJ clinical O
clinical NN outcome O
outcome IN from O
from JJ systemic T
systemic NN therapy T
therapy IN for O
for JJ primary O
primary JJ operable O
operable NN breast D
breast NN cancer D

Treatment NN CAPITAL Treatment O
Treatment IN of O
of NN hypertension D
hypertension IN with O
with JJ ascorbic T
ascorbic NN acid T

Postoperative JJ CAPITAL Postoperative D
Postoperative NN peritonitis D
peritonitis VBG originating O
originating IN from O
from DT the O
the NN duodenum O
duodenum : : O
: JJ operative O
operative NN management O
management IN by O
by NN intubation T
intubation CC and T
and JJ continuous T
continuous JJ intraluminal T
intraluminal NN irrigation T

Efficacy NN CAPITAL Efficacy O
Efficacy IN of O
of NN open-bite D
open-bite NN treatment O
treatment IN with O
with DT the O
the JJ CAPITAL Thera-spoon T

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NN CAPITAL Pompholyx D
Pompholyx NN ( D
( JJ vesicular D
vesicular NN eczema D
eczema NN ) D
) IN after O
after NN i.v T
i.v . . T
. NN immunoglobulin T
immunoglobulin NN therapy T
therapy IN for O
for JJ neurologic D
neurologic NN disease D

Mitomycin NN CAPITAL Mitomycin T
Mitomycin , , T
, NN ifosfamide T
ifosfamide , , T
, CC and T
and NN cisplatin T
cisplatin IN in O
in JJ unresectable D
unresectable JJ non-small-cell D
non-small-cell NN lung D
lung NN cancer D
cancer : : O
: NNS effects O
effects IN on O
on NN survival O
survival CC and O
and NN quality O
quality IN of O
of NN life O
life . . O

Hepatic JJ CAPITAL Hepatic O
Hepatic JJ arterial O
arterial NN infusion O
infusion IN of O
of NN chemotherapy T
chemotherapy IN after O
after NN resection T
resection IN of O
of JJ hepatic D
hepatic NNS metastases D
metastases IN from O
from JJ colorectal D
colorectal NN cancer D

Waiting VBG CAPITAL Waiting O
Waiting IN for O
for DT the O
the JJ definitive O
definitive NN trial O
trial IN of O
of JJ hepatic T
hepatic JJ arterial T
arterial NN chemotherapy T
chemotherapy IN for O
for JJ colorectal D
colorectal NN cancer D

Phase NN CAPITAL Phase O
Phase NNP CAPITAL III O
III VBN randomized O
randomized NN study O
study IN of O
of NN cisplatin T
cisplatin CC versus O
versus NN paclitaxel T
paclitaxel CC versus O
versus NN cisplatin T
cisplatin CC and T
and NN paclitaxel T
paclitaxel IN in O
in NNS patients O
patients IN with O
with JJ suboptimal O
suboptimal NN stage O
stage NNP CAPITAL III O
III CC or O
or CD CAPITAL IV O
IV JJ ovarian D
ovarian NN cancer D
cancer : : O
: DT a O
a JJ gynecologic O
gynecologic NN oncology O
oncology NN group O
group NN study O

Evidence NN CAPITAL Evidence O
Evidence IN for O
for JJ double O
double NN resistance O
resistance TO to O
to NN permethrin T
permethrin CC and T
and NN malathion T
malathion IN in O
in NN head D
head NN lice D

Urgent JJ CAPITAL Urgent O
Urgent NN colonoscopy T
colonoscopy IN for O
for DT the O
the NN diagnosis O
diagnosis CC and O
and NN treatment O
treatment IN of O
of JJ severe D
severe JJ diverticular D
diverticular NN hemorrhage D

Treatment NN CAPITAL Treatment O
Treatment IN of O
of NNP CAPITAL Parkinson D
Parkinson POS 's D
's NN disease D
disease MD should O
should VB begin O
begin IN with O
with DT a O
a NN dopamine T
dopamine NN agonist T

< JJR < O
< NN CAPITAL TO_SEE O
TO_SEE JJR > O
> NN CAPITAL Ulceration D
Ulceration IN in O
in DT an O
an JJ ileocolic D
ileocolic NN anastomosis D
anastomosis VBN treated O
treated IN with O
with NN ranitidin T

Low-molecular-weight JJ CAPITAL Low-molecular-weight T
Low-molecular-weight NN heparin T
heparin CC vs O
vs NN heparin T
heparin IN in O
in DT the O
the NN treatment O
treatment IN of O
of NNS patients O
patients IN with O
with JJ pulmonary D
pulmonary NN embolism D

Radiotherapy NN CAPITAL Radiotherapy T
Radiotherapy IN in O
in JJ breast-conserving T
breast-conserving NN treatment T
treatment IN for O
for JJ ductal D
ductal NN carcinoma D
carcinoma IN in O
in FW situ O
situ : : O
: RB first O
first NNS results O
results IN of O
of DT the O
the NN CAPITAL EORTC O
EORTC VBN randomised O
randomised NN phase O
phase NNP CAPITAL III O
III NN trial O
trial CD 10853 O

Methadone NNP CAPITAL Methadone T
Methadone NN maintenance T
maintenance CC vs O
vs JJ 180-day O
180-day RB psychosocially O
psychosocially JJ enriched O
enriched NN detoxification T
detoxification IN for O
for NN treatment O
treatment IN of O
of NN opioid D
opioid NN dependence D
dependence : : O
: DT a O
a VBN randomized O
randomized JJ controlled O
controlled NN trial O

Cryogen NN CAPITAL Cryogen O
Cryogen NN spray O
spray VBG cooling O
cooling IN during O
during NN CAPITAL Nd T
Nd : : T
: NN CAPITAL YAG T
YAG NN laser T
laser NN treatment T
treatment IN of O
of NN hemangiomas D

Effects NNS CAPITAL Effects O
Effects IN of O
of NN tolcapone T
tolcapone , , T
, DT a T
a NN catechol-O-methyltransferase T
catechol-O-methyltransferase NN inhibitor T
inhibitor , , O
, IN on O
on NN motor O
motor NNS symptoms O
symptoms CC and O
and NNS pharmacokinetics O
pharmacokinetics IN of O
of NN levodopa T
levodopa IN in O
in NNS patients O
patients IN with O
with NNP CAPITAL Parkinson D
Parkinson POS 's D
's NN disease D
disease . . O

Gene NNP CAPITAL Gene T
Gene NN therapy T
therapy IN for O
for NN cancer D

Therapeutic JJ CAPITAL Therapeutic O
Therapeutic NNS effects O
effects IN of O
of NN CAPITAL LDL T
LDL NN apheresis T
apheresis IN in O
in DT the O
the NN prevention O
prevention IN of O
of NN atherosclerosis D

Dry NNP CAPITAL Dry T
Dry JJ powdered T
powdered NN formoterol T
formoterol , , O
, RB twice O
twice DT a O
a NN day O
day CC versus O
versus VBN aerosolized T
aerosolized NN salbutamol T
salbutamol , , O
, CD four O
four NNS times O
times DT a O
a NN day O
day , , O
, IN in O
in NNS patients O
patients IN with O
with JJ stable D
stable NN asthma D

Cell-based JJ CAPITAL Cell-based T
Cell-based NN vaccination T
vaccination IN against O
against NN melanoma D
melanoma : -- O
-- NN background O
background , , O
, JJ preliminary O
preliminary NNS results O
results , , O
, CC and O
and NN perspective O

Celecoxib NNP CAPITAL Celecoxib T
Celecoxib IN for O
for NN arthritis D

Poliomyelitis NN CAPITAL Poliomyelitis D
Poliomyelitis NN prevention O
prevention : : O
: VBN revised O
revised NNS recommendations O
recommendations IN for O
for NN use O
use IN of O
of VBN inactivated O
inactivated CC and O
and JJ live O
live JJ oral O
oral NN poliovirus D
poliovirus NNS vaccines T

Mesh NN CAPITAL Mesh O
Mesh NN plug O
plug NN repair O
repair CC and O
and NN groin D
groin NN hernia D
hernia NN surgery T

Brimonidine NN CAPITAL Brimonidine T
Brimonidine JJ tartrate T
tartrate CD 0.2 O
0.2 NN % O
% RB twice O
twice RB daily O
daily CC vs O
vs NN timolol T
timolol CD 0.5 O
0.5 NN % O
% RB twice O
twice RB daily O
daily : : O
: JJ 1-year O
1-year NNS results O
results IN in O
in NN glaucoma D
glaucoma NNS patients O

Ticarcillin/clavulanate JJ CAPITAL Ticarcillin/clavulanate T
Ticarcillin/clavulanate CC versus O
versus NN imipenem/cilistatin T
imipenem/cilistatin IN for O
for DT the O
the NN treatment O
treatment IN of O
of NNS infections D
infections VBN associated D
associated IN with D
with JJ gangrenous D
gangrenous CC and D
and JJ perforated D
perforated NN appendicitis D

Is VBZ CAPITAL Is O
Is CD zero O
zero NN dose O
dose JJ oral O
oral NNP polio D
polio NN vaccine T
vaccine JJ effective O
effective IN in O
in NN preterm O
preterm NNS babies O
babies . ? O

An DT CAPITAL An O
An JJ economic O
economic NN analysis O
analysis IN of O
of JJ different O
different NNS strategies O
strategies IN of O
of NN immunization T
immunization IN against O
against NN hepatitis D
hepatitis DT CAPITAL A D
A NN virus D
virus IN in O
in VBN developed O
developed NNS countries O

Issues NNS CAPITAL Issues O
Issues CC and O
and NNS challenges O
challenges IN with O
with JJ antithrombotic T
antithrombotic NN therapy T
therapy IN in O
in JJ diabetic O
diabetic NNS patients O
patients IN with O
with JJ acute D
acute JJ coronary D
coronary NNS syndromes D

Global JJ CAPITAL Global O
Global NN risk O
risk NN assessment O
assessment IN for O
for NN lipid T
lipid NN therapy T
therapy TO to O
to VB prevent O
prevent JJ coronary D
coronary NN heart D
heart NN disease D

The DT CAPITAL The O
The NN role O
role IN of O
of JJ fibric T
fibric NN acid T
acid NNS derivatives T
derivatives IN in O
in DT the O
the JJ secondary O
secondary NN prevention O
prevention IN of O
of JJ coronary D
coronary NN heart D
heart NN disease D

Epoetin NN CAPITAL Epoetin T
Epoetin : : O
: DT a O
a JJ pharmacoeconomic O
pharmacoeconomic NN review O
review IN of O
of PRP$ its O
its NN use O
use IN in O
in JJ chronic D
chronic JJ renal D
renal NN failure D
failure CC and O
and PRP$ its O
its NNS effects O
effects IN on O
on NN quality O
quality IN of O
of NN life O

Rationale NN CAPITAL Rationale O
Rationale IN for O
for DT the O
the NN use O
use IN of O
of JJ antiplatelet T
antiplatelet NNS drugs T
drugs IN in O
in NNS patients O
patients IN with O
with JJ peripheral D
peripheral JJ vascular D
vascular NN disease D

The DT CAPITAL The O
The NNS fluoroquinolones T
fluoroquinolones IN for O
for JJ urinary D
urinary NN tract D
tract NNS infections D
infections : : O
: DT a O
a NN review O

Reduction NN CAPITAL Reduction O
Reduction IN of O
of NN vasoreactivity D
vasoreactivity CC and O
and NN thrombogenicity D
thrombogenicity IN with O
with JJ laser-thermal T
laser-thermal JJ angioplasty T
angioplasty : : O
: NN comparison O
comparison IN with O
with NN balloon T
balloon JJ angioplasty T

Effects NNS CAPITAL Effects O
Effects IN of O
of NN ultrasound T
ultrasound NN energy T
energy IN on O
on JJ total D
total JJ peripheral D
peripheral NN artery D
artery NNS occlusions D
occlusions : : O
: JJ initial O
initial JJ angiographic O
angiographic CC and O
and JJ angioscopic O
angioscopic NNS results O
results . . O

High-dose JJ CAPITAL High-dose T
High-dose NN chemotherapy T
chemotherapy IN with T
with JJ autologous T
autologous NN stem-cell T
stem-cell NN support T
support IN for O
for JJ epithelial D
epithelial JJ ovarian D
ovarian NN cancer D

Pelvic JJ CAPITAL Pelvic T
Pelvic NN floor T
floor NN stimulation T
stimulation IN in O
in DT the O
the NN treatment O
treatment IN of O
of JJ adult D
adult JJ urinary D
urinary NN incontinence D

Chronic JJ CAPITAL Chronic T
Chronic NN vagus T
vagus NN nerve T
nerve NN stimulation T
stimulation IN for O
for NN treatment O
treatment IN of O
of NNS seizures D

`` `` `` T
`` JJ CAPITAL Tandem T
Tandem '' '' T
'' JJ high-dose T
high-dose JJ chemoradiotherapy T
chemoradiotherapy IN with T
with JJ autologous T
autologous NN stem-cell T
stem-cell NN support T
support IN in O
in DT the O
the NN treatment O
treatment IN of O
of RB newly O
newly VBN diagnosed O
diagnosed CC or O
or JJ responsive O
responsive JJ multiple D
multiple NN myeloma D

Special JJ CAPITAL Special O
Special NN report O
report : : O
: JJ comparative O
comparative NN efficacy O
efficacy IN of O
of JJ different O
different NNS types O
types IN of O
of JJ pneumatic T
pneumatic NN compression T
compression NNS pumps T
pumps IN for O
for DT the O
the NN treatment O
treatment IN of O
of NN lymphedema D

Special JJ CAPITAL Special O
Special NN report O
report : : O
: JJ pressure-reducing T
pressure-reducing NN support T
support NNS surfaces T
surfaces IN in O
in DT the O
the NN prevention O
prevention CC and O
and NN treatment O
treatment IN of O
of NN pressure D
pressure NNS ulcers D
ulcers : : O
: NN group O
group CD 1 O
1 NNS technologies O

Intravenous JJ CAPITAL Intravenous T
Intravenous JJ immune T
immune NN globulin T
globulin IN for O
for JJ recurrent D
recurrent JJ spontaneous D
spontaneous NN abortion D

External JJ CAPITAL External T
External NN counterpulsation T
counterpulsation IN for O
for NN treatment O
treatment IN of O
of JJ chronic D
chronic JJ stable D
stable NN angina D
angina NN pectoris D

Intra-articular JJ CAPITAL Intra-articular T
Intra-articular NN hyaluronan T
hyaluronan NNS injections T
injections IN for O
for NN treatment O
treatment IN of O
of NN osteoarthritis D
osteoarthritis IN of O
of DT the O
the NN knee O

Pneumococcal JJ CAPITAL Pneumococcal D
Pneumococcal NN vaccine T
vaccine : : O
: DT a O
a JJ second O
second NN look O

